<SEC-DOCUMENT>0001725160-22-000155.txt : 20220809
<SEC-HEADER>0001725160-22-000155.hdr.sgml : 20220809
<ACCEPTANCE-DATETIME>20220809161305
ACCESSION NUMBER:		0001725160-22-000155
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220809
DATE AS OF CHANGE:		20220809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zentalis Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001725160
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				823607803
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39263
		FILM NUMBER:		221148449

	BUSINESS ADDRESS:	
		STREET 1:		1359 BROADWAY, SUITE 1710
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018
		BUSINESS PHONE:		(212) 433-3791

	MAIL ADDRESS:	
		STREET 1:		1359 BROADWAY, SUITE 1710
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zentalis Pharmaceuticals, LLC
		DATE OF NAME CHANGE:	20200107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zeno Pharma, LLC
		DATE OF NAME CHANGE:	20171212
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>zntl-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:dc6f2cb5-3684-47f2-a7ee-9069478f9aef,g:255d4c27-7dc3-44e2-be9a-0993a342da50,d:24da124e87454cab95fd92a2627099ed--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:zntl="http://www.zentalis.com/20220630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>zntl-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80L2ZyYWc6MmQwOTE4NWJkYmFmNDcxNWI2NjBkMTkzODZiOWIxNWUvdGFibGU6YmY3Zjg2YzA0MzA5NDJkNDhmZTEwYjdkNGU0NmJlYjIvdGFibGVyYW5nZTpiZjdmODZjMDQzMDk0MmQ0OGZlMTBiN2Q0ZTQ2YmViMl8wLTEtMS0xLTQ5Nzk4_4151f502-e12d-4550-a4d1-80e77c747d54">0001725160</ix:nonNumeric><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80L2ZyYWc6MmQwOTE4NWJkYmFmNDcxNWI2NjBkMTkzODZiOWIxNWUvdGFibGU6YmY3Zjg2YzA0MzA5NDJkNDhmZTEwYjdkNGU0NmJlYjIvdGFibGVyYW5nZTpiZjdmODZjMDQzMDk0MmQ0OGZlMTBiN2Q0ZTQ2YmViMl8xLTEtMS0xLTQ5Nzk4_eb95f121-ec07-4cf3-beff-f97c64ab6a9f">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80L2ZyYWc6MmQwOTE4NWJkYmFmNDcxNWI2NjBkMTkzODZiOWIxNWUvdGFibGU6YmY3Zjg2YzA0MzA5NDJkNDhmZTEwYjdkNGU0NmJlYjIvdGFibGVyYW5nZTpiZjdmODZjMDQzMDk0MmQ0OGZlMTBiN2Q0ZTQ2YmViMl8yLTEtMS0xLTQ5Nzk4_41544732-0385-4385-ad41-0bdf3137d07e">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80L2ZyYWc6MmQwOTE4NWJkYmFmNDcxNWI2NjBkMTkzODZiOWIxNWUvdGFibGU6YmY3Zjg2YzA0MzA5NDJkNDhmZTEwYjdkNGU0NmJlYjIvdGFibGVyYW5nZTpiZjdmODZjMDQzMDk0MmQ0OGZlMTBiN2Q0ZTQ2YmViMl8zLTEtMS0xLTQ5Nzk4_e8e8fad9-e2e7-4c74-a8a3-098e2afbd3f7">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80L2ZyYWc6MmQwOTE4NWJkYmFmNDcxNWI2NjBkMTkzODZiOWIxNWUvdGFibGU6YmY3Zjg2YzA0MzA5NDJkNDhmZTEwYjdkNGU0NmJlYjIvdGFibGVyYW5nZTpiZjdmODZjMDQzMDk0MmQ0OGZlMTBiN2Q0ZTQ2YmViMl80LTEtMS0xLTQ5Nzk4_463b0f2e-5bc4-42ab-96d8-91af609f5c16">2022</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i806b4c764dc54e6ebde6e45a7c23760d_I20220630" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83Ni9mcmFnOmI4MzkxZWJlZTNkMzRiMmQ4ZDJmODM1Y2ViMzYzZjFiL3RhYmxlOmVhMjU4Zjc5MjhlODQxNjRiZWZjOGQ5OTFmZWM5YjA4L3RhYmxlcmFuZ2U6ZWEyNThmNzkyOGU4NDE2NGJlZmM4ZDk5MWZlYzliMDhfMi0xLTEtMS00OTc5OA_26a40ade-14e7-4ddc-9b34-21847f711147">0</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="zntl-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fad63ac05584e07ac5c9962a8206885_I20220808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iccb4b475a51d40e8b00847b50b411bb2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea2c4236a736402f8b183ddfe915fbac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebc81bbd37134c8eb0227cec32909507_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9ed70ab246449f7ad763aa871442e27_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de8308633374277be1cf29a7379f05c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68ef53f7e30c4224922d1c036f351731_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i236b3f20c24e41bcaf1eabdc79111516_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia821fe0c70284513b205269e31ca09b2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id940216a8696400e848431386ab32d09_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0dac22d55a34bd28a43e412291b2c2b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0f23d89cf3e409993a8b87de890b508_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ce1ccd32b74f8f8a7021b222292233_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c7c555285da411b8145cd0a64ff4ebc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1477287ae34d47408281cf92c3a86f66_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c76f003ce48452898b59c299efffc95_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2527dedabd09467e89489d14d48942a7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96fbfda562ed4251a1b2805e02ad7a13_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ce25123e7d14a9b9e92dd7ef27fe5d7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d0b89a422d645d2aa975073d6e626b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f0a552beb41460d83598cfec7140d03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7134b43188594f1d9a9a436a5c024ce9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3823d94562d44181906d6305eee20514_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0de465fbe24b4aa737c25edf79d252_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if85ae8da9e964278af67cede62e6983c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4332f30a3194687b4ba50860e682c2b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c2ece8395d4a878161c8c8bb291feb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43893269fb514e64a84c7e6836451dab_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef202afe8ee4eb29a4286d1984f00e7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ided707c746324c85b99713cfd1f60a31_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03d6b1d603f9454bada2bf2d6fdaa5c1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21f5e3fdc0fe4e9abfb1657db69da8bd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80ee52788a39497ba42814448e5acd22_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6308a92c792f4032aaf192b33d9c615d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b3fd0d327c647f78519c288eabd7f13_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i347024f2e9ac451aa83164fdbd8d84fb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbd060dd7d6d4fdaacff3da2f0e05098_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81639f8b21714c96a90b50f632406ac7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bd2f39625b8425cb7b9aff6a3b1ad28_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia20e533d81cd4d089a7df4436d153672_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3cda99f88cd4c479dc77d9d5c051b50_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21514c2c23bb4db989a9c7ce3badc7fd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7db1887be0d42278bf24dd6a2ec6df7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5ccef6083cd4247a6cad6d8beaa3058_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5299c81f26ad457bb9835f9d797f5a03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eeadd6ca63a4a009a94aec18e5f62ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48ff54a3aa3044e380b7048409865567_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03477a9c65e34b128f96193a6cb1c953_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad53b504c7e14abca92ca74a46a07bbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace2148088e643e387d7d86483ae4b8d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie52aa73782a849fdaecd219b51650553_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9542e31388864d3fa1e1d2fdc142b92d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f89106493a4483a75fab892a90d82f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dc3ef43b05d4b4dab34c1ceec3046b9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if476a59e1bdc46f883f2c9950f451fe9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e26a8f313d147c899372ec9a56c6c9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f7d3ab172046598fe7dcdf7ffe8f23_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebb85fbd06c842c9b31131732a081288_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de358016f734a82a094e8ea4e3ef006_D20171221-20171221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">zntl:KalyraPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-21</xbrli:startDate><xbrli:endDate>2017-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d7db02ca8a24de29d50872ad8205e42_I20171221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">zntl:KalyraPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id24bd10e6cc1406aa94762219ea0191d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46207b8cc83c4695ab95cd14b58c03ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73d19273bd804eacb01818f0b3a0b9d6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib00284ea6567450d9a07b5d0bfc0d9e5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib28e2c6f83d847d8be4563b4c9a90eb4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40490dd28724db79d06f9d951fd8acd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia08925ab72244888b246b83bf82d4bed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15c97d107fb94103966853f5642d3a1f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i383f5a4611ed4191a940e97fba342d26_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a784f336c5848288d83ed9d20e70b9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i110e2b4c6b064ff1879c74f20d1b098c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if49279cde51c4e31967f61ac9e91cb63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>zntl:security</xbrli:measure></xbrli:unit><xbrli:context id="ic5ff574a6987485e9ac601606fe4d9da_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb9f2afeb6f4a43b04688b32531d990_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b1dd88afc154d7e9984607fd2f2361f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic005cf5c954c4ba5a5ccbadc693d99df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c59b2bf1e764cc0a86c5735a369a0b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48e3c115b00a44bcb25b3dfd9e2e39bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1784ad3c83464579a9a8932fbfe9e598_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3761f588efbc4816ae10a0d889c298a0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57dc0a40165448f8bf4b5ba74eb5fbe9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46288b24c23d45c4a2463d010ab350b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i608e66c1af484e6ea5e6d792778ed0d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00cfbef488eb418e92919ac20ba1da40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie217c38e068b4202a61b214386647f10_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2698997899df495f800f9a30eeb074a9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia69616f0679f42df9238c4e3b6a87d27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5b1bda2786c420f874b7c2291657c6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i039e0cbb5b7c4c79b65983450a20902b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd81d064eadd4c7bbc89294f9f777699_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86dee2bcbeca454481688921ef7935de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7c31a2718ae40079432589bc1229566_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41189229a4bd4e0caa35a0023153383e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e4123972044834800ac21f54e63593_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba6229d21df445539c2d6bf8fb6643fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccc8555322b941b49bd02a7e8765116e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f5fb8ff10c4cf1bb7736f876b4d48e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9278009b9182442fbf3eb96697bd192b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7014a45299de49eaa9a9df4f081d723f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31315f6337ae4500b1642edc83c1261b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81c66ad195194fe2b48c0fbe96882389_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1017f13dbbd0440db64ac087de0a0e59_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27efde771a3e4e359c95a3ae8018c908_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa741359e4446b9920193e9ce94fa0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia32cba1a7c584481935d18ab5b6e3052_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5f415d9e7e84e6390821b2aeca98c24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd1665e0a46248bdbece57a6438e0879_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee10f69caf0d40ba94ea1e00633d0b5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1bd11cea6cd49bfbd84c09bd6e1c561_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica13a2bb8504414b9caaf996da34fe6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f99dba567644e889110abb67dd9dc2e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b3eed1bbd49485bba0b0ac55976ff5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b47b8406e04436e962c6cf09f56a781_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife734a5c6be14dfeb15a20d958641bd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f1b085c0bc6418984b4a5652a0f3059_D20220429-20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">zntl:DirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-29</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i569a69ed2aa54cd6a4ae5aa666ff442a_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">zntl:DirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc20ff4317e549b195078a8c6d397c35_D20220429-20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-29</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if223d394e54b4750aa978efb34cba0d1_D20220518-20220518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">zntl:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5136c20b0b3448728a094b8bde8584e3_I20220518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">zntl:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1195842e7bad4796adc5d3f33b370980_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451d05a387bc4e28bfaa0c622d3e53b7_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i224274cfab6347e4af0e47b9f95e96ac_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84a3bb6a8e4a4aadaca19939a0d400a0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb817854a7743afa79c27dc1d29457d_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2022EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a591ae027674ec48804343c4347f2e3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieed3e9f3f3094029b5dfa3ccb2bc6788_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if24f63e9218a428f8bf2dd3b117c02ec_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ee6e27237af4336b5fc9bd4e9f7d48a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83eb79dfc5df4e11adeeb75938b1d7f0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44dd3cb1c0574feea2624c386be77ec7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if83d444b0887436c87fef11dcef2e86a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa2780f94d8d42288f13f874db45fd67_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie30a5375c819427c8694c4b2774b9e9b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:ZenteraStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i412b968f7b08436b9aa7f54bde3682ea_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:ZenteraStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644b2805dacd408b8e97b86dd46abb55_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94e8c09b4a3445298e64940b137301f9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i575ec7487094412380df5d1d84056a75_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8047842fd47f4f2f8278a39d6e1230e3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3f359d04969451b952bf5cfc0d87b34_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b6d6db52cc441d5980a322a0c13d3c3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9beff74796b74e7a9a2e80f6198c9feb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47314e35042849da943c497cbcc052f6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2715dfb0dea34fb2ba4b3115eda88efe_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f29867c289543609894effb0ecd7862_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaef89f53ab20478f942e34396c28ad99_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e90d2bfdd054eeebf7e538c70e8a560_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i340692408be44878952df6f49a437468_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0914aa0549284d0f8c6c232168700055_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07bfbcc2813a425a9f14affe9ac623f0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6848464a8da644618f62c064bead2a58_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0503299777e24da1a507027233084ab8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i198c9b7202d64e788574e76bcbac5063_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3258b88db0a48128947746c61ed2f7b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c688c67b897412c81a7a8199ad39a9d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if609506238d0461eac509be96d92ec01_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i382cf4d3dcbd43b484285308648a79c9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2ca05b7f8ef4c3cb04522bb5e0f01f0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f3ca918b964800a78e9ae83baa07fd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64103a278a8e4aa7ac8509ba56369056_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dff9cfed3a14c8d8c88926052fcee95_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bdc5cf068c740ae97ed383848a4f8b2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zntl:MasterServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i806b4c764dc54e6ebde6e45a7c23760d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zntl:MasterServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i24da124e87454cab95fd92a2627099ed_1"></div><div style="min-height:0pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.250%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjg1_5b7c17af-ece2-465b-b36f-78a084998e94">10-Q</ix:nonNumeric></span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.250%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjc3_6b3bef6e-c245-4cef-93fe-9958936dd49a">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjQ_81185903-745d-453e-b226-8b5be6cdcc0d">June&#160;30, 2022</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjc4_4977d22f-36e0-461c-b353-a37758ddec27">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ___________________ to ___________________</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjg3_93986343-1e0f-4ef1-904a-bc3ed636f17e">001-39263</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.250%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjgw_8211754b-0911-4e9d-85b2-666fce593be6">Zentalis Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.250%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF8wLTAtMS0xLTQ5Nzk4_61af9708-7da0-4731-8d65-0d0981cbcf0f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF8wLTEtMS0xLTQ5Nzk4_3149a429-c58e-4f04-b30b-1eeffb750275">82-3607803</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF8zLTAtMS0xLTQ5Nzk4L3RleHRyZWdpb246YTdhODI5N2I0YTdjNDdmZWI3Yjg2OWU3MjQ3MjAxMzdfNA_007d76bb-06e3-49fb-b009-f88351301d30">1359 Broadway</ix:nonNumeric>, <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF8zLTAtMS0xLTQ5Nzk4L3RleHRyZWdpb246YTdhODI5N2I0YTdjNDdmZWI3Yjg2OWU3MjQ3MjAxMzdfOA_7a5b6f69-7955-427a-852d-46ea9db25913">Suite 1710</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF81LTAtMS0xLTQ5Nzk4_ac42fc54-e6e6-402c-b502-ba6d79d3c126">New York,</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF82LTAtMS0xLTQ5Nzk4_7b635cd4-03fd-4290-b1ee-7412e931ccd3">New York</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF82LTEtMS0xLTQ5Nzk4_6d1d1629-85c4-40ca-a01e-2c2e8553f95d">10018</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjg5_1b39af9e-269d-479e-affc-c260385afbc9">212</ix:nonNumeric>) <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjc5_a517fbd3-a02e-40a9-a4e3-4d12e7edf67c">433-3791</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.250%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6NWI3NWM1YTcxZmRjNGQwMDhiZmRkOTI2NTc0NDA4ZmIvdGFibGVyYW5nZTo1Yjc1YzVhNzFmZGM0ZDAwOGJmZGQ5MjY1NzQ0MDhmYl8xLTAtMS0xLTQ5Nzk4_a2c52fde-32a2-44a7-a314-e4b876b87c0e"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common Stock,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.001 par value per share</span></div></ix:nonNumeric></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6NWI3NWM1YTcxZmRjNGQwMDhiZmRkOTI2NTc0NDA4ZmIvdGFibGVyYW5nZTo1Yjc1YzVhNzFmZGM0ZDAwOGJmZGQ5MjY1NzQ0MDhmYl8xLTEtMS0xLTQ5Nzk4_cc9a8fe4-9a1d-47f4-ad2a-bf2848bb3c1e">ZNTL</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6NWI3NWM1YTcxZmRjNGQwMDhiZmRkOTI2NTc0NDA4ZmIvdGFibGVyYW5nZTo1Yjc1YzVhNzFmZGM0ZDAwOGJmZGQ5MjY1NzQ0MDhmYl8xLTItMS0xLTQ5Nzk4L3RleHRyZWdpb246ZWRhNDYxYzUzNWU0NGQyMmIzNmY0NzY5Y2M2YjU1ZWJfNA_0d2799db-3a3c-4a3e-baf7-f76ff7959530">The Nasdaq Stock Market LLC</ix:nonNumeric> (The Nasdaq Global Market)</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjgy_067cbf7d-435c-4d58-86a3-93a46b6e4b41">Yes</ix:nonNumeric> &#9746;  &#160;No  &#9744;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjg0_d63907cc-6c73-4900-b965-d7c710539de4">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:3pt;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.722%"><tr><td style="width:1.0%"></td><td style="width:34.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6MGUxZDdiOGQxNjA3NGQ4Y2IxNDVhZTA2NDI3OGYwNjQvdGFibGVyYW5nZTowZTFkN2I4ZDE2MDc0ZDhjYjE0NWFlMDY0Mjc4ZjA2NF8wLTAtMS0xLTQ5Nzk4_fd10ab48-44ee-4266-bdcc-ecf5c5e6a026">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6MGUxZDdiOGQxNjA3NGQ4Y2IxNDVhZTA2NDI3OGYwNjQvdGFibGVyYW5nZTowZTFkN2I4ZDE2MDc0ZDhjYjE0NWFlMDY0Mjc4ZjA2NF8xLTQtMS0xLTQ5Nzk4_d6d7b2de-07af-4893-a211-79006b240488">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6MGUxZDdiOGQxNjA3NGQ4Y2IxNDVhZTA2NDI3OGYwNjQvdGFibGVyYW5nZTowZTFkN2I4ZDE2MDc0ZDhjYjE0NWFlMDY0Mjc4ZjA2NF8yLTQtMS0xLTQ5Nzk4_f60f94bb-5509-4579-91a7-51990d341fd2">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-bottom:6pt;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjgz_4018d65c-b502-4cb4-a970-f815d1a03061">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-bottom:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of August 8, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i0fad63ac05584e07ac5c9962a8206885_I20220808" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjA5_9e1cee55-fb96-474f-bfa4-4f03440be707">56,983,641</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_19">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_22">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_25">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_28">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_28">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_31">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_34">Condensed Consolidated Statement of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_34">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_37">Notes to Condensed Consolidated Financial Statements </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_82">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_85">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_88">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_88">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_91">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_91">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_94">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_94">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_97">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_97">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_100">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_100">99</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_103">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_103">99</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_106">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_106">99</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_109">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_109">99</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_112">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_112">100</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_115">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24da124e87454cab95fd92a2627099ed_115">102</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements within the meaning of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Quarterly Report, including without limitation statements regarding our future results of operations and financial position, the anticipated impact of the COVID-19 pandemic on our business, global supply chain issues and increased inflation, the sufficiency of our cash and cash equivalents to fund our operations, business strategy, prospective products and product candidates, clinical trial timelines and expected timing for the release of data, research and development costs, future revenue, timing and likelihood of success, activities under our existing collaborations and potential collaboration opportunities, and plans and objectives of management are forward-looking statements.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of known and unknown risks, uncertainties, assumptions and other important factors, including those described under &#8220;Summary Risk Factors&#8221; below and in the sections in this Quarterly Report entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Quarterly Report.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, they may turn out to be inaccurate and you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results, financial condition, performance or achievements could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we assume no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ZENTALIS</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, KALYRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and their associated logos are trademarks of Zentalis and/or its affiliates. All other trademarks, trade names and service marks appearing in this Quarterly Report are the property of their respective owners. All website addresses given in this Quarterly Report are for information only and are not intended to be an active link or to incorporate any website information into this document.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY RISK FACTORS</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A. &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and drug development programs or future commercialization efforts.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are substantially dependent on the success of our lead product candidates, ZN-c3 and/or ZN-d5, which are currently in clinical trials. If we are unable to complete development of, obtain approval for and commercialize ZN-c3 and/or ZN-d5 in a timely manner, our business will be harmed.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We intend to develop ZN-c3 and ZN-d5 and potentially other product candidates in combination with other therapies, which exposes us to additional risks.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The regulatory approval processes of the U.S. Food and Drug Administration, or FDA, and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We face significant competition and, if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our success depends on our ability to protect our intellectual property and our proprietary platform. If we are unable to adequately protect our intellectual property and our proprietary platform, or to obtain and maintain issued patents that are sufficient to protect our product candidates, then others could compete against us more directly, which would negatively impact our business.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our existing collaborations are important to our business and future collaborations may also be important to us and, if we are unable to maintain any of these collaborations, or if these arrangements are not successful, our business could be adversely affected.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The competition for qualified personnel is particularly intense in our industry. If we are unable to retain or hire key personnel, then we may not be able to sustain or grow our business.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The COVID-19 pandemic has adversely impacted, and we expect will continue to adversely impact, our business, including our preclinical studies and clinical trials. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BASIS OF PRESENTATION</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Quarterly Report on Form 10-Q, unless the context otherwise requires, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company,&#8221; &#8220;Zentalis&#8221; and similar references refer: (1) following the consummation of our statutory conversion to a Delaware corporation on April 2, 2020 in connection with our initial public offering, to Zentalis Pharmaceuticals, Inc., and (2) prior to the completion of such conversion, to Zentalis Pharmaceuticals, LLC.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i24da124e87454cab95fd92a2627099ed_22"></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts and par value)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNC0xLTEtMS00OTc5OA_6a97ad7e-b9b7-4101-b433-81056d448357">55,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNC0zLTEtMS00OTc5OA_1c38a8c4-6b7c-4650-9252-a0424b783ed1">59,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities, available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNS0xLTEtMS00OTc5OA_81464d48-8449-4d89-ad3c-9d99fc646ec3">400,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNS0zLTEtMS00OTc5OA_f755af62-29a9-4342-bc03-35a0d0997d62">280,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNy0xLTEtMS00OTc5OA_aa816d77-4bbd-40e6-b3ce-8d0d7b0dbba5">12,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNy0zLTEtMS00OTc5OA_82bdd202-b180-44d5-ba56-04675f63fb56">10,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfOC0xLTEtMS00OTc5OA_602786f1-307a-46de-ae88-c70e20e17060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfOC0zLTEtMS00OTc5OA_974bfbd2-d8c6-4a38-9bd7-b16cd268e743">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfOS0xLTEtMS00OTc5OA_3ecb845c-71fb-436f-80b6-480c6bff694a">467,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfOS0zLTEtMS00OTc5OA_3e320ed9-25fc-4037-a001-c6abdbf6bece">350,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTAtMS0xLTEtNDk3OTg_3c932885-9d1b-466a-895e-4f9185e79913">8,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTAtMy0xLTEtNDk3OTg_8fed9416-705c-4b0d-9d15-e751c8e1f3ec">8,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease&#160;right-of-use&#160;assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTEtMS0xLTEtNDk3OTg_ecaa8538-85d1-4590-af5d-531146b05ddf">43,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTEtMy0xLTEtNDk3OTg_32750e73-a9c2-45aa-8107-b1b6e1e33158">44,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTItMS0xLTEtNDk3OTg_4c4bbe6f-3578-42dc-a7da-f3a220ed08d0">11,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTItMy0xLTEtNDk3OTg_69d4d801-9ba0-4077-9cac-1f89e46f7b97">7,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTMtMS0xLTEtNDk3OTg_a280d341-7959-4162-b91e-fd18bc345e3f">3,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTMtMy0xLTEtNDk3OTg_a0a9eb8a-183e-4ec1-a381-fd1b8dd94d17">3,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in Zentera Therapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTUtMS0xLTEtNDk3OTg_60f88bb8-5e5d-4f17-b98b-c5c7d616774d">30,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTUtMy0xLTEtNDk3OTg_0d7e03ea-cd29-4e21-8cad-fcf3a26da510">37,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTYtMS0xLTEtNDk3OTg_fcd03bdc-bc4e-40e4-ac28-82677713a237">2,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTYtMy0xLTEtNDk3OTg_845e6d26-1825-4e38-abb0-cb44aad515f1">2,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTctMS0xLTEtNDk3OTg_820375c7-efda-4cfe-befc-4e69b9e1cd69">567,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTctMy0xLTEtNDk3OTg_bffc7a9b-7b63-4ebb-93fa-76560c38a3ea">454,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES&#160;AND&#160;STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjAtMS0xLTEtNDk3OTg_bc335ac5-be23-4682-a465-fffc74d0b49d">12,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjAtMy0xLTEtNDk3OTg_e98ab0c2-ed98-4c4c-aeed-7c683080ce38">11,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjEtMS0xLTEtNDk3OTg_df12dc43-0184-40e6-b837-e59f40cbb6c8">36,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjEtMy0xLTEtNDk3OTg_b8dc83e6-95fd-4b7f-8da6-1e94d041d502">32,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjItMS0xLTEtNDk3OTg_ac998b69-d51a-4dc4-8047-47782f6e8e0e">48,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjItMy0xLTEtNDk3OTg_7b555e00-c55b-43e6-b8ef-d8df45972325">43,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjMtMS0xLTEtNDk3OTg_52e395a4-9848-4470-9b57-196d9cf9d8fa">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjMtMy0xLTEtNDk3OTg_92a22ef2-dbbf-4e4d-98d4-cb503b73d961">1,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjQtMS0xLTEtNDk3OTg_add33fb4-cd56-432b-98b4-57ec2ca37064">45,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjQtMy0xLTEtNDk3OTg_bc51fb72-439c-4484-832b-01168343f8f7">44,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjUtMS0xLTEtNDk3OTg_8af896db-dec0-44a1-b1f4-8b239d9548cf">95,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjUtMy0xLTEtNDk3OTg_a52e1e2b-b9a9-4179-b259-8b12cf2284ad">90,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjYtMS0xLTEtNDk3OTg_ad3d9653-89fc-42ba-85bc-71759b72cdd2"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjYtMy0xLTEtNDk3OTg_e7ce9bdc-8fab-4840-9e3c-1ccb2efd6022"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl8yMQ_09eda77e-4944-49a3-98f7-153581d4528d"><ix:nonFraction unitRef="usdPerShare" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl8yMQ_fa2189f0-b042-4c64-9eed-58f42c8ef511">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl8zNQ_6666c008-1d8a-4b45-a16a-8d06f2a11698"><ix:nonFraction unitRef="shares" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl8zNQ_dd3533da-5125-42f0-b306-6899656681f4">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl81Nw_083968ec-744d-431e-afe5-73ab9e2f7a5c"><ix:nonFraction unitRef="shares" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl81Nw_18edfe3a-853b-478b-a80c-9847f99f40c7"><ix:nonFraction unitRef="shares" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl81Nw_33ff35b8-39f7-4f0c-adae-7fad9f2a7f37"><ix:nonFraction unitRef="shares" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl81Nw_758f4ebe-46a7-45de-9745-0229cfc7e797">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2022 and December 31, 2021 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMS0xLTEtNDk3OTg_1c09a36f-2b86-472e-99bc-e65393a9f7ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMy0xLTEtNDk3OTg_5c280a24-777f-4306-bf16-a86a1770c8db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV8xOA_b4bc2c55-b94e-4987-89f4-33bf74d54b83"><ix:nonFraction unitRef="usdPerShare" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV8xOA_e0aec2c8-81ca-493b-b20e-f38e95eb9fea">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV8zMg_1e1fa4bb-6e41-4ab2-83a7-5db6bb065c25"><ix:nonFraction unitRef="shares" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV8zMg_2f7ffbda-7f78-42e8-b0bc-5e8169a040d7">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV81NA_93d12d39-6153-4b88-901d-90960d055b23"><ix:nonFraction unitRef="shares" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV81NA_ec66f52c-0dd9-415e-9965-4092460cee81">56,969,118</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV82MQ_4f29d20f-301b-48ea-a61f-0776768558e3"><ix:nonFraction unitRef="shares" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV82MQ_bed3c691-1a06-4d8c-8ad4-aa20f5ed4111">45,490,764</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMS0xLTEtNDk3OTg_adc57ef0-63c6-4a84-bf44-eed2a11b2440">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMy0xLTEtNDk3OTg_cea2ec33-9c8b-485d-9da0-696f0cd454a8">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzMtMS0xLTEtNDk3OTg_18687bcf-88be-4c12-8a0b-68784f6dd699">961,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzMtMy0xLTEtNDk3OTg_8d58b404-0ca7-429e-af1f-82d7aa17a155">723,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzQtMS0xLTEtNDk3OTg_87f02754-fb69-4882-a22f-6c1eba0842fd">1,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzQtMy0xLTEtNDk3OTg_0a649ac0-213b-48f1-a60e-2150a56ade30">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzUtMS0xLTEtNDk3OTg_6b384fd0-3524-427f-8b1f-bcc9386b6718">486,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzUtMy0xLTEtNDk3OTg_8508e215-4ea6-4f12-b9f5-d1481834a936">359,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzYtMS0xLTEtNDk3OTg_3c6b3ed7-4b2d-43dc-9f0d-17333ea8f62f">472,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzYtMy0xLTEtNDk3OTg_81ece5d2-b013-465b-b9c3-2a5d3c32ac0d">363,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzctMS0xLTEtNDk3OTg_208cc5d2-b02c-4023-aaee-8c5261b5fbda">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzctMy0xLTEtNDk3OTg_24f9c7c6-5bca-492d-a5f1-e1b30a2b35bb">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzgtMS0xLTEtNDk3OTg_794d6795-3fcb-4266-998c-bb785b6d5d45">472,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzgtMy0xLTEtNDk3OTg_3dc3c1af-f59f-45d6-add7-55af2102ad7c">364,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzktMS0xLTEtNDk3OTg_613ccf5a-06f4-4868-99f3-38ae7883616a">567,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzktMy0xLTEtNDk3OTg_5e0b2c82-1ed1-4c1b-8a08-789e7de71999">454,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements. </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMy0xLTEtMS00OTc5OA_ff90c225-732a-443b-addf-5b4fa926b1bc">43,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMy0zLTEtMS00OTc5OA_a1466696-1900-4664-980f-a4e48c33813e">44,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMy01LTEtMS00OTc5OA_34dc45f4-4777-4b61-87c1-86863651a3af">89,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMy03LTEtMS00OTc5OA_19f940fe-94be-432a-9a74-59eb98cdcd9e">83,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNC0xLTEtMS00OTc5OA_fc2b5803-415f-4222-8237-5be88bced661">19,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNC0zLTEtMS00OTc5OA_190f46c8-cf82-416b-ace1-aa6d36f8ee7b">10,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNC01LTEtMS00OTc5OA_c8864128-ac79-48d3-b402-3934671277d4">31,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNC03LTEtMS00OTc5OA_53992ad6-fdfb-4461-b134-a22c1aa915e9">22,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNS0xLTEtMS00OTc5OA_82d2935c-cbf2-454b-8667-c4ff1cb036c4">63,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNS0zLTEtMS00OTc5OA_8c6553fd-0fb8-41b3-90dd-b95065da9702">55,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNS01LTEtMS00OTc5OA_71e894a1-62e1-4962-a02a-f270c9702552">121,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNS03LTEtMS00OTc5OA_4adca2e8-ab56-41a9-9af6-e42083cb6e59">105,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNi0xLTEtMS00OTc5OA_36ac06b4-e108-4a1d-83ab-1ef963e593fe">63,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNi0zLTEtMS00OTc5OA_75057527-e299-4097-9959-c3b1a0a3dfe6">55,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNi01LTEtMS00OTc5OA_af6d7829-ecaa-436a-b9eb-49dfb4ac7411">121,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNi03LTEtMS00OTc5OA_92cd02f1-1171-4e64-8342-32b964c0c558">105,479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="zntl:InvestmentAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfOC0xLTEtMS00OTc5OA_82a07c31-53d6-4cb8-be80-5c07a119b366">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="zntl:InvestmentAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfOC0zLTEtMS00OTc5OA_12dbf05a-26bc-498c-8eb5-0bde001f4687">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="zntl:InvestmentAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfOC01LTEtMS00OTc5OA_72b6e579-e783-41af-8768-07b3ac0564a1">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="zntl:InvestmentAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfOC03LTEtMS00OTc5OA_913766c2-bb1b-4929-8bc4-c68a4c083622">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTEtMS0xLTEtNDk3OTg_0b39bdbd-cf4a-40fb-a808-2f1208894dbc">63,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTEtMy0xLTEtNDk3OTg_073226b7-c013-4e27-958f-1f7c42a4df83">55,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTEtNS0xLTEtNDk3OTg_48c5da74-0860-49d3-ae75-5dd651464ed0">120,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTEtNy0xLTEtNDk3OTg_08ed23fe-8ccc-4f49-8f41-8087c6abfc3d">105,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTItMS0xLTEtNDk3OTg_c33436ae-6cee-44b9-8746-bd027d609613">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTItMy0xLTEtNDk3OTg_2d3280e8-5911-4354-bd67-310b27909c2e">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTItNS0xLTEtNDk3OTg_55a1fe6d-7e97-4fdb-a846-8b50ca255250">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTItNy0xLTEtNDk3OTg_15301a81-5d65-4e50-93d7-7ae53f5894b9">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTMtMS0xLTEtNDk3OTg_14f055fe-f7ca-40fd-a3af-ba03ac8d2d41">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTMtMy0xLTEtNDk3OTg_3db90376-6daa-49c7-8384-5c1ddf2eb38a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTMtNS0xLTEtNTA4NDE_773163d0-431b-49ce-8fc2-8f1f1d109a52">7,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTMtNy0xLTEtNTA4NDE_2cead9f0-2713-4a5a-9b28-4cd162857a51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTQtMS0xLTEtNDk3OTg_486a7943-742c-4ffb-9d48-c574a38087bc">68,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTQtMy0xLTEtNDk3OTg_3d2752e0-c7b8-4f28-a035-b79afcf4e0fb">55,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTQtNS0xLTEtNDk3OTg_96284aba-358a-430d-884e-33590b640350">127,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTQtNy0xLTEtNDk3OTg_0f1ed13d-dfef-46be-937a-e139ec1a9db2">105,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTUtMS0xLTEtNDk3OTg_4589862a-a2a5-4b14-81df-a02bcb1697c0">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTUtMy0xLTEtNDk3OTg_ed6c0cdf-a2dd-49ac-8b97-e1742fc51349">488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTUtNS0xLTEtNDk3OTg_656e10e9-15a1-431a-a60e-214a0ff68728">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTUtNy0xLTEtNDk3OTg_a58a1457-b27c-4fb6-a0fa-12b16f947e49">1,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTYtMS0xLTEtNDk3OTg_6b50aa4b-0444-42b4-adbd-ead9d8f5c05c">68,357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTYtMy0xLTEtNDk3OTg_cea5c019-d508-4a67-826e-2db59159da3b">54,574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTYtNS0xLTEtNDk3OTg_4234ebb5-d67c-4ba8-8069-a4efbdc90373">127,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTYtNy0xLTEtNDk3OTg_6c0d31c5-b596-4da8-9eec-1f348404229f">104,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share outstanding, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctMS0xLTEtNDk3OTg_bad9a982-a522-4124-ae5b-eb07b49fa811"><ix:nonFraction unitRef="usdPerShare" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctMS0xLTEtNDk3OTg_e66096fe-7207-43a1-846b-85bc65a99af6">1.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctMy0xLTEtNDk3OTg_0e8a9736-1a45-4c3b-8253-be6b6825b0b3"><ix:nonFraction unitRef="usdPerShare" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctMy0xLTEtNDk3OTg_8241bc56-42f6-4c6d-afb2-fbb8efd2a365">1.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctNS0xLTEtNDk3OTg_1e45c07a-6c27-4454-9225-728936f5643d"><ix:nonFraction unitRef="usdPerShare" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctNS0xLTEtNDk3OTg_f9d193bb-4837-4aee-ae25-00fc390b7ee9">2.64</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctNy0xLTEtNDk3OTg_34bda028-1533-4c6c-9878-7f24c202a85b"><ix:nonFraction unitRef="usdPerShare" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctNy0xLTEtNDk3OTg_a7c8690a-9588-4f19-834f-610eeaf6e310">2.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares used in computing net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktMS0xLTEtNDk3OTg_a05bcf19-9f35-43fa-beb6-d349fa320c83"><ix:nonFraction unitRef="shares" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktMS0xLTEtNDk3OTg_f3cc393e-dfd5-4a35-a89d-a942ca10885b">51,117</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktMy0xLTEtNDk3OTg_7ae4ee6f-e9c1-4e02-930c-74b31788efa2"><ix:nonFraction unitRef="shares" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktMy0xLTEtNDk3OTg_7da8f369-c61e-455e-8608-9519a8fb396c">40,738</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktNS0xLTEtNDk3OTg_94186af4-0eb1-446c-ad0b-e63df9ea6911"><ix:nonFraction unitRef="shares" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktNS0xLTEtNDk3OTg_e6c9864c-86eb-485e-a0b1-4be072172338">48,197</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktNy0xLTEtNDk3OTg_c3f37c0b-01cc-477c-9d92-e546d2e11b3c"><ix:nonFraction unitRef="shares" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktNy0xLTEtNDk3OTg_cdc1962c-51f3-4a8f-a07d-261c5c58a737">40,549</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:45.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfMi0xLTEtMS00OTc5OA_486a7943-742c-4ffb-9d48-c574a38087bc">68,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfMi0zLTEtMS00OTc5OA_3d2752e0-c7b8-4f28-a035-b79afcf4e0fb">55,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfMi01LTEtMS00OTc5OA_96284aba-358a-430d-884e-33590b640350">127,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfMi03LTEtMS00OTc5OA_0f1ed13d-dfef-46be-937a-e139ec1a9db2">105,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation effects</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNC0xLTEtMS00OTc5OA_68d006d3-8a55-4406-98fb-62065c74dcb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNC0zLTEtMS00OTc5OA_bbf195f7-03d9-499d-a6f6-06a7b6541235">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNC01LTEtMS00OTc5OA_a88fc8ee-5229-42d3-a8f0-e058bc2c6442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNC03LTEtMS00OTc5OA_ea61d788-bc27-4e0b-bfb2-073dcb913a37">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNS0xLTEtMS00OTc5OA_5d15d0ea-d3d3-4421-be79-1975d8a882e4">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNS0zLTEtMS00OTc5OA_76f7a029-8cb8-4452-813e-51bca3a3dff1">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNS01LTEtMS00OTc5OA_9df09f02-6b18-4db4-b41f-5dbc2bf7e656">1,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNS03LTEtMS00OTc5OA_4b4ec43d-9472-44a7-b578-981b1bd43918">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNi0xLTEtMS00OTc5OA_b8df3b6f-a179-44c5-bea0-408ea405f2a7">69,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNi0zLTEtMS00OTc5OA_03d10fca-fb45-4c9f-b360-7f80550fe68a">55,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNi01LTEtMS00OTc5OA_104412ac-a3af-4f08-b068-05b3d1aafd7d">129,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNi03LTEtMS00OTc5OA_04f1eec0-bd30-4d8f-8688-20ed0c773b2c">105,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNy0xLTEtMS00OTc5OA_362b2fd6-7589-4c1d-a70e-dd847a4e44fe">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNy0zLTEtMS00OTc5OA_334fc9bf-8de0-441a-b670-2da51087ceba">488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNy01LTEtMS00OTc5OA_834cb87b-95de-4758-826d-4580a5d080b0">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNy03LTEtMS00OTc5OA_dbe5c4de-cd69-4d51-8ec1-ea2998c3ba44">1,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Zentalis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfOC0xLTEtMS00OTc5OA_236d5cdc-0cfe-4315-a7f3-10416ff006ed">69,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfOC0zLTEtMS00OTc5OA_1393cf5a-d335-4a8d-b15c-f4ea38506820">54,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfOC01LTEtMS00OTc5OA_032483de-9a3c-462e-9247-372b4a82b16d">129,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfOC03LTEtMS00OTc5OA_7e59f789-758a-4f85-bc7c-a72ee3aadbac">104,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:1pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMy0xLTEtMS00OTc5OA_83c0ecfd-b7de-45bf-a19a-1839e3b4dded">127,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMy0zLTEtMS00OTc5OA_a366eff4-5cb1-4b12-b100-e36fa188935d">105,506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfNS0xLTEtMS00OTc5OA_5856c8f5-4f0f-4c86-b475-1ef6dd180a0b">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfNS0zLTEtMS00OTc5OA_b18596a0-a0f2-4f9c-b195-679f09b64e04">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfOS0xLTEtMS00OTc5OA_1e38a16f-6791-4898-a42e-b23a8c06f431">26,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfOS0zLTEtMS00OTc5OA_603a7a21-6b94-4a18-8911-ebb7eecde1ab">19,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTAtMS0xLTEtNDk3OTg_0bd479c1-1756-45cb-aa30-56f4a7b53563">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTAtMy0xLTEtNDk3OTg_176e32f9-68e1-487f-bf97-6690afb3e4fe">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTEtMS0xLTEtNDk3OTg_b0a1b459-1357-4480-bdf9-54a6573d5dcb">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTEtMy0xLTEtNDk3OTg_cb525bec-a172-4c0c-9720-f654cd5aaca8">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTItMS0xLTEtNDk3OTg_31c1155d-8af0-4e4b-afb5-cc56f56a12d7">7,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTItMy0xLTEtNDk3OTg_2098a8be-b01a-482f-b79b-7fb0cd543db4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTUtMS0xLTEtNDk3OTg_7e0b5290-95bc-4854-a007-1c082b5ea531">6,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTUtMy0xLTEtNDk3OTg_a869659f-fbea-4d9e-a31a-4be38b9fc740">3,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTYtMS0xLTEtNDk3OTg_3de11aaf-d99a-4393-b4af-87a46449bcb7">4,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTYtMy0xLTEtNDk3OTg_1617551d-f5b6-4f5f-9cca-6db471ecd6f6">4,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTctMS0xLTEtNDk3OTg_d52e14d6-3175-4fa7-bbab-259a86fe7cc1">2,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTctMy0xLTEtNDk3OTg_f57e3677-9788-4e84-8c4e-cf79d6789c8d">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTgtMS0xLTEtNDk3OTg_cb5b976a-1e87-4f31-b804-a106cd85945a">93,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTgtMy0xLTEtNDk3OTg_4446e077-86bf-40a8-9640-4c6f2bc055d0">83,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjAtMS0xLTEtNDk3OTg_ccf83faa-0f63-41cd-887a-f38a84f5a670">277,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjAtMy0xLTEtNDk3OTg_4ac22fbf-92f0-49bc-9fa5-de183a507a25">77,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjEtMS0xLTEtNDk3OTg_19722e21-5e9f-4a3d-bb10-779f22547b3c">156,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjEtMy0xLTEtNDk3OTg_dbc40ab2-3308-4282-873d-075b34a86b86">159,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjMtMS0xLTEtNDk3OTg_b33415af-1ff0-49ce-add5-62d13857a1c4">728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjMtMy0xLTEtNDk3OTg_5ffe15ba-3eb3-464c-9dd3-6c74b840c1d1">1,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjQtMS0xLTEtNDk3OTg_6796cc69-ff65-4e5b-a719-6d39b69552d4">122,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjQtMy0xLTEtNDk3OTg_1c4053f4-0db2-4b94-891e-22adfa3b0556">80,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjctMS0xLTEtNTAyMjk_e48b51b7-93e4-4da0-999e-b2ee1f75d3f9">209,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjctMy0xLTEtNTAyMjk_a9d7d363-9a2b-42a4-aa38-86946f7af8fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjctMS0xLTEtNDk3OTg_fcf7356e-0503-416d-8c6c-440b01b66139">1,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjctMy0xLTEtNDk3OTg_3e79e502-2f4d-4c9a-8e0f-9c58d39766b7">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzEtMS0xLTEtNDk3OTg_1f645481-2ce0-421a-81f6-472ebf04608b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzEtMy0xLTEtNDk3OTg_9fa75b16-819d-44ac-ab09-b0a9eccf3d30">386</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzItMS0xLTEtNDk3OTg_68328fe0-810a-41d5-b0e6-1167754c2419">210,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzItMy0xLTEtNDk3OTg_f2bed265-edd6-4d1d-9e6a-2e436db460d7">316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzMtMS0xLTEtNDk3OTg_cee7cea9-b3bf-406f-9d64-c13d8f0df159">4,814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzMtMy0xLTEtNDk3OTg_6f21ff0f-f099-42fa-ba0e-29b92612cbed">3,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzQtMS0xLTEtNDk3OTg_6cabc951-0fa6-49d2-8ccd-1db3967d3a87">62,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea2c4236a736402f8b183ddfe915fbac_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzQtMy0xLTEtNDk3OTg_fb4b4445-e48c-4d36-a504-bf1eef7852a1">56,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzUtMS0xLTEtNDk3OTg_c5d36f95-808a-4c2f-8eb8-40e600e1d365">57,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzUtMy0xLTEtNDk3OTg_083fa8b1-bcd4-41b0-aaf9-0ef5f431b3bc">52,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of&#160;non-cash&#160;investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzctMS0xLTEtNDk3OTg_161c252a-3b47-43f7-a61b-402575b1520f">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzctMy0xLTEtNDk3OTg_f3a7d05c-8f46-4895-9419-870b7a67fb9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued deferred financing costs </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfNDEtMS0xLTEtNDk3OTg_eb668baf-e853-4acf-86e2-c8b1607e3777">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfNDEtMy0xLTEtNDk3OTg_4068f754-c96b-4ea2-841a-fd25bfb63749">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Consolidated Statements of Cash Flows for the periods presented:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:1pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfMi0xLTEtMS00OTc5OA_dfb7655b-2497-4827-8cea-30a328f5ad0f">55,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfMi0zLTEtMS00OTc5OA_1bde9f89-13e2-45f5-b087-4e72db25cfd2">49,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfMy0xLTEtMS00OTc5OA_7856905f-7469-4e7e-99b6-18a921b18727">2,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfMy0zLTEtMS00OTc5OA_d10800d8-af5c-410b-addd-b08a224fe6d3">3,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash reported in the Condensed Consolidated Statement of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfNC0xLTEtMS00OTc5OA_a02ab541-d119-4b37-8469-46ac5d173646">57,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfNC0zLTEtMS00OTc5OA_32f96009-7e3b-45d9-a171-afc234b5e8f4">52,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_34"></div><hr style="page-break-after:always"/><div style="min-height:0pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.230%"><tr><td style="width:1.0%"></td><td style="width:34.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9ed70ab246449f7ad763aa871442e27_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC0xLTEtMS00OTc5OA_9e392109-18b2-4e18-b1a2-be4ec11bf71f">45,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ed70ab246449f7ad763aa871442e27_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC0zLTEtMS00OTc5OA_f9c8b5b6-a40b-496f-8920-72a878c5a31c">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de8308633374277be1cf29a7379f05c_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC01LTEtMS00OTc5OA_dbd811cb-3edb-4b10-b696-ea5695c1b664">734,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68ef53f7e30c4224922d1c036f351731_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC03LTEtMS00OTc5OA_2eead230-80f0-4d55-8204-d8e1f4d9916b">1,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i236b3f20c24e41bcaf1eabdc79111516_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC05LTEtMS00OTc5OA_14f8a2d1-933e-40fb-8979-a1224dd7c9b4">418,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia821fe0c70284513b205269e31ca09b2_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC0xMS0xLTEtNDk3OTg_66856784-7b8c-449a-b9a7-f82df8c172b3">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id940216a8696400e848431386ab32d09_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC0xMy0xLTEtNDk3OTg_9512d6e9-a560-490c-8d9c-9df334c48fce">315,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dac22d55a34bd28a43e412291b2c2b_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNS01LTEtMS00OTc5OA_f0f3f42c-d8c1-45ca-b279-cdca50e2e0cb">16,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNS0xMy0xLTEtNDk3OTg_759a38c2-0874-44c8-89d5-5bd577d5b183">16,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0f23d89cf3e409993a8b87de890b508_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNi03LTEtMS00OTc5OA_9e390f4b-931c-42eb-9ea4-2861bbfb4100">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNi0xMy0xLTEtNDk3OTg_449e24f8-0663-417a-9842-18a0be4c0d28">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNy0xLTEtMS00OTc5OA_1b62c99b-38dd-442d-b01f-198b36c3f84b">11,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNy0zLTEtMS00OTc5OA_5cd1dd7c-742a-46a3-bcfb-622008fb161f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dac22d55a34bd28a43e412291b2c2b_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNy01LTEtMS00OTc5OA_be27852b-f67d-409f-8ce8-3b4d6971ce82">209,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNy0xMy0xLTEtNDk3OTg_0cf25dc2-9751-4560-8c61-b45afaf022db">209,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with restricted stock unit vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfOC0xLTEtMS00OTc5OA_ac87b7a3-c841-4bc3-8cb5-7b0fc2e4176f">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTAtMS0xLTEtNDk3OTg_2d61daeb-f6ac-4ab7-89fc-9d4de2634b6b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dac22d55a34bd28a43e412291b2c2b_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTAtNS0xLTEtNDk3OTg_457b3ffa-c66b-4b28-87dd-8f734e3e7698">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTAtMTMtMS0xLTQ5Nzk4_45dddbdd-bac5-4141-88e8-64f2c165f5b7">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTItMS0xLTEtNDk3OTg_f6e63996-53c1-475a-88af-697c123ec42b">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80ce1ccd32b74f8f8a7021b222292233_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTMtMTEtMS0xLTQ5Nzk4_58d89c8b-d951-4faf-ae37-c077c0c5fe0c">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTMtMTMtMS0xLTQ5Nzk4_37b8f764-8ca0-45ab-a4a5-66ad1e4533a0">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c7c555285da411b8145cd0a64ff4ebc_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTQtOS0xLTEtNDk3OTg_61ba4151-707f-42c8-a9c0-ffcbce1b6de7">68,357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTQtMTMtMS0xLTQ5Nzk4_c42a9a90-bcf6-47ad-8822-7aeece525878">68,357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1477287ae34d47408281cf92c3a86f66_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtMS0xLTEtNDk3OTg_a81dac6d-1816-4163-95b5-a9f827b3e037">56,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1477287ae34d47408281cf92c3a86f66_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtMy0xLTEtNDk3OTg_5f51e82a-2829-4327-ad32-3543bc693609">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c76f003ce48452898b59c299efffc95_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtNS0xLTEtNDk3OTg_5a27d12d-4613-41c8-b852-bc8122ed7443">961,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2527dedabd09467e89489d14d48942a7_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtNy0xLTEtNDk3OTg_51405b6d-032e-4494-91c6-21a0dc7f5d72">1,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96fbfda562ed4251a1b2805e02ad7a13_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtOS0xLTEtNDk3OTg_9523171f-4a8b-479d-a134-49a0aacf27f9">486,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce25123e7d14a9b9e92dd7ef27fe5d7_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtMTEtMS0xLTQ5Nzk4_2b90d190-dc9b-4d2f-a6bf-a0f60ef1e685">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtMTMtMS0xLTQ5Nzk4_2e54ea6a-133d-496c-929f-9b33995da585">472,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.500%"><tr><td style="width:1.0%"></td><td style="width:37.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.003%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d0b89a422d645d2aa975073d6e626b8_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC0xLTEtMS01MDM0OA_391cdeaf-5f6c-4e6b-b5b6-236c69935053">45,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0b89a422d645d2aa975073d6e626b8_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC0zLTEtMS01MDM0OA_de2d1ea1-f016-4e26-9a0b-5d1d9d41c15d">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0a552beb41460d83598cfec7140d03_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC01LTEtMS01MDM0OA_43c11ccd-ddc2-4752-b27a-1aa041fb0911">723,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7134b43188594f1d9a9a436a5c024ce9_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC03LTEtMS01MDM0OA_9f67ac9c-49cc-4f77-ac73-8ae8a5f40195">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3823d94562d44181906d6305eee20514_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC05LTEtMS01MDM0OA_07cad8f4-088d-4918-943d-daedebd64fd0">359,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0de465fbe24b4aa737c25edf79d252_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC0xMS0xLTEtNTAzNDg_891a3b9c-5adf-4726-b882-faa54d98d348">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC0xMy0xLTEtNTAzNDg_b7e3120c-fac7-4678-9127-4fca9c680bbb">364,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85ae8da9e964278af67cede62e6983c_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNS01LTEtMS01MDM0OA_cd17e595-81b4-4c44-9421-39e19e9f43a1">26,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNS0xMy0xLTEtNTAzNDg_bc41b86a-6e9b-4f6a-8277-8426a97f0295">26,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4332f30a3194687b4ba50860e682c2b_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNi03LTEtMS01MDM0OA_69ef7532-30ec-4db8-ac12-bc2f82fa5c6b">1,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNi0xMy0xLTEtNTAzNDg_49b6ce79-8d0d-4135-8888-2178c62ccfb6">1,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNy0xLTEtMS01MDM0OA_2b57485d-03e7-42f8-ba4f-d8b1f6e6eb8b">11,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNy0zLTEtMS01MDM0OA_5838df48-fb91-48b8-b953-e6b3825f3970">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85ae8da9e964278af67cede62e6983c_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNy01LTEtMS01MDM0OA_0ff0bbfb-7137-496e-ae78-47a827c85b0c">209,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNy0xMy0xLTEtNTAzNDg_384c50fe-0b8b-436a-945f-d2b8d303f0a2">209,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with restricted stock unit vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfOC0xLTEtMS01MDM0OA_9785e068-86d9-442e-beb0-cec2064c00de">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfOC0zLTEtMS01MDM0OA_f9289777-aab7-4130-a4b7-d66ed901706f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfOC0xMy0xLTEtNTAzNDg_0b045ee0-2a1d-4388-b43a-99633b46dba1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTAtMS0xLTEtNTAzNDg_2f5f5131-df67-452b-ad3c-ee43381bf356">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85ae8da9e964278af67cede62e6983c_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTAtNS0xLTEtNTAzNDg_6901e4c5-8eb6-4b39-b3c5-9f0095067f28">803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTAtMTMtMS0xLTUwMzQ4_639893b3-4bea-47ac-8450-2eb92198ee90">803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTEtMS0xLTEtNTAzNDg_d8207059-7281-419f-b2a6-5bb76d0dacba">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85ae8da9e964278af67cede62e6983c_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTEtNS0xLTEtNTAzNDg_7fcf4f6d-5e6a-41ce-b235-a9726aca5c7e">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTEtMTMtMS0xLTUwMzQ4_857690b1-8af9-4334-bd02-b9f38bbae471">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTItMS0xLTEtNTAzNDg_cb751d48-2b7d-4ac0-9d06-b3d2d1b66536">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0c2ece8395d4a878161c8c8bb291feb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTMtMTEtMS0xLTUwMzQ4_755f1e17-4a1f-402b-9ca7-1e443844a51d">195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTMtMTMtMS0xLTUwMzQ4_da9c4106-8f77-41b9-85cf-5b5681d02ddd">195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43893269fb514e64a84c7e6836451dab_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTQtOS0xLTEtNTAzNDg_0a9ffd27-c22a-43a3-80d9-d5d395dfdcc1">127,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTQtMTMtMS0xLTUwMzQ4_a5c7c08f-c730-4c37-bab5-1487bd2dac59">127,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1477287ae34d47408281cf92c3a86f66_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtMS0xLTEtNTAzNDg_743952c3-15da-4c7b-ad19-0e3a2656081b">56,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1477287ae34d47408281cf92c3a86f66_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtMy0xLTEtNTAzNDg_cef13958-7f57-44a9-8ed5-14d2dd51ea7b">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c76f003ce48452898b59c299efffc95_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtNS0xLTEtNTAzNDg_46f0a927-07c9-4f14-bf0b-c791faf6b1c5">961,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2527dedabd09467e89489d14d48942a7_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtNy0xLTEtNTAzNDg_eab20bc6-0f94-435c-a4e1-e2f191a4bee5">1,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96fbfda562ed4251a1b2805e02ad7a13_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtOS0xLTEtNTAzNDg_8449fde7-b116-4ae5-95bf-64a425329f5f">486,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce25123e7d14a9b9e92dd7ef27fe5d7_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtMTEtMS0xLTUwMzQ4_4f7c390a-d719-46a7-8bb9-e2c00903f465">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtMTMtMS0xLTUwMzQ4_bb33ba40-8777-4c2c-93c4-a10e45f53481">472,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:0pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.965%"><tr><td style="width:1.0%"></td><td style="width:32.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ef202afe8ee4eb29a4286d1984f00e7_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC0xLTEtMS00OTc5OA_94b3ff50-fc30-4daa-bd72-680ceb50e702">41,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef202afe8ee4eb29a4286d1984f00e7_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC0zLTEtMS00OTc5OA_57a0f1d1-88b6-418c-a763-637f63396eab">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided707c746324c85b99713cfd1f60a31_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC01LTEtMS00OTc5OA_fb9c58ad-e2f5-4b6c-a6ff-063278da9898">519,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d6b1d603f9454bada2bf2d6fdaa5c1_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC03LTEtMS00OTc5OA_41c65090-9920-46f6-b20f-3c4ebf75f08c">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21f5e3fdc0fe4e9abfb1657db69da8bd_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC05LTEtMS00OTc5OA_23130692-a437-475e-bc9c-14c493ec2856">250,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ee52788a39497ba42814448e5acd22_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC0xMS0xLTEtNDk3OTg_113a7ecb-8066-4624-ac7d-368fad450b32">24,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6308a92c792f4032aaf192b33d9c615d_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC0xMy0xLTEtNDk3OTg_0cf57487-a6fc-4484-b3bf-fe6215838cd5">292,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3fd0d327c647f78519c288eabd7f13_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNS01LTEtMS00OTc5OA_57e35639-3291-4143-9856-6f8db7e52d11">9,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNS0xMy0xLTEtNDk3OTg_620ab4b2-94b7-479b-89dc-ac535b33bec2">9,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347024f2e9ac451aa83164fdbd8d84fb_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNi03LTEtMS00OTc5OA_b38b1bf1-94a3-4b3b-a1c5-70c3dfdafaf7">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNi0xMy0xLTEtNDk3OTg_5cf4ccb8-4852-4f9d-b19f-296a6c0d5486">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with restricted stock unit vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbd060dd7d6d4fdaacff3da2f0e05098_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfOC0xLTEtMS00OTc5OA_6583fbfb-702d-41bb-b8af-7b31bb923b0b">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbd060dd7d6d4fdaacff3da2f0e05098_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfOC0xLTEtMS01MDU5OA_e966a871-f7bc-4979-b52b-794afd0c8b02">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3fd0d327c647f78519c288eabd7f13_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfOC01LTEtMS01MDU5OA_d401fe8c-1fd4-4941-8f4e-762a780809d8">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfOC0xMy0xLTEtNTA1OTg_f2b184f1-acad-4309-a7f3-65d5e6f896cd">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icbd060dd7d6d4fdaacff3da2f0e05098_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfOS0xLTEtMS01MDU5OA_11ddaca9-515f-4cc6-aaaa-a4556fdecdb0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81639f8b21714c96a90b50f632406ac7_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTMtMTEtMS0xLTQ5Nzk4_8ad4b549-e13b-4328-9836-863a7daec747">488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTMtMTMtMS0xLTQ5Nzk4_26d58d5e-9573-47d7-862d-13e9da270a8d">488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bd2f39625b8425cb7b9aff6a3b1ad28_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTQtOS0xLTEtNDk3OTg_52ca8f3d-f31b-4ce2-b0b7-5ea6bf6e9cd9">54,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTQtMTMtMS0xLTQ5Nzk4_bc15cff6-1549-47e6-abbb-38dc1033b701">54,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia20e533d81cd4d089a7df4436d153672_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtMS0xLTEtNDk3OTg_2d041c1b-398e-46c9-90f4-0131f17bdc18">41,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia20e533d81cd4d089a7df4436d153672_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtMy0xLTEtNDk3OTg_73d211ca-66d6-4ab8-b796-a477544e4f19">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3cda99f88cd4c479dc77d9d5c051b50_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtNS0xLTEtNDk3OTg_fe623a8f-e0e5-4ce5-b014-fb7e59e836d9">529,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21514c2c23bb4db989a9c7ce3badc7fd_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtNy0xLTEtNDk3OTg_0e36daf3-4f79-4bbe-bf2c-f8dc91f1064a">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7db1887be0d42278bf24dd6a2ec6df7_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtOS0xLTEtNDk3OTg_e79abfd6-e983-4e86-873b-0a7a8dd83ae2">305,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ccef6083cd4247a6cad6d8beaa3058_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtMTEtMS0xLTQ5Nzk4_88ff80d7-9a81-41f5-8333-d57388ed7a87">23,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtMTMtMS0xLTQ5Nzk4_dd9cf782-b56f-4915-9653-d5d3cda94e44">247,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.965%"><tr><td style="width:1.0%"></td><td style="width:32.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5299c81f26ad457bb9835f9d797f5a03_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC0xLTEtMS01MDYwOQ_87687dba-99e6-48a9-8fb0-10a1081702f9">41,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5299c81f26ad457bb9835f9d797f5a03_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC0zLTEtMS01MDYwOQ_8133000d-8681-435e-8b3b-bb9d0f42659f">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eeadd6ca63a4a009a94aec18e5f62ad_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC01LTEtMS01MDYwOQ_d0bc4ece-dc31-4515-b724-8aedd8ad19a5">509,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ff54a3aa3044e380b7048409865567_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC03LTEtMS01MDYwOQ_6cd19a2f-0733-41dd-9a7e-91c77f08c798">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03477a9c65e34b128f96193a6cb1c953_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC05LTEtMS01MDYwOQ_1df09299-03ef-4c36-bdf5-61dd4ecd3029">200,834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad53b504c7e14abca92ca74a46a07bbd_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC0xMS0xLTEtNTA2MDk_ebdc2b9c-8bc5-4060-be06-d833edebabb1">24,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea2c4236a736402f8b183ddfe915fbac_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC0xMy0xLTEtNTA2MDk_a7d8825b-52c4-4046-af09-916e5cc5615a">333,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace2148088e643e387d7d86483ae4b8d_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNS01LTEtMS01MDYwOQ_1cd98187-b5e7-49d4-a1a6-1cc2f1058188">19,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNS0xMy0xLTEtNTA2MDk_01411a8d-6805-49a4-bf0f-d1b8990b5e12">19,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie52aa73782a849fdaecd219b51650553_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNi03LTEtMS01MDYwOQ_f0ff3292-c11c-46fa-9db3-a3493d3d8ae2">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNi0xMy0xLTEtNTA2MDk_3872930a-3177-4ec5-9e4b-2df79f8b0518">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with restricted stock unit vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9542e31388864d3fa1e1d2fdc142b92d_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNy0xLTEtMS01MDYwOQ_2895183a-e025-4df4-bc99-b36efe11f048">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9542e31388864d3fa1e1d2fdc142b92d_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfOC0xLTEtMS01MDYwOQ_625efd5c-ee7f-4297-be5d-e30fc5f32a94">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace2148088e643e387d7d86483ae4b8d_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfOC01LTEtMS01MDYwOQ_18637ed6-0a2d-4d6c-bca5-ec2276013bb1">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfOC0xMy0xLTEtNTA2MDk_e0b43b9f-be0c-4c91-a2f8-fa91db19527f">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9542e31388864d3fa1e1d2fdc142b92d_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfOS0xLTEtMS01MDYwOQ_4d648886-4286-4dba-9a5e-93ee7cbf4c30">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7f89106493a4483a75fab892a90d82f_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTAtMTEtMS0xLTUwNjA5_6ff5f155-417c-4766-827e-368d8c734837">1,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTAtMTMtMS0xLTUwNjA5_4f997e53-9c24-4f0f-bae4-3d648a82db85">1,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dc3ef43b05d4b4dab34c1ceec3046b9_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTEtOS0xLTEtNTA2MDk_76cb49ad-4c89-4034-bed6-8503e7378095">104,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTEtMTMtMS0xLTUwNjA5_739968b3-ffa6-422b-bc39-1faf28f90bbd">104,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia20e533d81cd4d089a7df4436d153672_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItMS0xLTEtNTA2MDk_524340c2-d05c-40a6-953f-1cb406e63342">41,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia20e533d81cd4d089a7df4436d153672_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItMy0xLTEtNTA2MDk_19df5e51-6ef1-44a2-adb5-92078426b96d">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3cda99f88cd4c479dc77d9d5c051b50_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItNS0xLTEtNTA2MDk_ddc905b8-e0be-4570-a3cf-270159b0938f">529,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21514c2c23bb4db989a9c7ce3badc7fd_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItNy0xLTEtNTA2MDk_41260b83-5dc7-4c89-956f-e775adb7da15">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7db1887be0d42278bf24dd6a2ec6df7_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItOS0xLTEtNTA2MDk_6772b32a-45f2-4e1a-8923-35bcbd3b0a11">305,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ccef6083cd4247a6cad6d8beaa3058_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItMTEtMS0xLTUwNjA5_6b9c7b50-145d-42c8-bc34-74847a956f67">23,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItMTMtMS0xLTUwNjA5_804ec0f0-f36f-476f-ada2-fefc55a81b5e">247,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i24da124e87454cab95fd92a2627099ed_40"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80MC9mcmFnOmY3MWExOGYxMjVlYzRmOWZhZmE2YWJjNmMzZGI1MjQ5L3RleHRyZWdpb246ZjcxYTE4ZjEyNWVjNGY5ZmFmYTZhYmM2YzNkYjUyNDlfMTEwNg_fa37e7c2-e298-4803-99f9-80a4ee0cfaf5" continuedAt="i93363198ab9c4acba7c3fbf7b4e8b66d" escape="true">Organization and Business</ix:nonNumeric></span></div><ix:continuation id="i93363198ab9c4acba7c3fbf7b4e8b66d" continuedAt="id773b2bb90394f11931e79924f86a3c5"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zentalis Pharmaceuticals, Inc. (&#8220;Zentalis&#8221;, &#8220;We&#8221; or the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#8217;s tangible assets are held in the United States.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div></ix:continuation><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id773b2bb90394f11931e79924f86a3c5">Substantial doubt about an entity&#8217;s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after the date that the interim unaudited condensed consolidated financial statements for the quarter ended June&#160;30, 2022 are issued.</ix:continuation> </span></div><div id="i24da124e87454cab95fd92a2627099ed_43"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80My9mcmFnOmZjNjZiZDZkMmMyMDRiY2ZiN2E0YmY5YWE1YTFiNmUzL3RleHRyZWdpb246ZmM2NmJkNmQyYzIwNGJjZmI3YTRiZjlhYTVhMWI2ZTNfMzk0Mg_159c5421-8cb0-44c6-9d10-894c6979cf87" continuedAt="ib264c65a33004e0a8c169480b61cd8bf" escape="true">Interim Unaudited Financial Statements </ix:nonNumeric></span></div><ix:continuation id="ib264c65a33004e0a8c169480b61cd8bf" continuedAt="i2dff5d7ba7c946f8b67fa7e1261e82c1"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80My9mcmFnOmZjNjZiZDZkMmMyMDRiY2ZiN2E0YmY5YWE1YTFiNmUzL3RleHRyZWdpb246ZmM2NmJkNmQyYzIwNGJjZmI3YTRiZjlhYTVhMWI2ZTNfMzk0MA_d074c3b3-ddbe-4d8c-a229-679c4a92ad3b" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company&#8217;s audited financial statements but does not include all disclosures required by U.S. GAAP. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February 24, 2022. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated balance sheet to conform to the current period presentation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80My9mcmFnOmZjNjZiZDZkMmMyMDRiY2ZiN2E0YmY5YWE1YTFiNmUzL3RleHRyZWdpb246ZmM2NmJkNmQyYzIwNGJjZmI3YTRiZjlhYTVhMWI2ZTNfMzkzNg_9a151337-d2ee-4457-8732-5fbd6ba6bc51" continuedAt="i9ced4aac732c4e70806dea11223825d9" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements include our wholly-owned subsidiaries and variable interest entities (&#8220;VIEs&#8221;) for the periods in which we determined we were the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1)&#160;the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2)&#160;the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="i2dff5d7ba7c946f8b67fa7e1261e82c1"><ix:continuation id="i9ced4aac732c4e70806dea11223825d9"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented, we have not provided any other material financial or other support to our VIEs that we were not contractually required to provide.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity method is used to account for investments in which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded on the balance sheet, and the share of net income or losses of equity investments is recognized on a one quarter lag in investment and other income (expense), net.</span></div></ix:continuation><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80My9mcmFnOmZjNjZiZDZkMmMyMDRiY2ZiN2E0YmY5YWE1YTFiNmUzL3RleHRyZWdpb246ZmM2NmJkNmQyYzIwNGJjZmI3YTRiZjlhYTVhMWI2ZTNfMzk0MQ_a016eb28-6a9b-488e-bc34-bcd2dc9ae5db" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div></ix:continuation><div id="i24da124e87454cab95fd92a2627099ed_46"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfNDM5NQ_ae09adce-5c53-4337-b56e-6b6b17e2a0a4" continuedAt="i0697f8dcd8c14ca3bc3993758c2fa476" escape="true">Significant Transactions</ix:nonNumeric></span></div><ix:continuation id="i0697f8dcd8c14ca3bc3993758c2fa476" continuedAt="ia882319d4dad4b0582a74fc666068600"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentera Therapeutics</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we became a majority common shareholder of Zentera Therapeutics, Ltd., a Shanghai-based clinical-stage biopharmaceutical company focused on developing cancer therapeutics (&#8220;Zentera&#8221;), concurrent with its Series A convertible preferred stock offering. The financial position and results of operations of Zentera were included in our consolidated financial statements from the date of the initial investment as a result of our control of the entity and our determination that we were the primary beneficiary of Zentera. In July 2021, Zentera completed a Series B convertible preferred stock offering which diluted our investment to a position of less than majority owned. Upon review of the facts and circumstances, together with the authoritative accounting literature, we determined that while Zentera is a VIE, consolidation of Zentera is no longer appropriate. After the July 2021 Series B convertible preferred offering in which we did not participate, our review concluded that we ceased to be the primary beneficiary of Zentera as our equity ownership was reduced and changes were made to the corporate governance of Zentera. As a result, we no longer individually have the ability to direct the activities that most significantly impact Zentera's economic performance. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in July 2021, the financial position and results of operations of Zentera are no longer included in our consolidated financial statements. During the period of deconsolidation we measured the fair value of our retained investment in Zentera using the backsolve method with consideration for a lack of marketability. An equity method investment of $<ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfMTcwMA_1378a5a7-7955-4f0f-b258-d000d66b0aec">30.4</ix:nonFraction> million is recorded on our balance sheet at June&#160;30, 2022. This amount represents our maximum exposure to loss as a result of our involvement with Zentera. A deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="if476a59e1bdc46f883f2c9950f451fe9_I20220630" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfMTg4OA_fde3f5c3-0120-4310-8226-55ce5097b0d9">6.4</ix:nonFraction> million representing the tax impact of the unrealized gain on deconsolidation is recorded on our balance sheet at June&#160;30, 2022. A gain of $<ix:nonFraction unitRef="usd" contextRef="i6e26a8f313d147c899372ec9a56c6c9f_D20210101-20211231" decimals="-5" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfMjAzMQ_035ebe59-fbbd-4c43-90df-fca6dec844b6">51.6</ix:nonFraction> million, measured as the difference between the fair value of our retained noncontrolling interest together with the carrying amount of the Zentera noncontrolling interest, and the carrying amount of Zentera&#8217;s assets and liabilities was recognized during the year ended December 31, 2021. The difference between the carrying amount of our investment in Zentera and our portion of the Zentera net assets was $<ix:nonFraction unitRef="usd" contextRef="if476a59e1bdc46f883f2c9950f451fe9_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfMjQ0MQ_d607572c-1b89-4e15-af6c-4911a16293da">5.2</ix:nonFraction> million as of </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="ia882319d4dad4b0582a74fc666068600"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022. This difference is accounted for in our equity method investment analogous to in-process research and development. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2020, each of our subsidiaries Zeno Alpha, Inc., K-Group Alpha, Inc., Zeno Management Inc., and K-Group Beta, Inc. entered into a collaboration and royalty-bearing license agreement with Zentera, which we refer to as the &#8220;Zentera Sublicenses,&#8221; pursuant to which we collaborate with Zentera on the development and commercialization of ZN-c3, ZN-d5 and ZN-c5, collectively referred to as the &#8220;Collaboration Products,&#8221; respectively, in the People&#8217;s Republic of China, Macau, Hong Kong and Taiwan, which is referred to as the &#8220;Zentera Collaboration Territory.&#8221; Under each Zentera Sublicense, Zentera will lead development, and upon regulatory approval, the commercialization, of the collaboration products in the Zentera Collaboration Territory.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Zentera Sublicenses, Zentera is responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of the costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Prior to the deconsolidation of Zentera in July 2021, these costs were eliminated in consolidation. For the three and six months ended June&#160;30, 2022, the amounts incurred under this arrangement totaled $<ix:nonFraction unitRef="usd" contextRef="i28f7d3ab172046598fe7dcdf7ffe8f23_D20220401-20220630" decimals="-5" name="zntl:ResearchAndDevelopmentExpenseReimbursements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfNTQ5NzU1ODE4MzYy_8fbab07a-b60c-4c49-8f38-d1e60bf0bff0">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iebb85fbd06c842c9b31131732a081288_D20220101-20220630" decimals="-5" name="zntl:ResearchAndDevelopmentExpenseReimbursements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfNDAwMQ_7212ec47-ecec-4c18-a5a9-b0b0c3ba97dd">5.1</ix:nonFraction> million, respectively, and are presented as contra-research and development expense in the unaudited condensed consolidated statement of operations. A corresponding receivable is recorded within prepaid expenses and other current assets on the unaudited condensed consolidated balance sheet. We have not provided material financial or other support to Zentera during the periods ended June&#160;30, 2022 and 2021 that was not previously contractually required.</span></div></ix:continuation><div id="i24da124e87454cab95fd92a2627099ed_49"></div><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RleHRyZWdpb246NzYzOTIwNjNlMTJkNDBlMmFiNzY1NTRkMjdjZmU4NDZfMTgxNQ_da4fc176-100e-494b-ab51-2c71d47f372e" continuedAt="i284e4df83e4f4a3e8d2abf1bb6e6b101" escape="true">Business Combinations</ix:nonNumeric></span></div><ix:continuation id="i284e4df83e4f4a3e8d2abf1bb6e6b101" continuedAt="idc116a4a76b64d80a466f940b152a835"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kalyra Pharmaceuticals, Inc.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;21, 2017, we acquired $<ix:nonFraction unitRef="usd" contextRef="i7de358016f734a82a094e8ea4e3ef006_D20171221-20171221" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RleHRyZWdpb246NzYzOTIwNjNlMTJkNDBlMmFiNzY1NTRkMjdjZmU4NDZfOTQ_fd632e46-0a5b-4cfd-adae-945dc7c93aa6">4.5</ix:nonFraction>&#160;million of Kalyra&#8217;s Series B Preferred Stock representing a <ix:nonFraction unitRef="number" contextRef="i8d7db02ca8a24de29d50872ad8205e42_I20171221" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RleHRyZWdpb246NzYzOTIwNjNlMTJkNDBlMmFiNzY1NTRkMjdjZmU4NDZfMTQ5_725291f5-26a0-4561-a8ce-b6dae989830a">25</ix:nonFraction>% equity interest in Kalyra for purposes of entering the analgesics therapeutic research space. The acquisition price was paid entirely in cash.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the authoritative guidance, we concluded that Kalyra is a business consisting of inputs, employees, intellectual property and processes capable of producing outputs. Additionally, we have concluded that Kalyra is a variable interest entity, we are the primary beneficiary and have the power to direct the activities that most significantly affect Kalyra&#8217;s economic performance through common management and our board representation. Prior to December 21, 2017, the Company and Kalyra transacted for the delivery of research and development services and support. The financial position and results of operations of Kalyra have been included in our consolidated financial statements from the date of the initial investment.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant with authoritative guidance, we have recorded the identifiable assets, liabilities and noncontrolling interests in the VIE at their fair value upon initial consolidation. The identified goodwill is comprised of the workforce and expected synergies from combining the entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otal assets and liabilities of Kalyra as of June&#160;30, 2022 and December&#160;31, 2021 are immaterial. The liabilities recognized as a result of consolidating Kalyra do not </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="idc116a4a76b64d80a466f940b152a835"><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represent additional claims on our general assets. Pursuant to the authoritative guidance, the equity interest in Kalyra not owned by Zentalis is reported as a noncontrolling interest on our condensed consolidated balance sheets.</span></div><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="zntl:ReconciliationOfNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RleHRyZWdpb246NzYzOTIwNjNlMTJkNDBlMmFiNzY1NTRkMjdjZmU4NDZfMTgxNA_555a79d2-d620-4202-ab0f-553fb55a9c24" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24bd10e6cc1406aa94762219ea0191d_I20211231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfMi0xLTEtMS00OTc5OA_a1d13ded-e42c-4963-beee-e96fef6b13a0">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46207b8cc83c4695ab95cd14b58c03ca_I20201231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfMi0zLTEtMS00OTc5OA_d0aa1a3e-50ea-4c77-b173-4a6cdd452c46">24,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73d19273bd804eacb01818f0b3a0b9d6_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfMy0xLTEtMS00OTc5OA_918884c7-4e30-434c-93b9-d98fc10fc6e7">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00284ea6567450d9a07b5d0bfc0d9e5_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfMy0zLTEtMS00OTc5OA_320ba166-68b3-4151-a1d5-1f863b97b892">7,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of Zentera</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73d19273bd804eacb01818f0b3a0b9d6_D20220101-20220630" decimals="-3" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfNS0xLTEtMS00OTc5OA_0ca3017f-1ba1-4836-add8-2071cf731274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00284ea6567450d9a07b5d0bfc0d9e5_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfNS0zLTEtMS00OTc5OA_ba108c48-1501-4d41-9fa1-0ba409e5c16c">16,899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28e2c6f83d847d8be4563b4c9a90eb4_I20220630" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfNy0xLTEtMS00OTc5OA_e52f4a42-971d-41dc-b588-f621191ada1f">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24bd10e6cc1406aa94762219ea0191d_I20211231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfNy0zLTEtMS00OTc5OA_508eab8c-33b0-4af8-b136-721d6fc1380a">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i24da124e87454cab95fd92a2627099ed_52"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMTUwNg_3cff8009-1ec4-4020-86d1-981309e9eda1" continuedAt="iafea6a2676da44e5ae00485d3d746376" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><ix:continuation id="iafea6a2676da44e5ae00485d3d746376" continuedAt="i4a2883345d9f41f090ba1414ae79761f"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMTUwNw_d3138255-87e5-4f73-9567-e81f9be461d4" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40490dd28724db79d06f9d951fd8acd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMi0xLTEtMS00OTc5OA_bf97fc13-2197-4273-96ad-dbcfea7ca61c">255,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40490dd28724db79d06f9d951fd8acd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMi0zLTEtMS00OTc5OA_4a45a11f-c3b2-4517-9a5c-0c50b6546d6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id40490dd28724db79d06f9d951fd8acd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMi01LTEtMS00OTc5OA_3288dc94-39bf-4682-b0cf-cd78d50f6d7a">763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40490dd28724db79d06f9d951fd8acd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMi03LTEtMS00OTc5OA_7d82981a-9160-473c-9a31-a68a61c07a7e">255,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08925ab72244888b246b83bf82d4bed_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMy0xLTEtMS00OTc5OA_7310900e-4f9c-477b-8f20-b7fd1fb99b8a">5,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08925ab72244888b246b83bf82d4bed_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMy0zLTEtMS00OTc5OA_66862544-d48c-434c-bb3d-1b36465e40af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia08925ab72244888b246b83bf82d4bed_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMy01LTEtMS00OTc5OA_ddf1b269-cec7-419b-a6e7-8449dd997563">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08925ab72244888b246b83bf82d4bed_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMy03LTEtMS00OTc5OA_d0d234eb-2db9-4465-a731-bb89390699e9">5,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c97d107fb94103966853f5642d3a1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNC0xLTEtMS00OTc5OA_cc810d46-f73c-459e-9123-420c21cd51bf">18,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c97d107fb94103966853f5642d3a1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNC0zLTEtMS00OTc5OA_381ff617-d740-41d3-8535-80542afc0849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15c97d107fb94103966853f5642d3a1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNC01LTEtMS00OTc5OA_45bbc97b-fca0-458f-9870-ce10f1c4bafc">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c97d107fb94103966853f5642d3a1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNC03LTEtMS00OTc5OA_6d884fc8-2483-4e21-8286-1da37ec6a883">18,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383f5a4611ed4191a940e97fba342d26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNS0xLTEtMS00OTc5OA_8b36359d-fd39-4a33-828b-43e81b4df0dd">121,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383f5a4611ed4191a940e97fba342d26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNS0zLTEtMS00OTc5OA_2efa04d9-46ec-4d0c-81e7-fc9a91d54abd">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i383f5a4611ed4191a940e97fba342d26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNS01LTEtMS00OTc5OA_b997db5e-b8d4-4c4b-9dde-03ad01b300a7">881</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383f5a4611ed4191a940e97fba342d26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNS03LTEtMS00OTc5OA_d060a578-b2c4-4a9f-b99b-9ef8b7d9ce05">121,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNi0xLTEtMS00OTc5OA_3ab49c55-cec9-4643-a1eb-04a7c35f1618">401,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNi0zLTEtMS00OTc5OA_c54d2fec-15aa-4561-8af7-b297c99e834c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNi01LTEtMS00OTc5OA_c8973600-0f1c-414d-9dd6-3e6ed1307b97">1,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNi03LTEtMS00OTc5OA_55f73b65-cbd1-4e6f-8aa1-69793c057a33">400,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMi0xLTEtMS00OTc5OA_fc4c6952-f6f7-49db-9b77-1d6ff76a3445">199,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMi0zLTEtMS00OTc5OA_c56271a2-3a16-4bea-b609-6c07db8997bb">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMi01LTEtMS00OTc5OA_3c2dea33-ef45-452a-8bc6-54dbdaaf9f9d">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMi03LTEtMS00OTc5OA_43c0ce49-c5a7-4324-995d-253f4b2ecdf5">199,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a784f336c5848288d83ed9d20e70b9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMy0xLTEtMS00OTc5OA_b6caf217-e22f-424e-8eaa-238a74efc0a1">10,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a784f336c5848288d83ed9d20e70b9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMy0zLTEtMS00OTc5OA_7993f670-8a4d-47ff-9770-18f262e07146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a784f336c5848288d83ed9d20e70b9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMy01LTEtMS00OTc5OA_2ee3db2b-cef9-4079-885c-f873a34d6e22">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a784f336c5848288d83ed9d20e70b9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMy03LTEtMS00OTc5OA_a5fa4120-eff9-4853-a89a-4c674996f980">10,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110e2b4c6b064ff1879c74f20d1b098c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNC0xLTEtMS00OTc5OA_d8306008-19ea-4d2f-bf10-661ba6cb7fab">20,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110e2b4c6b064ff1879c74f20d1b098c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNC0zLTEtMS00OTc5OA_5e89d35f-bdcf-49e5-a1fe-18c4277c7a25">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110e2b4c6b064ff1879c74f20d1b098c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNC01LTEtMS00OTc5OA_775c00d1-77c4-4fe3-b059-2f90c9c64811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110e2b4c6b064ff1879c74f20d1b098c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNC03LTEtMS00OTc5OA_25c36601-50c8-42fe-b643-8f4734f8f04d">20,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49279cde51c4e31967f61ac9e91cb63_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNS0xLTEtMS00OTc5OA_09d033d3-da78-419c-a9a8-72db73af3cb9">50,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49279cde51c4e31967f61ac9e91cb63_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNS0zLTEtMS00OTc5OA_15380b9a-5344-4e6d-b72f-cf944e9b1f11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if49279cde51c4e31967f61ac9e91cb63_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNS01LTEtMS00OTc5OA_fcc90a26-c7b3-47ae-acf8-c3d0d8ad77ba">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49279cde51c4e31967f61ac9e91cb63_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNS03LTEtMS00OTc5OA_2ce3ba11-a7fd-436e-acd2-6a682dff88e8">50,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNi0xLTEtMS00OTc5OA_da1a16c9-fe92-426c-9c3c-7624fe986a2a">280,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNi0zLTEtMS00OTc5OA_c7013219-d611-4850-bb0c-a2066de8cfd3">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNi01LTEtMS00OTc5OA_573d9344-2297-4fef-b789-c37a4aa97a81">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNi03LTEtMS00OTc5OA_9ac258ba-0a50-4ee0-b1b8-f117e644f3db">280,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June&#160;30, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="security" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMTQx_eb397ded-1851-4a02-9e81-f05f892a975b">sixty-two</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of our available-for-sale debt securities with a fair market value of $<ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-5" name="us-gaap:TradingSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMjE0_ee84a83c-2c9c-45b3-b91c-1eaf3b6530ca">399.2</ix:nonFraction> million were in a gross unrealized loss position of $<ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMjY5_d19405b2-2be8-42ce-ac02-818a91f0ca1f">1.8</ix:nonFraction> million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, our intent to sell or the likelihood that we would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of June&#160;30, 2022, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="i4a2883345d9f41f090ba1414ae79761f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">because we do not intend to sell these securities, and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMTUwMw_b9c6f435-473a-4d2a-aa43-e16a61a04a98" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.044%"><tr><td style="width:1.0%"></td><td style="width:51.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.256%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfMy0xLTEtMS00OTc5OA_856f57ca-58d9-48cb-90cc-7da1ed7e5e1a">396,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfMy0zLTEtMS00OTc5OA_7d74c334-ad6e-4f58-9813-d6fa9fb93891">258,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one but within five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfNC0xLTEtMS00OTc5OA_9eb3e57f-4b4a-423a-b973-277bfa56d738">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfNC0zLTEtMS00OTc5OA_14686d89-42c1-47d2-88f8-dc419ebb0cb2">21,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfNS0xLTEtMS00OTc5OA_9f2c307b-eab3-4cac-8643-9a4a7c5d0846">400,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfNS0zLTEtMS00OTc5OA_0089c5b0-e18d-4599-8fd1-285ca0da7bb4">280,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMTUwNA_516ddf83-466f-4b18-a2d9-7446051fafba" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:19.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ff574a6987485e9ac601606fe4d9da_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy0xLTEtMS00OTc5OA_6b9f7286-df32-492d-931f-7520bcd74e4d">30,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb9f2afeb6f4a43b04688b32531d990_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy0zLTEtMS00OTc5OA_1acc433b-492d-483f-9b1c-46649731b5e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1dd88afc154d7e9984607fd2f2361f_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy01LTEtMS00OTc5OA_abe39f91-08c6-4820-b532-8237e0fac037">30,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic005cf5c954c4ba5a5ccbadc693d99df_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy03LTEtMS00OTc5OA_e4932339-87d3-4fd0-a5ba-3c0f539ba05a">43,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c59b2bf1e764cc0a86c5735a369a0b5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy05LTEtMS00OTc5OA_e3ab148b-9b73-4e95-85ef-2d153898eebe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e3c115b00a44bcb25b3dfd9e2e39bb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy0xMS0xLTEtNDk3OTg_5e967e6a-1e1b-45b8-945a-9a5f45cffb52">43,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1784ad3c83464579a9a8932fbfe9e598_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC0xLTEtMS00OTc5OA_c3cef3d9-b7d7-4a77-a4dd-73220b497397">18,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3761f588efbc4816ae10a0d889c298a0_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC0zLTEtMS00OTc5OA_fe5d9d7a-c695-4542-9295-b79b2a3da57d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57dc0a40165448f8bf4b5ba74eb5fbe9_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC01LTEtMS00OTc5OA_015c75ad-8534-43f4-b959-2d4dbf23a5a5">18,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46288b24c23d45c4a2463d010ab350b2_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC03LTEtMS00OTc5OA_bd059bf4-219b-481c-be31-33c22f25356d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608e66c1af484e6ea5e6d792778ed0d4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC05LTEtMS00OTc5OA_c65c8aa2-d16d-4979-a47d-7286ddf7e6e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00cfbef488eb418e92919ac20ba1da40_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC0xMS0xLTEtNDk3OTg_00686dbe-04fc-472c-83f3-9a9d037db61c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie217c38e068b4202a61b214386647f10_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS0xLTEtMS00OTc5OA_63271cbf-0bcc-4756-a354-c90420626546">49,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2698997899df495f800f9a30eeb074a9_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS0zLTEtMS00OTc5OA_0f7f2c80-7840-40ac-a639-0d7edcd61470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS01LTEtMS00OTc5OA_2c25bbd0-ffd1-4db9-8176-5a6492711f84">49,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69616f0679f42df9238c4e3b6a87d27_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS03LTEtMS00OTc5OA_be46464c-d01b-482d-9ade-487861da9962">43,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b1bda2786c420f874b7c2291657c6b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS05LTEtMS00OTc5OA_007183b5-ea43-4207-bc9f-6cabbcf176b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS0xMS0xLTEtNDk3OTg_e648f08c-8b71-43fc-9035-555c4b4799d9">43,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039e0cbb5b7c4c79b65983450a20902b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC0xLTEtMS00OTc5OA_0563fbab-cba5-4947-a4d3-ed21752db37c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81d064eadd4c7bbc89294f9f777699_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC0zLTEtMS00OTc5OA_64caf512-9136-46df-9f7f-cd2662e2ed04">255,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40490dd28724db79d06f9d951fd8acd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC01LTEtMS00OTc5OA_79836a32-d254-49a6-900f-27262ba68fa8">255,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86dee2bcbeca454481688921ef7935de_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC03LTEtMS00OTc5OA_18693ae0-9ea3-4b64-8fc7-040af2e3527d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c31a2718ae40079432589bc1229566_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC05LTEtMS00OTc5OA_4de3fa5a-94f4-4fe5-aed4-31e63c8a9b5f">199,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC0xMS0xLTEtNDk3OTg_b3073666-2065-438f-8d17-3c77d3704d6a">199,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41189229a4bd4e0caa35a0023153383e_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS0xLTEtMS00OTc5OA_d6788bff-ff25-4658-8b5f-54a4e8bf1dc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e4123972044834800ac21f54e63593_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS0zLTEtMS00OTc5OA_0a58146b-fecf-4b32-a6f6-098fe21e4f34">5,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08925ab72244888b246b83bf82d4bed_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS01LTEtMS00OTc5OA_8fac47f6-c47e-4260-a3c6-41ca1fd4d877">5,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba6229d21df445539c2d6bf8fb6643fe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS03LTEtMS00OTc5OA_edd778d5-70ee-4032-a409-2239ca64ddc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc8555322b941b49bd02a7e8765116e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS05LTEtMS00OTc5OA_974c5ece-b7a5-4cac-a2d5-7d3e19641023">10,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a784f336c5848288d83ed9d20e70b9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS0xMS0xLTEtNDk3OTg_d8d0daa7-8497-404b-bedb-1019faa1c397">10,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f5fb8ff10c4cf1bb7736f876b4d48e_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtMS0xLTEtNDk3OTg_dd2bd7c3-406e-41af-88e9-bb02686cd075">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9278009b9182442fbf3eb96697bd192b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtMy0xLTEtNDk3OTg_193ae3c1-b610-4b6c-8b81-50a04c876004">18,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c97d107fb94103966853f5642d3a1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtNS0xLTEtNDk3OTg_8dc31691-601b-4ea0-a683-68f4fbafe545">18,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7014a45299de49eaa9a9df4f081d723f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtNy0xLTEtNDk3OTg_d207de64-fe06-4804-a4dc-ed6ede5ef98c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31315f6337ae4500b1642edc83c1261b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtOS0xLTEtNDk3OTg_6fcb67bd-4ad2-400d-9a44-407e17fab477">20,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110e2b4c6b064ff1879c74f20d1b098c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtMTEtMS0xLTQ5Nzk4_1cd0f672-3391-4f0f-b5ab-cc2e6d2bac62">20,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c66ad195194fe2b48c0fbe96882389_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtMS0xLTEtNDk3OTg_c0511a5d-d758-4143-9197-31fe83fa7881">121,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1017f13dbbd0440db64ac087de0a0e59_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtMy0xLTEtNDk3OTg_467a1dbd-1485-4271-902b-8a36455499f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383f5a4611ed4191a940e97fba342d26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtNS0xLTEtNDk3OTg_998988b7-6ed9-4e9d-8a1e-ee295fba1e33">121,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27efde771a3e4e359c95a3ae8018c908_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtNy0xLTEtNDk3OTg_91455be1-de52-42fa-b044-a8645313de78">50,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa741359e4446b9920193e9ce94fa0f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtOS0xLTEtNDk3OTg_d9ad6861-791d-4763-9f40-95b6f71dbf63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49279cde51c4e31967f61ac9e91cb63_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtMTEtMS0xLTQ5Nzk4_9c770962-39ff-4e68-b8b7-6d57bb32cac9">50,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale marketable securities:</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie217c38e068b4202a61b214386647f10_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItMS0xLTEtNDk3OTg_21fb7ebf-0658-4189-b602-ab27d7b4809b">121,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2698997899df495f800f9a30eeb074a9_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItMy0xLTEtNDk3OTg_caca9f13-d6e1-4140-8758-58b66fff5ba6">279,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItNS0xLTEtNDk3OTg_466d3ca3-fba8-4992-8893-bd5be43e9bfc">400,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69616f0679f42df9238c4e3b6a87d27_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItNy0xLTEtNDk3OTg_1aff6a2d-d211-4f12-add5-c7ac1488a12d">50,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b1bda2786c420f874b7c2291657c6b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItOS0xLTEtNDk3OTg_96b66350-e5fb-4df9-a865-c9743d8c424b">229,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItMTEtMS0xLTQ5Nzk4_c53c59cc-69b3-4236-94d0-c60320e34f11">280,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value<br/></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie217c38e068b4202a61b214386647f10_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtMS0xLTEtNDk3OTg_e7926379-17cd-40d1-9f9e-4037638274f4">170,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2698997899df495f800f9a30eeb074a9_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtMy0xLTEtNDk3OTg_fff78a26-e411-4c96-85fc-faacb330afc4">279,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtNS0xLTEtNDk3OTg_5982fd01-056d-42c5-8b30-7e99df9095fe">449,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69616f0679f42df9238c4e3b6a87d27_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtNy0xLTEtNDk3OTg_a25a2377-c9fe-42ac-961e-e0f24f8e9e53">94,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b1bda2786c420f874b7c2291657c6b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtOS0xLTEtNDk3OTg_9db5527e-d4d5-4ed4-901b-eb0a06e22486">229,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtMTEtMS0xLTQ5Nzk4_52c4b4f7-d2b2-495a-8967-288b85f1df72">323,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy during the six months ended June&#160;30, 2022. We had no instruments that were classified within Level&#160;3 as of June&#160;30, 2022 or December&#160;31, 2021.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:OtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RleHRyZWdpb246M2I4Y2I3MzZjMjU4NDYzNDhiNjAyNGNlODhiZWJjNmJfMTIw_85a53211-6a28-4c42-b2d8-ecdbac2bab8f" continuedAt="iebee3cd099c348fbaf3371746a842c0c" escape="true">Prepaid Expenses and Other Assets</ix:nonNumeric></span></div><ix:continuation id="iebee3cd099c348fbaf3371746a842c0c"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RleHRyZWdpb246M2I4Y2I3MzZjMjU4NDYzNDhiNjAyNGNlODhiZWJjNmJfMTIx_d70cd23d-ed71-4ea2-a8cd-bce8217487e1" escape="true"><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMi0xLTEtMS00OTc5OA_d15d4690-7e78-4a8b-8f25-2fe125094ca9">2,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMi0zLTEtMS00OTc5OA_3d78a08b-0af2-41e6-9a3d-dbb3e2925bef">990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software licenses and maintenance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="zntl:PrepaidSoftwareLicenseAndMaintenance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMy0xLTEtMS00OTc5OA_3d714318-a041-4d04-a768-ce2a1b90fa76">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="zntl:PrepaidSoftwareLicenseAndMaintenance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMy0zLTEtMS00OTc5OA_657a03d1-e2b4-482c-9e81-50b418fbcfa1">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign R&amp;D credit refund</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="zntl:ForeignResearchAndDevelopmentCreditRefund" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNC0xLTEtMS00OTc5OA_dece552a-4030-4900-a6fa-3fd883cf572b">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="zntl:ForeignResearchAndDevelopmentCreditRefund" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNC0zLTEtMS00OTc5OA_994657da-5e84-420b-b91c-76bba64e988a">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="zntl:PrepaidResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNS0xLTEtMS00OTc5OA_7ccee1a2-6897-493f-9c4e-0de4987addb6">15,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="zntl:PrepaidResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNS0zLTEtMS00OTc5OA_54656d9a-543c-4908-a388-d28e1dc05023">11,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNi0xLTEtMS00OTc5OA_cc8ca2dc-97aa-440b-8376-9755ad349c8c">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNi0zLTEtMS00OTc5OA_44b57f14-aa55-41e1-acb9-3dabdba271ca">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zentera receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNy0xLTEtMS00OTc5OA_337d63cf-60ed-4218-9c9a-04b9a7f618bd">2,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNy0zLTEtMS00OTc5OA_43abfda4-be7c-4ff6-a44c-736c20e6b964">2,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="zntl:OtherPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfOC0xLTEtMS00OTc5OA_075d5808-4c6b-4d45-a891-16101eb74d47">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="zntl:OtherPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfOC0zLTEtMS00OTc5OA_90161cc4-0b84-439e-a70b-af7be0a63a6c">644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfOS0xLTEtMS00OTc5OA_450d1e3b-d066-487d-8e5f-bd66144a27b8">24,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfOS0zLTEtMS00OTc5OA_51d5a772-3bcf-42a4-ac8a-94b8862526fc">17,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMTAtMS0xLTEtNDk3OTg_688461c8-c4f0-4d40-8057-dcc5f03abd75">11,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMTAtMy0xLTEtNDk3OTg_eb2a8998-d406-43ca-8711-73bbc0d261bc">7,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets, current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMTEtMS0xLTEtNDk3OTg_f76358f2-0e14-4991-b3dc-87c61a5dc34a">12,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMTEtMy0xLTEtNDk3OTg_52e05df5-b558-4833-a6bc-e7b4085c0223">10,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i24da124e87454cab95fd92a2627099ed_58"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfMjQ3_e732759c-b5df-4aaf-bfd3-82baf1643c93" continuedAt="i5015d7e8417541019e495dd7add0c0c6" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><ix:continuation id="i5015d7e8417541019e495dd7add0c0c6" continuedAt="i84637d8ad5da4ef498838a2a78be0007"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfMjQ2_acb1d1f3-8e29-42ac-92ac-76641287f720" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32cba1a7c584481935d18ab5b6e3052_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfMy0xLTEtMS00OTc5OA_3711e9f7-f8ae-4023-9e53-8347bd87de53">2,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5f415d9e7e84e6390821b2aeca98c24_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfMy0zLTEtMS00OTc5OA_e5883624-209b-4c00-9345-c5a18ab44923">2,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd1665e0a46248bdbece57a6438e0879_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNC0xLTEtMS00OTc5OA_64b2ffcf-6c96-4553-92ed-a031642a2482">4,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee10f69caf0d40ba94ea1e00633d0b5c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNC0zLTEtMS00OTc5OA_53a5f87e-0a25-4513-a8f5-391c13fab892">4,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bd11cea6cd49bfbd84c09bd6e1c561_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNS0xLTEtMS00OTc5OA_9911dcd1-7559-42cc-b6c4-fb7ddb264fb4">2,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica13a2bb8504414b9caaf996da34fe6c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNS0zLTEtMS00OTc5OA_62cde88a-d5b6-48a4-97d4-54ffaa85b635">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f99dba567644e889110abb67dd9dc2e_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNi0xLTEtMS00OTc5OA_740113e9-3d34-45f8-ae74-cf1bb421da50">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b3eed1bbd49485bba0b0ac55976ff5b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNi0zLTEtMS00OTc5OA_54572f26-2fa6-4276-a4ed-23e1a03a0b63">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b47b8406e04436e962c6cf09f56a781_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNy0xLTEtMS00OTc5OA_e2427f48-1d1f-47c6-b74e-bad1578c8bf0">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife734a5c6be14dfeb15a20d958641bd0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNy0zLTEtMS00OTc5OA_d61d0280-99aa-4eb0-86bd-4c59468acc88">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfOC0xLTEtMS00OTc5OA_6d2e4e03-ac42-4998-a199-fda18dfb45d4">9,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfOC0zLTEtMS00OTc5OA_2bba1c26-f629-4e75-82a4-4e3d265438cf">8,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfOS0xLTEtMS00OTc5OA_0d6a5f63-72ec-4595-a008-a55ead05427d">1,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfOS0zLTEtMS00OTc5OA_915f97bd-a711-484f-b1db-43ee4337f473">792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfMTAtMS0xLTEtNDk3OTg_f6231adc-27b6-4a8d-9242-c2eeac437b25">8,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfMTAtMy0xLTEtNDk3OTg_0eb1d9b2-1066-4819-a432-13a0f02bf474">8,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-indent:18pt"><ix:continuation id="i84637d8ad5da4ef498838a2a78be0007" continuedAt="i9c22ad8054a04bbd8f5cff0e5bd1a7a1"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended June&#160;30, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9c22ad8054a04bbd8f5cff0e5bd1a7a1"> was approximately $<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfOTg5NTYwNDY1MDM4OA_2fb72a9d-d0d2-4bab-a5d6-4c2886f590b0">348</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfMjIw_2479932f-ae76-4fd9-be44-1a87ee01aca4">119</ix:nonFraction> thousand, respectively. Depreciation and amortization expense for the six months ended June&#160;30, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfNTQ5NzU1ODE0MjQx_355c0573-6b13-430c-91b4-bcbe9d3734dc">692</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfNTQ5NzU1ODE0MjU1_62f67200-ada2-402e-a30d-75e15a1759ee">198</ix:nonFraction> thousand, respectively.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RleHRyZWdpb246NjQwMGMxMWZmMGI0NGM1MGI1ZDVkMGZjNDJiMDkyYjJfODM_a8e69bd3-fe0a-4c43-a4fd-032ba501c73c" continuedAt="ifa70add0ece74e889a115dbd9e426add" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="ifa70add0ece74e889a115dbd9e426add"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RleHRyZWdpb246NjQwMGMxMWZmMGI0NGM1MGI1ZDVkMGZjNDJiMDkyYjJfODQ_ad1f3cc3-70b2-441d-9128-fceeffeba9e6" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="zntl:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfMi0xLTEtMS00OTc5OA_767d8561-1111-4289-8415-de52adc0dd06">23,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="zntl:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfMi0zLTEtMS00OTc5OA_fb065cbc-4704-4499-8d30-05df708bd69a">18,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfMy0xLTEtMS00OTc5OA_a64d7a45-6042-4acd-90c9-677d0bc10fa3">8,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfMy0zLTEtMS00OTc5OA_aee5830c-4d9c-439c-a610-896ac1d8f5d4">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNC0xLTEtMS00OTc5OA_40fed080-1ce2-445b-919d-949b32363b6e">1,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNC0zLTEtMS00OTc5OA_5826867d-1cab-4435-8bca-9dd5dfc6f7f4">669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="zntl:AccruedGeneralAndAdministrativeCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNS0xLTEtMS00OTc5OA_a53c9032-2e37-431c-bbf2-cfd1d30f93a3">856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="zntl:AccruedGeneralAndAdministrativeCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNS0zLTEtMS00OTc5OA_5af3a954-17d3-4ba9-b7a5-8df676780ae5">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNi0xLTEtMS00OTc5OA_63f0aab7-ea26-437b-b3c5-a368ad56e84f">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNi0zLTEtMS00OTc5OA_d88476b6-e67f-49dd-9c66-be4b01c8e5c4">1,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNy0xLTEtMS00OTc5OA_a86b1038-57b1-41a1-bbe6-157302f03936">694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNy0zLTEtMS00OTc5OA_64ebbb2a-c75b-43e1-9290-345c055f469d">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfOS0xLTEtMS00OTc5OA_2347bb27-070d-4621-a440-6c07b4746482">36,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfOS0zLTEtMS00OTc5OA_8590435c-8441-4e3e-abc2-dc894d5d8f33">32,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i24da124e87454cab95fd92a2627099ed_64"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDM3NA_fb4cd72f-9903-42bc-b76b-ae5531b2c6a1" continuedAt="i650cf6a745964645be0648f7ec48f65f" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="i650cf6a745964645be0648f7ec48f65f" continuedAt="ie950fb498c4343169ea9acd1e4421006"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Direct Offering of Common Stock</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2022, pursuant to our Registration Statement on Form S-3 (Registration No. 333-255769), filed with the SEC on May 4, 2021, we completed a direct offering of common stock to Pfizer Inc. (&#8220;Pfizer&#8221;). We issued and sold <ix:nonFraction unitRef="shares" contextRef="i7f1b085c0bc6418984b4a5652a0f3059_D20220429-20220429" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODE4NTkz_490d5573-5dce-452d-9c63-9eb9badc6012">953,834</ix:nonFraction> shares of our common stock at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i569a69ed2aa54cd6a4ae5aa666ff442a_I20220429" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODE4NjQ4_ecb484bf-31e3-48e1-98d7-03c8d7c14768">26.21</ix:nonFraction> per share. The total gross proceeds for the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i7f1b085c0bc6418984b4a5652a0f3059_D20220429-20220429" decimals="-5" name="zntl:ProceedsFromIssuanceOfCommonStockGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIwNjc4_ae039bd9-b158-4cf5-889a-e31f5e3b9b18">25.0</ix:nonFraction> million, before deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i7f1b085c0bc6418984b4a5652a0f3059_D20220429-20220429" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIwNjg1_18745b3e-43bb-4abc-98a5-b753ac21696e">0.3</ix:nonFraction> million payable by us. The parties have entered into an agreement to collaborate to advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells. We did not grant Pfizer any economic ownership or control of ZN-c3 or the rest of our pipeline. $<ix:nonFraction unitRef="usd" contextRef="ifc20ff4317e549b195078a8c6d397c35_D20220429-20220429" decimals="-5" name="zntl:ProceedsFromIssuanceOfCommonStockGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNzY3NQ_6812deac-66d6-4308-968b-1f3339eb40c4">4.2</ix:nonFraction>&#160;million of the gross offering proceeds received from Pfizer represented a premium in excess of the fair value of our common stock on the date of the investment. This amount has been recorded as accrued research and development expense on the unaudited condensed consolidated balance sheet and will be recognized as a reduction of research and development expense over the term of the collaboration agreement.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-on Offering of Common Stock</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2022, we completed a follow-on offering in which we issued and sold <ix:nonFraction unitRef="shares" contextRef="if223d394e54b4750aa978efb34cba0d1_D20220518-20220518" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODE5OTQ5_466796a3-23bb-4eab-bd94-0db6a9f79994">10,330,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5136c20b0b3448728a094b8bde8584e3_I20220518" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIwMjMw_21fc1150-8750-4773-afe2-7d71a80ebf6b">19.38</ix:nonFraction> per share. The total gross proceeds for the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="if223d394e54b4750aa978efb34cba0d1_D20220518-20220518" decimals="-5" name="zntl:ProceedsFromIssuanceOfCommonStockGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIwMzI5_20aa831e-7667-49d6-ac2e-1f4f9683bce3">200.2</ix:nonFraction> million, before deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="if223d394e54b4750aa978efb34cba0d1_D20220518-20220518" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIwMzQ5_fc779e83-4d76-4501-980c-55ad876bf48a">11.4</ix:nonFraction> million payable by us.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, the Company&#8217;s Board of Directors adopted, and the Company&#8217;s stockholders approved the 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;), which allows for grants to selected employees, consultants and non-employee members of the Board of Directors. We currently grant stock options and restricted stock units (&#8220;RSUs&#8221;), under the 2020 Plan. The number of common shares available for issuance under the 2020 Plan is the sum of (1) <ix:nonFraction unitRef="shares" contextRef="i1195842e7bad4796adc5d3f33b370980_I20200430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDc4_6e0d0ac3-23e5-48b7-823e-4ae0e58e1a86">5,600,000</ix:nonFraction> shares of common stock; plus (2) any shares forfeited from the unvested restricted shares of our common stock issued upon conversion of unvested Class B common units (up to <ix:nonFraction unitRef="shares" contextRef="i451d05a387bc4e28bfaa0c622d3e53b7_I20200430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNjU0_c2028c02-cc19-464b-83d2-22852cbbdfb5">1,250,000</ix:nonFraction> shares); plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ending December 31, 2021 and continuing to, and including, the fiscal year ending December 31, 2030, equal to the lesser of (a) <ix:nonFraction unitRef="number" contextRef="i224274cfab6347e4af0e47b9f95e96ac_D20200401-20200430" decimals="INF" name="zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfODkw_dca396d3-4f2c-4b29-89bc-c47091dae06e">5</ix:nonFraction>% of the shares of common </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="ie950fb498c4343169ea9acd1e4421006" continuedAt="i9e4113e40a554744bbd96be0918a93af"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by our Board of Directors. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i84a3bb6a8e4a4aadaca19939a0d400a0_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNDM1Nw_0a9fe908-9e8d-45b4-ba74-c21649a24719">8,300,142</ix:nonFraction> shares were subject to outstanding awards under the 2020 Plan and <ix:nonFraction unitRef="shares" contextRef="i84a3bb6a8e4a4aadaca19939a0d400a0_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNDM2OA_fecf0ee0-297f-4bb9-a3b3-c4f6fca76978">284,429</ix:nonFraction> shares were available for future grants of share-based awards under the 2020 Plan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company&#8217;s Board of Directors approved the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (the &#8220;2022 Inducement Plan&#8221;), which is used exclusively for the grant of equity awards to new employees as an inducement material to the employees&#8217; entering into employment with the Company. The Board of Directors has initially reserved <ix:nonFraction unitRef="shares" contextRef="ibcb817854a7743afa79c27dc1d29457d_I20220731" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNzY4OQ_53f1bf92-d2d0-452c-ba1d-54dfc8ba30c4">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. </span></div><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDM2Ng_70066ad7-d221-48e2-a6e7-8076c787b3bc" continuedAt="i4e7513ea8623411aa3c29699d44c7109" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share based awards was comprised of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a591ae027674ec48804343c4347f2e3_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMi0xLTEtMS00OTc5OA_82d29b27-4806-4abf-a03d-3ce98740277c">5,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed3e9f3f3094029b5dfa3ccb2bc6788_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMi0zLTEtMS00OTc5OA_4d44e94e-2a3b-49a4-a6ca-4c9022248f82">3,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24f63e9218a428f8bf2dd3b117c02ec_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMi01LTEtMS00OTc5OA_94e10ae6-0895-48ec-881a-0eac2e5f5a96">10,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee6e27237af4336b5fc9bd4e9f7d48a_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMi03LTEtMS00OTc5OA_256eecc7-b829-4e38-ac6a-7a884402f778">7,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83eb79dfc5df4e11adeeb75938b1d7f0_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMy0xLTEtMS00OTc5OA_bf682314-8759-4a66-9672-c3f4c39f69d1">11,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dd3cb1c0574feea2624c386be77ec7_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMy0zLTEtMS00OTc5OA_6d81ac22-8d5f-48e3-8dd1-76f93ac47f87">5,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83d444b0887436c87fef11dcef2e86a_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMy01LTEtMS00OTc5OA_e3fcc46b-7843-47a4-9e41-dafc76fbe225">16,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2780f94d8d42288f13f874db45fd67_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMy03LTEtMS00OTc5OA_e3f7a0b2-9114-4e32-a750-7a774292ab3c">12,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfNC0xLTEtMS00OTc5OA_f5f957bf-43b7-4862-98a8-d8dd786588fb">16,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfNC0zLTEtMS00OTc5OA_4d4ecd6f-c511-46a4-920c-4af0037674ac">9,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfNC01LTEtMS00OTc5OA_34512fc3-ef9a-49f8-be5c-0725ceb187ec">26,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfNC03LTEtMS00OTc5OA_61caea73-d975-4f60-8f02-9de3983764d3">19,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense for the six months ended June&#160;30, 2022 and 2021 includes $<ix:nonFraction unitRef="usd" contextRef="ie30a5375c819427c8694c4b2774b9e9b_D20220101-20220630" decimals="-3" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTQwNA_2c9bc572-519f-43f2-9f53-cd70822a5ce0">0</ix:nonFraction> and  $<ix:nonFraction unitRef="usd" contextRef="i412b968f7b08436b9aa7f54bde3682ea_D20210101-20210630" decimals="-3" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTQxMg_a934d39c-1333-4683-99f0-8e60c1bacbee">138</ix:nonFraction>&#160;thousand, respectively, of share-based compensation expense for employees, consultants and directors of Zentera.  </span></div><div style="text-indent:18pt"><span><br/></span></div><ix:continuation id="i4e7513ea8623411aa3c29699d44c7109"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644b2805dacd408b8e97b86dd46abb55_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfMy0xLTEtMS00OTc5OA_d34f85df-9e0e-4ae5-b07f-ab4f8a0e10c7">12,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e8c09b4a3445298e64940b137301f9_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfMy0zLTEtMS00OTc5OA_cd93ee3c-c078-4aa4-8b07-b38dd486adc3">4,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfMy01LTEtMS00OTc5OA_ed066336-e7aa-4540-866c-ba4494614254">20,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfMy03LTEtMS00OTc5OA_9842c3bb-5f0f-4c53-b057-656459ed61f4">8,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8047842fd47f4f2f8278a39d6e1230e3_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNC0xLTEtMS00OTc5OA_99cb08a4-a747-4693-b6fe-f1cd982fec94">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f359d04969451b952bf5cfc0d87b34_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNC0zLTEtMS00OTc5OA_24af8d57-f947-44c5-b26e-539992b412c3">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNC01LTEtMS00OTc5OA_26858ff9-8fe3-4507-b352-45890d74b6a5">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6d6db52cc441d5980a322a0c13d3c3_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNC03LTEtMS00OTc5OA_6d7ac444-d2e8-4cba-8488-bbe876852365">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9beff74796b74e7a9a2e80f6198c9feb_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNS0xLTEtMS00OTc5OA_2892de02-df26-4f66-b2fc-b8fe1ff49ef5">4,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47314e35042849da943c497cbcc052f6_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNS0zLTEtMS00OTc5OA_f75d3aab-b430-4af3-bfcd-812bc5636a72">4,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2715dfb0dea34fb2ba4b3115eda88efe_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNS01LTEtMS00OTc5OA_88dfb88e-5306-44b4-b07e-50eb128dfe54">6,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f29867c289543609894effb0ecd7862_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNS03LTEtMS00OTc5OA_e8091701-a3e3-492e-a7d3-387e0fc4523f">10,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNi0xLTEtMS00OTc5OA_e274787d-b58c-4fc8-b32d-140d66e59cb8">16,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNi0zLTEtMS00OTc5OA_2a2944a6-a147-442b-b418-60a330ebe7a2">9,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNi01LTEtMS00OTc5OA_a147cd19-a5cd-402b-ab64-1b9a008cd2b7">26,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNi03LTEtMS00OTc5OA_fa688046-5f6a-4913-bec6-e588bcd06abd">19,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDM3MA_f2c0b56d-4974-4e55-b055-52405472283e" continuedAt="i62b58e41a90840759079a557da836556" escape="true"></ix:nonNumeric>Stock Options and Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted is equal to the closing price of the Company&#8217;s common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes model. Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company uses the &#8220;simplified method&#8221; for estimating the expected term of employee options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally <ix:nonNumeric contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630" name="zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMjU0MQ_fa788c08-0c71-478a-9054-33fdd8aa9234">10</ix:nonNumeric> years). The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be <ix:nonFraction unitRef="number" contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMjg4MQ_1545b9d8-34d1-412f-90a2-a1b6de63d62b">zero</ix:nonFraction>. <ix:continuation id="i62b58e41a90840759079a557da836556" continuedAt="ib509fb4a09a540208098f4d38ee6a262">The fair value of the stock options granted during the six months ended June&#160;30, 2022 and June&#160;30, 2021 was determined with the following assumptions:</ix:continuation></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="i9e4113e40a554744bbd96be0918a93af" continuedAt="i09b000fec03c4e898dd4dcbb73acf231"><div style="margin-bottom:12pt;text-indent:18pt"><ix:continuation id="ib509fb4a09a540208098f4d38ee6a262"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"><tr><td style="width:1.0%"></td><td style="width:44.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMS0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOmNhYjk0ODhkNDM1ZjRkZWVhODNjMjk1NTI0ZmE1ZjE4Xzk4OTU2MDQ2NTAwMDY_7aa0f6bf-bbb2-46eb-9ac4-0c8f015a7e4e">73.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMS0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOmNhYjk0ODhkNDM1ZjRkZWVhODNjMjk1NTI0ZmE1ZjE4Xzk4OTU2MDQ2NTAwMTM_23e60c5e-5edb-49a6-a67d-58c347f0e667">80.5</ix:nonFraction>%%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMS0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOjQ1YjQ3YjczNTA0ZTRkZGY4MGU3NTYwZDhjOTI3MGExXzQ_79c2c0cc-0025-4a42-a603-b32b4b5103d8">75.1</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMS0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOjQ1YjQ3YjczNTA0ZTRkZGY4MGU3NTYwZDhjOTI3MGExXzk_efc768ca-91c0-4a20-8285-f668da0b7c84">76.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaef89f53ab20478f942e34396c28ad99_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMi0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOjJjYWNjZmJjODBkNzQ1YzU4YWFmOGE0MGI2OGJlODg3XzQ_4dbd0665-9224-457b-ad81-fad13155bf21">6.0</ix:nonNumeric> - <ix:nonNumeric contextRef="i2e90d2bfdd054eeebf7e538c70e8a560_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMi0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOjJjYWNjZmJjODBkNzQ1YzU4YWFmOGE0MGI2OGJlODg3Xzk4OTU2MDQ2NTAwMDI_4283bcda-027e-49c0-afd5-9452747886a1">6.5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i340692408be44878952df6f49a437468_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMi0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOmM2ZDE0MGQ4NTk1NjRiNjM4Nzg2MTAyZmM2ZDVkMjg2XzQ_9eca643a-0d76-48c6-afe3-aff22a811345">5.3</ix:nonNumeric> - <ix:nonNumeric contextRef="i0914aa0549284d0f8c6c232168700055_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMi0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOmM2ZDE0MGQ4NTk1NjRiNjM4Nzg2MTAyZmM2ZDVkMjg2Xzk_e9f9e49a-d632-4796-bc12-a450b132d744">6.2</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMy0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOjdlZGYxYzVlM2U3ZjRlMjU4NjRiYjMyMjAxNDY3NmNmXzk4OTU2MDQ2NTAwMTA_2e483fde-dd90-4bce-b49e-3aabb23da1cd">1.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMy0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOjdlZGYxYzVlM2U3ZjRlMjU4NjRiYjMyMjAxNDY3NmNmXzk4OTU2MDQ2NTAwMDM_707cb3e8-c68c-445f-b0da-dba32b06478a">3.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMy0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOjkxYjIyYmY4ZWUyNTQ3MjJiNjQwNGZlOTkxODVjOGM4XzQ_8ad01238-30e0-4905-a351-4530ad1aae2f">0.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMy0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOjkxYjIyYmY4ZWUyNTQ3MjJiNjQwNGZlOTkxODVjOGM4Xzk_8b4e04e0-4348-487b-85dc-939fe35db9eb">1.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfNC0xLTEtMS00OTc5OA_773ac9d9-4717-46ab-9d26-55a5785a151f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfNC0zLTEtMS00OTc5OA_a1dbaae6-bfb4-4aae-b00e-bdb5dee639cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, the Company&#8217;s Board of Directors adopted, and the Company&#8217;s stockholders approved the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which was subsequently amended and restated effective March 15, 2021. The maximum aggregate number of shares of the Company&#8217;s common stock available for issuance under the ESPP at June 30, 2022 was <ix:nonFraction unitRef="shares" contextRef="i07bfbcc2813a425a9f14affe9ac623f0_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNzcwMA_c39fed57-048e-4b85-8599-730f4d74a2ea">1,969,608</ix:nonFraction>. Under the terms of the ESPP, the Company&#8217;s employees may elect to have up to <ix:nonFraction unitRef="number" contextRef="i07bfbcc2813a425a9f14affe9ac623f0_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIzMzY4_a89f2b51-772a-4d1e-98fe-8ff08e429b5e">20</ix:nonFraction>% of their compensation, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630" decimals="INF" name="zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIzNDE0_96d0b2b5-86e8-40a1-8882-196ee3973c5d">21,250</ix:nonFraction> per calendar year, withheld to purchase shares of the Company&#8217;s common stock for a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIzNTI1_a71c6418-b6ab-434b-a24e-472efdc132cb">85</ix:nonFraction>% of the lower of the fair market value per share (at closing) of the Company&#8217;s common stock on (i) the first trading day of a <ix:nonNumeric contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630" name="zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNzcxMA_a7b3e8b7-f99b-438a-a234-2bde6f41ac41">six-month</ix:nonNumeric> offering period, or (ii) the applicable purchase date, defined as the last trading day of the <ix:nonNumeric contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630" name="zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNzcxMQ_447d6837-4399-4a8f-8c11-345eb4c3be19">six-month</ix:nonNumeric> offering period. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDM3Mg_1e8fb9b9-2296-4b2f-bb7d-534005bb95c6" continuedAt="iff18920a6d344a05b4a9d29a15e3abb2" escape="true">The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-indent:18pt"><ix:continuation id="iff18920a6d344a05b4a9d29a15e3abb2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.846%"><tr><td style="width:1.0%"></td><td style="width:48.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.652%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjE0YzE2YjY5YTkwYTRkYzdhMTJhZjU1NzhiZTZjMGM5L3RhYmxlcmFuZ2U6MTRjMTZiNjlhOTBhNGRjN2ExMmFmNTU3OGJlNmMwYzlfMy0zLTEtMS00OTc5OA_fd162dd9-8744-42b4-a0eb-28bae745f2b9">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjE0YzE2YjY5YTkwYTRkYzdhMTJhZjU1NzhiZTZjMGM5L3RhYmxlcmFuZ2U6MTRjMTZiNjlhOTBhNGRjN2ExMmFmNTU3OGJlNmMwYzlfNC0zLTEtMS00OTc5OA_a558c45b-d279-4f7e-9cb4-60833db773d8">0.5</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjE0YzE2YjY5YTkwYTRkYzdhMTJhZjU1NzhiZTZjMGM5L3RhYmxlcmFuZ2U6MTRjMTZiNjlhOTBhNGRjN2ExMmFmNTU3OGJlNmMwYzlfNS0zLTEtMS00OTc5OA_46bb2aec-d35f-461a-8960-61c5b8785cba">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjE0YzE2YjY5YTkwYTRkYzdhMTJhZjU1NzhiZTZjMGM5L3RhYmxlcmFuZ2U6MTRjMTZiNjlhOTBhNGRjN2ExMmFmNTU3OGJlNmMwYzlfNi0zLTEtMS00OTc5OA_eddaee82-3b48-450f-a595-998a3cc64123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense Summary</span></div><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDM3Mw_a3947fc5-1c20-4697-bb24-2fd8de74b5db" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.256%"><tr><td style="width:1.0%"></td><td style="width:31.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.878%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized <br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining <br/>Weighted-Average Recognition Period <br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6848464a8da644618f62c064bead2a58_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfMi0xLTEtMS00OTc5OA_439331dc-5a72-43d2-912a-c576f0d2aa5b">117,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfMi0zLTEtMS00OTc5OA_7903e32b-0f4b-407a-9eb6-604e688c7560">3.26</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0503299777e24da1a507027233084ab8_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfMy0xLTEtMS00OTc5OA_5e10fd37-58ff-4351-a0ff-8a39209fcf09">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i198c9b7202d64e788574e76bcbac5063_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfMy0zLTEtMS00OTc5OA_8c9388bf-49f5-42d8-9f73-f033c4c60ca4">1.20</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3258b88db0a48128947746c61ed2f7b_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfNC0xLTEtMS00OTc5OA_7bd04436-ec38-454f-86f3-c05b10dec01c">13,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c688c67b897412c81a7a8199ad39a9d_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfNC0zLTEtMS00OTc5OA_f18761c0-fb1f-4430-96a6-961f8e4b8671">3.13</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07bfbcc2813a425a9f14affe9ac623f0_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfNS0xLTEtMS00OTc5OA_4008587f-01f5-4926-a2e8-7e314a1089ea">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfNS0zLTEtMS00OTc5OA_8c703a1c-90a0-4f72-92e9-2c5783ea6667">0.25</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, we issued <ix:nonFraction unitRef="shares" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNDM3Nw_f2fb0303-9b89-4900-83ff-a0f92d4fcba4">42.0</ix:nonFraction>&#160;thousand shares of common stock in connection with the exercises of stock options. For the six months ended June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDA0OQ_c87939f9-e399-4a1e-89f4-b60bebc6ecf6">0.1</ix:nonFraction> million shares of common stock </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i09b000fec03c4e898dd4dcbb73acf231">issued in conjunction with certain restricted stock awards (&#8220;RSAs&#8221;), vested. Outstanding stock options, unvested RSAs, and unvested RSUs totaling approximately <ix:nonFraction unitRef="shares" contextRef="i6848464a8da644618f62c064bead2a58_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNDM5NA_709666b9-5f2e-4169-b298-2cf0afc111e5">7.8</ix:nonFraction>&#160;million shares, <ix:nonFraction unitRef="shares" contextRef="i0503299777e24da1a507027233084ab8_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNDQwNw_74869aa1-2fb4-4b79-8cfd-47c674a5726b">0.2</ix:nonFraction>&#160;million shares and <ix:nonFraction unitRef="shares" contextRef="id3258b88db0a48128947746c61ed2f7b_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMjE5OTAyMzI2MjE5Ng_955cb043-a63d-4c9d-ad6a-5a6380ff3e27">0.5</ix:nonFraction>&#160;million shares of our common stock, respectively, were outstanding as of June&#160;30, 2022.</ix:continuation> </span></div><div id="i24da124e87454cab95fd92a2627099ed_67"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RleHRyZWdpb246MjE1Y2VhYTI3OWE0NDE0ODhlMTk1ZGZkYjFkODUxYmZfMTg4MQ_feabccef-8907-4009-91d4-0c92d9827836" continuedAt="ia3a6fb4c8897494a802d0305f71cc84e" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ia3a6fb4c8897494a802d0305f71cc84e" continuedAt="icfc728dfe3a244b990561a6eaabda5f5"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may be involved in various disputes, including lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any of these claims could subject us to costly legal expenses. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the consolidated financial statements not misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in our consolidated financial statements. While we do generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, or our policy limits may be inadequate to fully satisfy any damage awards or settlement. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings that require a loss liability to be recorded.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include payments related to operating leases. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RleHRyZWdpb246MjE1Y2VhYTI3OWE0NDE0ODhlMTk1ZGZkYjFkODUxYmZfMTg4Mg_91b7c0a3-f053-4dde-9d1f-0af1c3c044cd" continuedAt="ie0ab61c02a294aa08280bb41063e0f21" escape="true">Approximate annual future minimum operating lease payments as of June&#160;30, 2022 are as follows (in thousands): </ix:nonNumeric></span></div><div style="margin-bottom:12pt"><ix:continuation id="ie0ab61c02a294aa08280bb41063e0f21"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfMS0yLTEtMS00OTc5OA_a443e066-7931-456c-84e0-ce95a4b1fe3f">1,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfMi0yLTEtMS00OTc5OA_c946b104-b4eb-4838-9212-1df7b23b1e7b">6,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfMy0yLTEtMS00OTc5OA_25d772f9-3d7b-4a36-94fd-bbef84b1651a">6,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfNC0yLTEtMS00OTc5OA_906fcb74-66f7-4d73-8989-3e44a40c89c8">6,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfNS0yLTEtMS00OTc5OA_2c24569a-d9e2-4d57-a277-a0b5337131a1">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="zntl:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfNi0yLTEtMS00OTc5OA_5f2df474-f414-4db7-bcb0-a831d6e382a3">46,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfNy0yLTEtMS00OTc5OA_55f9abc0-95ba-420e-8ee8-ee5695317c51">74,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfOC0yLTEtMS00OTc5OA_417a0563-cf11-48ea-8516-d5980dd5537b">27,929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfOS0yLTEtMS00OTc5OA_34ccefaf-5dea-4c53-80e2-5068b83a5308">46,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: current portion</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfMTAtMi0xLTEtNDk3OTg_57fb0e35-eaea-4791-af30-e5ff28c5adac">1,733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfMTEtMi0xLTEtNDk3OTg_3493224d-e6ac-4e34-b559-146e16baf894">45,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icfc728dfe3a244b990561a6eaabda5f5">The weighted-average remaining lease term of our operating leases is approximately <ix:nonNumeric contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RleHRyZWdpb246MjE1Y2VhYTI3OWE0NDE0ODhlMTk1ZGZkYjFkODUxYmZfMTg3Ng_941f42f4-c063-425f-b383-8eebcd8a8385">10.3</ix:nonNumeric> years.</ix:continuation>  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RleHRyZWdpb246ZjRiMzMyZTFjOTE1NDQzMmIzZmVkOTJhZmFmNTY4ZmVfNjE0_43fcccea-7f43-45db-938b-fb40085330ca" continuedAt="ibc75f41d899644b1b7c93750669e23ab" escape="true">Net Loss Per Common Share </ix:nonNumeric></span></div><ix:continuation id="ibc75f41d899644b1b7c93750669e23ab"><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RleHRyZWdpb246ZjRiMzMyZTFjOTE1NDQzMmIzZmVkOTJhZmFmNTY4ZmVfNjEx_be7fb51c-1db0-419b-83b4-4c9c5812cfe7" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share were calculated as follows (in thousands except per share amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"></td><td style="width:52.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.776%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfMy0xLTEtMS00OTc5OA_6b50aa4b-0444-42b4-adbd-ead9d8f5c05c">68,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfMy0zLTEtMS00OTc5OA_cea5c019-d508-4a67-826e-2db59159da3b">54,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNS0xLTEtMS00OTc5OA_a05bcf19-9f35-43fa-beb6-d349fa320c83"><ix:nonFraction unitRef="shares" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNS0xLTEtMS00OTc5OA_f3cc393e-dfd5-4a35-a89d-a942ca10885b">51,117</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNS0zLTEtMS00OTc5OA_7ae4ee6f-e9c1-4e02-930c-74b31788efa2"><ix:nonFraction unitRef="shares" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNS0zLTEtMS00OTc5OA_7da8f369-c61e-455e-8608-9519a8fb396c">40,738</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNi0xLTEtMS00OTc5OA_0250e44c-54c6-47fb-9648-a2db767d10e4"><ix:nonFraction unitRef="usdPerShare" contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNi0xLTEtMS00OTc5OA_0e32e5ad-96cf-4752-a194-49faae128062">1.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNi0zLTEtMS00OTc5OA_83ffe1b7-3a52-4cc7-9c9a-6e68dc135be8"><ix:nonFraction unitRef="usdPerShare" contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNi0zLTEtMS00OTc5OA_d6f97ce5-0bf8-465a-8003-9decdcf58291">1.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential and dilutive securities, which include outstanding stock options, unvested RSAs and unvested RSUs have been excluded from the computation of diluted net loss per common share as the effect would be anti-dilutive. </span></div><ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RleHRyZWdpb246ZjRiMzMyZTFjOTE1NDQzMmIzZmVkOTJhZmFmNTY4ZmVfNjEz_ccf224f3-1093-4ade-8ad6-c5a4af2b2c2f" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents have been excluded from the calculations of diluted net loss per common share because their inclusion would be antidilutive (in thousands).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"></td><td style="width:52.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.776%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if609506238d0461eac509be96d92ec01_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfMi0xLTEtMS00OTc5OA_bb4c5f99-8e8b-48db-8368-57f6d349d0c0">7,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i382cf4d3dcbd43b484285308648a79c9_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfMi0zLTEtMS00OTc5OA_ab5bf58e-027e-498d-b081-aea214e0cd37">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2ca05b7f8ef4c3cb04522bb5e0f01f0_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfMy0xLTEtMS00OTc5OA_db8fcb77-2c1b-4a17-93eb-1555a7abc87f">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6f3ca918b964800a78e9ae83baa07fd_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfMy0zLTEtMS00OTc5OA_85c108ce-7e9d-4cb0-bb54-fc147f50de17">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64103a278a8e4aa7ac8509ba56369056_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfNC0xLTEtMS00OTc5OA_e02c6751-61dc-4b85-b9d9-43e1e42a8ed9">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dff9cfed3a14c8d8c88926052fcee95_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfNC0zLTEtMS00OTc5OA_9ae2f45a-44b4-423d-a9cc-1e2f9fdea18a">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfNS0xLTEtMS00OTc5OA_7f68ca93-e83b-4f9b-a875-3445737d4e57">8,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfNS0zLTEtMS00OTc5OA_e254c2d1-3314-4dea-853d-2c43c66ca12e">5,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i24da124e87454cab95fd92a2627099ed_73"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83My9mcmFnOjE1MjlhMzNjY2QzNjQwYjA4NGYwMWRjODRkMTg4YWRhL3RleHRyZWdpb246MTUyOWEzM2NjZDM2NDBiMDg0ZjAxZGM4NGQxODhhZGFfMTkyNw_85b8b1e4-63e1-424a-9084-60d1229c5016" continuedAt="i3a1250b9a1ba4c8e9e095a4a2edcd749" escape="true">Related Party Disclosures</ix:nonNumeric></span></div><ix:continuation id="i3a1250b9a1ba4c8e9e095a4a2edcd749" continuedAt="i526649807a324186a0697a269d4b50d5"><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tempus</span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kimberly Blackwell, M.D., our Chief Executive Officer and a member of our Board of Directors, was previously employed by Tempus Labs, Inc. ("Tempus") and now serves as an advisor of Tempus. The Company entered into a Master Services Agreement with Tempus in December 2020 to provide data licensing and research services. There were immaterial and $<ix:nonFraction unitRef="usd" contextRef="i1bdc5cf068c740ae97ed383848a4f8b2_I20210630" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83My9mcmFnOjE1MjlhMzNjY2QzNjQwYjA4NGYwMWRjODRkMTg4YWRhL3RleHRyZWdpb246MTUyOWEzM2NjZDM2NDBiMDg0ZjAxZGM4NGQxODhhZGFfMzQ3_439a1e6e-fddf-4f4a-98d6-3cdd06848330">1.0</ix:nonFraction> million fees incurred for services performed by Tempus for the six months ended June&#160;30, 2022 and 2021, respectively.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zentera</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin D. Bunker, Ph.D., our Chief Operating Officer, serves as a member of the Board of Directors of Zentera. Accordingly, the Company identifies Zentera as a related party.</span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered into the Zentera Sublicenses, pursuant to which we collaborate with Zentera on the development and comm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ercialization of the Collaboration Products in the Zentera Collaboration Territory. Under the terms of the Zentera Sublicenses, Zentera is responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are responsible for the costs of developing the Collaboration Products </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="i526649807a324186a0697a269d4b50d5"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of its costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Prior to the deconsolidation of Zentera during July 2021, these costs were eliminated in consolidation. For the six months ended June 30, 2022, the amounts incurred under this arrangement totaled $<ix:nonFraction unitRef="usd" contextRef="iebb85fbd06c842c9b31131732a081288_D20220101-20220630" decimals="-5" name="zntl:ResearchAndDevelopmentExpenseReimbursements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83My9mcmFnOjE1MjlhMzNjY2QzNjQwYjA4NGYwMWRjODRkMTg4YWRhL3RleHRyZWdpb246MTUyOWEzM2NjZDM2NDBiMDg0ZjAxZGM4NGQxODhhZGFfMTcwNg_7212ec47-ecec-4c18-a5a9-b0b0c3ba97dd">5.1</ix:nonFraction> million and are presented as contra-research and development expense in the consolidated statement of operations. </span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022 we divested an early stage asset to Zentera for $<ix:nonFraction unitRef="usd" contextRef="iebb85fbd06c842c9b31131732a081288_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83My9mcmFnOjE1MjlhMzNjY2QzNjQwYjA4NGYwMWRjODRkMTg4YWRhL3RleHRyZWdpb246MTUyOWEzM2NjZDM2NDBiMDg0ZjAxZGM4NGQxODhhZGFfMTkxNw_8364476a-607e-4e1e-85cf-65c8b4684114">0.2</ix:nonFraction> million.</span></div></ix:continuation><div id="i24da124e87454cab95fd92a2627099ed_82"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and operating results should be read together with our interim unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q contains forward-looking statements that involve significant risks and uncertainties. As a result of many important factors, such as those set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q, our actual results may differ materially from those anticipated in these forward-looking statements. For convenience of presentation some of the numbers have been rounded in the text below.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. We use our highly efficient drug discovery engine, which we refer to as our Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that we believe could result in potentially differentiated product profiles. Our discovery engine combines our extensive experience and capabilities across cancer biology and medicinal chemistry. We believe our product candidates are differentiated from current programs targeting similar pathways and, if approved, have the potential to significantly impact clinical outcomes of patients with cancer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are developing a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. We currently have two lead product candidates: ZN-c3, an inhibitor of Wee1, a protein tyrosine kinase, and ZN-d5, a selective inhibitor of B-cell lymphoma 2, or BCL-2. Our other clinical-stage product candidates include ZN-c5, an oral selective estrogen receptor degrader, or SERD, and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, or EGFR. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ZN-c3 is currently being evaluated in multiple ongoing clinical trials, including a Phase 2 clinical trial as a monotherapy for the treatment of advanced solid tumors including uterine serous carcinoma, or USC, in a Phase 1/2 clinical trial in combination with chemotherapies in patients with advanced ovarian cancer and osteosarcoma, and in a Phase 1/2 clinical trial in combination with a poly (ADP-ribose) polymerase (PARP) inhibitor in ovarian cancer. ZN-d5 is currently in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma, or NHL, and acute myelogenous leukemia, or AML. ZN-c5 is currently in Phase 1/2 clinical trials for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer, and ZN-e4 is currently in a Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer, or NSCLC. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently own worldwide development and commercialization rights to each of our product candidates, other than in select Asian countries (including China) for each of ZN-c3, ZN-d5 and ZN-c5, for which we have out-licensed these rights to our joint venture, Zentera Therapeutics (Cayman), Ltd., or Zentera, and for ZN-e4, for which we have out-licensed these rights to SciClone Pharmaceuticals International (Cayman) Development Ltd., or SciClone. As of June 30, 2022, we hold a 40.3% equity interest in Zentera.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ZN-c3 (Wee1 Inhibitor)</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ZN-c3 is currently being evaluated in multiple ongoing clinical trials, including a Phase 2 monotherapy clinical trial for the treatment of women with recurrent or persistent USC. The study was initiated following an end-of-Phase 1 meeting with the U.S. Food and Drug Administration, or FDA, which concurred in principle with the proposal that ZN-c3 has the potential for an accelerated approval pathway based on the proposed global study design. The FDA granted Fast Track designation in November 2021 to ZN-c3 for the treatment of patients with advanced metastatic uterine serous carcinoma who have received at least one prior platinum-based chemotherapy regimen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, ZN-c3 in combination with chemotherapy has received orphan drug designation and rare pediatric disease designation from the FDA for osteosarcoma. We initiated a Phase 1/2 clinical trial of ZN-c3 in combination with chemotherapy in pediatric and adult patients with osteosarcoma during the third quarter of 2021. We expect to report initial results from this trial in the second half of 2022. If ZN-c3 were to obtain approval for the designated indication, we believe it may be eligible for a rare pediatric disease priority voucher upon approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ZN-c3 is also being evaluated in an ongoing Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the fourth quarter of 2021, we initiated a Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker, subject to FDA feedback. We also initiated a Phase 1/2 clinical trial evaluating ZN-c3 in combination with GlaxoSmithKline&#8217;s PARP inhibitor niraparib (ZEJULA&#174;), as part of a clinical research collaboration in ovarian cancer. We also announced plans to initiate a Phase 1/2 combination trial of ZN-d5 and ZN-c3 in AML in 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have agreed to support two planned additional investigator-initiated trials of ZN-c3 that we expect to initiate in 2022: a trial with the Ivy Brain Center in glioblastoma multiforme and a trial in combination with immunotherapy with Dana Farber in triple negative breast cancer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ZN-d5 (BCL-2 Inhibitor)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ongoing Phase 1 monotherapy dose escalation trial for ZN-d5 is enrolling patients with relapsed/refractory NHL and additionally began enrolling patients with AML in the third quarter of 2021. We reported initial results from this Phase 1 trial in the fourth quarter of 2021. We initiated a Phase 1/2 monotherapy trial of ZN-d5 in Amyloidosis in the first quarter of 2022. We also announced plans to initiate a Phase 1/2 combination trial of ZN-d5 and ZN-c3 in AML in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ZN-c5 (Oral SERD)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported initial results from the ongoing Phase 1/2 trial evaluating ZN-c5 in combination with Pfizer Inc.&#8217;s, or Pfizer&#8217;s, CDK4/6 palbociclib, and the Phase 1b clinical trial evaluating ZN-c5 in combination with Elli Lilly and Company&#8217;s, or Lilly&#8217;s, CDK4/6 abemaciclib, in the second quarter of 2022. We plan to discontinue the clinical development of ZN-c5 following completion of these trials, which are closed to accrual.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ZN-e4 (EGFR Inhibitor)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ongoing Phase 1/2 dose escalation trial for ZN-e4 in patients with advanced NSCLC is evaluating ZN-e4 in both osimertinib-na&#239;ve and experienced patients. We plan to report results from the Phase 1/2 trial in 2022. We plan to discontinue the clinical development of ZN-e4 following completion of this trial, which is closed to accrual.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">BCL-xL Heterobifunctional Degrader</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. We believe that our discovery efforts to select a BCL-xL degrader will lead to an attractive candidate for evaluation as monotherapy and in combination with other therapies, such as ZN-d5 and ZN-c3, for the treatment of hematological and solid malignancies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zentera Therapeutics</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our China joint venture, Zentera, is also advancing corresponding clinical trials in China for ZN-c3, ZN-d5 and ZN-c5. See &#8220;Zentera Therapeutics&#8221; below and Notes 3 and 12 to our interim unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity Overview</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, our operations have been limited to organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and performing research and development of our product pipeline. We do not have any products approved for commercial sale and have not generated any revenues from product sales. We will not generate revenue from product sales unless and until we successfully complete clinical development, obtain regulatory approval for and commercialize one or more of our product candidates. We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2022, we entered into a securities purchase agreement with Pfizer pursuant to which Pfizer purchased 953,834 shares of our common stock, at a price of $26.21 per share. The shares were offered and sold in a registered direct offering conducted without an underwriter or placement agent and pursuant to an effective shelf Registration Statement on Form S-3 (Registration No. 333-255769), and a related prospectus supplement. The Pfizer offering closed on April 29, 2022, raising aggregate gross proceeds of approximately $25.0 million, before fees and expenses of $0.3 million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. Our net losses were $166.1 million for the year ended December 31, 2021, and $68.4 million and $55.1 million for the six months ended June&#160;30, 2022 and June&#160;30, 2021, respectively. We had an accumulated deficit of $487.0 million as of June&#160;30, 2022. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We had cash, cash equivalents and marketable securities of $455.2 million as of June&#160;30, 2022. We believe that our existing cash, cash equivalents and marketable securities as of June&#160;30, 2022 will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2025. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor how the COVID-19 pandemic is affecting our employees, business, preclinical studies and clinical trials. In response to the spread of COVID-19, we limited access to our executive offices, with the majority of our administrative employees continuing their work outside of our offices, and we limited the number of staff in any given research and development laboratory by operating on rotational schedules. As of June 30, 2022 our employees have begun working based on a hybrid work model, in which they work both from our executive office and remotely. Disruptions caused by the COVID-19 pandemic have resulted in difficulties including delays in initiating new trial sites and certain supply chain activities, suspension of enrollment at some of our existing trial sites, and the incurrence of additional costs as a result of preclinical study and clinical trial delays and adjustments and supply chain delays. Limited operations at our laboratory facilities have also resulted in delays in our research-stage programs. As a result, we expect that the COVID-19 pandemic will continue to impact our business, results of operations, clinical development timelines and financial condition. At this time, there is continuing uncertainty relating to the trajectory of the COVID-19 pandemic and impact of related responses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of COVID-19 on our future results will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, the impact of variants, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, the continued impact on financial markets and the global economy, the adoption and effectiveness of vaccines and vaccine distribution efforts, and the effectiveness of the global response to contain and treat the disease. See &#8220;Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has adversely impacted and we expect will continue to adversely impact our business, including our preclinical studies and clinical trials.&#8221; in Part II, Item 1A. of this Quarterly Report on Form 10-Q.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements and Strategic Collaborations Agreements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recurium IP Holdings, LLC</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2014, and as amended and restated effective as of December 2017 and September 2019 and as amended in May 2020, we entered into a license agreement, or the Recurium Agreement, with Recurium IP Holdings, LLC, or Recurium IP, under which we were granted an exclusive worldwide license to certain intellectual property rights owned or controlled by Recurium IP to develop and commercialize pharmaceutical products for the treatment or prevention of disease, other than for pain. In connection with the May 2020 amendment, we clarified certain aspects of the sublicensing payment provisions. We have the right to sublicense our rights under the Recurium Agreement, subject to certain conditions. We are required to use commercially reasonable efforts to develop and commercialize at least one product that comprises or contains a licensed compound and to execute certain development activities. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Recurium Agreement, we are obligated to make development and regulatory milestone payments, pay royalties for net sales and make sublicensing payments with respect to certain licensed products directed to one of ten specific biological targets, including ZN-c3, ZN-d5, ZN-c5 and ZN-e4. We are obligated to make development and regulatory milestone payments for such licensed products of up to $44.5 million. In addition, we are obligated to make milestone payments up to $150,000 for certain licensed products used in animals. We are also obligated to pay royalties on sales of such licensed products at a mid- to high-single digit percentage. In addition, if we choose to sublicense or assign to any third parties our rights under the Recurium Agreement with respect to such licensed products, we must pay to Recurium&#160;IP 20% of sublicensing income received in connection with such transaction. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SciClone Pharmaceuticals International (Cayman) Development Ltd. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, and as amended in December 2016 and December 2017, we entered into a collaboration and license agreement, or the SciClone Agreement, with SciClone Pharmaceuticals International (Cayman) Development Ltd., or SciClone, under which we granted an exclusive license certain intellectual property rights in the People&#8217;s Republic of China (including the territories of Macao and Hong Kong), South Korea, Taiwan and Vietnam, or the SciClone Territory, to SciClone for the development and commercialization of a licensed product for the treatment or prevention of oncologic diseases and an exclusive option to obtain a similar license for up to two additional licensed products. Under the SciClone Agreement, SciClone is responsible for clinical development activities required in order to obtain regulatory approval in the SciClone Territory. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SciClone paid to us a one-time upfront payment of $1.0&#160;million upon entering into the SciClone Agreement, and $4.0 million in aggregate milestone payments. No additional development or commercial milestones or reimbursement for research and development expenses are payable by SciClone under the SciClone Agreement, as amended. We are entitled to receive a mid-single digit royalty on net sales of licensed products in the SciClone Territory, which royalty is subject to certain reductions in the event that SciClone is unable to achieve certain gross margins or if generic products are sold or if technology covering a licensed product is licensed from a third party. We have also agreed to pay SciClone tiered royalties pursuant to the terms of the SciClone Agreement, the applicable rate of which are determined based on whether a compound is developed to a successful dual IND submission and the costs incurred by SciClone for the development of such product candidate. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the December 2016 amendment to the SciClone Agreement, SciClone retains the exclusive license to develop and commercialize our EGFR inhibitor product candidate, ZN-e4, in the SciClone Territory, and the exclusive option to obtain an exclusive license to develop up to two specified compounds under the SciClone Agreement for which we submit an IND by providing notice and paying $5 million to us. SciClone&#8217;s and our royalty obligations will expire on a licensed product-by-licensed product and country-by-country basis on the later of fifteen years from the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product in such country. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Agreements </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into a clinical trial collaboration and supply agreement with Pfizer to evaluate the safety, tolerability and efficacy of ZN-c5 in combination with their CDK4/6 inhibitor, palbociclib, in our ongoing Phase 1/2 clinical trial of ZN-c5. Pursuant to this agreement, we will be responsible for the conduct and cost of the relevant studies, under the supervision of a joint development committee made up of our representatives and representatives of Pfizer that meets quarterly. Pfizer will supply palbociclib for use in the trial, at no cost to us. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into an agreement with Pfizer to collaborate to advance the clinical development of ZN-c3. We did not grant Pfizer any economic ownership or control of ZN-c3 or the rest of our pipeline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company Clinical Trial Collaboration and Supply Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In July 2020, we entered into a clinical trial collaboration and supply agreement with Lilly to evaluate the safety, tolerability and efficacy of ZN-c5 in combination with their CDK4/6 inhibitor, abemaciclib, in a Phase 1b open label multi-center clinical trial that we initiated in November 2020.  Pursuant to this agreement, we are responsible for the conduct and cost of the relevant studies. Lilly is obligated to supply abemaciclib for use in the trial, at no cost to us. We are required to provide to Lilly clinical data and other reports at major decision points during the trial and no later than 60 days following completion of the planned Phase 1b clinical trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">This agreement does not grant any right of first negotiation to participate in future clinical trials, and each of the parties retains all rights and ability to evaluate their respective compounds in any clinical studies, either as monotherapy or in combination with any other product or compound, in any therapeutic area.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement with Lilly will expire upon completion of all obligations of the parties thereunder or upon termination by either party. We and Lilly each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations or if either party decides to discontinue development of its own compound for medical, scientific, legal or other reasons or if a regulatory authority takes any action preventing that party from supplying its compound for the study. Lilly also has the right to terminate this agreement if it notifies us in writing that it reasonably and in good faith believes that abemaciclib is being used in an unsafe manner, and we fail to incorporate changes to address such issue, and the issue is unable to be resolved following elevation to appropriate parties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">GlaxoSmithKline Clinical Trial Collaboration and Supply Agreement</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, we entered into a clinical trial collaboration and supply agreement with GlaxoSmithKline plc, or GSK, under which we will evaluate the combination of ZN-c3 and niraparib, GSK&#8217;s PARP inhibitor, in patients with advanced epithelial ovarian cancer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to this agreement, we will be responsible for the conduct and cost of the relevant studies, under the supervision of a joint development committee made up of our representatives and representatives of GSK that meets quarterly. GSK will supply niraparib for use in the collaboration, at no cost to us. We are required to provide to GSK clinical data and other reports upon completion of the study. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This agreement does not grant any right of first negotiation to participate in future clinical trials, and each of the parties retains all rights and ability to evaluate their respective compounds in any clinical studies, either as monotherapy or in combination with any other product or compound, in any therapeutic area. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement with GSK will expire upon completion of all obligations of the parties thereunder or upon termination by either party. We and GSK each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations or if either party decides to discontinue development of its own compound for medical, scientific, legal or other reasons or if a regulatory authority takes any action preventing that party from supplying its compound for the study or in the event the other party is subject to specified bankruptcy, insolvency or similar circumstances. GSK also has the right to terminate this agreement if it notifies us in writing that it reasonably and in good faith believes that niraparib is being </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">used in an unsafe manner, and we fail to incorporate changes to address such issue, and the issue is unable to be resolved following elevation to appropriate parties. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zentera Therapeutics</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, each of our subsidiaries Zeno Alpha, Inc., K-Group Alpha, Inc. Zeno Management, Inc. and K-Group Beta, Inc. entered into a collaboration and license agreement with our joint venture, Zentera, which we refer to as the Zentera Sublicenses, pursuant to which we collaborate with Zentera on the development and commercialization of ZN-c3, ZN-d5 and ZN-c5, respectively, whether alone or in a licensed product, or the Collaboration Products, in each case for the treatment or prevention of disease, other than for pain, which is referred to as the Zentera Field, in the People&#8217;s Republic of China, Macau, Hong Kong and Taiwan, which is referred to as the Zentera Collaboration Territory. Under each Zentera Sublicense, Zentera will lead development, and upon regulatory approval, the commercialization, of the Collaboration Products in the Zentera Collaboration Territory. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2020, Zentera issued an aggregate of 60.2% of its issued shares of common stock to Zeno Alpha, Inc., K-Group Alpha, Inc., K-Group Beta, Inc., Zeno Management, Inc. and Zeno Beta, Inc. In July 2021, Zentera entered into a Series B Preference Shares Purchase Agreement, pursuant to which it raised $75.0 million in gross proceeds. As of June&#160;30, 2022, we hold a 40.3% equity interest in Zentera. Kevin D. Bunker, Ph.D., our Chief Operating Officer, serves as a member of the Board of Directors of Zentera. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under each Zentera Sublicense, we granted Zentera an exclusive, royalty-bearing license under certain of our technology, including technology licensed from Recurium under the Recurium Agreement, to develop and commercialize the Collaboration Products in the Zentera Field and in the Zentera Collaboration Territory, subject to certain rights that we retain, and upon a successful manufacturing transfer, a non-exclusive license under certain of our manufacturing technology to manufacture Collaboration Products in the Zentera Field and in the Zentera Collaboration Territory. Zentera has the right to sublicense its rights under the Zentera Sublicenses subject to certain conditions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Zentera Sublicenses, Zentera is responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of its costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Under the Zentera Sublicenses, we will be eligible to receive future development and regulatory milestones of up to $4.45 million per Collaboration Product. Zentera will pay us royalties on net sales of Collaboration Products in the Zentera Collaboration Territory at a mid- to high-single digit percentage, subject to certain reductions. In addition, if Zentera or its affiliate chooses to sublicense or assign to any third parties its rights under the Zentera Sublicenses with respect to any Collaboration Product, Zentera must pay to us 20% of sublicensing income received by Zentera or its affiliates in connection with such transaction.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zentera&#8217;s royalty obligations will expire on a Collaboration Product-by-Collaboration Product and region-by-region basis upon the later of the date on which such product is no longer covered by a valid claim of a licensed patent and the 15th anniversary of the first commercial sale of such product in such region.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zentera filed four Clinical Trial Applications, or CTAs (China equivalent of IND), and four have been approved in China to date, for ZN-c3, ZN-d5, ZN-c5 and ZN-c3 in combination. Zentera has begun enrolling four clinical trials for ZN-c3, ZN-d5 and ZN-c5. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue, and we do not expect to generate any revenue in the foreseeable future from product sales. We have generated, and may in the future generate, revenue from payments received under our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration agreements, which includes payments of upfront fees, license fees, milestone-based payments and reimbursements for research and development efforts. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses incurred under agreements with third parties, including contract research organizations, or CROs, and other third parties that conduct research, preclinical activities and clinical trials on our behalf as well as contract manufacturing organizations, or CMOs, that manufacture drug material for use in our preclinical studies and clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">license payments made for intellectual property used in research and development activities; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">allocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Reimbursed research and development costs under government grants and certain collaborative arrangements are recorded as a reduction to research and development expenses and are recognized in the period in which the related costs are incurred. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We track external development costs by product candidate or development program, but we do not allocate personnel costs, general license payments made under our licensing arrangements or other internal costs to specific development programs or product candidates. These costs are included in unallocated research and development expenses in the table below. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses by product candidate or development program:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZN-c3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZN-d5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZN-c5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZN-e4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,825</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,770&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,937</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,164&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have a higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase substantially for the foreseeable future and will comprise a larger </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">percentage of our total expenses as we complete our ongoing clinical trials, initiate new clinical trials, continue to discover and develop additional product candidates and prepare regulatory filings for any product candidates that successfully complete clinical development. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our product candidates is highly uncertain. At this time, we cannot determine with certainty the duration and costs of our existing and future clinical trials of our product candidates or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of our product candidates and any other product candidate we may develop in the future will depend on a variety of factors, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">per patient trial costs; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients who enroll in each trial; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of trials required for approval; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of sites included in the trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the countries in which the trials are conducted; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of time required to enroll eligible patients; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the drop-out or discontinuation rates of patients; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any delays in clinical trials as a result of the COVID-19 pandemic;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential additional safety monitoring requested by regulatory agencies; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the duration of patient participation in the trials and follow-up; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the phase of development of the product candidate; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the efficacy and safety profile of the product candidate. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertainties in clinical trial design and patient enrollment rates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the actual probability of success for our product candidates, including the safety and efficacy, early clinical data, competition, manufacturing capability and commercial viability; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant and changing government regulation and regulatory guidance; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and receipt of any marketing approvals; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract and retain skilled personnel.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support research and development activities relating to our clinical stage programs, and any other product candidate we may develop. We also expect to incur increased expenses associated with being a public company, particularly now that we are no longer an emerging growth company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements; director and officer insurance costs; and investor and public relations costs. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on cash, cash equivalents and available-for-sale marketable securities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we and our corporate subsidiaries have generated cumulative federal, state and foreign net operating loss in certain jurisdictions for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within their respective carryforward periods.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Three Months Ended June 30, 2022 to Three Months Ended June 30, 2021 </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated, together with the changes in those items in dollars:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.442%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(945)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,461&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,132&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,461)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,132)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,329)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,037)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,017)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,392)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,062)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,330)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,357)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,574)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,783)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the three months ended June&#160;30, 2022 were $43.8 million, compared to $44.8 million for the three months ended June&#160;30, 2021. The decrease of $0.9 million was primarily due to licensing milestones and manufacturing expenditures incurred during the three months ended June 30, 2021, which did not recur during the comparable period in 2022. Increases of $4.7 million and $4.4 million were seen in personnel expenditures and clinical trial related costs, respectively. Increases of $1.4 million and $0.8 million were the result of additional overhead allocation to research and development, and collaboration costs, respectively. These amounts were partially offset by decreases of $5.0 million and $4.2 million in licensing milestone and manufacturing expenditures, respectively. During the three months ended June 30, 2022, we recognized $3.0 million as contra-research and development expense as part of our cost sharing arrangement with Zentera. The amount for the corresponding three months ended June 30, 2021 was eliminated in consolidation. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the three months ended June&#160;30, 2022 were $19.6 million, compared to $10.4 million during the three months ended June&#160;30, 2021. This increase of $9.3 million was primarily attributable to an increase in non-cash stock based compensation of $5.6 million and $2.0 million related to other non-recurring compensation. Increases of $1.8 million, $0.6 million and $0.5 million were seen in rent and depreciation expense, legal expense, and consulting expense, respectively. Office supplies and travel expenses each increased by $0.1 million. These amounts were partially offset by an allocation of overhead expenditures to research and development of $1.4 million.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment and Other Income, Net </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment and other income, net was $0.4 million for the three months ended June&#160;30, 2022, compared to $0.1 million for the three months ended June&#160;30, 2021. The increase of $0.3 million was driven by returns on an increase of invested cash and marketable securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Equity Method Investment</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on equity method investment was $5.3 million for the three months ended June&#160;30, 2022. We did not have a comparable loss on equity method investment during the three months ended June&#160;30, 2021. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Six Months Ended June 30, 2022 to Six Months Ended June 30, 2021</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.442%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,479&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,861&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,340)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,479)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,861)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,490)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,265)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,629)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,506)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,123)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,031)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,434)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,475)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,959)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the six months ended June 30, 2022 were $89.9 million, compared to $83.2 million for the six months ended June 30, 2021. The increase of $6.8 million was primarily due to increases in external research and development expenses related to our clinical product candidates as we advanced our clinical pipeline. In addition, in the six months ended June 30, 2022, we conducted additional preclinical studies, incurred additional manufacturing costs and incurred increased costs for study and lab materials. Increases of $13.1 million and $10.1 million were seen in clinical trial related costs and personnel expenditures, respectively. Increases of $3.0 million and $0.4 million were the result of additional overhead allocated to research and development as well as a decrease in grant revenue, respectively. Lab equipment, supplies, and travel expense increased by $0.4 million and $0.1 million, respectively. These amounts were partially offset by decreases of $9.5 million, $5.1 million and $5.0 million in drug substance and drug product expense, Zentera cost sharing recorded as contra-research and development, and licensing milestone fees, respectively. Collaboration expense also decreased by $0.8 million.  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the six months ended June 30, 2022 were $31.4 million, compared to $22.3 million during the six months ended June 30, 2021. This increase of $9.1 million was primarily attributable to an increase in non-cash stock based compensation of $4.1 million and $2.4 million in other compensation. Increases of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0 million and $0.7 million were seen in consulting and legal fees, respectively. Office supply and travel expenses each increased by $0.1 million. Overhead expenditures also increased by $0.7 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment and Other Income, Net </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment and other income, net was $0.9 million for the six months ended June 30, 2022, compared to $0.2 million for the six months ended June 30, 2021. The increase of $0.6 million was driven by returns on an increase of invested cash and marketable securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Equity Method Investment</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on equity method investment was $7.1 million for the six months ended June 30, 2022. We did not have a comparable loss on equity method investment during the six months ended June 30, 2021.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, our operations have been limited to organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and performing research and development of our product pipeline. We do not have any products approved for commercial sale and have not generated any revenues from product sales and we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our research programs and product candidates. We expect that our research and development and general and administrative costs will increase in connection with conducting additional preclinical studies and clinical trials for our current and future research programs and product candidates, contracting with CMOs to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all, particularly in light of the economic downturn and ongoing uncertainty related to the evolving COVID-19 pandemic, the conflict in Ukraine, ongoing global supply chain issues and increased inflation. The COVID-19 pandemic and related global events have resulted in an economic downturn that could adversely affect our operations, our ability to conduct our clinical trials, our ability to raise additional funds through public offerings and the volatility of our stock price and trading in our stock. Even after the COVID-19 pandemic has subsided, we expect we will continue to experience adverse impacts to our business as a result of any economic recession or depression that has occurred or may occur in the future. If we are unable to secure adequate additional funding as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with developing and commercializing therapeutics, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of equity securities. From inception through June&#160;30, 2022, we raised a total of $926.2 million in gross proceeds from the sale of our common stock and Series A, B and C convertible preferred units. As of June&#160;30, 2022, we had cash, cash equivalents, and marketable securities of $455.2 million, and an accumulated deficit of $487.0 million. We had no indebtedness as of June&#160;30, 2022. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Program</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into a sales agreement, or the Sales Agreement, with SVB Leerink LLC, or SVB Leerink, as sales agent, pursuant to which we may, from time to time, issue and sell common stock with an aggregate value of up to $200.0 million in &#8220;at-the-market&#8221; offerings, or the ATM, under our Registration Statement on Form S-3 (File No. 333-255769) filed with the U.S. Securities and Exchange Commission, or the SEC, on May 4, 2021. Sales of common stock, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a) of the Securities Act of 1933, as amended, or the Securities Act, including sales made directly through The Nasdaq Global Market or any other existing trading market for our common stock. During the quarter ended June 30, 2022, we did not sell any shares of common stock under the Sales Agreement. As of June 30, 2022, there was $190.0 million of common stock remaining available for sale under the Sales Agreement. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Direct Offering of Common Stock</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2022, pursuant to our registration statement on Form S-3 (Registration No. 333-255769), filed with the SEC on May 4, 2021, we completed a direct offering of common stock to Pfizer. We issued and sold 953,834 shares of our common stock at an offering price of $26.21 per share. The total gross proceeds for the offering were approximately $25.0&#160;million, before deducting offering expenses of $0.3&#160;million payable by us. We and Pfizer have entered into an agreement to collaborate to advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells. We did not grant Pfizer any economic ownership or control of ZN-c3 or the rest of our pipeline of product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-on Offering of Common Stock</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2022, we completed a follow-on offering in which we issued and sold 10,330,000 shares of common stock at a public offering price of $19.38 per share. The total gross proceeds for the offering were approximately $200.2 million, before deducting offering expenses of $11.4 million payable by us.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Cash Flows </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for the period presented: </span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,304)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,814)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,837)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses since inception. Net cash used in operating activities for the six months ended June&#160;30, 2022 was $93.2 million, consisting primarily of our net loss of $127.6 million as we incurred expenses associated with research and development activities for our product candidates and incurred general and administrative expenses, as well as changes in operating assets and liabilities of $0.4 million, partially offset by non-cash adjustments of $34.8 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the six months ended June 30, 2021 was $83.6 million, consisting primarily of our net loss of $105.5 million as we incurred expenses associated with research and development activities for our product candidates and incurred general and administrative expenses, as well as changes in operating assets and liabilities of $1.6 million, partially offset by non-cash adjustments of $20.3 million.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the six months ended June&#160;30, 2022 of $122.3 million was attributable to the proceeds from maturities of marketable securities of $156.0 million, offset by net investment of excess cash of $277.6 million and the purchases of property and equipment of $0.7 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the six months ended June 30, 2021 of $80.0 million was attributable to the proceeds from maturities of marketable securities of $159.1 million, offset by net investment of excess cash of $77.8 million and the purchases of property and equipment of $1.3 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the six months ended June&#160;30, 2022 of $210.7 million primarily relates to the May 2022 follow-on offering, which provided net cash of $188.8 million, and the April 2022 direct offering to Pfizer, which provided net cash of $20.5 million. Of the $25.0 million gross proceeds received from Pfizer, $4.2&#160;million of the proceeds represented a premium in excess of the fair value of our common stock on the date of the investment. This amount has been recorded as accrued research and development expense on the unaudited condensed consolidated balance sheet and will be recognized as a reduction of research and development expense over the term of the collaboration. An additional $1.4 million was provided from the issuance of common stock under equity incentive plans.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the six months ended June 30, 2021 of $0.3 million primarily relates to deferred financing costs of $0.4 million, partially offset by $70,000 from the issuance of common stock associated with the exercise of stock options.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses have increased substantially in 2021 and to date in 2022 and are expected to increase substantially in the future in connection with our ongoing activities. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, our expenses will increase as we:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">advance the clinical development of ZN-c3 and ZN-d5 for the treatment of oncology indications; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">pursue the preclinical and clinical development of other current and future research programs and product candidates;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">in-license or acquire the rights to other products, product candidates or technologies; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintain, expand and protect our intellectual property portfolio; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">hire and retain additional personnel, including in research, manufacturing and regulatory and clinical development, as well as management personnel; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek regulatory approval for any product candidates that successfully complete clinical development; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expand our operational, financial and management systems and increase personnel, including personnel to support our operations as a public company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents and marketable securities as of June&#160;30, 2022 will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2025.  We have based </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical drugs, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, costs and results of our clinical trials for our programs for ZN-c3 and ZN-d5;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, costs and results of additional research and preclinical studies in other research programs we initiate in the future; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which we in-license or acquire rights to other products, product candidates or technologies;  </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property-related claims; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">out ability to attract and retain skilled personnel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the magnitude and duration of the COVID-19 pandemic and its impact on our liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and future funding requirements is uncertain as of the filing date of this Quarterly Report on Form 10-Q, as the pandemic continues to evolve globally. We have considered and will continue to consider the availability of relief provided by such legislative actions as the Families First Act and the CARES Act, and have opted to pursue certain, but not all measures including the deferral of employer payroll taxes, but not including Payroll Protection Plan loans. See &#8220;Impact of COVID-19 Pandemic&#8221; and &#8220;Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has adversely impacted and we expect will continue to adversely impact our business, including our preclinical studies and clinical trials&#8221;. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our operating results may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no credit facility or committed sources of capital. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to our critical accounting estimates from our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any off-balance sheet arrangements.</span></div><div id="i24da124e87454cab95fd92a2627099ed_85"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i24da124e87454cab95fd92a2627099ed_88"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June&#160;30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in management&#8217;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act that occurred during the quarter ended June&#160;30, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i24da124e87454cab95fd92a2627099ed_94"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to any material legal proceedings.</span></div><div id="i24da124e87454cab95fd92a2627099ed_97"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the risks and uncertainties described below and the other information in this Quarterly Report on Form 10-Q, including our interim unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its potential impact on our business and the global economy. Our business, financial condition, results of operations or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. See &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain important factors, including those set forth below. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We have no products approved for commercial sale and have not generated any revenue from product sales. To date, we have devoted substantially all of our resources and efforts to organizing and staffing our company, business planning, executing partnerships, raising capital, discovering, identifying and developing potential product candidates, securing related intellectual property rights and conducting preclinical studies and clinical trials of our product candidates, including the ongoing clinical trials of ZN-c3, ZN-d5, ZN-c5 and ZN-e4. We have not yet demonstrated our ability to obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability than it could be if we had a longer operating history. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by clinical stage biopharmaceutical companies in rapidly evolving fields. We also may need to transition from a company with a research and development focus to a company capable of supporting commercial activities. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses in each reporting period since our inception, have not generated any revenue from product sales to date and have financed our operations principally through private financings, our initial public offering, or IPO, and follow-on public offerings of our common stock. We have incurred net losses of $166.1 million for the year ended December&#160;31, 2021, and $127.6 million and $105.5 million for the six months ended June&#160;30, 2022 and June&#160;30, 2021, respectively. As of June&#160;30, 2022, we had an accumulated deficit of $487.0 million. Our losses have resulted principally from expenses incurred in research and development of our product candidates and from management and administrative costs and other expenses that we have incurred while building our business infrastructure. Four of our product candidates, ZN-c3, ZN-d5, ZN-c5 and ZN-e4, are in clinical trials. Our other programs are in preclinical research. As a result, we expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses as we discover, develop and market additional potential products. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval and commercialization of our product candidates. The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital and our ability to achieve and maintain profitability. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve a number of objectives. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends entirely on the successful discovery, development and commercialization of our product candidates. We currently generate no revenues from sales of any products. We have no products approved for commercial sale and do not anticipate generating any revenue from product sales for the next several years, if ever. Our ability to generate revenue and achieve profitability depends significantly on our ability, or any future collaborator&#8217;s ability, to achieve a number of objectives, including: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successful and timely completion of preclinical and clinical development of our product candidates, including ZN-c3 and ZN-d5 and any other future product candidates, as well as the associated costs, including any unforeseen costs we have incurred and may continue to incur as a result of preclinical study or clinical trial delays due to the prolonged COVID-19 pandemic, global economic issues, including rising inflation and interest rates, or the ongoing military conflict in Ukraine, among other causes; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establishing and maintaining relationships with contract research organizations, or CROs, and clinical sites for the clinical development, both in the United States and internationally, of our product candidates, including ZN-c3, ZN-d5, and any other future product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete clinical development; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining marketing approvals, including making any required post-marketing approval commitments to applicable regulatory authorities; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developing an efficient and scalable manufacturing process for our product candidates, including obtaining finished products that are appropriately packaged for sale; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for product candidates that we develop, if approved; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successful commercial launch following any marketing approval, including the development of a commercial infrastructure, whether in-house or with one or more collaborators; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a continued acceptable safety profile following any marketing approval of our product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">commercial acceptance of our product candidates by patients, the medical community and third-party payors; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">identifying, assessing and developing new product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining, maintaining and expanding our intellectual property rights, including patents, trade secrets and know how, and regulatory exclusivity, both in the United States and internationally; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">protecting our rights in our intellectual property portfolio; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">defending against third-party interference or infringement claims, if any; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negotiating favorable terms in any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining adequate pricing, coverage and reimbursement by hospitals, government and third-party payors for product candidates that we develop; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">addressing any competing therapies and technological and market developments; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">attracting, hiring and retaining qualified personnel, especially in the current labor market.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we initiate and conduct clinical trials of, and seek marketing approval for, ZN-c3, ZN-d5 and our other product candidates. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. In addition, if we obtain marketing approval for any of our product candidates, including ZN-c3 and ZN-d5, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. We have also incurred, and expect to continue to incur, additional costs associated with operating as a public company, particularly now that we are no longer an emerging growth company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had cash and cash equivalents and marketable securities of $455.2 million. Based on current business plans, we believe that our existing cash, cash equivalents and marketable securities as of June&#160;30, 2022 will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2025, but will not be sufficient to fund all of the activities that are necessary to complete the development of our product candidates. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict our operating activities. We do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. Market volatility resulting from the COVID-19 pandemic, global supply chain disruptions, international political instability, rising inflation and interest rates or other factors could also adversely impact our ability to access capital as and when needed. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the success of our lead product candidates, ZN-c3, and/or ZN-d5, which are currently in clinical trials. If we are unable to complete development of, obtain approval for and commercialize these product candidates in a timely manner, our business will be harmed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is dependent on our ability to timely complete clinical trials, obtain marketing approval for and successfully commercialize our lead product candidates. We are investing significant efforts and financial resources in the research and development of ZN-c3 and ZN-d5. ZN-c3 and ZN-d5 will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval from government regulators, substantial investment and significant marketing efforts before we can generate any revenues from product sales. We are not permitted to market or promote ZN-c3 or ZN-d5, or any other product candidate, before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our lead product candidates will depend on several factors, including the following: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the successful and timely completion of our ongoing clinical trials of ZN-c3 and ZN-d5;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation and successful patient enrollment and completion of additional clinical trials of ZN-c3 and ZN-d5 on a timely basis; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining and establishing relationships with CROs and clinical sites for the clinical development of ZN-c3 and ZN-d5 both in the United States and internationally; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the frequency and severity of adverse events in the clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the efficacy, safety and tolerability profiles that are satisfactory to the FDA, EMA or any comparable foreign regulatory authority for marketing approval; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timely receipt of marketing approvals for ZN-c3 and ZN-d5 from applicable regulatory authorities; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the maintenance of existing or the establishment of new supply arrangements with third-party drug substance and drug product suppliers and manufacturers for clinical development of ZN-c3 and ZN-d5;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the maintenance of existing, or the establishment of new, scaled production arrangements with third-party manufacturers to obtain finished products that are appropriate for commercial sale of ZN-c3 and ZN-d5 if approved, including for supplies of drugs that we are testing in combination with ZN-c3 and ZN-d5; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining and maintaining our intellectual property rights, including patents, trade secrets and know how, and regulatory exclusivity, both in the United States and internationally; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the protection of our rights in our intellectual property portfolio; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the successful launch of commercial sales following any marketing approval; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a continued acceptable safety profile following any marketing approval; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">commercial acceptance by patients, the medical community and third-party payors; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to compete with other therapies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize ZN-c3 and ZN-d5, which would materially harm our business. If we do not receive marketing approvals for ZN-c3 and ZN-d5, we may not be able to continue our operations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have and in the future may enter into collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any of these collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have and in the future may seek third-party collaborators for the research, development and commercialization of one or more of our product candidates. Our likely collaborators in any future collaboration arrangements we may enter into include large and mid-size pharmaceutical companies and biotechnology companies. If we were to enter into any collaboration arrangements with third parties, those agreements may limit our control over the amount and timing of resources that our collaborators dedicate to the development and commercialization of any product candidates we may seek to develop with them. We cannot predict the success of any collaboration in which we have entered or may enter. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our research programs or any product candidates we may develop pose the following risks to us: </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations. </span></div><div style="padding-left:72pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;             Collaborators may not pursue development and commercialization of any product candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator's strategic focus or market considerations, including as a result of a sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition or business combination that diverts resources or creates competing priorities. If this were to happen, we may need additional capital to pursue further development or commercialization of the applicable product candidates. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;             Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;             Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;             Subject to certain diligence obligations, collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;             Collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use proprietary information in a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;             Collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in cases where that applies, we would not have the exclusive right to commercialize the collaboration intellectual property. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;             Disputes may arise between our collaborators and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;             We may lose certain rights under circumstances identified in our collaborations, including if we undergo a change of control. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;             Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;             Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;             Collaborators may be unable to maintain compliance with good practice quality guidelines and regulations, including good laboratory practice, or GLP, good clinical practice, or GCP, and current good manufacturing practice, or cGMP, requirements or to secure approval for clinical development plans from the FDA or foreign regulatory authorities. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed and we may need additional resources to develop our product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, marketing approval and commercialization described in this report apply to the activities of our collaborators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, these collaborations and other similar relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. We could also face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator's resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator's evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of those transactions if we are unable to successfully integrate them with our existing operations and company culture.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term prospects depend in part upon discovering, developing and commercializing additional product candidates, which may fail in development or suffer delays that adversely affect their commercial viability. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize product candidates beyond those we currently have in clinical development. A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical testing or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of other product candidates we may develop will depend on many factors, including the following: </span></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:68.5pt">generating sufficient data to support the initiation or continuation of clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:68.5pt">obtaining regulatory permission to initiate clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:68.5pt">contracting with the necessary parties to conduct clinical trials; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:68.5pt">successful enrollment of patients in, and the completion of, clinical trials on a timely basis; </span></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:68.5pt">the timely manufacture of sufficient quantities of the product candidate for use in clinical trials; and </span></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:68.5pt">adverse events in the clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we successfully advance any other product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this &#8220;Risk Factors&#8221; section. Accordingly, we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our other product candidates. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities impose similar requirements. The time required to obtain approval by the FDA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. For example, a U.S. federal government shutdown or budget sequestration, such as ones that occurred during 2013, 2018 and 2019, may result in significant reductions to the FDA&#8217;s budget, employees and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a New Drug Application, or NDA, or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be unable to demonstrate to the FDA or other comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the approval policies or regulations of the FDA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the policies of the FDA and other regulatory authorities with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the European Union, or EU, recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we obtain approval of our product candidates, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS, or similar risk management measures. Regulatory authorities may not approve the price we intend to charge for products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could seriously harm our business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The clinical trials of our product candidates may not demonstrate safety and efficacy to the satisfaction of the FDA or other comparable foreign regulatory authorities or otherwise produce positive results. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from the FDA or other comparable foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at any stage of the process. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may rely in part on preclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. While we have or will have agreements governing these third parties&#8217; services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed, and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether our future clinical trials will begin on time or enroll patients on time, or whether our ongoing and/or future clinical trials will be completed on schedule or at all. Clinical trials can be delayed for a variety of reasons, including delays related to: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining approval from one or more institutional review boards, or IRBs, or ethics committees; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">IRBs or ethics committees refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes to clinical trial protocol; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites deviating from trial protocol or dropping out of a trial; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manufacturing sufficient quantities of product candidate or obtaining sufficient quantities of combination therapies for use in clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post- treatment follow-up;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">lack of adequate funding to continue the clinical trial; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects experiencing severe or unexpected drug-related adverse effects; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of cGMP regulations or similar foreign requirements or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any changes to our manufacturing process that may be necessary or desired; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">third-party contractors not performing data collection or analysis in a timely or accurate manner; or </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, disruptions caused by the COVID-19 pandemic have caused and we expect will continue to cause difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs or ethics committees for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for their intended uses. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical studies and early-stage clinical trials does not mean that future clinical trials will be successful. We do not know whether ZN-c3, ZN-d5, ZN-c5 and ZN-e4 will perform in current or future clinical trials as ZN-c3, ZN-d5, ZN-c5 and ZN-e4 have performed in preclinical studies, or, with respect to ZN-c3, ZN-d5, ZN-c5 and ZN-e4, ongoing clinical trials to date, or with respect to ZN-c5, the completed clinical trial. Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, EMA and other comparable foreign regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidate. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could seriously harm our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority approval. We cannot guarantee that the FDA or foreign regulatory authorities will interpret trial results as we do, and more trials could be required before we are able to submit applications seeking approval of our product candidates. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential. Furthermore, the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA or comparable foreign regulatory authorities delaying, limiting or denying approval of our product candidates. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, initial, &#8220;topline&#8221;, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose initial, preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the initial, topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, initial, topline and preliminary data should be viewed with caution until the final data are available. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial, interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including: </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments; </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the timing of market introduction of the product candidate as well as competitive products; </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the clinical indications for which the product candidate is approved; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">restrictions on the use of our product candidates, such as boxed warnings or contraindications in labeling, or a REMS, or similar risk management measures if any, which may not be required of alternative treatments and competitor products; </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the potential and perceived advantages of product candidates over alternative treatments; </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the cost of treatment in relation to alternative treatments; </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the availability of coverage and adequate reimbursement, as well as pricing, by third-party payors, including government authorities; </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the availability of the approved product candidate for use as a combination therapy; </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">relative convenience and ease of administration; </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the effectiveness of sales and marketing efforts; </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">unfavorable publicity relating to our products or product candidates or similar approved products or product candidates in development by third parties; and </span></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the approval of other new therapies for the same indications.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#8217;s conclusion as required by the FDA or other comparable foreign regulatory authorities. Additionally, certain clinical trials for future product candidates may be focused on indications with relatively small patient populations, which may further limit enrollment of eligible patients or may result in slower enrollment than we anticipate. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment may also be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment for any of our clinical trials may be affected by other factors, including: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">size and nature of the patient population; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">severity of the disease under investigation; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">availability and efficacy of approved drugs for the disease under investigation; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patient eligibility criteria for the trial in question as defined in the protocol; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">perceived risks and benefits of the product candidate under study; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">efforts to facilitate timely enrollment in clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patient referral practices of physicians; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability to monitor patients adequately during and after treatment; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">proximity and availability of clinical trial sites for prospective patients; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continued enrollment of prospective patients by clinical trial sites; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to develop ZN-c3, ZN-d5, and potentially other product candidates in combination with other therapies, which exposes us to additional risks. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to develop ZN-c3, ZN-d5, and likely other future product candidates in combination with one or more other approved or unapproved therapies to treat cancer or other diseases. For example, we are currently evaluating ZN-c3 in combination with the approved agent niraparib. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may choose to evaluate ZN-c3, ZN-d5, or any other future product candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell ZN-c3, ZN-d5, or any product candidate we develop in combination with an unapproved cancer therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved cancer therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain approval of or market such combination therapy. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunity for any product candidate that we or our strategic partners develop is smaller than we believe, our revenue may be adversely affected and our business may suffer. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to initially focus our product candidate development on treatments for various oncology indications. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In addition, our products may need to compete with off-label drugs used by physicians to treat the indications for which we seek approval. This may make it difficult for us to replace existing therapies with our products. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, there is intense competition in the fields of oncology we are pursuing. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and in-licensing new product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have chosen to initially address well-validated biochemical targets, and therefore expect to face competition from existing products and products in development for each of our product candidates. There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. Many of these current and potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field before we do. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA or other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs, therapeutic platforms and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources and substantial monetary awards to trial participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business and financial condition. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics that we or our collaborators may develop. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the member states of the European Union, or EU, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing authorization. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval and Other Legal Compliance Matters </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize our product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. We cannot provide any assurance that any product candidate we may develop will progress through required clinical testing and obtain the regulatory approvals necessary for us to begin selling them. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not conducted, managed or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the FDA or any other regulatory authority. The time required to obtain approvals from the FDA and other regulatory authorities is unpredictable, and requires successful completion of extensive clinical trials which typically takes many years, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when evaluating clinical trial data can and often changes during drug development, which makes it difficult to predict with any certainty how they will be applied. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, or changes in FDA or foreign regulatory authorities policy during the period of drug development, clinical trials and FDA or foreign regulatory authorities regulatory review. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we developing and seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on the approved uses or indications for which we may market the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as part of approving a NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. Similar requirements may exist in foreign jurisdictions. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval in foreign jurisdictions may differ from that required to obtain FDA approval. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current or future product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product candidates&#8217; use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in our ongoing and planned clinical trials may in the future suffer significant adverse events or other side effects not observed in our preclinical studies or previous clinical trials. Some of our product candidates, may be used as chronic therapies or be used in pediatric populations, for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if our product candidates are used in combination with other therapies, our product candidates may exacerbate adverse events associated with the therapy. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate, but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if any of our product candidates obtains marketing approval, toxicities associated with such product candidates and not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early-stage clinical trials. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to conduct international clinical trials in the future. The acceptance of study data by the FDA, EMA or other comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless i)&#160;the data are applicable to the U.S. population and U.S. medical practice; ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to current GCP requirements; and iii) the FDA is able to validate the data through an on-site inspection or other appropriate mean. Additionally, the FDA&#8217;s clinical trial requirements, including the adequacy of the patient population studied and statistical powering, must be met. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of its applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs or similar foreign requirements and GCP for any clinical trials that we conduct post-approval. In addition, CMOs and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations or similar foreign requirements and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in or the rejection of product approvals; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the products, manufacturers or manufacturing process; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">warning or untitled letters; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">civil and criminal penalties; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injunctions; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or withdrawal of regulatory approvals; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product seizures, detentions or import bans; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">voluntary or mandatory product recalls and publicity requirements; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">total or partial suspension of production; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of restrictions on operations, including costly new manufacturing requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The&#160;FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are required by the FDA or similar regulatory authorities to obtain approval (or clearance, or certification) of a companion diagnostic test in connection with approval of any of our product candidates, and we do not obtain or face delays in obtaining approval (or clearance, or certification) of a diagnostic device, we will not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If safe and effective use of any of our product candidates depends on an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostic that is not otherwise commercially available, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates if at all. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. If a satisfactory companion diagnostic is not commercially available, we may be required to create or obtain one that would be subject to regulatory approval requirements. The process of obtaining or creating such diagnostic is time consuming and costly. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable regulatory authorities, and, to date, the FDA has generally required premarket approval of all companion diagnostics for cancer therapies. The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genetic alteration that the companion diagnostic was developed to detect. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or a comparable regulatory authority requires approval, clearance or certification of a companion diagnostic for any of our product candidates, whether before or after it obtains marketing approval, we, and/or future collaborators, may encounter difficulties in developing and obtaining approval for such product candidate. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval, clearance or certification of a companion diagnostic could delay or prevent approval or continued marketing of such product candidate. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our product candidate, if approved, on a timely or profitable basis, if at all. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, approval, clearance or certification of companion diagnostics may be subject to further legislative or regulatory reforms notably in the EU. On May 25, 2017, the In Vitro Medical Devices Regulation (2017/746, or IVDR), entered into force. The IVDR repeals and replaces the EU In Vitro Diagnostic Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EU member, regulations are directly applicable, i.e., without the need for adoption of EU member states laws implementing them, in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The IVDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation. The IVDR became applicable in May 2022; however, the European Parliament and Council adopted a &#8220;progressive&#8221; roll-out of the IVDR to prevent disruption in the supply of in vitro diagnostic medical devices, and there is a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the regulation. The IVDR also introduces a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue a CE certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a marketing authorization application for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a national competent authorities or the EMA. These modifications may make it more difficult and costly for us to obtain regulatory clearances or approvals or certifications for our companion diagnostics or to manufacture, market or distribute our products after clearance or approval or certification is obtained.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA, the SEC, and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA and other regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA&#8217;s and foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies, such as the EMA, following its relocation to Amsterdam and resulting staff changes, may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote interactive evaluations in situations where an in-person inspection would not be prioritized, deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remote evaluation would be appropriate. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways or any other form of expedited development or review. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future seek an accelerated approval or any other form of expedited development or review for our one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verity and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use may perform an accelerated assessment of a marketing authorization application. Applicants requesting an accelerated assessment procedure must justify that the drug candidate is expected to be of major public health interest, particularly from the point of view of therapeutic innovation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to seeking accelerated approval or any other form of expedited development or review for any of our product candidates, we intend to seek feedback from the FDA or foreign regulatory authorities and will otherwise evaluate our ability to seek and receive accelerated approval or any other form of expedited development or review. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA or foreign regulatory authorities feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face difficulties from changes to current regulations and future legislation. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was passed, which substantially changes the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration will impact our business. We are continuing to monitor any changes to the ACA that, in turn, may potentially impact our business in the future.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April&#160;1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through December 31, 2021 unless additional congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and government price reporting, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal, state and foreign healthcare laws and regulations include the following: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation;  </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Physician Payments Sunshine Act (renamed the Open Payments Act) requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians, as defined by such law, certain non-physician practitioners including physician assistants and nurse practitioners, and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information reported is publicly available on a searchable website, with disclosure required annually; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Some state laws require biotechnology companies to report information on the pricing of certain drug products. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation, and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. We do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties, but we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. Certain states have also adopted comparable privacy and security laws and regulations governing the privacy, processing and protection of personal information. For example, the State of California enacted the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act, or CPRA, recently passed in California. The CPRA significantly amends the CCPA and will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia and Colorado, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. For instance, the EU General Data Protection Regulation, or GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements, administrative penalties and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States. In July 2020, the Court of Justice of the EU, or CJEU, limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses, or SCCs. The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. The new SCCs apply only to the transfer of personal data outside of the EEA and not the UK; the UK&#8217;s Information Commissioner&#8217;s Office launched a public consultation on its draft revised data transfers mechanisms in August 2021. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. The GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms to ensure compliance. This may be onerous and if our efforts to comply with GDPR or other applicable EEA laws and regulations are not successful, it could adversely affect our business in Europe. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, from January 1, 2021, companies have had to comply with both the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in United Kingdom national law.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how the UK data protection laws or regulations will develop in the medium to longer term. On June 28, 2021, the European Commission adopted an adequacy decision in favor of the UK, enabling data transfers from member states in the EU to the UK without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission renews or extends that decision. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA and other foreign authorities regulations, provide accurate information to the FDA or foreign regulatory authorities, comply with federal, state and foreign health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business activities may be subject to the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits companies and their employees and third party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business, prospects, operating results and financial condition. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our products and activities may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell access to our products would likely adversely affect our business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic has adversely impacted and we expect will continue to adversely impact our business, including our preclinical studies and clinical trials. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, a strain of the novel coronavirus disease, COVID-19, was declared a pandemic and spread across the world, including throughout the United States, Europe and Asia. The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the spread of COVID-19, we limited access to our executive offices, with the majority of our administrative employees continuing their work outside of our offices, and we limited the number of staff in any given research and development laboratory by operating on rotational schedules. As of June&#160;30, 2022, our employees have begun working based on a hybrid work model, in which they work both from our executive office and remotely. As a result of the COVID-19 pandemic, we have experienced and we expect to continue to experience disruptions that could severely impact our business, preclinical studies and clinical trials, including: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continued delays or difficulties in enrolling patients in our clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continued delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in receiving authorizations from regulatory authorities to initiate our planned clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state or foreign governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risk that participants enrolled in our clinical trials will contract COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risk that we are unable to enroll participants in our clinical trials in adequate numbers;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruptions in preclinical studies due to restricted or limited operations at our laboratory facility; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in local regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption or delays to our sourced discovery and clinical activities; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, the impact of variants, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the adoption, the prolonged efficacy of available vaccines and effectiveness of vaccination efforts and other actions taken in the United States and other countries to contain and treat the disease. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and scientific and medical staff. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to commercialize any product candidates, if approved, we must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not be successful in accomplishing these required tasks. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishing an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming, and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of our product candidates that we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never commercialized a product candidate, and we currently have no sales force, marketing or distribution capabilities. To achieve commercial success for the product candidates, which we may license to others, we will rely on the assistance and guidance of those collaborators. For product candidates for which we retain commercialization rights, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may affect our ability to commercialize our product candidates on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our product candidates and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our product candidates. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may not generate revenues from them or be able to reach or sustain profitability. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to successfully implement our development and commercialization plans and strategies, and as we continue to operate as a public company, we expect to need additional managerial, operational, sales, marketing, financial, legal, compliance and other personnel. Future growth would impose significant added responsibilities on members of management, including: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">managing our internal development efforts effectively, including the clinical, FDA, EMA and other comparable foreign regulatory agencies&#8217; review process for ZN-c3, ZN-d5, and any other future product candidates, while complying with any contractual obligations to contractors and other third parties we may have; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our future financial performance and our ability to successfully develop and, if approved, commercialize, ZN-c3, ZN-d5, and any other future product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. Furthermore, certain of our employees, including members of our management team perform services on behalf of Kalyra Pharmaceuticals, Inc., and Zentera Therapeutics, Ltd., pursuant to intercompany and collaborative service agreements, respectively. As a result, such individuals do not allocate all of their time and resources to us and our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">other subsidiaries which, coupled with the need to manage growth activities, could further limit their ability to devote a sufficient amount of attention to day-to-day activities of our business. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of ZN-c3, ZN-d5, and any other future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize ZN-c3, ZN-d5, and any other future product candidates and, accordingly, may not achieve our research, development and commercialization goals. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of any of our CROs, CMOs, other contractors, consultants, collaborators or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs, CMOs and other contractors, consultants, collaborators and third-party service providers, are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If such an event were to occur and cause interruptions in our operations or result in the unauthorized acquisition of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations promulgated thereunder, and GDPR), it could result in a material disruption of our drug discovery and development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy and security laws.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EU pricing, drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In&#160;addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national laws of EU member states, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and/or approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A portion of our manufacturing of our lead product candidates takes place in China through third-party manufacturers. A significant disruption in the operation of those manufacturers, a trade war or political unrest in China could materially adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently contract manufacturing operations to third parties, and clinical quantities of our lead product candidates are manufactured by these third parties outside the United States, including in China, and we expect to continue to use such third-party manufacturers for such product candidates. Any disruption in production or inability of our manufacturers in China to produce adequate quantities to meet our needs, whether as a result of a natural disaster or other causes, could impair our ability to operate our business on a day-to-day basis and to continue our development of our product candidates. Furthermore, since these manufacturers are located in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, a trade war could lead to tariffs on the chemical intermediates we use that are manufactured in China. Any of these matters could materially and adversely affect our business and results of operations. Any recall of the manufacturing lots or similar action regarding our product candidates used in clinical trials could delay the trials or detract from the integrity of the trial data and its potential use in future regulatory filings. In addition, manufacturing interruptions or failure to comply with regulatory requirements by any of these manufacturers could significantly delay clinical development of potential products and reduce third-party or clinical researcher interest and support of proposed trials. These interruptions or failures could also impede commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currency in China. Future appreciation of the local currency could increase our costs. In addition, our labor costs could continue to rise as wage rates increase due to increased demand for skilled laborers and the availability of skilled labor declines in China. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations are vulnerable to interruption by fire, severe weather conditions, power loss, telecommunications failure, terrorist activity and other events beyond our control, which could harm our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facility is located in a region which experiences severe weather from time to time. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major tornado, flood, fire, earthquake, power loss, terrorist activity or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, we had available federal and state net operating loss, or NOL, carryforwards of approximately $361.1 million and $90.4 million, respectively. $340.2 million of our federal NOLs were generated in taxable years beginning after December 31, 2017 and can be carried forward indefinitely, but may only be used to offset 80% of our taxable income in future periods. This limitation may require us to pay U.S. federal income taxes in future years despite generating federal NOLs in prior years. Our federal NOLs generated in tax years beginning prior to January 1, 2018 are not subject to this limitation, but are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law, and will start to expire in 2033 if not utilized. Our state NOL carryforwards begin to expire in 2033.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a cumulative change in our ownership by one or more &#8220;5-percent shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period), the corporation&#8217;s ability to use its pre-ownership change federal NOLs and certain other pre-change tax attributes to offset its post-change taxable income and income tax liabilities may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. We have not conducted any studies to determine whether any such ownership changes have occurred or the annual limitations, if any, that could </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">result from such ownership changes. Our ability to utilize our NOLs and certain other tax attributes could be limited by an ownership change as described above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have a material adverse effect on our cash flows and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">differing regulatory requirements and reimbursement regimes in foreign countries; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign taxes, including withholding of payroll taxes; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulties staffing and managing foreign operations; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential liability under the FCPA or comparable foreign regulations; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business interruptions resulting from geo-political actions, including war and terrorism.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to protect our intellectual property and our proprietary platform. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses, our and our licensors&#8217; ability to operate without infringing the proprietary rights of others, and our and our licensors&#8217; ability to successfully defend our patents, including those that we have in-licensed, against third party challenges. If we or our licensors are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed. We and our licensors generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents, if issued, will not be infringed, designed around, invalidated or rendered unenforceable by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our and our licensors&#8217; proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our or our licensors&#8217; rights or permit us or our licensors to gain or keep any competitive advantage. These uncertainties and/or limitations in our and our licensors&#8217; ability to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we license issued patents in the United States and foreign countries, we cannot be certain that the claims in our other U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued patents will not be found invalid or unenforceable if challenged. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our licensors or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patent applications may not result in any patents being issued; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitors, many of whom have substantially greater resources than we or our licensors do and many of whom have made significant investments in competing technologies, may seek, may have filed patent applications, or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is also expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our licensors may not identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license, including those from our licensors and from third parties. We also may require the cooperation of our licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and, as a result, our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, CMOs, consultants, advisors, licensors, and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from our licensors and third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of license agreements under which we are granted rights to intellectual property that are important to our business and we may enter into additional license agreements in the future. For example, in September 2019, we entered into an exclusive license agreement with Recurium IP Holdings, LLC, or Recurium&#160;IP, to obtain an exclusive license to certain intellectual property rights to develop and commercialize ZN-c3, ZN-d5, ZN-c5 and ZN-e4. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This and our other existing license agreements impose on us, and we expect that any future license agreements where we in-license intellectual property will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, the licensors may have the right to terminate the licenses, in which event we would not be able to market products covered by the licenses. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our product candidates in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our right to sublicense patents and other rights to third parties; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our right to transfer or assign the license; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and its affiliates and sublicensees and by us and our partners and sublicensees.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, if we choose to sublicense or assign to any third parties our rights under our existing license agreement with Recurium with respect to any licensed product, we may be required to pay to Recurium a specified percentage of all revenue to be received in connection with such transaction. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the scope of any patent protection our licensors obtain is not sufficiently broad, or if our licensors lose any of the patent protection we license, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the existence, issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our product candidates or that effectively prevent others from commercializing competitive product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the scope of claims in a patent application can be significantly reduced before any claims in a patent issue, and claim scope can be reinterpreted after issuance. Even if patent applications we license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any patents that we license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner, which could materially adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our in-licensed patents may not cover our product candidates or may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity of our patents, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensors and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our patents and patent applications or those of our licensors has been found. There is also no assurance that there is not prior art of which we or licensors were or are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or those of our licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us. Such loss of in-licensed patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates may be dependent on our licensors and third parties. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects as to form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our in-licensed patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a licensee, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fails to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to us assuming control over patent prosecution. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology acquired or licensed from various third parties, including our licensors, may be subject to retained rights. Our licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for use in fields other than the fields licensed to us or for use in noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical licensed technology, we may be unable to successfully develop, out-license, market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our product candidate. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our intellectual property has been discovered through government-funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products relating to such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors might not have been the first to make the inventions covered by the issued patents or patent application that we own or license; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors might not have been the first to file patent applications covering certain of our inventions; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">it is possible that our licensors&#8217; pending patent applications will not lead to issued patents; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not develop additional proprietary technologies that are patentable; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, it could significantly harm our business, results of operations and prospects. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the biopharmaceutical industry expands and more patents issue, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes these patents. Any claims of patent infringement asserted by third parties would be time consuming and could: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">result in costly litigation that may cause negative publicity; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">divert the time and attention of our technical personnel and management; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cause development delays; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or unenforceable or not infringed in a court of law; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subject us to significant liability to third parties; or </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although no third party has asserted a claim of patent infringement against us as of the date of this Quarterly Report on Form 10-Q, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and operating results. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we and/or our licensors may be required to file infringement claims, which can be expensive and time-consuming. Further, our licensors may need to file infringement claims, and our licensors may elect not file such claims. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our licensors or potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty or written description, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent intentionally withheld material information from the USPTO or made a misleading statement during prosecution. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivation or interference proceedings provoked by third parties or brought by us or our licensors, or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions with respect to our or our licensors&#8217; patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our or our licensors&#8217; defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (1)&#160;file any patent application related to our product candidates or (2)&#160;invent any of the inventions claimed in our patents or patent applications. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our or our licensors&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensors&#8217; ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors may be subject to claims challenging the inventorship or ownership of our or our patents and other intellectual property. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we or our licensors are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the term of a patent, and the protection it affords, is limited. Even if patents directed to our product candidates are obtained, once the patent term has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents directed to our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our licensors do not obtain patent term extension for our product candidates, our business may be materially harmed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we or our licensors may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we or our licensors are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have issued patents and pending patent applications in the United States and certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our licensors have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our or our licensors patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our or our licensors&#8217; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our or our licensors&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly and our or our licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our or our licensors&#8217; efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants, licensors and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we or our licensors do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors, including CROs, are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations and similar foreign requirements. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal, state or foreign fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and government measures taken in response have also had a significant impact on our CROs, and we expect that they will face further disruption which may affect our ability to initiate and complete our preclinical studies and clinical trials. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contract with third parties for the manufacture of our product candidates for preclinical studies and our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. We do not have long-term supply agreements, and we purchase our required supply on a purchase order basis. Furthermore, the raw materials for our product candidates are sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. For example, the extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the failure of the third-party manufacturers to manufacture our product candidates according to our schedule, or at all, including if our third-party manufacturers give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the termination or nonrenewal of arrangements or agreements by our third-party manufacturers at a time that is costly or inconvenient for us; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the breach by the third-party manufacturers of our agreements with them; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the failure of third-party manufacturers to comply with applicable regulatory requirements; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the failure of the third-party manufacturers to manufacture our product candidates according to our specifications; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the misappropriation of our proprietary information, including our trade secrets and know-how.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our third party contract manufacturing partners for compliance with cGMP regulations or similar foreign requirements for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our third party contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we decide to establish collaborations in the future, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may continue to seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We would face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The&#160;potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have and in the future may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have and may in the future seek third-party collaborators for the development and commercialization of one or more of our product candidates. Our likely collaborators for any future collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates could pose numerous risks to us, including the following: </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may deemphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus, including as a result of a sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property related proceedings; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all; and </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our drug development or commercialization program could be delayed, diminished or terminated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock may be volatile, and you could lose all or part of your investment. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock is likely to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section, these factors include: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and results of preclinical studies and clinical trials of our product candidates or those of our competitors; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of competitive products or announcements by potential competitors of their product development efforts; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory actions with respect to our products or our competitors&#8217; products; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in our growth rate relative to our competitors; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory or legal developments in the United States and other countries; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the recruitment or departure of key personnel; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market conditions in the pharmaceutical and biotechnology sector; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the structure of healthcare payment systems; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">speculative trading in and short sales of our common stock, as well as trading phenomena such as the &#8220;short squeeze&#8221;;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcement or expectation of additional financing efforts; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of our common stock by us, our insiders or our other stockholders; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expiration of market stand-off or lock-up agreements; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general economic, industry and market conditions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trading prices for common stock of other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. The COVID-19 pandemic continues to evolve and the duration of its impact remains uncertain. The extent to which the pandemic may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">variations in the level of expense related to the ongoing development of our product candidates or future development programs; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">results of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future partners; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any such potential future arrangements; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">additions and departures of key personnel; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory developments affecting our product candidates or those of our competitors; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in general market and economic conditions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current beneficial owners of 5% or more of our common stock and management own a significant percentage of our stock and are able to exert significant influence over matters subject to stockholder approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially own approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 60.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">% of our outstanding common stock. As a result, these stockholders will be able to significantly influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Outstanding shares of our common stock may be freely sold in the public market at any time to the extent permitted by Rules 144 and 701 under the Securities Act, or to the extent that such shares have already been registered under the Securities Act and are held by non-affiliates of ours. Moreover, holders of a substantial number of shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also register shares of common stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. For example, in August 2020, July 2021 and May 2022, we completed underwritten public offerings of our common stock and in April 2022, we completed a direct offering of our common stock. To the extent that we raise additional capital through the sale of equity or convertible debt or equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation and bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish a classified Board of Directors so that not all members of our Board of Directors are elected at one time; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">permit only the Board of Directors to establish the number of directors and fill vacancies on the Board of Directors; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorize the issuance of &#8220;blank check&#8221; preferred stock that our Board of Directors could use to implement a stockholder rights plan (also known as a &#8220;poison pill&#8221;); </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">eliminate the ability of our stockholders to call special meetings of stockholders; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prohibit cumulative voting; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorize our Board of Directors to amend the bylaws; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish advance notice requirements for nominations for election to our Board of Directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require a super-majority vote of stockholders to amend some provisions described above.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware, or the DGCL, prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any derivative action or proceeding brought on our behalf; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any action asserting a claim of breach of fiduciary duty; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any action asserting a claim against us arising under the DGCL, our certificate of incorporation or our bylaws; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This exclusive-forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. If a court were to find this exclusive-forum provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. Nothing in our certificate of incorporation precludes stockholders that assert claims under the Securities Act or the Exchange Act from bringing such claims in state or federal court, subject to applicable law. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our equity securities. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of our common stock, which is not certain. </span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including: </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; increased operating expenses and cash requirements; </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; the assumption of additional indebtedness or contingent liabilities; </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; the issuance of our equity securities; </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition; </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships; </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </span></div><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports regarding us, our business, or our market, our stock price and trading volume could decline. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company may strain our resources, result in more litigation and divert management&#8217;s attention. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are and will continue to be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, the listing requirements of Nasdaq and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control over financial reporting on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We have invested and intend to continue to invest in resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These new rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our Board of Directors, particularly to serve on our Audit Committee and Compensation Committee, and qualified executive officers. By disclosing information in filings required of us as a public company, our business and financial condition will continue to become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#8217;s resources and seriously harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. Now that we are no longer an emerging growth company, our independent registered public accounting firm is required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Unfavorable global political or economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. In addition, the current military conflict between Russia and Ukraine could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions have and may in the future be initiated by nations including the U.S., the EU or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with which we conduct business. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i24da124e87454cab95fd92a2627099ed_100"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i24da124e87454cab95fd92a2627099ed_103"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i24da124e87454cab95fd92a2627099ed_106"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i24da124e87454cab95fd92a2627099ed_109"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 8, 2022, Dimitris Voliotis, M.D., employment as Senior Vice President, Clinical Development of Zeno Management, Inc. (&#8220;Zeno&#8221;), a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the &#8220;Company&#8221;), was terminated, effective immediately.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As previously disclosed, Zeno and Dr. Voliotis are parties to an Employment Agreement, dated March 25, 2020 (&#8220;Employment Agreement&#8221;). In connection with Dr. Voliotis&#8217;s termination other than for cause, the Company expects that Zeno will enter into an agreement with Dr. Voliotis pursuant to which he will be eligible to receive the following payments and benefits to which he is entitled under his Employment Agreement, subject to his timely execution and non-revocation of a general release of claims in favor of Zeno and its affiliates and his continued compliance with the restrictive covenants set forth in the Employment Agreement: (a) his fully-earned but unpaid base salary through the date of termination at the rate then in effect, plus all other amounts under any compensation plan or practice to which he is entitled; (b) a payment equal to 9 months of his then-current base salary, payable in a lump sum 60 days following the termination date; and (c) payment of the COBRA premiums for him and his eligible dependents for 9 months following his termination date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing information is included for the purpose of providing the disclosures required under</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;Item 5.02 &#8211; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers&#8221; of Form 8-K.</span></div><div id="i24da124e87454cab95fd92a2627099ed_112"></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:10.172%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.161%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:36.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1725160/000172516020000007/zentalis-eleaxplanofconv.htm">Plan of Conversion Converting Zentalis Pharmaceuticals, LLC (a Delaware limited liability company) into Zentalis Pharmaceuticals, Inc. (a Delaware corporation)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/15/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1725160/000172516020000007/zntl-certificateofconver.htm">Certificate of Conversion Converting Zentalis Pharmaceuticals, LLC (a Delaware limited liability company) into Zentalis Pharmaceuticals, Inc. (a Delaware corporation)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/15/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1725160/000119312520100536/d914800dex41.htm">Certificate of Incorporation of Zentalis Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-237593</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/07/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001725160/000172516021000063/exhibit-31xzntlxamendedres.htm">Bylaws of Zentalis Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/19/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1725160/000172516022000138/zentalis-2022employmentind.htm">Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07/22/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001725160/000172516022000138/zentalis-formofstockoption.htm">Form of Option Agreement pursuant to the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07/22/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1725160/000172516022000138/zentalis-formofrsuagreemen.htm">Form of RSU Agreement pursuant to the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07/22/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1725160/000119312522150883/d361453dex101.htm">Employment Agreement, dated May 11, 2022, between Zentalis Pharmaceuticals, Inc. and Kimberly Blackwell, M.D.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/16/22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:10.172%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.161%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:36.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1725160/000119312522150883/d361453dex102.htm">Release Agreement, dated May 10, 2022, between Zentalis Pharmaceuticals, Inc. and Anthony Y. Sun, M.D.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/16/22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1725160/000172516022000114/zenoaremploymentagreementg.htm">Amended and Restated Employment Agreement, dated May 30, 2022, between Zeno Management, Inc. and Cam S. Gallagher</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/31/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis-executiveemployme.htm">Employment Agreement, dated June 23, 2022, between Zeno Management, Inc. and Andrea Paul</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq22022ex311.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq22022ex311.htm">Certification of Chief Executive Officer pursuant to Exchange Act Rule&#160;13a-14(a).</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq22022ex312.htm">31.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq22022ex312.htm">Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq22022ex321.htm">32.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq22022ex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq22022ex322.htm">32.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq22022ex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data file (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.865%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"># &#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="i24da124e87454cab95fd92a2627099ed_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August 9, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Kimberly Blackwell, M.D.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberly Blackwell, M.D.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August 9, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Melissa B. Epperly</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa B. Epperly</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial and accounting officer)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8#
<SEQUENCE>2
<FILENAME>zentalis-executiveemployme.htm
<DESCRIPTION>EX-10.8#
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2d942d87774d4d41bf20c703b090cdd7_1"></div><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:2.55pt;padding-left:15.9pt;padding-right:15.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12.5pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:9.55pt;padding-left:41.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:116%">THIS EMPLOYMENT AGREEMENT (this </font><font style="color:#000000;font-family:'Gill Sans MT',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:116%">&#34;Agreement') </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:116%">is entered into as of June 23, 2022,</font></div><div style="margin-top:1.65pt;padding-left:5.15pt;padding-right:15.9pt;text-align:justify;text-indent:0.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">by and between Zeno Management, Inc., a Delaware corporation (the </font><font style="color:#000000;font-family:'Gill Sans MT',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:111%">&#34;Company&#34;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the </font><font style="color:#000000;font-family:'Gill Sans MT',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:111%">&#34;Parent&#34;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">and Andrea Paul </font><font style="color:#000000;font-family:'Gill Sans MT',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:111%">(&#34;Executive&#34;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">and shall be effective as of the date of Executive's commencement of employment with the Company (the </font><font style="color:#000000;font-family:'Gill Sans MT',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:111%">&#34;Effective Date&#34;).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:6.65pt;padding-left:5.95pt;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">WHEREAS, the Company desires to employ Executive, and Executive desires to commence employment with the Company, on the terms and conditions set forth in this Agreement.</font></div><div style="margin-top:11.8pt;padding-left:6pt;padding-right:10.95pt;text-indent:35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties agree as follows&#58;</font></div><div style="padding-right:10.95pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">. As used in this Agreement, the following terms shall have the following meanings&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(a) &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">'' means the Board of Directors of the Company.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(b) &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#34; means any of the following&#58; </font></div><div><font><br></font></div><div style="padding-left:4.5pt;text-indent:107.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(i) &#160;&#160;&#160;&#160;Executive's unauthorized use or disclosure of confidential information or trade secrets of the Company or its affiliates or any material breach of a written agreement between Executive and the Company or any affiliate, including without limitation a material breach of any employment, confidentiality, non-compete, non-solicit or similar agreement&#59;</font></div><div style="margin-top:11.8pt;padding-left:5.75pt;padding-right:16.3pt;text-align:justify;text-indent:107.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">(ii)&#160;&#160;&#160;&#160;Executive's commission of, indictment for or the entry of a plea of guilty or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:111%">nolo contendere </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">by Executive to, a felony under the laws of the United States or any state thereof or any crime involving dishonesty or moral turpitude (or any similar crime in any jurisdiction outside the United States)&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:6.65pt;padding-left:5.9pt;padding-right:16.45pt;text-align:justify;text-indent:107.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">(iii)&#160;&#160;&#160;&#160;Executive's gross negligence or willful misconduct or Executive's willful or repeated failure or refusal to substantially perform assigned duties&#59;</font></div><div style="margin-top:12.3pt;padding-left:5.95pt;padding-right:16.15pt;text-align:justify;text-indent:107.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:109%">(iv)&#160;&#160;&#160;&#160;any act of fraud, embezzlement, material misappropriation or dishonesty committed by Executive against the Company or its affiliates&#59; or</font></div><div style="margin-top:12.1pt;padding-left:5.2pt;padding-right:16.2pt;text-align:justify;text-indent:108.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">(v)&#160;&#160;&#160;&#160;any misconduct (including acts, omissions or statements that constitute misconduct) by Executive which the Company reasonably determines to be materially detrimental or damaging to the reputation, operations, prospects or business relations of the Company or its affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%;text-decoration:underline">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%"> that prior to the determination that &#34;Cause&#34; under clauses (i), (iii), (iv) or (v) of this Section l(b) has occurred, the Company shall (A) provide to Executive and her counsel in writing, in reasonable detail, the reasons for the determination that such &#34;Cause&#34; exists, (B) afford Executive a reasonable opportunity to remedy any such breach, (C) provide Executive an opportunity to be heard prior to the final decision to terminate Executive's employment hereunder for such &#34;Cause&#34; and (D) make any decision that such &#34;Cause&#34; exists in good faith.</font></div><div style="margin-top:11.6pt;padding-left:5.85pt;padding-right:16.15pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">The foregoing definition shall not in any way preclude or restrict the right of the Company or any successor or affiliate thereof to discharge or dismiss Executive for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this Agreement, to constitute grounds for termination for Cause.</font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_4"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.9pt;padding-left:5.9pt;padding-right:15.8pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Change in Control' </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">shall have the meaning ascribed to such term in the Zentalis Pharmaceuticals, Inc. 2020 Incentive Award Plan.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.55pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Code&#34; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">means the Internal Revenue Code of 1986, as amended from time to time, and the Treasury Regulations and other interpretive guidance issued thereunder.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.45pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Good Reason&#34; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">means the occurrence of any of the following events or conditions without Executive's written consent&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.45pt;text-align:justify;text-indent:108.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(i)&#160;&#160;&#160;&#160;a change in Executive's position or responsibilities that represents a substantial reduction in her position or responsibilities as in effect immediately prior thereto&#59; the assignment to Executive of any duties or responsibilities that are materially inconsistent with such position or responsibilities&#59; or any removal of Executive from or failure to reappoint or reelect Executive to any of such positions, except in connection with the termination of Executive's services for Cause, as a result of her Permanent Disability or death, or by Executive other than for Good Reason&#59;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:150.2pt;text-indent:-36.2pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;a material reduction in Executive's annual base salary&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.35pt;text-align:justify;text-indent:108.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(iii)&#160;&#160;&#160;&#160;the Company requiring Executive (without Executive's consent) to be based at any place outside a fifty (50)-mile radius of her then-current place of employment with the Company prior to any such relocation, except for reasonably required travel on the Company's business&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.5pt;text-align:justify;text-indent:108.15pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(iv)&#160;&#160;&#160;&#160;any material breach by the Company or any affiliate of its obligations to Executive under any applicable employment or services agreement between Executive and the Company or such affiliate.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.65pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive must provide written notice to the Company of the occurrence of any of the foregoing events or conditions without Executive's written consent within sixty (60) days of the occurrence of such event. The Company or any successor or affiliate shall have a period of thirty (30) days to cure such event or condition after receipt of written notice of such event from Executive. Executive's Separation from Service by reason of resignation from employment with the Company for Good Reason must occur within thirty (30) days following the expiration of the foregoing thirty (30) day cure period.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.45pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(t)  </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Involuntary Termination&#34; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">means (i) Executive's Separation from Service by reason of Executive's discharge by the Company other than for Cause, or (ii) Executive's Separation from Service by reason of Executive's resignation of employment with the Company for Good Reason. Executive's Separation from Service by reason of Executive's death or discharge by the Company following </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive's </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Permanent Disability shall not constitute an Involuntary Termination.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.5pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(g)&#160;&#160;&#160;&#160;Executive's </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Permanent Disability&#34; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">shall be deemed to have occurred if Executive shall become physically or mentally incapacitated or disabled or otherwise unable fully to discharge her duties hereunder for a period of ninety (90) consecutive calendar days or for one hundred twenty (120) calendar days in any one hundred eighty (180) calendar-day period. The existence of Executive's Permanent Disability shall be determined by the Company on the advice of a physician chosen by the Company and the Company reserves the right to have Executive examined by a physician chosen by the Company at the Company's expense.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.65pt;padding-right:16.1pt;text-align:justify;text-indent:72.35pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Separation from Service,&#34; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">with respect to Executive, means </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive's </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">&#34;separation from service,&#34; as defined in Treasury Regulation Section l.409A-l(h).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:6pt;padding-right:15.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Stock Awards&#34; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">means all stock options, restricted stock and such other awards granted pursuant to the Company's stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof, including the Options (as defined below).</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:78.05pt;text-indent:-35.95pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">Services to Be Rendered.</font></div><div><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.55pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Duties and Responsibilities</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Executive shall serve as General Counsel and Corporate Secretary of the Company. In the performance of such duties, Executive shall report directly to, and shall be subject to the direction of, the Chief Executive Officer of the Company (the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Supervising Officer&#34;) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">and to such limits upon Executive's authority as the Supervising Officer may from time to time impose. In the event of the Supervising Officer's unavailability or incapacity, Executive shall report directly to the Board. Executive hereby consents to serve as an officer and&#47;or director of the Company, Parent or any subsidiary or affiliate thereof without any additional salary or compensation, if so requested by the Board or the Supervising Officer. Executive shall be employed by the Company on a full time basis. Executive shall perform the services required by this Agreement remotely from her home office in Somerville, Massachusetts. Executive will also be expected to travel to the Company's locations as needed in connection with her duties, provided that the expenses incurred by Executive related to such travel shall be reimbursed by the Company in accordance with Section 3(d). Executive shall be subject to and comply with the policies and procedures generally applicable to senior executives of the Company to the extent the same are not inconsistent with any term of this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.5pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Exclusive Services</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Executive shall at all times faithfully, industriously and to the best of her ability, experience and talent perform all of the duties that may be assigned to Executive hereunder and shall devote substantially all of her productive time and efforts to the performance of such duties. Subject to the terms of the Proprietary Information and Inventions Agreement referred to in Section 5(b), this shall not preclude Executive from (i) serving on industry, trade, civic, or charitable boards or committees&#59; or (ii) managing personal, family and other investments&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">provided</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> that such activities do not interfere with her duties to the Company, as determined in good faith by the Supervising Officer or the Board.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.9pt;padding-right:15.5pt;text-indent:36.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">3.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Compensation and Benefits</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The Company shall pay or provide, as the case may be, to Executive the compensation and other benefits and rights set forth in this Section 3.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:15.8pt;text-align:justify;text-indent:72pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Base Salary</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The Company shall pay to Executive a base salary of $450,000 per year, payable in accordance with the Company's usual pay practices (and in any event no less frequently than monthly). Executive's base salary shall be subject to review for increase annually by and at the sole discretion of the Board or its designee.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.7pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Annual Bonus</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Executive shall participate in any annual bonus plan that the Board or its designee may approve for the senior executives of the Company. In addition to Executive's base salary, Executive may be eligible to earn, for each fiscal year of the Company ending during the term of Executive's employment with the Company, an annual cash performance bonus under the Company's bonus plan, as approved from time to time by the Board. Executive's target bonus under any such annual bonus plan shall be forty-five percent (45%) of Executive's base salary actually paid for the year to which such annual bonus relates (the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Target Bonus&#34;). </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive's </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">actual annual bonus will be determined on the basis of Executive's and&#47;or the Company's or its affiliates' attainment of financial or other performance criteria established by the Board or its designee in accordance with the terms and conditions of such bonus plan. Except as otherwise provided in this </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Agreement, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive must be employed by the Company on the date of payment of such annual bonus in order to be eligible to receive such annual bonus. Executive hereby acknowledges and agrees that nothing contained herein confers upon </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">any right to an annual bonus in any year, and that whether the Company pays Executive an annual bonus</font></div><div style="text-align:justify"><font><br></font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:5.9pt;padding-right:15.5pt;text-align:justify;text-indent:0.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">and the amount of any such annual bonus will be determined by the Company in its sole discretion. Executive's bonus for 2022 shall not be pro-rated to reflect the portion of the year that Executive is employed by the Company, and Executive shall be eligible for a full annual bonus for 2022.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.45pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Benefits</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Executive shall be entitled to participate in benefits under the Company's benefit plans and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">arrangements, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">including, without limitation, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">any </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">employee benefit plan or arrangement made available in the future by the Company to its senior executives, subject to and on a basis consistent with the terms, conditions and overall administration of such plans and arrangements. The Company shall have the right to amend or delete any such benefit plan or arrangement made available by the Company to its senior executives and not otherwise specifically provided for herein.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:16pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Expenses</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The Company shall reimburse Executive for reasonable out-of-pocket business expenses incurred in connection with the performance of her duties hereunder, subject to such policies as the Company may from time to time establish, and Executive furnishing the Company with evidence in the form of receipts satisfactory to the Company substantiating the claimed expenditures.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.85pt;padding-right:15.6pt;text-align:justify;text-indent:72.15pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Paid Time Off</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. Executive shall be entitled to such periods of paid time off </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(&#34;PTO&#34;) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">each year as provided from time to time under the Company's PTO policy and as otherwise provided for senior executive officers&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, that Executive shall be entitled to a minimum of twenty (20) days of PTO per year.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.5pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(t) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Initial Equity Award</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. As soon as practicable following the Effective Date, Executive will be granted stock options (the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:122%">&#34;Options&#34;) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">to purchase 290,500 shares of the common stock of Zentalis Pharmaceuticals, Inc. </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:122%">(&#34;Parent&#34;). </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">The Options will have an exercise price equal to the fair market value of Parent's common stock on the date of grant. The Options will be subject to the terms and conditions of the Zentalis Pharmaceuticals, Inc. 2020 Incentive Award Plan pursuant to which they will be granted and Executive's award agreement. The Options shall vest over a four (4)-year vesting schedule, with twenty-five percent (25%) of the Options vesting on the first anniversary of the Effective Date and the remaining Options vesting in equal monthly installments over the three (3) years thereafter.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.7pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(g) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Equity and Other Benefit Plans</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Executive shall be entitled to participate in any equity or other employee benefit plan that is generally available to senior executive officers of the Company. Except as otherwise provided in this Agreement, Executive's participation in and benefits under any such plan shall be on the terms and subject to the conditions specified in the governing document of the particular plan.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:16.35pt;text-indent:36pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">4.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%;text-decoration:underline">Severance</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">. Executive shall be entitled to receive benefits upon a Separation from Service only as set forth in this Section 4&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.55pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">At-Will Employment&#59; Termination</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The Company and Executive acknowledge that Executive's employment is and shall continue to be at-will, as defined under applicable law, and that Executive's employment with the Company may be terminated by either party at any time for any or no reason, with or without notice. If Executive's employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided in this Agreement. Executive's employment under this Agreement shall be terminated immediately on the death of Executive.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.85pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Upon Involuntary Termination</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. Subject to Sections 4(d) and 9(o) and Executive's continued compliance with Section 5, if Executive's employment is Involuntarily Terminated, Executive shall be entitled to receive, in lieu of any severance benefits to which Executive</font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_7"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.15pt;padding-left:6.1pt;text-indent:0.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">may otherwise be entitled under any severance plan or program of the Company, the benefits provided below&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.55pt;text-align:justify;text-indent:108.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(i)&#160;&#160;&#160;&#160;the Company shall pay to Executive her fully earned but unpaid base salary, when due, through the date of Executive's Involuntary Termination at the rate then in effect, accrued and unused PTO, plus all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other Company group benefit plan to which Executive may be entitled pursuant to the terms of such plans or agreements at the time of Executive's Involuntary Termination (the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Accrued Obligations&#34;)&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:6.05pt;padding-right:15.85pt;text-align:justify;text-indent:108pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Executive shall be entitled to receive severance pay in an amount equal to (A) Executive's monthly base salary as in effect immediately prior to the date of Executive's Involuntary Termination, multiplied by (B) nine (9), which amount shall be payable in a lump sum sixty</font></div><div style="margin-top:0.05pt;padding-left:5.9pt;text-align:justify"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(60) days following Executive's Involuntary Termination&#59;</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.7pt;text-align:justify;text-indent:108.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(iii)&#160;&#160;&#160;&#160;Executive shall be entitled to receive </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive's </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Target Bonus for the year in which Executive's Involuntary Termination occurs, prorated for the portion of the year that has elapsed prior to the date of Executive's Involuntary Termination, which amount shall be payable in a lump sum sixty (60) days following Executive's Involuntary Termination&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:15.45pt;text-align:justify;text-indent:108.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(iv)&#160;&#160;&#160;&#160;for the period beginning on the date of Executive's Involuntary Termination and ending on the date which is nine (9) full months following the date of Executive's Involuntary Termination (or, if earlier, (A) the date on which the applicable continuation period under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">(&#34;COBRA&#34;) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">expires or (B) the date Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment) (such period, the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;COBRA Coverage Period&#34;), </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">if Executive and</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">&#47;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">or her eligible dependents who were covered under the Company's health insurance plans as of the date of Executive's Involuntary Termination elect to have COBRA coverage and are eligible for such coverage, the Company shall pay for or reimburse Executive on a monthly basis for an amount equal to</font></div><div style="padding-left:5.9pt;padding-right:15.45pt;text-align:justify"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(1) the monthly premium Executive and&#47;or her covered dependents, as applicable, are required to pay for continuation coverage pursuant to COBRA for Executive and</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">&#47;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">or her eligible dependents, as applicable, who were covered under the Company's health plans as of the date of Executive's Involuntary Termination (calculated by reference to the premium as of the date of Executive's Involuntary Termination) less (2) the amount Executive would have had to pay to receive group health coverage for Executive and&#47;or her covered dependents, as applicable, based on the cost sharing levels in effect on the date of Executive's Involuntary Termination. If any of the Company's health benefits are self-funded as of the date of Executive's Involuntary Termination, or if the Company cannot provide the foregoing benefits in a manner that is exempt from Section 409A (as defined below) or that is otherwise compliant with applicable law (including, without limitation, Section 2716 of the Public Health Service Act), instead of providing the payments or reimbursements as set forth above, the Company shall instead pay to Executive the foregoing monthly amount as a taxable monthly payment for the COBRA Coverage Period (or any remaining portion thereof). </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums. Executive shall notify the Company immediately if Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:150.1pt;text-align:justify;text-indent:-36.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;(A) in the event of Executive's Involuntary Termination within eighteen</font></div><div style="margin-top:0.7pt;padding-left:6pt;padding-right:15.8pt;text-align:justify;text-indent:-0.15pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(18) months following a Change in Control, (1) the references to nine (9) months in clauses (ii) and (iv) shall be increased to twelve (12) months, and (2) the Target Bonus payable pursuant to clause (iii) shall not be subject to proration, which amount shall be payable as provided in clause (iii) above, and (B) in</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_10"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.9pt;padding-left:5.9pt;padding-right:15.4pt;text-align:justify;text-indent:0.3pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">the event of </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive's </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Involuntary Termination at any time following a Change in Control, all of Executive's Stock Awards will vest on an accelerated basis effective as of the date of Executive's Involuntary Termination. The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such Stock Award (and, for the avoidance of doubt, if any Stock Award is subject to more favorable vesting pursuant to any agreement or plan regarding such Stock Award, such more favorable provisions shall continue to apply and shall not be limited by this clause (v)).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.35pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Termination for Cause, Voluntary Resignation Without Good Reason, Death or</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Termination for Permanent Disability</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. In the event of Executive's termination of employment as a result of Executive's discharge by the Company for Cause, Executive's resignation without Good Reason, Executive's death or Executive's termination of employment following Executive's Permanent Disability, the Company shall not have any other or further obligations to Executive under this Agreement (including any financial obligations) except that Executive shall be entitled to receive the Accrued Obligations. The foregoing shall be in addition to, and not in lieu of, any and all other rights and remedies which may be available to the Company under the circumstances, whether at law or in equity.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.55pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Release</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. As a condition to Executive's receipt of any post-termination benefits pursuant to Section 4(b) above, Executive shall execute and not revoke a general release of all claims in favor of the Company and its affiliates (the &#34;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Release</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">&#34;) in the form attached hereto as </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Exhibit </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;text-decoration:underline">A</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">. </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">In the event the Release does not become effective within the fifty-five (55) day period following the date of Executive's Involuntary Termination, Executive shall not be entitled to the aforesaid payments and benefits.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.45pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Exclusive Remedy</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Except as otherwise expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive's rights to salary, severance, benefits, bonuses and other amounts hereunder (if any) accruing after the termination of Executive's employment shall cease upon such termination. In the event of Executive's termination of employment with the Company, Executive's sole remedy shall be to receive the payments and benefits described in this Section</font></div><div style="margin-top:0.05pt;padding-left:5.9pt;padding-right:15.75pt;text-align:justify"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">4. In addition, Executive acknowledges and agrees that she is not entitled to any reimbursement by the Company for any taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to this Section 4, including, without limitation, any excise tax imposed by Section 4999 of the Code. Any payments made to Executive under this Section 4 shall be inclusive ofany amounts or benefits to which Executive may be entitled pursuant to the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Sections 2101 et seq., and the Department of Labor regulations thereunder, or any similar state statute.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.65pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(t) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">No Mitigation</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Except as otherwise provided in Section 4(b)(iv) above, Executive shall not be required to mitigate the amount of any payment provided for in this Section 4 by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Section 4 be reduced by any compensation earned by Executive as the result of employment by another employer or self-employment or by retirement benefits&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">provided</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">however</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, that loans, advances or other amounts owed by Executive to the Company may be offset by the Company against amounts payable to Executive under this Section 4.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.95pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(g) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Termination of Offices and Directorships&#59;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Return of the Company's Property</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Upon termination of the Executive's employment for any reason, unless otherwise specified in a written agreement between the Executive and the Company, the Executive shall be deemed to have resigned from all offices, directorships, and other employment positions, if any, then held with the Company, and shall take all actions reasonably requested by the Company to effectuate the foregoing. In addition, in the event of Executive's termination of employment for any reason, the Company shall have the right, at its option,</font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_13"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.15pt;padding-left:5.95pt;padding-right:15.5pt;text-align:justify;text-indent:0.25pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">to require Executive to vacate her offices prior to or on the effective date of separation and to cease all activities on the Company's behalf. Upon Executive's termination of employment in any manner, as a condition to Executive's receipt of any severance benefits described in this Agreement, Executive shall immediately surrender to the Company all lists, books and records of, or in connection with, the Company's business, and all other property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. Executive shall deliver to the Company a signed statement certifying compliance with this Section 4(g) prior to the receipt of any severance benefits described in this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:78.05pt;text-indent:-36pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Covenants</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.7pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Noncompetition</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Except as may otherwise be approved by the Board, during the term of Executive's employment, Executive shall not have any ownership interest (of record or beneficial) in, or have any interest as an employee, salesman, consultant, officer or director in, or otherwise aid or assist in any manner, any firm, corporation, partnership, proprietorship or other business that engages in any county, city or part thereof in the United States and&#47;or any foreign country in a business which competes directly or indirectly (as determined by the Board) with the Company's business in such county, city or part thereof, so long as the Company, or any successor in interest of the Company to the business and goodwill of the Company, remains engaged in such business in such county, city or part thereof or continues to solicit customers or potential customers therein&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">provided</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">however</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, that Executive may own, directly or indirectly, solely as an investment, securities of any entity which are traded on any national securities exchange if Executive (i) is not a controlling person of, or a member of a group which controls, such entity&#59; or (ii) does not, directly or indirectly, own one percent (1</font><font style="color:#111111;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:122%">%) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">or more ofany class of securities of any such entity.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.9pt;padding-right:15.3pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Confidential Information</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Executive and the Company have entered into the Company's standard proprietary information and inventions assignment agreement (the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Proprietary Information and Inventions Agreement&#34;). </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive agrees to perform each and every obligation of Executive therein contained.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.2pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Solicitation of Employees</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. During the term of Executive's employment or service and for one (1) year thereafter (the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Restricted Period&#34;), </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive will not, either directly or through others, solicit or attempt to solicit any employee, independent contractor or consultant of the Company or its affiliates to terminate her relationship with the Company or its affiliates in order to become an employee, consultant or independent contractor to or for any other person or entity, or otherwise encourage or solicit any employee of the Company or its affiliates to leave the Company or such affiliates for any reason or to devote less than all of any such employee's efforts to the affairs of the Company&#59; provided that the foregoing shall not affect any responsibility Executive may have as an employee of the Company with respect to the bona fide hiring and firing of Company personnel.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:16pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Solicitation of Consultants</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Executive shall not during the term of Executive's employment or service and for the Restricted Period, directly or indirectly, hire, solicit or encourage to cease work with the Company or any of its affiliates any consultant then under contract with the Company or any of its affiliates.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.6pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Nondisparagement</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Executive agrees that neither she nor anyone acting by, through, under or in concert with her shall disparage or otherwise communicate negative statements or opinions about the Company, Parent, or their respective board members, officers, employees or businesses. The Company agrees that neither its Board members nor officers, nor the board members or officers of Parent, shall disparage or otherwise communicate negative statements or opinions about Executive. Except as may be required by law, neither Executive, nor any member of Executive's family,</font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_16"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.9pt;padding-left:5.95pt;text-indent:0.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">nor anyone else acting by, through, under or in concert with Executive will disclose to any individual or entity (other than Executive's legal or tax advisors) the terms of this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:15.3pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Rights and Remedies Upon Breach</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. If Executive breaches or threatens to commit a breach of any of the provisions of this Section 5 (the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:120%">&#34;Restrictive Covenants&#34;), </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">the Company shall have the following rights and remedies, each of which rights and remedies shall be independent of the other and severally enforceable, and all of which rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.5pt;text-align:justify;text-indent:108.3pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Specific Performance</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The right and remedy to have the Restrictive Covenants specifically enforced by any court having equity jurisdiction, all without the need to post a bond or any other security or to prove any amount of actual damage or that money damages would not provide an adequate remedy, it being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to the Company and that money damages will not provide adequate remedy to the Company&#59; and</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.6pt;text-align:justify;text-indent:108.35pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting and Indemnification</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. The right and remedy to require Executive (A) to account for and pay over to the Company all compensation, profits, monies, accruals, increments or other benefits derived or received by Executive or any associated party deriving such benefits as a result of any such breach of the Restrictive Covenants&#59; and (B) to indemnify the Company against any other losses, damages (including special and consequential damages), costs and expenses, including actual attorneys' fees and court costs, which may be incurred by them and which result from or arise out of any such breach or threatened breach of the Restrictive Covenants.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.55pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Severability of Covenants</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">&#47;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Blue Pencilling</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. If any court determines that any of the Restrictive Covenants, or any part thereof, is invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full effect, without regard to the invalid portions. If any court determines that any of the Restrictive Covenants, or any part thereof, are unenforceable because of the duration of such provision or the area covered thereby, such court shall have the power to reduce the duration or area of such provision and, in its reduced form, such provision shall then be enforceable and shall be enforced. Executive hereby waives any and all right to attack the validity of the Restrictive Covenants on the grounds of the breadth of their geographic scope or the length of their term.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.45pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Enforceability in Jurisdictions</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The Company and Executive intend to and do hereby confer jurisdiction to enforce the Restrictive Covenants upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of such jurisdictions hold the Restrictive Covenants wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the Company and Executive that such determination not bar or in any way affect the right of the Company to the relief provided above in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.45pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Whistleblower Provision</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. Nothing herein shall be construed to prohibit Executive from communicating directly with, cooperating with, or providing information to, any government regulator, including, but not limited to, the U.S. Securities and Exchange Commission, the</font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:16.05pt;text-align:justify;text-indent:0.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">U.S. Commodity Futures Trading Commission, or the U.S. Department of Justice. Executive acknowledges that the Company has provided Executive with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act&#58; (i) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary</font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_19"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.9pt;padding-left:5.95pt;padding-right:15.3pt;text-align:justify;text-indent:0.3pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">information that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, (ii) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (iii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the proprietary information to Executive's attorney and use the proprietary information in the court proceeding, if Executive files any document containing the proprietary information under seal, and does not disclose the proprietary information, except pursuant to court order.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.2pt;text-align:justify;text-indent:71.8pt"><font style="color:#111111;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. For purposes of this Section 5, the term </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#34;Company&#34; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">means not only Zeno Management, Inc., but also Parent as well as any company, partnership or entity which, directly or indirectly, controls, is controlled by or is under common control with Zeno Management, Inc.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:78.2pt;text-indent:-36.3pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">Insurance&#59; Indemnification</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.65pt;padding-right:15.8pt;text-align:justify;text-indent:72.35pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Insurance</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The Company shall have the right to take out life, health, accident, &#34;key-man&#34; or other insurance covering Executive, in the name of the Company and at the Company's expense in any amount deemed appropriate by the Company. Executive shall assist the Company in obtaining such insurance, including, without limitation, submitting to any required examinations and providing information and data required by insurance companies.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.7pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. Executive will be provided with indemnification against third party claims related to her work for the Company to the maximum extent permitted by Delaware law. The Company shall provide Executive with directors and officers liability insurance coverage at least as favorable as that which the Company may maintain from time to time for other executive officers.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.35pt;text-align:justify;text-indent:36.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">7.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Arbitration</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Any dispute, claim or controversy based on, arising out of or relating to Executive's employment or this Agreement shall be settled by final and binding arbitration in Boston, Massachusetts, before a single neutral arbitrator in accordance with the JAMS Employment Arbitration Rules and Procedures (the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:122%">&#34;Rules&#34;), </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. The Rules may be found online at </font><font style="color:#1111ff;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">www.jamsadr.com</font><font style="color:#1111ff;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">and will be provided to Executive upon request. If the parties are unable to agree upon an arbitrator, one shall be appointed by JAMS in accordance with its Rules. Each party shall pay the fees of its own attorneys, the expenses of its witnesses and all other expenses connected with presenting its case&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">provided</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">however</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, Executive and the Company agree that, to the extent permitted by law, the arbitrator may, in his or her discretion, award reasonable attorneys' fees to the prevailing party. Other costs of the arbitration, including the cost of any record or transcripts of the arbitration, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:122%">JAMS </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">administrative fees, the fee of the arbitrator, and all other fees and costs, shall be borne by the Company. This Section 7 is intended to be the exclusive method for resolving any and all claims by the parties against each other for payment of damages under this Agreement or relating to Executive's employment&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">provided</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">however</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, that Executive shall retain the right to file administrative charges with or seek relief through any government agency of competent jurisdiction, and to participate in any government investigation, including but not limited to</font></div><div style="padding-left:5.9pt;padding-right:15.35pt;text-align:justify;text-indent:-0.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(a) claims for workers' compensation, state disability insurance or unemployment insurance&#59; (b) administrative claims brought before any state or federal governmental authority&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">provided</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">however</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, that any appeal from an award or from denial of an award of wages and&#47;or waiting time penalties shall be arbitrated pursuant to the terms of this Agreement&#59; and (c) claims for administrative relief from the United States Equal Employment Opportunity Commission and</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">&#47;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">or any similar state agency in any applicable jurisdiction)&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">provided, further,</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> that Executive shall not be entitled to obtain any monetary relief through such agencies other than workers' compensation benefits or unemployment insurance benefits. This Agreement </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">shall </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">not limit either party's right to obtain any provisional remedy, including, without</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:9.6pt;padding-right:9.6pt;text-align:center"><font style="color:#111111;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div style="text-align:center"><font><br></font></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:6.1pt;padding-right:15.5pt;text-align:justify;text-indent:-0.15pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">limitation, injunctive or similar relief, from any court of competent jurisdiction as may be necessary to protect their rights and interests pending the outcome of arbitration, including without limitation injunctive relief, in any court of competent jurisdiction. Seeking any such relief shall not be deemed to be a waiver of such party's right to compel arbitration. Both Executive and the Company expressly waive their right to a jury trial.</font></div><div><font><br></font></div><div style="padding-left:6.2pt;padding-right:15.85pt;text-align:justify;text-indent:35.75pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">8.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">General Relationship</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Executive shall be considered an employee of the Company within the meaning of all federal, state and local laws and regulations including, but not limited to, laws and regulations governing unemployment insurance, workers' compensation, industrial accident, labor and taxes.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:78.05pt;text-indent:-36.15pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:15.85pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Modification&#59; Prior Claims</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. This Agreement and the Proprietary Information and Inventions Agreement (and the other documents referenced therein) set forth the entire understanding of the parties with respect to the subject matter hereof, and supersede all existing agreements between them concerning such subject matter, including any offer letter between the Company and Executive. This Agreement may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.45pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Assignment&#59; Assumption by Successor</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The rights of the Company under this Agreement may, without the consent of Executive, be assigned by the Company, in its sole and unfettered discretion, to any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly, acquires all or substantially all of the assets or business of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and to agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">provided</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">however</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, that no such assumption shall relieve the Company of its obligations hereunder. As used in this Agreement, the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Company&#34; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">shall mean the Company as hereinbefore defined and any successor to its business and&#47;or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law or otherwise.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.6pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Survival</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The covenants, agreements, representations and warranties contained in or made in Sections 4, 5, 6, 7 and 9 of this Agreement shall survive Executive's termination of employment.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:15.8pt;text-align:justify;text-indent:72pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Third-Party Beneficiaries</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Except as expressly set forth herein, this Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:16pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Waiver</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The failure of either party hereto at any time to enforce performance by the other party of any provision of this Agreement shall in no way affect such party's rights thereafter to enforce the same, nor shall the waiver by either party of any breach of any provision hereof be deemed to be a waiver by such party of any other breach of the same or any other provision hereof.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.8pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">(t) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;text-decoration:underline">Section Headings</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">. The headings of the several sections in this Agreement are inserted solely for the convenience of the parties and are not a part of and are not intended to govern, limit or aid in the construction of any term or provision hereof.</font></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_22"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.9pt;padding-left:5.95pt;padding-right:15.6pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Notices</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. Any notice required or permitted by this Agreement shall be </font><font style="color:#111111;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">in </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">writing and shall be delivered as follows with notice deemed given as indicated&#58; (i) by personal delivery when delivered personally&#59; (ii) by overnight courier upon written verification of receipt&#59; (iii) by email, telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission&#59; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to Executive at the address listed on the Company's personnel records and to the Company at its principal place of business, or such other address as either party may specify in writing.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:16pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Severability</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. All Sections, clauses and covenants contained in this Agreement are severable, and in the event any of them shall be held to be invalid by any court, this Agreement shall be interpreted as if such invalid Sections, clauses or covenants were not contained herein.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.5pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Governing Law and Venue</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. This Agreement is to be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Except as provided in Sections 5 and 7, any suit brought hereon shall be brought in the state or federal courts sitting in Boston, Massachusetts, the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by Massachusetts law.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.95pt;text-align:justify;text-indent:71.85pt"><font style="color:#111111;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Non-transferability of Interest</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement shall be assignable or transferable except through a testamentary disposition or by the laws of descent and distribution upon the death of Executive. Any attempted assignment, transfer, conveyance, or other disposition (other than as aforesaid) of any interest in the rights of Executive to receive any form of compensation to be made by the Company pursuant to this Agreement shall be void.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6.2pt;padding-right:15.6pt;text-align:justify;text-indent:71.75pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%;text-decoration:underline">Gender</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">. Where the context so requires, the use of the masculine gender shall include the feminine and</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">&#47;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">or neuter genders and the singular shall include the plural, and vice versa, and the word &#34;person&#34; shall include any corporation, firm, partnership or other form of association.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.6pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Counterparts&#59; Facsimile or .pdf Signatures</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Agreement may be executed and delivered by facsimile or by .pdf file and upon such delivery the facsimile or </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">.pdf </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">signature will be deemed to have the same effect as if the original signature had been delivered to the other party.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.6pt;text-align:justify;text-indent:72.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Construction</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The language in all parts of this Agreement shall in all cases be construed simply, according to its fair meaning, and not strictly for or against any of the parties hereto. Without limitation, there shall be no presumption against any party on the ground that such party was responsible for drafting this Agreement or any part thereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:16.2pt;text-align:justify;text-indent:71.95pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding and Other Deductions</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. All compensation payable to Executive hereunder shall be subject to such deductions as the Company is from time to time required to make pursuant to law, governmental regulation or order.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:114.1pt;text-indent:-36.15pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">Code Section 409A</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.55pt;text-align:justify;text-indent:108.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">(i)&#160;&#160;&#160;&#160;This Agreement is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and, accordingly, the severance payments payable under Sections 4(b)(ii), (iii) and (v) shall be paid no later than the later of&#58; (A) the fifteenth (15th) day of</font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.042%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.65pt;padding-left:3pt"><font style="color:#111111;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">11</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_25"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.9pt;padding-left:5.65pt;padding-right:15.55pt;text-align:justify;text-indent:0.55pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">the third month following Executive's first taxable year in which </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">such </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">amounts are no longer subject to a substantial risk of forfeiture, and (B) the fifteenth (15th) day of the third month following first taxable year of the Company in which </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">such </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">amounts are is no longer subject to substantial risk of forfeiture, as determined in accordance with Code Section 409A and any Treasury Regulations and other guidance issued thereunder. To the extent applicable, this Agreement shall be interpreted in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder. Each series of installment payments made under this Agreement is hereby designated as a series of &#34;separate payments&#34; within the meaning of Section 409A of the Code. For purposes of this Agreement, all references to Executive's &#34;termination of employment&#34; shall mean Executive's Separation from Service.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.3pt;text-align:justify;text-indent:108.15pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:122%">If </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive is a &#34;specified employee&#34; (as defined in Section 409A of the Code), as determined by the Company in accordance with Section 409A of the Code, on the date of Executive's Separation from Service, to the extent that the payments or benefits under this Agreement are subject to Section 409A of the Code and the delayed payment or distribution of all or any portion of such amounts to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, then such portion deferred pursuant to this Section 9(o)(ii) shall be paid or distributed to Executive in a lump sum on the earlier of (A) the date that is six (6)-months following Executive's Separation from Service, (B) the date of Executive's death or (C) the earliest date as is permitted under Section 409A of the Code. Any remaining payments due under the Agreement shall be paid as otherwise provided herein.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:15.5pt;text-align:justify;text-indent:108.3pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">To the extent applicable, this Agreement shall be interpreted in accordance with the applicable exemptions from Section 409A of the Code. </font><font style="color:#111111;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:122%">If </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive and the Company determine that any payments or benefits payable under this Agreement intended to comply with Sections 409A(a)(2), (3) and (4) of the Code do not comply with Section 409A of the Code, Executive and the Company agree to amend this Agreement, or take such other actions as Executive and the Company deem reasonably necessary or appropriate, to comply with the requirements of Section 409A of the Code and the Treasury Regulations thereunder (and any applicable transition relief) while preserving the economic agreement of the parties. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner that no payments payable under this Agreement shall be subject to an &#34;additional tax&#34; as defined in Section 409A(a)(l)(B) of the Code.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:15.75pt;text-align:justify;text-indent:108.3pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Any reimbursement of expenses or in-kind benefits payable under this Agreement shall be made in accordance with Treasury Regulation Section l.409A-3(i)(l)(iv) and shall be paid on or before the last day of </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive's </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">taxable year following the taxable year in which Executive incurred the expenses. The amount of expenses reimbursed or in-kind benefits payable during any taxable year of Executive's shall not affect the amount eligible for reimbursement or in-kind benefits payable in any other taxable year of Executive's, and Executive's right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:184.95pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.8pt;padding-left:20.25pt;padding-right:20.25pt;text-align:center"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_28"></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.7pt;padding-left:42.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth</font></div><div style="padding-left:5.95pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">above.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:258.6pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ZENO MANAGEMENT, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:258.4pt;padding-right:6.5pt;text-indent:-0.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">By&#58; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Kimberly Blackwell, M.D. </font></div><div style="margin-top:0.05pt;padding-left:258.4pt;padding-right:6.5pt;text-indent:-0.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Name&#58; Kimberly Blackwell, M.D.</font></div><div style="margin-top:0.3pt;padding-left:258.4pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:258.3pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EXECUTIVE</font></div><div style="margin-top:0.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   &#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrea Paul</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.45pt;padding-left:252pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:288px"></div><div style="padding-left:258.65pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Andrea Paul</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:12.2pt;padding-right:12.2pt;text-align:center"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SIGNATURE PAGE TO </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">EMPLOYMENT </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">AGREEMENT</font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_31"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.15pt;padding-left:11.9pt;padding-right:11.9pt;text-align:center"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:12.27pt;padding-right:12.27pt;text-align:center"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;text-decoration:underline">GENERAL RELEASE OF CLAIMS</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:11.55pt;padding-right:11.55pt;text-align:center"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:122%">&#91;The language </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:122%">in </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:122%">this Release may </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:122%">change </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:122%">based on legal developments and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:122%">evolving </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:122%">best practices&#59; this form is provided as an </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:122%">example </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:122%">of what </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:122%">will </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:122%">be included in the final Release document.&#93;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:42.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">This General Release of Claims </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:100%">(&#34;Release&#34;) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">is entered into as of this </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;day of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">,</font></div><div style="margin-top:0.65pt;padding-left:6.2pt;padding-right:6.5pt;text-indent:-0.15pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">between Andrea Paul </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">(&#34;Executive&#34;), </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">and Zeno Management, Inc. (the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Company&#34;) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(collectively referred to herein as the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Parties&#34;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:42pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">WHEREAS, Executive and the Company are parties to that certain Employment Agreement dated</font></div><div style="margin-top:0.45pt;padding-left:5.95pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">as of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">2022 (the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:100%">&#34;Agreement&#34;)&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:6.25pt;padding-right:8.5pt;text-align:justify;text-indent:35.75pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">WHEREAS, the Parties agree that Executive is entitled to certain severance benefits under the Agreement, subject to Executive's execution of this Release&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6.1pt;padding-right:8.8pt;text-align:justify;text-indent:35.85pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:124%">WHEREAS, the Company and Executive now wish to fully and finally to resolve all matters between them.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:8.25pt;text-align:justify;text-indent:36.15pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">NOW, THEREFORE, in consideration of, and subject to, the severance benefits payable to Executive pursuant to the Agreement, the adequacy of which is hereby acknowledged by Executive, and which Executive acknowledges that she would not otherwise be entitled to receive, Executive and the Company hereby agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:78.05pt;text-indent:-35.95pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">General Release of Claims by Executive</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:8.2pt;text-align:justify;text-indent:72.1pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(a)&#160;&#160;&#160;&#160;Executive, on behalf of herself and her executors, heirs, administrators, representatives and assigns, hereby agrees to release and forever discharge the Company and all predecessors, successors and their respective parent corporations, affiliates, related, and&#47;or subsidiary entities, and all of their past and present investors, directors, shareholders, officers, general or limited partners, employees, attorneys, agents and representatives, and the employee benefit plans in which Executive is or has been a participant by virtue of her employment with or service to the Company (collectively, the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Company Releasees&#34;), </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">from any and all claims, debts, demands, accounts, judgments, rights, causes of action, equitable relief, damages, costs, charges, complaints, obligations, promises, agreements, controversies, suits, expenses, compensation, responsibility and liability of every kind and character whatsoever (including attorneys' fees and costs), whether in law or equity, known or unknown, asserted or unasserted, suspected or unsuspected (collectively, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;Claims&#34;), </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">which Executive has or may have had against such entities based on any events or circumstances arising or occurring on or prior to the date hereof or on or prior to the date hereof, arising directly or indirectly out of, relating to, or in any other way involving in any manner whatsoever Executive's employment by or service to the Company or the termination thereof, including any and all claims arising under federal, state, or local laws relating to employment, including without limitation claims of wrongful discharge, breach of express or implied contract, fraud, misrepresentation, defamation, or liability in tort, and claims of any kind that may be brought in any court or administrative agency including, without limitation, claims under Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. Section 2000, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">et</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:122%;text-decoration:underline">seq</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">.&#59; the Americans with Disabilities Act, as amended, 42 U.S.C. &#167; 12101 </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">et</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:122%;text-decoration:underline">seq</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:122%">.&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">the Rehabilitation Act of 1973, as amended, 29 U.S.C. &#167; 701 </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">et</font></div><div style="padding-left:5.9pt;padding-right:8pt;text-align:justify;text-indent:-0.7pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:122%;text-decoration:underline">seq</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:122%">.&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">the Civil Rights Act of 1866, and the Civil Rights Act of 1991&#59; 42 U.S.C. Section 1981, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">et</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:122%;text-decoration:underline">seq</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">.&#59; the Age Discrimination in Employment Act, as amended, 29 U.S.C. Section 621, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">et</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">seq</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:122%">. </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:122%">&#34;ADEA&#34;)&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">the Equal Pay Act, as amended, 29 U.S.C. Section 206(d)&#59; regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section 60, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">et</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">seq</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">.&#59; the Family and Medical Leave Act, as amended,</font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_34"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.15pt;padding-left:5.9pt;padding-right:8.25pt;text-align:justify;text-indent:0.2pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">29 U.S.C. &#167; 2601 </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">et seq</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">.&#59; </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">the Fair Labor Standards Act of 1938, as amended, 29 U.S.C. &#167; 201 </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">et</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">seq</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">.&#59; </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">the Employee Retirement Income Security Act, as amended, 29 U.S.C. &#167; 1001 </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">et</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%"> </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">seq</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:42.05pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Notwithstanding the generality of the foregoing, Executive does not release the following claims&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:42.2pt;padding-right:9.3pt;text-align:justify;text-indent:35.8pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:124%">(i)&#160;&#160;&#160;&#160;Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:42.1pt;padding-right:8.8pt;text-align:justify;text-indent:35.9pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(ii)&#160;&#160;&#160;&#160;Claims for workers' compensation insurance benefits under the terms of any worker's compensation insurance policy or fund of the Company&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:114.1pt;text-indent:-36.15pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Claims pursuant to the terms and conditions of the federal law known as COBRA&#59;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:41.95pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">(iv)&#160;&#160;&#160;&#160;Claims for indemnity under the bylaws of the Company, as provided for by Delaware law or under any applicable insurance policy with respect to Executive's liability as an employee, director or officer of the Company&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:42pt;padding-right:8.25pt;text-align:justify;text-indent:36pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(v)&#160;&#160;&#160;&#160;Executive's right to bring to the attention of the Equal Employment Opportunity Commission or any other federal, state or local government agency claims of discrimination, or from participating in an investigation or proceeding conducted by the Equal Employment Opportunity Commission or any other federal, state or local government agency&#59; </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">provided</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">however</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">, that Executive does release her right to secure any damages for alleged discriminatory treatment&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:42pt;padding-right:9.45pt;text-align:justify;text-indent:36pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(vi)&#160;&#160;&#160;&#160;Claims based on any right Executive may have to enforce the Company's executory obligations under the Agreement&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:114.1pt;text-indent:-36.15pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;Claims Executive may have to vested or earned compensation and benefits&#59; and</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:114.3pt;text-indent:-36.35pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;Executive's right to communicate or cooperate with any government agency.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:8.45pt;text-align:justify;text-indent:72.05pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(b)&#160;&#160;&#160;&#160;EXECUTIVE ACKNOWLEDGES THAT SHE HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41.95pt;padding-right:44.55pt;text-align:justify;text-indent:-0.45pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:122%">&#34;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#34;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:8.45pt;text-align:justify"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS SHE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.</font></div><div style="margin-top:9.05pt;padding-left:25.15pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:100%">&#91;Note&#58; Clauses (c), (d) and (e) apply only </font><font style="color:#0f0f0f;font-family:'Arial',sans-serif;font-size:13.5pt;font-style:italic;font-weight:400;line-height:100%">if </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:100%">Executive is age 40 or older at time of termination&#93;</font></div><div style="margin-top:12.1pt;padding-left:6.2pt;padding-right:8.45pt;text-align:justify;text-indent:71.75pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">(c)&#160;&#160;&#160;&#160;Executive acknowledges that this Release was presented to her on the date indicated above and that Executive is entitled to have &#91;twenty-one (2l)&#93;&#91;forty-five (45)&#93; days' time in which to consider it. Executive further acknowledges that the Company has advised her that she is waiving her</font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.487%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:3pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_37"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.9pt;padding-left:5.9pt;padding-right:8.25pt;text-align:justify;text-indent:0.35pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">rights under the ADEA, and that Executive should consult with an attorney of her choice before signing this Release, and Executive has had sufficient time to consider the terms of this Release. Executive represents and acknowledges that if Executive executes this Release before &#91;twenty-one (2l)&#93;&#91;forty-five (45)&#93; days have elapsed, Executive does so knowingly, voluntarily, and upon the advice and with the approval of Executive's legal counsel (if any), and that Executive voluntarily waives any remaining consideration period.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:6.1pt;padding-right:8.3pt;text-align:justify;text-indent:71.85pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(d)&#160;&#160;&#160;&#160;Executive understands that after executing this Release, Executive has the right to revoke it within seven (7) days after her execution of it. Executive understands that this Release will not become effective and enforceable unless the seven (7) day revocation period passes and Executive does not revoke the Release in writing. </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Executive </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">understands that this Release may not be revoked after the seven</font></div><div style="margin-top:0.25pt;padding-left:6.1pt;padding-right:8.7pt;text-align:justify;text-indent:-0.25pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(7) day revocation period has passed. Executive also understands that any revocation of this Release must be made in writing and delivered to the Company at its principal place of business within the seven (7) day period.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:6.1pt;padding-right:8.6pt;text-align:justify;text-indent:71.85pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(e)&#160;&#160;&#160;&#160;Executive understands that this Release shall become effective, irrevocable, and binding upon Executive on the eighth (8</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:6.82pt;font-weight:400;line-height:122%;position:relative;top:-3.67pt;vertical-align:baseline">th</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:122%">) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">day after her execution of it, so long as Executive has not revoked it within the time period and in the manner specified in clause (d) above.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:8.8pt;text-align:justify;text-indent:72pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">(t)  Executive further understands that Executive will not be given any severance benefits under the Agreement unless this Release is effective on or before the date that is fifty-five (55) days following the date of Executive's termination of employment.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:8.5pt;text-align:justify;text-indent:36.2pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">No Assignment</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. Executive represents and warrants to the Company Releasees that there has been no assignment or other transfer of any interest in any Claim that Executive may have against the Company Releasees. Executive agrees to indemnify and hold harmless the Company Releasees from any liability, claims, demands, damages, costs, expenses and attorneys' fees incurred as a result of any such assignment or transfer from Executive.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:8.5pt;text-align:justify;text-indent:36pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">3.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Severability</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. In the event any provision of this Release is found to be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the benefit contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected thereby.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:8.6pt;text-align:justify;text-indent:36.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">4.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Interpretation&#59; Construction</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. The headings set forth in this Release are for convenience only and shall not be used in interpreting this Agreement. This Release has been drafted by legal counsel representing the Company, but Executive has participated in the negotiation of its terms. Furthermore, Executive acknowledges that Executive has had an opportunity to review and revise the Release and have it reviewed by legal counsel, if desired, and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Release. Either party's failure to enforce any provision of this Release shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing each and every other provision of this Release.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:8.5pt;text-align:justify;text-indent:36.15pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">5.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Governing Law and Venue</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. This Release will be governed by and construed in accordance with the laws of the United States of America and the Commonwealth of Massachusetts applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Any suit brought hereon shall be brought in the state or federal courts sitting in Boston, Massachusetts, the Parties hereby waiving any claim or defense that such forum is not convenient or proper.</font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.487%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:3pt"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_40"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.9pt;padding-left:6.05pt;text-indent:-0.2pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by Massachusetts law.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:8.15pt;text-align:justify;text-indent:36pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">6.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%;text-decoration:underline">Entire Agreement</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">. This Release and the Agreement constitute the entire agreement of the Parties in respect of the subject matter contained herein and therein and supersede all prior or simultaneous representations, discussions, negotiations and agreements, whether written or oral. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6.1pt;padding-right:8.55pt;text-align:justify;text-indent:35.85pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">7.&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%;text-decoration:underline">Counterparts</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">. This Release may be executed in multiple counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:11.87pt;padding-right:11.87pt;text-align:center"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(Signature Page Follows)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:1.02pt;padding-right:1.02pt;text-align:center"><font style="color:#111111;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">4</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i2d942d87774d4d41bf20c703b090cdd7_43"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT 10.8#</font></div></div><div style="margin-top:3.9pt;padding-left:5.95pt;text-indent:36.15pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed the foregoing Release as of the date first written above.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.9pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EXECUTIVE&#160;&#160;&#160;&#160;ZENO MANAGEMENT, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-bottom:0.2pt;padding-left:258.3pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:5.75pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div><div><font><br></font></div><div style="padding-left:258.4pt;padding-right:6.6pt;text-indent:-252.5pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:237%">Print Name&#58; Andrea Paul&#160;&#160;&#160;&#160;Print Name&#58; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:237%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:237%"> Title&#58; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:237%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.034%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>zentalis10-qq22022ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6374a998921449059d60cd6880ee39a2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">I, Kimberly Blackwell, M.D. certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.1</font></div></div><div style="margin-top:12pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 9, 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kimberly Blackwell</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberly Blackwell, M.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Chief Executive Officer</font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">(principal executive officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>zentalis10-qq22022ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i765d481792fc484d83eb4c130a17fcee_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">I, Melissa B. Epperly, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.2</font></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 9, 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Melissa B. Epperly</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa B. Epperly</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Chief Financial Officer</font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">principal financial officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>zentalis10-qq22022ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i29b064da07d7480d92f5a3769cace958_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In connection with the Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;padding-left:9pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 9, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kimberly Blackwell, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberly Blackwell, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Chief Executive Officer</font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">(principal executive officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>zentalis10-qq22022ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i86badec5f6b440f389b48f18ecf5d366_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In connection with the Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;padding-left:9pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.314%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 9, 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Melissa B. Epperly</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa B. Epperly</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Chief Financial Officer</font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">principal financial officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>zntl-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:dc6f2cb5-3684-47f2-a7ee-9069478f9aef,g:255d4c27-7dc3-44e2-be9a-0993a342da50-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zntl="http://www.zentalis.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.zentalis.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zntl-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zntl-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zntl-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zntl-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.zentalis.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusiness" roleURI="http://www.zentalis.com/role/OrganizationandBusiness">
        <link:definition>2101101 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimUnauditedFinancialStatements" roleURI="http://www.zentalis.com/role/InterimUnauditedFinancialStatements">
        <link:definition>2102102 - Disclosure - Interim Unaudited Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimUnauditedFinancialStatementsPolicies" roleURI="http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies">
        <link:definition>2203201 - Disclosure - Interim Unaudited Financial Statements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantTransactions" roleURI="http://www.zentalis.com/role/SignificantTransactions">
        <link:definition>2104103 - Disclosure - Significant Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantTransactionsDetails" roleURI="http://www.zentalis.com/role/SignificantTransactionsDetails">
        <link:definition>2405401 - Disclosure - Significant Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.zentalis.com/role/BusinessCombinations">
        <link:definition>2106104 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.zentalis.com/role/BusinessCombinationsTables">
        <link:definition>2307301 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNarrativeDetails" roleURI="http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails">
        <link:definition>2408402 - Disclosure - Business Combinations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails" roleURI="http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails">
        <link:definition>2409403 - Disclosure - Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.zentalis.com/role/FairValueMeasurement">
        <link:definition>2110105 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.zentalis.com/role/FairValueMeasurementTables">
        <link:definition>2311302 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" roleURI="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails">
        <link:definition>2412404 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementNarrativeDetails" roleURI="http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails">
        <link:definition>2413405 - Disclosure - Fair Value Measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" roleURI="http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails">
        <link:definition>2414406 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" roleURI="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails">
        <link:definition>2415407 - Disclosure - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssets" roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssets">
        <link:definition>2116106 - Disclosure - Prepaid Expenses and Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsTables" roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables">
        <link:definition>2317303 - Disclosure - Prepaid Expenses and Other Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsDetails" roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails">
        <link:definition>2418408 - Disclosure - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsDetails_1" roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1">
        <link:definition>2418408 - Disclosure - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://www.zentalis.com/role/PropertyandEquipmentnet">
        <link:definition>2119107 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetTables">
        <link:definition>2320304 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetSummaryDetails" roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails">
        <link:definition>2421409 - Disclosure - Property and Equipment, net - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetNarrativeDetails" roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails">
        <link:definition>2422410 - Disclosure - Property and Equipment, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.zentalis.com/role/AccruedExpenses">
        <link:definition>2123108 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.zentalis.com/role/AccruedExpensesTables">
        <link:definition>2324305 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.zentalis.com/role/AccruedExpensesDetails">
        <link:definition>2425411 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.zentalis.com/role/StockholdersEquity">
        <link:definition>2126109 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.zentalis.com/role/StockholdersEquityTables">
        <link:definition>2327306 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.zentalis.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2428412 - Disclosure - Stockholders&#8217; Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySharebasedCompensationDetails" roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails">
        <link:definition>2429413 - Disclosure - Stockholders&#8217; Equity - Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySharebasedCompensationExpenseDetails" roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails">
        <link:definition>2430414 - Disclosure - Stockholders&#8217; Equity - Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityFairValueAssumptionsforStockOptionsDetails" roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails">
        <link:definition>2431415 - Disclosure - Stockholders&#8217; Equity - Fair Value Assumptions for Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityFairValueAssumptionsforESPPDetails" roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails">
        <link:definition>2432416 - Disclosure - Stockholders&#8217; Equity - Fair Value Assumptions for ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityUnrecognizedCompensationCostDetails" roleURI="http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails">
        <link:definition>2433417 - Disclosure - Stockholders&#8217; Equity - Unrecognized Compensation Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.zentalis.com/role/CommitmentandContingencies">
        <link:definition>2134110 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesTables" roleURI="http://www.zentalis.com/role/CommitmentandContingenciesTables">
        <link:definition>2335307 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails">
        <link:definition>2436418 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2436418 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNarrativeDetails" roleURI="http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails">
        <link:definition>2437419 - Disclosure - Commitment and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShare" roleURI="http://www.zentalis.com/role/NetLossPerCommonShare">
        <link:definition>2138111 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareTables" roleURI="http://www.zentalis.com/role/NetLossPerCommonShareTables">
        <link:definition>2339308 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareCalculationDetails" roleURI="http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails">
        <link:definition>2440420 - Disclosure - Net Loss Per Common Share - Calculation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>2441421 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosures" roleURI="http://www.zentalis.com/role/RelatedPartyDisclosures">
        <link:definition>2142112 - Disclosure - Related Party Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosuresDetails" roleURI="http://www.zentalis.com/role/RelatedPartyDisclosuresDetails">
        <link:definition>2443422 - Disclosure - Related Party Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="zntl_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_AccruedGeneralAndAdministrativeCostsCurrent" abstract="false" name="AccruedGeneralAndAdministrativeCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_OtherPrepaidExpense" abstract="false" name="OtherPrepaidExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_ForeignResearchAndDevelopmentCreditRefund" abstract="false" name="ForeignResearchAndDevelopmentCreditRefund" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_InvestmentAndOtherIncomeExpense" abstract="false" name="InvestmentAndOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_ResearchAndDevelopmentExpenseReimbursements" abstract="false" name="ResearchAndDevelopmentExpenseReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_A2022EmploymentInducementIncentiveAwardPlanMember" abstract="true" name="A2022EmploymentInducementIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" abstract="true" name="RestrictedStockAwardsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_ZenteraStockPlanMember" abstract="true" name="ZenteraStockPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_ZenteraTherapeuticsLtdMember" abstract="true" name="ZenteraTherapeuticsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_EarningsPerShareNumeratorAbstract" abstract="true" name="EarningsPerShareNumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="zntl_A2020IncentiveAwardPlanMember" abstract="true" name="A2020IncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_EarningsPerShareDenominatorAbstract" abstract="true" name="EarningsPerShareDenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="zntl_FollowOnOfferingMember" abstract="true" name="FollowOnOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_KalyraPharmaceuticalsIncMember" abstract="true" name="KalyraPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_PrepaidSoftwareLicenseAndMaintenance" abstract="false" name="PrepaidSoftwareLicenseAndMaintenance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_ProceedsFromIssuanceOfCommonStockGross" abstract="false" name="ProceedsFromIssuanceOfCommonStockGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="zntl_PrepaidResearchAndDevelopmentCosts" abstract="false" name="PrepaidResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_MasterServicesAgreementMember" abstract="true" name="MasterServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" abstract="false" name="ReconciliationOfNoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="zntl_OfficeEquipmentAndFurnitureMember" abstract="true" name="OfficeEquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_DirectOfferingMember" abstract="true" name="DirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>zntl-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:dc6f2cb5-3684-47f2-a7ee-9069478f9aef,g:255d4c27-7dc3-44e2-be9a-0993a342da50-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="zntl-20220630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_26f8e6ed-f16c-4e55-b615-42c6ee1f7484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b2be67c-0dcf-4e47-b8d9-d1bf93e99b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_26f8e6ed-f16c-4e55-b615-42c6ee1f7484" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b2be67c-0dcf-4e47-b8d9-d1bf93e99b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fca67ecc-e325-49be-bc29-2882dcb78b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_26f8e6ed-f16c-4e55-b615-42c6ee1f7484" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fca67ecc-e325-49be-bc29-2882dcb78b20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_54bd4d13-d1c5-46f5-8a93-6400564ebb63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_26f8e6ed-f16c-4e55-b615-42c6ee1f7484" xlink:to="loc_us-gaap_Liabilities_54bd4d13-d1c5-46f5-8a93-6400564ebb63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6cbee689-8e33-4905-9bd8-88735683487e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_34c2e05e-7be7-440f-b631-d5bfd76d5db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6cbee689-8e33-4905-9bd8-88735683487e" xlink:to="loc_us-gaap_AccountsPayableCurrent_34c2e05e-7be7-440f-b631-d5bfd76d5db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ab08528a-237a-45c2-b365-2aac4cfff19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6cbee689-8e33-4905-9bd8-88735683487e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ab08528a-237a-45c2-b365-2aac4cfff19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5f5a5614-23f3-44ba-ab41-e3a4c36f5c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_448a51ba-208d-49d1-a8d2-d1fd6ab58de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f5a5614-23f3-44ba-ab41-e3a4c36f5c36" xlink:to="loc_us-gaap_CommonStockValue_448a51ba-208d-49d1-a8d2-d1fd6ab58de2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45051650-952b-4705-b27b-4a2b6e3e08f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f5a5614-23f3-44ba-ab41-e3a4c36f5c36" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45051650-952b-4705-b27b-4a2b6e3e08f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9ce36bee-0b60-4002-8a9b-8756c9c42946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f5a5614-23f3-44ba-ab41-e3a4c36f5c36" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9ce36bee-0b60-4002-8a9b-8756c9c42946" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6346d6fb-b581-486b-a179-670e1c1c7599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f5a5614-23f3-44ba-ab41-e3a4c36f5c36" xlink:to="loc_us-gaap_PreferredStockValue_6346d6fb-b581-486b-a179-670e1c1c7599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_217a5cca-a733-4e34-ba24-9d613d0b4a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f5a5614-23f3-44ba-ab41-e3a4c36f5c36" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_217a5cca-a733-4e34-ba24-9d613d0b4a5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7e428f59-32fa-4fbd-adc6-d603dec24576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_6866c671-cd2c-437d-8057-4f13c92dd5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7e428f59-32fa-4fbd-adc6-d603dec24576" xlink:to="loc_us-gaap_RestrictedCashCurrent_6866c671-cd2c-437d-8057-4f13c92dd5e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_da2153f4-fe7c-4199-913f-4453df231fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7e428f59-32fa-4fbd-adc6-d603dec24576" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_da2153f4-fe7c-4199-913f-4453df231fe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_43f018d9-960c-4c89-8aaa-6d9e7d2b213e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7e428f59-32fa-4fbd-adc6-d603dec24576" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_43f018d9-960c-4c89-8aaa-6d9e7d2b213e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c93c4e4-2bf2-4050-9ae6-ad25086bbb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7e428f59-32fa-4fbd-adc6-d603dec24576" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c93c4e4-2bf2-4050-9ae6-ad25086bbb2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94258f49-9858-4620-a226-ed60c7790fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_70e1db57-29fe-48e3-9b22-10fe3dfc344d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94258f49-9858-4620-a226-ed60c7790fc0" xlink:to="loc_us-gaap_MinorityInterest_70e1db57-29fe-48e3-9b22-10fe3dfc344d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dce68cd4-4c82-4a1d-8f31-e5225ba0436a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94258f49-9858-4620-a226-ed60c7790fc0" xlink:to="loc_us-gaap_StockholdersEquity_dce68cd4-4c82-4a1d-8f31-e5225ba0436a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a5ec2f07-5928-49e3-b7ec-0b00cc00ba96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cc521056-7fe4-45e1-a692-e3f014d71cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a5ec2f07-5928-49e3-b7ec-0b00cc00ba96" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cc521056-7fe4-45e1-a692-e3f014d71cd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c1dd3248-2797-419a-b67f-a2e84fd0d7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a5ec2f07-5928-49e3-b7ec-0b00cc00ba96" xlink:to="loc_us-gaap_Goodwill_c1dd3248-2797-419a-b67f-a2e84fd0d7b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_0b1922ef-9fac-4092-95aa-b31286c73d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a5ec2f07-5928-49e3-b7ec-0b00cc00ba96" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_0b1922ef-9fac-4092-95aa-b31286c73d1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_26ff52ec-fe69-4d40-a8ac-1c390afb0d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a5ec2f07-5928-49e3-b7ec-0b00cc00ba96" xlink:to="loc_us-gaap_EquityMethodInvestments_26ff52ec-fe69-4d40-a8ac-1c390afb0d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_32c4e5cf-4892-46d9-80dd-04776635b5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a5ec2f07-5928-49e3-b7ec-0b00cc00ba96" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_32c4e5cf-4892-46d9-80dd-04776635b5cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d82e3054-8afe-429a-b7dd-8bff4bde0e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a5ec2f07-5928-49e3-b7ec-0b00cc00ba96" xlink:to="loc_us-gaap_AssetsCurrent_d82e3054-8afe-429a-b7dd-8bff4bde0e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c2da28ae-0e59-4ab9-a835-652c91ac796b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a5ec2f07-5928-49e3-b7ec-0b00cc00ba96" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c2da28ae-0e59-4ab9-a835-652c91ac796b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_776370f1-aebe-450d-9d6a-20dc5d79bef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a8f2d1ce-d5ae-43d5-91df-b60877ceb91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_776370f1-aebe-450d-9d6a-20dc5d79bef8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a8f2d1ce-d5ae-43d5-91df-b60877ceb91a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e49d2c5d-fab8-42ff-9970-1cc3c5684c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_776370f1-aebe-450d-9d6a-20dc5d79bef8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e49d2c5d-fab8-42ff-9970-1cc3c5684c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c6be9c63-c254-4dc0-81a6-6c7f0a259cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_776370f1-aebe-450d-9d6a-20dc5d79bef8" xlink:to="loc_us-gaap_LiabilitiesCurrent_c6be9c63-c254-4dc0-81a6-6c7f0a259cbb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="zntl-20220630.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f85ed51c-0823-4418-bb03-0174a0c733f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_db18b626-545f-4774-b533-64430a075e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f85ed51c-0823-4418-bb03-0174a0c733f3" xlink:to="loc_us-gaap_OperatingExpenses_db18b626-545f-4774-b533-64430a075e37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_99e36a6e-e6cb-495e-b1bc-cc4db3dc94c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e97b55d8-e9b0-43cb-b1a6-be519f88c7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_99e36a6e-e6cb-495e-b1bc-cc4db3dc94c0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e97b55d8-e9b0-43cb-b1a6-be519f88c7fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4d384025-bb63-4172-b1dc-b4a80d4be250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_99e36a6e-e6cb-495e-b1bc-cc4db3dc94c0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4d384025-bb63-4172-b1dc-b4a80d4be250" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_603d2da6-e809-406f-bdfd-93a9c7b93a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_InvestmentAndOtherIncomeExpense_35295fb2-5f74-4ed3-af57-069c4f8baf45" xlink:href="zntl-20220630.xsd#zntl_InvestmentAndOtherIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_603d2da6-e809-406f-bdfd-93a9c7b93a38" xlink:to="loc_zntl_InvestmentAndOtherIncomeExpense_35295fb2-5f74-4ed3-af57-069c4f8baf45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_320fa1f3-f8d2-4995-89aa-cf5279d032cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_603d2da6-e809-406f-bdfd-93a9c7b93a38" xlink:to="loc_us-gaap_OperatingIncomeLoss_320fa1f3-f8d2-4995-89aa-cf5279d032cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7169d82a-7f9c-4342-9a54-8bca0d61bcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2c85b1e1-b008-4be0-a6ad-aae6a7eb7482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7169d82a-7f9c-4342-9a54-8bca0d61bcc5" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2c85b1e1-b008-4be0-a6ad-aae6a7eb7482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8776a3f3-7cf9-4090-ad73-362022aa2dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7169d82a-7f9c-4342-9a54-8bca0d61bcc5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8776a3f3-7cf9-4090-ad73-362022aa2dad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6e6f3d25-119e-480c-aa93-a494e6dd9b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7169d82a-7f9c-4342-9a54-8bca0d61bcc5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6e6f3d25-119e-480c-aa93-a494e6dd9b01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5816b80c-ed65-4d84-8698-aeb26648a3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_093c7957-61af-4cbb-b0dc-55dd8a822e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5816b80c-ed65-4d84-8698-aeb26648a3dc" xlink:to="loc_us-gaap_ProfitLoss_093c7957-61af-4cbb-b0dc-55dd8a822e94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5b03013b-1cb8-47ef-9b4d-c3d5f9e1cfae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5816b80c-ed65-4d84-8698-aeb26648a3dc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5b03013b-1cb8-47ef-9b4d-c3d5f9e1cfae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="zntl-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8350ac83-6326-47c3-b53a-a15ce4486070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e4e49f4e-52ec-4996-8018-5fe6314fd314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_8350ac83-6326-47c3-b53a-a15ce4486070" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e4e49f4e-52ec-4996-8018-5fe6314fd314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6b11a3ce-05ce-4b29-bdd8-b18c7e5ab415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_8350ac83-6326-47c3-b53a-a15ce4486070" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6b11a3ce-05ce-4b29-bdd8-b18c7e5ab415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4e0db8b-f3fc-48d9-9890-3cda3b848820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e3fcbe07-6dc9-4425-9e1f-94dded15b1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4e0db8b-f3fc-48d9-9890-3cda3b848820" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e3fcbe07-6dc9-4425-9e1f-94dded15b1e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_df34031b-596f-4449-8d5d-d1d2e0b31d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4e0db8b-f3fc-48d9-9890-3cda3b848820" xlink:to="loc_us-gaap_ProfitLoss_df34031b-596f-4449-8d5d-d1d2e0b31d0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0d669592-9fdb-4a1b-8a3e-e8a89825c05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4e0db8b-f3fc-48d9-9890-3cda3b848820" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0d669592-9fdb-4a1b-8a3e-e8a89825c05f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="zntl-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_084225b2-8032-4abe-bfee-90a40ea426c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6df20e1a-ae8f-4fbb-aa51-7ef02b384bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_084225b2-8032-4abe-bfee-90a40ea426c5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6df20e1a-ae8f-4fbb-aa51-7ef02b384bcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_c5f04261-be4d-4dc1-9508-aa0250e1e267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_084225b2-8032-4abe-bfee-90a40ea426c5" xlink:to="loc_us-gaap_RestrictedCash_c5f04261-be4d-4dc1-9508-aa0250e1e267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f07e96c6-a5a9-48a7-b73d-4a1e69e8238b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d44c8eab-6b3f-461c-9354-98616d218507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f07e96c6-a5a9-48a7-b73d-4a1e69e8238b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d44c8eab-6b3f-461c-9354-98616d218507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d2d6908f-6b6c-4f61-866a-ae62e3709850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f07e96c6-a5a9-48a7-b73d-4a1e69e8238b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d2d6908f-6b6c-4f61-866a-ae62e3709850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d877fd9a-99f8-4598-8330-888814564693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f07e96c6-a5a9-48a7-b73d-4a1e69e8238b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d877fd9a-99f8-4598-8330-888814564693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9be95c0e-a17e-4e8c-bf6b-4815b9ed351e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_4c06fee0-2401-4d44-94cb-86e8076a5553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9be95c0e-a17e-4e8c-bf6b-4815b9ed351e" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_4c06fee0-2401-4d44-94cb-86e8076a5553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_987de732-ff8b-4321-add6-22e430e93e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9be95c0e-a17e-4e8c-bf6b-4815b9ed351e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_987de732-ff8b-4321-add6-22e430e93e3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7bb0cfb2-3678-47fb-bcba-ca5b8d11ee1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9be95c0e-a17e-4e8c-bf6b-4815b9ed351e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7bb0cfb2-3678-47fb-bcba-ca5b8d11ee1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86c64a0e-7b85-459a-9ccb-d2c1d3959874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4a7291f3-e415-48c5-8fa1-86a0d2670456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86c64a0e-7b85-459a-9ccb-d2c1d3959874" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4a7291f3-e415-48c5-8fa1-86a0d2670456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9cb07b0c-cded-4da4-bc0c-9b28e2f46197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86c64a0e-7b85-459a-9ccb-d2c1d3959874" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9cb07b0c-cded-4da4-bc0c-9b28e2f46197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b9706cbe-7345-4ab7-a7c3-b6898f8589ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86c64a0e-7b85-459a-9ccb-d2c1d3959874" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b9706cbe-7345-4ab7-a7c3-b6898f8589ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a99f3ab-592f-4435-9dfe-db66760a6ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9f8298f0-b3b1-4ab0-87c0-7698b3c77e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a99f3ab-592f-4435-9dfe-db66760a6ee0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9f8298f0-b3b1-4ab0-87c0-7698b3c77e81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_080a0b24-2838-409a-9fe4-dbcc2450aac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a99f3ab-592f-4435-9dfe-db66760a6ee0" xlink:to="loc_us-gaap_ShareBasedCompensation_080a0b24-2838-409a-9fe4-dbcc2450aac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_79bf6c1d-00b3-40b0-b2df-d84185795976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a99f3ab-592f-4435-9dfe-db66760a6ee0" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_79bf6c1d-00b3-40b0-b2df-d84185795976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_6864d6a8-03fc-4e56-87f7-64cfb976164d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a99f3ab-592f-4435-9dfe-db66760a6ee0" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_6864d6a8-03fc-4e56-87f7-64cfb976164d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_546485ea-6ae5-4b64-80f5-f66a180836b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a99f3ab-592f-4435-9dfe-db66760a6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_546485ea-6ae5-4b64-80f5-f66a180836b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_05306ccb-f470-4aca-aa1e-04680b0a7eec" xlink:href="zntl-20220630.xsd#zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a99f3ab-592f-4435-9dfe-db66760a6ee0" xlink:to="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_05306ccb-f470-4aca-aa1e-04680b0a7eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c6bc73a4-5a1f-44be-bd99-96d147ca488d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a99f3ab-592f-4435-9dfe-db66760a6ee0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c6bc73a4-5a1f-44be-bd99-96d147ca488d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_612b8d4f-3eda-4800-a585-007bb3362b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a99f3ab-592f-4435-9dfe-db66760a6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_612b8d4f-3eda-4800-a585-007bb3362b3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7e2c98ae-65f3-43d7-8b0b-3143c4fcf2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a99f3ab-592f-4435-9dfe-db66760a6ee0" xlink:to="loc_us-gaap_ProfitLoss_7e2c98ae-65f3-43d7-8b0b-3143c4fcf2df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_07fcc71b-9130-40ea-9e92-1e4fe943696a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b154470a-ebfe-4cc4-a1cc-a34b89e4a4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_07fcc71b-9130-40ea-9e92-1e4fe943696a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b154470a-ebfe-4cc4-a1cc-a34b89e4a4e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_29a5960f-b7c0-4aac-84c5-d06c5805fe64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_07fcc71b-9130-40ea-9e92-1e4fe943696a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_29a5960f-b7c0-4aac-84c5-d06c5805fe64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_589e5f19-235b-40fd-9cde-16f480add368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_07fcc71b-9130-40ea-9e92-1e4fe943696a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_589e5f19-235b-40fd-9cde-16f480add368" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_fe0d733f-9eb4-458c-99b1-4cbfc3bcf777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_eb8c3b33-e0af-4727-8c47-7a1650621538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_fe0d733f-9eb4-458c-99b1-4cbfc3bcf777" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_eb8c3b33-e0af-4727-8c47-7a1650621538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_48d6c614-ce44-4da4-887e-b4ae484e82ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_fe0d733f-9eb4-458c-99b1-4cbfc3bcf777" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_48d6c614-ce44-4da4-887e-b4ae484e82ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a81db07d-2e97-4d39-9a98-b18d5ea30952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c45bf211-f41e-47db-8899-155e54a8383c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a81db07d-2e97-4d39-9a98-b18d5ea30952" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c45bf211-f41e-47db-8899-155e54a8383c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62b7865a-4586-4c7e-944f-dbd8e1b19924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a81db07d-2e97-4d39-9a98-b18d5ea30952" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62b7865a-4586-4c7e-944f-dbd8e1b19924" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#PrepaidExpensesandOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_5a9030f3-1e86-4038-bc77-1644ac736739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1e7e9dc0-e953-4833-9366-62fa472a5831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_5a9030f3-1e86-4038-bc77-1644ac736739" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1e7e9dc0-e953-4833-9366-62fa472a5831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_86c93daf-4235-4b8b-a31b-7182fe1bf03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_5a9030f3-1e86-4038-bc77-1644ac736739" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_86c93daf-4235-4b8b-a31b-7182fe1bf03a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1" xlink:type="simple" xlink:href="zntl-20220630.xsd#PrepaidExpensesandOtherAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_24e7920b-9e14-4458-b665-48aa93c7fd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_03f237e5-b25e-4014-a5ac-0efbaeca4102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_24e7920b-9e14-4458-b665-48aa93c7fd6c" xlink:to="loc_us-gaap_InterestReceivable_03f237e5-b25e-4014-a5ac-0efbaeca4102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OtherPrepaidExpense_607bc38f-062f-4dde-8e2f-675e837f7ddf" xlink:href="zntl-20220630.xsd#zntl_OtherPrepaidExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_24e7920b-9e14-4458-b665-48aa93c7fd6c" xlink:to="loc_zntl_OtherPrepaidExpense_607bc38f-062f-4dde-8e2f-675e837f7ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidResearchAndDevelopmentCosts_8e43e8f9-b110-46ef-84ed-ba9e5ec53293" xlink:href="zntl-20220630.xsd#zntl_PrepaidResearchAndDevelopmentCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_24e7920b-9e14-4458-b665-48aa93c7fd6c" xlink:to="loc_zntl_PrepaidResearchAndDevelopmentCosts_8e43e8f9-b110-46ef-84ed-ba9e5ec53293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_879160e6-6328-41ed-91ed-663aa3c7cfae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_24e7920b-9e14-4458-b665-48aa93c7fd6c" xlink:to="loc_us-gaap_PrepaidInsurance_879160e6-6328-41ed-91ed-663aa3c7cfae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_93f217b0-49f4-4ea7-b9ae-3844c4506028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_24e7920b-9e14-4458-b665-48aa93c7fd6c" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_93f217b0-49f4-4ea7-b9ae-3844c4506028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidSoftwareLicenseAndMaintenance_4a268868-ad56-45ea-ac35-3438f90da4b4" xlink:href="zntl-20220630.xsd#zntl_PrepaidSoftwareLicenseAndMaintenance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_24e7920b-9e14-4458-b665-48aa93c7fd6c" xlink:to="loc_zntl_PrepaidSoftwareLicenseAndMaintenance_4a268868-ad56-45ea-ac35-3438f90da4b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ForeignResearchAndDevelopmentCreditRefund_78066344-0009-41e7-bee8-d4786b0c4d16" xlink:href="zntl-20220630.xsd#zntl_ForeignResearchAndDevelopmentCreditRefund"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_24e7920b-9e14-4458-b665-48aa93c7fd6c" xlink:to="loc_zntl_ForeignResearchAndDevelopmentCreditRefund_78066344-0009-41e7-bee8-d4786b0c4d16" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#PropertyandEquipmentnetSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3421a402-d50d-4495-95db-6c2df13e7db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4d8b2296-328b-4bd7-baf3-84eba456353e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3421a402-d50d-4495-95db-6c2df13e7db6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4d8b2296-328b-4bd7-baf3-84eba456353e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c15c011f-12c2-45b8-a548-3dc61c3e4ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3421a402-d50d-4495-95db-6c2df13e7db6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c15c011f-12c2-45b8-a548-3dc61c3e4ef1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5f914e39-ebbe-46ec-8d9f-17dbe347dcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_be987b49-f9bb-4194-8c01-009d361083ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5f914e39-ebbe-46ec-8d9f-17dbe347dcf0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_be987b49-f9bb-4194-8c01-009d361083ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ca0fe847-fc06-43f6-93f8-6a63cc788b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5f914e39-ebbe-46ec-8d9f-17dbe347dcf0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ca0fe847-fc06-43f6-93f8-6a63cc788b14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_3ac5472e-6064-4eef-aa28-af60a1725b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5f914e39-ebbe-46ec-8d9f-17dbe347dcf0" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_3ac5472e-6064-4eef-aa28-af60a1725b93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent_54b6b246-3d84-4531-820c-101abcada00a" xlink:href="zntl-20220630.xsd#zntl_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5f914e39-ebbe-46ec-8d9f-17dbe347dcf0" xlink:to="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent_54b6b246-3d84-4531-820c-101abcada00a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3850ee7c-065f-467e-acfb-b053e9f2ef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5f914e39-ebbe-46ec-8d9f-17dbe347dcf0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3850ee7c-065f-467e-acfb-b053e9f2ef13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent_12c2ac99-3912-4f58-b961-1e50ea274318" xlink:href="zntl-20220630.xsd#zntl_AccruedGeneralAndAdministrativeCostsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5f914e39-ebbe-46ec-8d9f-17dbe347dcf0" xlink:to="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent_12c2ac99-3912-4f58-b961-1e50ea274318" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4438a1f-c088-4f82-905a-a100fce6f0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ade2e9d1-aef4-4fb2-9d2f-b6413c384fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4438a1f-c088-4f82-905a-a100fce6f0a3" xlink:to="loc_us-gaap_OperatingLeaseLiability_ade2e9d1-aef4-4fb2-9d2f-b6413c384fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_45253c9c-320e-4225-b0e5-e8677b72a272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4438a1f-c088-4f82-905a-a100fce6f0a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_45253c9c-320e-4225-b0e5-e8677b72a272" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e40687b5-139a-43ea-b58d-47cda0b0e0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7c0d1449-8d81-4ed1-a517-771a7879c12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e40687b5-139a-43ea-b58d-47cda0b0e0a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7c0d1449-8d81-4ed1-a517-771a7879c12e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7b1ef652-741f-462a-b40f-4eafd7f55fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e40687b5-139a-43ea-b58d-47cda0b0e0a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7b1ef652-741f-462a-b40f-4eafd7f55fc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="zntl-20220630.xsd#CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07a00853-c0eb-4727-aa3b-47733b5cf5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0213651e-c169-47a8-8083-6744f0ee81d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07a00853-c0eb-4727-aa3b-47733b5cf5f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0213651e-c169-47a8-8083-6744f0ee81d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a07412a2-2caf-4988-8b43-a913f98b3a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07a00853-c0eb-4727-aa3b-47733b5cf5f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a07412a2-2caf-4988-8b43-a913f98b3a85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_679b19f2-9c3c-4241-afd1-736e0c839555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07a00853-c0eb-4727-aa3b-47733b5cf5f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_679b19f2-9c3c-4241-afd1-736e0c839555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0f0a4a79-253a-4f1e-88ec-15a82051ef0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07a00853-c0eb-4727-aa3b-47733b5cf5f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0f0a4a79-253a-4f1e-88ec-15a82051ef0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_179fac61-7fbf-4c3f-a637-fb91ac43c097" xlink:href="zntl-20220630.xsd#zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07a00853-c0eb-4727-aa3b-47733b5cf5f6" xlink:to="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_179fac61-7fbf-4c3f-a637-fb91ac43c097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_42b7d3f7-d53f-4094-a1c3-1bcd5c0194bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07a00853-c0eb-4727-aa3b-47733b5cf5f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_42b7d3f7-d53f-4094-a1c3-1bcd5c0194bc" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>zntl-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:dc6f2cb5-3684-47f2-a7ee-9069478f9aef,g:255d4c27-7dc3-44e2-be9a-0993a342da50-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="zntl-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i2708511b18a84b1491f3873557723330_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_55e89b6f-64d6-42e1-8491-232e70b2b43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55e89b6f-64d6-42e1-8491-232e70b2b43e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_84a667a9-2231-43c3-91af-6232c87812a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_SharesOutstanding_84a667a9-2231-43c3-91af-6232c87812a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f6678643-0f53-457c-96d9-8f7d647703fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f6678643-0f53-457c-96d9-8f7d647703fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2a1fd431-c038-42bb-a9b9-b9f9626e8f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2a1fd431-c038-42bb-a9b9-b9f9626e8f00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_85010345-bd63-4bb0-a317-fece89a61bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_85010345-bd63-4bb0-a317-fece89a61bb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9d93018a-d804-4336-a0f0-3368d09696ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9d93018a-d804-4336-a0f0-3368d09696ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c11b80be-3408-4898-9750-197fddc427d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c11b80be-3408-4898-9750-197fddc427d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_293826ae-c1aa-43d3-a7cb-1f0ed4c041f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_293826ae-c1aa-43d3-a7cb-1f0ed4c041f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_fe87fc3c-2b3a-4f22-9fed-9a292d370e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_fe87fc3c-2b3a-4f22-9fed-9a292d370e06" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74974677-6e2c-4342-a41b-fbf129ed2fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74974677-6e2c-4342-a41b-fbf129ed2fb3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4d7ba003-f05a-4217-bb4e-a351e1c0a14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4d7ba003-f05a-4217-bb4e-a351e1c0a14d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_83d64787-cf18-4a4a-b6a7-cdd8816d2b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_83d64787-cf18-4a4a-b6a7-cdd8816d2b73" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0f3208f3-acf7-42fe-b931-f9da7f177236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0f3208f3-acf7-42fe-b931-f9da7f177236" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_831f5d8d-1d97-400e-80bb-fd7716d703a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_831f5d8d-1d97-400e-80bb-fd7716d703a8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7d2aed7b-83f9-4006-9a6e-63fc5911ba34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7d2aed7b-83f9-4006-9a6e-63fc5911ba34" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_28a80c99-ee6b-4c46-8dbd-d2a86c3c60f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_NetIncomeLoss_28a80c99-ee6b-4c46-8dbd-d2a86c3c60f7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2bd853a2-7c87-4114-911c-d9a9d7480af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_081e71e4-4fda-48c2-a158-c381f2e99663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_957aa484-07a2-4328-b282-8d35a21fa637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_55e89b6f-64d6-42e1-8491-232e70b2b43e" xlink:to="loc_us-gaap_StatementTable_957aa484-07a2-4328-b282-8d35a21fa637" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3be871d-a8e5-4421-8652-d208444b7fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_957aa484-07a2-4328-b282-8d35a21fa637" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3be871d-a8e5-4421-8652-d208444b7fad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3be871d-a8e5-4421-8652-d208444b7fad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3be871d-a8e5-4421-8652-d208444b7fad" xlink:to="loc_us-gaap_EquityComponentDomain_d3be871d-a8e5-4421-8652-d208444b7fad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3be871d-a8e5-4421-8652-d208444b7fad" xlink:to="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a0f36b35-4ad4-44f8-8766-7f592c8e625f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:to="loc_us-gaap_CommonStockMember_a0f36b35-4ad4-44f8-8766-7f592c8e625f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d242a629-e82f-4be0-99a5-8dc344208f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d242a629-e82f-4be0-99a5-8dc344208f50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8f152cb5-cef2-43ba-85dc-43bd827b75b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8f152cb5-cef2-43ba-85dc-43bd827b75b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9c3b464d-8c96-4fef-928d-c985da4bdb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:to="loc_us-gaap_RetainedEarningsMember_9c3b464d-8c96-4fef-928d-c985da4bdb0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_35fa00f3-13c4-4748-8274-6ba670bd6040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_35fa00f3-13c4-4748-8274-6ba670bd6040" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/SignificantTransactionsDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#SignificantTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/SignificantTransactionsDetails" xlink:type="extended" id="i5f579a39cbdb43e099ba8e4475d4c378_SignificantTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d09b2e81-d8d6-4360-82bf-1eec892027c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:to="loc_us-gaap_EquityMethodInvestments_d09b2e81-d8d6-4360-82bf-1eec892027c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_4ac486d0-3727-4c44-ad9f-a3b8fee9a32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_4ac486d0-3727-4c44-ad9f-a3b8fee9a32c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_fc075759-9f7f-43e7-8685-47df7f71a1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_fc075759-9f7f-43e7-8685-47df7f71a1bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_f9300f92-4ab6-40e6-a634-fbf20f9b9d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_f9300f92-4ab6-40e6-a634-fbf20f9b9d15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_454c32e1-0047-4f11-b172-9083d449f877" xlink:href="zntl-20220630.xsd#zntl_ResearchAndDevelopmentExpenseReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:to="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_454c32e1-0047-4f11-b172-9083d449f877" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bf0f03aa-4b22-4acd-bf97-8b7c1b2c6dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bf0f03aa-4b22-4acd-bf97-8b7c1b2c6dbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec8bc3c4-83bd-4863-b240-c03f7f51d5e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bf0f03aa-4b22-4acd-bf97-8b7c1b2c6dbd" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec8bc3c4-83bd-4863-b240-c03f7f51d5e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ec8bc3c4-83bd-4863-b240-c03f7f51d5e2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec8bc3c4-83bd-4863-b240-c03f7f51d5e2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ec8bc3c4-83bd-4863-b240-c03f7f51d5e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2679d190-8e3a-416f-b5fb-d22929fee977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec8bc3c4-83bd-4863-b240-c03f7f51d5e2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2679d190-8e3a-416f-b5fb-d22929fee977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraTherapeuticsLtdMember_2afcf924-5d70-418b-ad68-a09c3cb39113" xlink:href="zntl-20220630.xsd#zntl_ZenteraTherapeuticsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2679d190-8e3a-416f-b5fb-d22929fee977" xlink:to="loc_zntl_ZenteraTherapeuticsLtdMember_2afcf924-5d70-418b-ad68-a09c3cb39113" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended" id="id394a9c2d72c40b595e77d4969bb82e6_BusinessCombinationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_3f2cc412-d169-48f3-88b4-1d2e022b99e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_03554316-e6b8-4ec3-9a52-22f26310f508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3f2cc412-d169-48f3-88b4-1d2e022b99e7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_03554316-e6b8-4ec3-9a52-22f26310f508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_aa8e2e8e-78b9-41d9-aabf-d9758d09744a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3f2cc412-d169-48f3-88b4-1d2e022b99e7" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_aa8e2e8e-78b9-41d9-aabf-d9758d09744a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_92d8aed0-5258-490c-b790-df2ded3ad332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3f2cc412-d169-48f3-88b4-1d2e022b99e7" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_92d8aed0-5258-490c-b790-df2ded3ad332" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ad88ec6c-8879-4de0-936d-5f1f28a9c6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_92d8aed0-5258-490c-b790-df2ded3ad332" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ad88ec6c-8879-4de0-936d-5f1f28a9c6f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad88ec6c-8879-4de0-936d-5f1f28a9c6f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ad88ec6c-8879-4de0-936d-5f1f28a9c6f0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ad88ec6c-8879-4de0-936d-5f1f28a9c6f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039bcebd-93ed-4014-881e-36733b246944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ad88ec6c-8879-4de0-936d-5f1f28a9c6f0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039bcebd-93ed-4014-881e-36733b246944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_KalyraPharmaceuticalsIncMember_99166a81-fe17-422a-873e-7abb3185f287" xlink:href="zntl-20220630.xsd#zntl_KalyraPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039bcebd-93ed-4014-881e-36733b246944" xlink:to="loc_zntl_KalyraPharmaceuticalsIncMember_99166a81-fe17-422a-873e-7abb3185f287" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails" xlink:type="extended" id="i15bb3263143340cfba8caa0e61d16e7f_BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_29502c0c-3f60-488c-8fc6-44673ae7d290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_177fed02-b673-4f50-a076-d56439bd4377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_29502c0c-3f60-488c-8fc6-44673ae7d290" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_177fed02-b673-4f50-a076-d56439bd4377" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_17ddd9cd-2e86-4b69-8e53-6f6e4da0f715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_177fed02-b673-4f50-a076-d56439bd4377" xlink:to="loc_us-gaap_MinorityInterest_17ddd9cd-2e86-4b69-8e53-6f6e4da0f715" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c2790486-b1f9-4b11-8e26-06f9058f6414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_177fed02-b673-4f50-a076-d56439bd4377" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c2790486-b1f9-4b11-8e26-06f9058f6414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_d9c4943d-c6e6-4aeb-8e9e-5d18ea493b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_177fed02-b673-4f50-a076-d56439bd4377" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_d9c4943d-c6e6-4aeb-8e9e-5d18ea493b42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a8c9c07b-6551-41ee-b771-803310f1a7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4fc2b84a-ed76-47f7-a86d-8562ab987958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_29502c0c-3f60-488c-8fc6-44673ae7d290" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4fc2b84a-ed76-47f7-a86d-8562ab987958" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0a739598-1f77-4411-a7a7-ee767d14e5a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4fc2b84a-ed76-47f7-a86d-8562ab987958" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0a739598-1f77-4411-a7a7-ee767d14e5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0a739598-1f77-4411-a7a7-ee767d14e5a8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0a739598-1f77-4411-a7a7-ee767d14e5a8" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0a739598-1f77-4411-a7a7-ee767d14e5a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b98800e3-edd3-456d-bb99-ef23c83df5ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0a739598-1f77-4411-a7a7-ee767d14e5a8" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b98800e3-edd3-456d-bb99-ef23c83df5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_a5fdb977-257f-42b5-a237-cced63ad970d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b98800e3-edd3-456d-bb99-ef23c83df5ea" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_a5fdb977-257f-42b5-a237-cced63ad970d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended" id="i787e06cd38c04d4ba543bb99fbba29cf_FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e850f401-8023-4103-af97-7c3f3e3a005a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e850f401-8023-4103-af97-7c3f3e3a005a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23b2f0b9-d770-484c-b637-af6e66ba33f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23b2f0b9-d770-484c-b637-af6e66ba33f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6868ec86-a6c3-48a2-b2e0-ab2da1b12c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6868ec86-a6c3-48a2-b2e0-ab2da1b12c46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a3bef7a8-7580-474c-9551-cc008f760101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a3bef7a8-7580-474c-9551-cc008f760101" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c99996d6-f1ac-4074-9328-565704320c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c99996d6-f1ac-4074-9328-565704320c3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5c2b87b7-b756-45d8-bc71-b9df797fb676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c99996d6-f1ac-4074-9328-565704320c3c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5c2b87b7-b756-45d8-bc71-b9df797fb676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5c2b87b7-b756-45d8-bc71-b9df797fb676_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5c2b87b7-b756-45d8-bc71-b9df797fb676" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5c2b87b7-b756-45d8-bc71-b9df797fb676_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5c2b87b7-b756-45d8-bc71-b9df797fb676" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_53d294b8-934a-471c-a457-9c97f42bb10e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:to="loc_us-gaap_CommercialPaperMember_53d294b8-934a-471c-a457-9c97f42bb10e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7d6bd114-3290-4296-9b5f-4b7a274451c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7d6bd114-3290-4296-9b5f-4b7a274451c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8f6e825d-b179-49f6-be87-2709001ebe53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8f6e825d-b179-49f6-be87-2709001ebe53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a338b40f-0412-44e7-ba9a-75df4b2178cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a338b40f-0412-44e7-ba9a-75df4b2178cc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended" id="ib52fecceb1b74c88ab77a6bb7f1cf34b_FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ecc6c6b9-d56c-4257-ab2e-d7e819636469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_518d6288-9202-4415-b174-7c5eeda5d8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ecc6c6b9-d56c-4257-ab2e-d7e819636469" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_518d6288-9202-4415-b174-7c5eeda5d8cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f35ce582-3907-43e3-b933-6847729e4d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ecc6c6b9-d56c-4257-ab2e-d7e819636469" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f35ce582-3907-43e3-b933-6847729e4d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_bd27b3ae-35c9-4632-8db1-f8138b943187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ecc6c6b9-d56c-4257-ab2e-d7e819636469" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_bd27b3ae-35c9-4632-8db1-f8138b943187" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45aac886-0c1f-4b40-9184-65bcde6f2e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ecc6c6b9-d56c-4257-ab2e-d7e819636469" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45aac886-0c1f-4b40-9184-65bcde6f2e69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_499d09fd-4898-4b7d-a6a0-9872fa946b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45aac886-0c1f-4b40-9184-65bcde6f2e69" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_499d09fd-4898-4b7d-a6a0-9872fa946b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_499d09fd-4898-4b7d-a6a0-9872fa946b5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_499d09fd-4898-4b7d-a6a0-9872fa946b5c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_499d09fd-4898-4b7d-a6a0-9872fa946b5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c80df616-9184-4db8-bdf9-6e277f029e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_499d09fd-4898-4b7d-a6a0-9872fa946b5c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c80df616-9184-4db8-bdf9-6e277f029e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7db4abf0-d176-4451-8b79-d17c01b318e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c80df616-9184-4db8-bdf9-6e277f029e90" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7db4abf0-d176-4451-8b79-d17c01b318e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a24e2037-2f39-452f-b404-bce48d24bdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c80df616-9184-4db8-bdf9-6e277f029e90" xlink:to="loc_us-gaap_CommercialPaperMember_a24e2037-2f39-452f-b404-bce48d24bdc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_96d16e69-c0ca-43fb-bd0c-c95362af5900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45aac886-0c1f-4b40-9184-65bcde6f2e69" xlink:to="loc_us-gaap_FinancialInstrumentAxis_96d16e69-c0ca-43fb-bd0c-c95362af5900" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_96d16e69-c0ca-43fb-bd0c-c95362af5900_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_96d16e69-c0ca-43fb-bd0c-c95362af5900" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_96d16e69-c0ca-43fb-bd0c-c95362af5900_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_96d16e69-c0ca-43fb-bd0c-c95362af5900" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8a9d50fc-388a-4014-848d-bdddaa63999a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:to="loc_us-gaap_CommercialPaperMember_8a9d50fc-388a-4014-848d-bdddaa63999a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0767bbc2-4d3f-47cf-9445-32d4eac24b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0767bbc2-4d3f-47cf-9445-32d4eac24b75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6f707d41-a227-4259-8ce5-4c0b23e4db8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6f707d41-a227-4259-8ce5-4c0b23e4db8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_afdb1e26-6ce2-4e11-a198-e1b9209c2952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_afdb1e26-6ce2-4e11-a198-e1b9209c2952" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_646b211e-e94a-4963-834e-b40d0bb62b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45aac886-0c1f-4b40-9184-65bcde6f2e69" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_646b211e-e94a-4963-834e-b40d0bb62b7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_646b211e-e94a-4963-834e-b40d0bb62b7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_646b211e-e94a-4963-834e-b40d0bb62b7d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_646b211e-e94a-4963-834e-b40d0bb62b7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d896620-1a75-4b87-a052-005d00cdd362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_646b211e-e94a-4963-834e-b40d0bb62b7d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d896620-1a75-4b87-a052-005d00cdd362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5dac9799-270a-430d-bffe-24b3fcbc0642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d896620-1a75-4b87-a052-005d00cdd362" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5dac9799-270a-430d-bffe-24b3fcbc0642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d161912d-1f7d-4fcf-9ae1-8be1aa1e1fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d896620-1a75-4b87-a052-005d00cdd362" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d161912d-1f7d-4fcf-9ae1-8be1aa1e1fda" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#PropertyandEquipmentnetSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="extended" id="i3e53480568e946439ca33c411af12989_PropertyandEquipmentnetSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b317e30b-2b74-4114-b2bc-9c8a29ba6c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_13affc50-9043-41a9-8759-3d17fe345c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b317e30b-2b74-4114-b2bc-9c8a29ba6c4e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_13affc50-9043-41a9-8759-3d17fe345c79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bd022ee4-9be4-4cce-afec-30b8186170e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b317e30b-2b74-4114-b2bc-9c8a29ba6c4e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bd022ee4-9be4-4cce-afec-30b8186170e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ef574691-e61e-4f0a-abcc-c80bdf99f1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b317e30b-2b74-4114-b2bc-9c8a29ba6c4e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ef574691-e61e-4f0a-abcc-c80bdf99f1ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1166e2be-cdea-413d-bd3d-0548a6c0c3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b317e30b-2b74-4114-b2bc-9c8a29ba6c4e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1166e2be-cdea-413d-bd3d-0548a6c0c3f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d7323cc-47d8-4237-98f5-4cde63dd620c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1166e2be-cdea-413d-bd3d-0548a6c0c3f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d7323cc-47d8-4237-98f5-4cde63dd620c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d7323cc-47d8-4237-98f5-4cde63dd620c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d7323cc-47d8-4237-98f5-4cde63dd620c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d7323cc-47d8-4237-98f5-4cde63dd620c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d7323cc-47d8-4237-98f5-4cde63dd620c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LaboratoryEquipmentMember_d3f1cc8d-a4c4-4ce0-af27-b1ef5cf6ade2" xlink:href="zntl-20220630.xsd#zntl_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:to="loc_zntl_LaboratoryEquipmentMember_d3f1cc8d-a4c4-4ce0-af27-b1ef5cf6ade2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5263ee5c-ec0e-44fe-b0e3-4dbbfaa5b6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5263ee5c-ec0e-44fe-b0e3-4dbbfaa5b6b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OfficeEquipmentAndFurnitureMember_2a873fbc-58a8-47fa-95f6-fdb8d018ab4e" xlink:href="zntl-20220630.xsd#zntl_OfficeEquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:to="loc_zntl_OfficeEquipmentAndFurnitureMember_2a873fbc-58a8-47fa-95f6-fdb8d018ab4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_fa1c771e-fd54-4d1b-9e38-84594d067457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:to="loc_us-gaap_ComputerEquipmentMember_fa1c771e-fd54-4d1b-9e38-84594d067457" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b7292cf8-8ad3-46a7-ac18-1ce380cf439f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:to="loc_us-gaap_ConstructionInProgressMember_b7292cf8-8ad3-46a7-ac18-1ce380cf439f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i802b4898c1494800931448e4d13ef9a3_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_36c19887-1cba-4a02-9ddf-8db4b19d5672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_36c19887-1cba-4a02-9ddf-8db4b19d5672" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d411180d-b0e0-41be-ac90-9168bc884700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d411180d-b0e0-41be-ac90-9168bc884700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ProceedsFromIssuanceOfCommonStockGross_0c8912dd-24a2-485f-bc9f-bbf619f99e35" xlink:href="zntl-20220630.xsd#zntl_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_zntl_ProceedsFromIssuanceOfCommonStockGross_0c8912dd-24a2-485f-bc9f-bbf619f99e35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_defa6758-c278-46a1-a1ec-ba0747ec27f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_defa6758-c278-46a1-a1ec-ba0747ec27f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_17bdd6c6-ef58-45c6-af95-21e99428def1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_17bdd6c6-ef58-45c6-af95-21e99428def1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_2d4944e7-cc72-4c67-a1ce-8327fe1e32fe" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_2d4944e7-cc72-4c67-a1ce-8327fe1e32fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_58a4821f-7caa-4049-99c5-9a4ebec01f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_58a4821f-7caa-4049-99c5-9a4ebec01f86" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dfeafd2d-e5ee-4847-b6c0-b685a80702a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dfeafd2d-e5ee-4847-b6c0-b685a80702a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4e917f7b-92d0-49b6-ac99-2d57e68cdc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4e917f7b-92d0-49b6-ac99-2d57e68cdc61" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_7b582b30-a653-4c74-9a25-31b47f6a1e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_7b582b30-a653-4c74-9a25-31b47f6a1e99" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_32db9e31-20ea-4742-84b7-b0928c9bad89" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_32db9e31-20ea-4742-84b7-b0928c9bad89" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_afe67f00-797c-4ee7-9271-25c85c04054a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_afe67f00-797c-4ee7-9271-25c85c04054a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e70e56d0-096b-4d10-b310-8d42e36e01dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e70e56d0-096b-4d10-b310-8d42e36e01dc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_59c86d26-cac1-407a-81a8-dfc6b3d6c9bd" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_59c86d26-cac1-407a-81a8-dfc6b3d6c9bd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_92cb30c9-6984-46a8-a0cd-9a0c1a929437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_92cb30c9-6984-46a8-a0cd-9a0c1a929437" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_3339a6be-9570-4733-b8b6-d61deac2e468" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_3339a6be-9570-4733-b8b6-d61deac2e468" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b4eb2cda-e362-46e5-add7-19b5d6ab4687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b4eb2cda-e362-46e5-add7-19b5d6ab4687" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_05ac677f-8508-4df7-b66b-f7b49c2d44aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_05ac677f-8508-4df7-b66b-f7b49c2d44aa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0a72061d-c60a-468f-9010-7e165a4d7cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0a72061d-c60a-468f-9010-7e165a4d7cfa" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_93e27c11-88fd-460c-8e0a-98459a6e8c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_93e27c11-88fd-460c-8e0a-98459a6e8c24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_93e27c11-88fd-460c-8e0a-98459a6e8c24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_93e27c11-88fd-460c-8e0a-98459a6e8c24" xlink:to="loc_us-gaap_ClassOfStockDomain_93e27c11-88fd-460c-8e0a-98459a6e8c24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d2c4bfac-6910-42ac-8443-9a07ed64fb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_93e27c11-88fd-460c-8e0a-98459a6e8c24" xlink:to="loc_us-gaap_ClassOfStockDomain_d2c4bfac-6910-42ac-8443-9a07ed64fb65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_13fceea2-2bd8-42e7-952b-893f1a817c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d2c4bfac-6910-42ac-8443-9a07ed64fb65" xlink:to="loc_us-gaap_CommonStockMember_13fceea2-2bd8-42e7-952b-893f1a817c46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_0e53a7ab-1369-4540-a9b6-2f68b1f60f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d2c4bfac-6910-42ac-8443-9a07ed64fb65" xlink:to="loc_us-gaap_CommonClassBMember_0e53a7ab-1369-4540-a9b6-2f68b1f60f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_eab9f5cb-2795-4034-82d5-4c1fea7d8653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d2c4bfac-6910-42ac-8443-9a07ed64fb65" xlink:to="loc_us-gaap_RestrictedStockMember_eab9f5cb-2795-4034-82d5-4c1fea7d8653" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f2781d90-36be-4bda-9474-ae8a916b5790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_PlanNameAxis_f2781d90-36be-4bda-9474-ae8a916b5790" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f2781d90-36be-4bda-9474-ae8a916b5790_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f2781d90-36be-4bda-9474-ae8a916b5790" xlink:to="loc_us-gaap_PlanNameDomain_f2781d90-36be-4bda-9474-ae8a916b5790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_57a74dd7-6ee1-444f-aef1-ab6dd948b856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f2781d90-36be-4bda-9474-ae8a916b5790" xlink:to="loc_us-gaap_PlanNameDomain_57a74dd7-6ee1-444f-aef1-ab6dd948b856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2020IncentiveAwardPlanMember_d694bede-b053-4d36-933d-5e17e5e6bd3b" xlink:href="zntl-20220630.xsd#zntl_A2020IncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_57a74dd7-6ee1-444f-aef1-ab6dd948b856" xlink:to="loc_zntl_A2020IncentiveAwardPlanMember_d694bede-b053-4d36-933d-5e17e5e6bd3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_198ccf9c-511d-4d3a-a2d4-31d7eb902645" xlink:href="zntl-20220630.xsd#zntl_A2022EmploymentInducementIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_57a74dd7-6ee1-444f-aef1-ab6dd948b856" xlink:to="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_198ccf9c-511d-4d3a-a2d4-31d7eb902645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraStockPlanMember_09d5e8a6-691c-4616-9111-8a2c50c01a8b" xlink:href="zntl-20220630.xsd#zntl_ZenteraStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_57a74dd7-6ee1-444f-aef1-ab6dd948b856" xlink:to="loc_zntl_ZenteraStockPlanMember_09d5e8a6-691c-4616-9111-8a2c50c01a8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d10455e3-e9c9-4d2f-baa1-3b9a0d4413c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_srt_RangeAxis_d10455e3-e9c9-4d2f-baa1-3b9a0d4413c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d10455e3-e9c9-4d2f-baa1-3b9a0d4413c7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d10455e3-e9c9-4d2f-baa1-3b9a0d4413c7" xlink:to="loc_srt_RangeMember_d10455e3-e9c9-4d2f-baa1-3b9a0d4413c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78944888-d5ea-45be-8542-8ffafdcce7e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d10455e3-e9c9-4d2f-baa1-3b9a0d4413c7" xlink:to="loc_srt_RangeMember_78944888-d5ea-45be-8542-8ffafdcce7e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0200df54-7f75-4f99-8149-b6ab217ce787" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_78944888-d5ea-45be-8542-8ffafdcce7e0" xlink:to="loc_srt_MaximumMember_0200df54-7f75-4f99-8149-b6ab217ce787" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bddf48f5-78a9-4de9-b79d-eb80a0762d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_AwardTypeAxis_bddf48f5-78a9-4de9-b79d-eb80a0762d1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bddf48f5-78a9-4de9-b79d-eb80a0762d1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bddf48f5-78a9-4de9-b79d-eb80a0762d1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bddf48f5-78a9-4de9-b79d-eb80a0762d1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bddf48f5-78a9-4de9-b79d-eb80a0762d1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dfeb2eb1-800f-4f0d-80f0-065d8c5b2b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dfeb2eb1-800f-4f0d-80f0-065d8c5b2b5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0c4ef948-f301-4776-8985-278f1378ed3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:to="loc_us-gaap_EmployeeStockMember_0c4ef948-f301-4776-8985-278f1378ed3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8b3cd097-a399-455d-93f7-93441ff9e044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:to="loc_us-gaap_RestrictedStockMember_8b3cd097-a399-455d-93f7-93441ff9e044" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2c65eec9-2069-4cd9-abf4-fbb290057e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2c65eec9-2069-4cd9-abf4-fbb290057e57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8983ca66-c7f4-4760-b276-c5bb89d9f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8983ca66-c7f4-4760-b276-c5bb89d9f8bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8983ca66-c7f4-4760-b276-c5bb89d9f8bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8983ca66-c7f4-4760-b276-c5bb89d9f8bf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8983ca66-c7f4-4760-b276-c5bb89d9f8bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4ad2f40b-e7ef-4de9-8e75-b670dd9dcf51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8983ca66-c7f4-4760-b276-c5bb89d9f8bf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4ad2f40b-e7ef-4de9-8e75-b670dd9dcf51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_DirectOfferingMember_7ed55403-defc-4b0a-8933-392f987d2aa7" xlink:href="zntl-20220630.xsd#zntl_DirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4ad2f40b-e7ef-4de9-8e75-b670dd9dcf51" xlink:to="loc_zntl_DirectOfferingMember_7ed55403-defc-4b0a-8933-392f987d2aa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_FollowOnOfferingMember_17d66952-1deb-423d-8efb-e88dd3ac9b5e" xlink:href="zntl-20220630.xsd#zntl_FollowOnOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4ad2f40b-e7ef-4de9-8e75-b670dd9dcf51" xlink:to="loc_zntl_FollowOnOfferingMember_17d66952-1deb-423d-8efb-e88dd3ac9b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d3cbef67-5ee9-468c-b6c2-6a9577e96c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d3cbef67-5ee9-468c-b6c2-6a9577e96c2e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3cbef67-5ee9-468c-b6c2-6a9577e96c2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d3cbef67-5ee9-468c-b6c2-6a9577e96c2e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3cbef67-5ee9-468c-b6c2-6a9577e96c2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c2324ad-8abe-45bc-b4c7-c760407806a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d3cbef67-5ee9-468c-b6c2-6a9577e96c2e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c2324ad-8abe-45bc-b4c7-c760407806a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_c47242cd-d9c8-4486-a1de-5952cc770a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c2324ad-8abe-45bc-b4c7-c760407806a9" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_c47242cd-d9c8-4486-a1de-5952cc770a7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7904ccdf-d6f5-4029-a0d0-a88c7f4e602e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7904ccdf-d6f5-4029-a0d0-a88c7f4e602e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7904ccdf-d6f5-4029-a0d0-a88c7f4e602e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7904ccdf-d6f5-4029-a0d0-a88c7f4e602e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7904ccdf-d6f5-4029-a0d0-a88c7f4e602e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a71ec8e8-6710-492e-b7f8-988b181686ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7904ccdf-d6f5-4029-a0d0-a88c7f4e602e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a71ec8e8-6710-492e-b7f8-988b181686ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_05987b06-1303-442b-a82d-e7e4ead30140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a71ec8e8-6710-492e-b7f8-988b181686ef" xlink:to="loc_us-gaap_SubsequentEventMember_05987b06-1303-442b-a82d-e7e4ead30140" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquitySharebasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails" xlink:type="extended" id="i8df01cba5298460fbb3e37e8619bdbed_StockholdersEquitySharebasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc7d56c2-f614-4fe5-a67b-225592e2b6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_27e48854-3c43-4432-9be4-30fbf5508927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc7d56c2-f614-4fe5-a67b-225592e2b6d5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_27e48854-3c43-4432-9be4-30fbf5508927" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deb20d40-2946-412b-9300-314301420be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc7d56c2-f614-4fe5-a67b-225592e2b6d5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deb20d40-2946-412b-9300-314301420be7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_39217b9d-5188-40d2-bd05-1b45ee513563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deb20d40-2946-412b-9300-314301420be7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_39217b9d-5188-40d2-bd05-1b45ee513563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_39217b9d-5188-40d2-bd05-1b45ee513563_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_39217b9d-5188-40d2-bd05-1b45ee513563" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_39217b9d-5188-40d2-bd05-1b45ee513563_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d5b434f-131b-4bcc-b5f9-62398db7180e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_39217b9d-5188-40d2-bd05-1b45ee513563" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d5b434f-131b-4bcc-b5f9-62398db7180e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f8ba5e5f-b4f1-49b9-94ca-f301b77311a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d5b434f-131b-4bcc-b5f9-62398db7180e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f8ba5e5f-b4f1-49b9-94ca-f301b77311a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c1241f1c-9292-4954-8070-0e2ebc9bb155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d5b434f-131b-4bcc-b5f9-62398db7180e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c1241f1c-9292-4954-8070-0e2ebc9bb155" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquitySharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails" xlink:type="extended" id="idd3fdff5047d43368c482e6cf7340622_StockholdersEquitySharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1772d108-d530-4125-8603-bbf36f17ec6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_df30b44e-15cb-4f26-b133-707612984553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1772d108-d530-4125-8603-bbf36f17ec6b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_df30b44e-15cb-4f26-b133-707612984553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3efb9fd0-8d88-42ba-a6cc-c45ba3b246d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1772d108-d530-4125-8603-bbf36f17ec6b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3efb9fd0-8d88-42ba-a6cc-c45ba3b246d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ba5fbb19-2160-42df-8ecb-baa51366ffc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3efb9fd0-8d88-42ba-a6cc-c45ba3b246d8" xlink:to="loc_us-gaap_AwardTypeAxis_ba5fbb19-2160-42df-8ecb-baa51366ffc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba5fbb19-2160-42df-8ecb-baa51366ffc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ba5fbb19-2160-42df-8ecb-baa51366ffc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba5fbb19-2160-42df-8ecb-baa51366ffc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c55c94e-abe7-4650-ab93-96df5c6bff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ba5fbb19-2160-42df-8ecb-baa51366ffc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c55c94e-abe7-4650-ab93-96df5c6bff5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_00899ce1-a6b1-4365-9bc5-cbafa1fcacc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c55c94e-abe7-4650-ab93-96df5c6bff5e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_00899ce1-a6b1-4365-9bc5-cbafa1fcacc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b64bfc3c-2430-45ef-87b0-03432914d85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c55c94e-abe7-4650-ab93-96df5c6bff5e" xlink:to="loc_us-gaap_EmployeeStockMember_b64bfc3c-2430-45ef-87b0-03432914d85e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_b298f164-e618-482e-bd0f-237e7d027498" xlink:href="zntl-20220630.xsd#zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c55c94e-abe7-4650-ab93-96df5c6bff5e" xlink:to="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_b298f164-e618-482e-bd0f-237e7d027498" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquityFairValueAssumptionsforStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails" xlink:type="extended" id="i02e6b9954f814525a84b8aef4545fc1d_StockholdersEquityFairValueAssumptionsforStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b5c95e4d-f4cc-464c-b650-c8302268e554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b5c95e4d-f4cc-464c-b650-c8302268e554" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6cebd3cf-39f2-4c0c-aa3e-b7a3fa6cf7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6cebd3cf-39f2-4c0c-aa3e-b7a3fa6cf7d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_392e7978-0094-4d2a-83f0-c870a0523853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_392e7978-0094-4d2a-83f0-c870a0523853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a9450282-a88c-4a79-a299-e219049b3e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a9450282-a88c-4a79-a299-e219049b3e66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_918b3c01-47d5-47b0-a394-3987e2b88049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_918b3c01-47d5-47b0-a394-3987e2b88049" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_efe26f7e-cb06-476d-bdeb-f84ac8121f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_efe26f7e-cb06-476d-bdeb-f84ac8121f49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_171971f6-0dd9-40c8-9be5-b4255016004d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_171971f6-0dd9-40c8-9be5-b4255016004d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7970bedc-6847-4b82-a033-5fd4ced78f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_171971f6-0dd9-40c8-9be5-b4255016004d" xlink:to="loc_us-gaap_AwardTypeAxis_7970bedc-6847-4b82-a033-5fd4ced78f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7970bedc-6847-4b82-a033-5fd4ced78f85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7970bedc-6847-4b82-a033-5fd4ced78f85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7970bedc-6847-4b82-a033-5fd4ced78f85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae8ec84b-87cb-4676-9434-72f69af351ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7970bedc-6847-4b82-a033-5fd4ced78f85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae8ec84b-87cb-4676-9434-72f69af351ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_30a58f26-c882-4b95-9633-3f17c5c4801b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae8ec84b-87cb-4676-9434-72f69af351ed" xlink:to="loc_us-gaap_EmployeeStockOptionMember_30a58f26-c882-4b95-9633-3f17c5c4801b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f22058d-5a39-48f8-82a9-d5cc40e1c563" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_171971f6-0dd9-40c8-9be5-b4255016004d" xlink:to="loc_srt_RangeAxis_7f22058d-5a39-48f8-82a9-d5cc40e1c563" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f22058d-5a39-48f8-82a9-d5cc40e1c563_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7f22058d-5a39-48f8-82a9-d5cc40e1c563" xlink:to="loc_srt_RangeMember_7f22058d-5a39-48f8-82a9-d5cc40e1c563_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c1cf0a96-fa02-4709-889b-bfcdd5cfd0da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7f22058d-5a39-48f8-82a9-d5cc40e1c563" xlink:to="loc_srt_RangeMember_c1cf0a96-fa02-4709-889b-bfcdd5cfd0da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1793a6fb-01c1-4d81-8993-427358fc1beb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c1cf0a96-fa02-4709-889b-bfcdd5cfd0da" xlink:to="loc_srt_MinimumMember_1793a6fb-01c1-4d81-8993-427358fc1beb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d59926a-ae8b-4fb3-b0c7-389c6491e1c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c1cf0a96-fa02-4709-889b-bfcdd5cfd0da" xlink:to="loc_srt_MaximumMember_5d59926a-ae8b-4fb3-b0c7-389c6491e1c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquityFairValueAssumptionsforESPPDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails" xlink:type="extended" id="i018de2ae450646689d5271938e02e99d_StockholdersEquityFairValueAssumptionsforESPPDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86bd93c2-cd1d-4e9e-b74d-2aaee1beca0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86bd93c2-cd1d-4e9e-b74d-2aaee1beca0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8674bc1b-4d57-4fe3-86c3-2308bb13951e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8674bc1b-4d57-4fe3-86c3-2308bb13951e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ce9cfefa-bfde-4a62-a1c6-cc36e3bd7ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ce9cfefa-bfde-4a62-a1c6-cc36e3bd7ad9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_86890344-aadf-459f-a017-cab896eb35fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_86890344-aadf-459f-a017-cab896eb35fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ed92d7-4196-49f4-8a95-ea5f716410b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ed92d7-4196-49f4-8a95-ea5f716410b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_653847e2-6e9b-4643-9277-4ce90f6819e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ed92d7-4196-49f4-8a95-ea5f716410b6" xlink:to="loc_us-gaap_AwardTypeAxis_653847e2-6e9b-4643-9277-4ce90f6819e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_653847e2-6e9b-4643-9277-4ce90f6819e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_653847e2-6e9b-4643-9277-4ce90f6819e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_653847e2-6e9b-4643-9277-4ce90f6819e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd52edd-75ba-451c-abfb-f7c6e287656f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_653847e2-6e9b-4643-9277-4ce90f6819e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd52edd-75ba-451c-abfb-f7c6e287656f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8d3fdad5-78c5-441c-a636-d51a4b78a5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd52edd-75ba-451c-abfb-f7c6e287656f" xlink:to="loc_us-gaap_EmployeeStockMember_8d3fdad5-78c5-441c-a636-d51a4b78a5a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquityUnrecognizedCompensationCostDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails" xlink:type="extended" id="i74f6621aac56477d9d52ebf9dbb248a0_StockholdersEquityUnrecognizedCompensationCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c36e26e2-6dfa-4c38-809e-d73116df1467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eabfd427-6054-4459-b8b8-58cef724bf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c36e26e2-6dfa-4c38-809e-d73116df1467" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eabfd427-6054-4459-b8b8-58cef724bf71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_576bfaa7-00ae-4ff8-9dfe-f8e116817095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c36e26e2-6dfa-4c38-809e-d73116df1467" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_576bfaa7-00ae-4ff8-9dfe-f8e116817095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aace82f0-7eeb-4a2b-a866-9b4f6e2d1909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c36e26e2-6dfa-4c38-809e-d73116df1467" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aace82f0-7eeb-4a2b-a866-9b4f6e2d1909" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d217e3b-8406-4acc-9ce4-1bbfd9a2c22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c36e26e2-6dfa-4c38-809e-d73116df1467" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d217e3b-8406-4acc-9ce4-1bbfd9a2c22d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd8faeb0-25c2-44f9-bf0d-19cc83223106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d217e3b-8406-4acc-9ce4-1bbfd9a2c22d" xlink:to="loc_us-gaap_AwardTypeAxis_bd8faeb0-25c2-44f9-bf0d-19cc83223106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd8faeb0-25c2-44f9-bf0d-19cc83223106_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bd8faeb0-25c2-44f9-bf0d-19cc83223106" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd8faeb0-25c2-44f9-bf0d-19cc83223106_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bd8faeb0-25c2-44f9-bf0d-19cc83223106" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a23a2f8c-b59b-4424-bd0f-531af0550293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a23a2f8c-b59b-4424-bd0f-531af0550293" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_da7c1c98-7a36-4533-b14e-a3fe147046a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:to="loc_us-gaap_RestrictedStockMember_da7c1c98-7a36-4533-b14e-a3fe147046a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dcb0d4f9-ed6e-421b-a378-336d749a0053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dcb0d4f9-ed6e-421b-a378-336d749a0053" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4bd17f73-25b1-4c1a-9987-d9c3a4a464ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:to="loc_us-gaap_EmployeeStockMember_4bd17f73-25b1-4c1a-9987-d9c3a4a464ff" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#NetLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="id8a88d7ad2fd40d99576d6a998468f00_NetLossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4fa75c8e-931c-42c4-a1e9-7366c4a524e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c91405c-eae9-4df0-a722-bdacddd30f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4fa75c8e-931c-42c4-a1e9-7366c4a524e7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c91405c-eae9-4df0-a722-bdacddd30f46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b8afe4-6e4e-4492-ab3f-226f76425f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4fa75c8e-931c-42c4-a1e9-7366c4a524e7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b8afe4-6e4e-4492-ab3f-226f76425f88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9a0b8a6-95cb-4327-826a-5883bf779b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b8afe4-6e4e-4492-ab3f-226f76425f88" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9a0b8a6-95cb-4327-826a-5883bf779b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c9a0b8a6-95cb-4327-826a-5883bf779b11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9a0b8a6-95cb-4327-826a-5883bf779b11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c9a0b8a6-95cb-4327-826a-5883bf779b11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_53951165-fdf1-4fd2-be92-6ec9107c0b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9a0b8a6-95cb-4327-826a-5883bf779b11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_53951165-fdf1-4fd2-be92-6ec9107c0b65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bed665ad-3902-4bfc-a309-6779fada882f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_53951165-fdf1-4fd2-be92-6ec9107c0b65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bed665ad-3902-4bfc-a309-6779fada882f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ba4536da-7cf5-4578-8f41-0aaa721ab2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_53951165-fdf1-4fd2-be92-6ec9107c0b65" xlink:to="loc_us-gaap_RestrictedStockMember_ba4536da-7cf5-4578-8f41-0aaa721ab2bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b784aeee-e5dd-4e97-b2d0-1d427acbf0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_53951165-fdf1-4fd2-be92-6ec9107c0b65" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b784aeee-e5dd-4e97-b2d0-1d427acbf0c7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#RelatedPartyDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" xlink:type="extended" id="i71ae1466decf4567b8bf6f973812249e_RelatedPartyDisclosuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_beea7d54-7ed4-4323-b515-abe3b039724a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_760747ba-6d7f-4ba0-881f-a7e3d97d2cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_beea7d54-7ed4-4323-b515-abe3b039724a" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_760747ba-6d7f-4ba0-881f-a7e3d97d2cea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_86224cfd-ec80-4203-87a5-fff5fd8a1a5f" xlink:href="zntl-20220630.xsd#zntl_ResearchAndDevelopmentExpenseReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_beea7d54-7ed4-4323-b515-abe3b039724a" xlink:to="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_86224cfd-ec80-4203-87a5-fff5fd8a1a5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_b0e93390-86a5-4bce-a772-c3312acda1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_beea7d54-7ed4-4323-b515-abe3b039724a" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_b0e93390-86a5-4bce-a772-c3312acda1a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_450ee3e6-9c61-431e-a165-b3bf8d7c457f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_beea7d54-7ed4-4323-b515-abe3b039724a" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_450ee3e6-9c61-431e-a165-b3bf8d7c457f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2cbba8c7-4389-4b19-9983-74f56ddee343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_450ee3e6-9c61-431e-a165-b3bf8d7c457f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2cbba8c7-4389-4b19-9983-74f56ddee343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2cbba8c7-4389-4b19-9983-74f56ddee343_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2cbba8c7-4389-4b19-9983-74f56ddee343" xlink:to="loc_us-gaap_RelatedPartyDomain_2cbba8c7-4389-4b19-9983-74f56ddee343_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ffb2cdf7-e6da-43bd-89e0-0632fe254fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2cbba8c7-4389-4b19-9983-74f56ddee343" xlink:to="loc_us-gaap_RelatedPartyDomain_ffb2cdf7-e6da-43bd-89e0-0632fe254fd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_97019691-58aa-4ee0-99c7-d6ddf24e2c0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ffb2cdf7-e6da-43bd-89e0-0632fe254fd4" xlink:to="loc_srt_AffiliatedEntityMember_97019691-58aa-4ee0-99c7-d6ddf24e2c0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5f3e016e-f7c9-41e9-8c20-0e22f1cd94b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_450ee3e6-9c61-431e-a165-b3bf8d7c457f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5f3e016e-f7c9-41e9-8c20-0e22f1cd94b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5f3e016e-f7c9-41e9-8c20-0e22f1cd94b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5f3e016e-f7c9-41e9-8c20-0e22f1cd94b0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5f3e016e-f7c9-41e9-8c20-0e22f1cd94b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c8e2ca8d-ea8e-41f6-b702-a1f36e944fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5f3e016e-f7c9-41e9-8c20-0e22f1cd94b0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c8e2ca8d-ea8e-41f6-b702-a1f36e944fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_MasterServicesAgreementMember_3dc36a3f-6554-4d32-8f11-ad6aec65ff0d" xlink:href="zntl-20220630.xsd#zntl_MasterServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c8e2ca8d-ea8e-41f6-b702-a1f36e944fe6" xlink:to="loc_zntl_MasterServicesAgreementMember_3dc36a3f-6554-4d32-8f11-ad6aec65ff0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_18159ec4-7601-428f-bd44-ec4006792716" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_450ee3e6-9c61-431e-a165-b3bf8d7c457f" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_18159ec4-7601-428f-bd44-ec4006792716" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_18159ec4-7601-428f-bd44-ec4006792716_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_18159ec4-7601-428f-bd44-ec4006792716" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_18159ec4-7601-428f-bd44-ec4006792716_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_28c44657-9e72-47eb-8632-02ca9637b45d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_18159ec4-7601-428f-bd44-ec4006792716" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_28c44657-9e72-47eb-8632-02ca9637b45d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraTherapeuticsLtdMember_3e8def63-7091-4525-99e9-c36e675c5883" xlink:href="zntl-20220630.xsd#zntl_ZenteraTherapeuticsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_28c44657-9e72-47eb-8632-02ca9637b45d" xlink:to="loc_zntl_ZenteraTherapeuticsLtdMember_3e8def63-7091-4525-99e9-c36e675c5883" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>zntl-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:dc6f2cb5-3684-47f2-a7ee-9069478f9aef,g:255d4c27-7dc3-44e2-be9a-0993a342da50-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5c12e1f5-9525-43b3-855e-3480de2cd251_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_2d75590d-2e33-461c-bd34-a973d920aab6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0673870d-f44a-44a8-8606-ddbcd54063f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e258dd1-5d1a-47bc-9370-7616bfd0de54_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08c59464-b50b-4406-aaf4-a0a30d075edb_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments:</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_86769141-d74b-4003-a6d3-a6d19e369813_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_ee12ae17-575e-41c1-9fc5-e4bf61cd4e81_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_82391350-b5cc-47da-9995-a1e96d9ad41f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_91e6da5d-ac7a-4c48-8d87-c6018503572a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_80b87d4d-250b-48a5-b7ea-774816cbd699_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIE, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_c574f2f5-b7d4-4eaf-9374-fc894ce21139_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3d4acb74-2cf3-45e7-9f01-6dd50d09543d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_670dd7c8-f8b7-49a7-a3bb-0bd1df57b67c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9ca7e083-9200-496a-97b4-4b92f0346df3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c5fc4edf-babe-4c90-9f1d-e90753fafe60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ForeignResearchAndDevelopmentCreditRefund_14de99ad-ae54-4596-a034-f2dc9639c055_terseLabel_en-US" xlink:label="lab_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign R&amp;D credit refund</link:label>
    <link:label id="lab_zntl_ForeignResearchAndDevelopmentCreditRefund_label_en-US" xlink:label="lab_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Research and Development Credit Refund</link:label>
    <link:label id="lab_zntl_ForeignResearchAndDevelopmentCreditRefund_documentation_en-US" xlink:label="lab_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Research and Development Credit Refund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:href="zntl-20220630.xsd#zntl_ForeignResearchAndDevelopmentCreditRefund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:to="lab_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3dd47521-a690-49f0-983b-37bc23c6e6f7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_58fa5d44-c080-474d-a10b-a0520f67761e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_6559d847-22c6-4dc4-b90e-9ae43b9c98b8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7ff1ec6e-a358-4b11-a1cc-a87b6b59b5fc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares used in computing net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07216686-63ad-4a4f-9367-4dfbd5c06846_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b1da1bea-7552-4ede-ac5c-db37585ba3f8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0ca04aed-30f8-4c11-a480-f33d7389c570_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_072b352d-bf60-4e5e-99b6-4ea918b9d841_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8047175e-7131-4171-b025-b8d7a98dcbb1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4b6ef7f2-74eb-4791-ba15-8a4d721838a6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c6d90368-d95b-4c60-ae74-ed0d47eca418_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10f88300-b5a8-48c8-afaa-caf52222f43f_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_OfficeEquipmentAndFurnitureMember_8fb75539-4ba9-40c8-8acc-2a532cb29aca_terseLabel_en-US" xlink:label="lab_zntl_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:label id="lab_zntl_OfficeEquipmentAndFurnitureMember_label_en-US" xlink:label="lab_zntl_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment And Furniture [Member]</link:label>
    <link:label id="lab_zntl_OfficeEquipmentAndFurnitureMember_documentation_en-US" xlink:label="lab_zntl_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment And Furniture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OfficeEquipmentAndFurnitureMember" xlink:href="zntl-20220630.xsd#zntl_OfficeEquipmentAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_OfficeEquipmentAndFurnitureMember" xlink:to="lab_zntl_OfficeEquipmentAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2458a3bf-5fe4-47a4-9425-6f1d77bdf2a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_de4cd9f0-0c3e-401c-a2d7-17f7ec06a6f7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestiture of early stage asset</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_31004285-603d-49fb-8a78-1fd4464629bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 250,000,000 shares authorized; 56,969,118 and 45,490,764 shares issued and outstanding at June&#160;30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_7e9a4951-be1b-4536-9f68-e00533751872_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_92a6a7bc-a64d-4ebc-a83c-cfb7ca9a5c41_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_b2ccc29b-5f99-497b-b03e-33bedd19b5b2_terseLabel_en-US" xlink:label="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:label id="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_label_en-US" xlink:label="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Employment Inducement Incentive Award Plan [Member]</link:label>
    <link:label id="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Employment Inducement Incentive Award Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:href="zntl-20220630.xsd#zntl_A2022EmploymentInducementIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:to="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b13608f9-92b7-43c4-b9a7-77dae56d3956_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale marketable securities:</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3b6a5fe9-161f-4674-ad40-3f6d8b0ecfee_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_41b1fabb-0ab2-478f-9233-f71b535a10fc_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with restricted stock unit vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_5c185a58-8ba4-49aa-ba3f-70a68c0c043d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon vesting of certain RSAs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b2ae7eba-e139-4f2b-be6d-b7fc471e7217_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Unit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3845b35a-8988-4650-a1e5-1d64ad241423_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_EarningsPerShareNumeratorAbstract_8b5c44a1-7b47-4172-857b-75d588bfcff5_terseLabel_en-US" xlink:label="lab_zntl_EarningsPerShareNumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_zntl_EarningsPerShareNumeratorAbstract_label_en-US" xlink:label="lab_zntl_EarningsPerShareNumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:label id="lab_zntl_EarningsPerShareNumeratorAbstract_documentation_en-US" xlink:label="lab_zntl_EarningsPerShareNumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Numerator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_EarningsPerShareNumeratorAbstract" xlink:href="zntl-20220630.xsd#zntl_EarningsPerShareNumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_EarningsPerShareNumeratorAbstract" xlink:to="lab_zntl_EarningsPerShareNumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9ca4b1f5-c8ee-42b7-afd5-ce09046c5589_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1544d855-8bfd-49cd-89fe-290b34091075_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_91ac7c82-30e7-41b5-8d89-9719a42aa856_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13e9e70c-11c2-4f19-8763-6bb52388cf51_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2577dab1-15fa-4f86-a9dc-9f59a8e6ef0f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2c98f2aa-12a3-49aa-ab54-e73c8e343845_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash reported in the Condensed Consolidated Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3e8901c1-688a-45a3-b814-4db8fcb64d91_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation effects</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_becb5e71-1f44-4385-a2fa-fd4f4f40a188_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9689a380-d0b0-46cd-85ec-6d0359ad0104_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ed2d53f4-143b-4151-a9bf-b2544c451677_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_LaboratoryEquipmentMember_1ef0ab73-0c15-4ffb-8757-3b41ddb4ca29_terseLabel_en-US" xlink:label="lab_zntl_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_zntl_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_zntl_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_zntl_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_zntl_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LaboratoryEquipmentMember" xlink:href="zntl-20220630.xsd#zntl_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_LaboratoryEquipmentMember" xlink:to="lab_zntl_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a62ba4d0-bb13-461a-a7d8-288b6ba74ae6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_183a8741-d529-47c4-b732-b3ab71221f97_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_05e315dc-c135-46b5-ba45-c442ec93b3b8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Zentalis</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1b67f346-8870-4310-a5e2-7aa6cae8836e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Zentalis</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_44749522-f205-47e8-ba4a-13023e0cb1c6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Zentera Therapeutics</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_79ad3666-72a3-4b43-aa59-2bf2136095c4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_21a4d1ba-5261-471a-963d-76d59038a93d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions, ESPP</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_061da8b0-1c08-4e7c-92e8-513b0b7a2429_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per unit (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_518222b4-4467-45cb-b6bf-24f2ed5fa173_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one but within five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_865858fe-7988-4802-952a-ef16e8f1015f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_2e84a543-ab90-4961-bb3a-40b6be617ce4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4ee7e410-ed88-4601-90d2-e365f923a04c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9d5c05fb-fb9c-498c-80d5-b460d9fc63a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of available-for-sale securities in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_bbc87dbb-4bfe-4324-b5e9-6f1942508f49_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1c45a7ec-9c92-4a3d-b0ee-f832633a2aa7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value of available-for-sale securities in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d5f8ca8a-075b-4d5f-8003-f5bd549abdc8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_eb16ea7d-d428-4a32-96d2-4a6b1eb4161d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_41534535-87a0-483e-85bc-b1fb9e5f7fac_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5c8a3d5f-0c1e-4ea8-abb6-be4a3ef531fe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d3927e30-c94d-4a4d-b955-909344f3b6b1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2be067d4-fec7-4c1e-b430-c5a5b43c6a19_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a583c823-f4ad-4b48-af37-3ab8bf05f4c6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Zentalis</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_c3501b80-3314-4ab2-afcc-314b8ca748ec_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_beaadbc0-66f8-44e3-910d-c90fac88a538_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e3816283-f6a1-4c41-a13d-bd23d34d39cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_8f79a6a8-9c76-4c83-81f3-cf530e79a04e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_60dddaf5-12f2-48c0-af91-636a1bfe6111_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_f8ff9429-1071-4239-9015-d70e182387c5_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_74ff1d1c-eb74-4eef-a917-f67cf317c496_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_46810081-c923-4599-9631-77510e664d87_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_594a89c7-19a8-478a-a46f-beda88de3896_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a382fc0e-9678-4789-a168-677c72bae53c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_0a4208b1-c9ab-4cd6-9fdb-22c488c1f06a_terseLabel_en-US" xlink:label="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_label_en-US" xlink:label="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:label id="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_documentation_en-US" xlink:label="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:href="zntl-20220630.xsd#zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:to="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e9d933b7-0d05-49e0-b255-4e0cbf397a56_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8c9f3191-8b8a-449a-a78d-6ad072296c7e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase price of common stock, percent of market price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4b52afe6-dd4a-444a-b8d8-50005f185c40_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized expense, other than options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8db89657-bb08-4105-8297-b4b0bb9130fd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fae32156-a062-4e98-bb0a-e8ff359791dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_e5754765-1140-42b4-ae61-bf9ea5aa284d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_657f5385-9679-4182-ac45-eb35c3783b75_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a907882c-e22f-4807-ba41-55f43e01fb43_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_65f13995-4082-4468-8484-d43a3afe0b53_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_f4b4103a-08b1-45a0-a217-6313ce0e9856_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_9a52a916-f0e6-458c-bc8b-e1f5231906b1_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_41a5edd4-fb16-4311-8b44-461adc9f7616_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2617b999-2a19-422b-b044-58fba7107ad0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_ec37ba85-e81e-4c6f-90f8-1725e54c95b2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_43117f0c-f0d6-480b-af86-e734ff76ad68_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_a8e68604-e5c1-4aea-8e13-693d8123b00d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_652940f7-fa8f-42fe-b70a-8825564056a5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3b445a36-f7d1-456a-9368-fac1c437c7d2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e26d5f33-cf6c-46ee-9952-6d83c0099029_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e4b806c7-2f12-4edd-9f2a-d90b15772cbf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_05749502-1b1b-4d6f-bcba-a5d5341a8199_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c77cada9-cd25-4fad-92bd-b38b68d09aac_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_eadcd5ec-86d6-4bcf-a650-3752e8d46a72_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d11b6e01-7540-4701-ac58-734c572168cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Available-for-sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_6319f34b-3c7a-4b1e-9c38-3dd842ebdfd6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f6dc7671-d8ff-4dfc-b97d-6a4d02a28b4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9a894762-2656-4745-84e8-fff2b2466cf6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_690f05a2-912a-4c11-abc6-c6a13bcd4c44_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_78109a5f-c72d-44b6-88b3-f0f03371bb5c_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d90f36ba-632b-4999-92c4-e81c21c37dc7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5d8449a3-3835-4a17-9d48-fc1ee990a661_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c3d2a6b3-ba39-4b2b-8b8f-e48974fc4c62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_1ecc8b25-2de4-44a0-ab68-3f21ac0ec942_terseLabel_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution amount</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_label_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_documentation_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:to="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_98f5c687-aa5d-4e3f-a950-5a4624835bc0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_a029d959-33bd-4f47-b694-54dcaf220ac5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_736b3309-487a-4f7a-8432-9fd0c3fbe8e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_f83e876b-83ab-489d-b297-60023b19a9e6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8606c146-32e9-47fa-a8f6-22475ff59972_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6bca144f-ba38-4a2f-9fbd-8e9931b76da1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_183d0458-56ab-4bb8-be1d-bbfeac5368b1_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2a459c62-9b76-4e0e-a931-5cfca43e2b83_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_606ac214-d69a-4881-8e64-71b1c6eab03c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ee82401-5c26-4a30-993e-57e6355d06cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_4424c6ff-9d9c-4875-88e2-bbb11726622c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_90da036a-088e-4e04-baf8-0cc41ee0425c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_115ad548-336a-46b9-80a4-22d6d233213b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_70b1f761-2207-4a2f-a79c-6975646c084c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7e7487b9-4eee-46d3-91ef-4c4f698b2a94_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_10f6401f-5af4-4f7d-bd9e-5f425523531c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_0a013075-9adb-43c5-8bed-060f5d3b8d87_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_bf23ef46-915a-45fb-bc78-5f4787983d71_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less long-term portion</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_376b80ed-dcd3-4769-abe8-a1b673d416f2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11263bd9-178f-428b-a452-3a1960db6e19_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_96de46bc-fb32-479f-9097-64fa3c9bcccd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b4695fb1-92f9-4b9b-a431-2a640757ac31_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d96b81fe-a69d-4e25-bb32-1ff37187dfb4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_23e61f2b-637b-489f-baf3-18e620f87a61_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_9c01db2e-e455-40ce-8243-8aba984c4803_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_08c9515e-51c2-45b4-9a60-e7d01d80479b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ProceedsFromIssuanceOfCommonStockGross_33dd999d-f7ad-4806-9c6e-1f424c51f176_terseLabel_en-US" xlink:label="lab_zntl_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
    <link:label id="lab_zntl_ProceedsFromIssuanceOfCommonStockGross_label_en-US" xlink:label="lab_zntl_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Gross</link:label>
    <link:label id="lab_zntl_ProceedsFromIssuanceOfCommonStockGross_documentation_en-US" xlink:label="lab_zntl_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ProceedsFromIssuanceOfCommonStockGross" xlink:href="zntl-20220630.xsd#zntl_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ProceedsFromIssuanceOfCommonStockGross" xlink:to="lab_zntl_ProceedsFromIssuanceOfCommonStockGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2c6be72d-25f1-4933-bd47-590c001bb0cd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5bc42a9b-d6fc-4caa-9242-f7a4783c9873_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8c56cc7f-b26d-4d72-b26a-7c50b8a31516_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_32d8f83e-6ffb-4837-b32d-e1f071ca8b15_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_10c455ad-95c4-4ce1-8361-6635fe3f13de_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3626aeb2-b28f-4040-b4a9-d421dc53b3ec_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_d1bf733e-bb72-46ff-afeb-db7855400767_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_65520b3d-f18a-4bad-890e-1144092f1ac1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, deconsolidation of Zentera</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investment in Noncontrolled Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_06ab9d58-5ea1-4e9d-ba92-790362e25ff4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_f56be3da-66c9-457f-9dc0-49dcce2d6ae7_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Unaudited Financial Statements</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_eca5a47c-0225-41e8-be47-3dc8dc38e6d0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3fbc9c94-0116-407d-8283-003c1b8c1717_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ff89d05c-1a2b-46e7-a545-e88548874488_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f3d90e06-d027-42d2-9cf4-14cccbcac893_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_128c7a4d-e54d-4d12-b6e4-cd0d32e5ed4f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_af40c6d6-d420-49d9-a2c2-ddf995341553_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_InvestmentAndOtherIncomeExpense_98ab39c0-41fd-46ef-9d4a-1a84991731fb_terseLabel_en-US" xlink:label="lab_zntl_InvestmentAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and other income, net</link:label>
    <link:label id="lab_zntl_InvestmentAndOtherIncomeExpense_label_en-US" xlink:label="lab_zntl_InvestmentAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and Other Income (Expense)</link:label>
    <link:label id="lab_zntl_InvestmentAndOtherIncomeExpense_documentation_en-US" xlink:label="lab_zntl_InvestmentAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_InvestmentAndOtherIncomeExpense" xlink:href="zntl-20220630.xsd#zntl_InvestmentAndOtherIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_InvestmentAndOtherIncomeExpense" xlink:to="lab_zntl_InvestmentAndOtherIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0be43e02-5fbb-429f-a1ad-bb24f5aae75d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock_9544fc6b-9179-4dc0-9800-a920148b82b5_terseLabel_en-US" xlink:label="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Equity Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Noncontrolling Interest [Table Text Block]</link:label>
    <link:label id="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:href="zntl-20220630.xsd#zntl_ReconciliationOfNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:to="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_bb2ffe9f-4245-44d3-8ec9-94c54761e88c_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_c201afed-0fcb-4541-8c02-377165f33f57_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_419e7449-2f58-40fc-aed5-ea5b0d238b7f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_efd22172-5460-47a4-b085-33452c9be08a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_14b819fd-576e-4c82-b011-9fd270a2e1c0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_PrepaidResearchAndDevelopmentCosts_825efa8f-4939-432a-8a8a-bc92e6b10758_terseLabel_en-US" xlink:label="lab_zntl_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_zntl_PrepaidResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_zntl_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Costs</link:label>
    <link:label id="lab_zntl_PrepaidResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_zntl_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidResearchAndDevelopmentCosts" xlink:href="zntl-20220630.xsd#zntl_PrepaidResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_PrepaidResearchAndDevelopmentCosts" xlink:to="lab_zntl_PrepaidResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_a234ca0f-cf56-4660-9723-fdb65867d255_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_371159ea-9afb-4530-a72e-a917d7151e15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c5bd2d29-a30e-4836-8b97-2b161b1a5b1d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_26320c4f-16ca-4dd2-91b5-2aa25c9eb845_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a4480f41-512a-4c9c-8f80-0ddb8a8c771a_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f986590e-f1a2-4759-8e93-858154ab6244_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_04e17893-dca9-4db2-b3f3-af9b2d12c17f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d87fff1-d27f-425c-a3b3-25411c0c0f8b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25894fdc-1e9c-42a9-8076-316212cce58a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES&#160;AND&#160;STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_160d9734-ec0b-4e51-8907-25ed5c8d1fe4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_26aef37f-0438-4de6-a545-bb74c59aa52f_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_437f820d-e7c0-4c82-ae57-0402dfe1bf63_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_52fc1206-775b-434c-933a-e797d4b2707d_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_71a72db3-456a-4adc-9d50-4f6bef0759da_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f93009fc-007c-40ee-b806-afddf0edf3df_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_bbe8a8d8-2eff-4333-996a-0909d9521eec_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ffbf475e-df06-4869-87f0-fd07dc99ea21_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent_28c7ef8f-1554-48df-b5ad-4ee980b1c0ef_terseLabel_en-US" xlink:label="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued general and administrative expenses</link:label>
    <link:label id="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent_label_en-US" xlink:label="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General And Administrative Costs, Current</link:label>
    <link:label id="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent_documentation_en-US" xlink:label="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General And Administrative Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:href="zntl-20220630.xsd#zntl_AccruedGeneralAndAdministrativeCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:to="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_de57e7a4-2d96-4421-b757-29acb0140331_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72a7d7f0-1597-4b50-b6c8-f6e179e8a6a0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5b9e3eda-4fe5-44e4-9ee0-55c90a98a4d6_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other assets, current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_30ccae1f-b9ee-407c-9dae-74b24d21565c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_90a1a840-c020-49ce-a57b-3e6fd10b99aa_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense by Type of Share-based Award</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8f37a776-352c-4dbb-980b-58c2deae87c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_OtherPrepaidExpense_f67aa9f6-daf5-43fe-8438-d496b96342f7_terseLabel_en-US" xlink:label="lab_zntl_OtherPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_zntl_OtherPrepaidExpense_label_en-US" xlink:label="lab_zntl_OtherPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense</link:label>
    <link:label id="lab_zntl_OtherPrepaidExpense_documentation_en-US" xlink:label="lab_zntl_OtherPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OtherPrepaidExpense" xlink:href="zntl-20220630.xsd#zntl_OtherPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_OtherPrepaidExpense" xlink:to="lab_zntl_OtherPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_fad914f8-99a5-4104-9c41-67347f885afb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturities of Available-for-sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a697d63d-ffbd-4b46-8fb9-e2c470d0815e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_be79a333-fc07-4488-b479-f2835ea15436_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_c9a44495-682e-4fb3-b2cd-c146600e8afd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3eb9d08d-8001-44f9-b2ed-10f7f2b31946_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e18d1d86-4d81-406f-ada4-f5eedbd8ea00_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares used in computing net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_13f11694-cc98-4086-9fac-284be4c8561f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_661d0bf4-5c75-465d-b5b7-af2acc7a40c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_12303ec2-84a3-4a16-a831-b331b11c3778_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Weighted-Average Recognition Period (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_de15790b-de5e-4c02-b653-c11eb5a3973e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with restricted stock unit vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_e794aec3-8ed8-4661-ac69-fb47732fab1e_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_5ba11601-87cf-47b4-9f5f-6bd66da00648_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities fair market value</link:label>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecuritiesDebt" xlink:to="lab_us-gaap_TradingSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_627d9283-a3fd-4e91-a233-a80d54de6441_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b33ae939-0eb3-4cbc-bc03-a9f6dd508047_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of&#160;non-cash&#160;investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e167e7c1-343f-4377-b2a5-0d33260289a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_84f77f39-3832-4f1d-b4db-b84036f33b7e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_86e50fa2-a833-4517-aa03-93cf2fb034c4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b8e4c67d-7f80-415e-bf63-54a5f3461492_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_381ff312-6717-4904-aab7-89cd1aefee15_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June&#160;30, 2022 and December 31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40ea2d01-b656-4478-8a87-2a170d29e977_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a2af2a1e-5344-4e4a-ae44-992507fe1faa_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_c4fbe35d-5898-4acb-8dee-72120cef6bfe_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_7bab6bb8-e555-4faa-b01e-30d2371854da_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSAs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_289a3a89-06d0-4c18-bd35-b60a6799323f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSAs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d908c69c-e13f-447e-9ac4-86f66546581c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_b8ffcb7a-7938-4a57-b7e2-f896415d73cb_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_50a53021-b7e8-4c10-ade6-189ce0da32aa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_dd8a3941-4544-4511-99e1-731d59b79f9b_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of Zentera</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_aa31b4d2-d4c7-4625-8b6e-8944bd1d2afe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_36755994-e801-4a70-afd4-7ad8f0b11453_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5bf47943-b658-4fb5-9c0e-057894887f14_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a45c9940-5d1e-492a-ae15-387bea1eb30b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_83730dd4-c456-40ed-8889-d9b2efeabb4c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_fe97a80c-c43e-4de9-96d2-550a01551560_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ResearchAndDevelopmentExpenseReimbursements_63623007-f13f-49a6-a845-677875d64469_terseLabel_en-US" xlink:label="lab_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contra-research and development expense</link:label>
    <link:label id="lab_zntl_ResearchAndDevelopmentExpenseReimbursements_label_en-US" xlink:label="lab_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Reimbursements</link:label>
    <link:label id="lab_zntl_ResearchAndDevelopmentExpenseReimbursements_documentation_en-US" xlink:label="lab_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:href="zntl-20220630.xsd#zntl_ResearchAndDevelopmentExpenseReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:to="lab_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ZenteraStockPlanMember_b2592730-eea8-4f00-b98e-5613435908eb_terseLabel_en-US" xlink:label="lab_zntl_ZenteraStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zentera Stock Plan</link:label>
    <link:label id="lab_zntl_ZenteraStockPlanMember_label_en-US" xlink:label="lab_zntl_ZenteraStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zentera Stock Plan [Member]</link:label>
    <link:label id="lab_zntl_ZenteraStockPlanMember_documentation_en-US" xlink:label="lab_zntl_ZenteraStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zentera Stock Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraStockPlanMember" xlink:href="zntl-20220630.xsd#zntl_ZenteraStockPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ZenteraStockPlanMember" xlink:to="lab_zntl_ZenteraStockPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5dbfb3e8-b775-497f-943b-8e4b5c15400c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_KalyraPharmaceuticalsIncMember_ee52b8a1-ce31-4f34-a20f-fe3a670cc565_terseLabel_en-US" xlink:label="lab_zntl_KalyraPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kalyra Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_zntl_KalyraPharmaceuticalsIncMember_label_en-US" xlink:label="lab_zntl_KalyraPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kalyra Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_zntl_KalyraPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_zntl_KalyraPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kalyra Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_KalyraPharmaceuticalsIncMember" xlink:href="zntl-20220630.xsd#zntl_KalyraPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_KalyraPharmaceuticalsIncMember" xlink:to="lab_zntl_KalyraPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_2b70499f-6bc7-4899-8f26-8e1f5d382a04_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_14c9c32a-4341-471e-ab79-2ca50b12e294_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest at beginning of period</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_ba9f5040-f824-4aaa-acba-a4a2ef3d8be7_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest at end of period</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0858b165-ee4c-4848-a53d-ba4ae75cdf7d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_FollowOnOfferingMember_c4722c92-c22d-44d4-917c-6d014db5081f_terseLabel_en-US" xlink:label="lab_zntl_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Offering</link:label>
    <link:label id="lab_zntl_FollowOnOfferingMember_label_en-US" xlink:label="lab_zntl_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Offering [Member]</link:label>
    <link:label id="lab_zntl_FollowOnOfferingMember_documentation_en-US" xlink:label="lab_zntl_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_FollowOnOfferingMember" xlink:href="zntl-20220630.xsd#zntl_FollowOnOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_FollowOnOfferingMember" xlink:to="lab_zntl_FollowOnOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a9ae57f2-af11-47b3-acfc-1ec86269e1c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_166ce611-720a-43b5-9acf-1f875fab434f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_230a912f-2f23-4e41-a597-01bf119c004a_terseLabel_en-US" xlink:label="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net</link:label>
    <link:label id="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:href="zntl-20220630.xsd#zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:to="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_48b5cb64-8239-4330-b440-adc50b404ade_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a5f0f4d9-bb7b-49f1-91fd-65c38cb2d946_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9c4c2419-0704-493d-8b22-3d48b4527c13_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_e262a272-69dd-4a82-97a6-4d393ec34c7c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a6bb748c-9717-4e38-851f-e4491de7c2bf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b99cd4fb-3b9f-4a44-b3d5-068da930ea76_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a9bbacd4-2f70-4949-82da-c9dddcab631a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b7c0f70d-1c89-4564-a10e-053d8c446f33_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_5dbac152-1330-4c98-afc2-029c4f6c74f2_terseLabel_en-US" xlink:label="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSAs and RSUs</link:label>
    <link:label id="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards And Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:href="zntl-20220630.xsd#zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:to="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_feaa5cb9-4415-46e6-a415-a303fe9f4d80_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent_2dbfffe5-7fa6-4713-8dbd-60eda4d97e2e_terseLabel_en-US" xlink:label="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Costs, Current</link:label>
    <link:label id="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="zntl-20220630.xsd#zntl_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_666058af-e31e-4d1f-93d2-6202ee72a7b8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_744cb4a0-ff30-4666-8c36-b273c7fdf380_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_82604a9a-3733-4252-8054-6bfb1d6028a9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_35666f90-9bef-43fb-a348-867e9b64026c_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_578e8c84-f6a4-42f6-a5cd-7df695773612_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_PrepaidSoftwareLicenseAndMaintenance_0e89eb05-6bf5-41af-98ad-d9d9769304bb_terseLabel_en-US" xlink:label="lab_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid software licenses and maintenance</link:label>
    <link:label id="lab_zntl_PrepaidSoftwareLicenseAndMaintenance_label_en-US" xlink:label="lab_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Software License And Maintenance</link:label>
    <link:label id="lab_zntl_PrepaidSoftwareLicenseAndMaintenance_documentation_en-US" xlink:label="lab_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Software License And Maintenance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:href="zntl-20220630.xsd#zntl_PrepaidSoftwareLicenseAndMaintenance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:to="lab_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_8f901bb6-70b5-4f94-95b0-434cc7f51cf5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_90e9474b-af86-4aee-82fb-79dfad9aa073_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e90fcaa3-f8b6-4a10-8b9c-d748b2519f99_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1746edd6-4aa2-438d-9ba8-70f212ef7cfb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a42d6d7f-2166-4517-9189-cbba3761522b_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_cc616417-b5cf-47c0-9469-43a8ab9342e0_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zentera receivable</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9e785510-8895-43f4-a875-501f307bb49b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share outstanding, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2cbf2258-45fc-4ec9-947e-c379b42041d8_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_99c572ca-e61e-4f04-8921-a1cd8099a8bb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_859515da-2cb5-4f44-acff-e9e4bbd65731_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_50c45b5b-9499-4aa3-8918-82bf30bc7eb2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_ab75d247-0e42-4f49-8350-1c5b71e6fe41_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_e2efab2c-6bdb-4512-b266-469db07da2fb_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance fees and expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_f8549fb8-df53-4da9-8c76-8095748cab50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d564af7-25b2-487f-8ac1-e71e2b5559bb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_576e5ac7-aef2-4b7a-9d3c-75b77a4185d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b3375ba2-8cb0-4745-a728-ee4a697fe556_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_162a5e0b-3fa2-4259-82c0-5d35f20da3ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d3087dee-9455-469c-9c12-77b7f2ff863f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0411001f-8758-4871-ac8d-bf9443831580_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_996d5f52-0984-4afc-8faa-eb984e78a091_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_9aaf7e1d-4a33-4e2f-a2ce-984cdaa2b2cc_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e72d5a8b-f8a9-4cab-a40b-5271cc1b5856_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_5f53ed61-9502-4bb0-a368-abe3d6abc99c_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6487bcd4-3154-4ec5-986d-e24d92f31ac8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share outstanding, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_45bcbbfe-5725-4026-8db9-b139f5a172e9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_419ae05b-ab34-484d-a869-82b5e9002428_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_1e205a1d-9450-4011-afe4-9291edd2ef2b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c7a4502f-fbdd-44e9-a44d-b715970783ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_35c1718e-4387-4df5-8b47-c4ca9f9ad0f4_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_68ae4a3c-91c0-4a84-b734-dcf4dde3cfd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0cb30c5e-6b8a-41b5-850b-3adb57cb50c3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_06068d4c-b64c-4b6c-8aa3-68503dabe4ac_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fdf386d5-48e3-4f4a-99ef-f1364f874096_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_fc658eba-4ea1-4619-80bd-1d2b3bbb25f9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_a313dec0-7bf6-4efb-917f-606fbe22bdf6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_27e510a1-1f83-4a18-a316-acb28f141f3c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Amortization of Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_e29a9060-5389-4993-aaff-2b2d9e3bead3_terseLabel_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period (in months)</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_be7bd1ec-c343-4690-b842-42a06e5e427e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d2d72583-93a4-4712-8c8e-ee4101025117_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued and sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fe0894a3-2969-45d4-9d63-02ba048b25c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0384aae6-95af-431c-a4da-8f1e5afde238_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f0e677e1-28b6-4108-90ff-08f826e382dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_37080197-6e40-416f-a8e0-96ea149f19f7_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a4de166c-5aba-46d1-879d-4e4b8a571002_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c86b2ab0-fb37-4f57-9024-cef930db8467_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_28802de7-101e-4436-b485-b1bd32a0808c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ec7186a4-8f3b-4d46-9014-874fef6be8ca_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_aafab044-0d5f-4160-8f48-b192c22fd077_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized expense, stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_DirectOfferingMember_f9d2ad89-5bd5-43f9-b5c6-9565df29e601_terseLabel_en-US" xlink:label="lab_zntl_DirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Offering</link:label>
    <link:label id="lab_zntl_DirectOfferingMember_label_en-US" xlink:label="lab_zntl_DirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Offering [Member]</link:label>
    <link:label id="lab_zntl_DirectOfferingMember_documentation_en-US" xlink:label="lab_zntl_DirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_DirectOfferingMember" xlink:href="zntl-20220630.xsd#zntl_DirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_DirectOfferingMember" xlink:to="lab_zntl_DirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8acf840b-b1d3-4e63-ada6-b94beb9010b1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_98f6a25d-af3c-4402-a7f0-eacb1e4a0210_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized to be issued under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_704cfaeb-10b3-4fd1-a605-2605eaecb1bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_c9fddece-911f-4bc5-8ac7-9b0bee446544_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP maximum percent of compensation to contribute</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cdfe4240-0036-4cf2-9f62-2617115f2fb4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e3af949f-dd9b-4dfc-b2aa-f9d264f1599e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_33c798ce-e7d5-404d-87c1-bd5138c862f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Option equity instruments, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_344c45f9-5e69-4e2a-8bf0-c2373bcd655d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_cca3ca58-72ff-4e54-b48a-3b443d786bf0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8914ef01-ee81-4696-abb4-21c6ea3e5416_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_c3d7e3a3-c0b5-44aa-8009-b7cf919293c3_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_EarningsPerShareDenominatorAbstract_fb371677-c56c-40d3-83ba-43e2a9d2568a_terseLabel_en-US" xlink:label="lab_zntl_EarningsPerShareDenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_zntl_EarningsPerShareDenominatorAbstract_label_en-US" xlink:label="lab_zntl_EarningsPerShareDenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:label id="lab_zntl_EarningsPerShareDenominatorAbstract_documentation_en-US" xlink:label="lab_zntl_EarningsPerShareDenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Denominator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_EarningsPerShareDenominatorAbstract" xlink:href="zntl-20220630.xsd#zntl_EarningsPerShareDenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_EarningsPerShareDenominatorAbstract" xlink:to="lab_zntl_EarningsPerShareDenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_251ff457-58f2-4fc6-8d7e-64f3e3ddb51d_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1f30bbf3-d865-4d54-b51b-f208332a743e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_070dcbe8-02ed-4150-9f56-22452a66f8a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_9900be08-82ed-492d-b61c-05cc1eedd14b_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Zentera, net of tax</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_390ba9fc-ffd4-49b6-847f-783e754ce4fd_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_15f76233-3c30-49d4-99ee-810aa9a3d4b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_MasterServicesAgreementMember_7605b9eb-13c4-4302-8efe-c65e80ad6fd0_terseLabel_en-US" xlink:label="lab_zntl_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Services Agreement</link:label>
    <link:label id="lab_zntl_MasterServicesAgreementMember_label_en-US" xlink:label="lab_zntl_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Services Agreement [Member]</link:label>
    <link:label id="lab_zntl_MasterServicesAgreementMember_documentation_en-US" xlink:label="lab_zntl_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_MasterServicesAgreementMember" xlink:href="zntl-20220630.xsd#zntl_MasterServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_MasterServicesAgreementMember" xlink:to="lab_zntl_MasterServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_21fdca2e-b5cd-4fc9-a519-3216de30758b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_A2020IncentiveAwardPlanMember_5f779092-7174-46a7-ad65-9fd2b2de207a_terseLabel_en-US" xlink:label="lab_zntl_A2020IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2020 Plan</link:label>
    <link:label id="lab_zntl_A2020IncentiveAwardPlanMember_label_en-US" xlink:label="lab_zntl_A2020IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Incentive Award Plan [Member]</link:label>
    <link:label id="lab_zntl_A2020IncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_zntl_A2020IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Incentive Award Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2020IncentiveAwardPlanMember" xlink:href="zntl-20220630.xsd#zntl_A2020IncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_A2020IncentiveAwardPlanMember" xlink:to="lab_zntl_A2020IncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_ac96a53a-7d8b-464d-92d8-def0df7d9971_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_c2c85401-509b-4518-9f71-c29ed4e56952_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_defe500d-e0db-4811-8d5b-8823d1e926ae_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_a38fc893-2ec0-4231-b6a5-780617bb74fb_terseLabel_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generally expected vesting term of the option contract (in years)</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_label_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_documentation_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:to="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_263139e7-03d1-43f4-b50b-5b004302b962_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_bc00c596-df37-4df0-ad73-4b5dc0029f62_netLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_f828934e-c645-45d2-a46e-46602b96e02b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_165aeeb3-1030-48be-a3e5-c52a76a26f7c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6dfd8efe-e7e9-45f2-a353-c6b2ff93bb78_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_85651299-79b4-4491-bff4-63399f9a851f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4ce328b1-c2bc-42a2-b114-f2a43409c980_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Disclosures</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1296441-eea9-492a-bf72-66d372c5065d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_52f9b613-e738-42b3-b40e-8e9c96dc99c6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments to acquire interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1619e851-6e41-4a00-afb7-ead67fe594ee_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64cb1563-7709-4507-a1e2-5c2efe101de9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_526af8a7-c49b-4659-9ebf-c9135a4cd92d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_bd7bc205-0cda-47c4-8bc6-ba9787a77656_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f6d28a92-9d78-4022-89b9-b118cd53ede2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e52e8638-908d-49ab-b17c-64ee5eb33b4f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ace1b822-6bcc-4fd9-b1e8-be118162f898_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_21aff5a2-7183-4cf2-8884-5b9574f11e71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_a2891486-f4ed-4411-a1e4-a3795afb1c7c_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_c5e461da-ebb8-421a-8e1f-eb788764ce28_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_274ba75a-3786-404e-aeca-6cb4ad8181f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5b5928e3-1c68-41cf-a631-abbfe95b60e4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e274789a-a25a-44b5-b48f-21b807a83806_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a257c6be-ff7e-4125-bc8a-614b172f887b_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8b840da4-e3ca-4c6d-976a-33ce92b6070c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease&#160;right-of-use&#160;assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1bd673af-d854-421c-bb87-097783967745_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_ace66019-1cd1-4304-9831-890fa2ce7755_terseLabel_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of common stock outstanding used as threshold to calculate shares available for issuance</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_label_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_documentation_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:to="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_bfbe540e-8f06-43de-805f-d7b9a240ed92_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0d77f0fe-6a3a-427d-9e37-a71317e8624c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits and share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits and Share-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3dd2ccd1-187d-4f67-bf23-3ae27bcc65db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1ec890bf-78ce-42a6-b33f-48370f86a2f6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_4f346d49-aca1-4366-b924-d1a99ad8f2c0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Transactions</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_3650f264-bba9-4068-b5e1-ab1160d237d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1569b032-5ca3-44cf-a76e-d03f5228e116_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8e54bd58-7f88-4454-a500-4e21e4d21996_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_063e0581-2362-4a60-91ca-4bcaf06bc649_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8cdc54c1-c654-44e3-8b38-3cacf21c7e42_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_132c86cf-d3a0-42ae-94ce-2a229abb7203_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_e2235e52-ef7c-4275-9e33-8f9aeca74e00_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_fdde7d34-b1af-4b59-a1f5-66291eefff22_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_196a1a9f-b107-407d-8263-f925bd8d3e62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Unit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ZenteraTherapeuticsLtdMember_fdf83f4c-8c76-4f88-9772-123d1f65c6df_terseLabel_en-US" xlink:label="lab_zntl_ZenteraTherapeuticsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zentera</link:label>
    <link:label id="lab_zntl_ZenteraTherapeuticsLtdMember_label_en-US" xlink:label="lab_zntl_ZenteraTherapeuticsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zentera Therapeutics Ltd. [Member]</link:label>
    <link:label id="lab_zntl_ZenteraTherapeuticsLtdMember_documentation_en-US" xlink:label="lab_zntl_ZenteraTherapeuticsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zentera Therapeutics Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraTherapeuticsLtdMember" xlink:href="zntl-20220630.xsd#zntl_ZenteraTherapeuticsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ZenteraTherapeuticsLtdMember" xlink:to="lab_zntl_ZenteraTherapeuticsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c8a4c1a2-d682-461e-a3a6-533ffde81d70_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_84746da3-458b-4224-b9c2-eb90874bf5a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_3fcdf1f6-7922-4b20-b1e2-15ab0ef92a4b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>zntl-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:dc6f2cb5-3684-47f2-a7ee-9069478f9aef,g:255d4c27-7dc3-44e2-be9a-0993a342da50-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.zentalis.com/role/Cover" xlink:type="simple" xlink:href="zntl-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0615fc2b-8785-418b-921b-7e6fbe92d689" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_DocumentType_0615fc2b-8785-418b-921b-7e6fbe92d689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e6b3b597-6e0c-4a56-addc-e9bd39039f85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_DocumentQuarterlyReport_e6b3b597-6e0c-4a56-addc-e9bd39039f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b2d1a40b-c9dd-4625-9d52-9161f1136697" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_DocumentPeriodEndDate_b2d1a40b-c9dd-4625-9d52-9161f1136697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_37d23646-c033-4b1e-832d-9bb1b557ddf3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_DocumentTransitionReport_37d23646-c033-4b1e-832d-9bb1b557ddf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_179ad0ac-251a-4a0b-9ccd-478d413974a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityFileNumber_179ad0ac-251a-4a0b-9ccd-478d413974a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_681272da-d13b-46a9-826d-6418649a984f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityRegistrantName_681272da-d13b-46a9-826d-6418649a984f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e4546c66-51dd-413a-a8dc-32477b9b2e20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e4546c66-51dd-413a-a8dc-32477b9b2e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_506ef522-2771-4f8e-a504-d1114c762d24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityTaxIdentificationNumber_506ef522-2771-4f8e-a504-d1114c762d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a9c36026-0eee-447c-9a38-4945a7dbdcd9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityAddressAddressLine1_a9c36026-0eee-447c-9a38-4945a7dbdcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_4653c014-e519-41b5-9db1-1a916170cd75" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityAddressAddressLine2_4653c014-e519-41b5-9db1-1a916170cd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_339b4605-c3db-4188-894a-2ed3c02126b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityAddressCityOrTown_339b4605-c3db-4188-894a-2ed3c02126b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_bf497cc0-8d2e-4889-8572-fda812fab1cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityAddressStateOrProvince_bf497cc0-8d2e-4889-8572-fda812fab1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c8a4db2d-58b0-4f94-af3d-ff3c847f682f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityAddressPostalZipCode_c8a4db2d-58b0-4f94-af3d-ff3c847f682f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_30fe488a-73d9-4101-9097-44d64fa84a80" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_CityAreaCode_30fe488a-73d9-4101-9097-44d64fa84a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_63af3fa2-b7b3-43c3-806b-4168b270d73b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_LocalPhoneNumber_63af3fa2-b7b3-43c3-806b-4168b270d73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5b36a042-6eeb-457d-a814-d6cc856e02ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_Security12bTitle_5b36a042-6eeb-457d-a814-d6cc856e02ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_df4b08bd-0e0c-424c-920f-a2ba01c3eec0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_TradingSymbol_df4b08bd-0e0c-424c-920f-a2ba01c3eec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_df9d2d6d-c23a-461f-902c-215b905b2e4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_SecurityExchangeName_df9d2d6d-c23a-461f-902c-215b905b2e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4b11ef76-88be-483e-8e5c-9c7bcd24009f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityCurrentReportingStatus_4b11ef76-88be-483e-8e5c-9c7bcd24009f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3e93dcf9-ea0e-4217-a81f-8eab90e2ce87" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityInteractiveDataCurrent_3e93dcf9-ea0e-4217-a81f-8eab90e2ce87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_13ac0e65-fd65-444a-8880-ec132f6239b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityFilerCategory_13ac0e65-fd65-444a-8880-ec132f6239b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9d2b1f74-6d26-4271-bef3-5158ee248d62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntitySmallBusiness_9d2b1f74-6d26-4271-bef3-5158ee248d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c8b61aa1-ce8e-4dc1-9705-5024f9acf9cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityEmergingGrowthCompany_c8b61aa1-ce8e-4dc1-9705-5024f9acf9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b57adc70-012d-4df4-9df0-80f078e29fb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityShellCompany_b57adc70-012d-4df4-9df0-80f078e29fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5e809f9a-8fa8-4755-9159-b1c6afa5ffe3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5e809f9a-8fa8-4755-9159-b1c6afa5ffe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f772009a-f704-477f-a2e9-bf243fb0f7ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_EntityCentralIndexKey_f772009a-f704-477f-a2e9-bf243fb0f7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d29fa31a-ec4e-4ae1-a7c1-ba0aa218d608" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_AmendmentFlag_d29fa31a-ec4e-4ae1-a7c1-ba0aa218d608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5eff3504-0b48-4e58-86db-b522bc06b87a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5eff3504-0b48-4e58-86db-b522bc06b87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_96fefe72-2926-45a7-a1a2-2562453698bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_CurrentFiscalYearEndDate_96fefe72-2926-45a7-a1a2-2562453698bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_366dc5ec-3338-498b-9278-846bb66b045e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34186b35-53cd-4593-8920-fc13459c0ebe" xlink:to="loc_dei_DocumentFiscalYearFocus_366dc5ec-3338-498b-9278-846bb66b045e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="zntl-20220630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_48470899-29b0-4cb6-ae37-7a376170e502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_975b12fd-f796-43c7-9f47-ebc49f73a439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48470899-29b0-4cb6-ae37-7a376170e502" xlink:to="loc_us-gaap_AssetsAbstract_975b12fd-f796-43c7-9f47-ebc49f73a439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1d6c9271-e953-4977-8da2-ed0e916d7236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_975b12fd-f796-43c7-9f47-ebc49f73a439" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1d6c9271-e953-4977-8da2-ed0e916d7236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d71b465-e102-469d-b4cb-b120b8c9a64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d6c9271-e953-4977-8da2-ed0e916d7236" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d71b465-e102-469d-b4cb-b120b8c9a64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5741f54-dc74-4af2-9dea-4cd887be7613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d6c9271-e953-4977-8da2-ed0e916d7236" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5741f54-dc74-4af2-9dea-4cd887be7613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bcd59cb2-09a3-49d9-a70c-37ee4d79a147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d6c9271-e953-4977-8da2-ed0e916d7236" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bcd59cb2-09a3-49d9-a70c-37ee4d79a147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_69c65352-ba06-46ef-beaf-a6b3dff7461c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d6c9271-e953-4977-8da2-ed0e916d7236" xlink:to="loc_us-gaap_RestrictedCashCurrent_69c65352-ba06-46ef-beaf-a6b3dff7461c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d093332d-37cb-4ec8-b5d0-77418249b160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d6c9271-e953-4977-8da2-ed0e916d7236" xlink:to="loc_us-gaap_AssetsCurrent_d093332d-37cb-4ec8-b5d0-77418249b160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_99386b36-f765-4b1a-83ec-286444cdb345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_975b12fd-f796-43c7-9f47-ebc49f73a439" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_99386b36-f765-4b1a-83ec-286444cdb345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e824b448-f862-4880-81b3-b1a595301b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_975b12fd-f796-43c7-9f47-ebc49f73a439" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e824b448-f862-4880-81b3-b1a595301b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_8231e2c1-2846-457f-b560-cd421a1518a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_975b12fd-f796-43c7-9f47-ebc49f73a439" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_8231e2c1-2846-457f-b560-cd421a1518a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_729ed7fa-a2d0-40c4-91e8-bc4933ed8bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_975b12fd-f796-43c7-9f47-ebc49f73a439" xlink:to="loc_us-gaap_Goodwill_729ed7fa-a2d0-40c4-91e8-bc4933ed8bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b0402b5a-80f6-4681-8db1-ef937a90d8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_975b12fd-f796-43c7-9f47-ebc49f73a439" xlink:to="loc_us-gaap_EquityMethodInvestments_b0402b5a-80f6-4681-8db1-ef937a90d8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_55a224db-411c-4a27-8812-b90a4708edbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_975b12fd-f796-43c7-9f47-ebc49f73a439" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_55a224db-411c-4a27-8812-b90a4708edbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a7667c8a-e707-4eea-9dd5-ec4078dd6b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_975b12fd-f796-43c7-9f47-ebc49f73a439" xlink:to="loc_us-gaap_Assets_a7667c8a-e707-4eea-9dd5-ec4078dd6b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a047f64b-529b-4028-bd04-28ffd8b65e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48470899-29b0-4cb6-ae37-7a376170e502" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a047f64b-529b-4028-bd04-28ffd8b65e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_078a134c-2387-4cc1-b3f4-c5b603dfe434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a047f64b-529b-4028-bd04-28ffd8b65e20" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_078a134c-2387-4cc1-b3f4-c5b603dfe434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f8b925fc-92df-4b4f-824a-e04548ee6bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_078a134c-2387-4cc1-b3f4-c5b603dfe434" xlink:to="loc_us-gaap_AccountsPayableCurrent_f8b925fc-92df-4b4f-824a-e04548ee6bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bfc9fb4a-5c8c-416e-b6c1-36f808023e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_078a134c-2387-4cc1-b3f4-c5b603dfe434" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bfc9fb4a-5c8c-416e-b6c1-36f808023e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bbc499d6-b9f0-4104-8590-d2cc94f50daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_078a134c-2387-4cc1-b3f4-c5b603dfe434" xlink:to="loc_us-gaap_LiabilitiesCurrent_bbc499d6-b9f0-4104-8590-d2cc94f50daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_65e509b6-bac7-41e4-a7eb-f9f269c80a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a047f64b-529b-4028-bd04-28ffd8b65e20" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_65e509b6-bac7-41e4-a7eb-f9f269c80a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b477ad52-f407-4400-8e71-dfc80d2def30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a047f64b-529b-4028-bd04-28ffd8b65e20" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b477ad52-f407-4400-8e71-dfc80d2def30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_52b9b580-ad6e-4946-a4e9-122f30992d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a047f64b-529b-4028-bd04-28ffd8b65e20" xlink:to="loc_us-gaap_Liabilities_52b9b580-ad6e-4946-a4e9-122f30992d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_46f179c0-9942-4e88-8f55-ed2a2bb3397e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a047f64b-529b-4028-bd04-28ffd8b65e20" xlink:to="loc_us-gaap_CommitmentsAndContingencies_46f179c0-9942-4e88-8f55-ed2a2bb3397e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_89711d87-c91d-40d5-864d-566e68cbd9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a047f64b-529b-4028-bd04-28ffd8b65e20" xlink:to="loc_us-gaap_EquityAbstract_89711d87-c91d-40d5-864d-566e68cbd9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c09d0a99-836a-4261-a319-c9c3e07fac2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89711d87-c91d-40d5-864d-566e68cbd9c6" xlink:to="loc_us-gaap_PreferredStockValue_c09d0a99-836a-4261-a319-c9c3e07fac2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fba25954-ff6b-4693-a436-4d4938d278e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89711d87-c91d-40d5-864d-566e68cbd9c6" xlink:to="loc_us-gaap_CommonStockValue_fba25954-ff6b-4693-a436-4d4938d278e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_add9498f-38f2-4575-8055-4642c0c6797c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89711d87-c91d-40d5-864d-566e68cbd9c6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_add9498f-38f2-4575-8055-4642c0c6797c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2352f1c4-d589-4731-ad3d-30455499c02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89711d87-c91d-40d5-864d-566e68cbd9c6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2352f1c4-d589-4731-ad3d-30455499c02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_61896e98-4102-4cce-aba3-2dcc84a7355b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89711d87-c91d-40d5-864d-566e68cbd9c6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_61896e98-4102-4cce-aba3-2dcc84a7355b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c4409ce8-a7fd-4864-8ab4-6d001d2a9d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89711d87-c91d-40d5-864d-566e68cbd9c6" xlink:to="loc_us-gaap_StockholdersEquity_c4409ce8-a7fd-4864-8ab4-6d001d2a9d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9f7222ce-af15-4681-b51b-55c71eb6ee21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89711d87-c91d-40d5-864d-566e68cbd9c6" xlink:to="loc_us-gaap_MinorityInterest_9f7222ce-af15-4681-b51b-55c71eb6ee21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_021bf900-0d4c-4bdc-bc2b-bacb85d65489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89711d87-c91d-40d5-864d-566e68cbd9c6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_021bf900-0d4c-4bdc-bc2b-bacb85d65489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7db72350-7158-44d0-bf4a-efffacd7bbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a047f64b-529b-4028-bd04-28ffd8b65e20" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7db72350-7158-44d0-bf4a-efffacd7bbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="zntl-20220630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_28ecf82d-537b-4fce-a499-09ce4ced6adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b1127614-4998-4365-b8c8-582c6316e3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28ecf82d-537b-4fce-a499-09ce4ced6adb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b1127614-4998-4365-b8c8-582c6316e3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_10215fda-5816-42d6-bf2d-8aa9ec631500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28ecf82d-537b-4fce-a499-09ce4ced6adb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_10215fda-5816-42d6-bf2d-8aa9ec631500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_121e54ff-5213-4a54-bf99-0b1006f05aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28ecf82d-537b-4fce-a499-09ce4ced6adb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_121e54ff-5213-4a54-bf99-0b1006f05aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7882429c-78ae-4d2e-a0d6-48c003674eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28ecf82d-537b-4fce-a499-09ce4ced6adb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7882429c-78ae-4d2e-a0d6-48c003674eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5437c631-bc32-43a5-b4c0-1a29467cce18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28ecf82d-537b-4fce-a499-09ce4ced6adb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5437c631-bc32-43a5-b4c0-1a29467cce18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_741148c7-9801-4a83-8d86-2eff33708175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28ecf82d-537b-4fce-a499-09ce4ced6adb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_741148c7-9801-4a83-8d86-2eff33708175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_10129256-e440-4a83-867d-bbe5f28f09b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28ecf82d-537b-4fce-a499-09ce4ced6adb" xlink:to="loc_us-gaap_CommonStockSharesIssued_10129256-e440-4a83-867d-bbe5f28f09b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_365c038d-55e3-464d-a791-6e9eb1a00204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28ecf82d-537b-4fce-a499-09ce4ced6adb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_365c038d-55e3-464d-a791-6e9eb1a00204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="zntl-20220630.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_2b07e197-eec4-4748-8e1e-2bdd93c8ffa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_2b07e197-eec4-4748-8e1e-2bdd93c8ffa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_30d9a9ea-6c8c-4420-97f1-16abbe7776e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2b07e197-eec4-4748-8e1e-2bdd93c8ffa8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_30d9a9ea-6c8c-4420-97f1-16abbe7776e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3b3e2687-a6be-4aa9-8970-2a7cc51d9e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2b07e197-eec4-4748-8e1e-2bdd93c8ffa8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3b3e2687-a6be-4aa9-8970-2a7cc51d9e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_681ccd26-23f8-4c38-b87f-731d72705484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2b07e197-eec4-4748-8e1e-2bdd93c8ffa8" xlink:to="loc_us-gaap_OperatingExpenses_681ccd26-23f8-4c38-b87f-731d72705484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_832e02a2-7738-49f5-b7d7-00a0ee630584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_OperatingIncomeLoss_832e02a2-7738-49f5-b7d7-00a0ee630584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ba8f6b35-6c4d-41c4-b6aa-3e7d31510703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ba8f6b35-6c4d-41c4-b6aa-3e7d31510703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_InvestmentAndOtherIncomeExpense_8dc09d16-3af1-4474-9652-86788a5b02cf" xlink:href="zntl-20220630.xsd#zntl_InvestmentAndOtherIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ba8f6b35-6c4d-41c4-b6aa-3e7d31510703" xlink:to="loc_zntl_InvestmentAndOtherIncomeExpense_8dc09d16-3af1-4474-9652-86788a5b02cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b01d8244-6dc4-47fe-a062-3b6edf60e7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b01d8244-6dc4-47fe-a062-3b6edf60e7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6590f117-9ca9-4725-ade9-9cea8ee13912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6590f117-9ca9-4725-ade9-9cea8ee13912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5d77e29f-ec9c-41a3-b18f-c141f37fdf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5d77e29f-ec9c-41a3-b18f-c141f37fdf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f2972932-13c7-44d5-b60d-5e5b187dea0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_ProfitLoss_f2972932-13c7-44d5-b60d-5e5b187dea0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f3ef2f21-a8c3-4555-b3b0-618f62fd4706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f3ef2f21-a8c3-4555-b3b0-618f62fd4706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dc86b018-aae9-4c61-96ac-ef4687bca5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_NetIncomeLoss_dc86b018-aae9-4c61-96ac-ef4687bca5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c468ff4c-3b66-4d5c-9277-6448fedc9e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_EarningsPerShareBasic_c468ff4c-3b66-4d5c-9277-6448fedc9e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_250795fb-bf91-43df-8ff6-a46119e5b1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_EarningsPerShareDiluted_250795fb-bf91-43df-8ff6-a46119e5b1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1d8d8a7f-292a-418b-aec5-24d230079c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1d8d8a7f-292a-418b-aec5-24d230079c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_51a3ee41-b0ec-4cdc-82da-bca7b037e70a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54839a80-4b99-4ea0-9ede-9e602fea8e69" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_51a3ee41-b0ec-4cdc-82da-bca7b037e70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="zntl-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_60f18fad-70e6-42cb-9469-430331fc7e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4ef4b1f3-3968-4610-ae61-84a78c0b03df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_60f18fad-70e6-42cb-9469-430331fc7e6a" xlink:to="loc_us-gaap_ProfitLoss_4ef4b1f3-3968-4610-ae61-84a78c0b03df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_33c762cb-c90f-4428-b8cb-43c60b954fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_60f18fad-70e6-42cb-9469-430331fc7e6a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_33c762cb-c90f-4428-b8cb-43c60b954fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_865b4b63-5684-426d-a83b-df8dafd3b73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_33c762cb-c90f-4428-b8cb-43c60b954fbb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_865b4b63-5684-426d-a83b-df8dafd3b73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f91b4854-381c-441d-82be-7aa04f9e5e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_33c762cb-c90f-4428-b8cb-43c60b954fbb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f91b4854-381c-441d-82be-7aa04f9e5e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d0dad042-e49b-4fcc-8da4-2c6c819e47be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_60f18fad-70e6-42cb-9469-430331fc7e6a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d0dad042-e49b-4fcc-8da4-2c6c819e47be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3dc60498-1d5b-449e-bd2b-8ea9dbdd0cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_60f18fad-70e6-42cb-9469-430331fc7e6a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3dc60498-1d5b-449e-bd2b-8ea9dbdd0cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fcf22ee7-c5f4-4ec8-821f-63a01e003eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_60f18fad-70e6-42cb-9469-430331fc7e6a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fcf22ee7-c5f4-4ec8-821f-63a01e003eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="zntl-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_30f30fc0-0a79-48a9-bea0-9ec291206209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25176537-b236-41a6-8826-56a6eae97d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30f30fc0-0a79-48a9-bea0-9ec291206209" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25176537-b236-41a6-8826-56a6eae97d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_04bc894d-d020-40fe-8335-b394266e5f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25176537-b236-41a6-8826-56a6eae97d97" xlink:to="loc_us-gaap_ProfitLoss_04bc894d-d020-40fe-8335-b394266e5f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f60d35e4-14b4-4190-9505-930930eaa558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25176537-b236-41a6-8826-56a6eae97d97" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f60d35e4-14b4-4190-9505-930930eaa558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_29a6635e-cec3-4590-b051-12e2d0a611e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f60d35e4-14b4-4190-9505-930930eaa558" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_29a6635e-cec3-4590-b051-12e2d0a611e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a2a90e8b-1871-4403-a469-d6432f7fd86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f60d35e4-14b4-4190-9505-930930eaa558" xlink:to="loc_us-gaap_ShareBasedCompensation_a2a90e8b-1871-4403-a469-d6432f7fd86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0ec556c9-573e-4fcd-8f82-c988b2a17fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f60d35e4-14b4-4190-9505-930930eaa558" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0ec556c9-573e-4fcd-8f82-c988b2a17fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_d880e162-a3c8-4abf-9c85-0cba8276491d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f60d35e4-14b4-4190-9505-930930eaa558" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_d880e162-a3c8-4abf-9c85-0cba8276491d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fee1b62d-606c-478e-b256-7b63def1bc38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f60d35e4-14b4-4190-9505-930930eaa558" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fee1b62d-606c-478e-b256-7b63def1bc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59b05efe-b9da-4fe8-a351-7deae060c996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f60d35e4-14b4-4190-9505-930930eaa558" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59b05efe-b9da-4fe8-a351-7deae060c996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d075bb13-28ad-4863-8d8a-5073c4b6b032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59b05efe-b9da-4fe8-a351-7deae060c996" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d075bb13-28ad-4863-8d8a-5073c4b6b032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e98379ce-7f09-4bde-ac4a-a405d479fd38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59b05efe-b9da-4fe8-a351-7deae060c996" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e98379ce-7f09-4bde-ac4a-a405d479fd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_ccebcf79-0e61-47b9-bb48-5e839cf18d95" xlink:href="zntl-20220630.xsd#zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59b05efe-b9da-4fe8-a351-7deae060c996" xlink:to="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_ccebcf79-0e61-47b9-bb48-5e839cf18d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_186ce258-4be1-4a8d-b80c-1883112fc201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25176537-b236-41a6-8826-56a6eae97d97" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_186ce258-4be1-4a8d-b80c-1883112fc201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8aecafe5-b2bc-4f1a-ab53-b14069e135cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30f30fc0-0a79-48a9-bea0-9ec291206209" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8aecafe5-b2bc-4f1a-ab53-b14069e135cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c42d6d08-e550-45a0-87b4-78e581866994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8aecafe5-b2bc-4f1a-ab53-b14069e135cf" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c42d6d08-e550-45a0-87b4-78e581866994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c2b6acbf-27f4-4f47-9759-bb163acbd2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8aecafe5-b2bc-4f1a-ab53-b14069e135cf" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c2b6acbf-27f4-4f47-9759-bb163acbd2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2c2ac0ba-8de0-4748-9b93-b93c44e368cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8aecafe5-b2bc-4f1a-ab53-b14069e135cf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2c2ac0ba-8de0-4748-9b93-b93c44e368cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_573d3a09-b76c-4f49-8748-cc637d167740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8aecafe5-b2bc-4f1a-ab53-b14069e135cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_573d3a09-b76c-4f49-8748-cc637d167740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40c28de8-f394-4b54-9d0b-7b7f3c07f5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30f30fc0-0a79-48a9-bea0-9ec291206209" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40c28de8-f394-4b54-9d0b-7b7f3c07f5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f0a03384-89d7-46b0-862c-1f645aa17df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40c28de8-f394-4b54-9d0b-7b7f3c07f5c7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f0a03384-89d7-46b0-862c-1f645aa17df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_292515c7-7475-4c43-a330-6a8d5cb4304a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40c28de8-f394-4b54-9d0b-7b7f3c07f5c7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_292515c7-7475-4c43-a330-6a8d5cb4304a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_b2325708-51f1-467e-be72-7dff3d1bcb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40c28de8-f394-4b54-9d0b-7b7f3c07f5c7" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_b2325708-51f1-467e-be72-7dff3d1bcb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04642636-0598-4608-89a0-a0eb0c9629e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40c28de8-f394-4b54-9d0b-7b7f3c07f5c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04642636-0598-4608-89a0-a0eb0c9629e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a1dace38-0d08-4606-8f3b-b681761edd24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30f30fc0-0a79-48a9-bea0-9ec291206209" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a1dace38-0d08-4606-8f3b-b681761edd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75b30db1-7617-4cd5-8d2a-d0d207c20b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30f30fc0-0a79-48a9-bea0-9ec291206209" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75b30db1-7617-4cd5-8d2a-d0d207c20b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e811b082-16a0-41f6-bc63-42f8d0f189bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30f30fc0-0a79-48a9-bea0-9ec291206209" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e811b082-16a0-41f6-bc63-42f8d0f189bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_71d0c50d-789a-4a92-831f-fcf7d408075b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30f30fc0-0a79-48a9-bea0-9ec291206209" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_71d0c50d-789a-4a92-831f-fcf7d408075b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b7708c29-ad05-464d-94ce-4928dc395223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_71d0c50d-789a-4a92-831f-fcf7d408075b" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b7708c29-ad05-464d-94ce-4928dc395223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4bb95cea-aa66-46d0-a0e4-2ecd23b817af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_71d0c50d-789a-4a92-831f-fcf7d408075b" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4bb95cea-aa66-46d0-a0e4-2ecd23b817af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fbd2a992-ec91-4c0b-9127-8c5f0b8c50a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30f30fc0-0a79-48a9-bea0-9ec291206209" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fbd2a992-ec91-4c0b-9127-8c5f0b8c50a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_85cf6604-fd91-4295-9128-7e85464f9b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fbd2a992-ec91-4c0b-9127-8c5f0b8c50a1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_85cf6604-fd91-4295-9128-7e85464f9b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_50478c5f-516d-4a02-836c-120c6d015683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fbd2a992-ec91-4c0b-9127-8c5f0b8c50a1" xlink:to="loc_us-gaap_RestrictedCash_50478c5f-516d-4a02-836c-120c6d015683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77252517-a39b-4959-a639-e17faad99820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fbd2a992-ec91-4c0b-9127-8c5f0b8c50a1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77252517-a39b-4959-a639-e17faad99820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="zntl-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_aa9e8025-874f-4c65-94d2-f820e6745a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_957aa484-07a2-4328-b282-8d35a21fa637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_aa9e8025-874f-4c65-94d2-f820e6745a3f" xlink:to="loc_us-gaap_StatementTable_957aa484-07a2-4328-b282-8d35a21fa637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3be871d-a8e5-4421-8652-d208444b7fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_957aa484-07a2-4328-b282-8d35a21fa637" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3be871d-a8e5-4421-8652-d208444b7fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3be871d-a8e5-4421-8652-d208444b7fad" xlink:to="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a0f36b35-4ad4-44f8-8766-7f592c8e625f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:to="loc_us-gaap_CommonStockMember_a0f36b35-4ad4-44f8-8766-7f592c8e625f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d242a629-e82f-4be0-99a5-8dc344208f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d242a629-e82f-4be0-99a5-8dc344208f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8f152cb5-cef2-43ba-85dc-43bd827b75b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8f152cb5-cef2-43ba-85dc-43bd827b75b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9c3b464d-8c96-4fef-928d-c985da4bdb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:to="loc_us-gaap_RetainedEarningsMember_9c3b464d-8c96-4fef-928d-c985da4bdb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_35fa00f3-13c4-4748-8274-6ba670bd6040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7d27f318-099d-401f-bcfb-7d5d3524b03e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_35fa00f3-13c4-4748-8274-6ba670bd6040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_55e89b6f-64d6-42e1-8491-232e70b2b43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_957aa484-07a2-4328-b282-8d35a21fa637" xlink:to="loc_us-gaap_StatementLineItems_55e89b6f-64d6-42e1-8491-232e70b2b43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55e89b6f-64d6-42e1-8491-232e70b2b43e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_84a667a9-2231-43c3-91af-6232c87812a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_SharesOutstanding_84a667a9-2231-43c3-91af-6232c87812a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f6678643-0f53-457c-96d9-8f7d647703fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f6678643-0f53-457c-96d9-8f7d647703fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2a1fd431-c038-42bb-a9b9-b9f9626e8f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2a1fd431-c038-42bb-a9b9-b9f9626e8f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_85010345-bd63-4bb0-a317-fece89a61bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_85010345-bd63-4bb0-a317-fece89a61bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9d93018a-d804-4336-a0f0-3368d09696ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9d93018a-d804-4336-a0f0-3368d09696ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c11b80be-3408-4898-9750-197fddc427d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c11b80be-3408-4898-9750-197fddc427d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_293826ae-c1aa-43d3-a7cb-1f0ed4c041f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_293826ae-c1aa-43d3-a7cb-1f0ed4c041f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_fe87fc3c-2b3a-4f22-9fed-9a292d370e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_fe87fc3c-2b3a-4f22-9fed-9a292d370e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74974677-6e2c-4342-a41b-fbf129ed2fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74974677-6e2c-4342-a41b-fbf129ed2fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4d7ba003-f05a-4217-bb4e-a351e1c0a14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4d7ba003-f05a-4217-bb4e-a351e1c0a14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_83d64787-cf18-4a4a-b6a7-cdd8816d2b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_83d64787-cf18-4a4a-b6a7-cdd8816d2b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0f3208f3-acf7-42fe-b931-f9da7f177236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0f3208f3-acf7-42fe-b931-f9da7f177236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_831f5d8d-1d97-400e-80bb-fd7716d703a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_831f5d8d-1d97-400e-80bb-fd7716d703a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7d2aed7b-83f9-4006-9a6e-63fc5911ba34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7d2aed7b-83f9-4006-9a6e-63fc5911ba34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_28a80c99-ee6b-4c46-8dbd-d2a86c3c60f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_NetIncomeLoss_28a80c99-ee6b-4c46-8dbd-d2a86c3c60f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2bd853a2-7c87-4114-911c-d9a9d7480af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_SharesOutstanding_2bd853a2-7c87-4114-911c-d9a9d7480af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_081e71e4-4fda-48c2-a158-c381f2e99663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ccb5ad4-4e7f-4757-9bc0-74fc102c68c0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_081e71e4-4fda-48c2-a158-c381f2e99663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/OrganizationandBusiness" xlink:type="simple" xlink:href="zntl-20220630.xsd#OrganizationandBusiness"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/OrganizationandBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3eb95ec9-1604-4f93-8ad2-fb88ea6a7d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_30a7da16-9163-49e4-9833-3c981e11e9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3eb95ec9-1604-4f93-8ad2-fb88ea6a7d8e" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_30a7da16-9163-49e4-9833-3c981e11e9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/InterimUnauditedFinancialStatements" xlink:type="simple" xlink:href="zntl-20220630.xsd#InterimUnauditedFinancialStatements"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/InterimUnauditedFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_41770c48-b872-49af-9fda-09696fc74154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c4767261-b78f-4f20-a868-4fdbc8b1dcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41770c48-b872-49af-9fda-09696fc74154" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c4767261-b78f-4f20-a868-4fdbc8b1dcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies" xlink:type="simple" xlink:href="zntl-20220630.xsd#InterimUnauditedFinancialStatementsPolicies"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9d951c1c-1d8c-48e5-a9fd-92aac96f4588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2d9be6b6-2fa7-4ec9-b66b-bf5a39feed1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d951c1c-1d8c-48e5-a9fd-92aac96f4588" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2d9be6b6-2fa7-4ec9-b66b-bf5a39feed1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_91942386-ad3e-4638-a446-65d70ac92620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d951c1c-1d8c-48e5-a9fd-92aac96f4588" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_91942386-ad3e-4638-a446-65d70ac92620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_316bb398-8327-4733-84d5-54e036fd00e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d951c1c-1d8c-48e5-a9fd-92aac96f4588" xlink:to="loc_us-gaap_UseOfEstimates_316bb398-8327-4733-84d5-54e036fd00e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/SignificantTransactions" xlink:type="simple" xlink:href="zntl-20220630.xsd#SignificantTransactions"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/SignificantTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_dabc5fa5-454a-4ca7-8f24-7bac58a3f540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_41314897-8971-4359-97d8-a1555568d8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_dabc5fa5-454a-4ca7-8f24-7bac58a3f540" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_41314897-8971-4359-97d8-a1555568d8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/SignificantTransactionsDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#SignificantTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/SignificantTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_8aaff021-dce3-4832-bf1f-d939c7509dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bf0f03aa-4b22-4acd-bf97-8b7c1b2c6dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_8aaff021-dce3-4832-bf1f-d939c7509dd5" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bf0f03aa-4b22-4acd-bf97-8b7c1b2c6dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec8bc3c4-83bd-4863-b240-c03f7f51d5e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bf0f03aa-4b22-4acd-bf97-8b7c1b2c6dbd" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec8bc3c4-83bd-4863-b240-c03f7f51d5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2679d190-8e3a-416f-b5fb-d22929fee977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec8bc3c4-83bd-4863-b240-c03f7f51d5e2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2679d190-8e3a-416f-b5fb-d22929fee977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraTherapeuticsLtdMember_2afcf924-5d70-418b-ad68-a09c3cb39113" xlink:href="zntl-20220630.xsd#zntl_ZenteraTherapeuticsLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2679d190-8e3a-416f-b5fb-d22929fee977" xlink:to="loc_zntl_ZenteraTherapeuticsLtdMember_2afcf924-5d70-418b-ad68-a09c3cb39113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_bf0f03aa-4b22-4acd-bf97-8b7c1b2c6dbd" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d09b2e81-d8d6-4360-82bf-1eec892027c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:to="loc_us-gaap_EquityMethodInvestments_d09b2e81-d8d6-4360-82bf-1eec892027c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_4ac486d0-3727-4c44-ad9f-a3b8fee9a32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_4ac486d0-3727-4c44-ad9f-a3b8fee9a32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_fc075759-9f7f-43e7-8685-47df7f71a1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_fc075759-9f7f-43e7-8685-47df7f71a1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_f9300f92-4ab6-40e6-a634-fbf20f9b9d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_f9300f92-4ab6-40e6-a634-fbf20f9b9d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_454c32e1-0047-4f11-b172-9083d449f877" xlink:href="zntl-20220630.xsd#zntl_ResearchAndDevelopmentExpenseReimbursements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb1b2786-3bea-47d0-8282-87b691db4c9b" xlink:to="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_454c32e1-0047-4f11-b172-9083d449f877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinations" xlink:type="simple" xlink:href="zntl-20220630.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_be7767dc-dfcd-4551-96cf-1eca8c5157a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_bb30e1c5-b6d9-4917-a0ca-773599273101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_be7767dc-dfcd-4551-96cf-1eca8c5157a0" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_bb30e1c5-b6d9-4917-a0ca-773599273101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="zntl-20220630.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_92c3f0f1-317a-4313-9cbd-42d76ec5e864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock_9568dfd1-f173-4223-9f37-5897ae38cedd" xlink:href="zntl-20220630.xsd#zntl_ReconciliationOfNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_92c3f0f1-317a-4313-9cbd-42d76ec5e864" xlink:to="loc_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock_9568dfd1-f173-4223-9f37-5897ae38cedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fe250b10-469c-4f8a-a2ab-aedc16baf433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_92d8aed0-5258-490c-b790-df2ded3ad332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fe250b10-469c-4f8a-a2ab-aedc16baf433" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_92d8aed0-5258-490c-b790-df2ded3ad332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ad88ec6c-8879-4de0-936d-5f1f28a9c6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_92d8aed0-5258-490c-b790-df2ded3ad332" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ad88ec6c-8879-4de0-936d-5f1f28a9c6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039bcebd-93ed-4014-881e-36733b246944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ad88ec6c-8879-4de0-936d-5f1f28a9c6f0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039bcebd-93ed-4014-881e-36733b246944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_KalyraPharmaceuticalsIncMember_99166a81-fe17-422a-873e-7abb3185f287" xlink:href="zntl-20220630.xsd#zntl_KalyraPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039bcebd-93ed-4014-881e-36733b246944" xlink:to="loc_zntl_KalyraPharmaceuticalsIncMember_99166a81-fe17-422a-873e-7abb3185f287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_3f2cc412-d169-48f3-88b4-1d2e022b99e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_92d8aed0-5258-490c-b790-df2ded3ad332" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_3f2cc412-d169-48f3-88b4-1d2e022b99e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_03554316-e6b8-4ec3-9a52-22f26310f508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3f2cc412-d169-48f3-88b4-1d2e022b99e7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_03554316-e6b8-4ec3-9a52-22f26310f508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_aa8e2e8e-78b9-41d9-aabf-d9758d09744a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3f2cc412-d169-48f3-88b4-1d2e022b99e7" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_aa8e2e8e-78b9-41d9-aabf-d9758d09744a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_022643a7-7459-409b-bfc0-5119107be56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4fc2b84a-ed76-47f7-a86d-8562ab987958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_022643a7-7459-409b-bfc0-5119107be56e" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4fc2b84a-ed76-47f7-a86d-8562ab987958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0a739598-1f77-4411-a7a7-ee767d14e5a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4fc2b84a-ed76-47f7-a86d-8562ab987958" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0a739598-1f77-4411-a7a7-ee767d14e5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b98800e3-edd3-456d-bb99-ef23c83df5ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0a739598-1f77-4411-a7a7-ee767d14e5a8" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b98800e3-edd3-456d-bb99-ef23c83df5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_a5fdb977-257f-42b5-a237-cced63ad970d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b98800e3-edd3-456d-bb99-ef23c83df5ea" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_a5fdb977-257f-42b5-a237-cced63ad970d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_29502c0c-3f60-488c-8fc6-44673ae7d290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4fc2b84a-ed76-47f7-a86d-8562ab987958" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_29502c0c-3f60-488c-8fc6-44673ae7d290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_177fed02-b673-4f50-a076-d56439bd4377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_29502c0c-3f60-488c-8fc6-44673ae7d290" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_177fed02-b673-4f50-a076-d56439bd4377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_17ddd9cd-2e86-4b69-8e53-6f6e4da0f715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_177fed02-b673-4f50-a076-d56439bd4377" xlink:to="loc_us-gaap_MinorityInterest_17ddd9cd-2e86-4b69-8e53-6f6e4da0f715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c2790486-b1f9-4b11-8e26-06f9058f6414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_177fed02-b673-4f50-a076-d56439bd4377" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c2790486-b1f9-4b11-8e26-06f9058f6414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_d9c4943d-c6e6-4aeb-8e9e-5d18ea493b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_177fed02-b673-4f50-a076-d56439bd4377" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_d9c4943d-c6e6-4aeb-8e9e-5d18ea493b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a8c9c07b-6551-41ee-b771-803310f1a7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_177fed02-b673-4f50-a076-d56439bd4377" xlink:to="loc_us-gaap_MinorityInterest_a8c9c07b-6551-41ee-b771-803310f1a7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="zntl-20220630.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2272de9d-ac92-421a-89c8-9b3ee5089a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_df47080d-9db6-4752-8d86-156213aa8277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2272de9d-ac92-421a-89c8-9b3ee5089a04" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_df47080d-9db6-4752-8d86-156213aa8277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="zntl-20220630.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c8ad5e97-0be8-431b-b3a0-00f3c17b2a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_cd981d50-c7e7-49b1-bb7e-7428f5c44502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c8ad5e97-0be8-431b-b3a0-00f3c17b2a43" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_cd981d50-c7e7-49b1-bb7e-7428f5c44502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_5fba08e4-6646-438f-a1a4-d005e9506226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c8ad5e97-0be8-431b-b3a0-00f3c17b2a43" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_5fba08e4-6646-438f-a1a4-d005e9506226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_bfe8775c-8eed-499b-bb48-31b47256119e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c8ad5e97-0be8-431b-b3a0-00f3c17b2a43" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_bfe8775c-8eed-499b-bb48-31b47256119e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_453456e6-663f-4bfc-8789-033769774e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c99996d6-f1ac-4074-9328-565704320c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_453456e6-663f-4bfc-8789-033769774e25" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c99996d6-f1ac-4074-9328-565704320c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5c2b87b7-b756-45d8-bc71-b9df797fb676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c99996d6-f1ac-4074-9328-565704320c3c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5c2b87b7-b756-45d8-bc71-b9df797fb676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5c2b87b7-b756-45d8-bc71-b9df797fb676" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_53d294b8-934a-471c-a457-9c97f42bb10e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:to="loc_us-gaap_CommercialPaperMember_53d294b8-934a-471c-a457-9c97f42bb10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7d6bd114-3290-4296-9b5f-4b7a274451c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7d6bd114-3290-4296-9b5f-4b7a274451c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8f6e825d-b179-49f6-be87-2709001ebe53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8f6e825d-b179-49f6-be87-2709001ebe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a338b40f-0412-44e7-ba9a-75df4b2178cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37454b78-c876-4d62-944e-1fc68162f909" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a338b40f-0412-44e7-ba9a-75df4b2178cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c99996d6-f1ac-4074-9328-565704320c3c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e850f401-8023-4103-af97-7c3f3e3a005a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e850f401-8023-4103-af97-7c3f3e3a005a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23b2f0b9-d770-484c-b637-af6e66ba33f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23b2f0b9-d770-484c-b637-af6e66ba33f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6868ec86-a6c3-48a2-b2e0-ab2da1b12c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6868ec86-a6c3-48a2-b2e0-ab2da1b12c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a3bef7a8-7580-474c-9551-cc008f760101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3476c254-98cb-42c0-8056-90404a91f568" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a3bef7a8-7580-474c-9551-cc008f760101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4078e69f-d5a1-44ed-b65c-080057df9c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f814e540-81bc-4dd0-8d16-2f26fca5058d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4078e69f-d5a1-44ed-b65c-080057df9c4c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f814e540-81bc-4dd0-8d16-2f26fca5058d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_eef6c9a7-2920-45bb-8fca-2f274d8932e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4078e69f-d5a1-44ed-b65c-080057df9c4c" xlink:to="loc_us-gaap_TradingSecuritiesDebt_eef6c9a7-2920-45bb-8fca-2f274d8932e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_93abe11f-db9d-4d0b-933b-ad9becca9fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4078e69f-d5a1-44ed-b65c-080057df9c4c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_93abe11f-db9d-4d0b-933b-ad9becca9fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_483fb9ac-bd5f-4fde-bae2-61c798acd5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_bf568427-8c93-4c5e-96ec-7fcf5170912c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_483fb9ac-bd5f-4fde-bae2-61c798acd5ed" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_bf568427-8c93-4c5e-96ec-7fcf5170912c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f3efaf4b-1606-4319-a10d-e649a8e001d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_483fb9ac-bd5f-4fde-bae2-61c798acd5ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f3efaf4b-1606-4319-a10d-e649a8e001d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4e138f99-fdc9-4e4b-a58a-1493924adf83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_483fb9ac-bd5f-4fde-bae2-61c798acd5ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4e138f99-fdc9-4e4b-a58a-1493924adf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6454afe0-4b66-4ce5-bff3-dce7a29b5a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45aac886-0c1f-4b40-9184-65bcde6f2e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6454afe0-4b66-4ce5-bff3-dce7a29b5a23" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45aac886-0c1f-4b40-9184-65bcde6f2e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_499d09fd-4898-4b7d-a6a0-9872fa946b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45aac886-0c1f-4b40-9184-65bcde6f2e69" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_499d09fd-4898-4b7d-a6a0-9872fa946b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c80df616-9184-4db8-bdf9-6e277f029e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_499d09fd-4898-4b7d-a6a0-9872fa946b5c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c80df616-9184-4db8-bdf9-6e277f029e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7db4abf0-d176-4451-8b79-d17c01b318e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c80df616-9184-4db8-bdf9-6e277f029e90" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7db4abf0-d176-4451-8b79-d17c01b318e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a24e2037-2f39-452f-b404-bce48d24bdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c80df616-9184-4db8-bdf9-6e277f029e90" xlink:to="loc_us-gaap_CommercialPaperMember_a24e2037-2f39-452f-b404-bce48d24bdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_96d16e69-c0ca-43fb-bd0c-c95362af5900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45aac886-0c1f-4b40-9184-65bcde6f2e69" xlink:to="loc_us-gaap_FinancialInstrumentAxis_96d16e69-c0ca-43fb-bd0c-c95362af5900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_96d16e69-c0ca-43fb-bd0c-c95362af5900" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8a9d50fc-388a-4014-848d-bdddaa63999a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:to="loc_us-gaap_CommercialPaperMember_8a9d50fc-388a-4014-848d-bdddaa63999a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0767bbc2-4d3f-47cf-9445-32d4eac24b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0767bbc2-4d3f-47cf-9445-32d4eac24b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6f707d41-a227-4259-8ce5-4c0b23e4db8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6f707d41-a227-4259-8ce5-4c0b23e4db8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_afdb1e26-6ce2-4e11-a198-e1b9209c2952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5543df1-f70d-49ac-86a2-265e4ab3d42b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_afdb1e26-6ce2-4e11-a198-e1b9209c2952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_646b211e-e94a-4963-834e-b40d0bb62b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45aac886-0c1f-4b40-9184-65bcde6f2e69" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_646b211e-e94a-4963-834e-b40d0bb62b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d896620-1a75-4b87-a052-005d00cdd362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_646b211e-e94a-4963-834e-b40d0bb62b7d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d896620-1a75-4b87-a052-005d00cdd362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5dac9799-270a-430d-bffe-24b3fcbc0642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d896620-1a75-4b87-a052-005d00cdd362" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5dac9799-270a-430d-bffe-24b3fcbc0642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d161912d-1f7d-4fcf-9ae1-8be1aa1e1fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d896620-1a75-4b87-a052-005d00cdd362" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d161912d-1f7d-4fcf-9ae1-8be1aa1e1fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ecc6c6b9-d56c-4257-ab2e-d7e819636469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45aac886-0c1f-4b40-9184-65bcde6f2e69" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ecc6c6b9-d56c-4257-ab2e-d7e819636469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_518d6288-9202-4415-b174-7c5eeda5d8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ecc6c6b9-d56c-4257-ab2e-d7e819636469" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_518d6288-9202-4415-b174-7c5eeda5d8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f35ce582-3907-43e3-b933-6847729e4d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ecc6c6b9-d56c-4257-ab2e-d7e819636469" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f35ce582-3907-43e3-b933-6847729e4d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_bd27b3ae-35c9-4632-8db1-f8138b943187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ecc6c6b9-d56c-4257-ab2e-d7e819636469" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_bd27b3ae-35c9-4632-8db1-f8138b943187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssets" xlink:type="simple" xlink:href="zntl-20220630.xsd#PrepaidExpensesandOtherAssets"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_29f7ad1f-8274-444a-bdc4-734c634dba24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_b8df8e62-06d2-41c5-8afe-009b8834960d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_29f7ad1f-8274-444a-bdc4-734c634dba24" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_b8df8e62-06d2-41c5-8afe-009b8834960d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables" xlink:type="simple" xlink:href="zntl-20220630.xsd#PrepaidExpensesandOtherAssetsTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0c969f9b-c4fa-4ccc-8dc8-6970f8add4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_c4f8a416-d544-42b4-883d-a101ff84fcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0c969f9b-c4fa-4ccc-8dc8-6970f8add4ce" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_c4f8a416-d544-42b4-883d-a101ff84fcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#PrepaidExpensesandOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_51b5b104-7a01-41a4-aa1a-9af2578b61c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_fe623479-3ba2-4729-b8f5-2a363d2ec41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_51b5b104-7a01-41a4-aa1a-9af2578b61c3" xlink:to="loc_us-gaap_PrepaidInsurance_fe623479-3ba2-4729-b8f5-2a363d2ec41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidSoftwareLicenseAndMaintenance_35f88226-0aa6-4159-9628-b194a6a17ae0" xlink:href="zntl-20220630.xsd#zntl_PrepaidSoftwareLicenseAndMaintenance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_51b5b104-7a01-41a4-aa1a-9af2578b61c3" xlink:to="loc_zntl_PrepaidSoftwareLicenseAndMaintenance_35f88226-0aa6-4159-9628-b194a6a17ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ForeignResearchAndDevelopmentCreditRefund_6e0cd572-3688-4df3-bb80-9896655b9ee7" xlink:href="zntl-20220630.xsd#zntl_ForeignResearchAndDevelopmentCreditRefund"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_51b5b104-7a01-41a4-aa1a-9af2578b61c3" xlink:to="loc_zntl_ForeignResearchAndDevelopmentCreditRefund_6e0cd572-3688-4df3-bb80-9896655b9ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidResearchAndDevelopmentCosts_aa535b44-828d-4dad-981a-aef188ab21e6" xlink:href="zntl-20220630.xsd#zntl_PrepaidResearchAndDevelopmentCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_51b5b104-7a01-41a4-aa1a-9af2578b61c3" xlink:to="loc_zntl_PrepaidResearchAndDevelopmentCosts_aa535b44-828d-4dad-981a-aef188ab21e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_dbabe485-46c8-4396-8e77-45f81807d719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_51b5b104-7a01-41a4-aa1a-9af2578b61c3" xlink:to="loc_us-gaap_InterestReceivable_dbabe485-46c8-4396-8e77-45f81807d719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_77b53794-6dda-4dd7-b4c2-02431ddd670a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_51b5b104-7a01-41a4-aa1a-9af2578b61c3" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_77b53794-6dda-4dd7-b4c2-02431ddd670a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OtherPrepaidExpense_f837ae22-73be-44d8-b436-5e086d9addde" xlink:href="zntl-20220630.xsd#zntl_OtherPrepaidExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_51b5b104-7a01-41a4-aa1a-9af2578b61c3" xlink:to="loc_zntl_OtherPrepaidExpense_f837ae22-73be-44d8-b436-5e086d9addde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_0a5e366d-810d-4602-abab-50de2874e7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_51b5b104-7a01-41a4-aa1a-9af2578b61c3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_0a5e366d-810d-4602-abab-50de2874e7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_5057c49c-2fb7-4b0f-99a7-5f4090685c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_51b5b104-7a01-41a4-aa1a-9af2578b61c3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_5057c49c-2fb7-4b0f-99a7-5f4090685c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_34b4947d-ba19-4c21-9ecf-bab6a19cc46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_51b5b104-7a01-41a4-aa1a-9af2578b61c3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_34b4947d-ba19-4c21-9ecf-bab6a19cc46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1" xlink:type="simple" xlink:href="zntl-20220630.xsd#PrepaidExpensesandOtherAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="zntl-20220630.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ffaecc73-2a63-4043-b02b-8311585e33b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_50ad5e0e-015d-47b5-aafa-daa0059e7519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ffaecc73-2a63-4043-b02b-8311585e33b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_50ad5e0e-015d-47b5-aafa-daa0059e7519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="zntl-20220630.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5091dbd3-b553-4051-85c1-8f6520d05b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f5def400-0ba2-4d6a-8899-bfef8615237c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5091dbd3-b553-4051-85c1-8f6520d05b77" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f5def400-0ba2-4d6a-8899-bfef8615237c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#PropertyandEquipmentnetSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e36cf566-90f4-4db3-b1dd-bc2c5d1daf96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1166e2be-cdea-413d-bd3d-0548a6c0c3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e36cf566-90f4-4db3-b1dd-bc2c5d1daf96" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1166e2be-cdea-413d-bd3d-0548a6c0c3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d7323cc-47d8-4237-98f5-4cde63dd620c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1166e2be-cdea-413d-bd3d-0548a6c0c3f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d7323cc-47d8-4237-98f5-4cde63dd620c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d7323cc-47d8-4237-98f5-4cde63dd620c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LaboratoryEquipmentMember_d3f1cc8d-a4c4-4ce0-af27-b1ef5cf6ade2" xlink:href="zntl-20220630.xsd#zntl_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:to="loc_zntl_LaboratoryEquipmentMember_d3f1cc8d-a4c4-4ce0-af27-b1ef5cf6ade2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5263ee5c-ec0e-44fe-b0e3-4dbbfaa5b6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5263ee5c-ec0e-44fe-b0e3-4dbbfaa5b6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OfficeEquipmentAndFurnitureMember_2a873fbc-58a8-47fa-95f6-fdb8d018ab4e" xlink:href="zntl-20220630.xsd#zntl_OfficeEquipmentAndFurnitureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:to="loc_zntl_OfficeEquipmentAndFurnitureMember_2a873fbc-58a8-47fa-95f6-fdb8d018ab4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_fa1c771e-fd54-4d1b-9e38-84594d067457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:to="loc_us-gaap_ComputerEquipmentMember_fa1c771e-fd54-4d1b-9e38-84594d067457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b7292cf8-8ad3-46a7-ac18-1ce380cf439f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e513c4de-3592-464a-84d2-1c2180d1286d" xlink:to="loc_us-gaap_ConstructionInProgressMember_b7292cf8-8ad3-46a7-ac18-1ce380cf439f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b317e30b-2b74-4114-b2bc-9c8a29ba6c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1166e2be-cdea-413d-bd3d-0548a6c0c3f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b317e30b-2b74-4114-b2bc-9c8a29ba6c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_13affc50-9043-41a9-8759-3d17fe345c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b317e30b-2b74-4114-b2bc-9c8a29ba6c4e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_13affc50-9043-41a9-8759-3d17fe345c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bd022ee4-9be4-4cce-afec-30b8186170e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b317e30b-2b74-4114-b2bc-9c8a29ba6c4e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bd022ee4-9be4-4cce-afec-30b8186170e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ef574691-e61e-4f0a-abcc-c80bdf99f1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b317e30b-2b74-4114-b2bc-9c8a29ba6c4e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ef574691-e61e-4f0a-abcc-c80bdf99f1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#PropertyandEquipmentnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4af899fe-76eb-48f1-aa1c-6381bf123cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2fd42133-65d3-45eb-ba23-c88365471a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4af899fe-76eb-48f1-aa1c-6381bf123cc0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2fd42133-65d3-45eb-ba23-c88365471a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/AccruedExpenses" xlink:type="simple" xlink:href="zntl-20220630.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ceb15dc1-5678-411f-905f-5e82b707cc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_9b681651-c8ce-4b78-89d0-02cbf1f24295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ceb15dc1-5678-411f-905f-5e82b707cc98" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_9b681651-c8ce-4b78-89d0-02cbf1f24295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="zntl-20220630.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_858de8f5-261f-40a8-aa81-7fefdf7cfbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d3ae59d4-6588-4018-b364-b940ff61bbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_858de8f5-261f-40a8-aa81-7fefdf7cfbdb" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d3ae59d4-6588-4018-b364-b940ff61bbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_495e642a-444c-4d45-8ef0-677f9dfa3b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent_727ef424-84e8-4a97-a42f-bd2d32993ec9" xlink:href="zntl-20220630.xsd#zntl_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_495e642a-444c-4d45-8ef0-677f9dfa3b67" xlink:to="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent_727ef424-84e8-4a97-a42f-bd2d32993ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7c04de14-ebbb-4adf-b994-dc564572d862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_495e642a-444c-4d45-8ef0-677f9dfa3b67" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7c04de14-ebbb-4adf-b994-dc564572d862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_c6dd4ad6-1b8c-49a1-9916-18680512ce07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_495e642a-444c-4d45-8ef0-677f9dfa3b67" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_c6dd4ad6-1b8c-49a1-9916-18680512ce07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent_38782edf-2a42-417a-8e84-e03d73ae53c5" xlink:href="zntl-20220630.xsd#zntl_AccruedGeneralAndAdministrativeCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_495e642a-444c-4d45-8ef0-677f9dfa3b67" xlink:to="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent_38782edf-2a42-417a-8e84-e03d73ae53c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_90964894-0bf1-41df-a1b7-a4d19ef157ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_495e642a-444c-4d45-8ef0-677f9dfa3b67" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_90964894-0bf1-41df-a1b7-a4d19ef157ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_87010959-eea2-46a8-a136-cf26dea04673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_495e642a-444c-4d45-8ef0-677f9dfa3b67" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_87010959-eea2-46a8-a136-cf26dea04673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_aabd0cdc-8582-4913-b3f2-79c771c032a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_495e642a-444c-4d45-8ef0-677f9dfa3b67" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_aabd0cdc-8582-4913-b3f2-79c771c032a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquity" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9ca0de41-d210-467f-9f7a-96d2f24f5836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1f0813fb-7941-4438-b832-59f061401424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9ca0de41-d210-467f-9f7a-96d2f24f5836" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1f0813fb-7941-4438-b832-59f061401424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2702b816-be38-4a19-b26a-f3e6b4c0d593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_419b17d6-6c09-41be-8742-203c5d91dd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2702b816-be38-4a19-b26a-f3e6b4c0d593" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_419b17d6-6c09-41be-8742-203c5d91dd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_63c65f78-161b-4e82-990a-b9938802bda4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2702b816-be38-4a19-b26a-f3e6b4c0d593" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_63c65f78-161b-4e82-990a-b9938802bda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_5e0c76c6-0b32-4f1b-b514-9868b3c312cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2702b816-be38-4a19-b26a-f3e6b4c0d593" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_5e0c76c6-0b32-4f1b-b514-9868b3c312cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_997bd629-2873-48df-987d-03219b00440c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2702b816-be38-4a19-b26a-f3e6b4c0d593" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_997bd629-2873-48df-987d-03219b00440c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ec1a67e6-784e-45fd-8896-a4e34a8cdbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec1a67e6-784e-45fd-8896-a4e34a8cdbcd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_93e27c11-88fd-460c-8e0a-98459a6e8c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_93e27c11-88fd-460c-8e0a-98459a6e8c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d2c4bfac-6910-42ac-8443-9a07ed64fb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_93e27c11-88fd-460c-8e0a-98459a6e8c24" xlink:to="loc_us-gaap_ClassOfStockDomain_d2c4bfac-6910-42ac-8443-9a07ed64fb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_13fceea2-2bd8-42e7-952b-893f1a817c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d2c4bfac-6910-42ac-8443-9a07ed64fb65" xlink:to="loc_us-gaap_CommonStockMember_13fceea2-2bd8-42e7-952b-893f1a817c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_0e53a7ab-1369-4540-a9b6-2f68b1f60f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d2c4bfac-6910-42ac-8443-9a07ed64fb65" xlink:to="loc_us-gaap_CommonClassBMember_0e53a7ab-1369-4540-a9b6-2f68b1f60f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_eab9f5cb-2795-4034-82d5-4c1fea7d8653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d2c4bfac-6910-42ac-8443-9a07ed64fb65" xlink:to="loc_us-gaap_RestrictedStockMember_eab9f5cb-2795-4034-82d5-4c1fea7d8653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f2781d90-36be-4bda-9474-ae8a916b5790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_PlanNameAxis_f2781d90-36be-4bda-9474-ae8a916b5790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_57a74dd7-6ee1-444f-aef1-ab6dd948b856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f2781d90-36be-4bda-9474-ae8a916b5790" xlink:to="loc_us-gaap_PlanNameDomain_57a74dd7-6ee1-444f-aef1-ab6dd948b856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2020IncentiveAwardPlanMember_d694bede-b053-4d36-933d-5e17e5e6bd3b" xlink:href="zntl-20220630.xsd#zntl_A2020IncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_57a74dd7-6ee1-444f-aef1-ab6dd948b856" xlink:to="loc_zntl_A2020IncentiveAwardPlanMember_d694bede-b053-4d36-933d-5e17e5e6bd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_198ccf9c-511d-4d3a-a2d4-31d7eb902645" xlink:href="zntl-20220630.xsd#zntl_A2022EmploymentInducementIncentiveAwardPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_57a74dd7-6ee1-444f-aef1-ab6dd948b856" xlink:to="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_198ccf9c-511d-4d3a-a2d4-31d7eb902645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraStockPlanMember_09d5e8a6-691c-4616-9111-8a2c50c01a8b" xlink:href="zntl-20220630.xsd#zntl_ZenteraStockPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_57a74dd7-6ee1-444f-aef1-ab6dd948b856" xlink:to="loc_zntl_ZenteraStockPlanMember_09d5e8a6-691c-4616-9111-8a2c50c01a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d10455e3-e9c9-4d2f-baa1-3b9a0d4413c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_srt_RangeAxis_d10455e3-e9c9-4d2f-baa1-3b9a0d4413c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78944888-d5ea-45be-8542-8ffafdcce7e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d10455e3-e9c9-4d2f-baa1-3b9a0d4413c7" xlink:to="loc_srt_RangeMember_78944888-d5ea-45be-8542-8ffafdcce7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0200df54-7f75-4f99-8149-b6ab217ce787" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_78944888-d5ea-45be-8542-8ffafdcce7e0" xlink:to="loc_srt_MaximumMember_0200df54-7f75-4f99-8149-b6ab217ce787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bddf48f5-78a9-4de9-b79d-eb80a0762d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_AwardTypeAxis_bddf48f5-78a9-4de9-b79d-eb80a0762d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bddf48f5-78a9-4de9-b79d-eb80a0762d1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dfeb2eb1-800f-4f0d-80f0-065d8c5b2b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dfeb2eb1-800f-4f0d-80f0-065d8c5b2b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0c4ef948-f301-4776-8985-278f1378ed3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:to="loc_us-gaap_EmployeeStockMember_0c4ef948-f301-4776-8985-278f1378ed3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8b3cd097-a399-455d-93f7-93441ff9e044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:to="loc_us-gaap_RestrictedStockMember_8b3cd097-a399-455d-93f7-93441ff9e044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2c65eec9-2069-4cd9-abf4-fbb290057e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659fd00-75d2-449c-8f27-7c8dec1a913a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2c65eec9-2069-4cd9-abf4-fbb290057e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8983ca66-c7f4-4760-b276-c5bb89d9f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8983ca66-c7f4-4760-b276-c5bb89d9f8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4ad2f40b-e7ef-4de9-8e75-b670dd9dcf51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8983ca66-c7f4-4760-b276-c5bb89d9f8bf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4ad2f40b-e7ef-4de9-8e75-b670dd9dcf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_DirectOfferingMember_7ed55403-defc-4b0a-8933-392f987d2aa7" xlink:href="zntl-20220630.xsd#zntl_DirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4ad2f40b-e7ef-4de9-8e75-b670dd9dcf51" xlink:to="loc_zntl_DirectOfferingMember_7ed55403-defc-4b0a-8933-392f987d2aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_FollowOnOfferingMember_17d66952-1deb-423d-8efb-e88dd3ac9b5e" xlink:href="zntl-20220630.xsd#zntl_FollowOnOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4ad2f40b-e7ef-4de9-8e75-b670dd9dcf51" xlink:to="loc_zntl_FollowOnOfferingMember_17d66952-1deb-423d-8efb-e88dd3ac9b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d3cbef67-5ee9-468c-b6c2-6a9577e96c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d3cbef67-5ee9-468c-b6c2-6a9577e96c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c2324ad-8abe-45bc-b4c7-c760407806a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d3cbef67-5ee9-468c-b6c2-6a9577e96c2e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c2324ad-8abe-45bc-b4c7-c760407806a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_c47242cd-d9c8-4486-a1de-5952cc770a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c2324ad-8abe-45bc-b4c7-c760407806a9" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_c47242cd-d9c8-4486-a1de-5952cc770a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7904ccdf-d6f5-4029-a0d0-a88c7f4e602e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7904ccdf-d6f5-4029-a0d0-a88c7f4e602e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a71ec8e8-6710-492e-b7f8-988b181686ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7904ccdf-d6f5-4029-a0d0-a88c7f4e602e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a71ec8e8-6710-492e-b7f8-988b181686ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_05987b06-1303-442b-a82d-e7e4ead30140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a71ec8e8-6710-492e-b7f8-988b181686ef" xlink:to="loc_us-gaap_SubsequentEventMember_05987b06-1303-442b-a82d-e7e4ead30140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9d39e0ee-c266-4948-8995-0fd8ada0c8a9" xlink:to="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_36c19887-1cba-4a02-9ddf-8db4b19d5672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_36c19887-1cba-4a02-9ddf-8db4b19d5672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d411180d-b0e0-41be-ac90-9168bc884700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d411180d-b0e0-41be-ac90-9168bc884700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ProceedsFromIssuanceOfCommonStockGross_0c8912dd-24a2-485f-bc9f-bbf619f99e35" xlink:href="zntl-20220630.xsd#zntl_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_zntl_ProceedsFromIssuanceOfCommonStockGross_0c8912dd-24a2-485f-bc9f-bbf619f99e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_defa6758-c278-46a1-a1ec-ba0747ec27f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_defa6758-c278-46a1-a1ec-ba0747ec27f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_17bdd6c6-ef58-45c6-af95-21e99428def1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_17bdd6c6-ef58-45c6-af95-21e99428def1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_2d4944e7-cc72-4c67-a1ce-8327fe1e32fe" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_2d4944e7-cc72-4c67-a1ce-8327fe1e32fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_58a4821f-7caa-4049-99c5-9a4ebec01f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_58a4821f-7caa-4049-99c5-9a4ebec01f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dfeafd2d-e5ee-4847-b6c0-b685a80702a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dfeafd2d-e5ee-4847-b6c0-b685a80702a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4e917f7b-92d0-49b6-ac99-2d57e68cdc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4e917f7b-92d0-49b6-ac99-2d57e68cdc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_7b582b30-a653-4c74-9a25-31b47f6a1e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_7b582b30-a653-4c74-9a25-31b47f6a1e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_32db9e31-20ea-4742-84b7-b0928c9bad89" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_32db9e31-20ea-4742-84b7-b0928c9bad89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_afe67f00-797c-4ee7-9271-25c85c04054a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_afe67f00-797c-4ee7-9271-25c85c04054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e70e56d0-096b-4d10-b310-8d42e36e01dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e70e56d0-096b-4d10-b310-8d42e36e01dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_59c86d26-cac1-407a-81a8-dfc6b3d6c9bd" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_59c86d26-cac1-407a-81a8-dfc6b3d6c9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_92cb30c9-6984-46a8-a0cd-9a0c1a929437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_92cb30c9-6984-46a8-a0cd-9a0c1a929437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_3339a6be-9570-4733-b8b6-d61deac2e468" xlink:href="zntl-20220630.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_3339a6be-9570-4733-b8b6-d61deac2e468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b4eb2cda-e362-46e5-add7-19b5d6ab4687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b4eb2cda-e362-46e5-add7-19b5d6ab4687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_05ac677f-8508-4df7-b66b-f7b49c2d44aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_05ac677f-8508-4df7-b66b-f7b49c2d44aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0a72061d-c60a-468f-9010-7e165a4d7cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a7ac981f-0a0e-43ee-9dd3-9f9ce8594288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0a72061d-c60a-468f-9010-7e165a4d7cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquitySharebasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b5f72353-f1b2-4b3c-ad08-20a842bd7825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deb20d40-2946-412b-9300-314301420be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b5f72353-f1b2-4b3c-ad08-20a842bd7825" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deb20d40-2946-412b-9300-314301420be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_39217b9d-5188-40d2-bd05-1b45ee513563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deb20d40-2946-412b-9300-314301420be7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_39217b9d-5188-40d2-bd05-1b45ee513563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d5b434f-131b-4bcc-b5f9-62398db7180e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_39217b9d-5188-40d2-bd05-1b45ee513563" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d5b434f-131b-4bcc-b5f9-62398db7180e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f8ba5e5f-b4f1-49b9-94ca-f301b77311a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d5b434f-131b-4bcc-b5f9-62398db7180e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f8ba5e5f-b4f1-49b9-94ca-f301b77311a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c1241f1c-9292-4954-8070-0e2ebc9bb155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d5b434f-131b-4bcc-b5f9-62398db7180e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c1241f1c-9292-4954-8070-0e2ebc9bb155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc7d56c2-f614-4fe5-a67b-225592e2b6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deb20d40-2946-412b-9300-314301420be7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc7d56c2-f614-4fe5-a67b-225592e2b6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_27e48854-3c43-4432-9be4-30fbf5508927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bc7d56c2-f614-4fe5-a67b-225592e2b6d5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_27e48854-3c43-4432-9be4-30fbf5508927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquitySharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_83ce3e75-8417-4359-814e-d9c39cb25ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3efb9fd0-8d88-42ba-a6cc-c45ba3b246d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_83ce3e75-8417-4359-814e-d9c39cb25ae9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3efb9fd0-8d88-42ba-a6cc-c45ba3b246d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ba5fbb19-2160-42df-8ecb-baa51366ffc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3efb9fd0-8d88-42ba-a6cc-c45ba3b246d8" xlink:to="loc_us-gaap_AwardTypeAxis_ba5fbb19-2160-42df-8ecb-baa51366ffc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c55c94e-abe7-4650-ab93-96df5c6bff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ba5fbb19-2160-42df-8ecb-baa51366ffc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c55c94e-abe7-4650-ab93-96df5c6bff5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_00899ce1-a6b1-4365-9bc5-cbafa1fcacc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c55c94e-abe7-4650-ab93-96df5c6bff5e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_00899ce1-a6b1-4365-9bc5-cbafa1fcacc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b64bfc3c-2430-45ef-87b0-03432914d85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c55c94e-abe7-4650-ab93-96df5c6bff5e" xlink:to="loc_us-gaap_EmployeeStockMember_b64bfc3c-2430-45ef-87b0-03432914d85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_b298f164-e618-482e-bd0f-237e7d027498" xlink:href="zntl-20220630.xsd#zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c55c94e-abe7-4650-ab93-96df5c6bff5e" xlink:to="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_b298f164-e618-482e-bd0f-237e7d027498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1772d108-d530-4125-8603-bbf36f17ec6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3efb9fd0-8d88-42ba-a6cc-c45ba3b246d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1772d108-d530-4125-8603-bbf36f17ec6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_df30b44e-15cb-4f26-b133-707612984553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1772d108-d530-4125-8603-bbf36f17ec6b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_df30b44e-15cb-4f26-b133-707612984553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquityFairValueAssumptionsforStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_57f6249a-55ef-4ff8-84fa-456804f19a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_171971f6-0dd9-40c8-9be5-b4255016004d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_57f6249a-55ef-4ff8-84fa-456804f19a32" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_171971f6-0dd9-40c8-9be5-b4255016004d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7970bedc-6847-4b82-a033-5fd4ced78f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_171971f6-0dd9-40c8-9be5-b4255016004d" xlink:to="loc_us-gaap_AwardTypeAxis_7970bedc-6847-4b82-a033-5fd4ced78f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae8ec84b-87cb-4676-9434-72f69af351ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7970bedc-6847-4b82-a033-5fd4ced78f85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae8ec84b-87cb-4676-9434-72f69af351ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_30a58f26-c882-4b95-9633-3f17c5c4801b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae8ec84b-87cb-4676-9434-72f69af351ed" xlink:to="loc_us-gaap_EmployeeStockOptionMember_30a58f26-c882-4b95-9633-3f17c5c4801b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f22058d-5a39-48f8-82a9-d5cc40e1c563" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_171971f6-0dd9-40c8-9be5-b4255016004d" xlink:to="loc_srt_RangeAxis_7f22058d-5a39-48f8-82a9-d5cc40e1c563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c1cf0a96-fa02-4709-889b-bfcdd5cfd0da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7f22058d-5a39-48f8-82a9-d5cc40e1c563" xlink:to="loc_srt_RangeMember_c1cf0a96-fa02-4709-889b-bfcdd5cfd0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1793a6fb-01c1-4d81-8993-427358fc1beb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c1cf0a96-fa02-4709-889b-bfcdd5cfd0da" xlink:to="loc_srt_MinimumMember_1793a6fb-01c1-4d81-8993-427358fc1beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d59926a-ae8b-4fb3-b0c7-389c6491e1c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c1cf0a96-fa02-4709-889b-bfcdd5cfd0da" xlink:to="loc_srt_MaximumMember_5d59926a-ae8b-4fb3-b0c7-389c6491e1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_171971f6-0dd9-40c8-9be5-b4255016004d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b5c95e4d-f4cc-464c-b650-c8302268e554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b5c95e4d-f4cc-464c-b650-c8302268e554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6cebd3cf-39f2-4c0c-aa3e-b7a3fa6cf7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6cebd3cf-39f2-4c0c-aa3e-b7a3fa6cf7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_392e7978-0094-4d2a-83f0-c870a0523853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_392e7978-0094-4d2a-83f0-c870a0523853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a9450282-a88c-4a79-a299-e219049b3e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a9450282-a88c-4a79-a299-e219049b3e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_918b3c01-47d5-47b0-a394-3987e2b88049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_918b3c01-47d5-47b0-a394-3987e2b88049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_efe26f7e-cb06-476d-bdeb-f84ac8121f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81571c07-2677-48ea-85dc-cef7cb87fe97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_efe26f7e-cb06-476d-bdeb-f84ac8121f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquityFairValueAssumptionsforESPPDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_28b219b6-d6a6-4248-a7c3-690753bfad36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ed92d7-4196-49f4-8a95-ea5f716410b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_28b219b6-d6a6-4248-a7c3-690753bfad36" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ed92d7-4196-49f4-8a95-ea5f716410b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_653847e2-6e9b-4643-9277-4ce90f6819e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ed92d7-4196-49f4-8a95-ea5f716410b6" xlink:to="loc_us-gaap_AwardTypeAxis_653847e2-6e9b-4643-9277-4ce90f6819e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd52edd-75ba-451c-abfb-f7c6e287656f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_653847e2-6e9b-4643-9277-4ce90f6819e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd52edd-75ba-451c-abfb-f7c6e287656f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8d3fdad5-78c5-441c-a636-d51a4b78a5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd52edd-75ba-451c-abfb-f7c6e287656f" xlink:to="loc_us-gaap_EmployeeStockMember_8d3fdad5-78c5-441c-a636-d51a4b78a5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ed92d7-4196-49f4-8a95-ea5f716410b6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86bd93c2-cd1d-4e9e-b74d-2aaee1beca0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86bd93c2-cd1d-4e9e-b74d-2aaee1beca0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8674bc1b-4d57-4fe3-86c3-2308bb13951e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8674bc1b-4d57-4fe3-86c3-2308bb13951e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ce9cfefa-bfde-4a62-a1c6-cc36e3bd7ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ce9cfefa-bfde-4a62-a1c6-cc36e3bd7ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_86890344-aadf-459f-a017-cab896eb35fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_56c3a4ba-d3dc-48ce-9256-09f8b02a0b60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_86890344-aadf-459f-a017-cab896eb35fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#StockholdersEquityUnrecognizedCompensationCostDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4572a8f0-ae75-4f97-8b7d-cbc8dc417dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d217e3b-8406-4acc-9ce4-1bbfd9a2c22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4572a8f0-ae75-4f97-8b7d-cbc8dc417dbb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d217e3b-8406-4acc-9ce4-1bbfd9a2c22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd8faeb0-25c2-44f9-bf0d-19cc83223106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d217e3b-8406-4acc-9ce4-1bbfd9a2c22d" xlink:to="loc_us-gaap_AwardTypeAxis_bd8faeb0-25c2-44f9-bf0d-19cc83223106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bd8faeb0-25c2-44f9-bf0d-19cc83223106" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a23a2f8c-b59b-4424-bd0f-531af0550293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a23a2f8c-b59b-4424-bd0f-531af0550293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_da7c1c98-7a36-4533-b14e-a3fe147046a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:to="loc_us-gaap_RestrictedStockMember_da7c1c98-7a36-4533-b14e-a3fe147046a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dcb0d4f9-ed6e-421b-a378-336d749a0053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dcb0d4f9-ed6e-421b-a378-336d749a0053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4bd17f73-25b1-4c1a-9987-d9c3a4a464ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af1c6914-3e4c-4975-88de-ad1bdde769f2" xlink:to="loc_us-gaap_EmployeeStockMember_4bd17f73-25b1-4c1a-9987-d9c3a4a464ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c36e26e2-6dfa-4c38-809e-d73116df1467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d217e3b-8406-4acc-9ce4-1bbfd9a2c22d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c36e26e2-6dfa-4c38-809e-d73116df1467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eabfd427-6054-4459-b8b8-58cef724bf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c36e26e2-6dfa-4c38-809e-d73116df1467" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eabfd427-6054-4459-b8b8-58cef724bf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_576bfaa7-00ae-4ff8-9dfe-f8e116817095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c36e26e2-6dfa-4c38-809e-d73116df1467" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_576bfaa7-00ae-4ff8-9dfe-f8e116817095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aace82f0-7eeb-4a2b-a866-9b4f6e2d1909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c36e26e2-6dfa-4c38-809e-d73116df1467" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aace82f0-7eeb-4a2b-a866-9b4f6e2d1909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="zntl-20220630.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2aa488b1-e126-4385-bc05-22d2cae4c213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_659c4ef5-72a9-4200-b15f-af999618c625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2aa488b1-e126-4385-bc05-22d2cae4c213" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_659c4ef5-72a9-4200-b15f-af999618c625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="zntl-20220630.xsd#CommitmentandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20fca720-956f-403a-bcc1-98b8f9ff5d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6e018940-bdee-4772-b75b-4ef122c237e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20fca720-956f-403a-bcc1-98b8f9ff5d4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6e018940-bdee-4772-b75b-4ef122c237e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_795539ec-6c78-4dae-9c2a-64e8bf8f7665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_795539ec-6c78-4dae-9c2a-64e8bf8f7665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b653e40b-4eaf-4f78-a212-5731ba4033c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b653e40b-4eaf-4f78-a212-5731ba4033c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88bba736-2efc-4872-a947-1881f5d5dbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88bba736-2efc-4872-a947-1881f5d5dbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8bd652f1-aebb-42e1-b4d9-898930c87298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8bd652f1-aebb-42e1-b4d9-898930c87298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f61d0fe8-88a3-450d-aec4-33f8a7500d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f61d0fe8-88a3-450d-aec4-33f8a7500d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_e16d986d-dcb6-4192-8d5c-4092968c1bf6" xlink:href="zntl-20220630.xsd#zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:to="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_e16d986d-dcb6-4192-8d5c-4092968c1bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9b6c3355-4c17-41da-9d9e-95733c3815f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9b6c3355-4c17-41da-9d9e-95733c3815f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4f50fef3-ab56-4966-8c66-d5f6aa780968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4f50fef3-ab56-4966-8c66-d5f6aa780968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c54fad27-3fda-4a90-b44f-f37ed0346b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:to="loc_us-gaap_OperatingLeaseLiability_c54fad27-3fda-4a90-b44f-f37ed0346b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_87390c1d-26a4-4195-b27e-47c662e44100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_87390c1d-26a4-4195-b27e-47c662e44100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_58d53ca7-3e71-4337-a86f-edd1b80d210c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89e09a3a-d015-44c2-86e3-315578c966c6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_58d53ca7-3e71-4337-a86f-edd1b80d210c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="zntl-20220630.xsd#CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f389c00-ff83-4b8e-8cf4-2d33dd549f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_31aecb1c-4623-4f8b-b957-1700d5eda853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f389c00-ff83-4b8e-8cf4-2d33dd549f74" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_31aecb1c-4623-4f8b-b957-1700d5eda853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/NetLossPerCommonShare" xlink:type="simple" xlink:href="zntl-20220630.xsd#NetLossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/NetLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5f03268b-07a2-4f6d-a591-25dfff202aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_77f9dda8-5c5b-4c0a-aab5-9745ffab19bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5f03268b-07a2-4f6d-a591-25dfff202aa9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_77f9dda8-5c5b-4c0a-aab5-9745ffab19bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/NetLossPerCommonShareTables" xlink:type="simple" xlink:href="zntl-20220630.xsd#NetLossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/NetLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7e766756-2834-41e9-8a2d-1dcae0a2e87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_748361dc-3ace-4403-ad59-8575caf37414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7e766756-2834-41e9-8a2d-1dcae0a2e87f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_748361dc-3ace-4403-ad59-8575caf37414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_bb28c0c7-7fa3-4b75-ad30-0df48477b12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7e766756-2834-41e9-8a2d-1dcae0a2e87f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_bb28c0c7-7fa3-4b75-ad30-0df48477b12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#NetLossPerCommonShareCalculationDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dbc6e615-d99f-4b88-80b9-d5d60ecd69dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_EarningsPerShareNumeratorAbstract_d475c416-5745-4a6f-9f8f-428e14d50bbf" xlink:href="zntl-20220630.xsd#zntl_EarningsPerShareNumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dbc6e615-d99f-4b88-80b9-d5d60ecd69dd" xlink:to="loc_zntl_EarningsPerShareNumeratorAbstract_d475c416-5745-4a6f-9f8f-428e14d50bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cb0c6b45-c4f9-4016-9377-d2c59c2202d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_zntl_EarningsPerShareNumeratorAbstract_d475c416-5745-4a6f-9f8f-428e14d50bbf" xlink:to="loc_us-gaap_NetIncomeLoss_cb0c6b45-c4f9-4016-9377-d2c59c2202d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_EarningsPerShareDenominatorAbstract_659f9fab-4bb1-4280-95b0-072199591002" xlink:href="zntl-20220630.xsd#zntl_EarningsPerShareDenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dbc6e615-d99f-4b88-80b9-d5d60ecd69dd" xlink:to="loc_zntl_EarningsPerShareDenominatorAbstract_659f9fab-4bb1-4280-95b0-072199591002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d26e22b6-0cc1-435f-b154-ae3b4cf20bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_zntl_EarningsPerShareDenominatorAbstract_659f9fab-4bb1-4280-95b0-072199591002" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d26e22b6-0cc1-435f-b154-ae3b4cf20bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3509e353-d4d7-470a-869b-053d2f6e2b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_zntl_EarningsPerShareDenominatorAbstract_659f9fab-4bb1-4280-95b0-072199591002" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3509e353-d4d7-470a-869b-053d2f6e2b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_86d72a13-5927-4ad5-b2c0-7e7bc680963a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dbc6e615-d99f-4b88-80b9-d5d60ecd69dd" xlink:to="loc_us-gaap_EarningsPerShareBasic_86d72a13-5927-4ad5-b2c0-7e7bc680963a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_538fcfa2-89b4-4c1c-9585-b633ddf57f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dbc6e615-d99f-4b88-80b9-d5d60ecd69dd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_538fcfa2-89b4-4c1c-9585-b633ddf57f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#NetLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ec1b5523-b464-4bb6-919a-4c708f58a15b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b8afe4-6e4e-4492-ab3f-226f76425f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ec1b5523-b464-4bb6-919a-4c708f58a15b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b8afe4-6e4e-4492-ab3f-226f76425f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9a0b8a6-95cb-4327-826a-5883bf779b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b8afe4-6e4e-4492-ab3f-226f76425f88" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9a0b8a6-95cb-4327-826a-5883bf779b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_53951165-fdf1-4fd2-be92-6ec9107c0b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9a0b8a6-95cb-4327-826a-5883bf779b11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_53951165-fdf1-4fd2-be92-6ec9107c0b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bed665ad-3902-4bfc-a309-6779fada882f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_53951165-fdf1-4fd2-be92-6ec9107c0b65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bed665ad-3902-4bfc-a309-6779fada882f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ba4536da-7cf5-4578-8f41-0aaa721ab2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_53951165-fdf1-4fd2-be92-6ec9107c0b65" xlink:to="loc_us-gaap_RestrictedStockMember_ba4536da-7cf5-4578-8f41-0aaa721ab2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b784aeee-e5dd-4e97-b2d0-1d427acbf0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_53951165-fdf1-4fd2-be92-6ec9107c0b65" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b784aeee-e5dd-4e97-b2d0-1d427acbf0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4fa75c8e-931c-42c4-a1e9-7366c4a524e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b8afe4-6e4e-4492-ab3f-226f76425f88" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4fa75c8e-931c-42c4-a1e9-7366c4a524e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c91405c-eae9-4df0-a722-bdacddd30f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4fa75c8e-931c-42c4-a1e9-7366c4a524e7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c91405c-eae9-4df0-a722-bdacddd30f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/RelatedPartyDisclosures" xlink:type="simple" xlink:href="zntl-20220630.xsd#RelatedPartyDisclosures"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/RelatedPartyDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_23181897-837f-496f-acde-cde1f18cf71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1e731486-41d2-4971-953e-247cb7f47f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_23181897-837f-496f-acde-cde1f18cf71c" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1e731486-41d2-4971-953e-247cb7f47f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" xlink:type="simple" xlink:href="zntl-20220630.xsd#RelatedPartyDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_d9cac570-2475-41b0-8cbb-92098364d08d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_450ee3e6-9c61-431e-a165-b3bf8d7c457f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_d9cac570-2475-41b0-8cbb-92098364d08d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_450ee3e6-9c61-431e-a165-b3bf8d7c457f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2cbba8c7-4389-4b19-9983-74f56ddee343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_450ee3e6-9c61-431e-a165-b3bf8d7c457f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2cbba8c7-4389-4b19-9983-74f56ddee343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ffb2cdf7-e6da-43bd-89e0-0632fe254fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2cbba8c7-4389-4b19-9983-74f56ddee343" xlink:to="loc_us-gaap_RelatedPartyDomain_ffb2cdf7-e6da-43bd-89e0-0632fe254fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_97019691-58aa-4ee0-99c7-d6ddf24e2c0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ffb2cdf7-e6da-43bd-89e0-0632fe254fd4" xlink:to="loc_srt_AffiliatedEntityMember_97019691-58aa-4ee0-99c7-d6ddf24e2c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5f3e016e-f7c9-41e9-8c20-0e22f1cd94b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_450ee3e6-9c61-431e-a165-b3bf8d7c457f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5f3e016e-f7c9-41e9-8c20-0e22f1cd94b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c8e2ca8d-ea8e-41f6-b702-a1f36e944fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5f3e016e-f7c9-41e9-8c20-0e22f1cd94b0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c8e2ca8d-ea8e-41f6-b702-a1f36e944fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_MasterServicesAgreementMember_3dc36a3f-6554-4d32-8f11-ad6aec65ff0d" xlink:href="zntl-20220630.xsd#zntl_MasterServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c8e2ca8d-ea8e-41f6-b702-a1f36e944fe6" xlink:to="loc_zntl_MasterServicesAgreementMember_3dc36a3f-6554-4d32-8f11-ad6aec65ff0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_18159ec4-7601-428f-bd44-ec4006792716" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_450ee3e6-9c61-431e-a165-b3bf8d7c457f" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_18159ec4-7601-428f-bd44-ec4006792716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_28c44657-9e72-47eb-8632-02ca9637b45d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_18159ec4-7601-428f-bd44-ec4006792716" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_28c44657-9e72-47eb-8632-02ca9637b45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraTherapeuticsLtdMember_3e8def63-7091-4525-99e9-c36e675c5883" xlink:href="zntl-20220630.xsd#zntl_ZenteraTherapeuticsLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_28c44657-9e72-47eb-8632-02ca9637b45d" xlink:to="loc_zntl_ZenteraTherapeuticsLtdMember_3e8def63-7091-4525-99e9-c36e675c5883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_beea7d54-7ed4-4323-b515-abe3b039724a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_450ee3e6-9c61-431e-a165-b3bf8d7c457f" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_beea7d54-7ed4-4323-b515-abe3b039724a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_760747ba-6d7f-4ba0-881f-a7e3d97d2cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_beea7d54-7ed4-4323-b515-abe3b039724a" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_760747ba-6d7f-4ba0-881f-a7e3d97d2cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_86224cfd-ec80-4203-87a5-fff5fd8a1a5f" xlink:href="zntl-20220630.xsd#zntl_ResearchAndDevelopmentExpenseReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_beea7d54-7ed4-4323-b515-abe3b039724a" xlink:to="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_86224cfd-ec80-4203-87a5-fff5fd8a1a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_b0e93390-86a5-4bce-a772-c3312acda1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_beea7d54-7ed4-4323-b515-abe3b039724a" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_b0e93390-86a5-4bce-a772-c3312acda1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  !=T    %" (    _G-)-    +TE$051X7NW!
M@0D   P"H/Y_NLX8##4!                     ."E @   '!A^!J&:=?V
..5SP     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@  !.0    (" (   #6:K>A    34E$051X7NW7
M,1$ ( S P/HW78X5 V3X'^,@,P   %"RNV\"  " O\PJ    .685  " G#NK
L"P   #%F%0  @!RS"@  0(Y9!0  (.< =.6$JQ*FZ;<     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502256960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Zentalis Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3607803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1359 Broadway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">433-3791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock,$0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZNTL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,983,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001725160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502450800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,143<span></span>
</td>
<td class="nump">$ 59,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">400,078<span></span>
</td>
<td class="nump">280,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,405<span></span>
</td>
<td class="nump">10,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">467,626<span></span>
</td>
<td class="nump">350,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,218<span></span>
</td>
<td class="nump">8,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease&#160;right-of-use&#160;assets</a></td>
<td class="nump">43,305<span></span>
</td>
<td class="nump">44,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">11,938<span></span>
</td>
<td class="nump">7,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,736<span></span>
</td>
<td class="nump">3,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Zentera Therapeutics</a></td>
<td class="nump">30,406<span></span>
</td>
<td class="nump">37,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,627<span></span>
</td>
<td class="nump">2,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">567,856<span></span>
</td>
<td class="nump">454,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,041<span></span>
</td>
<td class="nump">11,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">36,595<span></span>
</td>
<td class="nump">32,354<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">48,636<span></span>
</td>
<td class="nump">43,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">1,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">45,072<span></span>
</td>
<td class="nump">44,459<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">95,033<span></span>
</td>
<td class="nump">90,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June&#160;30, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 250,000,000 shares authorized; 56,969,118 and 45,490,764 shares issued and outstanding at June&#160;30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">961,205<span></span>
</td>
<td class="nump">723,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,779)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(486,993)<span></span>
</td>
<td class="num">(359,559)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">472,490<span></span>
</td>
<td class="nump">363,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">472,823<span></span>
</td>
<td class="nump">364,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 567,856<span></span>
</td>
<td class="nump">$ 454,507<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775503297808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">56,969,118<span></span>
</td>
<td class="nump">45,490,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">56,969,118<span></span>
</td>
<td class="nump">45,490,764<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502309984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 43,825<span></span>
</td>
<td class="nump">$ 44,770<span></span>
</td>
<td class="nump">$ 89,937<span></span>
</td>
<td class="nump">$ 83,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">19,636<span></span>
</td>
<td class="nump">10,362<span></span>
</td>
<td class="nump">31,403<span></span>
</td>
<td class="nump">22,315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">63,461<span></span>
</td>
<td class="nump">55,132<span></span>
</td>
<td class="nump">121,340<span></span>
</td>
<td class="nump">105,479<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(63,461)<span></span>
</td>
<td class="num">(55,132)<span></span>
</td>
<td class="num">(121,340)<span></span>
</td>
<td class="num">(105,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_InvestmentAndOtherIncomeExpense', window );">Investment and other income, net</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(63,037)<span></span>
</td>
<td class="num">(55,017)<span></span>
</td>
<td class="num">(120,490)<span></span>
</td>
<td class="num">(105,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,089<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(68,392)<span></span>
</td>
<td class="num">(55,062)<span></span>
</td>
<td class="num">(127,629)<span></span>
</td>
<td class="num">(105,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(1,031)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Zentalis</a></td>
<td class="num">$ (68,357)<span></span>
</td>
<td class="num">$ (54,574)<span></span>
</td>
<td class="num">$ (127,434)<span></span>
</td>
<td class="num">$ (104,475)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share outstanding, basic (in dollars per share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (2.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share outstanding, diluted (in dollars per share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (2.58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Common shares used in computing net loss per share, basic (in shares)</a></td>
<td class="nump">51,117<span></span>
</td>
<td class="nump">40,738<span></span>
</td>
<td class="nump">48,197<span></span>
</td>
<td class="nump">40,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Common shares used in computing net loss per share, diluted (in shares)</a></td>
<td class="nump">51,117<span></span>
</td>
<td class="nump">40,738<span></span>
</td>
<td class="nump">48,197<span></span>
</td>
<td class="nump">40,549<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_InvestmentAndOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment and Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_InvestmentAndOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775503185856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (68,392)<span></span>
</td>
<td class="num">$ (55,062)<span></span>
</td>
<td class="num">$ (127,629)<span></span>
</td>
<td class="num">$ (105,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation effects</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(670)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1,654)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive loss</a></td>
<td class="num">(69,062)<span></span>
</td>
<td class="num">(55,018)<span></span>
</td>
<td class="num">(129,283)<span></span>
</td>
<td class="num">(105,448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interests</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(1,031)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Zentalis</a></td>
<td class="num">$ (69,027)<span></span>
</td>
<td class="num">$ (54,530)<span></span>
</td>
<td class="num">$ (129,088)<span></span>
</td>
<td class="num">$ (104,417)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775503061200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">$ (68,392)<span></span>
</td>
<td class="num">$ (55,062)<span></span>
</td>
<td class="num">$ (127,629)<span></span>
</td>
<td class="num">$ (105,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">692<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,911<span></span>
</td>
<td class="nump">19,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of premiums on marketable securities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,089<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,663)<span></span>
</td>
<td class="num">(3,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025<span></span>
</td>
<td class="nump">4,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,278<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,223)<span></span>
</td>
<td class="num">(83,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(277,576)<span></span>
</td>
<td class="num">(77,812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,000<span></span>
</td>
<td class="nump">159,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(728)<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122,304)<span></span>
</td>
<td class="nump">80,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,297<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,416<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(386)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,713<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,814)<span></span>
</td>
<td class="num">(3,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,584<span></span>
</td>
<td class="nump">56,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">57,770<span></span>
</td>
<td class="nump">52,434<span></span>
</td>
<td class="nump">57,770<span></span>
</td>
<td class="nump">52,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of&#160;non-cash&#160;investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Accrued deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">55,143<span></span>
</td>
<td class="nump">49,170<span></span>
</td>
<td class="nump">55,143<span></span>
</td>
<td class="nump">49,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">2,627<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
<td class="nump">2,627<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash reported in the Condensed Consolidated Statement of Cash Flows</a></td>
<td class="nump">$ 57,770<span></span>
</td>
<td class="nump">$ 52,434<span></span>
</td>
<td class="nump">$ 57,770<span></span>
</td>
<td class="nump">$ 52,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775498757888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 333,377<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 509,339<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="num">$ (200,834)<span></span>
</td>
<td class="nump">$ 24,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">19,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock in connection with restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(1,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Zentalis</a></td>
<td class="num">(104,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">247,609<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">529,019<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="num">(305,309)<span></span>
</td>
<td class="nump">23,764<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">333,377<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">509,339<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="num">(200,834)<span></span>
</td>
<td class="nump">24,795<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,491,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">364,482<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">723,593<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="num">(359,559)<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">292,638<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">519,030<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="num">(250,735)<span></span>
</td>
<td class="nump">24,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">9,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock in connection with restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(488)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Zentalis</a></td>
<td class="num">(54,574)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,574)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">247,609<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">529,019<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="num">(305,309)<span></span>
</td>
<td class="nump">23,764<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,491,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">364,482<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">723,593<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="num">(359,559)<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">26,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">(1,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs</a></td>
<td class="nump">$ 209,297<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">209,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock in connection with restricted stock unit vesting (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock in connection with restricted stock unit vesting</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net (in shares)</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net</a></td>
<td class="nump">$ 803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued under employee stock purchase plan</a></td>
<td class="nump">612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Zentalis</a></td>
<td class="num">(127,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">472,823<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">961,205<span></span>
</td>
<td class="num">(1,779)<span></span>
</td>
<td class="num">(486,993)<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,584,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">315,666<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">734,997<span></span>
</td>
<td class="num">(1,109)<span></span>
</td>
<td class="num">(418,636)<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">16,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">(670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs</a></td>
<td class="nump">209,297<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">209,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock in connection with restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net</a></td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Zentalis</a></td>
<td class="num">(68,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 472,823<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 961,205<span></span>
</td>
<td class="num">$ (1,779)<span></span>
</td>
<td class="num">$ (486,993)<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775588427808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Business</a></td>
<td class="text">Organization and Business<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zentalis Pharmaceuticals, Inc. (&#8220;Zentalis&#8221;, &#8220;We&#8221; or the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#8217;s tangible assets are held in the United States.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div>Substantial doubt about an entity&#8217;s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after the date that the interim unaudited condensed consolidated financial statements for the quarter ended June&#160;30, 2022 are issued.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775508052848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Unaudited Financial Statements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Interim Unaudited Financial Statements</a></td>
<td class="text">Interim Unaudited Financial Statements <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company&#8217;s audited financial statements but does not include all disclosures required by U.S. GAAP. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February 24, 2022. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated balance sheet to conform to the current period presentation.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements include our wholly-owned subsidiaries and variable interest entities (&#8220;VIEs&#8221;) for the periods in which we determined we were the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1)&#160;the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2)&#160;the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented, we have not provided any other material financial or other support to our VIEs that we were not contractually required to provide.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity method is used to account for investments in which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded on the balance sheet, and the share of net income or losses of equity investments is recognized on a one quarter lag in investment and other income (expense), net.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775595582448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Significant Transactions</a></td>
<td class="text">Significant Transactions<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentera Therapeutics</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we became a majority common shareholder of Zentera Therapeutics, Ltd., a Shanghai-based clinical-stage biopharmaceutical company focused on developing cancer therapeutics (&#8220;Zentera&#8221;), concurrent with its Series A convertible preferred stock offering. The financial position and results of operations of Zentera were included in our consolidated financial statements from the date of the initial investment as a result of our control of the entity and our determination that we were the primary beneficiary of Zentera. In July 2021, Zentera completed a Series B convertible preferred stock offering which diluted our investment to a position of less than majority owned. Upon review of the facts and circumstances, together with the authoritative accounting literature, we determined that while Zentera is a VIE, consolidation of Zentera is no longer appropriate. After the July 2021 Series B convertible preferred offering in which we did not participate, our review concluded that we ceased to be the primary beneficiary of Zentera as our equity ownership was reduced and changes were made to the corporate governance of Zentera. As a result, we no longer individually have the ability to direct the activities that most significantly impact Zentera's economic performance. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in July 2021, the financial position and results of operations of Zentera are no longer included in our consolidated financial statements. During the period of deconsolidation we measured the fair value of our retained investment in Zentera using the backsolve method with consideration for a lack of marketability. An equity method investment of $30.4 million is recorded on our balance sheet at June&#160;30, 2022. This amount represents our maximum exposure to loss as a result of our involvement with Zentera. A deferred tax liability of $6.4 million representing the tax impact of the unrealized gain on deconsolidation is recorded on our balance sheet at June&#160;30, 2022. A gain of $51.6 million, measured as the difference between the fair value of our retained noncontrolling interest together with the carrying amount of the Zentera noncontrolling interest, and the carrying amount of Zentera&#8217;s assets and liabilities was recognized during the year ended December 31, 2021. The difference between the carrying amount of our investment in Zentera and our portion of the Zentera net assets was $5.2 million as of </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022. This difference is accounted for in our equity method investment analogous to in-process research and development. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2020, each of our subsidiaries Zeno Alpha, Inc., K-Group Alpha, Inc., Zeno Management Inc., and K-Group Beta, Inc. entered into a collaboration and royalty-bearing license agreement with Zentera, which we refer to as the &#8220;Zentera Sublicenses,&#8221; pursuant to which we collaborate with Zentera on the development and commercialization of ZN-c3, ZN-d5 and ZN-c5, collectively referred to as the &#8220;Collaboration Products,&#8221; respectively, in the People&#8217;s Republic of China, Macau, Hong Kong and Taiwan, which is referred to as the &#8220;Zentera Collaboration Territory.&#8221; Under each Zentera Sublicense, Zentera will lead development, and upon regulatory approval, the commercialization, of the collaboration products in the Zentera Collaboration Territory.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Zentera Sublicenses, Zentera is responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of the costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Prior to the deconsolidation of Zentera in July 2021, these costs were eliminated in consolidation. For the three and six months ended June&#160;30, 2022, the amounts incurred under this arrangement totaled $3.0 million and $5.1 million, respectively, and are presented as contra-research and development expense in the unaudited condensed consolidated statement of operations. A corresponding receivable is recorded within prepaid expenses and other current assets on the unaudited condensed consolidated balance sheet. We have not provided material financial or other support to Zentera during the periods ended June&#160;30, 2022 and 2021 that was not previously contractually required.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504762832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kalyra Pharmaceuticals, Inc.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;21, 2017, we acquired $4.5&#160;million of Kalyra&#8217;s Series B Preferred Stock representing a 25% equity interest in Kalyra for purposes of entering the analgesics therapeutic research space. The acquisition price was paid entirely in cash.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the authoritative guidance, we concluded that Kalyra is a business consisting of inputs, employees, intellectual property and processes capable of producing outputs. Additionally, we have concluded that Kalyra is a variable interest entity, we are the primary beneficiary and have the power to direct the activities that most significantly affect Kalyra&#8217;s economic performance through common management and our board representation. Prior to December 21, 2017, the Company and Kalyra transacted for the delivery of research and development services and support. The financial position and results of operations of Kalyra have been included in our consolidated financial statements from the date of the initial investment.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant with authoritative guidance, we have recorded the identifiable assets, liabilities and noncontrolling interests in the VIE at their fair value upon initial consolidation. The identified goodwill is comprised of the workforce and expected synergies from combining the entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otal assets and liabilities of Kalyra as of June&#160;30, 2022 and December&#160;31, 2021 are immaterial. The liabilities recognized as a result of consolidating Kalyra do not </span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represent additional claims on our general assets. Pursuant to the authoritative guidance, the equity interest in Kalyra not owned by Zentalis is reported as a noncontrolling interest on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,368)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of Zentera</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,899)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504596080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June&#160;30, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sixty-two</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of our available-for-sale debt securities with a fair market value of $399.2 million were in a gross unrealized loss position of $1.8 million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, our intent to sell or the likelihood that we would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of June&#160;30, 2022, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">because we do not intend to sell these securities, and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.044%"><tr><td style="width:1.0%"/><td style="width:51.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.256%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one but within five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:19.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.357%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,166&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,166&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,653&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,653&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale marketable securities:</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value<br/></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,826&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy during the six months ended June&#160;30, 2022. We had no instruments that were classified within Level&#160;3 as of June&#160;30, 2022 or December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504655536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Assets</a></td>
<td class="text">Prepaid Expenses and Other Assets<div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software licenses and maintenance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign R&amp;D credit refund</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zentera receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,680&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets, current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,405&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504661648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, net<div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(792)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,218&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended June&#160;30, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span> was approximately $348 thousand and $119 thousand, respectively. Depreciation and amortization expense for the six months ended June&#160;30, 2022 and 2021 was approximately $692 and $198 thousand, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504651056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,595&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504632656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Direct Offering of Common Stock</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2022, pursuant to our Registration Statement on Form S-3 (Registration No. 333-255769), filed with the SEC on May 4, 2021, we completed a direct offering of common stock to Pfizer Inc. (&#8220;Pfizer&#8221;). We issued and sold 953,834 shares of our common stock at an offering price of $26.21 per share. The total gross proceeds for the offering were approximately $25.0 million, before deducting offering expenses of $0.3 million payable by us. The parties have entered into an agreement to collaborate to advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells. We did not grant Pfizer any economic ownership or control of ZN-c3 or the rest of our pipeline. $4.2&#160;million of the gross offering proceeds received from Pfizer represented a premium in excess of the fair value of our common stock on the date of the investment. This amount has been recorded as accrued research and development expense on the unaudited condensed consolidated balance sheet and will be recognized as a reduction of research and development expense over the term of the collaboration agreement.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-on Offering of Common Stock</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2022, we completed a follow-on offering in which we issued and sold 10,330,000 shares of common stock at a public offering price of $19.38 per share. The total gross proceeds for the offering were approximately $200.2 million, before deducting offering expenses of $11.4 million payable by us.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, the Company&#8217;s Board of Directors adopted, and the Company&#8217;s stockholders approved the 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;), which allows for grants to selected employees, consultants and non-employee members of the Board of Directors. We currently grant stock options and restricted stock units (&#8220;RSUs&#8221;), under the 2020 Plan. The number of common shares available for issuance under the 2020 Plan is the sum of (1) 5,600,000 shares of common stock; plus (2) any shares forfeited from the unvested restricted shares of our common stock issued upon conversion of unvested Class B common units (up to 1,250,000 shares); plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ending December 31, 2021 and continuing to, and including, the fiscal year ending December 31, 2030, equal to the lesser of (a) 5% of the shares of common </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by our Board of Directors. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, 8,300,142 shares were subject to outstanding awards under the 2020 Plan and 284,429 shares were available for future grants of share-based awards under the 2020 Plan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company&#8217;s Board of Directors approved the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (the &#8220;2022 Inducement Plan&#8221;), which is used exclusively for the grant of equity awards to new employees as an inducement material to the employees&#8217; entering into employment with the Company. The Board of Directors has initially reserved 1,500,000 shares of the Company&#8217;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share based awards was comprised of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.276%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense for the six months ended June&#160;30, 2022 and 2021 includes $0 and  $138&#160;thousand, respectively, of share-based compensation expense for employees, consultants and directors of Zentera.  </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.340%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,610&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted is equal to the closing price of the Company&#8217;s common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes model. Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company uses the &#8220;simplified method&#8221; for estimating the expected term of employee options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero. The fair value of the stock options granted during the six months ended June&#160;30, 2022 and June&#160;30, 2021 was determined with the following assumptions:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"><tr><td style="width:1.0%"/><td style="width:44.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.6% - 80.5%%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.1% - 76.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 - 6.5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 - 6.2</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 3.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5% - 1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, the Company&#8217;s Board of Directors adopted, and the Company&#8217;s stockholders approved the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which was subsequently amended and restated effective March 15, 2021. The maximum aggregate number of shares of the Company&#8217;s common stock available for issuance under the ESPP at June 30, 2022 was 1,969,608. Under the terms of the ESPP, the Company&#8217;s employees may elect to have up to 20% of their compensation, up to a maximum of $21,250 per calendar year, withheld to purchase shares of the Company&#8217;s common stock for a purchase price equal to 85% of the lower of the fair market value per share (at closing) of the Company&#8217;s common stock on (i) the first trading day of a six-month offering period, or (ii) the applicable purchase date, defined as the last trading day of the six-month offering period. The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP are as follows:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.846%"><tr><td style="width:1.0%"/><td style="width:48.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.652%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense Summary</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.256%"><tr><td style="width:1.0%"/><td style="width:31.878%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.878%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized <br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining <br/>Weighted-Average Recognition Period <br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, we issued 42.0&#160;thousand shares of common stock in connection with the exercises of stock options. For the six months ended June&#160;30, 2022, 0.1 million shares of common stock </span></div>issued in conjunction with certain restricted stock awards (&#8220;RSAs&#8221;), vested. Outstanding stock options, unvested RSAs, and unvested RSUs totaling approximately 7.8&#160;million shares, 0.2&#160;million shares and 0.5&#160;million shares of our common stock, respectively, were outstanding as of June&#160;30, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504710640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may be involved in various disputes, including lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any of these claims could subject us to costly legal expenses. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the consolidated financial statements not misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in our consolidated financial statements. While we do generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, or our policy limits may be inadequate to fully satisfy any damage awards or settlement. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings that require a loss liability to be recorded.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include payments related to operating leases. Approximate annual future minimum operating lease payments as of June&#160;30, 2022 are as follows (in thousands): </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,929)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: current portion</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The weighted-average remaining lease term of our operating leases is approximately 10.3 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504596080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">Net Loss Per Common Share <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share were calculated as follows (in thousands except per share amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"/><td style="width:52.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.34)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.34)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential and dilutive securities, which include outstanding stock options, unvested RSAs and unvested RSUs have been excluded from the computation of diluted net loss per common share as the effect would be anti-dilutive. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents have been excluded from the calculations of diluted net loss per common share because their inclusion would be antidilutive (in thousands).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"/><td style="width:52.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504623072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Disclosures</a></td>
<td class="text">Related Party Disclosures<div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tempus</span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kimberly Blackwell, M.D., our Chief Executive Officer and a member of our Board of Directors, was previously employed by Tempus Labs, Inc. ("Tempus") and now serves as an advisor of Tempus. The Company entered into a Master Services Agreement with Tempus in December 2020 to provide data licensing and research services. There were immaterial and $1.0 million fees incurred for services performed by Tempus for the six months ended June&#160;30, 2022 and 2021, respectively.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zentera</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin D. Bunker, Ph.D., our Chief Operating Officer, serves as a member of the Board of Directors of Zentera. Accordingly, the Company identifies Zentera as a related party.</span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered into the Zentera Sublicenses, pursuant to which we collaborate with Zentera on the development and comm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ercialization of the Collaboration Products in the Zentera Collaboration Territory. Under the terms of the Zentera Sublicenses, Zentera is responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are responsible for the costs of developing the Collaboration Products </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of its costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Prior to the deconsolidation of Zentera during July 2021, these costs were eliminated in consolidation. For the six months ended June 30, 2022, the amounts incurred under this arrangement totaled $5.1 million and are presented as contra-research and development expense in the consolidated statement of operations. </span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022 we divested an early stage asset to Zentera for $0.2 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502343120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Unaudited Financial Statements (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company&#8217;s audited financial statements but does not include all disclosures required by U.S. GAAP. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February 24, 2022. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated balance sheet to conform to the current period presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements include our wholly-owned subsidiaries and variable interest entities (&#8220;VIEs&#8221;) for the periods in which we determined we were the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1)&#160;the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2)&#160;the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented, we have not provided any other material financial or other support to our VIEs that we were not contractually required to provide.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity method is used to account for investments in which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded on the balance sheet, and the share of net income or losses of equity investments is recognized on a one quarter lag in investment and other income (expense), net.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504655536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock', window );">Reconciliation of Equity Attributable to Noncontrolling Interest</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,368)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of Zentera</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,899)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ReconciliationOfNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504897136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Components of Available-for-sale Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Maturities of Available-for-sale Debt Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.044%"><tr><td style="width:1.0%"/><td style="width:51.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.256%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one but within five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:19.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.357%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,166&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,166&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,653&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,653&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale marketable securities:</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value<br/></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,826&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775505107552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses and Other Assets</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software licenses and maintenance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign R&amp;D credit refund</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zentera receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,680&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets, current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,405&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504623072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, net</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(792)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,218&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504668944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,595&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502389520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share based awards was comprised of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.276%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.340%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,610&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text">The fair value of the stock options granted during the six months ended June&#160;30, 2022 and June&#160;30, 2021 was determined with the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"><tr><td style="width:1.0%"/><td style="width:44.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.6% - 80.5%%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.1% - 76.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 - 6.5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 - 6.2</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 3.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5% - 1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions, ESPP</a></td>
<td class="text">The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.846%"><tr><td style="width:1.0%"/><td style="width:48.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.652%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Share-based Compensation Expense by Type of Share-based Award</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.256%"><tr><td style="width:1.0%"/><td style="width:31.878%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.878%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized <br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining <br/>Weighted-Average Recognition Period <br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775505245904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments</a></td>
<td class="text">Approximate annual future minimum operating lease payments as of June&#160;30, 2022 are as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,929)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: current portion</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504648416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Unit</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share were calculated as follows (in thousands except per share amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"/><td style="width:52.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.34)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.34)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Unit</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents have been excluded from the calculations of diluted net loss per common share because their inclusion would be antidilutive (in thousands).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"/><td style="width:52.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502222944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Zentera Therapeutics</a></td>
<td class="nump">$ 30,406<span></span>
</td>
<td class="nump">$ 30,406<span></span>
</td>
<td class="nump">$ 37,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsLtdMember', window );">Zentera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">Deferred tax liability, deconsolidation of Zentera</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Zentera, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">In-process research and development</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_ResearchAndDevelopmentExpenseReimbursements', window );">Contra-research and development expense</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ResearchAndDevelopmentExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ResearchAndDevelopmentExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502797888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Narrative (Details) - Kalyra Pharmaceuticals, Inc.<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 21, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Cash payments to acquire interest</a></td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=zntl_KalyraPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=zntl_KalyraPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502416080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">$ (35)<span></span>
</td>
<td class="num">$ (488)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">$ (1,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest at end of period</a></td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">VIE, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">528<span></span>
</td>
<td class="nump">$ 24,795<span></span>
</td>
<td class="nump">24,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of Zentera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest at end of period</a></td>
<td class="nump">$ 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775503075872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 401,854<span></span>
</td>
<td class="nump">$ 280,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,781)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">400,078<span></span>
</td>
<td class="nump">280,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">255,912<span></span>
</td>
<td class="nump">199,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(763)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">255,149<span></span>
</td>
<td class="nump">199,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,063<span></span>
</td>
<td class="nump">10,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">5,004<span></span>
</td>
<td class="nump">10,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">18,997<span></span>
</td>
<td class="nump">20,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(78)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">18,919<span></span>
</td>
<td class="nump">20,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">121,882<span></span>
</td>
<td class="nump">50,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(881)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 121,006<span></span>
</td>
<td class="nump">$ 50,785<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502735808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of available-for-sale securities in unrealized loss position | security</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Debt securities fair market value</a></td>
<td class="nump">$ 399.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair market value of available-for-sale securities in unrealized loss position</a></td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775503151296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">$ 396,203<span></span>
</td>
<td class="nump">$ 258,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one but within five years</a></td>
<td class="nump">3,875<span></span>
</td>
<td class="nump">21,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 400,078<span></span>
</td>
<td class="nump">$ 280,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269825-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775501721520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 49,166<span></span>
</td>
<td class="nump">$ 43,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">400,078<span></span>
</td>
<td class="nump">280,173<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">449,244<span></span>
</td>
<td class="nump">323,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">49,166<span></span>
</td>
<td class="nump">43,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">121,006<span></span>
</td>
<td class="nump">50,785<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">170,172<span></span>
</td>
<td class="nump">94,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">279,072<span></span>
</td>
<td class="nump">229,388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">279,072<span></span>
</td>
<td class="nump">229,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">255,149<span></span>
</td>
<td class="nump">199,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">255,149<span></span>
</td>
<td class="nump">199,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">5,004<span></span>
</td>
<td class="nump">10,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">5,004<span></span>
</td>
<td class="nump">10,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">18,919<span></span>
</td>
<td class="nump">20,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">18,919<span></span>
</td>
<td class="nump">20,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">121,006<span></span>
</td>
<td class="nump">50,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">121,006<span></span>
</td>
<td class="nump">50,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,223<span></span>
</td>
<td class="nump">43,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,223<span></span>
</td>
<td class="nump">43,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">18,943<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">18,943<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775501636976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 2,324<span></span>
</td>
<td class="nump">$ 990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_PrepaidSoftwareLicenseAndMaintenance', window );">Prepaid software licenses and maintenance</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_ForeignResearchAndDevelopmentCreditRefund', window );">Foreign R&amp;D credit refund</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_PrepaidResearchAndDevelopmentCosts', window );">Prepaid research and development expenses</a></td>
<td class="nump">15,909<span></span>
</td>
<td class="nump">11,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Zentera receivable</a></td>
<td class="nump">2,981<span></span>
</td>
<td class="nump">2,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_OtherPrepaidExpense', window );">Other prepaid expenses</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total prepaid expenses and other assets</a></td>
<td class="nump">24,343<span></span>
</td>
<td class="nump">17,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Less long-term portion</a></td>
<td class="nump">11,938<span></span>
</td>
<td class="nump">7,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other assets, current</a></td>
<td class="nump">$ 12,405<span></span>
</td>
<td class="nump">$ 10,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ForeignResearchAndDevelopmentCreditRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Research and Development Credit Refund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ForeignResearchAndDevelopmentCreditRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_OtherPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Prepaid Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_OtherPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_PrepaidResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_PrepaidResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_PrepaidSoftwareLicenseAndMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Software License And Maintenance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_PrepaidSoftwareLicenseAndMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775498718576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 9,546<span></span>
</td>
<td class="nump">$ 8,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(1,328)<span></span>
</td>
<td class="num">(792)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,218<span></span>
</td>
<td class="nump">8,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_LaboratoryEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">2,585<span></span>
</td>
<td class="nump">2,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">4,649<span></span>
</td>
<td class="nump">4,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_OfficeEquipmentAndFurnitureMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="nump">2,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_OfficeEquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_OfficeEquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502010112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 348<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775503000832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 23,745<span></span>
</td>
<td class="nump">$ 18,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee expenses</a></td>
<td class="nump">8,195<span></span>
</td>
<td class="nump">9,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal expenses</a></td>
<td class="nump">1,372<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_AccruedGeneralAndAdministrativeCostsCurrent', window );">Accrued general and administrative expenses</a></td>
<td class="nump">856<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Taxes payable</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">971<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 36,595<span></span>
</td>
<td class="nump">$ 32,354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_AccruedGeneralAndAdministrativeCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued General And Administrative Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_AccruedGeneralAndAdministrativeCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775499449456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 18, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued upon vesting of certain RSAs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_ProceedsFromIssuanceOfCommonStockGross', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm', window );">Generally expected vesting term of the option contract (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,969,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">ESPP maximum percent of compensation to contribute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Maximum contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">ESPP purchase price of common stock, percent of market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-Option equity instruments, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-Option equity instruments, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zntl_A2020IncentiveAwardPlanMember', window );">The 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-Option equity instruments, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,300,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zntl_A2022EmploymentInducementIncentiveAwardPlanMember', window );">2022 Inducement Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zntl_ZenteraStockPlanMember', window );">Zentera Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee benefits and share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">953,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_ProceedsFromIssuanceOfCommonStockGross', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Follow-On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold (in shares)</a></td>
<td class="nump">10,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 19.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_ProceedsFromIssuanceOfCommonStockGross', window );">Gross proceeds from issuance of common stock</a></td>
<td class="nump">$ 200,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance fees and expenses</a></td>
<td class="nump">$ 11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | The 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized to be issued under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease', window );">Percent of common stock outstanding used as threshold to calculate shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B | The 2020 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized to be issued under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=zntl_A2020IncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=zntl_A2020IncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=zntl_A2022EmploymentInducementIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=zntl_A2022EmploymentInducementIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=zntl_ZenteraStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=zntl_ZenteraStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=zntl_DirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=zntl_DirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=zntl_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=zntl_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502232192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Share-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 16,764<span></span>
</td>
<td class="nump">$ 9,919<span></span>
</td>
<td class="nump">$ 26,911<span></span>
</td>
<td class="nump">$ 19,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">5,155<span></span>
</td>
<td class="nump">3,923<span></span>
</td>
<td class="nump">10,197<span></span>
</td>
<td class="nump">7,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 11,609<span></span>
</td>
<td class="nump">$ 5,996<span></span>
</td>
<td class="nump">$ 16,714<span></span>
</td>
<td class="nump">$ 12,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775498739376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 16,764<span></span>
</td>
<td class="nump">$ 9,919<span></span>
</td>
<td class="nump">$ 26,911<span></span>
</td>
<td class="nump">$ 19,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">12,524<span></span>
</td>
<td class="nump">4,820<span></span>
</td>
<td class="nump">20,302<span></span>
</td>
<td class="nump">8,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember', window );">RSAs and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 4,130<span></span>
</td>
<td class="nump">$ 4,989<span></span>
</td>
<td class="nump">$ 6,397<span></span>
</td>
<td class="nump">$ 10,829<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502237344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Fair Value Assumptions for Stock Options (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">73.60%<span></span>
</td>
<td class="nump">75.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">80.50%<span></span>
</td>
<td class="nump">76.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (in years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775505136592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Fair Value Assumptions for ESPP (Details) - Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">73.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775499281520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Unrecognized Compensation Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense, stock options</a></td>
<td class="nump">$ 117,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">3 years 3 months 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense, other than options</a></td>
<td class="nump">$ 569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense, other than options</a></td>
<td class="nump">$ 13,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense, other than options</a></td>
<td class="nump">$ 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775498534528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remaining)</a></td>
<td class="nump">$ 1,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">6,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">6,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">6,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">7,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">46,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments:</a></td>
<td class="nump">74,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(27,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">46,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(1,733)<span></span>
</td>
<td class="num">$ (1,453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">$ 45,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775504780640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted-average remaining lease term (in years)</a></td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502977360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Calculation (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_EarningsPerShareNumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Zentalis</a></td>
<td class="num">$ (68,357)<span></span>
</td>
<td class="num">$ (54,574)<span></span>
</td>
<td class="num">$ (127,434)<span></span>
</td>
<td class="num">$ (104,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_EarningsPerShareDenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic (in shares)</a></td>
<td class="nump">51,117<span></span>
</td>
<td class="nump">40,738<span></span>
</td>
<td class="nump">48,197<span></span>
</td>
<td class="nump">40,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted (in shares)</a></td>
<td class="nump">51,117<span></span>
</td>
<td class="nump">40,738<span></span>
</td>
<td class="nump">48,197<span></span>
</td>
<td class="nump">40,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (2.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (2.58)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_EarningsPerShareDenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Denominator</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_EarningsPerShareDenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_EarningsPerShareNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Numerator</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_EarningsPerShareNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502413776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per unit (in shares)</a></td>
<td class="nump">8,522<span></span>
</td>
<td class="nump">5,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per unit (in shares)</a></td>
<td class="nump">7,828<span></span>
</td>
<td class="nump">4,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per unit (in shares)</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per unit (in shares)</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139775502826080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsLtdMember', window );">Zentera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_zntl_ResearchAndDevelopmentExpenseReimbursements', window );">Contra-research and development expense</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Divestiture of early stage asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Master Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ResearchAndDevelopmentExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ResearchAndDevelopmentExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=zntl_MasterServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=zntl_MasterServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>zntl-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:zntl="http://www.zentalis.com/20220630">
    <link:schemaRef xlink:href="zntl-20220630.xsd" xlink:type="simple"/>
    <context id="i0159adf80fe24766a99096c944e7113d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0fad63ac05584e07ac5c9962a8206885_I20220808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2022-08-08</instant>
        </period>
    </context>
    <context id="iccb4b475a51d40e8b00847b50b411bb2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iea2c4236a736402f8b183ddfe915fbac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebc81bbd37134c8eb0227cec32909507_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib9ed70ab246449f7ad763aa871442e27_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7de8308633374277be1cf29a7379f05c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i68ef53f7e30c4224922d1c036f351731_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i236b3f20c24e41bcaf1eabdc79111516_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia821fe0c70284513b205269e31ca09b2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id940216a8696400e848431386ab32d09_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if0dac22d55a34bd28a43e412291b2c2b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id0f23d89cf3e409993a8b87de890b508_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i80ce1ccd32b74f8f8a7021b222292233_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0c7c555285da411b8145cd0a64ff4ebc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1477287ae34d47408281cf92c3a86f66_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0c76f003ce48452898b59c299efffc95_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2527dedabd09467e89489d14d48942a7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i96fbfda562ed4251a1b2805e02ad7a13_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9ce25123e7d14a9b9e92dd7ef27fe5d7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1d0b89a422d645d2aa975073d6e626b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f0a552beb41460d83598cfec7140d03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7134b43188594f1d9a9a436a5c024ce9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3823d94562d44181906d6305eee20514_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e0de465fbe24b4aa737c25edf79d252_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if85ae8da9e964278af67cede62e6983c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic4332f30a3194687b4ba50860e682c2b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if0c2ece8395d4a878161c8c8bb291feb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i43893269fb514e64a84c7e6836451dab_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2ef202afe8ee4eb29a4286d1984f00e7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ided707c746324c85b99713cfd1f60a31_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i03d6b1d603f9454bada2bf2d6fdaa5c1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i21f5e3fdc0fe4e9abfb1657db69da8bd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i80ee52788a39497ba42814448e5acd22_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6308a92c792f4032aaf192b33d9c615d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7b3fd0d327c647f78519c288eabd7f13_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i347024f2e9ac451aa83164fdbd8d84fb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icbd060dd7d6d4fdaacff3da2f0e05098_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i81639f8b21714c96a90b50f632406ac7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5bd2f39625b8425cb7b9aff6a3b1ad28_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia20e533d81cd4d089a7df4436d153672_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie3cda99f88cd4c479dc77d9d5c051b50_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i21514c2c23bb4db989a9c7ce3badc7fd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia7db1887be0d42278bf24dd6a2ec6df7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic5ccef6083cd4247a6cad6d8beaa3058_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5299c81f26ad457bb9835f9d797f5a03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5eeadd6ca63a4a009a94aec18e5f62ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48ff54a3aa3044e380b7048409865567_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03477a9c65e34b128f96193a6cb1c953_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad53b504c7e14abca92ca74a46a07bbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iace2148088e643e387d7d86483ae4b8d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie52aa73782a849fdaecd219b51650553_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9542e31388864d3fa1e1d2fdc142b92d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if7f89106493a4483a75fab892a90d82f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5dc3ef43b05d4b4dab34c1ceec3046b9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if476a59e1bdc46f883f2c9950f451fe9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6e26a8f313d147c899372ec9a56c6c9f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28f7d3ab172046598fe7dcdf7ffe8f23_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iebb85fbd06c842c9b31131732a081288_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7de358016f734a82a094e8ea4e3ef006_D20171221-20171221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">zntl:KalyraPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-21</startDate>
            <endDate>2017-12-21</endDate>
        </period>
    </context>
    <context id="i8d7db02ca8a24de29d50872ad8205e42_I20171221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">zntl:KalyraPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-21</instant>
        </period>
    </context>
    <context id="id24bd10e6cc1406aa94762219ea0191d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46207b8cc83c4695ab95cd14b58c03ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73d19273bd804eacb01818f0b3a0b9d6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib00284ea6567450d9a07b5d0bfc0d9e5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib28e2c6f83d847d8be4563b4c9a90eb4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id40490dd28724db79d06f9d951fd8acd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia08925ab72244888b246b83bf82d4bed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i15c97d107fb94103966853f5642d3a1f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i383f5a4611ed4191a940e97fba342d26_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a784f336c5848288d83ed9d20e70b9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i110e2b4c6b064ff1879c74f20d1b098c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if49279cde51c4e31967f61ac9e91cb63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5ff574a6987485e9ac601606fe4d9da_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0fb9f2afeb6f4a43b04688b32531d990_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6b1dd88afc154d7e9984607fd2f2361f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic005cf5c954c4ba5a5ccbadc693d99df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c59b2bf1e764cc0a86c5735a369a0b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48e3c115b00a44bcb25b3dfd9e2e39bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1784ad3c83464579a9a8932fbfe9e598_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3761f588efbc4816ae10a0d889c298a0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i57dc0a40165448f8bf4b5ba74eb5fbe9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i46288b24c23d45c4a2463d010ab350b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i608e66c1af484e6ea5e6d792778ed0d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00cfbef488eb418e92919ac20ba1da40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie217c38e068b4202a61b214386647f10_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2698997899df495f800f9a30eeb074a9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia69616f0679f42df9238c4e3b6a87d27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5b1bda2786c420f874b7c2291657c6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i039e0cbb5b7c4c79b65983450a20902b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idd81d064eadd4c7bbc89294f9f777699_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i86dee2bcbeca454481688921ef7935de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7c31a2718ae40079432589bc1229566_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41189229a4bd4e0caa35a0023153383e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i99e4123972044834800ac21f54e63593_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iba6229d21df445539c2d6bf8fb6643fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccc8555322b941b49bd02a7e8765116e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60f5fb8ff10c4cf1bb7736f876b4d48e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9278009b9182442fbf3eb96697bd192b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7014a45299de49eaa9a9df4f081d723f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31315f6337ae4500b1642edc83c1261b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81c66ad195194fe2b48c0fbe96882389_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1017f13dbbd0440db64ac087de0a0e59_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i27efde771a3e4e359c95a3ae8018c908_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fa741359e4446b9920193e9ce94fa0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia32cba1a7c584481935d18ab5b6e3052_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id5f415d9e7e84e6390821b2aeca98c24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd1665e0a46248bdbece57a6438e0879_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iee10f69caf0d40ba94ea1e00633d0b5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1bd11cea6cd49bfbd84c09bd6e1c561_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ica13a2bb8504414b9caaf996da34fe6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f99dba567644e889110abb67dd9dc2e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0b3eed1bbd49485bba0b0ac55976ff5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b47b8406e04436e962c6cf09f56a781_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ife734a5c6be14dfeb15a20d958641bd0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f1b085c0bc6418984b4a5652a0f3059_D20220429-20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">zntl:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="i569a69ed2aa54cd6a4ae5aa666ff442a_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">zntl:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="ifc20ff4317e549b195078a8c6d397c35_D20220429-20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="if223d394e54b4750aa978efb34cba0d1_D20220518-20220518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">zntl:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="i5136c20b0b3448728a094b8bde8584e3_I20220518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">zntl:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-18</instant>
        </period>
    </context>
    <context id="i1195842e7bad4796adc5d3f33b370980_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i451d05a387bc4e28bfaa0c622d3e53b7_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i224274cfab6347e4af0e47b9f95e96ac_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i84a3bb6a8e4a4aadaca19939a0d400a0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibcb817854a7743afa79c27dc1d29457d_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2022EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i0a591ae027674ec48804343c4347f2e3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ieed3e9f3f3094029b5dfa3ccb2bc6788_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if24f63e9218a428f8bf2dd3b117c02ec_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8ee6e27237af4336b5fc9bd4e9f7d48a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i83eb79dfc5df4e11adeeb75938b1d7f0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i44dd3cb1c0574feea2624c386be77ec7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if83d444b0887436c87fef11dcef2e86a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaa2780f94d8d42288f13f874db45fd67_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie30a5375c819427c8694c4b2774b9e9b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:ZenteraStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i412b968f7b08436b9aa7f54bde3682ea_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:ZenteraStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i644b2805dacd408b8e97b86dd46abb55_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i94e8c09b4a3445298e64940b137301f9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i575ec7487094412380df5d1d84056a75_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8047842fd47f4f2f8278a39d6e1230e3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib3f359d04969451b952bf5cfc0d87b34_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7b6d6db52cc441d5980a322a0c13d3c3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9beff74796b74e7a9a2e80f6198c9feb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i47314e35042849da943c497cbcc052f6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2715dfb0dea34fb2ba4b3115eda88efe_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3f29867c289543609894effb0ecd7862_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaef89f53ab20478f942e34396c28ad99_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2e90d2bfdd054eeebf7e538c70e8a560_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i340692408be44878952df6f49a437468_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0914aa0549284d0f8c6c232168700055_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07bfbcc2813a425a9f14affe9ac623f0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6848464a8da644618f62c064bead2a58_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0503299777e24da1a507027233084ab8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i198c9b7202d64e788574e76bcbac5063_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id3258b88db0a48128947746c61ed2f7b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2c688c67b897412c81a7a8199ad39a9d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if609506238d0461eac509be96d92ec01_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i382cf4d3dcbd43b484285308648a79c9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2ca05b7f8ef4c3cb04522bb5e0f01f0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id6f3ca918b964800a78e9ae83baa07fd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64103a278a8e4aa7ac8509ba56369056_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3dff9cfed3a14c8d8c88926052fcee95_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1bdc5cf068c740ae97ed383848a4f8b2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zntl:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i806b4c764dc54e6ebde6e45a7c23760d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zntl:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>zntl:security</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80L2ZyYWc6MmQwOTE4NWJkYmFmNDcxNWI2NjBkMTkzODZiOWIxNWUvdGFibGU6YmY3Zjg2YzA0MzA5NDJkNDhmZTEwYjdkNGU0NmJlYjIvdGFibGVyYW5nZTpiZjdmODZjMDQzMDk0MmQ0OGZlMTBiN2Q0ZTQ2YmViMl8wLTEtMS0xLTQ5Nzk4_4151f502-e12d-4550-a4d1-80e77c747d54">0001725160</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80L2ZyYWc6MmQwOTE4NWJkYmFmNDcxNWI2NjBkMTkzODZiOWIxNWUvdGFibGU6YmY3Zjg2YzA0MzA5NDJkNDhmZTEwYjdkNGU0NmJlYjIvdGFibGVyYW5nZTpiZjdmODZjMDQzMDk0MmQ0OGZlMTBiN2Q0ZTQ2YmViMl8xLTEtMS0xLTQ5Nzk4_eb95f121-ec07-4cf3-beff-f97c64ab6a9f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80L2ZyYWc6MmQwOTE4NWJkYmFmNDcxNWI2NjBkMTkzODZiOWIxNWUvdGFibGU6YmY3Zjg2YzA0MzA5NDJkNDhmZTEwYjdkNGU0NmJlYjIvdGFibGVyYW5nZTpiZjdmODZjMDQzMDk0MmQ0OGZlMTBiN2Q0ZTQ2YmViMl8yLTEtMS0xLTQ5Nzk4_41544732-0385-4385-ad41-0bdf3137d07e">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80L2ZyYWc6MmQwOTE4NWJkYmFmNDcxNWI2NjBkMTkzODZiOWIxNWUvdGFibGU6YmY3Zjg2YzA0MzA5NDJkNDhmZTEwYjdkNGU0NmJlYjIvdGFibGVyYW5nZTpiZjdmODZjMDQzMDk0MmQ0OGZlMTBiN2Q0ZTQ2YmViMl8zLTEtMS0xLTQ5Nzk4_e8e8fad9-e2e7-4c74-a8a3-098e2afbd3f7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80L2ZyYWc6MmQwOTE4NWJkYmFmNDcxNWI2NjBkMTkzODZiOWIxNWUvdGFibGU6YmY3Zjg2YzA0MzA5NDJkNDhmZTEwYjdkNGU0NmJlYjIvdGFibGVyYW5nZTpiZjdmODZjMDQzMDk0MmQ0OGZlMTBiN2Q0ZTQ2YmViMl80LTEtMS0xLTQ5Nzk4_463b0f2e-5bc4-42ab-96d8-91af609f5c16">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i806b4c764dc54e6ebde6e45a7c23760d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83Ni9mcmFnOmI4MzkxZWJlZTNkMzRiMmQ4ZDJmODM1Y2ViMzYzZjFiL3RhYmxlOmVhMjU4Zjc5MjhlODQxNjRiZWZjOGQ5OTFmZWM5YjA4L3RhYmxlcmFuZ2U6ZWEyNThmNzkyOGU4NDE2NGJlZmM4ZDk5MWZlYzliMDhfMi0xLTEtMS00OTc5OA_26a40ade-14e7-4ddc-9b34-21847f711147"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <dei:DocumentType
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjg1_5b7c17af-ece2-465b-b36f-78a084998e94">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjc3_6b3bef6e-c245-4cef-93fe-9958936dd49a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjQ_81185903-745d-453e-b226-8b5be6cdcc0d">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjc4_4977d22f-36e0-461c-b353-a37758ddec27">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjg3_93986343-1e0f-4ef1-904a-bc3ed636f17e">001-39263</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjgw_8211754b-0911-4e9d-85b2-666fce593be6">Zentalis Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF8wLTAtMS0xLTQ5Nzk4_61af9708-7da0-4731-8d65-0d0981cbcf0f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF8wLTEtMS0xLTQ5Nzk4_3149a429-c58e-4f04-b30b-1eeffb750275">82-3607803</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF8zLTAtMS0xLTQ5Nzk4L3RleHRyZWdpb246YTdhODI5N2I0YTdjNDdmZWI3Yjg2OWU3MjQ3MjAxMzdfNA_007d76bb-06e3-49fb-b009-f88351301d30">1359 Broadway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF8zLTAtMS0xLTQ5Nzk4L3RleHRyZWdpb246YTdhODI5N2I0YTdjNDdmZWI3Yjg2OWU3MjQ3MjAxMzdfOA_7a5b6f69-7955-427a-852d-46ea9db25913">Suite 1710</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF81LTAtMS0xLTQ5Nzk4_ac42fc54-e6e6-402c-b502-ba6d79d3c126">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF82LTAtMS0xLTQ5Nzk4_7b635cd4-03fd-4290-b1ee-7412e931ccd3">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6Nzk4OTQ0ZTQ1ZjE4NGE0NWFmNWJlNjZiMjMxMTMzNWQvdGFibGVyYW5nZTo3OTg5NDRlNDVmMTg0YTQ1YWY1YmU2NmIyMzExMzM1ZF82LTEtMS0xLTQ5Nzk4_6d1d1629-85c4-40ca-a01e-2c2e8553f95d">10018</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjg5_1b39af9e-269d-479e-affc-c260385afbc9">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjc5_a517fbd3-a02e-40a9-a4e3-4d12e7edf67c">433-3791</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6NWI3NWM1YTcxZmRjNGQwMDhiZmRkOTI2NTc0NDA4ZmIvdGFibGVyYW5nZTo1Yjc1YzVhNzFmZGM0ZDAwOGJmZGQ5MjY1NzQ0MDhmYl8xLTAtMS0xLTQ5Nzk4_a2c52fde-32a2-44a7-a314-e4b876b87c0e">Common Stock,$0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6NWI3NWM1YTcxZmRjNGQwMDhiZmRkOTI2NTc0NDA4ZmIvdGFibGVyYW5nZTo1Yjc1YzVhNzFmZGM0ZDAwOGJmZGQ5MjY1NzQ0MDhmYl8xLTEtMS0xLTQ5Nzk4_cc9a8fe4-9a1d-47f4-ad2a-bf2848bb3c1e">ZNTL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6NWI3NWM1YTcxZmRjNGQwMDhiZmRkOTI2NTc0NDA4ZmIvdGFibGVyYW5nZTo1Yjc1YzVhNzFmZGM0ZDAwOGJmZGQ5MjY1NzQ0MDhmYl8xLTItMS0xLTQ5Nzk4L3RleHRyZWdpb246ZWRhNDYxYzUzNWU0NGQyMmIzNmY0NzY5Y2M2YjU1ZWJfNA_0d2799db-3a3c-4a3e-baf7-f76ff7959530">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjgy_067cbf7d-435c-4d58-86a3-93a46b6e4b41">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjg0_d63907cc-6c73-4900-b965-d7c710539de4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6MGUxZDdiOGQxNjA3NGQ4Y2IxNDVhZTA2NDI3OGYwNjQvdGFibGVyYW5nZTowZTFkN2I4ZDE2MDc0ZDhjYjE0NWFlMDY0Mjc4ZjA2NF8wLTAtMS0xLTQ5Nzk4_fd10ab48-44ee-4266-bdcc-ecf5c5e6a026">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6MGUxZDdiOGQxNjA3NGQ4Y2IxNDVhZTA2NDI3OGYwNjQvdGFibGVyYW5nZTowZTFkN2I4ZDE2MDc0ZDhjYjE0NWFlMDY0Mjc4ZjA2NF8xLTQtMS0xLTQ5Nzk4_d6d7b2de-07af-4893-a211-79006b240488">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGFibGU6MGUxZDdiOGQxNjA3NGQ4Y2IxNDVhZTA2NDI3OGYwNjQvdGFibGVyYW5nZTowZTFkN2I4ZDE2MDc0ZDhjYjE0NWFlMDY0Mjc4ZjA2NF8yLTQtMS0xLTQ5Nzk4_f60f94bb-5509-4579-91a7-51990d341fd2">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjgz_4018d65c-b502-4cb4-a970-f815d1a03061">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0fad63ac05584e07ac5c9962a8206885_I20220808"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8xL2ZyYWc6NGY3ZTJiMzFiZDc2NDQ1ODg2NzI1YjZjZWNmMzMyNzAvdGV4dHJlZ2lvbjo0ZjdlMmIzMWJkNzY0NDU4ODY3MjViNmNlY2YzMzI3MF8yMjA5_9e1cee55-fb96-474f-bfa4-4f03440be707"
      unitRef="shares">56983641</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNC0xLTEtMS00OTc5OA_6a97ad7e-b9b7-4101-b433-81056d448357"
      unitRef="usd">55143000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNC0zLTEtMS00OTc5OA_1c38a8c4-6b7c-4650-9252-a0424b783ed1"
      unitRef="usd">59714000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNS0xLTEtMS00OTc5OA_81464d48-8449-4d89-ad3c-9d99fc646ec3"
      unitRef="usd">400078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNS0zLTEtMS00OTc5OA_f755af62-29a9-4342-bc03-35a0d0997d62"
      unitRef="usd">280173000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNy0xLTEtMS00OTc5OA_aa816d77-4bbd-40e6-b3ce-8d0d7b0dbba5"
      unitRef="usd">12405000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfNy0zLTEtMS00OTc5OA_82bdd202-b180-44d5-ba56-04675f63fb56"
      unitRef="usd">10640000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfOC0xLTEtMS00OTc5OA_602786f1-307a-46de-ae88-c70e20e17060"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfOC0zLTEtMS00OTc5OA_974bfbd2-d8c6-4a38-9bd7-b16cd268e743"
      unitRef="usd">243000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfOS0xLTEtMS00OTc5OA_3ecb845c-71fb-436f-80b6-480c6bff694a"
      unitRef="usd">467626000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfOS0zLTEtMS00OTc5OA_3e320ed9-25fc-4037-a001-c6abdbf6bece"
      unitRef="usd">350770000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTAtMS0xLTEtNDk3OTg_3c932885-9d1b-466a-895e-4f9185e79913"
      unitRef="usd">8218000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTAtMy0xLTEtNDk3OTg_8fed9416-705c-4b0d-9d15-e751c8e1f3ec"
      unitRef="usd">8148000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTEtMS0xLTEtNDk3OTg_ecaa8538-85d1-4590-af5d-531146b05ddf"
      unitRef="usd">43305000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTEtMy0xLTEtNDk3OTg_32750e73-a9c2-45aa-8107-b1b6e1e33158"
      unitRef="usd">44691000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTItMS0xLTEtNDk3OTg_4c4bbe6f-3578-42dc-a7da-f3a220ed08d0"
      unitRef="usd">11938000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTItMy0xLTEtNDk3OTg_69d4d801-9ba0-4077-9cac-1f89e46f7b97"
      unitRef="usd">7040000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:Goodwill
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTMtMS0xLTEtNDk3OTg_a280d341-7959-4162-b91e-fd18bc345e3f"
      unitRef="usd">3736000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTMtMy0xLTEtNDk3OTg_a0a9eb8a-183e-4ec1-a381-fd1b8dd94d17"
      unitRef="usd">3736000</us-gaap:Goodwill>
    <us-gaap:EquityMethodInvestments
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTUtMS0xLTEtNDk3OTg_60f88bb8-5e5d-4f17-b98b-c5c7d616774d"
      unitRef="usd">30406000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTUtMy0xLTEtNDk3OTg_0d7e03ea-cd29-4e21-8cad-fcf3a26da510"
      unitRef="usd">37495000</us-gaap:EquityMethodInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTYtMS0xLTEtNDk3OTg_fcd03bdc-bc4e-40e4-ac28-82677713a237"
      unitRef="usd">2627000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTYtMy0xLTEtNDk3OTg_845e6d26-1825-4e38-abb0-cb44aad515f1"
      unitRef="usd">2627000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTctMS0xLTEtNDk3OTg_820375c7-efda-4cfe-befc-4e69b9e1cd69"
      unitRef="usd">567856000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMTctMy0xLTEtNDk3OTg_bffc7a9b-7b63-4ebb-93fa-76560c38a3ea"
      unitRef="usd">454507000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjAtMS0xLTEtNDk3OTg_bc335ac5-be23-4682-a465-fffc74d0b49d"
      unitRef="usd">12041000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjAtMy0xLTEtNDk3OTg_e98ab0c2-ed98-4c4c-aeed-7c683080ce38"
      unitRef="usd">11590000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjEtMS0xLTEtNDk3OTg_df12dc43-0184-40e6-b837-e59f40cbb6c8"
      unitRef="usd">36595000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjEtMy0xLTEtNDk3OTg_b8dc83e6-95fd-4b7f-8da6-1e94d041d502"
      unitRef="usd">32354000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjItMS0xLTEtNDk3OTg_ac998b69-d51a-4dc4-8047-47782f6e8e0e"
      unitRef="usd">48636000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjItMy0xLTEtNDk3OTg_7b555e00-c55b-43e6-b8ef-d8df45972325"
      unitRef="usd">43944000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjMtMS0xLTEtNDk3OTg_52e395a4-9848-4470-9b57-196d9cf9d8fa"
      unitRef="usd">1325000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjMtMy0xLTEtNDk3OTg_92a22ef2-dbbf-4e4d-98d4-cb503b73d961"
      unitRef="usd">1622000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjQtMS0xLTEtNDk3OTg_add33fb4-cd56-432b-98b4-57ec2ca37064"
      unitRef="usd">45072000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjQtMy0xLTEtNDk3OTg_bc51fb72-439c-4484-832b-01168343f8f7"
      unitRef="usd">44459000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjUtMS0xLTEtNDk3OTg_8af896db-dec0-44a1-b1f4-8b239d9548cf"
      unitRef="usd">95033000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjUtMy0xLTEtNDk3OTg_a52e1e2b-b9a9-4179-b259-8b12cf2284ad"
      unitRef="usd">90025000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjYtMS0xLTEtNDk3OTg_ad3d9653-89fc-42ba-85bc-71759b72cdd2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMjYtMy0xLTEtNDk3OTg_e7ce9bdc-8fab-4840-9e3c-1ccb2efd6022"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl8yMQ_09eda77e-4944-49a3-98f7-153581d4528d"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl8yMQ_fa2189f0-b042-4c64-9eed-58f42c8ef511"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl8zNQ_6666c008-1d8a-4b45-a16a-8d06f2a11698"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl8zNQ_dd3533da-5125-42f0-b306-6899656681f4"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl81Nw_083968ec-744d-431e-afe5-73ab9e2f7a5c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl81Nw_18edfe3a-853b-478b-a80c-9847f99f40c7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl81Nw_33ff35b8-39f7-4f0c-adae-7fad9f2a7f37"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjozM2FlOGJlYjAyNGQ0MmMyOWU3N2ExZTIzODI4NTMyYl81Nw_758f4ebe-46a7-45de-9745-0229cfc7e797"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMS0xLTEtNDk3OTg_1c09a36f-2b86-472e-99bc-e65393a9f7ae"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzEtMy0xLTEtNDk3OTg_5c280a24-777f-4306-bf16-a86a1770c8db"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV8xOA_b4bc2c55-b94e-4987-89f4-33bf74d54b83"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV8xOA_e0aec2c8-81ca-493b-b20e-f38e95eb9fea"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV8zMg_1e1fa4bb-6e41-4ab2-83a7-5db6bb065c25"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV8zMg_2f7ffbda-7f78-42e8-b0bc-5e8169a040d7"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV81NA_93d12d39-6153-4b88-901d-90960d055b23"
      unitRef="shares">56969118</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV81NA_ec66f52c-0dd9-415e-9965-4092460cee81"
      unitRef="shares">56969118</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV82MQ_4f29d20f-301b-48ea-a61f-0776768558e3"
      unitRef="shares">45490764</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMC0xLTEtNDk3OTgvdGV4dHJlZ2lvbjoxMjU0ZmI0NWIwYzc0Njg3OWRjOTVlY2NmN2IwYTE5OV82MQ_bed3c691-1a06-4d8c-8ad4-aa20f5ed4111"
      unitRef="shares">45490764</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMS0xLTEtNDk3OTg_adc57ef0-63c6-4a84-bf44-eed2a11b2440"
      unitRef="usd">57000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzItMy0xLTEtNDk3OTg_cea2ec33-9c8b-485d-9da0-696f0cd454a8"
      unitRef="usd">45000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzMtMS0xLTEtNDk3OTg_18687bcf-88be-4c12-8a0b-68784f6dd699"
      unitRef="usd">961205000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzMtMy0xLTEtNDk3OTg_8d58b404-0ca7-429e-af1f-82d7aa17a155"
      unitRef="usd">723593000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzQtMS0xLTEtNDk3OTg_87f02754-fb69-4882-a22f-6c1eba0842fd"
      unitRef="usd">-1779000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzQtMy0xLTEtNDk3OTg_0a649ac0-213b-48f1-a60e-2150a56ade30"
      unitRef="usd">-125000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzUtMS0xLTEtNDk3OTg_6b384fd0-3524-427f-8b1f-bcc9386b6718"
      unitRef="usd">-486993000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzUtMy0xLTEtNDk3OTg_8508e215-4ea6-4f12-b9f5-d1481834a936"
      unitRef="usd">-359559000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzYtMS0xLTEtNDk3OTg_3c6b3ed7-4b2d-43dc-9f0d-17333ea8f62f"
      unitRef="usd">472490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzYtMy0xLTEtNDk3OTg_81ece5d2-b013-465b-b9c3-2a5d3c32ac0d"
      unitRef="usd">363954000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzctMS0xLTEtNDk3OTg_208cc5d2-b02c-4023-aaee-8c5261b5fbda"
      unitRef="usd">333000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzctMy0xLTEtNDk3OTg_24f9c7c6-5bca-492d-a5f1-e1b30a2b35bb"
      unitRef="usd">528000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzgtMS0xLTEtNDk3OTg_794d6795-3fcb-4266-998c-bb785b6d5d45"
      unitRef="usd">472823000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzgtMy0xLTEtNDk3OTg_3dc3c1af-f59f-45d6-add7-55af2102ad7c"
      unitRef="usd">364482000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzktMS0xLTEtNDk3OTg_613ccf5a-06f4-4868-99f3-38ae7883616a"
      unitRef="usd">567856000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yMi9mcmFnOjQ2ZDk3MmU3NTk2ODQ0MDg4NzIyYjE1NDJiOTc1M2M0L3RhYmxlOjlhZTQzODZkMTE4NjQxMTRiYTFlZmJmNjgyYzgyN2Q3L3RhYmxlcmFuZ2U6OWFlNDM4NmQxMTg2NDExNGJhMWVmYmY2ODJjODI3ZDdfMzktMy0xLTEtNDk3OTg_5e0b2c82-1ed1-4c1b-8a08-789e7de71999"
      unitRef="usd">454507000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMy0xLTEtMS00OTc5OA_ff90c225-732a-443b-addf-5b4fa926b1bc"
      unitRef="usd">43825000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMy0zLTEtMS00OTc5OA_a1466696-1900-4664-980f-a4e48c33813e"
      unitRef="usd">44770000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMy01LTEtMS00OTc5OA_34dc45f4-4777-4b61-87c1-86863651a3af"
      unitRef="usd">89937000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMy03LTEtMS00OTc5OA_19f940fe-94be-432a-9a74-59eb98cdcd9e"
      unitRef="usd">83164000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNC0xLTEtMS00OTc5OA_fc2b5803-415f-4222-8237-5be88bced661"
      unitRef="usd">19636000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNC0zLTEtMS00OTc5OA_190f46c8-cf82-416b-ace1-aa6d36f8ee7b"
      unitRef="usd">10362000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNC01LTEtMS00OTc5OA_c8864128-ac79-48d3-b402-3934671277d4"
      unitRef="usd">31403000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNC03LTEtMS00OTc5OA_53992ad6-fdfb-4461-b134-a22c1aa915e9"
      unitRef="usd">22315000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNS0xLTEtMS00OTc5OA_82d2935c-cbf2-454b-8667-c4ff1cb036c4"
      unitRef="usd">63461000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNS0zLTEtMS00OTc5OA_8c6553fd-0fb8-41b3-90dd-b95065da9702"
      unitRef="usd">55132000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNS01LTEtMS00OTc5OA_71e894a1-62e1-4962-a02a-f270c9702552"
      unitRef="usd">121340000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNS03LTEtMS00OTc5OA_4adca2e8-ab56-41a9-9af6-e42083cb6e59"
      unitRef="usd">105479000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNi0xLTEtMS00OTc5OA_36ac06b4-e108-4a1d-83ab-1ef963e593fe"
      unitRef="usd">-63461000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNi0zLTEtMS00OTc5OA_75057527-e299-4097-9959-c3b1a0a3dfe6"
      unitRef="usd">-55132000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNi01LTEtMS00OTc5OA_af6d7829-ecaa-436a-b9eb-49dfb4ac7411"
      unitRef="usd">-121340000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfNi03LTEtMS00OTc5OA_92cd02f1-1171-4e64-8342-32b964c0c558"
      unitRef="usd">-105479000</us-gaap:OperatingIncomeLoss>
    <zntl:InvestmentAndOtherIncomeExpense
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfOC0xLTEtMS00OTc5OA_82a07c31-53d6-4cb8-be80-5c07a119b366"
      unitRef="usd">424000</zntl:InvestmentAndOtherIncomeExpense>
    <zntl:InvestmentAndOtherIncomeExpense
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfOC0zLTEtMS00OTc5OA_12dbf05a-26bc-498c-8eb5-0bde001f4687"
      unitRef="usd">115000</zntl:InvestmentAndOtherIncomeExpense>
    <zntl:InvestmentAndOtherIncomeExpense
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfOC01LTEtMS00OTc5OA_72b6e579-e783-41af-8768-07b3ac0564a1"
      unitRef="usd">850000</zntl:InvestmentAndOtherIncomeExpense>
    <zntl:InvestmentAndOtherIncomeExpense
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfOC03LTEtMS00OTc5OA_913766c2-bb1b-4929-8bc4-c68a4c083622"
      unitRef="usd">214000</zntl:InvestmentAndOtherIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTEtMS0xLTEtNDk3OTg_0b39bdbd-cf4a-40fb-a808-2f1208894dbc"
      unitRef="usd">-63037000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTEtMy0xLTEtNDk3OTg_073226b7-c013-4e27-958f-1f7c42a4df83"
      unitRef="usd">-55017000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTEtNS0xLTEtNDk3OTg_48c5da74-0860-49d3-ae75-5dd651464ed0"
      unitRef="usd">-120490000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTEtNy0xLTEtNDk3OTg_08ed23fe-8ccc-4f49-8f41-8087c6abfc3d"
      unitRef="usd">-105265000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTItMS0xLTEtNDk3OTg_c33436ae-6cee-44b9-8746-bd027d609613"
      unitRef="usd">17000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTItMy0xLTEtNDk3OTg_2d3280e8-5911-4354-bd67-310b27909c2e"
      unitRef="usd">45000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTItNS0xLTEtNDk3OTg_55a1fe6d-7e97-4fdb-a846-8b50ca255250"
      unitRef="usd">50000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTItNy0xLTEtNDk3OTg_15301a81-5d65-4e50-93d7-7ae53f5894b9"
      unitRef="usd">241000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTMtMS0xLTEtNDk3OTg_14f055fe-f7ca-40fd-a3af-ba03ac8d2d41"
      unitRef="usd">-5338000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTMtMy0xLTEtNDk3OTg_3db90376-6daa-49c7-8384-5c1ddf2eb38a"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTMtNS0xLTEtNTA4NDE_773163d0-431b-49ce-8fc2-8f1f1d109a52"
      unitRef="usd">-7089000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTMtNy0xLTEtNTA4NDE_2cead9f0-2713-4a5a-9b28-4cd162857a51"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTQtMS0xLTEtNDk3OTg_486a7943-742c-4ffb-9d48-c574a38087bc"
      unitRef="usd">-68392000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTQtMy0xLTEtNDk3OTg_3d2752e0-c7b8-4f28-a035-b79afcf4e0fb"
      unitRef="usd">-55062000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTQtNS0xLTEtNDk3OTg_96284aba-358a-430d-884e-33590b640350"
      unitRef="usd">-127629000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTQtNy0xLTEtNDk3OTg_0f1ed13d-dfef-46be-937a-e139ec1a9db2"
      unitRef="usd">-105506000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTUtMS0xLTEtNDk3OTg_4589862a-a2a5-4b14-81df-a02bcb1697c0"
      unitRef="usd">-35000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTUtMy0xLTEtNDk3OTg_ed6c0cdf-a2dd-49ac-8b97-e1742fc51349"
      unitRef="usd">-488000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTUtNS0xLTEtNDk3OTg_656e10e9-15a1-431a-a60e-214a0ff68728"
      unitRef="usd">-195000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTUtNy0xLTEtNDk3OTg_a58a1457-b27c-4fb6-a0fa-12b16f947e49"
      unitRef="usd">-1031000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTYtMS0xLTEtNDk3OTg_6b50aa4b-0444-42b4-adbd-ead9d8f5c05c"
      unitRef="usd">-68357000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTYtMy0xLTEtNDk3OTg_cea5c019-d508-4a67-826e-2db59159da3b"
      unitRef="usd">-54574000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTYtNS0xLTEtNDk3OTg_4234ebb5-d67c-4ba8-8069-a4efbdc90373"
      unitRef="usd">-127434000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTYtNy0xLTEtNDk3OTg_6c0d31c5-b596-4da8-9eec-1f348404229f"
      unitRef="usd">-104475000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctMS0xLTEtNDk3OTg_bad9a982-a522-4124-ae5b-eb07b49fa811"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctMS0xLTEtNDk3OTg_e66096fe-7207-43a1-846b-85bc65a99af6"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctMy0xLTEtNDk3OTg_0e8a9736-1a45-4c3b-8253-be6b6825b0b3"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctMy0xLTEtNDk3OTg_8241bc56-42f6-4c6d-afb2-fbb8efd2a365"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctNS0xLTEtNDk3OTg_1e45c07a-6c27-4454-9225-728936f5643d"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctNS0xLTEtNDk3OTg_f9d193bb-4837-4aee-ae25-00fc390b7ee9"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctNy0xLTEtNDk3OTg_34bda028-1533-4c6c-9878-7f24c202a85b"
      unitRef="usdPerShare">-2.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTctNy0xLTEtNDk3OTg_a7c8690a-9588-4f19-834f-610eeaf6e310"
      unitRef="usdPerShare">-2.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktMS0xLTEtNDk3OTg_a05bcf19-9f35-43fa-beb6-d349fa320c83"
      unitRef="shares">51117000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktMS0xLTEtNDk3OTg_f3cc393e-dfd5-4a35-a89d-a942ca10885b"
      unitRef="shares">51117000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktMy0xLTEtNDk3OTg_7ae4ee6f-e9c1-4e02-930c-74b31788efa2"
      unitRef="shares">40738000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktMy0xLTEtNDk3OTg_7da8f369-c61e-455e-8608-9519a8fb396c"
      unitRef="shares">40738000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktNS0xLTEtNDk3OTg_94186af4-0eb1-446c-ad0b-e63df9ea6911"
      unitRef="shares">48197000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktNS0xLTEtNDk3OTg_e6c9864c-86eb-485e-a0b1-4be072172338"
      unitRef="shares">48197000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktNy0xLTEtNDk3OTg_c3f37c0b-01cc-477c-9d92-e546d2e11b3c"
      unitRef="shares">40549000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yNS9mcmFnOjA1YzlkNjFjOWJlODQ4OGI4ZDJhNDQ0NDlhZTg5YTBhL3RhYmxlOjQyMTRmZGY4ZDJiMDRjZTJhOThlODdhNTViZmY5MzIzL3RhYmxlcmFuZ2U6NDIxNGZkZjhkMmIwNGNlMmE5OGU4N2E1NWJmZjkzMjNfMTktNy0xLTEtNDk3OTg_cdc1962c-51f3-4a8f-a07d-261c5c58a737"
      unitRef="shares">40549000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfMi0xLTEtMS00OTc5OA_486a7943-742c-4ffb-9d48-c574a38087bc"
      unitRef="usd">-68392000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfMi0zLTEtMS00OTc5OA_3d2752e0-c7b8-4f28-a035-b79afcf4e0fb"
      unitRef="usd">-55062000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfMi01LTEtMS00OTc5OA_96284aba-358a-430d-884e-33590b640350"
      unitRef="usd">-127629000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfMi03LTEtMS00OTc5OA_0f1ed13d-dfef-46be-937a-e139ec1a9db2"
      unitRef="usd">-105506000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNC0xLTEtMS00OTc5OA_68d006d3-8a55-4406-98fb-62065c74dcb0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNC0zLTEtMS00OTc5OA_bbf195f7-03d9-499d-a6f6-06a7b6541235"
      unitRef="usd">45000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNC01LTEtMS00OTc5OA_a88fc8ee-5229-42d3-a8f0-e058bc2c6442"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNC03LTEtMS00OTc5OA_ea61d788-bc27-4e0b-bfb2-073dcb913a37"
      unitRef="usd">45000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNS0xLTEtMS00OTc5OA_5d15d0ea-d3d3-4421-be79-1975d8a882e4"
      unitRef="usd">-670000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNS0zLTEtMS00OTc5OA_76f7a029-8cb8-4452-813e-51bca3a3dff1"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNS01LTEtMS00OTc5OA_9df09f02-6b18-4db4-b41f-5dbc2bf7e656"
      unitRef="usd">-1654000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNS03LTEtMS00OTc5OA_4b4ec43d-9472-44a7-b578-981b1bd43918"
      unitRef="usd">13000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNi0xLTEtMS00OTc5OA_b8df3b6f-a179-44c5-bea0-408ea405f2a7"
      unitRef="usd">-69062000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNi0zLTEtMS00OTc5OA_03d10fca-fb45-4c9f-b360-7f80550fe68a"
      unitRef="usd">-55018000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNi01LTEtMS00OTc5OA_104412ac-a3af-4f08-b068-05b3d1aafd7d"
      unitRef="usd">-129283000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNi03LTEtMS00OTc5OA_04f1eec0-bd30-4d8f-8688-20ed0c773b2c"
      unitRef="usd">-105448000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNy0xLTEtMS00OTc5OA_362b2fd6-7589-4c1d-a70e-dd847a4e44fe"
      unitRef="usd">-35000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNy0zLTEtMS00OTc5OA_334fc9bf-8de0-441a-b670-2da51087ceba"
      unitRef="usd">-488000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNy01LTEtMS00OTc5OA_834cb87b-95de-4758-826d-4580a5d080b0"
      unitRef="usd">-195000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfNy03LTEtMS00OTc5OA_dbe5c4de-cd69-4d51-8ec1-ea2998c3ba44"
      unitRef="usd">-1031000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfOC0xLTEtMS00OTc5OA_236d5cdc-0cfe-4315-a7f3-10416ff006ed"
      unitRef="usd">-69027000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfOC0zLTEtMS00OTc5OA_1393cf5a-d335-4a8d-b15c-f4ea38506820"
      unitRef="usd">-54530000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfOC01LTEtMS00OTc5OA_032483de-9a3c-462e-9247-372b4a82b16d"
      unitRef="usd">-129088000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8yOC9mcmFnOjcyYzFjOGVjYWI5ZTQ1MGI4NTkyNGVmNjhhZWQxYmEyL3RhYmxlOjQyNGI1M2IwMmNiZjRhOTdiMDkxZjFmMmI2NmRkZDU5L3RhYmxlcmFuZ2U6NDI0YjUzYjAyY2JmNGE5N2IwOTFmMWYyYjY2ZGRkNTlfOC03LTEtMS00OTc5OA_7e59f789-758a-4f85-bc7c-a72ee3aadbac"
      unitRef="usd">-104417000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMy0xLTEtMS00OTc5OA_83c0ecfd-b7de-45bf-a19a-1839e3b4dded"
      unitRef="usd">-127629000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMy0zLTEtMS00OTc5OA_a366eff4-5cb1-4b12-b100-e36fa188935d"
      unitRef="usd">-105506000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfNS0xLTEtMS00OTc5OA_5856c8f5-4f0f-4c86-b475-1ef6dd180a0b"
      unitRef="usd">692000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfNS0zLTEtMS00OTc5OA_b18596a0-a0f2-4f9c-b195-679f09b64e04"
      unitRef="usd">198000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfOS0xLTEtMS00OTc5OA_1e38a16f-6791-4898-a42e-b23a8c06f431"
      unitRef="usd">26911000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfOS0zLTEtMS00OTc5OA_603a7a21-6b94-4a18-8911-ebb7eecde1ab"
      unitRef="usd">19610000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTAtMS0xLTEtNDk3OTg_0bd479c1-1756-45cb-aa30-56f4a7b53563"
      unitRef="usd">-57000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTAtMy0xLTEtNDk3OTg_176e32f9-68e1-487f-bf97-6690afb3e4fe"
      unitRef="usd">-15000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTEtMS0xLTEtNDk3OTg_b0a1b459-1357-4480-bdf9-54a6573d5dcb"
      unitRef="usd">17000</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTEtMy0xLTEtNDk3OTg_cb525bec-a172-4c0c-9720-f654cd5aaca8"
      unitRef="usd">521000</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTItMS0xLTEtNDk3OTg_31c1155d-8af0-4e4b-afb5-cc56f56a12d7"
      unitRef="usd">-7089000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTItMy0xLTEtNDk3OTg_2098a8be-b01a-482f-b79b-7fb0cd543db4"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTUtMS0xLTEtNDk3OTg_7e0b5290-95bc-4854-a007-1c082b5ea531"
      unitRef="usd">6663000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTUtMy0xLTEtNDk3OTg_a869659f-fbea-4d9e-a31a-4be38b9fc740"
      unitRef="usd">3525000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTYtMS0xLTEtNDk3OTg_3de11aaf-d99a-4393-b4af-87a46449bcb7"
      unitRef="usd">4025000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTYtMy0xLTEtNDk3OTg_1617551d-f5b6-4f5f-9cca-6db471ecd6f6"
      unitRef="usd">4838000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTctMS0xLTEtNDk3OTg_d52e14d6-3175-4fa7-bbab-259a86fe7cc1"
      unitRef="usd">2278000</zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTctMy0xLTEtNDk3OTg_f57e3677-9788-4e84-8c4e-cf79d6789c8d"
      unitRef="usd">267000</zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTgtMS0xLTEtNDk3OTg_cb5b976a-1e87-4f31-b804-a106cd85945a"
      unitRef="usd">-93223000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMTgtMy0xLTEtNDk3OTg_4446e077-86bf-40a8-9640-4c6f2bc055d0"
      unitRef="usd">-83582000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjAtMS0xLTEtNDk3OTg_ccf83faa-0f63-41cd-887a-f38a84f5a670"
      unitRef="usd">277576000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjAtMy0xLTEtNDk3OTg_4ac22fbf-92f0-49bc-9fa5-de183a507a25"
      unitRef="usd">77812000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjEtMS0xLTEtNDk3OTg_19722e21-5e9f-4a3d-bb10-779f22547b3c"
      unitRef="usd">156000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjEtMy0xLTEtNDk3OTg_dbc40ab2-3308-4282-873d-075b34a86b86"
      unitRef="usd">159128000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjMtMS0xLTEtNDk3OTg_b33415af-1ff0-49ce-add5-62d13857a1c4"
      unitRef="usd">728000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjMtMy0xLTEtNDk3OTg_5ffe15ba-3eb3-464c-9dd3-6c74b840c1d1"
      unitRef="usd">1255000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjQtMS0xLTEtNDk3OTg_6796cc69-ff65-4e5b-a719-6d39b69552d4"
      unitRef="usd">-122304000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjQtMy0xLTEtNDk3OTg_1c4053f4-0db2-4b94-891e-22adfa3b0556"
      unitRef="usd">80061000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjctMS0xLTEtNTAyMjk_e48b51b7-93e4-4da0-999e-b2ee1f75d3f9"
      unitRef="usd">209297000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjctMy0xLTEtNTAyMjk_a9d7d363-9a2b-42a4-aa38-86946f7af8fe"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjctMS0xLTEtNDk3OTg_fcf7356e-0503-416d-8c6c-440b01b66139"
      unitRef="usd">1416000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMjctMy0xLTEtNDk3OTg_3e79e502-2f4d-4c9a-8e0f-9c58d39766b7"
      unitRef="usd">70000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzEtMS0xLTEtNDk3OTg_1f645481-2ce0-421a-81f6-472ebf04608b"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzEtMy0xLTEtNDk3OTg_9fa75b16-819d-44ac-ab09-b0a9eccf3d30"
      unitRef="usd">386000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzItMS0xLTEtNDk3OTg_68328fe0-810a-41d5-b0e6-1167754c2419"
      unitRef="usd">210713000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzItMy0xLTEtNDk3OTg_f2bed265-edd6-4d1d-9e6a-2e436db460d7"
      unitRef="usd">-316000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzMtMS0xLTEtNDk3OTg_cee7cea9-b3bf-406f-9d64-c13d8f0df159"
      unitRef="usd">-4814000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzMtMy0xLTEtNDk3OTg_6f21ff0f-f099-42fa-ba0e-29b92612cbed"
      unitRef="usd">-3837000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzQtMS0xLTEtNDk3OTg_6cabc951-0fa6-49d2-8ccd-1db3967d3a87"
      unitRef="usd">62584000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iea2c4236a736402f8b183ddfe915fbac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzQtMy0xLTEtNDk3OTg_fb4b4445-e48c-4d36-a504-bf1eef7852a1"
      unitRef="usd">56271000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzUtMS0xLTEtNDk3OTg_c5d36f95-808a-4c2f-8eb8-40e600e1d365"
      unitRef="usd">57770000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzUtMy0xLTEtNDk3OTg_083fa8b1-bcd4-41b0-aaf9-0ef5f431b3bc"
      unitRef="usd">52434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzctMS0xLTEtNDk3OTg_161c252a-3b47-43f7-a61b-402575b1520f"
      unitRef="usd">91000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfMzctMy0xLTEtNDk3OTg_f3a7d05c-8f46-4895-9419-870b7a67fb9d"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfNDEtMS0xLTEtNDk3OTg_eb668baf-e853-4acf-86e2-c8b1607e3777"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOmNkZjZiMzI2ZGQ5YTRiNjBiMTYxYWJkOTlmNGE5MWNkL3RhYmxlcmFuZ2U6Y2RmNmIzMjZkZDlhNGI2MGIxNjFhYmQ5OWY0YTkxY2RfNDEtMy0xLTEtNDk3OTg_4068f754-c96b-4ea2-841a-fd25bfb63749"
      unitRef="usd">330000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfMi0xLTEtMS00OTc5OA_dfb7655b-2497-4827-8cea-30a328f5ad0f"
      unitRef="usd">55143000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfMi0zLTEtMS00OTc5OA_1bde9f89-13e2-45f5-b087-4e72db25cfd2"
      unitRef="usd">49170000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfMy0xLTEtMS00OTc5OA_7856905f-7469-4e7e-99b6-18a921b18727"
      unitRef="usd">2627000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfMy0zLTEtMS00OTc5OA_d10800d8-af5c-410b-addd-b08a224fe6d3"
      unitRef="usd">3264000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfNC0xLTEtMS00OTc5OA_a02ab541-d119-4b37-8469-46ac5d173646"
      unitRef="usd">57770000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zMS9mcmFnOjVkMjNiZmJmMmUyYjQyMGJiNTJkMWEyM2IyMzcxYWE2L3RhYmxlOjMxNzM2NDllMDc3YzQ1M2ZhZjI0OTEyNjEyNGQyMjIyL3RhYmxlcmFuZ2U6MzE3MzY0OWUwNzdjNDUzZmFmMjQ5MTI2MTI0ZDIyMjJfNC0zLTEtMS00OTc5OA_32f96009-7e3b-45d9-a171-afc234b5e8f4"
      unitRef="usd">52434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SharesOutstanding
      contextRef="ib9ed70ab246449f7ad763aa871442e27_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC0xLTEtMS00OTc5OA_9e392109-18b2-4e18-b1a2-be4ec11bf71f"
      unitRef="shares">45584000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9ed70ab246449f7ad763aa871442e27_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC0zLTEtMS00OTc5OA_f9c8b5b6-a40b-496f-8920-72a878c5a31c"
      unitRef="usd">46000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7de8308633374277be1cf29a7379f05c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC01LTEtMS00OTc5OA_dbd811cb-3edb-4b10-b696-ea5695c1b664"
      unitRef="usd">734997000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68ef53f7e30c4224922d1c036f351731_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC03LTEtMS00OTc5OA_2eead230-80f0-4d55-8204-d8e1f4d9916b"
      unitRef="usd">-1109000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i236b3f20c24e41bcaf1eabdc79111516_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC05LTEtMS00OTc5OA_14f8a2d1-933e-40fb-8979-a1224dd7c9b4"
      unitRef="usd">-418636000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia821fe0c70284513b205269e31ca09b2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC0xMS0xLTEtNDk3OTg_66856784-7b8c-449a-b9a7-f82df8c172b3"
      unitRef="usd">368000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id940216a8696400e848431386ab32d09_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNC0xMy0xLTEtNDk3OTg_9512d6e9-a560-490c-8d9c-9df334c48fce"
      unitRef="usd">315666000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if0dac22d55a34bd28a43e412291b2c2b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNS01LTEtMS00OTc5OA_f0f3f42c-d8c1-45ca-b279-cdca50e2e0cb"
      unitRef="usd">16764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNS0xMy0xLTEtNDk3OTg_759a38c2-0874-44c8-89d5-5bd577d5b183"
      unitRef="usd">16764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id0f23d89cf3e409993a8b87de890b508_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNi03LTEtMS00OTc5OA_9e390f4b-931c-42eb-9ea4-2861bbfb4100"
      unitRef="usd">-670000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNi0xMy0xLTEtNDk3OTg_449e24f8-0663-417a-9842-18a0be4c0d28"
      unitRef="usd">-670000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNy0xLTEtMS00OTc5OA_1b62c99b-38dd-442d-b01f-198b36c3f84b"
      unitRef="shares">11284000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNy0zLTEtMS00OTc5OA_5cd1dd7c-742a-46a3-bcfb-622008fb161f"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if0dac22d55a34bd28a43e412291b2c2b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNy01LTEtMS00OTc5OA_be27852b-f67d-409f-8ce8-3b4d6971ce82"
      unitRef="usd">209286000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfNy0xMy0xLTEtNDk3OTg_0cf25dc2-9751-4560-8c61-b45afaf022db"
      unitRef="usd">209297000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfOC0xLTEtMS00OTc5OA_ac87b7a3-c841-4bc3-8cb5-7b0fc2e4176f"
      unitRef="shares">104000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTAtMS0xLTEtNDk3OTg_2d61daeb-f6ac-4ab7-89fc-9d4de2634b6b"
      unitRef="shares">9000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if0dac22d55a34bd28a43e412291b2c2b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTAtNS0xLTEtNDk3OTg_457b3ffa-c66b-4b28-87dd-8f734e3e7698"
      unitRef="usd">158000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTAtMTMtMS0xLTQ5Nzk4_45dddbdd-bac5-4141-88e8-64f2c165f5b7"
      unitRef="usd">158000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i202bac2e5c2d4ccb995bb8372d1a4080_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTItMS0xLTEtNDk3OTg_f6e63996-53c1-475a-88af-697c123ec42b"
      unitRef="shares">14000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i80ce1ccd32b74f8f8a7021b222292233_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTMtMTEtMS0xLTQ5Nzk4_58d89c8b-d951-4faf-ae37-c077c0c5fe0c"
      unitRef="usd">-35000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTMtMTMtMS0xLTQ5Nzk4_37b8f764-8ca0-45ab-a4a5-66ad1e4533a0"
      unitRef="usd">-35000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0c7c555285da411b8145cd0a64ff4ebc_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTQtOS0xLTEtNDk3OTg_61ba4151-707f-42c8-a9c0-ffcbce1b6de7"
      unitRef="usd">-68357000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTQtMTMtMS0xLTQ5Nzk4_c42a9a90-bcf6-47ad-8822-7aeece525878"
      unitRef="usd">-68357000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i1477287ae34d47408281cf92c3a86f66_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtMS0xLTEtNDk3OTg_a81dac6d-1816-4163-95b5-a9f827b3e037"
      unitRef="shares">56967000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1477287ae34d47408281cf92c3a86f66_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtMy0xLTEtNDk3OTg_5f51e82a-2829-4327-ad32-3543bc693609"
      unitRef="usd">57000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c76f003ce48452898b59c299efffc95_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtNS0xLTEtNDk3OTg_5a27d12d-4613-41c8-b852-bc8122ed7443"
      unitRef="usd">961205000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2527dedabd09467e89489d14d48942a7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtNy0xLTEtNDk3OTg_51405b6d-032e-4494-91c6-21a0dc7f5d72"
      unitRef="usd">-1779000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96fbfda562ed4251a1b2805e02ad7a13_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtOS0xLTEtNDk3OTg_9523171f-4a8b-479d-a134-49a0aacf27f9"
      unitRef="usd">-486993000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ce25123e7d14a9b9e92dd7ef27fe5d7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtMTEtMS0xLTQ5Nzk4_2b90d190-dc9b-4d2f-a6bf-a0f60ef1e685"
      unitRef="usd">333000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVjN2JjM2E0YmE4OTQ0NjE4YWRkOTk4ZmVkZmE0Nzk1L3RhYmxlcmFuZ2U6ZWM3YmMzYTRiYTg5NDQ2MThhZGQ5OThmZWRmYTQ3OTVfMTUtMTMtMS0xLTQ5Nzk4_2e54ea6a-133d-496c-929f-9b33995da585"
      unitRef="usd">472823000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i1d0b89a422d645d2aa975073d6e626b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC0xLTEtMS01MDM0OA_391cdeaf-5f6c-4e6b-b5b6-236c69935053"
      unitRef="shares">45491000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d0b89a422d645d2aa975073d6e626b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC0zLTEtMS01MDM0OA_de2d1ea1-f016-4e26-9a0b-5d1d9d41c15d"
      unitRef="usd">45000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f0a552beb41460d83598cfec7140d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC01LTEtMS01MDM0OA_43c11ccd-ddc2-4752-b27a-1aa041fb0911"
      unitRef="usd">723593000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7134b43188594f1d9a9a436a5c024ce9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC03LTEtMS01MDM0OA_9f67ac9c-49cc-4f77-ac73-8ae8a5f40195"
      unitRef="usd">-125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3823d94562d44181906d6305eee20514_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC05LTEtMS01MDM0OA_07cad8f4-088d-4918-943d-daedebd64fd0"
      unitRef="usd">-359559000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e0de465fbe24b4aa737c25edf79d252_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC0xMS0xLTEtNTAzNDg_891a3b9c-5adf-4726-b882-faa54d98d348"
      unitRef="usd">528000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNC0xMy0xLTEtNTAzNDg_b7e3120c-fac7-4678-9127-4fca9c680bbb"
      unitRef="usd">364482000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if85ae8da9e964278af67cede62e6983c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNS01LTEtMS01MDM0OA_cd17e595-81b4-4c44-9421-39e19e9f43a1"
      unitRef="usd">26911000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNS0xMy0xLTEtNTAzNDg_bc41b86a-6e9b-4f6a-8277-8426a97f0295"
      unitRef="usd">26911000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic4332f30a3194687b4ba50860e682c2b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNi03LTEtMS01MDM0OA_69ef7532-30ec-4db8-ac12-bc2f82fa5c6b"
      unitRef="usd">-1654000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNi0xMy0xLTEtNTAzNDg_49b6ce79-8d0d-4135-8888-2178c62ccfb6"
      unitRef="usd">-1654000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNy0xLTEtMS01MDM0OA_2b57485d-03e7-42f8-ba4f-d8b1f6e6eb8b"
      unitRef="shares">11284000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNy0zLTEtMS01MDM0OA_5838df48-fb91-48b8-b953-e6b3825f3970"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if85ae8da9e964278af67cede62e6983c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNy01LTEtMS01MDM0OA_0ff0bbfb-7137-496e-ae78-47a827c85b0c"
      unitRef="usd">209286000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfNy0xMy0xLTEtNTAzNDg_384c50fe-0b8b-436a-945f-d2b8d303f0a2"
      unitRef="usd">209297000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfOC0xLTEtMS01MDM0OA_9785e068-86d9-442e-beb0-cec2064c00de"
      unitRef="shares">149000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfOC0zLTEtMS01MDM0OA_f9289777-aab7-4130-a4b7-d66ed901706f"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfOC0xMy0xLTEtNTAzNDg_0b045ee0-2a1d-4388-b43a-99633b46dba1"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTAtMS0xLTEtNTAzNDg_2f5f5131-df67-452b-ad3c-ee43381bf356"
      unitRef="shares">42000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if85ae8da9e964278af67cede62e6983c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTAtNS0xLTEtNTAzNDg_6901e4c5-8eb6-4b39-b3c5-9f0095067f28"
      unitRef="usd">803000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTAtMTMtMS0xLTUwMzQ4_639893b3-4bea-47ac-8450-2eb92198ee90"
      unitRef="usd">803000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTEtMS0xLTEtNTAzNDg_d8207059-7281-419f-b2a6-5bb76d0dacba"
      unitRef="shares">16000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if85ae8da9e964278af67cede62e6983c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTEtNS0xLTEtNTAzNDg_7fcf4f6d-5e6a-41ce-b235-a9726aca5c7e"
      unitRef="usd">612000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTEtMTMtMS0xLTUwMzQ4_857690b1-8af9-4334-bd02-b9f38bbae471"
      unitRef="usd">612000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i8156466dea7d4a6d8b2a4074a376cdf1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTItMS0xLTEtNTAzNDg_cb751d48-2b7d-4ac0-9d06-b3d2d1b66536"
      unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if0c2ece8395d4a878161c8c8bb291feb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTMtMTEtMS0xLTUwMzQ4_755f1e17-4a1f-402b-9ca7-1e443844a51d"
      unitRef="usd">-195000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTMtMTMtMS0xLTUwMzQ4_da9c4106-8f77-41b9-85cf-5b5681d02ddd"
      unitRef="usd">-195000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i43893269fb514e64a84c7e6836451dab_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTQtOS0xLTEtNTAzNDg_0a9ffd27-c22a-43a3-80d9-d5d395dfdcc1"
      unitRef="usd">-127434000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTQtMTMtMS0xLTUwMzQ4_a5c7c08f-c730-4c37-bab5-1487bd2dac59"
      unitRef="usd">-127434000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i1477287ae34d47408281cf92c3a86f66_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtMS0xLTEtNTAzNDg_743952c3-15da-4c7b-ad19-0e3a2656081b"
      unitRef="shares">56967000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1477287ae34d47408281cf92c3a86f66_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtMy0xLTEtNTAzNDg_cef13958-7f57-44a9-8ed5-14d2dd51ea7b"
      unitRef="usd">57000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c76f003ce48452898b59c299efffc95_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtNS0xLTEtNTAzNDg_46f0a927-07c9-4f14-bf0b-c791faf6b1c5"
      unitRef="usd">961205000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2527dedabd09467e89489d14d48942a7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtNy0xLTEtNTAzNDg_eab20bc6-0f94-435c-a4e1-e2f191a4bee5"
      unitRef="usd">-1779000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96fbfda562ed4251a1b2805e02ad7a13_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtOS0xLTEtNTAzNDg_8449fde7-b116-4ae5-95bf-64a425329f5f"
      unitRef="usd">-486993000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ce25123e7d14a9b9e92dd7ef27fe5d7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtMTEtMS0xLTUwMzQ4_4f7c390a-d719-46a7-8bb9-e2c00903f465"
      unitRef="usd">333000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmYwNDliMDY1N2E3NDQ2OTY5NGQzNzdhNzk1ZjhkNDAwL3RhYmxlcmFuZ2U6ZjA0OWIwNjU3YTc0NDY5Njk0ZDM3N2E3OTVmOGQ0MDBfMTUtMTMtMS0xLTUwMzQ4_bb33ba40-8777-4c2c-93c4-a10e45f53481"
      unitRef="usd">472823000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i2ef202afe8ee4eb29a4286d1984f00e7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC0xLTEtMS00OTc5OA_94b3ff50-fc30-4daa-bd72-680ceb50e702"
      unitRef="shares">41040000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ef202afe8ee4eb29a4286d1984f00e7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC0zLTEtMS00OTc5OA_57a0f1d1-88b6-418c-a763-637f63396eab"
      unitRef="usd">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ided707c746324c85b99713cfd1f60a31_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC01LTEtMS00OTc5OA_fb9c58ad-e2f5-4b6c-a6ff-063278da9898"
      unitRef="usd">519030000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03d6b1d603f9454bada2bf2d6fdaa5c1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC03LTEtMS00OTc5OA_41c65090-9920-46f6-b20f-3c4ebf75f08c"
      unitRef="usd">50000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21f5e3fdc0fe4e9abfb1657db69da8bd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC05LTEtMS00OTc5OA_23130692-a437-475e-bc9c-14c493ec2856"
      unitRef="usd">-250735000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i80ee52788a39497ba42814448e5acd22_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC0xMS0xLTEtNDk3OTg_113a7ecb-8066-4624-ac7d-368fad450b32"
      unitRef="usd">24252000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6308a92c792f4032aaf192b33d9c615d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNC0xMy0xLTEtNDk3OTg_0cf57487-a6fc-4484-b3bf-fe6215838cd5"
      unitRef="usd">292638000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7b3fd0d327c647f78519c288eabd7f13_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNS01LTEtMS00OTc5OA_57e35639-3291-4143-9856-6f8db7e52d11"
      unitRef="usd">9919000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNS0xMy0xLTEtNDk3OTg_620ab4b2-94b7-479b-89dc-ac535b33bec2"
      unitRef="usd">9919000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i347024f2e9ac451aa83164fdbd8d84fb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNi03LTEtMS00OTc5OA_b38b1bf1-94a3-4b3b-a1c5-70c3dfdafaf7"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfNi0xMy0xLTEtNDk3OTg_5cf4ccb8-4852-4f9d-b19f-296a6c0d5486"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="icbd060dd7d6d4fdaacff3da2f0e05098_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfOC0xLTEtMS00OTc5OA_6583fbfb-702d-41bb-b8af-7b31bb923b0b"
      unitRef="shares">272000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icbd060dd7d6d4fdaacff3da2f0e05098_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfOC0xLTEtMS01MDU5OA_e966a871-f7bc-4979-b52b-794afd0c8b02"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7b3fd0d327c647f78519c288eabd7f13_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfOC01LTEtMS01MDU5OA_d401fe8c-1fd4-4941-8f4e-762a780809d8"
      unitRef="usd">70000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfOC0xMy0xLTEtNTA1OTg_f2b184f1-acad-4309-a7f3-65d5e6f896cd"
      unitRef="usd">70000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="icbd060dd7d6d4fdaacff3da2f0e05098_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfOS0xLTEtMS01MDU5OA_11ddaca9-515f-4cc6-aaaa-a4556fdecdb0"
      unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i81639f8b21714c96a90b50f632406ac7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTMtMTEtMS0xLTQ5Nzk4_8ad4b549-e13b-4328-9836-863a7daec747"
      unitRef="usd">-488000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTMtMTMtMS0xLTQ5Nzk4_26d58d5e-9573-47d7-862d-13e9da270a8d"
      unitRef="usd">-488000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5bd2f39625b8425cb7b9aff6a3b1ad28_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTQtOS0xLTEtNDk3OTg_52ca8f3d-f31b-4ce2-b0b7-5ea6bf6e9cd9"
      unitRef="usd">-54574000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTQtMTMtMS0xLTQ5Nzk4_bc15cff6-1549-47e6-abbb-38dc1033b701"
      unitRef="usd">-54574000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ia20e533d81cd4d089a7df4436d153672_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtMS0xLTEtNDk3OTg_2d041c1b-398e-46c9-90f4-0131f17bdc18"
      unitRef="shares">41315000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia20e533d81cd4d089a7df4436d153672_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtMy0xLTEtNDk3OTg_73d211ca-66d6-4ab8-b796-a477544e4f19"
      unitRef="usd">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3cda99f88cd4c479dc77d9d5c051b50_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtNS0xLTEtNDk3OTg_fe623a8f-e0e5-4ce5-b014-fb7e59e836d9"
      unitRef="usd">529019000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21514c2c23bb4db989a9c7ce3badc7fd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtNy0xLTEtNDk3OTg_0e36daf3-4f79-4bbe-bf2c-f8dc91f1064a"
      unitRef="usd">94000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7db1887be0d42278bf24dd6a2ec6df7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtOS0xLTEtNDk3OTg_e79abfd6-e983-4e86-873b-0a7a8dd83ae2"
      unitRef="usd">-305309000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic5ccef6083cd4247a6cad6d8beaa3058_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtMTEtMS0xLTQ5Nzk4_88ff80d7-9a81-41f5-8333-d57388ed7a87"
      unitRef="usd">23764000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOjU4MDJhNGIyYzI4ZTQwMGY5OTExNWE3OTEzYjE5ODNhL3RhYmxlcmFuZ2U6NTgwMmE0YjJjMjhlNDAwZjk5MTE1YTc5MTNiMTk4M2FfMTUtMTMtMS0xLTQ5Nzk4_dd9cf782-b56f-4915-9653-d5d3cda94e44"
      unitRef="usd">247609000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i5299c81f26ad457bb9835f9d797f5a03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC0xLTEtMS01MDYwOQ_87687dba-99e6-48a9-8fb0-10a1081702f9"
      unitRef="shares">41040000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5299c81f26ad457bb9835f9d797f5a03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC0zLTEtMS01MDYwOQ_8133000d-8681-435e-8b3b-bb9d0f42659f"
      unitRef="usd">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5eeadd6ca63a4a009a94aec18e5f62ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC01LTEtMS01MDYwOQ_d0bc4ece-dc31-4515-b724-8aedd8ad19a5"
      unitRef="usd">509339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48ff54a3aa3044e380b7048409865567_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC03LTEtMS01MDYwOQ_6cd19a2f-0733-41dd-9a7e-91c77f08c798"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03477a9c65e34b128f96193a6cb1c953_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC05LTEtMS01MDYwOQ_1df09299-03ef-4c36-bdf5-61dd4ecd3029"
      unitRef="usd">-200834000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad53b504c7e14abca92ca74a46a07bbd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC0xMS0xLTEtNTA2MDk_ebdc2b9c-8bc5-4060-be06-d833edebabb1"
      unitRef="usd">24795000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea2c4236a736402f8b183ddfe915fbac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNC0xMy0xLTEtNTA2MDk_a7d8825b-52c4-4046-af09-916e5cc5615a"
      unitRef="usd">333377000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iace2148088e643e387d7d86483ae4b8d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNS01LTEtMS01MDYwOQ_1cd98187-b5e7-49d4-a1a6-1cc2f1058188"
      unitRef="usd">19610000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNS0xMy0xLTEtNTA2MDk_01411a8d-6805-49a4-bf0f-d1b8990b5e12"
      unitRef="usd">19610000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie52aa73782a849fdaecd219b51650553_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNi03LTEtMS01MDYwOQ_f0ff3292-c11c-46fa-9db3-a3493d3d8ae2"
      unitRef="usd">58000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNi0xMy0xLTEtNTA2MDk_3872930a-3177-4ec5-9e4b-2df79f8b0518"
      unitRef="usd">58000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i9542e31388864d3fa1e1d2fdc142b92d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfNy0xLTEtMS01MDYwOQ_2895183a-e025-4df4-bc99-b36efe11f048"
      unitRef="shares">272000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9542e31388864d3fa1e1d2fdc142b92d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfOC0xLTEtMS01MDYwOQ_625efd5c-ee7f-4297-be5d-e30fc5f32a94"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iace2148088e643e387d7d86483ae4b8d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfOC01LTEtMS01MDYwOQ_18637ed6-0a2d-4d6c-bca5-ec2276013bb1"
      unitRef="usd">70000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfOC0xMy0xLTEtNTA2MDk_e0b43b9f-be0c-4c91-a2f8-fa91db19527f"
      unitRef="usd">70000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i9542e31388864d3fa1e1d2fdc142b92d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfOS0xLTEtMS01MDYwOQ_4d648886-4286-4dba-9a5e-93ee7cbf4c30"
      unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if7f89106493a4483a75fab892a90d82f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTAtMTEtMS0xLTUwNjA5_6ff5f155-417c-4766-827e-368d8c734837"
      unitRef="usd">-1031000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTAtMTMtMS0xLTUwNjA5_4f997e53-9c24-4f0f-bae4-3d648a82db85"
      unitRef="usd">-1031000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5dc3ef43b05d4b4dab34c1ceec3046b9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTEtOS0xLTEtNTA2MDk_76cb49ad-4c89-4034-bed6-8503e7378095"
      unitRef="usd">-104475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTEtMTMtMS0xLTUwNjA5_739968b3-ffa6-422b-bc39-1faf28f90bbd"
      unitRef="usd">-104475000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ia20e533d81cd4d089a7df4436d153672_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItMS0xLTEtNTA2MDk_524340c2-d05c-40a6-953f-1cb406e63342"
      unitRef="shares">41315000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia20e533d81cd4d089a7df4436d153672_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItMy0xLTEtNTA2MDk_19df5e51-6ef1-44a2-adb5-92078426b96d"
      unitRef="usd">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3cda99f88cd4c479dc77d9d5c051b50_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItNS0xLTEtNTA2MDk_ddc905b8-e0be-4570-a3cf-270159b0938f"
      unitRef="usd">529019000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21514c2c23bb4db989a9c7ce3badc7fd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItNy0xLTEtNTA2MDk_41260b83-5dc7-4c89-956f-e775adb7da15"
      unitRef="usd">94000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7db1887be0d42278bf24dd6a2ec6df7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItOS0xLTEtNTA2MDk_6772b32a-45f2-4e1a-8923-35bcbd3b0a11"
      unitRef="usd">-305309000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic5ccef6083cd4247a6cad6d8beaa3058_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItMTEtMS0xLTUwNjA5_6b9c7b50-145d-42c8-bc34-74847a956f67"
      unitRef="usd">23764000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iebc81bbd37134c8eb0227cec32909507_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF8zNC9mcmFnOjRlZjQ0ODU1NDlhNDQ1OGM5OTdjOGUzNmZkOTk4NDNhL3RhYmxlOmVhNGJjZmFhMTkwMDQ5OTk5Mzc4YmExNGQyNjdjMTRiL3RhYmxlcmFuZ2U6ZWE0YmNmYWExOTAwNDk5OTkzNzhiYTE0ZDI2N2MxNGJfMTItMTMtMS0xLTUwNjA5_804ec0f0-f36f-476f-ada2-fefc55a81b5e"
      unitRef="usd">247609000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80MC9mcmFnOmY3MWExOGYxMjVlYzRmOWZhZmE2YWJjNmMzZGI1MjQ5L3RleHRyZWdpb246ZjcxYTE4ZjEyNWVjNGY5ZmFmYTZhYmM2YzNkYjUyNDlfMTEwNg_fa37e7c2-e298-4803-99f9-80a4ee0cfaf5">Organization and Business&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Zentalis Pharmaceuticals, Inc. (&#x201c;Zentalis&#x201d;, &#x201c;We&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage pharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#x2019;s tangible assets are held in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;Substantial doubt about an entity&#x2019;s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after the date that the interim unaudited condensed consolidated financial statements for the quarter ended June&#160;30, 2022 are issued.</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80My9mcmFnOmZjNjZiZDZkMmMyMDRiY2ZiN2E0YmY5YWE1YTFiNmUzL3RleHRyZWdpb246ZmM2NmJkNmQyYzIwNGJjZmI3YTRiZjlhYTVhMWI2ZTNfMzk0Mg_159c5421-8cb0-44c6-9d10-894c6979cf87">Interim Unaudited Financial Statements &lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company&#x2019;s audited financial statements but does not include all disclosures required by U.S. GAAP. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February 24, 2022. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated balance sheet to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements include our wholly-owned subsidiaries and variable interest entities (&#x201c;VIEs&#x201d;) for the periods in which we determined we were the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1)&#160;the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2)&#160;the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;periods presented, we have not provided any other material financial or other support to our VIEs that we were not contractually required to provide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The equity method is used to account for investments in which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded on the balance sheet, and the share of net income or losses of equity investments is recognized on a one quarter lag in investment and other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six months ended June 30, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there have been no changes to the Company&#x2019;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80My9mcmFnOmZjNjZiZDZkMmMyMDRiY2ZiN2E0YmY5YWE1YTFiNmUzL3RleHRyZWdpb246ZmM2NmJkNmQyYzIwNGJjZmI3YTRiZjlhYTVhMWI2ZTNfMzk0MA_d074c3b3-ddbe-4d8c-a229-679c4a92ad3b">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company&#x2019;s audited financial statements but does not include all disclosures required by U.S. GAAP. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February 24, 2022. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated balance sheet to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80My9mcmFnOmZjNjZiZDZkMmMyMDRiY2ZiN2E0YmY5YWE1YTFiNmUzL3RleHRyZWdpb246ZmM2NmJkNmQyYzIwNGJjZmI3YTRiZjlhYTVhMWI2ZTNfMzkzNg_9a151337-d2ee-4457-8732-5fbd6ba6bc51">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements include our wholly-owned subsidiaries and variable interest entities (&#x201c;VIEs&#x201d;) for the periods in which we determined we were the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1)&#160;the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2)&#160;the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;periods presented, we have not provided any other material financial or other support to our VIEs that we were not contractually required to provide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The equity method is used to account for investments in which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded on the balance sheet, and the share of net income or losses of equity investments is recognized on a one quarter lag in investment and other income (expense), net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80My9mcmFnOmZjNjZiZDZkMmMyMDRiY2ZiN2E0YmY5YWE1YTFiNmUzL3RleHRyZWdpb246ZmM2NmJkNmQyYzIwNGJjZmI3YTRiZjlhYTVhMWI2ZTNfMzk0MQ_a016eb28-6a9b-488e-bc34-bcd2dc9ae5db">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfNDM5NQ_ae09adce-5c53-4337-b56e-6b6b17e2a0a4">Significant Transactions&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Zentera Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we became a majority common shareholder of Zentera Therapeutics, Ltd., a Shanghai-based clinical-stage biopharmaceutical company focused on developing cancer therapeutics (&#x201c;Zentera&#x201d;), concurrent with its Series A convertible preferred stock offering. The financial position and results of operations of Zentera were included in our consolidated financial statements from the date of the initial investment as a result of our control of the entity and our determination that we were the primary beneficiary of Zentera. In July 2021, Zentera completed a Series B convertible preferred stock offering which diluted our investment to a position of less than majority owned. Upon review of the facts and circumstances, together with the authoritative accounting literature, we determined that while Zentera is a VIE, consolidation of Zentera is no longer appropriate. After the July 2021 Series B convertible preferred offering in which we did not participate, our review concluded that we ceased to be the primary beneficiary of Zentera as our equity ownership was reduced and changes were made to the corporate governance of Zentera. As a result, we no longer individually have the ability to direct the activities that most significantly impact Zentera's economic performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in July 2021, the financial position and results of operations of Zentera are no longer included in our consolidated financial statements. During the period of deconsolidation we measured the fair value of our retained investment in Zentera using the backsolve method with consideration for a lack of marketability. An equity method investment of $30.4 million is recorded on our balance sheet at June&#160;30, 2022. This amount represents our maximum exposure to loss as a result of our involvement with Zentera. A deferred tax liability of $6.4 million representing the tax impact of the unrealized gain on deconsolidation is recorded on our balance sheet at June&#160;30, 2022. A gain of $51.6 million, measured as the difference between the fair value of our retained noncontrolling interest together with the carrying amount of the Zentera noncontrolling interest, and the carrying amount of Zentera&#x2019;s assets and liabilities was recognized during the year ended December 31, 2021. The difference between the carrying amount of our investment in Zentera and our portion of the Zentera net assets was $5.2 million as of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022. This difference is accounted for in our equity method investment analogous to in-process research and development. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2020, each of our subsidiaries Zeno Alpha, Inc., K-Group Alpha, Inc., Zeno Management Inc., and K-Group Beta, Inc. entered into a collaboration and royalty-bearing license agreement with Zentera, which we refer to as the &#x201c;Zentera Sublicenses,&#x201d; pursuant to which we collaborate with Zentera on the development and commercialization of ZN-c3, ZN-d5 and ZN-c5, collectively referred to as the &#x201c;Collaboration Products,&#x201d; respectively, in the People&#x2019;s Republic of China, Macau, Hong Kong and Taiwan, which is referred to as the &#x201c;Zentera Collaboration Territory.&#x201d; Under each Zentera Sublicense, Zentera will lead development, and upon regulatory approval, the commercialization, of the collaboration products in the Zentera Collaboration Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Zentera Sublicenses, Zentera is responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of the costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Prior to the deconsolidation of Zentera in July 2021, these costs were eliminated in consolidation. For the three and six months ended June&#160;30, 2022, the amounts incurred under this arrangement totaled $3.0 million and $5.1 million, respectively, and are presented as contra-research and development expense in the unaudited condensed consolidated statement of operations. A corresponding receivable is recorded within prepaid expenses and other current assets on the unaudited condensed consolidated balance sheet. We have not provided material financial or other support to Zentera during the periods ended June&#160;30, 2022 and 2021 that was not previously contractually required.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfMTcwMA_1378a5a7-7955-4f0f-b258-d000d66b0aec"
      unitRef="usd">30400000</us-gaap:EquityMethodInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="if476a59e1bdc46f883f2c9950f451fe9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfMTg4OA_fde3f5c3-0120-4310-8226-55ce5097b0d9"
      unitRef="usd">6400000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i6e26a8f313d147c899372ec9a56c6c9f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfMjAzMQ_035ebe59-fbbd-4c43-90df-fca6dec844b6"
      unitRef="usd">51600000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="if476a59e1bdc46f883f2c9950f451fe9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfMjQ0MQ_d607572c-1b89-4e15-af6c-4911a16293da"
      unitRef="usd">5200000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <zntl:ResearchAndDevelopmentExpenseReimbursements
      contextRef="i28f7d3ab172046598fe7dcdf7ffe8f23_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfNTQ5NzU1ODE4MzYy_8fbab07a-b60c-4c49-8f38-d1e60bf0bff0"
      unitRef="usd">3000000.0</zntl:ResearchAndDevelopmentExpenseReimbursements>
    <zntl:ResearchAndDevelopmentExpenseReimbursements
      contextRef="iebb85fbd06c842c9b31131732a081288_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80Ni9mcmFnOjU2NWNhOWYzZTFkMTQ0MGZiNGY3NjE3NjgxNGEzYzRhL3RleHRyZWdpb246NTY1Y2E5ZjNlMWQxNDQwZmI0Zjc2MTc2ODE0YTNjNGFfNDAwMQ_7212ec47-ecec-4c18-a5a9-b0b0c3ba97dd"
      unitRef="usd">5100000</zntl:ResearchAndDevelopmentExpenseReimbursements>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RleHRyZWdpb246NzYzOTIwNjNlMTJkNDBlMmFiNzY1NTRkMjdjZmU4NDZfMTgxNQ_da4fc176-100e-494b-ab51-2c71d47f372e">Business Combinations&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Kalyra Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;21, 2017, we acquired $4.5&#160;million of Kalyra&#x2019;s Series B Preferred Stock representing a 25% equity interest in Kalyra for purposes of entering the analgesics therapeutic research space. The acquisition price was paid entirely in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the authoritative guidance, we concluded that Kalyra is a business consisting of inputs, employees, intellectual property and processes capable of producing outputs. Additionally, we have concluded that Kalyra is a variable interest entity, we are the primary beneficiary and have the power to direct the activities that most significantly affect Kalyra&#x2019;s economic performance through common management and our board representation. Prior to December 21, 2017, the Company and Kalyra transacted for the delivery of research and development services and support. The financial position and results of operations of Kalyra have been included in our consolidated financial statements from the date of the initial investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant with authoritative guidance, we have recorded the identifiable assets, liabilities and noncontrolling interests in the VIE at their fair value upon initial consolidation. The identified goodwill is comprised of the workforce and expected synergies from combining the entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;otal assets and liabilities of Kalyra as of June&#160;30, 2022 and December&#160;31, 2021 are immaterial. The liabilities recognized as a result of consolidating Kalyra do not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;represent additional claims on our general assets. Pursuant to the authoritative guidance, the equity interest in Kalyra not owned by Zentalis is reported as a noncontrolling interest on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deconsolidation of Zentera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i7de358016f734a82a094e8ea4e3ef006_D20171221-20171221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RleHRyZWdpb246NzYzOTIwNjNlMTJkNDBlMmFiNzY1NTRkMjdjZmU4NDZfOTQ_fd632e46-0a5b-4cfd-adae-945dc7c93aa6"
      unitRef="usd">4500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i8d7db02ca8a24de29d50872ad8205e42_I20171221"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RleHRyZWdpb246NzYzOTIwNjNlMTJkNDBlMmFiNzY1NTRkMjdjZmU4NDZfMTQ5_725291f5-26a0-4561-a8ce-b6dae989830a"
      unitRef="number">0.25</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <zntl:ReconciliationOfNoncontrollingInterestTableTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RleHRyZWdpb246NzYzOTIwNjNlMTJkNDBlMmFiNzY1NTRkMjdjZmU4NDZfMTgxNA_555a79d2-d620-4202-ab0f-553fb55a9c24">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deconsolidation of Zentera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</zntl:ReconciliationOfNoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="id24bd10e6cc1406aa94762219ea0191d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfMi0xLTEtMS00OTc5OA_a1d13ded-e42c-4963-beee-e96fef6b13a0"
      unitRef="usd">528000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i46207b8cc83c4695ab95cd14b58c03ca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfMi0zLTEtMS00OTc5OA_d0aa1a3e-50ea-4c77-b173-4a6cdd452c46"
      unitRef="usd">24795000</us-gaap:MinorityInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i73d19273bd804eacb01818f0b3a0b9d6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfMy0xLTEtMS00OTc5OA_918884c7-4e30-434c-93b9-d98fc10fc6e7"
      unitRef="usd">-195000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib00284ea6567450d9a07b5d0bfc0d9e5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfMy0zLTEtMS00OTc5OA_320ba166-68b3-4151-a1d5-1f863b97b892"
      unitRef="usd">-7368000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i73d19273bd804eacb01818f0b3a0b9d6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfNS0xLTEtMS00OTc5OA_0ca3017f-1ba1-4836-add8-2071cf731274"
      unitRef="usd">0</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="ib00284ea6567450d9a07b5d0bfc0d9e5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfNS0zLTEtMS00OTc5OA_ba108c48-1501-4d41-9fa1-0ba409e5c16c"
      unitRef="usd">16899000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:MinorityInterest
      contextRef="ib28e2c6f83d847d8be4563b4c9a90eb4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfNy0xLTEtMS00OTc5OA_e52f4a42-971d-41dc-b588-f621191ada1f"
      unitRef="usd">333000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="id24bd10e6cc1406aa94762219ea0191d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF80OS9mcmFnOjc2MzkyMDYzZTEyZDQwZTJhYjc2NTU0ZDI3Y2ZlODQ2L3RhYmxlOmU0ZDExMTBjNDcxNTRkYWVhYjEyYzQxM2I4YzExZDkzL3RhYmxlcmFuZ2U6ZTRkMTExMGM0NzE1NGRhZWFiMTJjNDEzYjhjMTFkOTNfNy0zLTEtMS00OTc5OA_508eab8c-33b0-4af8-b136-721d6fc1380a"
      unitRef="usd">528000</us-gaap:MinorityInterest>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMTUwNg_3cff8009-1ec4-4020-86d1-981309e9eda1">Fair Value Measurement&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of June&#160;30, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;sixty-two&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; of our available-for-sale debt securities with a fair market value of $399.2 million were in a gross unrealized loss position of $1.8 million. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, our intent to sell or the likelihood that we would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of June&#160;30, 2022, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;because we do not intend to sell these securities, and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of available-for-sale debt securities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.044%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one but within five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy during the six months ended June&#160;30, 2022. We had no instruments that were classified within Level&#160;3 as of June&#160;30, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMTUwNw_d3138255-87e5-4f73-9567-e81f9be461d4">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id40490dd28724db79d06f9d951fd8acd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMi0xLTEtMS00OTc5OA_bf97fc13-2197-4273-96ad-dbcfea7ca61c"
      unitRef="usd">255912000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id40490dd28724db79d06f9d951fd8acd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMi0zLTEtMS00OTc5OA_4a45a11f-c3b2-4517-9a5c-0c50b6546d6f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id40490dd28724db79d06f9d951fd8acd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMi01LTEtMS00OTc5OA_3288dc94-39bf-4682-b0cf-cd78d50f6d7a"
      unitRef="usd">763000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id40490dd28724db79d06f9d951fd8acd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMi03LTEtMS00OTc5OA_7d82981a-9160-473c-9a31-a68a61c07a7e"
      unitRef="usd">255149000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia08925ab72244888b246b83bf82d4bed_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMy0xLTEtMS00OTc5OA_7310900e-4f9c-477b-8f20-b7fd1fb99b8a"
      unitRef="usd">5063000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia08925ab72244888b246b83bf82d4bed_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMy0zLTEtMS00OTc5OA_66862544-d48c-434c-bb3d-1b36465e40af"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia08925ab72244888b246b83bf82d4bed_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMy01LTEtMS00OTc5OA_ddf1b269-cec7-419b-a6e7-8449dd997563"
      unitRef="usd">59000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia08925ab72244888b246b83bf82d4bed_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfMy03LTEtMS00OTc5OA_d0d234eb-2db9-4465-a731-bb89390699e9"
      unitRef="usd">5004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i15c97d107fb94103966853f5642d3a1f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNC0xLTEtMS00OTc5OA_cc810d46-f73c-459e-9123-420c21cd51bf"
      unitRef="usd">18997000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i15c97d107fb94103966853f5642d3a1f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNC0zLTEtMS00OTc5OA_381ff617-d740-41d3-8535-80542afc0849"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i15c97d107fb94103966853f5642d3a1f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNC01LTEtMS00OTc5OA_45bbc97b-fca0-458f-9870-ce10f1c4bafc"
      unitRef="usd">78000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15c97d107fb94103966853f5642d3a1f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNC03LTEtMS00OTc5OA_6d884fc8-2483-4e21-8286-1da37ec6a883"
      unitRef="usd">18919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i383f5a4611ed4191a940e97fba342d26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNS0xLTEtMS00OTc5OA_8b36359d-fd39-4a33-828b-43e81b4df0dd"
      unitRef="usd">121882000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i383f5a4611ed4191a940e97fba342d26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNS0zLTEtMS00OTc5OA_2efa04d9-46ec-4d0c-81e7-fc9a91d54abd"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i383f5a4611ed4191a940e97fba342d26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNS01LTEtMS00OTc5OA_b997db5e-b8d4-4c4b-9dde-03ad01b300a7"
      unitRef="usd">881000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i383f5a4611ed4191a940e97fba342d26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNS03LTEtMS00OTc5OA_d060a578-b2c4-4a9f-b99b-9ef8b7d9ce05"
      unitRef="usd">121006000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNi0xLTEtMS00OTc5OA_3ab49c55-cec9-4643-a1eb-04a7c35f1618"
      unitRef="usd">401854000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNi0zLTEtMS00OTc5OA_c54d2fec-15aa-4561-8af7-b297c99e834c"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNi01LTEtMS00OTc5OA_c8973600-0f1c-414d-9dd6-3e6ed1307b97"
      unitRef="usd">1781000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjFhMjc1Yjg0MzNlNjRhZDNhNWVjNzIzNTFmNGRkOWFmL3RhYmxlcmFuZ2U6MWEyNzViODQzM2U2NGFkM2E1ZWM3MjM1MWY0ZGQ5YWZfNi03LTEtMS00OTc5OA_55f73b65-cbd1-4e6f-8aa1-69793c057a33"
      unitRef="usd">400078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMi0xLTEtMS00OTc5OA_fc4c6952-f6f7-49db-9b77-1d6ff76a3445"
      unitRef="usd">199321000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMi0zLTEtMS00OTc5OA_c56271a2-3a16-4bea-b609-6c07db8997bb"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMi01LTEtMS00OTc5OA_3c2dea33-ef45-452a-8bc6-54dbdaaf9f9d"
      unitRef="usd">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMi03LTEtMS00OTc5OA_43c0ce49-c5a7-4324-995d-253f4b2ecdf5"
      unitRef="usd">199277000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8a784f336c5848288d83ed9d20e70b9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMy0xLTEtMS00OTc5OA_b6caf217-e22f-424e-8eaa-238a74efc0a1"
      unitRef="usd">10085000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a784f336c5848288d83ed9d20e70b9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMy0zLTEtMS00OTc5OA_7993f670-8a4d-47ff-9770-18f262e07146"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a784f336c5848288d83ed9d20e70b9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMy01LTEtMS00OTc5OA_2ee3db2b-cef9-4079-885c-f873a34d6e22"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a784f336c5848288d83ed9d20e70b9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfMy03LTEtMS00OTc5OA_a5fa4120-eff9-4853-a89a-4c674996f980"
      unitRef="usd">10078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i110e2b4c6b064ff1879c74f20d1b098c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNC0xLTEtMS00OTc5OA_d8306008-19ea-4d2f-bf10-661ba6cb7fab"
      unitRef="usd">20032000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i110e2b4c6b064ff1879c74f20d1b098c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNC0zLTEtMS00OTc5OA_5e89d35f-bdcf-49e5-a1fe-18c4277c7a25"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i110e2b4c6b064ff1879c74f20d1b098c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNC01LTEtMS00OTc5OA_775c00d1-77c4-4fe3-b059-2f90c9c64811"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i110e2b4c6b064ff1879c74f20d1b098c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNC03LTEtMS00OTc5OA_25c36601-50c8-42fe-b643-8f4734f8f04d"
      unitRef="usd">20033000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if49279cde51c4e31967f61ac9e91cb63_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNS0xLTEtMS00OTc5OA_09d033d3-da78-419c-a9a8-72db73af3cb9"
      unitRef="usd">50860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if49279cde51c4e31967f61ac9e91cb63_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNS0zLTEtMS00OTc5OA_15380b9a-5344-4e6d-b72f-cf944e9b1f11"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if49279cde51c4e31967f61ac9e91cb63_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNS01LTEtMS00OTc5OA_fcc90a26-c7b3-47ae-acf8-c3d0d8ad77ba"
      unitRef="usd">75000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if49279cde51c4e31967f61ac9e91cb63_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNS03LTEtMS00OTc5OA_2ce3ba11-a7fd-436e-acd2-6a682dff88e8"
      unitRef="usd">50785000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNi0xLTEtMS00OTc5OA_da1a16c9-fe92-426c-9c3c-7624fe986a2a"
      unitRef="usd">280298000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNi0zLTEtMS00OTc5OA_c7013219-d611-4850-bb0c-a2066de8cfd3"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNi01LTEtMS00OTc5OA_573d9344-2297-4fef-b789-c37a4aa97a81"
      unitRef="usd">137000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkyOGU4YWIzMzYxNTQ0NGY5OTYyNDk2NTYxOWQ0NDg3L3RhYmxlcmFuZ2U6OTI4ZThhYjMzNjE1NDQ0Zjk5NjI0OTY1NjE5ZDQ0ODdfNi03LTEtMS00OTc5OA_9ac258ba-0a50-4ee0-b1b8-f117e644f3db"
      unitRef="usd">280173000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMTQx_eb397ded-1851-4a02-9e81-f05f892a975b"
      unitRef="security">62</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:TradingSecuritiesDebt
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMjE0_ee84a83c-2c9c-45b3-b91c-1eaf3b6530ca"
      unitRef="usd">399200000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMjY5_d19405b2-2be8-42ce-ac02-818a91f0ca1f"
      unitRef="usd">1800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMTUwMw_b9c6f435-473a-4d2a-aa43-e16a61a04a98">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of available-for-sale debt securities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.044%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one but within five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfMy0xLTEtMS00OTc5OA_856f57ca-58d9-48cb-90cc-7da1ed7e5e1a"
      unitRef="usd">396203000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfMy0zLTEtMS00OTc5OA_7d74c334-ad6e-4f58-9813-d6fa9fb93891"
      unitRef="usd">258948000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfNC0xLTEtMS00OTc5OA_9eb3e57f-4b4a-423a-b973-277bfa56d738"
      unitRef="usd">3875000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfNC0zLTEtMS00OTc5OA_14686d89-42c1-47d2-88f8-dc419ebb0cb2"
      unitRef="usd">21225000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfNS0xLTEtMS00OTc5OA_9f2c307b-eab3-4cac-8643-9a4a7c5d0846"
      unitRef="usd">400078000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOmViYzlmYWY1MmYzODRhNjE4OWM5NzgyNmMzN2JmODY4L3RhYmxlcmFuZ2U6ZWJjOWZhZjUyZjM4NGE2MTg5Yzk3ODI2YzM3YmY4NjhfNS0zLTEtMS00OTc5OA_0089c5b0-e18d-4599-8fd1-285ca0da7bb4"
      unitRef="usd">280173000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RleHRyZWdpb246M2VhZWVlMDg1MjU1NDhkM2I2YjE4YmQwYmI0NjJlZGNfMTUwNA_516ddf83-466f-4b18-a2d9-7446051fafba">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic5ff574a6987485e9ac601606fe4d9da_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy0xLTEtMS00OTc5OA_6b9f7286-df32-492d-931f-7520bcd74e4d"
      unitRef="usd">30223000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0fb9f2afeb6f4a43b04688b32531d990_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy0zLTEtMS00OTc5OA_1acc433b-492d-483f-9b1c-46649731b5e4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6b1dd88afc154d7e9984607fd2f2361f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy01LTEtMS00OTc5OA_abe39f91-08c6-4820-b532-8237e0fac037"
      unitRef="usd">30223000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic005cf5c954c4ba5a5ccbadc693d99df_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy03LTEtMS00OTc5OA_e4932339-87d3-4fd0-a5ba-3c0f539ba05a"
      unitRef="usd">43653000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6c59b2bf1e764cc0a86c5735a369a0b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy05LTEtMS00OTc5OA_e3ab148b-9b73-4e95-85ef-2d153898eebe"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i48e3c115b00a44bcb25b3dfd9e2e39bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMy0xMS0xLTEtNDk3OTg_5e967e6a-1e1b-45b8-945a-9a5f45cffb52"
      unitRef="usd">43653000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1784ad3c83464579a9a8932fbfe9e598_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC0xLTEtMS00OTc5OA_c3cef3d9-b7d7-4a77-a4dd-73220b497397"
      unitRef="usd">18943000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3761f588efbc4816ae10a0d889c298a0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC0zLTEtMS00OTc5OA_fe5d9d7a-c695-4542-9295-b79b2a3da57d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i57dc0a40165448f8bf4b5ba74eb5fbe9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC01LTEtMS00OTc5OA_015c75ad-8534-43f4-b959-2d4dbf23a5a5"
      unitRef="usd">18943000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i46288b24c23d45c4a2463d010ab350b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC03LTEtMS00OTc5OA_bd059bf4-219b-481c-be31-33c22f25356d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i608e66c1af484e6ea5e6d792778ed0d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC05LTEtMS00OTc5OA_c65c8aa2-d16d-4979-a47d-7286ddf7e6e5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i00cfbef488eb418e92919ac20ba1da40_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNC0xMS0xLTEtNDk3OTg_00686dbe-04fc-472c-83f3-9a9d037db61c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie217c38e068b4202a61b214386647f10_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS0xLTEtMS00OTc5OA_63271cbf-0bcc-4756-a354-c90420626546"
      unitRef="usd">49166000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2698997899df495f800f9a30eeb074a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS0zLTEtMS00OTc5OA_0f7f2c80-7840-40ac-a639-0d7edcd61470"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS01LTEtMS00OTc5OA_2c25bbd0-ffd1-4db9-8176-5a6492711f84"
      unitRef="usd">49166000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia69616f0679f42df9238c4e3b6a87d27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS03LTEtMS00OTc5OA_be46464c-d01b-482d-9ade-487861da9962"
      unitRef="usd">43653000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic5b1bda2786c420f874b7c2291657c6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS05LTEtMS00OTc5OA_007183b5-ea43-4207-bc9f-6cabbcf176b4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfNS0xMS0xLTEtNDk3OTg_e648f08c-8b71-43fc-9035-555c4b4799d9"
      unitRef="usd">43653000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i039e0cbb5b7c4c79b65983450a20902b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC0xLTEtMS00OTc5OA_0563fbab-cba5-4947-a4d3-ed21752db37c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd81d064eadd4c7bbc89294f9f777699_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC0zLTEtMS00OTc5OA_64caf512-9136-46df-9f7f-cd2662e2ed04"
      unitRef="usd">255149000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id40490dd28724db79d06f9d951fd8acd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC01LTEtMS00OTc5OA_79836a32-d254-49a6-900f-27262ba68fa8"
      unitRef="usd">255149000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86dee2bcbeca454481688921ef7935de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC03LTEtMS00OTc5OA_18693ae0-9ea3-4b64-8fc7-040af2e3527d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia7c31a2718ae40079432589bc1229566_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC05LTEtMS00OTc5OA_4de3fa5a-94f4-4fe5-aed4-31e63c8a9b5f"
      unitRef="usd">199277000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ad21f6f392a4d0eab53c3e15b4bfb98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOC0xMS0xLTEtNDk3OTg_b3073666-2065-438f-8d17-3c77d3704d6a"
      unitRef="usd">199277000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41189229a4bd4e0caa35a0023153383e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS0xLTEtMS00OTc5OA_d6788bff-ff25-4658-8b5f-54a4e8bf1dc6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99e4123972044834800ac21f54e63593_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS0zLTEtMS00OTc5OA_0a58146b-fecf-4b32-a6f6-098fe21e4f34"
      unitRef="usd">5004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia08925ab72244888b246b83bf82d4bed_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS01LTEtMS00OTc5OA_8fac47f6-c47e-4260-a3c6-41ca1fd4d877"
      unitRef="usd">5004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba6229d21df445539c2d6bf8fb6643fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS03LTEtMS00OTc5OA_edd778d5-70ee-4032-a409-2239ca64ddc6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccc8555322b941b49bd02a7e8765116e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS05LTEtMS00OTc5OA_974c5ece-b7a5-4cac-a2d5-7d3e19641023"
      unitRef="usd">10078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a784f336c5848288d83ed9d20e70b9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfOS0xMS0xLTEtNDk3OTg_d8d0daa7-8497-404b-bedb-1019faa1c397"
      unitRef="usd">10078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60f5fb8ff10c4cf1bb7736f876b4d48e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtMS0xLTEtNDk3OTg_dd2bd7c3-406e-41af-88e9-bb02686cd075"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9278009b9182442fbf3eb96697bd192b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtMy0xLTEtNDk3OTg_193ae3c1-b610-4b6c-8b81-50a04c876004"
      unitRef="usd">18919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15c97d107fb94103966853f5642d3a1f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtNS0xLTEtNDk3OTg_8dc31691-601b-4ea0-a683-68f4fbafe545"
      unitRef="usd">18919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7014a45299de49eaa9a9df4f081d723f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtNy0xLTEtNDk3OTg_d207de64-fe06-4804-a4dc-ed6ede5ef98c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31315f6337ae4500b1642edc83c1261b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtOS0xLTEtNDk3OTg_6fcb67bd-4ad2-400d-9a44-407e17fab477"
      unitRef="usd">20033000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i110e2b4c6b064ff1879c74f20d1b098c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTAtMTEtMS0xLTQ5Nzk4_1cd0f672-3391-4f0f-b5ab-cc2e6d2bac62"
      unitRef="usd">20033000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81c66ad195194fe2b48c0fbe96882389_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtMS0xLTEtNDk3OTg_c0511a5d-d758-4143-9197-31fe83fa7881"
      unitRef="usd">121006000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1017f13dbbd0440db64ac087de0a0e59_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtMy0xLTEtNDk3OTg_467a1dbd-1485-4271-902b-8a36455499f7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i383f5a4611ed4191a940e97fba342d26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtNS0xLTEtNDk3OTg_998988b7-6ed9-4e9d-8a1e-ee295fba1e33"
      unitRef="usd">121006000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27efde771a3e4e359c95a3ae8018c908_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtNy0xLTEtNDk3OTg_91455be1-de52-42fa-b044-a8645313de78"
      unitRef="usd">50785000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5fa741359e4446b9920193e9ce94fa0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtOS0xLTEtNDk3OTg_d9ad6861-791d-4763-9f40-95b6f71dbf63"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if49279cde51c4e31967f61ac9e91cb63_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTEtMTEtMS0xLTQ5Nzk4_9c770962-39ff-4e68-b8b7-6d57bb32cac9"
      unitRef="usd">50785000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie217c38e068b4202a61b214386647f10_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItMS0xLTEtNDk3OTg_21fb7ebf-0658-4189-b602-ab27d7b4809b"
      unitRef="usd">121006000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2698997899df495f800f9a30eeb074a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItMy0xLTEtNDk3OTg_caca9f13-d6e1-4140-8758-58b66fff5ba6"
      unitRef="usd">279072000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItNS0xLTEtNDk3OTg_466d3ca3-fba8-4992-8893-bd5be43e9bfc"
      unitRef="usd">400078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia69616f0679f42df9238c4e3b6a87d27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItNy0xLTEtNDk3OTg_1aff6a2d-d211-4f12-add5-c7ac1488a12d"
      unitRef="usd">50785000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic5b1bda2786c420f874b7c2291657c6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItOS0xLTEtNDk3OTg_96b66350-e5fb-4df9-a865-c9743d8c424b"
      unitRef="usd">229388000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTItMTEtMS0xLTQ5Nzk4_c53c59cc-69b3-4236-94d0-c60320e34f11"
      unitRef="usd">280173000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie217c38e068b4202a61b214386647f10_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtMS0xLTEtNDk3OTg_e7926379-17cd-40d1-9f9e-4037638274f4"
      unitRef="usd">170172000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2698997899df495f800f9a30eeb074a9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtMy0xLTEtNDk3OTg_fff78a26-e411-4c96-85fc-faacb330afc4"
      unitRef="usd">279072000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtNS0xLTEtNDk3OTg_5982fd01-056d-42c5-8b30-7e99df9095fe"
      unitRef="usd">449244000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia69616f0679f42df9238c4e3b6a87d27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtNy0xLTEtNDk3OTg_a25a2377-c9fe-42ac-961e-e0f24f8e9e53"
      unitRef="usd">94438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic5b1bda2786c420f874b7c2291657c6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtOS0xLTEtNDk3OTg_9db5527e-d4d5-4ed4-901b-eb0a06e22486"
      unitRef="usd">229388000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81Mi9mcmFnOjNlYWVlZTA4NTI1NTQ4ZDNiNmIxOGJkMGJiNDYyZWRjL3RhYmxlOjkzN2NkZjc4M2VjMjQ5MmU5MjM4ZDY5NmY5MDgxMWY3L3RhYmxlcmFuZ2U6OTM3Y2RmNzgzZWMyNDkyZTkyMzhkNjk2ZjkwODExZjdfMTQtMTEtMS0xLTQ5Nzk4_52c4b4f7-d2b2-495a-8967-288b85f1df72"
      unitRef="usd">323826000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:OtherAssetsDisclosureTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RleHRyZWdpb246M2I4Y2I3MzZjMjU4NDYzNDhiNjAyNGNlODhiZWJjNmJfMTIw_85a53211-6a28-4c42-b2d8-ecdbac2bab8f">Prepaid Expenses and Other Assets&lt;div style="margin-bottom:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid software licenses and maintenance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign R&amp;amp;D credit refund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zentera receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RleHRyZWdpb246M2I4Y2I3MzZjMjU4NDYzNDhiNjAyNGNlODhiZWJjNmJfMTIx_d70cd23d-ed71-4ea2-a8cd-bce8217487e1">&lt;div style="margin-bottom:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid software licenses and maintenance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign R&amp;amp;D credit refund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zentera receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMi0xLTEtMS00OTc5OA_d15d4690-7e78-4a8b-8f25-2fe125094ca9"
      unitRef="usd">2324000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMi0zLTEtMS00OTc5OA_3d78a08b-0af2-41e6-9a3d-dbb3e2925bef"
      unitRef="usd">990000</us-gaap:PrepaidInsurance>
    <zntl:PrepaidSoftwareLicenseAndMaintenance
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMy0xLTEtMS00OTc5OA_3d714318-a041-4d04-a768-ce2a1b90fa76"
      unitRef="usd">483000</zntl:PrepaidSoftwareLicenseAndMaintenance>
    <zntl:PrepaidSoftwareLicenseAndMaintenance
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMy0zLTEtMS00OTc5OA_657a03d1-e2b4-482c-9e81-50b418fbcfa1"
      unitRef="usd">403000</zntl:PrepaidSoftwareLicenseAndMaintenance>
    <zntl:ForeignResearchAndDevelopmentCreditRefund
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNC0xLTEtMS00OTc5OA_dece552a-4030-4900-a6fa-3fd883cf572b"
      unitRef="usd">1719000</zntl:ForeignResearchAndDevelopmentCreditRefund>
    <zntl:ForeignResearchAndDevelopmentCreditRefund
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNC0zLTEtMS00OTc5OA_994657da-5e84-420b-b91c-76bba64e988a"
      unitRef="usd">1808000</zntl:ForeignResearchAndDevelopmentCreditRefund>
    <zntl:PrepaidResearchAndDevelopmentCosts
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNS0xLTEtMS00OTc5OA_7ccee1a2-6897-493f-9c4e-0de4987addb6"
      unitRef="usd">15909000</zntl:PrepaidResearchAndDevelopmentCosts>
    <zntl:PrepaidResearchAndDevelopmentCosts
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNS0zLTEtMS00OTc5OA_54656d9a-543c-4908-a388-d28e1dc05023"
      unitRef="usd">11204000</zntl:PrepaidResearchAndDevelopmentCosts>
    <us-gaap:InterestReceivable
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNi0xLTEtMS00OTc5OA_cc8ca2dc-97aa-440b-8376-9755ad349c8c"
      unitRef="usd">465000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNi0zLTEtMS00OTc5OA_44b57f14-aa55-41e1-acb9-3dabdba271ca"
      unitRef="usd">258000</us-gaap:InterestReceivable>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNy0xLTEtMS00OTc5OA_337d63cf-60ed-4218-9c9a-04b9a7f618bd"
      unitRef="usd">2981000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfNy0zLTEtMS00OTc5OA_43abfda4-be7c-4ff6-a44c-736c20e6b964"
      unitRef="usd">2373000</us-gaap:DueFromRelatedPartiesCurrent>
    <zntl:OtherPrepaidExpense
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfOC0xLTEtMS00OTc5OA_075d5808-4c6b-4d45-a891-16101eb74d47"
      unitRef="usd">462000</zntl:OtherPrepaidExpense>
    <zntl:OtherPrepaidExpense
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfOC0zLTEtMS00OTc5OA_90161cc4-0b84-439e-a70b-af7be0a63a6c"
      unitRef="usd">644000</zntl:OtherPrepaidExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfOS0xLTEtMS00OTc5OA_450d1e3b-d066-487d-8e5f-bd66144a27b8"
      unitRef="usd">24343000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfOS0zLTEtMS00OTc5OA_51d5a772-3bcf-42a4-ac8a-94b8862526fc"
      unitRef="usd">17680000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMTAtMS0xLTEtNDk3OTg_688461c8-c4f0-4d40-8057-dcc5f03abd75"
      unitRef="usd">11938000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMTAtMy0xLTEtNDk3OTg_eb2a8998-d406-43ca-8711-73bbc0d261bc"
      unitRef="usd">7040000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMTEtMS0xLTEtNDk3OTg_f76358f2-0e14-4991-b3dc-87c61a5dc34a"
      unitRef="usd">12405000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81NS9mcmFnOjNiOGNiNzM2YzI1ODQ2MzQ4YjYwMjRjZTg4YmViYzZiL3RhYmxlOmI2YmViOTUyYjkxODQ4YTlhNGFkYmUzYWIwMWFmMmJiL3RhYmxlcmFuZ2U6YjZiZWI5NTJiOTE4NDhhOWE0YWRiZTNhYjAxYWYyYmJfMTEtMy0xLTEtNDk3OTg_52e05df5-b558-4833-a6bc-e7b4085c0223"
      unitRef="usd">10640000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfMjQ3_e732759c-b5df-4aaf-bfd3-82baf1643c93">Property and Equipment, net&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for the three months ended June&#160;30, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt; was approximately $348 thousand and $119 thousand, respectively. Depreciation and amortization expense for the six months ended June&#160;30, 2022 and 2021 was approximately $692 and $198 thousand, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfMjQ2_acb1d1f3-8e29-42ac-92ac-76641287f720">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia32cba1a7c584481935d18ab5b6e3052_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfMy0xLTEtMS00OTc5OA_3711e9f7-f8ae-4023-9e53-8347bd87de53"
      unitRef="usd">2585000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id5f415d9e7e84e6390821b2aeca98c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfMy0zLTEtMS00OTc5OA_e5883624-209b-4c00-9345-c5a18ab44923"
      unitRef="usd">2057000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icd1665e0a46248bdbece57a6438e0879_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNC0xLTEtMS00OTc5OA_64b2ffcf-6c96-4553-92ed-a031642a2482"
      unitRef="usd">4649000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iee10f69caf0d40ba94ea1e00633d0b5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNC0zLTEtMS00OTc5OA_53a5f87e-0a25-4513-a8f5-391c13fab892"
      unitRef="usd">4515000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia1bd11cea6cd49bfbd84c09bd6e1c561_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNS0xLTEtMS00OTc5OA_9911dcd1-7559-42cc-b6c4-fb7ddb264fb4"
      unitRef="usd">2065000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ica13a2bb8504414b9caaf996da34fe6c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNS0zLTEtMS00OTc5OA_62cde88a-d5b6-48a4-97d4-54ffaa85b635"
      unitRef="usd">2123000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0f99dba567644e889110abb67dd9dc2e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNi0xLTEtMS00OTc5OA_740113e9-3d34-45f8-ae74-cf1bb421da50"
      unitRef="usd">150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0b3eed1bbd49485bba0b0ac55976ff5b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNi0zLTEtMS00OTc5OA_54572f26-2fa6-4276-a4ed-23e1a03a0b63"
      unitRef="usd">211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7b47b8406e04436e962c6cf09f56a781_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNy0xLTEtMS00OTc5OA_e2427f48-1d1f-47c6-b74e-bad1578c8bf0"
      unitRef="usd">97000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ife734a5c6be14dfeb15a20d958641bd0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfNy0zLTEtMS00OTc5OA_d61d0280-99aa-4eb0-86bd-4c59468acc88"
      unitRef="usd">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfOC0xLTEtMS00OTc5OA_6d2e4e03-ac42-4998-a199-fda18dfb45d4"
      unitRef="usd">9546000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfOC0zLTEtMS00OTc5OA_2bba1c26-f629-4e75-82a4-4e3d265438cf"
      unitRef="usd">8940000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfOS0xLTEtMS00OTc5OA_0d6a5f63-72ec-4595-a008-a55ead05427d"
      unitRef="usd">1328000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfOS0zLTEtMS00OTc5OA_915f97bd-a711-484f-b1db-43ee4337f473"
      unitRef="usd">792000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfMTAtMS0xLTEtNDk3OTg_f6231adc-27b6-4a8d-9242-c2eeac437b25"
      unitRef="usd">8218000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RhYmxlOjIwMDc2MWViZjRjMjQ3ZWE5MTlkOWIzNWY4ZjQzZWM3L3RhYmxlcmFuZ2U6MjAwNzYxZWJmNGMyNDdlYTkxOWQ5YjM1ZjhmNDNlYzdfMTAtMy0xLTEtNDk3OTg_0eb1d9b2-1066-4819-a432-13a0f02bf474"
      unitRef="usd">8148000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfOTg5NTYwNDY1MDM4OA_2fb72a9d-d0d2-4bab-a5d6-4c2886f590b0"
      unitRef="usd">348000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfMjIw_2479932f-ae76-4fd9-be44-1a87ee01aca4"
      unitRef="usd">119000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfNTQ5NzU1ODE0MjQx_355c0573-6b13-430c-91b4-bcbe9d3734dc"
      unitRef="usd">692000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF81OC9mcmFnOjQ1ZWI1NjAxZDQ1ODQ5NThiMzNmODhkMDM4NTdlZGM3L3RleHRyZWdpb246NDVlYjU2MDFkNDU4NDk1OGIzM2Y4OGQwMzg1N2VkYzdfNTQ5NzU1ODE0MjU1_62f67200-ada2-402e-a30d-75e15a1759ee"
      unitRef="usd">198000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RleHRyZWdpb246NjQwMGMxMWZmMGI0NGM1MGI1ZDVkMGZjNDJiMDkyYjJfODM_a8e69bd3-fe0a-4c43-a4fd-032ba501c73c">Accrued Expenses&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RleHRyZWdpb246NjQwMGMxMWZmMGI0NGM1MGI1ZDVkMGZjNDJiMDkyYjJfODQ_ad1f3cc3-70b2-441d-9128-fceeffeba9e6">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <zntl:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfMi0xLTEtMS00OTc5OA_767d8561-1111-4289-8415-de52adc0dd06"
      unitRef="usd">23745000</zntl:AccruedResearchAndDevelopmentCostsCurrent>
    <zntl:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfMi0zLTEtMS00OTc5OA_fb065cbc-4704-4499-8d30-05df708bd69a"
      unitRef="usd">18531000</zntl:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfMy0xLTEtMS00OTc5OA_a64d7a45-6042-4acd-90c9-677d0bc10fa3"
      unitRef="usd">8195000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfMy0zLTEtMS00OTc5OA_aee5830c-4d9c-439c-a610-896ac1d8f5d4"
      unitRef="usd">9250000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNC0xLTEtMS00OTc5OA_40fed080-1ce2-445b-919d-949b32363b6e"
      unitRef="usd">1372000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNC0zLTEtMS00OTc5OA_5826867d-1cab-4435-8bca-9dd5dfc6f7f4"
      unitRef="usd">669000</us-gaap:AccruedProfessionalFeesCurrent>
    <zntl:AccruedGeneralAndAdministrativeCostsCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNS0xLTEtMS00OTc5OA_a53c9032-2e37-431c-bbf2-cfd1d30f93a3"
      unitRef="usd">856000</zntl:AccruedGeneralAndAdministrativeCostsCurrent>
    <zntl:AccruedGeneralAndAdministrativeCostsCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNS0zLTEtMS00OTc5OA_5af3a954-17d3-4ba9-b7a5-8df676780ae5"
      unitRef="usd">1480000</zntl:AccruedGeneralAndAdministrativeCostsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNi0xLTEtMS00OTc5OA_63f0aab7-ea26-437b-b3c5-a368ad56e84f"
      unitRef="usd">1733000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNi0zLTEtMS00OTc5OA_d88476b6-e67f-49dd-9c66-be4b01c8e5c4"
      unitRef="usd">1453000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNy0xLTEtMS00OTc5OA_a86b1038-57b1-41a1-bbe6-157302f03936"
      unitRef="usd">694000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfNy0zLTEtMS00OTc5OA_64ebbb2a-c75b-43e1-9290-345c055f469d"
      unitRef="usd">971000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfOS0xLTEtMS00OTc5OA_2347bb27-070d-4621-a440-6c07b4746482"
      unitRef="usd">36595000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82MS9mcmFnOjY0MDBjMTFmZjBiNDRjNTBiNWQ1ZDBmYzQyYjA5MmIyL3RhYmxlOjM0ZjUzNDA1ZjlmMTRkY2ZhNGViOWQzNDIzYmUwYjc3L3RhYmxlcmFuZ2U6MzRmNTM0MDVmOWYxNGRjZmE0ZWI5ZDM0MjNiZTBiNzdfOS0zLTEtMS00OTc5OA_8590435c-8441-4e3e-abc2-dc894d5d8f33"
      unitRef="usd">32354000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDM3NA_fb4cd72f-9903-42bc-b76b-ae5531b2c6a1">Stockholders&#x2019; Equity &lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Direct Offering of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 29, 2022, pursuant to our Registration Statement on Form S-3 (Registration No. 333-255769), filed with the SEC on May 4, 2021, we completed a direct offering of common stock to Pfizer Inc. (&#x201c;Pfizer&#x201d;). We issued and sold 953,834 shares of our common stock at an offering price of $26.21 per share. The total gross proceeds for the offering were approximately $25.0 million, before deducting offering expenses of $0.3 million payable by us. The parties have entered into an agreement to collaborate to advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells. We did not grant Pfizer any economic ownership or control of ZN-c3 or the rest of our pipeline. $4.2&#160;million of the gross offering proceeds received from Pfizer represented a premium in excess of the fair value of our common stock on the date of the investment. This amount has been recorded as accrued research and development expense on the unaudited condensed consolidated balance sheet and will be recognized as a reduction of research and development expense over the term of the collaboration agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Follow-on Offering of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 18, 2022, we completed a follow-on offering in which we issued and sold 10,330,000 shares of common stock at a public offering price of $19.38 per share. The total gross proceeds for the offering were approximately $200.2 million, before deducting offering expenses of $11.4 million payable by us.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2020, the Company&#x2019;s Board of Directors adopted, and the Company&#x2019;s stockholders approved the 2020 Incentive Award Plan (the &#x201c;2020 Plan&#x201d;), which allows for grants to selected employees, consultants and non-employee members of the Board of Directors. We currently grant stock options and restricted stock units (&#x201c;RSUs&#x201d;), under the 2020 Plan. The number of common shares available for issuance under the 2020 Plan is the sum of (1) 5,600,000 shares of common stock; plus (2) any shares forfeited from the unvested restricted shares of our common stock issued upon conversion of unvested Class B common units (up to 1,250,000 shares); plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ending December 31, 2021 and continuing to, and including, the fiscal year ending December 31, 2030, equal to the lesser of (a) 5% of the shares of common &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by our Board of Directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2022, 8,300,142 shares were subject to outstanding awards under the 2020 Plan and 284,429 shares were available for future grants of share-based awards under the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company&#x2019;s Board of Directors approved the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (the &#x201c;2022 Inducement Plan&#x201d;), which is used exclusively for the grant of equity awards to new employees as an inducement material to the employees&#x2019; entering into employment with the Company. The Board of Directors has initially reserved 1,500,000 shares of the Company&#x2019;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to share based awards was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense for the six months ended June&#160;30, 2022 and 2021 includes $0 and  $138&#160;thousand, respectively, of share-based compensation expense for employees, consultants and directors of Zentera.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options granted is equal to the closing price of the Company&#x2019;s common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes model. Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company uses the &#x201c;simplified method&#x201d; for estimating the expected term of employee options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero. The fair value of the stock options granted during the six months ended June&#160;30, 2022 and June&#160;30, 2021 was determined with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.6% - 80.5%%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.1% - 76.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 - 6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 - 6.2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5% - 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5% - 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2020, the Company&#x2019;s Board of Directors adopted, and the Company&#x2019;s stockholders approved the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which was subsequently amended and restated effective March 15, 2021. The maximum aggregate number of shares of the Company&#x2019;s common stock available for issuance under the ESPP at June 30, 2022 was 1,969,608. Under the terms of the ESPP, the Company&#x2019;s employees may elect to have up to 20% of their compensation, up to a maximum of $21,250 per calendar year, withheld to purchase shares of the Company&#x2019;s common stock for a purchase price equal to 85% of the lower of the fair market value per share (at closing) of the Company&#x2019;s common stock on (i) the first trading day of a six-month offering period, or (ii) the applicable purchase date, defined as the last trading day of the six-month offering period. The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.846%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense Summary&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.256%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized &lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining &lt;br/&gt;Weighted-Average Recognition Period &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022, we issued 42.0&#160;thousand shares of common stock in connection with the exercises of stock options. For the six months ended June&#160;30, 2022, 0.1 million shares of common stock &lt;/span&gt;&lt;/div&gt;issued in conjunction with certain restricted stock awards (&#x201c;RSAs&#x201d;), vested. Outstanding stock options, unvested RSAs, and unvested RSUs totaling approximately 7.8&#160;million shares, 0.2&#160;million shares and 0.5&#160;million shares of our common stock, respectively, were outstanding as of June&#160;30, 2022.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7f1b085c0bc6418984b4a5652a0f3059_D20220429-20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODE4NTkz_490d5573-5dce-452d-9c63-9eb9badc6012"
      unitRef="shares">953834</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i569a69ed2aa54cd6a4ae5aa666ff442a_I20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODE4NjQ4_ecb484bf-31e3-48e1-98d7-03c8d7c14768"
      unitRef="usdPerShare">26.21</us-gaap:SaleOfStockPricePerShare>
    <zntl:ProceedsFromIssuanceOfCommonStockGross
      contextRef="i7f1b085c0bc6418984b4a5652a0f3059_D20220429-20220429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIwNjc4_ae039bd9-b158-4cf5-889a-e31f5e3b9b18"
      unitRef="usd">25000000.0</zntl:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i7f1b085c0bc6418984b4a5652a0f3059_D20220429-20220429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIwNjg1_18745b3e-43bb-4abc-98a5-b753ac21696e"
      unitRef="usd">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <zntl:ProceedsFromIssuanceOfCommonStockGross
      contextRef="ifc20ff4317e549b195078a8c6d397c35_D20220429-20220429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNzY3NQ_6812deac-66d6-4308-968b-1f3339eb40c4"
      unitRef="usd">4200000</zntl:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if223d394e54b4750aa978efb34cba0d1_D20220518-20220518"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODE5OTQ5_466796a3-23bb-4eab-bd94-0db6a9f79994"
      unitRef="shares">10330000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5136c20b0b3448728a094b8bde8584e3_I20220518"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIwMjMw_21fc1150-8750-4773-afe2-7d71a80ebf6b"
      unitRef="usdPerShare">19.38</us-gaap:SaleOfStockPricePerShare>
    <zntl:ProceedsFromIssuanceOfCommonStockGross
      contextRef="if223d394e54b4750aa978efb34cba0d1_D20220518-20220518"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIwMzI5_20aa831e-7667-49d6-ac2e-1f4f9683bce3"
      unitRef="usd">200200000</zntl:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="if223d394e54b4750aa978efb34cba0d1_D20220518-20220518"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIwMzQ5_fc779e83-4d76-4501-980c-55ad876bf48a"
      unitRef="usd">11400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i1195842e7bad4796adc5d3f33b370980_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDc4_6e0d0ac3-23e5-48b7-823e-4ae0e58e1a86"
      unitRef="shares">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i451d05a387bc4e28bfaa0c622d3e53b7_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNjU0_c2028c02-cc19-464b-83d2-22852cbbdfb5"
      unitRef="shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease
      contextRef="i224274cfab6347e4af0e47b9f95e96ac_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfODkw_dca396d3-4f2c-4b29-89bc-c47091dae06e"
      unitRef="number">0.05</zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i84a3bb6a8e4a4aadaca19939a0d400a0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNDM1Nw_0a9fe908-9e8d-45b4-ba74-c21649a24719"
      unitRef="shares">8300142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i84a3bb6a8e4a4aadaca19939a0d400a0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNDM2OA_fecf0ee0-297f-4bb9-a3b3-c4f6fca76978"
      unitRef="shares">284429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ibcb817854a7743afa79c27dc1d29457d_I20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNzY4OQ_53f1bf92-d2d0-452c-ba1d-54dfc8ba30c4"
      unitRef="shares">1500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDM2Ng_70066ad7-d221-48e2-a6e7-8076c787b3bc">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to share based awards was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0a591ae027674ec48804343c4347f2e3_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMi0xLTEtMS00OTc5OA_82d29b27-4806-4abf-a03d-3ce98740277c"
      unitRef="usd">5155000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieed3e9f3f3094029b5dfa3ccb2bc6788_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMi0zLTEtMS00OTc5OA_4d44e94e-2a3b-49a4-a6ca-4c9022248f82"
      unitRef="usd">3923000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if24f63e9218a428f8bf2dd3b117c02ec_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMi01LTEtMS00OTc5OA_94e10ae6-0895-48ec-881a-0eac2e5f5a96"
      unitRef="usd">10197000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ee6e27237af4336b5fc9bd4e9f7d48a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMi03LTEtMS00OTc5OA_256eecc7-b829-4e38-ac6a-7a884402f778"
      unitRef="usd">7049000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i83eb79dfc5df4e11adeeb75938b1d7f0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMy0xLTEtMS00OTc5OA_bf682314-8759-4a66-9672-c3f4c39f69d1"
      unitRef="usd">11609000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i44dd3cb1c0574feea2624c386be77ec7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMy0zLTEtMS00OTc5OA_6d81ac22-8d5f-48e3-8dd1-76f93ac47f87"
      unitRef="usd">5996000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if83d444b0887436c87fef11dcef2e86a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMy01LTEtMS00OTc5OA_e3fcc46b-7843-47a4-9e41-dafc76fbe225"
      unitRef="usd">16714000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa2780f94d8d42288f13f874db45fd67_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfMy03LTEtMS00OTc5OA_e3f7a0b2-9114-4e32-a750-7a774292ab3c"
      unitRef="usd">12561000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfNC0xLTEtMS00OTc5OA_f5f957bf-43b7-4862-98a8-d8dd786588fb"
      unitRef="usd">16764000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfNC0zLTEtMS00OTc5OA_4d4ecd6f-c511-46a4-920c-4af0037674ac"
      unitRef="usd">9919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfNC01LTEtMS00OTc5OA_34512fc3-ef9a-49f8-be5c-0725ceb187ec"
      unitRef="usd">26911000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjkzZDFkNTg4NWYzMzRhMjZhNTc1YTE1YTQ2NjQwYzJkL3RhYmxlcmFuZ2U6OTNkMWQ1ODg1ZjMzNGEyNmE1NzVhMTVhNDY2NDBjMmRfNC03LTEtMS00OTc5OA_61caea73-d975-4f60-8f02-9de3983764d3"
      unitRef="usd">19610000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="ie30a5375c819427c8694c4b2774b9e9b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTQwNA_2c9bc572-519f-43f2-9f53-cd70822a5ce0"
      unitRef="usd">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="i412b968f7b08436b9aa7f54bde3682ea_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTQxMg_a934d39c-1333-4683-99f0-8e60c1bacbee"
      unitRef="usd">138000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i644b2805dacd408b8e97b86dd46abb55_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfMy0xLTEtMS00OTc5OA_d34f85df-9e0e-4ae5-b07f-ab4f8a0e10c7"
      unitRef="usd">12524000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94e8c09b4a3445298e64940b137301f9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfMy0zLTEtMS00OTc5OA_cd93ee3c-c078-4aa4-8b07-b38dd486adc3"
      unitRef="usd">4820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfMy01LTEtMS00OTc5OA_ed066336-e7aa-4540-866c-ba4494614254"
      unitRef="usd">20302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfMy03LTEtMS00OTc5OA_9842c3bb-5f0f-4c53-b057-656459ed61f4"
      unitRef="usd">8671000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8047842fd47f4f2f8278a39d6e1230e3_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNC0xLTEtMS00OTc5OA_99cb08a4-a747-4693-b6fe-f1cd982fec94"
      unitRef="usd">110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib3f359d04969451b952bf5cfc0d87b34_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNC0zLTEtMS00OTc5OA_24af8d57-f947-44c5-b26e-539992b412c3"
      unitRef="usd">110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNC01LTEtMS00OTc5OA_26858ff9-8fe3-4507-b352-45890d74b6a5"
      unitRef="usd">212000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7b6d6db52cc441d5980a322a0c13d3c3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNC03LTEtMS00OTc5OA_6d7ac444-d2e8-4cba-8488-bbe876852365"
      unitRef="usd">110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9beff74796b74e7a9a2e80f6198c9feb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNS0xLTEtMS00OTc5OA_2892de02-df26-4f66-b2fc-b8fe1ff49ef5"
      unitRef="usd">4130000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i47314e35042849da943c497cbcc052f6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNS0zLTEtMS00OTc5OA_f75d3aab-b430-4af3-bfcd-812bc5636a72"
      unitRef="usd">4989000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2715dfb0dea34fb2ba4b3115eda88efe_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNS01LTEtMS00OTc5OA_88dfb88e-5306-44b4-b07e-50eb128dfe54"
      unitRef="usd">6397000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f29867c289543609894effb0ecd7862_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNS03LTEtMS00OTc5OA_e8091701-a3e3-492e-a7d3-387e0fc4523f"
      unitRef="usd">10829000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNi0xLTEtMS00OTc5OA_e274787d-b58c-4fc8-b32d-140d66e59cb8"
      unitRef="usd">16764000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNi0zLTEtMS00OTc5OA_2a2944a6-a147-442b-b418-60a330ebe7a2"
      unitRef="usd">9919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNi01LTEtMS00OTc5OA_a147cd19-a5cd-402b-ab64-1b9a008cd2b7"
      unitRef="usd">26911000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjVhYjYxYTYyNDdhNzQwMGFiNmFkMzliMDE4Y2NmM2QxL3RhYmxlcmFuZ2U6NWFiNjFhNjI0N2E3NDAwYWI2YWQzOWIwMThjY2YzZDFfNi03LTEtMS00OTc5OA_fa688046-5f6a-4913-bec6-e588bcd06abd"
      unitRef="usd">19610000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDM3MA_f2c0b56d-4974-4e55-b055-52405472283e">The fair value of the stock options granted during the six months ended June&#160;30, 2022 and June&#160;30, 2021 was determined with the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.6% - 80.5%%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.1% - 76.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 - 6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 - 6.2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5% - 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5% - 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm
      contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMjU0MQ_fa788c08-0c71-478a-9054-33fdd8aa9234">P10Y</zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMjg4MQ_1545b9d8-34d1-412f-90a2-a1b6de63d62b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMS0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOmNhYjk0ODhkNDM1ZjRkZWVhODNjMjk1NTI0ZmE1ZjE4Xzk4OTU2MDQ2NTAwMDY_7aa0f6bf-bbb2-46eb-9ac4-0c8f015a7e4e"
      unitRef="number">0.736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMS0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOmNhYjk0ODhkNDM1ZjRkZWVhODNjMjk1NTI0ZmE1ZjE4Xzk4OTU2MDQ2NTAwMTM_23e60c5e-5edb-49a6-a67d-58c347f0e667"
      unitRef="number">0.805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMS0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOjQ1YjQ3YjczNTA0ZTRkZGY4MGU3NTYwZDhjOTI3MGExXzQ_79c2c0cc-0025-4a42-a603-b32b4b5103d8"
      unitRef="number">0.751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMS0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOjQ1YjQ3YjczNTA0ZTRkZGY4MGU3NTYwZDhjOTI3MGExXzk_efc768ca-91c0-4a20-8285-f668da0b7c84"
      unitRef="number">0.766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iaef89f53ab20478f942e34396c28ad99_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMi0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOjJjYWNjZmJjODBkNzQ1YzU4YWFmOGE0MGI2OGJlODg3XzQ_4dbd0665-9224-457b-ad81-fad13155bf21">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2e90d2bfdd054eeebf7e538c70e8a560_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMi0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOjJjYWNjZmJjODBkNzQ1YzU4YWFmOGE0MGI2OGJlODg3Xzk4OTU2MDQ2NTAwMDI_4283bcda-027e-49c0-afd5-9452747886a1">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i340692408be44878952df6f49a437468_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMi0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOmM2ZDE0MGQ4NTk1NjRiNjM4Nzg2MTAyZmM2ZDVkMjg2XzQ_9eca643a-0d76-48c6-afe3-aff22a811345">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0914aa0549284d0f8c6c232168700055_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMi0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOmM2ZDE0MGQ4NTk1NjRiNjM4Nzg2MTAyZmM2ZDVkMjg2Xzk_e9f9e49a-d632-4796-bc12-a450b132d744">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMy0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOjdlZGYxYzVlM2U3ZjRlMjU4NjRiYjMyMjAxNDY3NmNmXzk4OTU2MDQ2NTAwMTA_2e483fde-dd90-4bce-b49e-3aabb23da1cd"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMy0xLTEtMS00OTc5OC90ZXh0cmVnaW9uOjdlZGYxYzVlM2U3ZjRlMjU4NjRiYjMyMjAxNDY3NmNmXzk4OTU2MDQ2NTAwMDM_707cb3e8-c68c-445f-b0da-dba32b06478a"
      unitRef="number">0.032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMy0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOjkxYjIyYmY4ZWUyNTQ3MjJiNjQwNGZlOTkxODVjOGM4XzQ_8ad01238-30e0-4905-a351-4530ad1aae2f"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfMy0zLTEtMS00OTc5OC90ZXh0cmVnaW9uOjkxYjIyYmY4ZWUyNTQ3MjJiNjQwNGZlOTkxODVjOGM4Xzk_8b4e04e0-4348-487b-85dc-939fe35db9eb"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfNC0xLTEtMS00OTc5OA_773ac9d9-4717-46ab-9d26-55a5785a151f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8105fc10f58247869a63e399e7cf42bc_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOmIyMjVhYjNhMGM0ZjQ1MTY4ODA0N2U5NDRhNzAyMDY0L3RhYmxlcmFuZ2U6YjIyNWFiM2EwYzRmNDUxNjg4MDQ3ZTk0NGE3MDIwNjRfNC0zLTEtMS00OTc5OA_a1dbaae6-bfb4-4aae-b00e-bdb5dee639cc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i07bfbcc2813a425a9f14affe9ac623f0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNzcwMA_c39fed57-048e-4b85-8599-730f4d74a2ea"
      unitRef="shares">1969608</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i07bfbcc2813a425a9f14affe9ac623f0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIzMzY4_a89f2b51-772a-4d1e-98fe-8ff08e429b5e"
      unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount
      contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIzNDE0_96d0b2b5-86e8-40a1-8882-196ee3973c5d"
      unitRef="usd">21250</zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNTQ5NzU1ODIzNTI1_a71c6418-b6ab-434b-a24e-472efdc132cb"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNzcxMA_a7b3e8b7-f99b-438a-a234-2bde6f41ac41">P6M</zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNzcxMQ_447d6837-4399-4a8f-8c11-345eb4c3be19">P6M</zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDM3Mg_1e8fb9b9-2296-4b2f-bb7d-534005bb95c6">The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.846%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjE0YzE2YjY5YTkwYTRkYzdhMTJhZjU1NzhiZTZjMGM5L3RhYmxlcmFuZ2U6MTRjMTZiNjlhOTBhNGRjN2ExMmFmNTU3OGJlNmMwYzlfMy0zLTEtMS00OTc5OA_fd162dd9-8744-42b4-a0eb-28bae745f2b9"
      unitRef="number">0.733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjE0YzE2YjY5YTkwYTRkYzdhMTJhZjU1NzhiZTZjMGM5L3RhYmxlcmFuZ2U6MTRjMTZiNjlhOTBhNGRjN2ExMmFmNTU3OGJlNmMwYzlfNC0zLTEtMS00OTc5OA_a558c45b-d279-4f7e-9cb4-60833db773d8">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjE0YzE2YjY5YTkwYTRkYzdhMTJhZjU1NzhiZTZjMGM5L3RhYmxlcmFuZ2U6MTRjMTZiNjlhOTBhNGRjN2ExMmFmNTU3OGJlNmMwYzlfNS0zLTEtMS00OTc5OA_46bb2aec-d35f-461a-8960-61c5b8785cba"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjE0YzE2YjY5YTkwYTRkYzdhMTJhZjU1NzhiZTZjMGM5L3RhYmxlcmFuZ2U6MTRjMTZiNjlhOTBhNGRjN2ExMmFmNTU3OGJlNmMwYzlfNi0zLTEtMS00OTc5OA_eddaee82-3b48-450f-a595-998a3cc64123"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDM3Mw_a3947fc5-1c20-4697-bb24-2fd8de74b5db">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.256%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized &lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining &lt;br/&gt;Weighted-Average Recognition Period &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i6848464a8da644618f62c064bead2a58_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfMi0xLTEtMS00OTc5OA_439331dc-5a72-43d2-912a-c576f0d2aa5b"
      unitRef="usd">117461000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i575ec7487094412380df5d1d84056a75_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfMi0zLTEtMS00OTc5OA_7903e32b-0f4b-407a-9eb6-604e688c7560">P3Y3M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i0503299777e24da1a507027233084ab8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfMy0xLTEtMS00OTc5OA_5e10fd37-58ff-4351-a0ff-8a39209fcf09"
      unitRef="usd">569000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i198c9b7202d64e788574e76bcbac5063_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfMy0zLTEtMS00OTc5OA_8c9388bf-49f5-42d8-9f73-f033c4c60ca4">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id3258b88db0a48128947746c61ed2f7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfNC0xLTEtMS00OTc5OA_7bd04436-ec38-454f-86f3-c05b10dec01c"
      unitRef="usd">13278000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2c688c67b897412c81a7a8199ad39a9d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfNC0zLTEtMS00OTc5OA_f18761c0-fb1f-4430-96a6-961f8e4b8671">P3Y1M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i07bfbcc2813a425a9f14affe9ac623f0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfNS0xLTEtMS00OTc5OA_4008587f-01f5-4926-a2e8-7e314a1089ea"
      unitRef="usd">110000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RhYmxlOjBlNzRhZTU3NDVmMTRkYzM5Y2NiZjk5ZDU3MTM4OTczL3RhYmxlcmFuZ2U6MGU3NGFlNTc0NWYxNGRjMzljY2JmOTlkNTcxMzg5NzNfNS0zLTEtMS00OTc5OA_8c703a1c-90a0-4f72-92e9-2c5783ea6667">P0Y3M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNDM3Nw_f2fb0303-9b89-4900-83ff-a0f92d4fcba4"
      unitRef="shares">42000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfNDA0OQ_c87939f9-e399-4a1e-89f4-b60bebc6ecf6"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6848464a8da644618f62c064bead2a58_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNDM5NA_709666b9-5f2e-4169-b298-2cf0afc111e5"
      unitRef="shares">7800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i0503299777e24da1a507027233084ab8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMTA5OTUxMTYzNDQwNw_74869aa1-2fb4-4b79-8cfd-47c674a5726b"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="id3258b88db0a48128947746c61ed2f7b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82NC9mcmFnOmViMjQ2NWFkZTQwMzQyY2ViYTEwZDMwMmMxMTI5MzU4L3RleHRyZWdpb246ZWIyNDY1YWRlNDAzNDJjZWJhMTBkMzAyYzExMjkzNThfMjE5OTAyMzI2MjE5Ng_955cb043-a63d-4c9d-ad6a-5a6380ff3e27"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RleHRyZWdpb246MjE1Y2VhYTI3OWE0NDE0ODhlMTk1ZGZkYjFkODUxYmZfMTg4MQ_feabccef-8907-4009-91d4-0c92d9827836">Commitments and Contingencies&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;From time to time, we may be involved in various disputes, including lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any of these claims could subject us to costly legal expenses. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the consolidated financial statements not misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in our consolidated financial statements. While we do generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, or our policy limits may be inadequate to fully satisfy any damage awards or settlement. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings that require a loss liability to be recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our commitments include payments related to operating leases. Approximate annual future minimum operating lease payments as of June&#160;30, 2022 are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted-average remaining lease term of our operating leases is approximately 10.3 years.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RleHRyZWdpb246MjE1Y2VhYTI3OWE0NDE0ODhlMTk1ZGZkYjFkODUxYmZfMTg4Mg_91b7c0a3-f053-4dde-9d1f-0af1c3c044cd">Approximate annual future minimum operating lease payments as of June&#160;30, 2022 are as follows (in thousands): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfMS0yLTEtMS00OTc5OA_a443e066-7931-456c-84e0-ce95a4b1fe3f"
      unitRef="usd">1602000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfMi0yLTEtMS00OTc5OA_c946b104-b4eb-4838-9212-1df7b23b1e7b"
      unitRef="usd">6340000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfMy0yLTEtMS00OTc5OA_25d772f9-3d7b-4a36-94fd-bbef84b1651a"
      unitRef="usd">6486000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfNC0yLTEtMS00OTc5OA_906fcb74-66f7-4d73-8989-3e44a40c89c8"
      unitRef="usd">6799000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfNS0yLTEtMS00OTc5OA_2c24569a-d9e2-4d57-a277-a0b5337131a1"
      unitRef="usd">7278000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <zntl:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfNi0yLTEtMS00OTc5OA_5f2df474-f414-4db7-bcb0-a831d6e382a3"
      unitRef="usd">46229000</zntl:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfNy0yLTEtMS00OTc5OA_55f9abc0-95ba-420e-8ee8-ee5695317c51"
      unitRef="usd">74734000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfOC0yLTEtMS00OTc5OA_417a0563-cf11-48ea-8516-d5980dd5537b"
      unitRef="usd">27929000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfOS0yLTEtMS00OTc5OA_34ccefaf-5dea-4c53-80e2-5068b83a5308"
      unitRef="usd">46805000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfMTAtMi0xLTEtNDk3OTg_57fb0e35-eaea-4791-af30-e5ff28c5adac"
      unitRef="usd">1733000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RhYmxlOmZhYTU2NmU3Y2MwYzQzYWM4YzZjOGQ3YzQ1Y2IwYWUzL3RhYmxlcmFuZ2U6ZmFhNTY2ZTdjYzBjNDNhYzhjNmM4ZDdjNDVjYjBhZTNfMTEtMi0xLTEtNDk3OTg_3493224d-e6ac-4e34-b559-146e16baf894"
      unitRef="usd">45072000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iccb4b475a51d40e8b00847b50b411bb2_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF82Ny9mcmFnOjIxNWNlYWEyNzlhNDQxNDg4ZTE5NWRmZGIxZDg1MWJmL3RleHRyZWdpb246MjE1Y2VhYTI3OWE0NDE0ODhlMTk1ZGZkYjFkODUxYmZfMTg3Ng_941f42f4-c063-425f-b383-8eebcd8a8385">P10Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RleHRyZWdpb246ZjRiMzMyZTFjOTE1NDQzMmIzZmVkOTJhZmFmNTY4ZmVfNjE0_43fcccea-7f43-45db-938b-fb40085330ca">Net Loss Per Common Share &lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share were calculated as follows (in thousands except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Zentalis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our potential and dilutive securities, which include outstanding stock options, unvested RSAs and unvested RSUs have been excluded from the computation of diluted net loss per common share as the effect would be anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents have been excluded from the calculations of diluted net loss per common share because their inclusion would be antidilutive (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RleHRyZWdpb246ZjRiMzMyZTFjOTE1NDQzMmIzZmVkOTJhZmFmNTY4ZmVfNjEx_be7fb51c-1db0-419b-83b4-4c9c5812cfe7">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share were calculated as follows (in thousands except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Zentalis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfMy0xLTEtMS00OTc5OA_6b50aa4b-0444-42b4-adbd-ead9d8f5c05c"
      unitRef="usd">-68357000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfMy0zLTEtMS00OTc5OA_cea5c019-d508-4a67-826e-2db59159da3b"
      unitRef="usd">-54574000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNS0xLTEtMS00OTc5OA_a05bcf19-9f35-43fa-beb6-d349fa320c83"
      unitRef="shares">51117000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNS0xLTEtMS00OTc5OA_f3cc393e-dfd5-4a35-a89d-a942ca10885b"
      unitRef="shares">51117000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNS0zLTEtMS00OTc5OA_7ae4ee6f-e9c1-4e02-930c-74b31788efa2"
      unitRef="shares">40738000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNS0zLTEtMS00OTc5OA_7da8f369-c61e-455e-8608-9519a8fb396c"
      unitRef="shares">40738000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNi0xLTEtMS00OTc5OA_0250e44c-54c6-47fb-9648-a2db767d10e4"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNi0xLTEtMS00OTc5OA_0e32e5ad-96cf-4752-a194-49faae128062"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNi0zLTEtMS00OTc5OA_83ffe1b7-3a52-4cc7-9c9a-6e68dc135be8"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5887e1b6136c495ea9277b67eb230105_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmFkNTc0YTBjMDE3YjRmZGViOWFmMTQyZmI1MWUxZTIyL3RhYmxlcmFuZ2U6YWQ1NzRhMGMwMTdiNGZkZWI5YWYxNDJmYjUxZTFlMjJfNi0zLTEtMS00OTc5OA_d6f97ce5-0bf8-465a-8003-9decdcf58291"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RleHRyZWdpb246ZjRiMzMyZTFjOTE1NDQzMmIzZmVkOTJhZmFmNTY4ZmVfNjEz_ccf224f3-1093-4ade-8ad6-c5a4af2b2c2f">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents have been excluded from the calculations of diluted net loss per common share because their inclusion would be antidilutive (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if609506238d0461eac509be96d92ec01_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfMi0xLTEtMS00OTc5OA_bb4c5f99-8e8b-48db-8368-57f6d349d0c0"
      unitRef="shares">7828000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i382cf4d3dcbd43b484285308648a79c9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfMi0zLTEtMS00OTc5OA_ab5bf58e-027e-498d-b081-aea214e0cd37"
      unitRef="shares">4078000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id2ca05b7f8ef4c3cb04522bb5e0f01f0_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfMy0xLTEtMS00OTc5OA_db8fcb77-2c1b-4a17-93eb-1555a7abc87f"
      unitRef="shares">222000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id6f3ca918b964800a78e9ae83baa07fd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfMy0zLTEtMS00OTc5OA_85c108ce-7e9d-4cb0-bb54-fc147f50de17"
      unitRef="shares">536000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i64103a278a8e4aa7ac8509ba56369056_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfNC0xLTEtMS00OTc5OA_e02c6751-61dc-4b85-b9d9-43e1e42a8ed9"
      unitRef="shares">472000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3dff9cfed3a14c8d8c88926052fcee95_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfNC0zLTEtMS00OTc5OA_9ae2f45a-44b4-423d-a9cc-1e2f9fdea18a"
      unitRef="shares">534000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfNS0xLTEtMS00OTc5OA_7f68ca93-e83b-4f9b-a875-3445737d4e57"
      unitRef="shares">8522000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83MC9mcmFnOmY0YjMzMmUxYzkxNTQ0MzJiM2ZlZDkyYWZhZjU2OGZlL3RhYmxlOmVhNDVmZmU3MGMxNDRkNGQ5YzQ4YjA5MzhhMWI1NjljL3RhYmxlcmFuZ2U6ZWE0NWZmZTcwYzE0NGQ0ZDljNDhiMDkzOGExYjU2OWNfNS0zLTEtMS00OTc5OA_e254c2d1-3314-4dea-853d-2c43c66ca12e"
      unitRef="shares">5148000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i0159adf80fe24766a99096c944e7113d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83My9mcmFnOjE1MjlhMzNjY2QzNjQwYjA4NGYwMWRjODRkMTg4YWRhL3RleHRyZWdpb246MTUyOWEzM2NjZDM2NDBiMDg0ZjAxZGM4NGQxODhhZGFfMTkyNw_85b8b1e4-63e1-424a-9084-60d1229c5016">Related Party Disclosures&lt;div style="margin-bottom:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tempus&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Kimberly Blackwell, M.D., our Chief Executive Officer and a member of our Board of Directors, was previously employed by Tempus Labs, Inc. ("Tempus") and now serves as an advisor of Tempus. The Company entered into a Master Services Agreement with Tempus in December 2020 to provide data licensing and research services. There were immaterial and $1.0 million fees incurred for services performed by Tempus for the six months ended June&#160;30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zentera&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Kevin D. Bunker, Ph.D., our Chief Operating Officer, serves as a member of the Board of Directors of Zentera. Accordingly, the Company identifies Zentera as a related party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we entered into the Zentera Sublicenses, pursuant to which we collaborate with Zentera on the development and comm&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ercialization of the Collaboration Products in the Zentera Collaboration Territory. Under the terms of the Zentera Sublicenses, Zentera is responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are responsible for the costs of developing the Collaboration Products &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of its costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Prior to the deconsolidation of Zentera during July 2021, these costs were eliminated in consolidation. For the six months ended June 30, 2022, the amounts incurred under this arrangement totaled $5.1 million and are presented as contra-research and development expense in the consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2022 we divested an early stage asset to Zentera for $0.2 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i1bdc5cf068c740ae97ed383848a4f8b2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83My9mcmFnOjE1MjlhMzNjY2QzNjQwYjA4NGYwMWRjODRkMTg4YWRhL3RleHRyZWdpb246MTUyOWEzM2NjZDM2NDBiMDg0ZjAxZGM4NGQxODhhZGFfMzQ3_439a1e6e-fddf-4f4a-98d6-3cdd06848330"
      unitRef="usd">1000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <zntl:ResearchAndDevelopmentExpenseReimbursements
      contextRef="iebb85fbd06c842c9b31131732a081288_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83My9mcmFnOjE1MjlhMzNjY2QzNjQwYjA4NGYwMWRjODRkMTg4YWRhL3RleHRyZWdpb246MTUyOWEzM2NjZDM2NDBiMDg0ZjAxZGM4NGQxODhhZGFfMTcwNg_7212ec47-ecec-4c18-a5a9-b0b0c3ba97dd"
      unitRef="usd">5100000</zntl:ResearchAndDevelopmentExpenseReimbursements>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="iebb85fbd06c842c9b31131732a081288_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZGExMjRlODc0NTRjYWI5NWZkOTJhMjYyNzA5OWVkL3NlYzoyNGRhMTI0ZTg3NDU0Y2FiOTVmZDkyYTI2MjcwOTllZF83My9mcmFnOjE1MjlhMzNjY2QzNjQwYjA4NGYwMWRjODRkMTg4YWRhL3RleHRyZWdpb246MTUyOWEzM2NjZDM2NDBiMDg0ZjAxZGM4NGQxODhhZGFfMTkxNw_8364476a-607e-4e1e-85cf-65c8b4684114"
      unitRef="usd">200000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZ9M>2. [8*T\W"GO=Z4=#]77Y.SEG+V*+5-Q&$*R$:"\'G&O&0\3:T6BLIJ
M_1RPCQ;J.M:!WI";(!3D/HVF0MG < _'H4WWC'5=&QPJK0EWEL.=58%[%//
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M87:.WJ.WR$8J@5$UL35H,LQV5*U_7:[O[5G_<\Y[J.]<(,_QO!;X[##\AD0
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MH/Y^5Y;-IS?M ^@?RNI#9^/V_U!+ P04    " ";@0E5VQU]#"D#  #T!@
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M-;@0S6AA$:7&;":G3#B42^]X5W&>GW]PE3#JE^A;9"0L.N(0HFGJ&3X$I<4
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M#$?,[6=HC\%!5.N.,TG!8$=(/SN:9\>8?;1F38JY!*(4L?@STJ74@2EQBD5
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M"!N_C<8;;YKP/7)IO#=5N"Q1TLFR -ZOC/'=#6_0?Z"^^"]02P,$%     @
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M*;P7ZP=T> [9J)@684^*<WB/W&:-:2N0JK/F%KV5@WPTR6>\%FD!'^M:EGB
MX?G6O=62>HL>9U+PFF9CN#:JZXDI/!BG10)9FK)*<\'[83YP"/S8AHOG8'8.
MXQQN^C49$BW,1D4^@>EHEB=P69:]ZEOA\U AU[J48I@OS$ H8TG^/PA.TM$X
MFY["R?DL.SV:V>>,G:73L*?YE+-V#!?O>"([GWX;RD"-100U=![ZSGO(?TBY
M1_!I?^I#C ]&AT*["0/2<:U[3<,4V4OW,_AR&#T/YL, _R#L1FH'+=;LFIR=
M%Q'882@.%S)=&$1K0SS6PK'A_PA:;\#ZVABZO_@']G^FY4]02P,$%     @
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MN4O,@QE8M!#EX9GS";$O;%LBP]:JTL3"^M@B^S#Y:VLX.8NM&J(I1D?Z'RN
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MU)IZIF<M!,/N.(;[2K6T((_$,,[G9!PPU;CO5]SR9N9.DFG.U\21&VJX]_C
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M!+&&:V&0V)A#>HYF/*SG,458$;3<6'"N@=$[W6>&-;..H--E]HQU%]@>34-
MXCU5WE"%#A>T+TM-EZ2[4Z""P*H@+C'&/$(%0;^N#COT]R6W.,Q A&LNA+42
MKP(5EPE\AJ$_IM$?],XF0[@EEIFD\MBG^"&]_F38A<Y9+QB-NY83O1^9\:35
M_PNM*X.33V._[Y]3P*@WGDRZQX@BU>,NQ2 (&J*'BL?=>?XYJG75Y#3$LA2F
M[@2MM>VCB[I]_'.OF_ -4W1$&C)<4:AW>D9M2]6-K5X8653-))*&6E,U3>E?
M@,HZT/Y*2K-=V 3MWR7\"U!+ P04    " ";@0E5R35:/T %  ""#@  &0
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MPQP?B4SH#;B^X5SU$WV ?78N_@-02P,$%     @ FX$)56CI@Y(\ P  '0<
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MV4\\T.TH:P6KJF9\+)6E8=1\%C3]43L#.L^5LEO!!=C]3Z;_ %!+ P04
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M'X5)(X#O5P(3LW\P!MI_/>-_ %!+ P04    " ";@0E592XSH0,#  "&!@
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M(9O%C"WAP7AR<[3QH_@5S+-X/LE(@J.!4'7CL0"A"8_.PP6;QTNV'/4DK_=
M"KX34OAPP:C:(IWV1'EC;7B M;%MI[H84Y7)J#^[(^PY!DU-FG;O=?Y;R*9Q
M.F=PZE(E+WJ#0KMO.Z"#W#3:=VUBF!V:[%776_Y+[SKT+;=[H1W9*0F:7LZG
M$=BNZW4#;^JVT^R,I[[5AA5]*-"&!%HOC?''02@P?'JV_P)02P,$%     @
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M]7V=YE R?2@K$/AF+E7)# [5PM>5 I8Y4%GX(:617S(NO'CJYJY4/)6U*;B
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M72X=F"7D$=\B>A2U8Y"5\L#84W;R<3VW8,:(QG0E,PBBO@YT2>,X0U(\_BE
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M:-$<[C'*,%,!\OZ64O%THO98^CVUY%]02P,$%     @ FX$)576H%)RC @
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M8&1'IYC=H,CQK7Y*OZ7T+Z*DL,)T$-'OC&Z[H7."V T*@JB?,&@)@XL(5U
M5XQZ^7&J3A:B=[\^4P>Q@^[,^L$)=3?&]D9G)C9LL<-![.^@SFI$"5X02N2^
M#RWL#ANZ[@E;3Y#GN_ULHY9M-,CVA'?J,"GK4Z6/;-1=QL@[ >O&1.&9DHE:
MKFB8BTF]P(?"&5C5J%.Q;N!W"J8GRG%][P32/+J,](? #\Q7I!"J))9*9]V$
MRB.O+]>Z(UE9W4\+)M5M5S4S]3T"7 >H]TO&Y*&CK[SV"R?^!U!+ P04
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MF0*14Z(2D,]7E(J'C5+0_+,1_ 102P,$%     @ FX$)54!+FM?N P  )Q4
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M6>I6?EC0\X#:&=#^4BF[GSB"]L%)?P-02P,$%     @ FX$)568T)I"# P
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MF%2W<5,LU(L,<0U0_6O&Y*&B [1OO/D_4$L#!!0    ( )N!"569<Q#47@,
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M'-^RO_:Q4RQ7S.")$I]X9N?CX"" #*=L(>R%6KW!=3Q[CB]5POA?6)6V@RB
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M._NMF^R>@LGX%$R>1$WV3\%D<@(F>Z_VK7G09%B?,K:.,CL'F28:P(%Q2'[
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MI]XIG]J8KCT_:WS^/:G.YWOC]?&7Y<])?%_4%YP#_/U=? -02P,$%     @
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MH<BJ4&15*+(J%%D5BJS#_Y3UW9C57_^3;.YII8OZF,_:'[_33U!+ 0(4 Q0
M   ( )N!"54'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ FX$)52U),Q+N    *P(  !$
M     ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ FX$)59E<
MG",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    " ";@0E5&53(P/H%  #('P  &               @($-
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ FX$)53R(
M,:5J!@  0!H  !@              ("!/0X  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( )N!"55 B)],"P,  %T*   8
M  " @=T4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " ";
M@0E597=;+W\%  #'%P  &               @($>&   >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ FX$)50&#-'SG P  C0X  !@
M         ("!TQT  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( )N!"54T\O1B0@@  +DQ   8              " @? A  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " ";@0E5 "CLZ=0,  ! @0
M&               @(%H*@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ FX$)5=L=?0PI P  ] 8  !@              ("!<C<  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( )N!"564]%1&-0@
M -@4   8              " @=$Z  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " ";@0E5D\QET<T(  "L%@  &0              @($\
M0P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( )N!"55H
MU/'6J04  /P,   9              " @4!,  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ FX$)5?32_XVI!@  $!$  !D
M     ("!(%(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )N!"57*SEWXR 4  "0-   9              "
M@99O  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ FX$)
M53O/#L2* P  ,@@  !D              ("!E74  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " ";@0E5$1M>??<$  #4"P  &0
M        @(%6>0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( )N!"57;:]F;&@@  +84   9              " @81^  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ FX$)56CPM?'4 @  :08
M !D              ("!U88  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " ";@0E5R35:/T %  ""#@  &0              @('@B0
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( )N!"55HZ8.2
M/ ,  !T'   9              " @5>/  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ FX$)562R+.GH @  6P8  !D
M ("!RI(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " ";
M@0E5R/2I_]("   F!@  &0              @('IE0  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( )N!"54@,4MR'@4   $-   9
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M970S,"YX;6Q02P$"% ,4    " ";@0E5I](S#S8$    %P  &0
M    @(%_JP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M )N!"55:V/J2V@0  'H9   9              " @>RO  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ FX$)54_R=I9R @  K 4  !D
M             ("!_;0  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " ";@0E5"D52=9L"  "%!@  &0              @(&FMP  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( )N!"56UC2K-@@<
M +I#   9              " @7BZ  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ FX$)55A=TZ>2 P  40L  !D              ("!
M,<(  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " ";@0E5
M^I"K$]\#  !?$P  &0              @('ZQ0  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( )N!"55UJ!2<HP(  .('   9
M      " @1#*  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ FX$)58";DU[W @  [0@  !D              ("!ZLP  'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " ";@0E5:Q8&:RT+  "%>@
M&0              @($8T   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( )N!"54!^;"MGP,  .40   9              " @7S;  !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ FX$)54!+FM?N
M P  )Q4  !D              ("!4M\  'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " ";@0E5F@AI IT#  ">#@  &0
M@(%WXP  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( )N!
M"54%XDPKN0(  'P&   9              " @4OG  !X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ FX$)568T)I"# P  PPX  !D
M         ("!.^H  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
M    " ";@0E5\VO72'8#   .#0  &0              @('U[0  >&PO=V]R
M:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( )N!"55""XT:( (  ($$
M   9              " @:+Q  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
M4$L! A0#%     @ FX$)5;I,YZ&5 P  [PT  !D              ("!^?,
M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " ";@0E5F7,0
MU%X#  !"#P  &0              @('%]P  >&PO=V]R:W-H965T<R]S:&5E
M=#0Y+GAM;%!+ 0(4 Q0    ( )N!"57UY(K:.@,  *H,   9
M  " @5K[  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
MFX$)53T,13A" P  )A0   T              ( !R_X  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " ";@0E5EXJ[',     3 @  "P              @ $X
M @$ 7W)E;',O+G)E;'-02P$"% ,4    " ";@0E5!VFQ"QH$  "N(0  #P
M            @ $A P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ FX$)
M53B#;R;$ 0  #1X  !H              ( !: <! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ FX$)58"$^)W  0   !X  !,
M         ( !9 D! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #H .@#-
)#P  50L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>172</ContextCount>
  <ElementCount>224</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/OrganizationandBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Interim Unaudited Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/InterimUnauditedFinancialStatements</Role>
      <ShortName>Interim Unaudited Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Significant Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/SignificantTransactions</Role>
      <ShortName>Significant Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106104 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110105 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Prepaid Expenses and Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PrepaidExpensesandOtherAssets</Role>
      <ShortName>Prepaid Expenses and Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119107 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123108 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126109 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138111 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2142112 - Disclosure - Related Party Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/RelatedPartyDisclosures</Role>
      <ShortName>Related Party Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Interim Unaudited Financial Statements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies</Role>
      <ShortName>Interim Unaudited Financial Statements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/BusinessCombinations</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/FairValueMeasurement</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Prepaid Expenses and Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/PrepaidExpensesandOtherAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/CommitmentandContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2339308 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/NetLossPerCommonShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Significant Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/SignificantTransactionsDetails</Role>
      <ShortName>Significant Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/SignificantTransactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Business Combinations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails</Role>
      <ShortName>Business Combinations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails</Role>
      <ShortName>Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Fair Value Measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>Fair Value Measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Prepaid Expenses and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Property and Equipment, net - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails</Role>
      <ShortName>Property and Equipment, net - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Property and Equipment, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails</Role>
      <ShortName>Property and Equipment, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/AccruedExpensesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2428412 - Disclosure - Stockholders??? Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders??? Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2429413 - Disclosure - Stockholders??? Equity - Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails</Role>
      <ShortName>Stockholders??? Equity - Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Stockholders??? Equity - Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders??? Equity - Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Stockholders??? Equity - Fair Value Assumptions for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails</Role>
      <ShortName>Stockholders??? Equity - Fair Value Assumptions for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Stockholders??? Equity - Fair Value Assumptions for ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails</Role>
      <ShortName>Stockholders??? Equity - Fair Value Assumptions for ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Stockholders??? Equity - Unrecognized Compensation Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails</Role>
      <ShortName>Stockholders??? Equity - Unrecognized Compensation Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitment and Contingencies - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Commitment and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2440420 - Disclosure - Net Loss Per Common Share - Calculation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails</Role>
      <ShortName>Net Loss Per Common Share - Calculation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="zntl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - Related Party Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/RelatedPartyDisclosuresDetails</Role>
      <ShortName>Related Party Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/RelatedPartyDisclosures</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="zntl-20220630.htm">zntl-20220630.htm</File>
    <File>zentalis-executiveemployme.htm</File>
    <File>zentalis10-qq22022ex311.htm</File>
    <File>zentalis10-qq22022ex312.htm</File>
    <File>zentalis10-qq22022ex321.htm</File>
    <File>zentalis10-qq22022ex322.htm</File>
    <File>zntl-20220630.xsd</File>
    <File>zntl-20220630_cal.xml</File>
    <File>zntl-20220630_def.xml</File>
    <File>zntl-20220630_lab.xml</File>
    <File>zntl-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="618">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "zntl-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 172,
   "dts": {
    "calculationLink": {
     "local": [
      "zntl-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "zntl-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "zntl-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "zntl-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zntl-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "zntl-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 359,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 16,
   "keyStandard": 208,
   "memberCustom": 11,
   "memberStandard": 28,
   "nsprefix": "zntl",
   "nsuri": "http://www.zentalis.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.zentalis.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Significant Transactions",
     "role": "http://www.zentalis.com/role/SignificantTransactions",
     "shortName": "Significant Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106104 - Disclosure - Business Combinations",
     "role": "http://www.zentalis.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110105 - Disclosure - Fair Value Measurement",
     "role": "http://www.zentalis.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Prepaid Expenses and Other Assets",
     "role": "http://www.zentalis.com/role/PrepaidExpensesandOtherAssets",
     "shortName": "Prepaid Expenses and Other Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119107 - Disclosure - Property and Equipment, net",
     "role": "http://www.zentalis.com/role/PropertyandEquipmentnet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123108 - Disclosure - Accrued Expenses",
     "role": "http://www.zentalis.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126109 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://www.zentalis.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Commitment and Contingencies",
     "role": "http://www.zentalis.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138111 - Disclosure - Net Loss Per Common Share",
     "role": "http://www.zentalis.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142112 - Disclosure - Related Party Disclosures",
     "role": "http://www.zentalis.com/role/RelatedPartyDisclosures",
     "shortName": "Related Party Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Interim Unaudited Financial Statements (Policies)",
     "role": "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies",
     "shortName": "Interim Unaudited Financial Statements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "zntl:ReconciliationOfNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Business Combinations (Tables)",
     "role": "http://www.zentalis.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "zntl:ReconciliationOfNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.zentalis.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Prepaid Expenses and Other Assets (Tables)",
     "role": "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables",
     "shortName": "Prepaid Expenses and Other Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Property and Equipment, net (Tables)",
     "role": "http://www.zentalis.com/role/PropertyandEquipmentnetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.zentalis.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "role": "http://www.zentalis.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Commitment and Contingencies (Tables)",
     "role": "http://www.zentalis.com/role/CommitmentandContingenciesTables",
     "shortName": "Commitment and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339308 - Disclosure - Net Loss Per Common Share (Tables)",
     "role": "http://www.zentalis.com/role/NetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Significant Transactions (Details)",
     "role": "http://www.zentalis.com/role/SignificantTransactionsDetails",
     "shortName": "Significant Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i6e26a8f313d147c899372ec9a56c6c9f_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i7de358016f734a82a094e8ea4e3ef006_D20171221-20171221",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Business Combinations - Narrative (Details)",
     "role": "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails",
     "shortName": "Business Combinations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i7de358016f734a82a094e8ea4e3ef006_D20171221-20171221",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "ife5ec6b3d5cb4c2e865c079c2e04fc1e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details)",
     "role": "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails",
     "shortName": "Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "zntl:ReconciliationOfNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i73d19273bd804eacb01818f0b3a0b9d6_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)",
     "role": "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Fair Value Measurement - Narrative (Details)",
     "role": "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails",
     "shortName": "Fair Value Measurement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)",
     "role": "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails",
     "shortName": "Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)",
     "role": "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Prepaid Expenses and Other Assets (Details)",
     "role": "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails",
     "shortName": "Prepaid Expenses and Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Property and Equipment, net - Summary (Details)",
     "role": "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails",
     "shortName": "Property and Equipment, net - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Property and Equipment, net - Narrative (Details)",
     "role": "http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails",
     "shortName": "Property and Equipment, net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "zntl:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.zentalis.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "zntl:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428412 - Disclosure - Stockholders\u2019 Equity - Narrative (Details)",
     "role": "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders\u2019 Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "ifc20ff4317e549b195078a8c6d397c35_D20220429-20220429",
      "decimals": "-5",
      "lang": "en-US",
      "name": "zntl:ProceedsFromIssuanceOfCommonStockGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429413 - Disclosure - Stockholders\u2019 Equity - Share-based Compensation (Details)",
     "role": "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails",
     "shortName": "Stockholders\u2019 Equity - Share-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0a591ae027674ec48804343c4347f2e3_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Stockholders\u2019 Equity - Share-based Compensation Expense (Details)",
     "role": "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
     "shortName": "Stockholders\u2019 Equity - Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i644b2805dacd408b8e97b86dd46abb55_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i575ec7487094412380df5d1d84056a75_D20220101-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Stockholders\u2019 Equity - Fair Value Assumptions for Stock Options (Details)",
     "role": "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
     "shortName": "Stockholders\u2019 Equity - Fair Value Assumptions for Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i575ec7487094412380df5d1d84056a75_D20220101-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Stockholders\u2019 Equity - Fair Value Assumptions for ESPP (Details)",
     "role": "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
     "shortName": "Stockholders\u2019 Equity - Fair Value Assumptions for ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i7ec82b59582b40deb497c3587af8dbbd_D20220101-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i6848464a8da644618f62c064bead2a58_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Stockholders\u2019 Equity - Unrecognized Compensation Cost (Details)",
     "role": "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails",
     "shortName": "Stockholders\u2019 Equity - Unrecognized Compensation Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i6848464a8da644618f62c064bead2a58_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details)",
     "role": "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails",
     "shortName": "Commitment and Contingencies - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Commitment and Contingencies - Narrative (Details)",
     "role": "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails",
     "shortName": "Commitment and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iccb4b475a51d40e8b00847b50b411bb2_I20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440420 - Disclosure - Net Loss Per Common Share - Calculation (Details)",
     "role": "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails",
     "shortName": "Net Loss Per Common Share - Calculation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)",
     "role": "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i28f7d3ab172046598fe7dcdf7ffe8f23_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "zntl:ResearchAndDevelopmentExpenseReimbursements",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - Related Party Disclosures (Details)",
     "role": "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails",
     "shortName": "Related Party Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "iebb85fbd06c842c9b31131732a081288_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i3694c84e1cf74c9e9a54efa395daf639_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i5299c81f26ad457bb9835f9d797f5a03_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i8653fbebbecc47f2916b94ddc6e5aaff_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Business",
     "role": "http://www.zentalis.com/role/OrganizationandBusiness",
     "shortName": "Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Interim Unaudited Financial Statements",
     "role": "http://www.zentalis.com/role/InterimUnauditedFinancialStatements",
     "shortName": "Interim Unaudited Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20220630.htm",
      "contextRef": "i0159adf80fe24766a99096c944e7113d_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 44,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r264",
      "r385",
      "r386",
      "r388",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r92",
      "r209",
      "r214",
      "r220",
      "r336",
      "r337",
      "r346",
      "r347",
      "r391",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r92",
      "r209",
      "r214",
      "r220",
      "r336",
      "r337",
      "r346",
      "r347",
      "r391",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails",
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r222",
      "r232",
      "r267",
      "r269",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r429",
      "r488",
      "r489",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r222",
      "r232",
      "r267",
      "r269",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r429",
      "r488",
      "r489",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r198",
      "r203",
      "r204",
      "r205",
      "r206",
      "r222",
      "r232",
      "r256",
      "r267",
      "r269",
      "r297",
      "r298",
      "r299",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r429",
      "r488",
      "r489",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r198",
      "r203",
      "r204",
      "r205",
      "r206",
      "r222",
      "r232",
      "r256",
      "r267",
      "r269",
      "r297",
      "r298",
      "r299",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r429",
      "r488",
      "r489",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails",
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r394"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r17",
      "r449",
      "r471"
     ],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails",
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued legal expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r12",
      "r194"
     ],
     "calculation": {
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r44",
      "r45",
      "r46",
      "r473",
      "r494",
      "r495"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r46",
      "r53",
      "r54",
      "r55",
      "r94",
      "r95",
      "r96",
      "r344",
      "r382",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r394"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r306",
      "r307",
      "r308",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r271",
      "r309",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per unit (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r15",
      "r88",
      "r138",
      "r141",
      "r145",
      "r172",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r336",
      "r346",
      "r368",
      "r392",
      "r394",
      "r448",
      "r470"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r29",
      "r88",
      "r172",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r336",
      "r346",
      "r368",
      "r392",
      "r394"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total fair value of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r151",
      "r180"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r155",
      "r156",
      "r466"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one but within five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r155",
      "r157",
      "r467"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r148",
      "r152",
      "r180",
      "r452"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities, available-for-sale",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r266",
      "r268",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r266",
      "r268",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r326",
      "r327",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Cash payments to acquire interest"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r325",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r9",
      "r79"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r79",
      "r83"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash reported in the Condensed Consolidated Statement of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r369"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r86",
      "r88",
      "r110",
      "r111",
      "r112",
      "r114",
      "r116",
      "r124",
      "r125",
      "r126",
      "r172",
      "r209",
      "r214",
      "r215",
      "r216",
      "r220",
      "r221",
      "r230",
      "r231",
      "r235",
      "r239",
      "r246",
      "r368",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "netLabel": "Commercial paper",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r454",
      "r478"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r207",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r394"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 250,000,000 shares authorized; 56,969,118 and 45,490,764 shares issued and outstanding at June\u00a030, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r61",
      "r460",
      "r484"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Zentalis"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r51",
      "r60",
      "r334",
      "r335",
      "r355",
      "r459",
      "r483"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r51",
      "r59",
      "r333",
      "r355",
      "r458",
      "r482"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r257",
      "r265",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Accrued deferred financing costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Components of Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r162",
      "r181",
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair market value of available-for-sale securities in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r163",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of available-for-sale securities in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "terseLabel": "Gain on deconsolidation of Zentera, net of tax"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.",
        "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates",
        "terseLabel": "Deferred tax liability, deconsolidation of Zentera"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r77",
      "r135"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r273",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Share-based Compensation Expense by Type of Share-based Award"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r4",
      "r21",
      "r90",
      "r212",
      "r214",
      "r215",
      "r219",
      "r220",
      "r221",
      "r386"
     ],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Zentera receivable"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r90",
      "r212",
      "r214",
      "r215",
      "r219",
      "r220",
      "r221",
      "r386",
      "r453",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r62",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r108",
      "r110",
      "r114",
      "r115",
      "r116",
      "r120",
      "r121",
      "r360",
      "r361",
      "r461",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share outstanding, basic (in dollars per share)",
        "verboseLabel": "Net loss per common share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r62",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r110",
      "r114",
      "r115",
      "r116",
      "r120",
      "r121",
      "r360",
      "r361",
      "r461",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share outstanding, diluted (in dollars per share)",
        "verboseLabel": "Net loss per common share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Employee benefits and share-based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Remaining Weighted-Average Recognition Period (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized expense, other than options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized expense, stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "netLabel": "Outstanding stock options",
        "terseLabel": "Stock Options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r123",
      "r174",
      "r246",
      "r253",
      "r306",
      "r307",
      "r308",
      "r317",
      "r318",
      "r359",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r382",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r10",
      "r139",
      "r168"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Zentera Therapeutics"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Significant Transactions"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r365",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r223",
      "r225",
      "r226",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r363",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r223",
      "r257",
      "r258",
      "r263",
      "r265",
      "r363",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r223",
      "r225",
      "r226",
      "r257",
      "r258",
      "r263",
      "r265",
      "r363",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r223",
      "r225",
      "r226",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r165",
      "r166",
      "r167",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r183",
      "r184",
      "r185",
      "r186",
      "r224",
      "r244",
      "r357",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r13",
      "r189",
      "r190",
      "r191",
      "r192",
      "r394",
      "r446"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r158",
      "r161",
      "r464",
      "r465"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r56",
      "r138",
      "r140",
      "r143",
      "r144",
      "r146",
      "r444",
      "r456",
      "r462",
      "r486"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r57",
      "r77",
      "r136",
      "r168",
      "r455",
      "r480"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss on equity method investment",
        "negatedTerseLabel": "Loss on equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r196",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r89",
      "r105",
      "r106",
      "r137",
      "r314",
      "r319",
      "r320",
      "r487"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfPremium": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization of purchase premium on nonoperating securities.",
        "label": "Investment Income, Amortization of Premium",
        "terseLabel": "Amortization of premiums on marketable securities, net"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Maturities of Available-for-sale Debt Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r88",
      "r142",
      "r172",
      "r209",
      "r210",
      "r211",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r337",
      "r346",
      "r347",
      "r368",
      "r392",
      "r393"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r88",
      "r172",
      "r368",
      "r394",
      "r451",
      "r476"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES\u00a0AND\u00a0STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r34",
      "r88",
      "r172",
      "r209",
      "r210",
      "r211",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r337",
      "r346",
      "r347",
      "r368",
      "r392",
      "r393",
      "r394"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r39",
      "r88",
      "r172",
      "r209",
      "r214",
      "r215",
      "r216",
      "r220",
      "r221",
      "r368",
      "r450",
      "r475"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Noncontrolling interest at end of period",
        "periodStartLabel": "Noncontrolling interest at beginning of period",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails",
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r75",
      "r78"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r47",
      "r50",
      "r55",
      "r58",
      "r78",
      "r88",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r105",
      "r106",
      "r113",
      "r138",
      "r140",
      "r143",
      "r144",
      "r146",
      "r172",
      "r209",
      "r210",
      "r211",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r361",
      "r368",
      "r457",
      "r481"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Zentalis",
        "totalLabel": "Net loss attributable to Zentalis"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r47",
      "r50",
      "r55",
      "r105",
      "r106",
      "r340",
      "r354"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interests",
        "verboseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of\u00a0non-cash\u00a0investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r254",
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "negatedLabel": "Deconsolidation of Zentera"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r253",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r138",
      "r140",
      "r143",
      "r144",
      "r146"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: current portion",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails",
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease\u00a0right-of-use\u00a0assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r93",
      "r107",
      "r134",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Business"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/OrganizationandBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Assets"
       }
      }
     },
     "localname": "OtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r41",
      "r42",
      "r44"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r48",
      "r51",
      "r333",
      "r334",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedTerseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance fees and expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r66",
      "r69",
      "r150"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r394"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June\u00a030, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "totalLabel": "Total prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Total prepaid expenses and other assets, current"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r15",
      "r447",
      "r469"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "terseLabel": "Prepaid expenses and other assets",
        "verboseLabel": "Less long-term portion"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r6",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r71",
      "r305"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r66",
      "r67",
      "r150"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Divestiture of early stage asset"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r47",
      "r50",
      "r55",
      "r73",
      "r88",
      "r97",
      "r105",
      "r106",
      "r138",
      "r140",
      "r143",
      "r144",
      "r146",
      "r172",
      "r209",
      "r210",
      "r211",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r333",
      "r339",
      "r341",
      "r354",
      "r355",
      "r361",
      "r368",
      "r462"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Consolidated net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r197",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r11",
      "r193"
     ],
     "calculation": {
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r195",
      "r394",
      "r468",
      "r477"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r264",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r264",
      "r385",
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r264",
      "r385",
      "r388",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r383",
      "r384",
      "r386",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Disclosures"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r311",
      "r430",
      "r505"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r9",
      "r83",
      "r445",
      "r472"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r9",
      "r83"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r14",
      "r83",
      "r497"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "RSAs",
        "verboseLabel": "Unvested RSAs"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs",
        "verboseLabel": "Unvested RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r253",
      "r394",
      "r474",
      "r493",
      "r495"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r174",
      "r306",
      "r307",
      "r308",
      "r317",
      "r318",
      "r359",
      "r490",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued and sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Unit"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Unit"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r2",
      "r88",
      "r171",
      "r172",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r270",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions, ESPP"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r86",
      "r124",
      "r125",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r239",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r336",
      "r337",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "ESPP maximum percent of compensation to contribute"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Non-Option equity instruments, outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized to be issued under plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Average expected term (in years)",
        "verboseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "ESPP purchase price of common stock, percent of market price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r84",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Interim Unaudited Financial Statements"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/InterimUnauditedFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r86",
      "r88",
      "r110",
      "r111",
      "r112",
      "r114",
      "r116",
      "r124",
      "r125",
      "r126",
      "r172",
      "r209",
      "r214",
      "r215",
      "r216",
      "r220",
      "r221",
      "r230",
      "r231",
      "r235",
      "r239",
      "r246",
      "r368",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r53",
      "r54",
      "r55",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r123",
      "r174",
      "r246",
      "r253",
      "r306",
      "r307",
      "r308",
      "r317",
      "r318",
      "r359",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r382",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r123",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r19",
      "r20",
      "r246",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r246",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r19",
      "r20",
      "r246",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedTerseLabel": "Cancellation of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r246",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued upon vesting of certain RSAs (in shares)",
        "verboseLabel": "Issuance of common stock in connection with restricted stock unit vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r246",
      "r253",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock upon exercise of options, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r19",
      "r20",
      "r246",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Shares issued under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r246",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r19",
      "r20",
      "r246",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock in connection with restricted stock unit vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r246",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r26",
      "r27",
      "r88",
      "r147",
      "r172",
      "r368",
      "r394"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r54",
      "r88",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r172",
      "r174",
      "r253",
      "r306",
      "r307",
      "r308",
      "r317",
      "r318",
      "r331",
      "r332",
      "r353",
      "r359",
      "r368",
      "r370",
      "r371",
      "r375",
      "r382",
      "r491",
      "r492"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r253",
      "r255",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r376",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r376",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r376",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingSecuritiesDebt": {
     "auth_ref": [
      "r5",
      "r16",
      "r148",
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Trading",
        "terseLabel": "Debt securities fair market value"
       }
      }
     },
     "localname": "TradingSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r165",
      "r166",
      "r167",
      "r224",
      "r244",
      "r357",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Available-for-sale marketable securities:"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r91",
      "r257",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agencies",
        "verboseLabel": "US Government Agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r91",
      "r257",
      "r265",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury",
        "verboseLabel": "US Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r336",
      "r337",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "VIE, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r109",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Common shares used in computing net loss per share, diluted (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r108",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Common shares used in computing net loss per share, basic (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "zntl_A2020IncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Incentive Award Plan",
        "label": "2020 Incentive Award Plan [Member]",
        "terseLabel": "The 2020 Plan"
       }
      }
     },
     "localname": "A2020IncentiveAwardPlanMember",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_A2022EmploymentInducementIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Employment Inducement Incentive Award Plan",
        "label": "2022 Employment Inducement Incentive Award Plan [Member]",
        "terseLabel": "2022 Inducement Plan"
       }
      }
     },
     "localname": "A2022EmploymentInducementIncentiveAwardPlanMember",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_AccruedGeneralAndAdministrativeCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued General And Administrative Costs, Current",
        "label": "Accrued General And Administrative Costs, Current",
        "terseLabel": "Accrued general and administrative expenses"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeCostsCurrent",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development Costs, Current",
        "label": "Accrued Research And Development Costs, Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_DirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct Offering",
        "label": "Direct Offering [Member]",
        "terseLabel": "Direct Offering"
       }
      }
     },
     "localname": "DirectOfferingMember",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_EarningsPerShareDenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Denominator",
        "label": "Earnings Per Share, Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareDenominatorAbstract",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "zntl_EarningsPerShareNumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Numerator",
        "label": "Earnings Per Share, Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareNumeratorAbstract",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "zntl_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-On Offering",
        "label": "Follow-On Offering [Member]",
        "terseLabel": "Follow-On Offering"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_ForeignResearchAndDevelopmentCreditRefund": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": {
       "order": 7.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Research and Development Credit Refund",
        "label": "Foreign Research and Development Credit Refund",
        "terseLabel": "Foreign R&amp;D credit refund"
       }
      }
     },
     "localname": "ForeignResearchAndDevelopmentCreditRefund",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net",
        "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_InvestmentAndOtherIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment and Other Income (Expense)",
        "label": "Investment and Other Income (Expense)",
        "terseLabel": "Investment and other income, net"
       }
      }
     },
     "localname": "InvestmentAndOtherIncomeExpense",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_KalyraPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kalyra Pharmaceuticals, Inc.",
        "label": "Kalyra Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Kalyra Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "KalyraPharmaceuticalsIncMember",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_MasterServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Services Agreement",
        "label": "Master Services Agreement [Member]",
        "terseLabel": "Master Services Agreement"
       }
      }
     },
     "localname": "MasterServicesAgreementMember",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_OfficeEquipmentAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Equipment And Furniture",
        "label": "Office Equipment And Furniture [Member]",
        "terseLabel": "Office equipment and furniture"
       }
      }
     },
     "localname": "OfficeEquipmentAndFurnitureMember",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_OtherPrepaidExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Prepaid Expense",
        "label": "Other Prepaid Expense",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpense",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_PrepaidResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research And Development Costs",
        "label": "Prepaid Research And Development Costs",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentCosts",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_PrepaidSoftwareLicenseAndMaintenance": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Software License And Maintenance",
        "label": "Prepaid Software License And Maintenance",
        "terseLabel": "Prepaid software licenses and maintenance"
       }
      }
     },
     "localname": "PrepaidSoftwareLicenseAndMaintenance",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock, Gross",
        "label": "Proceeds From Issuance Of Common Stock, Gross",
        "terseLabel": "Gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_ReconciliationOfNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Noncontrolling Interest",
        "label": "Reconciliation Of Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Reconciliation of Equity Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ReconciliationOfNoncontrollingInterestTableTextBlock",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "zntl_ResearchAndDevelopmentExpenseReimbursements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Expense, Reimbursements",
        "label": "Research and Development Expense, Reimbursements",
        "terseLabel": "Contra-research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseReimbursements",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails",
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Awards And Restricted Stock Units",
        "label": "Restricted Stock Awards And Restricted Stock Units [Member]",
        "terseLabel": "RSAs and RSUs"
       }
      }
     },
     "localname": "RestrictedStockAwardsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term",
        "terseLabel": "Generally expected vesting term of the option contract (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "terseLabel": "Maximum contribution amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase",
        "terseLabel": "Percent of common stock outstanding used as threshold to calculate shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "terseLabel": "Offering period (in months)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "zntl_ZenteraStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zentera Stock Plan",
        "label": "Zentera Stock Plan [Member]",
        "terseLabel": "Zentera Stock Plan"
       }
      }
     },
     "localname": "ZenteraStockPlanMember",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_ZenteraTherapeuticsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zentera Therapeutics Ltd.",
        "label": "Zentera Therapeutics Ltd. [Member]",
        "terseLabel": "Zentera"
       }
      }
     },
     "localname": "ZenteraTherapeuticsLtdMember",
     "nsuri": "http://www.zentalis.com/20220630",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails",
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r506": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r507": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r508": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r509": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r510": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r511": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r512": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r513": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r514": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r515": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r516": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r517": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r518": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001725160-22-000155-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001725160-22-000155-xbrl.zip
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MH@$P>TPID$HXRJT"7 B.Q+YM%6FBW4?7]!WIHEL"NSA> .H'+BGY#IAQ2A\
M<PLV!<4UX69I9R-!(7-&12(7!K%W^YEI.1<T0M1XI<.+95?A6-9Z:N\7U0^[
M28]=KKP\2]I4$_@"%%*'5)XK8VX8A=:U0JH?$@UPJS"-FZ3X1;Z5C+=FB?\%
M Z:JBT,=63>'^JT";VDJ3+8DAR264UBXS#IOS5A4'<BJFH'C(@49,E'A:747
M&IO  QC[I;!+.'8MN6/@4,,Z9F,/H:+W%5B$@??)U<W]R NQ^)LF!B0:8O>>
MUJAL(MS?[;4[PIVQ6O4[YBE=,+!%1_@3QN[Q:8APZ7*0+0Q+/D%46I]Q9!#&
M3@<E&8^?RAI9(9/0UYV_/UU?=(Z9Q]%0QHL\3Y [I8ZN"9PF$QW>@<66S$XW
M!KNI?T?%6% 8]<Y1;8M/0/>H-ERA+IV-Q?,CFP!U/3V5D$FC@/ <M*VG!0.]
M)9?'T&!UH[TLD2)=8"9> (U.WFU]SZ*=>(;=:[S(.>6"52K:[=KT/,*0(3J$
MF4(1,7.-Q6]W2N3*N&U/J,]JI7ID)'39KE7T^Z0Y\F_)D,L2WLY5&PX( TY%
MZD\0F# \[+N[_;Y1GBSACU/L><13.U[6@V*]YEO:$53!U0*,\ P3?FW4<-/V
M97)+H_![EF(!E?BS\'3YT]@+L> N15?KUHL*<IGXK61?VW*%[/0OG0QV\:RG
MUFLPYZ7M\V_H.V+5T>LV@_>U<VNY9PARH#OHRGE[_*R[;JFXXU90^#XI4F=C
M9W.+;#3\!$5'YD]$4&#U&3N=I- J()VA!.F8E?7J>CF3XS#-L)POA@O3S"B0
MM<62)HE*Q=0+J95+]8;($T^K*L&/#G;$A'=A<@!Z%UJ(";RVL[&]27HVX\I"
MRM=UD8QHAU/L-O1SL[Y*5RI;W!P7E*>760@Z'IU'?AZ6BB!P'[^/1A UAY')
MV@RM&D4=*FTH4=2N3@VZV HB9(!TK!80>O22N1X7H9).T;%>&\\GCWXI$BNR
MTI"0,GZKA@,R#0\RG?\@\0N%O:&0%PVHP);4L\:F3(]T:/<,,GQ=U=+-^1Q@
MV^&=]2MI@7$MING = ,HM"X'V.* *I!6N:MGE%V91T:;Q!'5],^O4]EYCD8T
MWT!4TJES]_+J4X[RK<]H:YUJM#5'DPP^W*YUD)E]L,/T!JRP$K^P\>-A9E3>
M(LPPQ$9D#&GTX/DP :[)S"=%?UDU'WEW!J*N)4I=@>1UFUX"GXB0@;4>LJ[+
M1AP4&]2-6E.LB>%$BK1,DU1GJ)F.ON><S07+Z\=E^I;J9E5A(:$U5HB'T8$R
M0:_$ALNMNS%7*WFP*CP5)@&W&0*M:>#>O&&KT*A%(:%EFC&'9@LEY<LP4[8Q
M)1VTB3A8;_G47]>"G65\6%+1.K^CYII#V=UU8L4HMY=Z,G-V-H)-DAF'&\EF
MS8%54DC2>81U.I!=UZ)_KDFT<BJPW/U:'Y#Z,6^V":AE>A2*0J/Z]%1K:T$[
MY?J6KR#?%PKR#5KW:=Y_C#[-^[V]@^\+&&PA? ?U@NJ2%5M#=SN2]>0:H/%1
MNL2F"# <6WWB%8()%/=-ZDUK%%?,EB*E@M;N1"OY ']@^[G;!W??SZU5-[<Y
MU=AH43%%/]96XGP7:"=16MZJR[R;B-@)"N0FF*1)<3.Q(KRF"IFC/U5-="J)
MRN*R9:6+)5QI(6.P15P@J=6GZPL7]DS!3*HVW0&I+=HTY493+WH#HYLY"/U.
MV<#C8LPXB3'LR5&20+'-6/8E?U$&ETH"58L_U849\Z)\8NQ4^14>H3T*.QY5
M4W2ZQ%4=FRKCJ^;4,?"%%397GE2)H&BU#NM;M7DD=\%%V0*.\R4/:.BX4A."
M/1N$^"![&\Y_E^;V@F:.+>,VAH3VF#PN5K48.O^S<61W.%+) ZN6>$D3VN2A
M$L-UID64AV"YLEN[\6Z3VH(X&X>;KCQ+<J#Z!4WF""<JIC,X.E-N#O=MG#US
M:W:>=<VY8>I>O05;B^EL/D3/F:/I7E5^^VE9DQK1SJO(S0I[FS@ CEY%SRU0
M1M2&B.DQN?)*W6INR=4$Y(P@'RSX!LGR8.GA/.JI^Z:4Z4KH^9?29'U^3UF]
M,[A'U$C ),1&COQ!MBA2'3)%B'DU[XHPTVJ&B_)(VU4;7C[D<1M)2B8K;&)0
M9O SZM/R)G$)2S CPC)^(XU3?FL3W1EG210&=&HNIG$X@H/XK@CP5%X*N-8G
M"@:\]LBG]-_@\&"764FPV$0LK-/JQ ADH,SQQ;O+H[7 )5%/4T$F-]H>>L%*
M5<&=TK)&T@+BMP5GXI;9/0VZJ$ Z$3[2W?I45<2-%[ES!-G[HXRYJFH=CJ/Q
M5OFG36?#0%2S#[UNJUHN*NQ9^:Z?:+R\R)W7Z)D4[R 8%HQF>X3_/>EHB%>E
MVPGALJ]R3P<"JT;(W;R;@!,KU*X502/:7'K(89P59>2'RF44J^T#1*>(9-";
M(&J\C?21X5J[2B4U'0CU%==I#H*,N<ES4XT1):\-!R=42:ZJ5_0478B[T[P#
M%G#JQ6>IF(;%U#X:BO0'MX?: >7N4(Q74G^YM#2:O)V@/#SQEF+3BVD&/WB=
M\;NO1[/=T:Q-_D..ZK<<T W?BQ!/)'//1.1,M6N*0EINI)7NOLG$C1O#39,B
MPL!>)T44L&B8>'J/&4J8XW#R-?56JVVL!V[L$2EQ:3GZ248N!#'-1>)61&8@
MY.'&*27>*4L_;EZMDO05F\VC03 NR)Y;:8J)$#NTV?-\+V:B;0K"JQ)$V<U=
M/YZ\)-C4L4@UV$Y\!>,D5X ?">?I'QXUM(IB'F:^K,PBJ%2EHOVW !+.QI*"
M>O7(X?Y@3W.1%R.XA?,;3YY"(8%-O.D2^%5XU'"67U99]PJ?8"D)&7(UH4O>
M*+EM5#+JSK6(NSV92MS*G8W[S,F]K_3"6A1+]BSE #7:4NAC2""&@OXJ%SKG
MKB#K0X&W+BV1D2@FHDZZW#Q)4;&@R^?E.6)!.;6,FR*QU1;LF/F:R^B7UKQ/
MR3>(=+LAVV;1*&Z,ZAOK3YN4A&E#YQ0$[8PK=#A&#-8R<KOV6AC^9>CSIX#X
M#7;[;9H(;VWO=17QX&#N_( '!@G"2@NC-AH9-QPJ('R*$'&[2=Y_+/;NK7YW
M!=QLR!YLUB,VGG,\0=X,G-!C^#!-(M=1-J^V60B-HF,_\B;('1!Y!?()4#\(
M/)T8IRK#AN4)09OG3D1PCC8&0W4'AO4I&\8*G*J HRE!^&$.!:MM$)T! .=X
M:8M09@4I9]U<*B\:W3O<:TN1-SNOL)N7#+L9]!\#=_/]$?*MQ*RWTX99;[M#
M26@ICC4Q_3K/6RU IQ@PZ85J0[90,M_);$',A85<&LC)=-\'6X_36QQ/$KIJ
M;R67C?'JI1-! CYCFJI4$^(&B!$)% 2=T.!X?^*1,,:KFE5EV"D'=!AS3W&_
M!.\6M SI)_4$S1JO\=,)%Q*!$KV!NU'-8U%Y G9D<+7[ C<- T6Y$R3%*%=P
M'NLB;/E4ZKLIO*PQ'E7-:.K-AP[+Y;]4[FS,91W+C][HO8'SEWJ9+'NC/Z%2
MLK>;;?LA/VISNNT6B;ZNJUA>'G.C*2QP*Q_C&KO./_0!O21*<O["9^GS_8H-
MJ2YE:<0)EQ!T2,-!O;=>R@1_$LC,A6?Y),QDZ[RNZX2J'66MM@TFK&%L>L 4
MU4E%5D2UBY"F=H(>096]S]ABYO=38Y/=-6TRZ^9RP[4<9C.NH6D9F@)>* LE
MC8!$!>.3QT7*/Y:0/CL<UEB34X;YZ&Y&TX#R-IN.X+K<-JPR9G2C 6585:B&
M9V=V+7$U=6)9UN ZJF:LA*G*1ES4DPMU,)+%L9>F>CB:A<CF5)8Q>C],_6**
M1&X^ED0IAG5X58R#4EA&0E5;JICA7ZU0\N5Q,5Z"F>AEW=7[EGPX7EE=7NW6
M(SD(544/N/;YEBE32F"T89OI5,#&2(<=JD>6*_&%/F.IN$V^H.4J"_@Q%DO-
MMO#):)@AJ2&%9\AZJW8 HBY@5B\21CX3Z.!U!RS,<Q+VQN2>Q"8NR&1"O@4:
MPMVZ<8L)32?A*,R?F@-HU5KH[H:%1[MKW]NPGO GN=W!"X3'L#.%F0G#/Y:Q
M;.; &2OJG(W=7<)B*E3<RLB\5O7*Y+2B<9!A58S.#)I,'FW=O+\<0_\ZLJFV
M;4)^B;9;YRY'$_N,^#J#W9A1[E+":\!]H 2YZ-WT7,Y"4H;=R^:P>S.S=V,T
M2]JO&!22U5^Z1L2LUZ<F%9)/G U?3D(8[,E@R9.9L,D57F308XQ95S<9GLB<
M,F09A2$Y0<PB%+7)+;S$2EY9O>.?>1TU$2'KW>@"6O$D&D4!MB;STW!D,!-(
MZ^>1FT;OKQF";,=J\FA*UH6MN;()-4]!N5LEB;" %TT.,D5LO:^B3*3!EXSG
MVG[W_"63BQK8E]O5>"8_S=+\/K%4?24F/1B?$T[!3.;;ZWL<'AZ6)FL@P.PV
M:#&8VG^>HZSO8:4@I=1*QF3]RI.8&#VB5RA _)RD7^"I1P%N+HYEQ!AKR%.)
M,3E'V &(%H4S=YWAH?-[[ZIWW"MI"H:#_L 1L-3BSYZKT0TGR ^4*V3#!_ *
M$&IS@U R#A,8'.QRK3.88F2N K<X%_2_X#!TP,.Q]P+<WS4F@3U/G(\@)&[6
M@OIG&;N;Z;I2VG^.^RH-1Q/O.N67%"9V4;G-$M-CL6_7>+!08&1"?*$Z%8/J
M3F4X](BQOCF5 YG_L%(8+'TNODA0^"RS"!)H5DJK6O&*L&4LA1*WQE#I'A97
M7]H "Z+QW9NEVTIT=<T^OG@[=\\^/NR8?7SQ_'3./CXLV<>C!.X".BBXI<!J
M6;BO%>9==6-70K1292;C,:) *T:)=^,A\%/?39DE2S5YVR#N8SJ0AR_!@5QC
M6M5KV[6X(/Y0MBQ/0()A<Y9L$LXRJP2TFVE<VSD$4[)(XTKL%K-.:3(3:?<)
M/V($J_B0Q+O<[*Q6V?"*F( 4M4Y;;%IXSET:YKF(#=S"2.1W0L3V0[3-;)'E
M-.2\2LP'I>(X6ZC:A+"G3YO4=0)SA[J&#V^\C8+M&7PK1-PR$5'0X#Z7N(C<
MP\ ]=DJ3'H#NV<01"Y%IN(35KXSC?H4RF71"KN)9+@+%+DIOVFM33V':;=E<
M3+:AW\14_NXK+=GWCX_<?N4E6X&7;"Y]5AN$Y+!+\X(">N2PV0;?K>>C$"+D
M@E3KFFL"348I@'2:0J4<LI+S6,+J.'"I9.%M2-WEY/5F#U400&.I;MJ),PG$
MX_HKKE!KG;1MH&&L1RV;&,U5<9-169)AASVV:&U#&;\8A1E'BI,O"@\!5@"U
M_G(EB*'2E\^MSHQLZN=6,!8S:2!0,5E\(TMT+'T4HC8E#O00T8)^'DF 198C
M8H;\ ;PA!93GC=14C8I+/>/25JYNE,.HD\;;4Q:(*+QMF"1':F@*:='"^BB;
MQ_<X\"IOI^TSH&UL,:!\TRH_95^'_0,.:U<*;SHLN]E=/SKX_F*6VF/8%A[!
MD,'L\>(.6TC3!#YV2]COI@_(R^-G/T]BBN[EX7K%8VOTHMX,0VVEY_ N(1AW
M4*0J]8_J<GXNL3EH6X(6[T"3HC\$PA%NA #^#6ZZ"HJ@#)XB$!'1,:3 ],7Z
M$E3$L6Y)XF(*56139);$1M-%A*U97=5LA#H^2T],W;)\980;4 H7^U/7%#X!
M(],IWC>=Z6HPS*G(UR!6+5 00KIY9;!+=\HE'2CB&^1=5P_P,70%ZM.7/5:H
M<$#6$"O7Z_>8 .]7.>&JC )ZF9F#)8WY1BE3"I:/Y!04;SB1R;>/[MD:T+]Q
MN3A;/Y4%WZRYGH:9@ ^3Q;3SWP(6)7'0:JBT\"WS3(4/)E_&!HI>V0K 3"I=
M_62T$V[ L*#RCRJY+5=E9W*N SW,!XW;*;DSN%0QHU;$8#* ($RFU+L&KDBP
MESFB9<L_YYSM?XVCO\;1'R>.;J>007*Z<TZRJZKL62Z&,9;NL##.X!:I=(C8
M8J4\]+VJ:$43._4"9MK C]D/@HUM7"F^^K)"RZQPWP@W%:B O"(LW(JH8 A.
M [E2?-:=J9B.R,E#G"EQA2CY1-=DLDB(!\;'!]G L'I6@=;FOSE,"PS=Z/0V
M>.#:':5PC+\-\_<?79.HP9Q0B17C$OS(RY@KH+;XQD2W-2X?C3"QL8QJ_7/\
MZ]AK8[$,.T[B,?:V)_UT%B.X>$U0 '-"[6SA";(!4&W;_CL"Q<"@"X@K7!I;
M'ID\^LT8B!YCK)HK-#/T^!E+4Q:\K"UQWR?CK<XJ;W56OI4.(ZQ'@U-C.274
M+$$I3%AV*H E E!0IO=&29'E."B3B32!AT;H4]?9-'J\PQ?@\;Z\6LXKMIO+
M59?>6N>],$_:NK(,GV$J*]S+Q&>(O"6#3<65K!JVKK%PN01;, U]="77B1&T
MTMN;;#S94\TT]50C#/*I,U=[8VA8YCGQH!D^&MFW.BJ 9U?2R[&MZ5$(@!T\
M&26H.IQH7=H%3:B,5%,F2E9PRA'N@.Y^K5E<_08AMJZ0L7M9>V$%+\S!I/,&
MS3D1W5N.P_/2SDZE15>);(@8_%SBC\)]W#!#K=X]$BIA:WR-S$CC>W;:U^'Q
M!N(6O&1F.>"&<NRSEW:H',</1-:0I R?Y4H0;(1=[1++KH%&U9&/9#.]E0$G
MCYD!>5"2>HS*:BM>%<>6K'!2=5IHB?$F1E_8$;A(#AI9SB1,N80VP$@1@0C'
M^E)>H5A$CVQLM^D-^P*4VLNK'JTJM6-]=CM7:TUAU]91VR95Q\5C%>4QWQ&'
M@R L^5S*'YVBO4O2+XTB4U)Q5L0/1TJU="1<# /[E&1L?[,G;JG>B&!??^?V
MY96.G6/Z/4,$P WY0NMS[,R"FUB:,EAX$_.61,L1X0G([GJO.WRI[EHZ3X^9
M:=[5?#WEM=4+VPH>3(EI$8>$HHC%C<>'7^6X&7<["V/VB$=8/F.%RS]Y*84(
M^:B'J=)QQ%Z)20 9N,MT)@5^4DJ2JUYD8%UDE>Z^#3.!I_&=>5>:E_+&L90X
MUI,=XRMXI-60'WE:RG:SE<R866O Q7^N?B%]D:M6V ATFE*6M]XKM.TO &W;
M>Z7^6XGZKXI;Z7=KF!H26T39 \5VQ;%%\J$HR82JMT23"?P7[&Z@'3=GPVB[
M;8J.",07?0\+'+W@-LR2--O4]IQTD%9 &+6F^UVQ#U*[N'YGB]SGXKWULWT6
MPY,NN6:<RT,EYQ&A&=^E&'#MNGOVF<5_34-B.P$.C0#UR[14J)XQ$"&_H2("
MJG:XI 94>ULWTEZ_(%N_&F3#-]?@L>X#;7W)4#H'@E]2>C2P:;F.6A[.UC81
M;AFET6742JZD+/G">@7"2%+_6TQN@"O(G4L4UK3E$]JQA,UG!UM""%:E_'I(
M/^1'34>T;"'W%*RW@V_OA[RN?N.5).C . 9EV$!E=^T[7JLRF'*CWNNZ(C/\
M8HD5FVM$'BFCAKA("6^'QUKV6?ZC2,,L"'W)FP '2O$IX$-B(3L'88\5#T.;
M@6/%F26,X%[&=0D?Z)0$""3!L:((C!UO*MTQ\OVF8$'=RS]FLH^,V?,$8\(!
M=GK*%0V( 2@W""V"DM!"0<I5#%DID5+)X%3P'\G^\HDF-DQ3JAK@QI,P'_<U
MD'@<- Y:)B?*,=L#KMSF@5T7!L\<;B*Y\11&5QO!L:R5\KI:74<^X055E/\,
M/IG&FI"C:Z-KG@RIE]Q0/\P$28+HU'+.AIOG)$U5$\3+7!(2$-*528G@B)"!
M0'Q#'@*XJ#M#&5[)S4;R#LPD$;\0]T@3"8R4-EZ6)7Y(%-Z(R+SG"S6M=-F2
MR::<J<F"\7S9J<\G-YM,R'#!U9Q38JYE(+AP&95T2KE@L*>2. ;AAW?%:#5W
M9PFU.,PV7>I?Q>:(^(HS*C*#WD9)3R_/DQ2$3_:#,Q:RR)G%.5WNVORF<#E6
M!2G<[I2^+@TIGALJ2,6Y33$LAN*^:;::).>B*7QJMNUFF^AEE-&OGVA;8A21
M92X3HY3.6E[W\N1- !<-N//V@(L&]RXJL%,8-@5&'&S7UJ7L<,<21./\L]*
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MLF&2%9MM,/EU3R17(K<9!73+^"/5]6Y:'D-BI6</6#4O-+MXUT)B^D("A<]
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M_-IUSLZ/'U:_\.!V6FU=OR4]N'#:=FI:;J\,3!J=/3O93[LPO>_N&0?W-+Y
MFS$L@I52061&_^O\=X@E5-&]\R[R_"]W(HI<YV/OI P0?I?K<^Y-!:_0O/=O
MO:<;W[XCV^H:TT7T7O-"#L<3;*I:^GP7XW'HE]7'3W/R5Q"8\W;6$X1RV@G,
MTW^>'O]^??:/TX<*N\>S1^HA@'EN5_/:OY3_G;/A'G$BOZMI=!S'%.@+5,XC
M3EFS_#F* S#OG4]>L:A!1F<KUYY\K"IXN$]$.+UQO"@'!V@*KLS_]'M_S&[
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M]\\#04X2D2/(#B^+H-:!/U1'L5XJ%WD".J%.$.%W+$N&/@&<I0C6 3KA**A
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MNUP2#F!&J%NIZ^',,C"D8TGWS(2)I3(E^CGNU$H&L!1:Q9SAM2%[P ;C %L
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MU=FG7] $^]9+^N!Y8,TJ^WH*F6-B+.7]*0\:<>M:G6;J<]7!OU!+ P04
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M*U3#Y?/7+WA9SL(]Q!RC4CK5+A1#,HVNP_L[Q:O4>GI!!![+HFGES<&K_],
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M&4/$91:L^\P:X:7VU&$BUC822QQUBD_K/^&D/E,#IEJ?GI8PE#[(?O&NZ%R
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M#BCE&EG!$@M4V1ZR+<B&UEXMT-^L;(\"_25!?SHY(^+@$TF#CR$"$S: IM)
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M#D69LTI:2$I/ )8V3%!$>&!<(<,]4BCG7V)=]LH&HG(MUGRQWE<,V6GKW=O
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M>U;]616TJ].<*\@NX+T/>*=+@W!%E8],0;0: U,V@5=S"D%8J@B/5$N4P5N
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MT)UD=64+]6F=<Y;4PB*E(J4BI2*E(J4BI2*ENIS9<^(9D"/!!44U]\PHJ;#
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M/VG,B3V(R/6C_8IL@K;^8CNG]FRP]J]+7>JVC]',\%W7\Z[M'\"5XS$CM-K
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MM3810QUCP7A)Q \88H'#E8?#L\MPB'T2BFN5K8(>P9;'D6,NH10E)4(S[8,
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M42*NK4$Z.8P(M@1KHC!-5;3N.N;+JNVZ4HY2]W1X>LTN3:_%:6EIP%:BKYX
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MA2G?W[7?V]U1MQ&_GU0J38:HNM[UXKX-:RNOU>Z4J5S@(:R(,>8/[7?8E":
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M'3SG/C$307'7OGA..((9;+],W!)C&]L'OA"U&H$6CA9C^/5O5K?$(@G,(D!
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M^'C<./U.FO3KX<YI2(V#CVPO*D:5,![4+R3$K4W(I<"0ILXF(B&2-6RZBXR
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M.JUN:S#LEP6F=8[B4?>3/E0+D2LB+RW#Y<1JC40W1Z)9ZB,KF#>8440C4Q#
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M3"1SY(%3TNJ"'P,&QG[OQ\JI@K]+1E2(B %%\I\V_,B+5,*-!_\MA[F7R-Q
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M6Q(:V+5B(133<TG"?TGZ]DQHWC[_:M[=23$\.8IS:5Q?,8&;QN8A.-% IQZ
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MYF52^@(A9M4'CS&<HT+JM=N]XWP#>RYO;^8$@)<\X6OCP[$[JK)3? 1.1O[
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M)C>AO+$_;*M=GCS-E N9U<!V?03K$\9\!GG\F4?ATH&^\@FNM%C5[:<9.A7
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MG6@]2X_3>ANZ=L\='9GYUOH"3A2;!@.[Y[38U&+3+7F6>OW>D2'3X_ L*;U
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M;&$7Z#Z#VW#>;"+'-,/!K2(_*%:9[ND5QCBA..<)O[C<D"_N6*"EUJ8F3(=
M*W)0Y2HS7\!G0'8*3WK#H6UX8EU+C8>AR7 _>MV1WA(N%'[PRCWBZ>9")/AT
M.3>YLGP:HJWF'X-Y1!/J*[/(RQ&7\W7]\X[Q-?I\SP 7?1YWPZ/L:.YP&-+8
M2FR1!H2/$YS5 &U\ D"P;7ZS+<=]S^?^-,V,(=SU!7ZDF9W^ CA9D?,::(8R
M? :'KT<Y6(/3M48,WL>@VZL?8U__ (?7@!A7X$5]6>=[8T>?)JKB[-*+!$@3
M%N.:JZ.9\D7F=[9.NI:TB+?BSFF"(,UFS8$_SWQ:AY]E.!N0[J=Y@9]H/H;/
M5,.GI^DM2#/<3)J$O(7=R$VD)>;Q(DX(C7!H:YJ08""P'?N<YF;.9[;#/:M.
M,G]>:_%WUPMN'K5YF@)F>]?AFXD89](=;A$Q.&A/D]?53'Q3RL2Y,:$>F,FD
MZVX1,W4'E)]4!M\G:=*AJ=C 8((OUI0FQN-:8=_,\9A7#:N\JF^P!\6[<;(]
MM8K =Y)XH7V9+]ODY880!D8^K'/V0;-@R51OBE LX4LQKU1"2\Z5+_]D+IZ@
M0##:8]:YY5N:!6_EJ^5R'DLI!7CP5<Q+-! ^\#YU?"'R=%BCH]:XMR  &!@2
M"'FE$DP5.;E#--4E83OT69.SZU3/HAWZ? ,15&L%\Y;H^Z5L!8-.[I/D^%<U
MN"$6^J/)HP_B_S5F;W"(ZY@3%3[?J_'Y, ,J3I"G9 *81D)IY":+AX<XCQS9
M.O)Y5B&S+T(.4D8^#10N=LR-OV=0'HBR*IG^.2?3O^9D^I>;R?1'MLV]-K6M
M0H Q=F!@QT$8V[7^%-HRG(',LWS3'IQ?]?7#59ACA<*!&F]UN/R'^-L5H^5W
MWN'<^%#:X>CM9/#V"-KAZ-=D@^UP]&963]O>RKK;T>CUR-=# GL[&KT=B]V.
M1F]QH!V-7N8XM*/1'UPM0SL:O7W'#=[1CD:_I='H=<@<<H"-26%'=WH;N7,'
M;?&X\]W&$WOBMDVO6L0].<1U;6?8-OYO$??4$'=HCT:'UK+=(MZVX]G;\>P/
MO5C4=6RO=X_UHL=BXSQ\2/?[MGOP7)@6TB<(Z8G=&Y]^*[5V//L#%YH/L8^1
MTW=LU^L=X_#CMC76B:)4;V![HZ.<I]VBU(FBU, >#YUCQ*C'$(UK)[2W<[1T
M"3WK"T<VK>9 !&Q''QT-.K&NT*)3BTZW@DZD)QP9-CV&#G/MD/9'/%AK/+BF
M_^"!Q6H?.)C[3AN2?P1@'KK#HXU@']\\[8=W9PN">[_S,3B5VB'MK7-IT[G4
ML[U)ZUQJO0&WYESJ#P\?$-&B4XM.S<ZE?O_8L.EQ.)?:.>UML@J.W&SS5-JD
M@MOS9WE'F5'0HM-IHM,39W) Y*E-3FFGU1\K)H_LWOC0]+TV[_X$ =U.JW\T
MH+YGFGX,9FH[K?Z1ZW_]D3WL'Y#+UIH3K3FQVWL]Z U;=&K1Z3;0J=^WG?ZU
M9Y^U!FH[K_YXU(?35<.?.)-V8/U#!['=<P_/06^!?$I 'A^<)-D:T\<WLO[0
M9EO?;5;NT1W_P4VZ;N5HCIOFR<#WW'94]Y&.ZFZIN:7F@_PKGNV-#M#&6VIN
MJ?D8,+>EYF;WUF1P;=_[O1 SJ?'_(,7VE].9/-<\$;#2A/S<F S;CH:^O;&+
MVSJ];PZ&SN-O.\:KRXG0XTEWLF4B]-@UIK_O]=*F\:##<IYR;0QTN");+M;C
MEV.<EUR(+/'GVZ<,ZVV:,YYQKCL<%5(9?" -5T%A!? DSEK'N<DX^-CRPZ]^
M$L 3U=OCI<!3QCG0%A)T02=!HS>N.D,:41^D"7Y/A/II6H307\B+51B+'-^)
M ZBK-P(^K"(_*%9R,'5>\)AG?6\YVIDO(B#PC6NZ;>Y/X15P9K$_SS=&6;O&
MF%>:7NV8@U\KXZOU:@M\E3[<<D%+D>5IDJC1TW(@='UB=74!KC&26T[/]JJ?
MQS.&-ZSF-#[:.!<]?EI.I69 ;\4*@O!\CO_KPX5RF/A%YL/E#&Y-5AOSM5_!
MZ6'*&+W#UG.V[89!VQLCMKWZSIR2C*I?V7,"MUIU+J>G#XPQY(,Z( ?&R<(N
MPVQU <N?Y@5B.)\._J1H0<\7_T1#;GR"JY7/?,(ZP%64<2&>'@4C_,ZV@^:C
M ?X*K\-'80TB+U*@B4AL8L,S'.\)\K,R"QT@FJ=ZM^HXQ^7$\D/X\M'(/K,1
M]5FE$74K_6Y1^FWO]WU-^><:$^MK\J_?-V87&^.$KQ:!<5Z5@1.3ZU9D8-VQ
M:<[)!KI.TJ1#([*!QH(OUE3*@07NE(D*7^_5N4/?X$[P%F[$8CY68]1;4<$<
M-+],<V+./Y-L@!/?.GI>8DZO?,2?@MJ\*K8_LC&'ZY[PR^U7S\+\[TQ/4USZ
M%Z(SA?/[TO$C6.S/_OS27^<__*-*1T!$Y@%NV_M6KO8+#7AL6M")4.N/SJ8"
M,-JB?Z0):@%(8R1AQ 50>9-,>1M%('U85J\;!#40I0]RJRZNG5*^O%6JA:G(
ML%2J/Z47>\@D^J.12;5^3&^)#;R4_9@PMG*2(N"J+E,\=[Y7FC5["H0:]^_=
MAO'3ZPXKC#_, (L31*Y, -HE5+1@\GQXB*L6D,\CX\<M C2^"#E'78!9 #Q5
MY(=@Y#$[#53IQG,NW7C-I1LO-TLWCFR;>VUJ6ST*X^C(D-O[X6C7^E-88-6"
M8E!8,V![EB^QEK!C?M5G]]=BCH+?[51@7\6PRQ#WB33RS%\BREGO10[F?=!J
MV[>!QA]BM";178+_6+)G!/\L6P S%DY1BL_C1:P<,MF%G\1_*VD.9BE(;?B#
M/"^(K\G:MJ8K,"$%8.QR[B<)7 91[\=D5@8,3=L"Q 7,CO.9>AH3Y.9S4 =6
M[.J!A0 &+-.LB%(@).6J '):L&F[Q6$ C!9?IPSDT@N$!)8:])6LU4V@(RSA
MGU]ABTBML(^%R +TEN3^G(UN>@2?O2 [A9Q"R5JY'V3_9/5-?(I]*Y>"G]1.
MGQQ@'X.>@[Z+<DH#DC<P?EPBJB[P"G:?P3[,![0B1.*Q]K1F--AO!Y0OXAO1
M"G6@JIN,;C+=6/@V_4?#4>JCAOU=9/Y"NHTVO'&5]<_\HOKPAF,'_K[8;O2Q
M?^H2F&C%;@K04Q60@709%S/EHR-\W.FDJ^Z2?&%\9(2Y"!RY)GED^V[:EHX5
M7@.MZ=GKMSD"$#590-]]5V/CV>%[]R,(6RWH:TR/[#A+M1"UW9+(NZ?)OL[0
M&<C>1?+4$IHD0KH2@=4(Y3-#9YR)&9+_F.!AU@5W)BLZ^I(#T@&OLGS%K/(B
M2R\+M-B1_B_ 8OD#'@*0K@!+"MB>)#/ #<TE*N0KF44#K["M.++@:D:[0:Z)
M"P3&ZBLV;:RJF&7IZF+&LA[Y$Y IZP4V$-BTD,_!7D!ER)2/0.Y;RE#XSBR&
M92_\-9+7?!4BQ1D^O9Q1N70P -<7QOOD(<0!&FE)[@<2G4!11GZ3(;.$\\A7
M&6XA9WZ@(#5%\ 3P<QZMYN3'F!9^G+!0 6C!;O#LYL@M<'=Z0^0%1K8Z ZF$
M\&:(;SDHX!%@PB/E!BCCE"=F1=N Y?ASD$/DL U6<S^;XU& K ,TPX_B\0K
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MH+F?D+F!75=VE)\='V$K]>APHJY*4,/.::;F4/4+*;_$[1?W,MI_'''5U]6
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MK_1 X.EGAB3:=_50%7\:7W+UGJT%  T6$6&T53;1"*2_A@>D^UQ=22X>BGZ
MA1V7&1QD?.I3B_.**8AL9&U]7H47?#4Q@8(?FP(J1C$K&F"BY>3AV;949>W)
MCBAQQH'LX] @#J3,Y_(<.(182I%;(,E[;%)08H)=MIR@)A9!O-2[16I\-L-
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M*>QD;V6/,G>9/RT+@1/D16I]V^ZNWQJ#CV&V/1'%\<6BB^2VE^;H&+H/Z.]
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MI3"&[S(PJ>$5)27 M$=_EKTIO,1O?.*_"M'.1&<_J/"(!2\<S?M[DBF?Y^?
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M+!='K,QE0V\S,U'5 U_#4QI/N:AX'P31;0-!*")PY;"&""4Q@/>Y6#VW0X1
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M]XC Y4F95>4H7XOC)V%FEKR-</4Z[ KN,EOFS%$$?A_F.8S?-(('4.I5U)J
MK9X4MT?)OM3; PH*W 70.75&/M,!G!)]E8WT\17.,'%G"$JEQU,PDF#F6ART
M?* $L-XUX2Y;&A0R$4D+30E8=24/M1FFZ_.$G=Z$G:1SD<1JXO\/C8P>$:OU
MR2A6:1E-"7*Q#+01$*F0%V^^\3R0<P7AHO3Y,5RUIL15#9009I088=G:R##-
M"1F!4$-:TMU:-3W#:-V%D(@]&EPAAH=7VXG%?$1?-<QP+3(6,=01R;?9#91<
M%JEDWAVF4P=!2PI].*5D!8"*/[TP(G.M],KRRJ3CP=33-2<0 >B/8^&4/QZB
M8$WS%<8OG?/6.C845^7Q,"(&K_B_2A'-*6^A74Y2=/0.\\>C,'*45(JR?I[H
M%ON',0[_V/7WI+J"]^XCE]Y"@O>:LE0=MV$2>@9L&I%&0_Z$6-I?U*6/?]<_
M= _S=T$1-JYOFLW$H&*E4']1\&.SKIR:T\Z<A2OT,DBG8,SZG_L9/B*DX_%1
MH>(*1<+3A*(13E'%-NMER!H8Q"J<\3L?>K*+/&1:PM#49V]-U"C(B'PEF(.Y
M5$A< R&>GJS\7\Z\=/)E7A;GR?[0D\VLCI*"$$+:%2H9.I-=SOYNSED&%AA;
M:Q=FNN:PH[FF(4;?59]B<L?352==Y*E+P3WEE)@!9T5\"'?O\^KY>*8BS27Z
M3!8!<]K]9'(%Z"R][(E+%L['JS=_X1]R_,-Y/C_X?-)<%*>"61$4=L)E%VIU
M'D&8S^R]IB>GI!@,(=HSK.>.,JW7"O^A_5IIWQBP&@G9FP\.V&CP$B'[LQEJ
M)?)HASR>YIN>%\Z'7C@J^CZ#UE&DN._#HYWGY(//B7G2=#A2?-SRYN1R3S([
M./N'_O:6,:R\"<^;Z>-,7(IV7Z1)G->\>]]]N_@]IT-&)G.H;S6KMD2O>%X
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MA_HXHUUJI&XK<^[#,T4S##A3$A#6FS"7+6L!4%]!#.W>,ZN?*<.XQUB:3%
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M[Z+G^"DH.?J7]H63=Z?,I'H)4+D8-D&T;9KN\%BS?8K)_%=DQ]I=)0CE,)S
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M;O>!?IZ LAE*-!>!O=)NY 3K5QTKN3H4KM^9!22=]#;B)>0M'=9W*"'M3C,
MUVQ25"Q_0**3M $:@B9I$5(5CF%_80JY6GY[$X*K,$1D7?7XKGPSUFU]H"/.
MRB^1V8: >?56!=GW!\>SD18-M0IUHCM3!W]AR+5CJ9#I@XT^V*1<8V=\P!GA
M9IU-@VULO2'^EBE6+X<DS.#KK/'$0?JQ%NB?(0#TAS\27</#_!9/F=7AS'"Q
M_\]G?U()H!+4(,SE%0FKU:,'*VP*/-*2!Y7>XQ+#[<\AHSE/[,^86.V>MCW<
M$NX5W<7.PYRYE:ZI5>,5FD]%')UG\^/,IJ.QBJB)R!1=GLO@)*M]/C/2QDG^
MXK-?09WSO+5^B:U%'<U#JY0>[!,=*X52SQSJJ2'4[7^B1&<-95%-*H>#TF]0
M@+$)$T/E/V ?W[Q\_;;R/)-(R8&@@%N[=DT](NW;PL\J(!T,)$&>6/'(U>A)
MLDUGX_V1C;?# 72@O=6BP89H(>KK!>V/D05GSV[5IS27U#D+[\DD'$#<L[4L
MTWFZ/J7IDGJ#-6RN:4M1SPCCOB6P'IIV=SD-(TQP2NP23@=8;Q S1#I CJA]
M4LQ1^;FDV'G>/XUYCXGW4J["E)+0LSP74SJ<I_%C^&8<@I!?===T#+KGUB_V
MT#R%4_]S=&;/4_0S=AIE^<*O.VFP1NH!$/]"6Q?JT,,!/4I[DRE#6O+*93%1
MC0H^\'IH+QOIDK>/G^?YHR4*N>=99SJ2>41<=_A0/YR]G8\Q1U-W5=_U#$GE
M4BX=?6Q$F9/21;2C+Q^G>@T:F!:;#<OM-IXF1OTD+AC3=J45<EX.'\4)\N!B
MH&=2PZMT#,#-N;S%B?(Q/T BX=.AJTL(@PAM@94^7:UM2VL:7D8L?86U[4MM
M-STUKP.26JZUQ5J<0U@:\Q%0X ,Y. Z"+G1(BMNK"XV:!O?P7'^,@[1&HJZY
MAN]D+:T$[#O%,O82#9B .XT56^J9#I 61NEW /F F$-+EYZ.= 8L3ML#//<5
MMQ.WGMI'2+DR](EU$BLSXHE6L+^=(_QH^R3M6%S$U:&/]:9%=IWXD1+0CRO%
M3&)/AT>E"=GQMF%:1V.)HJ[NH5D/4[N/,XJ.<=7 -)2//4-:UXH,MY9.-;U4
M%:8" KO AR^DZRK>P>C$_&V6N7@ILRN-?;$U>-NO=6N+*FSMS4*LG#=A<:!5
M\\A[B\=L)".1!YV.JJ=__')TP!P:D=AW6- H> ?JHK1?V+A5"T,C .YE/,]5
MOYX$2^8SZD*3LE7K-NX(;%XDD(B)\RN&'DK?4BI+/Q]/009&;":QY(5ON^\%
MP]QQ&XH..^,F^&*<= C!"_!I"\M=H.7-N*\%>5T5GI6SQST?1+'#L4!3\6NQ
M,IY!([++7LT M,#@+Q'K7)5=54=PL8&60;3P2ZX0[8ZE2I _XL-JZU?W.!OB
M:7#9Q.6UQ(1,;"_47B:[OK!=^MG+RRXN-HL5AC3K&"Q1 OG!-DG%7Q2D<Y:@
M>2<GWK05E2^GJ_?3<(0QYZSY].%E+ZECQ]%0<Q."&)>$EN<\.1]<O<_G_Q->
MK#YB8IDGR6S_>0(_H0FT%J.22Z4S9K(X1A /R&((C!FM*+ HD("=$5 . ?7T
MUX: .N^R]]MEAD5AJ1*RE"*9-"YC1-E H@WH;!@_])2Q^TX92 T#?!QBH0%-
M[*V%,-IL'H%("?2H/,W<5LRMJ9L<YB*,A#$FU:RRQT10U$$IY\BS[;1R[116
M:Y[$^9P@<8=P=WU>:Q]ZK4DY#PW_K/M-ZT)$2GUJ<!:UGN?J8SE,0W/5# /8
M3REMO19PH=4MSC/SX65D&]_ON&.IRI@ZTIH3M=XR5S? :>1R103A>=H^^(8:
M^I\H"<OQXPQ(F/8^$R^MY1U97_,NYI3/D_?!O22IRVRR=']I=BCC69K.GPE=
M.,_<>UO+R%-B<V2"DH4,.3>:#OTM49=D-);"I.EK?D-%;"1@Q+9FV^"/$BV3
M$LI3N7CP]7NZ ]@PI^&N%7D:XON)/'MS?843Q5%\,U'RRQU8QPN2D<%EH<)Q
MGU&=^!)RK.;/!6?KR[#]:+X<5<V,9GF[[Z]!OWVQ>ADW>E3&6BIXQ,=1=O!-
M4@^"0-:Q(NYQY:ME>NY8:-H>U=5+.!0;Z2?/^&!_WL14B=Z2H2D.#)D0&9?4
M>J*0["$417G84\29_*,1 1?FZ<9"R&0]$&9K +W5(ED9$><AY$Q8P^1%,4CF
MZG3S$ZF(C[KB,VG>$ZWJ/G(LM^V/S38C)7_L:'KVJE0:@8#\G?TK8MV /&Z@
MQ0;;;O &R?K3EB/1ZI]J.B@JW6JB*Q-YW6A3X%V*#Y:T&1"74=B0;7B">F@O
M3W0VC4BD.Q1R1/<F$AA^9!EG9;<HR8H.H*WWO"X;Z[U8WC;-3RUK*/G]T\C!
M$I76>Z:OGS&>C3,:[\>SMP:' JH9<L!_WT$%X.W>R;P-S5W_8PJVA/\ALAY
ML13?S5E^' JU:N]45JV"IN!$A7@.#(51FV!]XSC9(X3E-0KKCDD0$H'3?. N
M5J_\XX&TO%D>_F4MK*&YW=9K6N4L/4N:-9MP&"(VH@\L9/6$;^J1+,;O10B<
MNA$%$O"2H+F3X7,4)WNG=)Y3MM%SDW2F)C>KE&Z'LZ=#L^,<I_(PJC;'(!\
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MUNN>B3.W4)RG#"*+FV?%G@QRGS_?(OOME1U"LW6TQ;*P( (#J8O%^0\Q)P!
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M)X?M%!E(.HAI*=-@'W1(_+J45E0W)/4AX\OC*BC:8! =)QH2B@O!^G2=HH\
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M+S$12#=!91';.48EEEMB;*G.#G?T\,:;$TB)F$%4X)C)=PLI@X% 4Y6\0O!
M+\(MGJG>7^\!,2HTTW;YFDD&]5S&LC+6GTZ_C/7)1&+?1.%;U%QC!JH4J"XG
M/6@3=.F2C9N9?)25$A5HBX5K;$GXC-[]OC/?_%1S3!]D,JZG8(C#]FUF,Y+U
M&GO^T]+]-=4_&_Z+U=>>6[)Q>5(Z$JZ'FI/U,U^KG-NN'I$[7T:KDBO*H H7
MG2S)SJ<]M&6:S7(V%]:[][PPCI>QM@:27E7['ESRI3FT0DD=(9*QBV3_0+.;
M;A5*\29_VTS4:'8')GY@G=,A1+D1C"IW_?:NF7NQ69<2M_U(>]$8E974D>W'
MIMCQF]0HXF'^2!!3/:MOITF@XF#F$796<$X76-'.*)51.F1'6%1*Q1N-EPQ;
M=35CJY!>YW:OOE_R68BOMF)C,U],"7\H8U#)ZFV=. ('6LNT,<QKD8'_3YR&
M-QK:AX@4,L'CS"RO(^$$@KR'6B%R-.F<VZ^*15"E^.!N0NG/CIC4F:S,'D7V
M/<^:$Y>)\]BY9)-9*::?26ECO*! U-JDESU$G,-B[WR7I1Z-6RA>2XE/G+<[
M/P\$E)&J4^IAI1Q#M<B,N/XYI>7F_.96'\ CSQ^D2Z?*UJGJ$&MA<N$5CY+.
M['T7[$*;WRWQ?<7I6EH'F!D(Q81'.U%#\;S<&)EJO^N +O-MI43$C)BYW+6C
MPF&8[T/428OG#W--#'=-N!"'^[U1D'%GD!=L K_(HK/"P"YA#%QLX'1PH&ET
MB'=MW!1F4-J"UP2,Z:=;5_VKDM(? MY9I5!1GMJ.&$Z[3=.-#!@(2\P\&$Y\
MT9E(,FM1<"C+TR1>IWJ;/$%)UR=\6V*3VT>O< D")W J6-P&TF_I(F>FT@@H
M"NYU./BKV#II;9!BNG>[J=//4E)!H!/F[C1;N3)Z&L&[2'-+<Q"U/W4RFHS/
M151 *P<=1B>DKB!IGL4HLH"GDH'WVP*NSB5Q'DBC/32,,Z=;O5+Z8Z2X<<PV
M_KVJ%(CDZ7&,%,<QX52>!H<Z=8=]!13+L!>7WI'M/+AK4SL861<PGH+Y7#"!
MQ99<7>W1 B#;Y#:P,*NG5K8EM;)=[>(2F(Q*IUC%N6(;8=\]X:?+O93U7U]_
MRYAYR7O&R<W,-R6ME5%N)GEK3+)<;DRV;+:67KS^QA+>!*>)FG 9+9-PCR(%
MBR@" 1DBB79=@6*GZXF!9^.RWJ.OQ3W(MW&EI"+9B"1ME(\9'*.]\#[4#+!Z
M8$;KNR8"<8,3-77,DQQ&*_@^.V$BL=@@[O0<@7>5T0Q9YQ7MT8%[Y0Z5R)V[
M2\,7BL,>T\RZ[%NO* R)U<*KN-;W.40CHN)*^UUN?N#6=Q_KQ;YN%>[+-?..
M0#IRN;VK]+;9.M0P//-FTW5S/%<]Z\K7U<M"7$P 2@=+&A3W%#EN6N&QY#$D
M/L5NG5.!_.<[>4JW]'+=]9-M<R4IS+GOQ+\*1V]XYO]\\OD?/@"I7]F;HH+D
MLS]\^?%J0NEP??[LX@L:"\>JK@K)/S060NG",]_OR_,$?> )RFW-3#^:3Z"2
M?+71Z[!=0:N!1\/<]-L-7U..<OJ0=&_P9<[3_;&GVYG_A ^"2$CZ!?79\ZQ]
MZ%F3R(][O/?M?@L],+"P'IF,WU[U\L^G7[T\[Y=?8+^LV[N6,=GKH26IJVT(
M=,+_DW]^MEX?>C9(%EM\\?/@?^C!/Z:77LJ^GF?H0\^0!D%CT_Z3JL45%/HZ
M2Y9PEFUU69^WSX>?G+O@^71[$9$BY5C>+CIGG%61?ISIDL0#]FD>XSQE'WK*
M]J N=@%IFL.ZM2(N(\C/T_.!O8&=!A9\!&7I!Y, \RD&09<2]4T:D285@9.L
M@E(_3>1_46%TKL70&H;;>IA1&OJVU%G*YF']"<>SN$_U?A1&X75=(?^W2:J9
M+*?%?)_A%FN&\5!O$='*N2O930Q597;R1.O6WV4=( ]5192_P+1EHBY.)1@O
MJU"6R:Q-N;*KU]PX;02" E!11D##P+T3J!&]FX A90V<E!T"7UY[T_>;BJ3;
M!&DGVL[ADL5'CCR(]4"]X]Q"]2X\W$V+(2W*5X#8:NCKS;ML^4\&0O+=T6J:
M$+%@'.Z(J+"AXN2:"TKH<>!=%Q='F$_8 >,>-XPE3?C5U1,FT9M.FCGC>%NX
MM+(Q:(][AO [(R, LC.</"1Q2$PX/$;4=I&,SUR:RTGXK0D\L<C.+0:8&R0?
MGEX^];:V49MTZI!&)Z:PN)&@O4(2)Y".%U9I%A2+#WM<'3+3]GK5.7H@CYYT
M\$T;*,;(-8[5QK4E;K*.33S&D;5-*(NK;:/X49>$CE;5I&\%P:"58$4$%3#.
M"QKKE2?;9L8\PC.PO*SQ<P, RLU%[9"PYA#'?->Q^"&*N<$Q,='P6 ).GU@?
M=[X,;4AYE)(%^'[+#?V95PU)729'"-&T;ZG6+P(?JT)>[(IZ<,+4$*W"WJDU
M8BRWP5;3%,G&.6):<%&Z7]/]T$.E#=7S>NLO28= TUT#A8*2H%W!+HP7XJY2
M)9K'P83R^^@./[TH\LT$BNR9T19HS_70"#]7,X2Y8^%62T*)WJ7P9AG4*ME\
MVN<]RDG->BD3(3RWV#N87#DN$^DEAE 5+/'#6[)BS >W5#UJ_M,^+,<>,E,#
M3#JN:+(*9"*G"<F,^\RHAS)K9*3_2[2U.4'WOP,$W]0#LRW3OP@ =27@LO_@
M;@I9A-0 TM;774^]NF -85*T8#+6D1,M:<0X=IB9/+%0W<2.D1#V-$69\G=\
M;O>TFV =Z)/:J:*@_:*479E%I802GD46BO9R*Y0HSFBR3M<G 7904*'"J&#"
M$\>\%58(4HWW?W%\OKB9RJ\5UM5=NQ_ZC]E;G&PG.7*Q$\BAN&_'3+C6Z:CO
MB6W7>J&,0"%!",>-Z/:*<8_%6U<KAI%![+&TU:N5- 6/]4Y(_U.-)K;J2\X8
M#+^P3IAB,&T>//O4;G@/.Z@HI86''<YK=L+*%HCW- T:84"%&DPU#A97+.M1
MY<1?2@44L<75TOCF+!4+5Z(<3NE/\0[ZRL67DZ7@N\XV-I/BI@JEF5X/AW4=
M]1W(_A^[]M+B6M#R!O]DE"Q",Y1C+DHAKJ6P?(9JM:XR,B&>Q SW8N9*:MU.
MGCR54K3FEC-+K[<L?_CL5P 0^&2.P!>%3<2Q>$(^&!:ENMZ""%: V"T);M:[
MT81_'&^;00,I03:4-A'0VJ/QTK#9F^&5'^QOK5C3-UR78T7],H4>T<39E@_A
MHM( >H]NNRW:%(%$DRE/> "_NVG2[Y<MDM/06C"I%B^;CA<2@6-.ZU8RN>3X
M=I#"0,;#2T8U/]T.1LW"$=(:HX&GVNXE21\/O.+CW]>>AY)&.)Q@ZU/M5\J8
M-QY86;9D1M<!YOR-S#4_L@BT2>!(Q*!$>]+)VJN\6KL_RIAXSPGHWSD*6=><
M*"3549DQZ9X$5W"B@U>(1ZXT%S1[:*;"G(D ALW+$B->8BIY*%Y&3,08#]UB
MO]U[C?9" VCB-7(C1>/5LHRT>/ZB)[G8$VW.GZA+!.6I&'WZR:<**TT#^TE#
MPX/0TLY ,T<PS]*&6D"3FO$O3@?K9>S#-(Y7S2#ZFMP-@2\G02J,92?0U:ZY
M[O=M+0T^RN23=GZC2:Q2=;'(/I,+,*@Z+$UT@4([XYS1CQ42D4FRA\XO^&U;
M66K]5<OTOZ#@JGR$L+B(/H45\_0+:N=,:-(>NPO+A^:<R4]9@JUXQ'T?2?,(
M-7'!A0]C:%H +[^_6'W3K5Z'*S[[HEH]^^SI'_F,?]6M_H<BW=5K<2"^$@?B
M370O_IT^_KL__OX/R*6\^I^OWOQ'Q1E'N#;T7%2;X?.<_DR+O]'V]O#SMEXW
MHSQ'O.-7<7WG-_\JG!BB:?)]1Z6W,"[R&^N85$J#EA;ECKF4\3#@;-+.<,^'
M%6Z^:W:7Q)?A*T=PU7#Y[<&UBX>%=]%<5'#6J-:044'UMSIY=EEPU34CW],>
M2R7.*R31PQZ;?5Z=.T](UVR1F0XQE3+_*<N%%)E=?[RV)64N(#-MY'>+LU06
M2T1BWSV'DA.$33IU+2VNB@U1L#(HN3IA:>DA-BOH%^95<'&;^W[X<56OAWZT
MY7#5#_,GI]B<.U-%#VQ+=C9K8A1V\+ :B*V::??8S(4@OK8T.J_(RV9-^0G'
M!M#*=OCLV;,O29ZY,>7"EQ/E^8/M^+8>MFT-&TDW?$%]@50YH,FG$ML*X)(0
M I(''^QP6)[XS=,O5Z28\T1(XO?Z$"P1?<>S.9)(D:/EHC?8PK_1[),_ ;(A
MJK37<4"*@PPH=N-X&/?-CNO2QK@8HHNUB3$S"2&\#A[L?X]2W2:1A/[=]38$
M(BYK*FX5^O=1PME#2H+S_=KON)^Q-Z3S@*-4.21HJI$*26^E;Z%]E'/+R!:
MRV_WYIHC1-DT5RB\D-.=YJ--B8$)&A_*!)G#CZ%G]+0V'P8'K25D4SAG4OT
MK0J.DYQAZ%6P?^&05RF-BU4Y=$0>20=8A#K@IZ$_%QIXU-4\J@PL):WV7+RY
M[#>'B]5?$B:7=AP)U+)Z\=*=.Q+A)5]DBTHZSO3VZQ;O1\Y'<&] 7ZE]D2#H
MU45+;V9*48L.C)CEV5"J4@O9[JN%CUP!6]C\!'$/@ %HB>FN68>M:K=NB &
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MA"1Q2!=.4B4<M8;5<MV#+R[KO>5E)5I\Y'JA(4B#_7IUW1+KY'5#U?+;&ZK
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M!P0ITR&JU4F4MI*>JIF!=8XMC(RZ9GCL)-P:O:3WRY?/+_XU-; 34%YZ$0L
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MH8^%",>%L+TBOU5+F[)2N^47K\RE"^ME50LT.K@6I"+!1!*4#%)J00'FM$:
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M21Z1;621K=E%7)JM]BKR%(.%>.VZ2"++IQ>NP-G> Q_@7 B]BEOW]^HA$XB
MH#Y-K&W'QX\(=%HA) (EE!?H+OKC2]SCRX:VCK:_:N>D%^EM=-]AG>7-1G<.
M742=+&),4GY/),U2B5Y;FJYCK#-T.AU!6([;K=8Y'*:"J"28[BE!5. ,[SEY
MA,,LC,2V%5L\@P73*9PBF>;)[*3#+-@,<73!+@?^!".I:WZ*O!(2]SV]^F\C
M1,F C+E9SPN\$@+.=?9FV#',MD"]LE%*ZVEQ/:4E8_($UBU:@9SXL%E@WV1J
M\)%-5OIXH97.R "3(47RR^6TANA12Y3-R-YUS)[9HR?)=XJMA!&",ULDF<D4
M=#G_'!XSV*MU0K\G1[!',F7/$R(+Y.!Y@&"[TD,G+9J&A^9FBDJ= ^8. W$=
MS&B!N>%,O2*?ZDDF#+[Q*?_"'-['.KH/^[E_*F. ]5B2[Z)+@O^5R+RRR4"_
M7LSAR%G+E0=IH)M=1YT&X9#KA^RR][?4YFC6I;*2XK K+,2HREML=)/^_[E7
M[\R70X0D_GWDP>?PLS0*GI(4X:(!BUJ:&%6-SK^%3+E_#8T.2&0MDRZ/ )#%
MAZ 0'M^(&WVK#6P&A-V!S10+*5T\<7T$9Z8+;M[*+2-#%2%)<=ON];3+5-L-
M0\/DZ7#,[2QWYW_EX,+A8V&W-G*@X\E<ENY$<5L64ESA,SY3,JCSM_&)04N4
M,27)VGLQ5JWZ#R3/NI9K"OK*<G\BMFE#7 C<7QC<'LU+M/BI9UVG:HC/&)-L
M3#+E\RC42WO;;J+T)'-ZR6)*B#;")U?!5(+43COR4[;4P:&C= YDR"N!BLG"
M<>./,4NNDY^LJN*UUBI3L@BOCWIG^G7\K#L:=$RRM6MO08]FI:8H1HI)3_>+
MA[G3"7KZT2AG971?A2,TSA6+AB)]I.4VN\J]Q/M@Q#W95GNI%KEJT>?G7RWZ
MIP]=.5/W+;!ZWT;Y@3^*'W7U#>M!5>$?74TL7@CU_C3T]U+E>05O=78!^M1_
M:4!XCLE+"ME?OOKOK[]\\OP/5Y15HL)M\ U&MR$9GB<A8^S7T%;"8&FXKIY_
M8Q'-QU:@L63_> B_5V\ZIVH_.TQ^\$J9!JB^$BUFXTJB(&W5#\'BWK7#-%)4
MU$#V5:>@(K@,&=\0Y3$GBDX)3N$P:#4YML'%YW;<^W[8KE.<$[+_U!5<2 )R
M]RZN]6)49LGD%E[]46(P@&@[AOJ"'*)Q9+Q$"E "<U;,#<"Y**N8#."![SM'
M-"DA%"J:DI,&]B.<WB1 =Z.%G7Z%*NKZ"^XO.!+E'K6$QZJ/%$7H(YMZ): *
MC1_5<8P?'Z<1K1#K+Z2,L9-PP-P2TMI-W;"(U#3!+770V$MB]:T*&VC<AY-M
M#=@TR6'$ZVO+X/+5P[(!'R)=9@-F02">;/PE02KK@2B'X_IIC%4J/79%>N].
MTGN<AQ J!L]%B:,\Q<G&<%.VN_CP[8#)\IGGF :(0&)]'NR!"4WM3 ^UH7P;
M'#Q.9RS6E1Q:+SA6,:REYO/>4*VD&TCRH"-H<I! ZAHB,GCVQ:?/F *IR@ _
MLAQN)H8<T36OX?5 (.OV>#VT:W['7;^F&;&D,?K,\!<L=$.7Y<.L>8V>TIAX
M,%\Q/I3,+R813T:6-GB;W6IF?.'!1],;/VBU06OX$^H=H@)8M,V/M,;.TEQD
MU=^W!IC.]UH#8R"T:)%-0J,>(JE.FQ4(@ZY].: Q2&?RHASY,4Y?W(/M(>(B
M*+L53_C\.V'G#E.;HB?DZZY%+]W-^#L,\&4=O.]U$+-:Q/K-I;\DA2>EPG)7
M(1?JL"XXPTPUUJZ96>K+O+[W>6W1F\/)2=?E$XOK=8C ([#8%3"63UE!V/LK
M6QD/;B.+FLP-/+8X[WHKV;''14ZJ= T5ZBB79?2!EY$!IF2^WQ"#9#JUOE:D
M$4-A]KGW=]<':]$SYD#P[QE3/P<;FK;EPKY0I7(B4TG:^V&N+I5DHL6O]@5C
M:6I*WRE_6"G+$-1!\][!!TTZ<WZC+TKMY)2N-89?VF/KA@J'J(]34(E\Y[]K
MPZK":@4RX)KI-G9K#%5Z1.()PMWV/=%27C;"^]X(D<3 NBK)G64/5U0%Y@8K
M9J50,[78BH-P&+QT\;6T!\"ME38XNQ7C5+_F%_#&^MK(--6ZQG"WOR9[W43T
M*8I0XQ>79?6AEI6T.$>F6%Y:Z7);6&6M P_Q'%]F\L.>E$-6+O; R(UG[5#^
M^3)GQ^S((%)HTJ^A@CB5$>]H$817@YSRY53XP.Y1E4Z\153&0C-FM4O?B6 Y
M.SLNHGHU5T\]ZE^<)SC18&+4_'3E\\OCMK]?]_<,/:4V@#U2V-(N;(DY%'^W
MY-<?E=;YLI8^Y%H:F;5CG@65:5>P 3O(FM'V[=6<4G69:BE"'"\3^^%2+"P?
M7 ]'C[H5  31KF_C04#QRR%8?Z'J.1P,7J?L5+3?"6A*VF$1_&>8SU)XY;!Z
M+A' \1,E]3?3L$6W#M$JQ]*;%2B6G8I?'^[A#^>/>[CL[E\BD2Z*==2*Z+<P
MF^$1_COZ)6;UTE*ES?R]M(.1;\(U=K$E_-%2- "M8<ZC2<'7KJE0KZDS%4F1
MO&!Q=%"(21T/*8[9M0UX> DPWO-"R_)D!4/N% %C@\PU<36L)JDB%W*L;U]L
MI7;)6F65VM4;P(T(KFB%;&X9; D]'$:GM=\$-W.D59U\F+ Z=WW+IY?1NVP)
MNZAMGU  ZO?;YK+J/HZP5E <O/+6;#?NM W45DY,#0/5<IF[]YQ<:C93I$)"
MQH$ERIK]P2FVE;))RBY@RD!-[.B<(;G>AESMXVG7*&,-]?C#$@]OWJY)A0)]
M<Z+>*GWJ?43>Q&]SEF9\-SB+JH 0#@S"7$S.X9!'EA&B(YXZK<*SF8H87](T
ML<)-UQPA,H=(WVV(Q9)0;8;K(H,\#4E?2/1%I$NDYI/BKAY:YN.5 DU"*H$B
M28\NGF *2*Z+CHF2!*Z+81QZW;H8B146%9;>M3;Z5(5RHD'<!%@$Z4R%2,J:
MN$?"D*Y03JGOZG:+=.I=6/1&466,FGIN\5\3[A+WF$97KKC#1[V30J)T8L#5
MI@QEA+(\7W8!X5] QRFOP4CC/ ??%_K%Y%OCFQ:EDQRC)@4[<Q#.M!WL^YY'
M"CZXM+L+.D:%I(BFMP,3%[4"]P>6@O_'1$KAK4-1A"V[:L% BXU)S:-\OJ*#
MF*Z .-U8^@WK"$G8E-"-F M:Z\WRD#[[.O/"11.33"]O-R7>9E4@2VNZAX%)
ML*?F1U64*B4MM0-(*,9DJ'#X\(I1[F(>*OHI#HQ[TZ0/M3;Q.WT,D?(^K9>6
M](K08FPR&1IB#@!X0;O49KV,,ZYJ>@XBX<70N&Y-;=F=+WIK65HWP81(YQZ(
ML(4Y0HR[+*(KXN.5#C>(UQGQ=<TE@:.( /*YE<]\83#5N*4-RAO(LK9"A"U]
MZXYJR.N'Q.I5@L2?FX#2W6-V3,D<5=5'#,ZLN?8'Y4>4!Y?/ ZQJP+2C7U#%
M]:[>K @&R[::"06"&&:]H)(1HS"IT;GX#--EFR*,@"AV&T_66=JW;YSJAE"$
M)^O&$2Q(?5-I4[11>VD98OY4_2T5(M%RF0QVA6EN0&>&4BJ8@ZUE5)73;MM1
MI#L%<R%$\.'!.K9!V"/'2#^FI(G8LHQXHB(>)5VG+D+YKQMJU(E-S@S8#Z83
MLJ)WU(]*\_[TZCOJW[1&]U6P(]3#,E!CW,H:@G&S>K\7YOBPY,@ /\$0'8Z^
M5L0/+L.*X=).<36K:2WY@=V8W,;95L -5"! =R'=5(E*2%]&8S\CAO,]%&"%
M:Y9*7G!XKUV+@#AW3BZ\'QS?$S$-#/V]-NV8?=;KD'DF;9AS]*Q*TQ9<;%+D
M&V\="SQW1--I8@S_JWIOM)VB:P,V?YKLL(V6!>&H@$@=D7:UA8DR$R^QA3Y?
M,C./NI+H@' CN:]Z2S'[3&WAURESHUOY9"1+ TJJ17AG[QY>3RVX&V1B3?""
M8JJAO9XXX&'O9DA-(H'-HF.8KPCFMWE 'I U=$F+0<R4=1/!4R1N)3'WE!("
MC"_C+:(EPLU8ADUXY K#6>Y66,KR3^PWU-\_WD:.N7@RU^.;<SU#_Z@;G)W=
MR/=3V.6'IM[)M-D\PYTY*)F0P]+Z%9.NAMD*?< V&QT>6^=$04SB#/ID24.,
MNE@[3Y!0<'I!OD3KF1N]E6U",XUZ9"><HQM/%+$MJ\(L#T >!SAHW9S*-&KM
MG;)G8>E?*J.ZIG__[%^@,OK16 CE7'$&E1=Z)4&AQ,]L=C,%)-8T7S#UXN$B
M&6B67J4;FMMZ&T+T%UMA90B[[ZAW7-WV_2ANI>IQ1?8WEF-F]C>T+>IA<7QR
M?7QB/U!C8QN;/I.'HRTE,1SZ==D8 J,@J2$UFTVVT06\9 ]#'M!TPU:#HO;[
MSE]L;BA4TYZ)+K9M,UD7Z2._BL-<;:>/'KOFIN<^&;R!<]%FQS*F)!T3-A@<
M%$C"D_'Q<0I8Q:CD1<9[<>8WN2'1\71-LR8_I.^D.L!?;88=5X:9;>Q17N#<
M^WG =C)(KBDY@RIJRI7HF6V&AIOK-+4^-E<I+8_(B2=&.D@<LZ+C)BM+-HH(
M,"G+;3(;,IL^^9-,*G?_2LY";R6,1KR$Q@GD7Y+,<]3A_I"-Q)FL^72>X<\/
M$L=VU!B<S@F(!_*94+9FS=4$2_>&,>Z613+GJ'*Y!8YZ'<'H ZLWDLRD$RXH
M"-VPDHE+! K/U"=]VYFP9+/PRF\E!NAZ;S"]?\9:#F7W#'S0(=1HP]V]]*-F
M'S0U6 Q2?1P2EETC8!MN_8F6&8WGDLJNQY$+5KR4;J9P,28=%<+$;$J_ZLO@
MW?!KN[UD5>862X7(]$$T<Z.)D^2@R3U:(9KP,&#F:#OP:BYP;Q/AJN. /=,%
M^94 &J-X=3%S_ZBHQNUBY5]T'<MIN2%OJ0!J)<O#L/G1:7*I,_;;F&G=>"\&
M?&*JUTN7=^K%K#8YKHA?>.EM8O@_$8-8F/ZF6]+LH72J19FQHE-Z#;_$2&8:
MBQ/???#CCPH;'4\E!WFHE=13QQF&QV4(]"SGG$G=/3 UZ3N5G *^D*Z.Q$"E
ME\J3*ZR>MHZG &VVCF94C54QKGQ$JHU9GP^->@6C]>ONF+7>1F'@] PE2T?E
M[=O0XV![G*=+X)-JR2G=$JFL.?54G-,V31JLF[9Q)I9<6[H Y8V9I0;609QZ
MMR@J[V8E!"8IP<%.*;D@MW0#3JXS-:R/'.!$4B%+[?-J+D^!U E1^(GE!R%Y
MY@IBPL5]K%)&&4R=<V]CWK.*K0XHCF?'916+1A4S^XOZ<6OG/%M-5_'^BMUP
MGD\!47(/<NYM-VM%\K;1"G2^$A[+SQ>&F@\)71317JR(>,JK@&FM0LG,P*[G
MDL P^(2VM1=;("[3^)ZGT0QNDO3U1DDQ6^8!,/.\)ZV(2)JOOGQ17?WQ&Z_"
M#O,SJ+)BDXNH2X.-JO])"R;8 "0@^9^_/5E]6M'_UI]%"4:1>$_C^RQ>V39"
M?4L/RLS%712Z),E<IZ6KE5SM\(EOD":+7"6&V>0N2_8]6YX=LJNR9I.S*H4S
M.*!2I/J..LJ:CA360&&?F,-MW_N;/_]$L("RNN-;204Q'K1ID):X&0XOD!5$
MDUBN>K?]Y>&T8,JC[5&5Z(&CV8AXO*->F#V"RE[&31EB4::=E#B>@"+!28!4
M)65H!TP[>3L[ H9"TH.",RN,11*>=7U\<NB?K.F:,83WBBAAN/H#Q,J=(EZ\
M,,585DZ+=5+Q:.(U,\9P10_/I22B!5U&^:$HJ55C7T7@"@)]XR_U]CC45Z\3
MC8MP^:^[U5,>UO]!AKJ&V$6]QR?"W_]Z6(>_[R<*F!EP#>/O05HNW7IGY6J'
M>:A4=@.3F] ="@K:"Z=)):7>4A\7#?16H?/MP*,[2QY.4?+@4@"T N#S<RD
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M!@)G2--RO[]%NTQ\&&Y("R\LAGX@5)!(I#+["82OXA=59Y0/.FIOC]+J/A/
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MI85B2@%!PH+$^U$Y,I3X+=2<8]ZT<!>/3)N1"XD-S'*<.*:\/4*"3E@FZ"F
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MJMM6W7Y^_M7MC^<T?3$^8'@(,U73P8JR:C_$4TB8;!G)-KXA T6@'G5U3E/
MS(] [L]8.*>7C^7_DB)QL?4<^Y\KNDRJZ57=&>-I67[2O>[7N$-+C$'A(""R
MC=LF4K!E(N;2V=*LT_X L+[I@V8FQY]?^K8XE8MJ-0^T#J:*EGGS,S52-V+'
MTZ)'D=+86:=Z?C= GUR'3*1-OCXQ_H3X K9Q1V\"ZFW+LXJDI#$X&F?QJ5/!
MAH^>U?-?E%*')Q:@#GW.4[66-B)'SY7/8>+W&$^*+!"I,OM^'-]'E(T5NY#,
MWDTN2S,@?EVS) !]C4%A[!X F"O]:KO>!HC[P$"83BQL]:&^QAY4;D*[.S!M
MU,L_CAKA"(%S[&24O3B#0N8,KIEGF$+&([4U@^4B[5[69,)S,*8D LQ7$FU"
MR=EA1H(2LZYA_(!)94T+Q:##2;T@-MYW_B9N4J*BVQX]HZ%M(MX777/#93L&
M98<(XI(N?=_3%4:X&9AVQL1VZ\-!,.5^([/413.,)%:RS2@#+Q/WOB>.MY!/
M1R K=*DXO/>9F'-?I-2A)]TZYW?:,6?\PGMT'U""8^0"*!&3,UR]7 CE[J"#
M\S5!C@YV;*0YZOO+^GC_)Z+O2=&B5$98G[0?6SN+./J&?.AY-L?#$U-SN0K^
M7WO9]>]]5C6BY5GU++LQ@S]7H0W[\S)1'W+[(97%'>^L:7^,8)-$Y'DL[,/Z
MKFZWM6S$I,/'M3>)\"$E&T#OCG_*I8!X(!V0M'_54P-$_SG'2]R$& R/R!40
MR2N.]2YALSC+(L^++97D;JBM*6E3I=9).Q:5!'XI2J3Q&0]".2KI)$YF(+ ?
MK_[O1#H)U$/T;<,EB([0_;NKY\^>_-\J*37WVV*9R%4_O&Q<X5B')\!<Y0P%
M(6;2J"MCZO*>@\N_ EZ5OJT50&9":-Y('U?3D7JJ+S;-9 **"AI1(EVJR8D9
M\\UTA3)DPD$S-+3:]?&8:0,9*.LJ1G:)8'=,FJ&S527\Y'QCR3#4OD4[R[(;
M'_="ROS+2,G'&08E[YW1A+>4LA]:DG440A9(="2E(1>U"CL+Y]],UR_Y-*(H
MU02)41$S).[VV_[8-(YWT"C8([599#44#0RCGJ%AM15'A,!>2,"105F3J@ZA
M*55*#VY7H'"T]T''Y;)]FPN[A@EG^^:S@XX-4A#:DB02WI)V=67RNU@KVM&1
MS[_FF6\</3'I-?R"-G.A"3))A9U,MYH^0P-MTL?L.<JV4I4ZL5P82VM=#U9B
MM>H'VF/;8T+*-Y>3N (M&&BYP_RNP]]:#+1 U:3$5_'J:- ,3I,1QSLVS&N/
M;969-PUJ7/$M+WN;-,RB0.\"C6!1:(E+J(Q;0>,WP"QG"EYX;4E4V&UE6(UF
M/FML&L/3UD;^/G(%1.4QY=!SE@GU&:_K"%:O>Y47Y!3!@13_4.-/6YYO(*0P
M^([XKT*8&$S.#H0_^GTY2<MU<R6H.49K4]"S+=?"W8N<6KZCE@Y0OD?IB6F"
M'8U.4N?Q(,\20SCDQHPI+-OQ9"6M)5'.U9EP>4OT][6M5B&[3.HX,QV7Q\E3
MN\AAJ D+XK"+U#,]IDB1M].\7H"&+6_#Q^#%?GT%Z4_.OR#]T4#ZHOJ:UTE3
M=$O"ISPDU'@.U)$C1DN"3V8'V)F#!T'Y[B=IS<C34I@Y9 A85G*T"[)4U&)"
MKMUD:G7(Q9WI<?;2H_==7?7A1N]%12ZP3JBSD0(":"CK*7QM"(^X9DS9?:/P
MI+G62B;.CMIW<D4-"&1)L 2O+0@NH29K(EL"Z>V4JGCY/JIXF'ZOH3%B_0SZ
MIJ,/S\O37D;87]^[=IK<I2NOFQ7CU.I#_.:\HT882D1# BWX?L7*^,JG+)/L
M!$R6.)AC]%BD6V9X0J^G9R.Q;X)/$\\H):MRK)CV6JP_1ED!.N9.8*DXD@!?
M^[KN-'I'&TEP8&/=VHG7M.-)H0X&IO4"9F3\*:9NYJ!5Z7WMCJ"+:&X8J^IE
M$;-[B>PX1G*WZSL0]SZ]^M/0PQ5@0(M]W^Q,)$KK^$;4Y1)]?Q!CR1R.A'$E
M6.VA/DQAEHX9TU*,]\.MW] WNN#N2=;L?B"J_RZ\Y+@:VKT(IUS?$86NTBT@
MTX7$&%TQ>_:N\+(J&AG)4I-7<85D<@!IZL7;)%P..9L99[,#%4%PAITI$:Y#
M4<6\)^\XFJ]G ID<(1/#*C400A..4*!<>BN(/IZEA2>&=;=H=<MJZ@'UATS=
M<R[N65K%5<QC@+NL1A_F>,#NJ00?.MS6^U%RIHM:>9V(,<S)0-^/"-WB49;+
MTWUX#3J(!]8FK3@?S/N3H<F_E*J/"FU0N&MZO)2@(BG#*@M&&<(]/Y_R'.M)
MGR<"77A6A??958J4][F*@"5:+$SSE0(O4KB%PV&HH6K)U@;K!8J[?5BH+39>
M:^L@?4/_5I8)3@C1&-V)QXCI&%I*C>KGF#!IS&S&#.*F'Y;:.,6%T-1@O6U&
M)4\6]4T,0GL]90T5IM9L_9Y.UB4&L3:!\;F8/PT;9#P]&)%"*(Q;DF)(?=^'
MLC8/W.91J1M+5VNN)KZCR]K\_6>F*^9Y)1O ^2J)>90Y/QTKP\I \'R*QW*6
M%N-#9L-^"0/TS\V;J<^#RMKA"&'BA];0>;8=EBGA?!J6$,I"*C%U41O78(T\
M\)3_'J6=;#\=W(:DE36Z74/:'"MO>7;D]83O:V?ZBI[R3+?5E[INO+XIG0</
M[0M=S[8VA<N7"C24LMUI!BBS>::W9A-64S!*ZF"CSXC>-O7 ^>9AVF*W(<7N
M:.9B9]<0PD:_+TW?2^^!<)F"@8'/O'!T;X_C061;[IH1!PF7)J4FE[Y'/1H^
M5E@R@_?7@+\U^-J3K0YT3GF9GBH2PO=+!L*&<-TBZWZ+ZK2O.Y46HZS ;%D>
M^A 82OJ!ER6[G<G;\ V%#EG*0&X72!9/;KA):X=E"86W2WU?$M@N@?WI)8']
MBQT.7X8+W=DBAFE0;M_$W9,2MB<H-YS$E>D-)U+0;'.0)(EGBBJSS<FN5W#7
M)^OVL Z?V)W">D\$[][M#UZ832(6\Q@EWN>^')3%S_.H>=SD4 :@?U/J+PG?
MN@:7\8'^QKI(67T!8<YJ6SLR04L9*4M9=E*4.VL?6",\+:5U,E.Q1LB6/:@Q
M9)ULAB6(4G&Y*=;A%UYP%!4?3BV[1/S&3BTZ0LBWWA2_=;7N&TY><^_YY/1\
M'P3N\2V71B^7_<RW. 2[PZZ-2)A83ZHRH@<?0G#4".8C'_YG2")V/Q1/5&*P
M3RO7]3CVJ[:VS.CLD7]695H9XC/9!8DN.3PDAP#IBX.T5"=_-<HG=5@JFR9W
M2:=E-E/0XZJ@(3H3Z2/?:ZUK@X!'M^T^88B_;;9[6B/7PS*0A>%HY)R<9PCS
M6GH9J=5_1V%E.VY]H&?9GL(B0L: EF>(^I"\-\*4--'N"B@S06C0RA<5@(UM
M,RFOGNEY$_;C=\T^&+OKL"(_>?;\.>_*OS;U[?')=SO:@R\(>;BJP]9E=I\7
MJP/.D.0S]+O[FAEM6 :\IYHX:XQDG]0*"1FY;L*=R3JY+./JMN:^RYYI&C3?
M(Q<<8[W($?%S$9$M +U#\/T6>ZY-,%5$QLC+EZ_.<DM2* N[=S6%H[%RX@JS
M(9@K,D#D!_:.4RO?P'R$D?Z4&YE%HX7[G_F$Y".(2JTJ;#6&.*S9&;U$%=4O
MN1 HJ4,G'&-),E^2VS7RB.6[E=NN5:T<!"S;R ZAS<8)5%41H&DUE!:&-7CS
M7:^,N!K#(HY!.,S3,BJ]'3W:6'XVU<!@$A#R^?WX$F^V4(5,>G(<O,03-<*O
M =/6YN(HB>MD:GB_CQXJ2O+TK/B1"-K(W8*#0*^,#UP+[-6]EFAJ)"+B[)\@
M>Q6VP?_2)KCID1+M!WI*$VRDCD><*HF,SH:="4I+%,8I@\GE)%,"9/7*P:>U
MY)V2GTZX-G)K/_AU<[B'W'VF8RJ6E95<B06)Y,[O\X_Q4$1>.Q9W3;X88O86
M7G%AAQ>E49@=8M3=$ED9N5@]8UU(V19D=>DX#]($AS)9>(P'<+=SFH.FQ5/\
MYKF(0XG84<EB>>*#9<3N;SZ1*\G^BMCIA$/<=EP.22JZUF=YI)5.'!CXQQ\[
M_[23)#V\L/8E(VTD#L')WH5EI94.VRAB=MG6:?7>RJ/FUN A$O;(5;.>) T;
MPAK"1-!UK/KM;48P5F)+!=H*POD]=>^QKE&"<8U(B]=_^A;,3950H5H,FV32
M7YP"AFM[@']]'X9&[+J6\,95OV\<R$Y-6K^I)&5)KQA>K/*.GA8:?&(NU[ ^
M0<MUECOBOV(EB$KK]Q22W8FY(W'B$-.MZ8P)\\#3GT9<NWT]Q'-_\9N)M56E
M+D"]LG@KSHP[><DP59G?(+A^Q6BQ1 K=7AYBU3#B+'_HI,8JB5K^3+@[&J6T
M,4M!4SC:I:'+VBWL)M9RTG;NRNF;F#]#'@*;^3U%B]U!6YJY0KPZ"/R-^V#R
MWHGD_:%_&3,12@GL7M=VMGL2M]@3[CZ\1"HW$+^UCH_MP)^2'?+/!-KJ"+<Y
M]6;?WTYC(9Q8<6J P+(MM0F "?*?$-F=SB?]_(BO@H(2G-YWS?$7<>P_EP[U
MUU<=^.VE.O"+Y5U>B@]$%CT-O7&J$LX=WF/J1&L/EA;GU,7@HI]C86+)O:T4
M1J]58UOS6"XL\6I8;\4W^#&?Q"\$<D?!PBA2H#R4<WX[@]ZQ_Z(TLB#6J._:
MK2JJPU9UY;)IY1(76R-Y>WKU"C&?]A"PU8L.Y2/8/JT#M;ZZ#>_G]-4BA9:"
MP$3:@'O"6HY_3:2]7WB2^:TCJY_P-!7[(=J.K@V>-CL[GEZY52V1ETMA8$TS
M,/H@VJ!#.+M--GZ3?' QN,SC2A28B_MA&0:CRG"_Q!GX;N=<GM6<=_DF&-5-
MXF,HRHSB&F;VE1N5(DX,Y(R ,"L1O.R[FT& V3S 6HJRE# Y,_U:1WQ?AP];
M;FJ6/,9CHH$@5HS@6IVI07%2?TX1^+MI3XG ,'KDCQ$EP3!1ZH[ #P*?5P\1
M5'P0+J8SG"D0*]TD71U6V+VN+PFX2JC<"*(D])AD/U+I64+?-R3#;<4W(\S4
MJN(]NJS=%8(G,FDNPBT+@:;2#J&+Q?UQU,(B8U1.UQ7G*; B6V#%>+%@OJXU
M7@V/+$SW-+0K(!W7I<>P^F;I. RVCX(+OC>A6;YLE%FR[] 9PWEM+='2Q.IV
M<'.=1EI5C! J7\^5KB35)-%-].,TM"/M:J[> Q!$1H[1LE%>G'5P_0DAV$K8
M5;KBU(E]8 '[X%GYL(-G_BVGHPM;Q#?-]4D[7401S=#O(^A.P5PBETIF]#P+
M8C^4).26J&HUAM.]IJE^*B7B,O=25\R"I;FBP +GP%D:R[<:0JX]A//#%[#C
M,906=57H(XXKO(AF/!0.OI,#^]<4I#E'5U#D;5UG"L,S[V,^_8M3[]KCTB'9
M"&4'WTOYX%S7'S?Z.6.\KR$LO^L[YIXQ\A6A'4;_#-D_.2*6$< &Q<MP'&^+
MG?OCC-8COA]45Z.6>_JF,K#)V\XZXQ\+B9#A>0@4<8[F2.KS+&IO#=':BI '
M<*5DJDY:B8J(6^WL:A&O3A[_F5J?UV(!9"E#BX+HE-I-0X\##V<663!KS7;+
MI;F&DD7A&&ND;$6C@;".VF+IN\%!F<@9 !%C9'=P;:(2@(=O??),"*^YG!B>
M+/RT;<EFP;&@/D@KKU-9C&M?W+CVW_5 /9/A1@?J128?09U_=04K$2YFF))_
MCLK5 <V%; \BQ#VBPU>&)^YD*SYJ&^UR.0STYN)6B9?EPCT\#3ENS%:YKAPY
M>K!%7>P,:6-?94E2[>G5G]H[$6U-5VALIM#TL\/YA)EJV'-Q7A;WL=ZU8:EQ
MK]^L)_@MWI]='WX]K4F3+Q@\P .*'%3*9 N7#EK2L4?XZJA1F!11B(ILTV_;
MWEJ;-#$_C0K<LCQY!,Z!"RE\2&C+BM2C)J3B]%*YX !0%M[YDOWTV<_/+MG/
M7ZYQINPQB%YC$B:R'3'[9RT I;WK?1,U->K*B"(:;;>S/-9BU#KM^TY!*F!Z
M6$]#;!FB6)@*[8CXO_KRA6N?9)VD>GN*$@&,"0,W(<K'7'[:1K4)(])J,Z<>
ML7["!O2Q\&-%(->7PW1S]1I=(R^=Z8?X$'_Y>_KRM^[+5,<*#_+\#Y__UNC*
M_EP?5K=/?JA_"J-*N+ENO>.<UO?+?R2@":E2U3%K%6^B)^>T9Y1/.'WXS*ZY
M,!O6GC3_1P@'OK,EI$OL\<=PYD)@],0T$?,C2.C?"(ZUJW]J=Q,>@J9 [J&C
M3:N?$%3A'>A23TSQ2N]9>L[\+/;/^JAG*F] 25/R,PF\>R>YY=P#"0]_["F.
M"L-ZX(7W_+?>'3HX)DY[%UVF<.([=,#VQMH8P6-,<Z@CL::E)9>@ B]++V$@
M&(C>(@6;_"&% ;>S\7YZ];HX!"@8$P(E87YU"37-^\0L-3:M&^V']Z(3FBO*
MVD?R66!& (QQSQC;4B%7%;.7&T'$$TYEOQ>Z"PHT.8$-ZLZF7I,%&@N?9J0,
MO SO^YKR21Z @XW,7846Z+@Y^MMY1*7GC(3#%S\&CT_A8L.#J5(XN8TVSU\3
MJ<PX6C,UW3,8@,7@G-RTJ<M(*,L;HA\26R*/9EM!8_KX!7*["\]2%;O)%3;H
MUHM\Q'MQP4L4C)-S'^,,1<8A\"E-KE62D3[!.Q<J\:,[,1W+42M,N= <'<N/
M"H6?>DW+H+YQ%1CJ:80U1 H@,XZ _U/R=6@8U:@O81T"7)!O[&>2MN&"5SUU
M@'R*?"8V$ =7 P^N)"=M'5XW5A0\SW2 8SEP- ,^!7"2>.)PBYZE7@+&^W[8
MGJL_9,30]T)V^):Z@HOU1;7AL]([!^95K/]):!FS6JZP0;F$:/U+XQ[A3N&"
MM^UU*W0/CH=.-^U#BI&C)/#D;HNRE,IL!NLC]NBNX:W"9VQI5 K=1%S*W?"-
MYX>=^/&Z+$\O24>\BT>",Z/5%GBT]!3+16%4:T8RH1V*U?<+6Z01/+S/)\,'
MV2.%:';'P7AG\[@\LD2W [GX\*8"768UT\1, ZK.[DCA5ITT=!2OSLLQ*20]
MO<II]R8AW\CTM=*O$9A\:&S?Q(@KNO#N''7"%&QHB3/.7@@=;1L])$!B]Q,3
MJ)O-=5(6]C5ZR688Z,$AUJ4/-#N&\83SAZ*,EZ^M"R4=-<8<!I)$JZ6P4%XP
M# ]VLW(TCA*&BIS0V2O5UAY9=?#T/[(\HU@')8X2T&-<L<TN28X1^^!9FNQO
MR!>*3%>8VW#@,_U=D^B7TY@1,QS+.,O$S^SM0W:Q6'[E*)'!,MSPH\JMQV53
M!A3#'-*Q>6PESRW>%!--JL@4>41M0(Y8X"H?>--=Y7*8CVSC=<1)1:>1&E @
M*.W[]&;2!B$(<C#EK#K\ /CS@:EX=)D'2F2H1K-B>29&QJSYW!'%N$U]G8@
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M_(=)(UIZ7-6!,5$.*1+Q(5PN3"C38WW(*!XSNY8462A3^?4FW6O2[L4@ UR
M$R)63,(6<^98T8#95DHR++.AD:0#J/-!],A1D@94CSOD3D,8&2OCT&*)K(@@
M:#CU ZKJ2$6Z<48MOK>=""<.;V]UBB?.DE7&>,VX'%/,BS\"AU,'3&FD?VSZ
ML'#7#'8^RWT8U>@6.ICT&+ZG\B.K&M\"F4[NJ.K\8K/4#C=CZKQQ*<4>J/QZ
MD]CJ:+A5PFGQN.WSP]]T(]*.JY-0[X]Y7EY(GSH(QQ_LII\U5"4##G>BZ6XH
MSP](0C/<(4I%]<R\$:F]M"S3*O=,^$67$7W?)-8N<7%$QL5V<_)8 W/94BA-
MS@K_B2I@E=IY+I3'S^Q5NZB/N7=6!K(_,MM3IZ&8O>ZAKQXF2\A<&0\%Z[W>
MF_N#:;1<-SB5%G=2E6T$P#;C8/E(>GM,@8;S/9*M_UB@C[LD,9S]P@817%_\
M"\6KHK6TVK:<+GN7KD)3^(/E_Y!-@9@YE0]Z!'57L0WP,5U_AT2%_:W;_B"R
MGO7^9:3(AZ;>O643X*^OK/#[\R\K_-.'KIQ>^;8=WXQ7WT;"2*(&_U)<Z!6X
MQ+^'OZXRW^>80_J!DR!\-%',)[9:B;J14$;1OLMS /%P<)%%1/0R))@VO8;T
M+[]]16Y[U.)2%&:&Y_ XX/$PK8VI):43AS5E*Y/&3>*>1P.UI13M,)# WT'L
MN]:"R4*NIX/0+NT4*I\BUUW[A*<%'EA+DT>-NA,BHOYDB%_J$-BPGYC*_"VU
M9&:EV5@+2D7<SCI5IR6.L/I:(@39JRCYMNY**]3BWY^U1#V)SB^\7/GZ/9WA
MB JBI!^#W37*#:% SPBN)D''VP]*EP]7RV4P71J+>T%R=O;'/:<E]PY#O^76
MG,*+\R[RVGQ_HU)#^/468 %Q$DR,4+K(0@"M=9J:8/RK6WTZ_T0R8'#Z,?1"
M^YC50[+6$0I6^[ \*\;]5<D^(X@Q4)>$_#&NS='W3$C]PP8S-RJB*H$%>8?N
M7'GTQ$#DXHL_-'8+O[@<%L4O4UYS/')1R]H;IC^]?)V)] H49VCFM>4I1 >P
M2)$[2AAPJ"],D_WUH)*-*-_Y87-,-^ 1V)[H94)OE/5OQ%CI:3A#BU=4@!</
M=W@QP]!+!U"8J>!*[IN5D8=A95QAC#%RP:7O5NV^O)?YLRVCVS/UZM(4RP:D
M.6 7/1MZM];H83D#E7:L,"/ (7)TY49 (H8UI94I18]EAP9_WT4H9;+'3<Q<
M"RB,'LBZ''=Q_AS2R<[GCP9X21=I6FZ69!6R[LW5L9]X!\/HQCFBU14& 9W\
MA:<-;@2"G-*?N*[N!6]J(]XN#>1\3]C:SY+/Q6D(9QM#U=2^J'@T%C7_'Q-$
M8+?5G[YY/=M<FF*-L^,Q%>0K.M%M_[0*P8B7F\_@$ ZK^C WS;S7.4\9MC97
MZXL.A56\8W:YU#D]!V4)KG-IDS"8.+(25]*ZT<>1V SU) S>UVA6H*'8QN;.
M(BM6^-!M4V\/MRMF F_OZI78;9;18QSKF7HSUF)W$-+RDF\,&XZ4<)(9T40]
M[8_,H913NC(>I1I;4 ^7*J/3,-58?^10:4<75O@X,6'>]0*97?8_9[[X]X6U
M8BVTZLGQ7$."Q]%U.A N'="YZY:EGKC3]?Z6,;K'I$]7MC.27MF.MZ10L8/;
M_)@L(V*\]>V@5E6=!.RFYK;>;G"Z> <SG=X^.U)D?#VKAQ<J?G2FL9)2 B[^
M;C$/1N5Z*YF9TR$-RVV%F*9AIP30,Z".UO(@].3_F*1<0<YAV+>TB04NDIZ4
MN)8RRK$Y5Z%9AZQR)K1>WRK6PQMT]?K&ZE2@MG$X=E+\&A>.A;0UO&(;RR^H
M)/M21'K7""^=H4>$>P7FF&70+5>.;#M%#.XRHT9>]5*0\&C$A$:@JHZL*R"I
MPZ,]QRX8=6.'T&.B3#5M\ 'JVF=IQU^I?\AP#&7>E%XW7A\:&V6PAUA'X,HJ
MVL:)Z!+(, ,J<9&_5#\70Q!O3ZQ><2;R^PLV'!7\PJ-L@)5B<)JIX)'Q#_$I
M)5V1\T*Q%XV;F^9@&UER^J, SX+[K3"OTIZZ#U8()166[HE2%94DD]$=I:[S
M%F67&P:<*<'%=?C3IC53N"*<@9K6F)#>MF'/HWGG3!<7M:R]?/7?7W_YY/D?
MPM@&"[2#OK$'"1,Z<&2A F"!8&P0#TF^1,[;==;H0L#^B'N3,)/-F&;]9++%
M$]\0G%2:/BD//TQ[KI'C>,2A&XL$;AEJ*Y%%E\#ZO55:[Y*]M^S]Y^>?O?]X
M]E<$HDC")W='7;SC<H#1LB[E=9NH00EC=^.-;8AIPMYE;FU<CJ$5P6$+&_5A
M/=+OPD56MP*!HA.!HO,8U^.*PA\_)@$_$0%QD 57:$PJ9U#AZJA-8#45>O\'
M(+IJHT",PGO*S0)D> U:X? (_!( X]WWPYO,98$C,"I$5_QK(NZ(;5-JGE);
M E^4?K=N1N3"2NDE)FXD'S5'J6-L4!U5H:95'6XC%R<C,%R#<9_ZV<)C;_MZ
MS=-#)U+?)</IOCE.>VY_#T]&WC"B'\5I4OC*SITD=Q?66C3#/-YR%'=]1#8:
M:L1"/VNDMNR#"<R,S#V/D4X8F@U^PJM;)R/YJMU@"3:='A\G>\+2YJ_S1%;_
MT%BP5("_FE\2J:6:$VG13;]\]OF$?S$/7R[)L?'8B$582/$! [P-NR,\A>#4
M?+QA*FKMF"6__:NJ[S^*LSN^F:]*;D6)X6R( 26,/S$JM%J'Z6:\4G2K^Q8R
M?Q0_-GONT"!CED;F6,:5P129B:-N!S$7B1#P[*VUR_A,_<2P.B7<CV@?BT>(
M1J .#ORTTLV/-G:U8<ZXNL5+%FU[>KZ8L: IT3L55M5;EY6?J$J7/=00]YD\
M3LI@\#;;+-\:D:R02B2\\C?AN*%V)!N$?KBI._]&,NC<$!QV[1/0?V'L/&#>
M'.O]- 0;.^H1(/4<^3P92O>)@1[HNA[;,1,8Q;:K[\TDGPSE@<M!*FE=1<X@
M[DX27"*A>+?-$_Z43OR@!1)MIZ$I&UK '!"D6D)(FW;T+1*7JKS-W0?D1%ID
MJ58'J(KBM]&1$ */2.97V5.0*]P/=-J"("HEIN,. E@-]UI\#E8NM!GI>N->
M*9A=RD>J3TBX7:>E.2*%(T5)\,-1SK[B3FP5GU@T[V&:^TQN1)B1PE4M&UN(
M!_DH'G-?B?+]O)7-#MNN+A G9U-F+=NSY!!79>A]M%$&JB>M".P8+:GF!O:D
M9J,_W;7#-,;25BV%/&P_CE_%*%#2S%X5@%8J?X!'&U'F&9OJ9>OW../GTGF/
MW72<($>E2,F["PRQ#JKI&LAB6U)8G2,=O\1F8$N^V!=4?/XLS'&GN40V&9[0
M@BF[Z:/O5<T=F.(C45-INTW")/)H?+7A/]]JG>TY('NR;3825<]7'O^J167@
M/Y]\^KOW@&<KKT4(H/_N"WV_]_\(Z7!]^LG3SV@L?)I?A;D79S#S6Y:.066;
MT6K!N+IMUA/963IFT"R6@(,V,WQ&>ENJ:',K"0I(+5>LE=7.=F528)+>[N5S
M,0*:M7@#UE2 0DB1SJKX_FT.PCJJ(!R_250G?+):P.Z+RW+^ ,L9S4;6F^'$
MF2,!LOR1X#ETFC8CB]NS-S8:"?90MZ-P>^V'5J2_B-_@IJ<LJQZ\M" N4_TA
MICJ975!N*/L$G=(^&=@G)2'J]C]I<M#.B3R=RNRQ4"-'=,&5"*>GB3)/E]G_
M(+,OK<)>VKGL"_$!,W=H+A;Z(W X3C@;;P<)O\SE!Y_+?X;S*&(;G >XS/&'
MF.,=B<Y>-UOE.;4DGZ0XJMB-B"J:HYZAKZ/!-KC9HZ+A1F'\E.^O&:^$&ATT
M)BB72-"FZUYJ?<*I&GQRJE:M&4C>K$^LAE]?L?H/_P+%ZLN&_?D;=K8[W1Z2
M@$?Z&NR#[8&)UQB,NFUJ-<!IUI1K&3%?VX,\##NV="_J'FVOIX-U46@B+?C.
M:^:]%2>;R[4=(703XP$YG;'>-L'N4TQ]L?T?Q/9'VIH%%NO'$O!@$I4-Z>FY
MII1](<H@5M:Q15DG:M1)N[4R'21I#T!5 TC]H;F* &9MFXBUX @JSR\4_MAI
MOCJG^)LU3CAJFE+?1$&P*<S!;7(T2X_C2DI[&]#M9MI00&0LN8$% (]W\T\]
M\R+"6(B,9*AS98W-8P:3'DVZ;!*,L'=9#9>!G  Q@O24"BPZJE9U(2.X.BP_
M^\:W';&<9.6 @-E0H1NC45I*JQ84!.@V1J:0SFCXEW7'Y81LZ<IV"QJISDC^
MS!#EXACZ&H:1:2DLW1HF]!<1;$/#A=^27Q<I$K3+6 >H?F1GUC%V#(I\F0!P
MXNN_)8Z$P:XM(U+6 S?1'+U"&@Y(!_V)>#7![&^(&=0#TI9F)NTT<D#21:R6
MU!:KY7J3(N#Y+XM-#=1^)'IO21N5Y41=O'<RA58]',"7]0G"<N"_B"J D/>2
MR&'2F+*1QHCNQTF^45VMVKMV2^7?,,H81ZTSQ](RO8=.H>0)982,! ]P^EZ9
M-,>F_5] ?I'[#<[0=BP+VQJHIM*^@/"45*$>5(L!8(@!+,';J'&$)Y>2H@?9
MI/,NK'PI1<@CD".&]*$+4(_!G'*RV-!PIB5?6K+*&<,\@X*1)U9FQC^L(XD$
M&BA5P_=MS0$/*[#8)>J6B+;80/:0QBS"SMS>3=M0@%^8WP]'3EA^#=N-N=ZH
M\Z5S&E$!MIPC%/#[^83PL$O3TK;YJ=C@/?<Y(GC3:!9%N2G6A#Q;WNDK.B@H
M'0#^DE4!&\*\F7H<NI+E,H*@U$'G$2-"?-<RYLF9;=5AF?4 W8&-]$SW]3?)
M42EF%CTV F$.T6)X_,8!&:M\D?A&7]KIK-T9OMJ%+82=XD6]GE[]D:H+VUZ;
MA8HZJ-S+#$C-#=6'>^Z@5UUTFB7.5Z']^A#LTLWAUAR@BC!H"N9!#FUU!(59
M_JX11^X<&/,XP37:T'DAW//,"ZYB.FS9PF"$F]%ARC''V._#[XASC#YSPB.+
MCIL1A0O8S9BWGEY]MT4G5O!#6G. CRPZ)DY1,0)*#_0MJ_]IKI&4XE=OZAL&
MFPG$#(]^V^[W*B^0/R,<;Q[^2J9<?8LM9*;@OX"]@&?0#G7RX?L0:=PT3Z]^
M((3]ZK8&0+N&\[^VOLB%5[DW0(_'J.GV7V0404/F>,O:HH(Y4A?W,6M'R>!B
MKZ<9">49H(-P8]9*7@O6;M>NAOZZI4[RNW9@CG"CLCS4$8"'$+4=(0T,7CSQ
M!FTUBCGS=E((!]R'O#M,'<-,(,=+-M%@A@+M1DJPO>OI;<1EV37KHXR6>\X"
M3+F(S(XG]LPE8O$RL0W7+:R!;K&AO0.YQ WUP"%^H\8!-'U1U@R-#6#_-<H,
MNGS*A+,Q0@TD"H+=:%<$O%S%K!H-BYQVNDC=&$J#KHC)9@-@\6Y6S\YIRHE@
M80$UOG#Z%!'L.4)4:.>LMZ'*L* Y/KP(8#89*NN-C<(X/C"R-LR3[/)O+9US
M,_3WS$;Q[DT4I03XK[DZ\8=GYU^=^&B<8@:+K\/AO\XPF^&9PN'9ZVK.TA$D
MZ:DD%W.\IRC IU=XJ$/.#CWN@.@YO?'(;4YD8N<<9\(/]*^IW&"6_$M(6K.W
M7W;_D?A31]7S<R8=<31E?9A;:?$@?3?#%'NL\]@T;_C_6VY(YVZD73[5W'=@
M#-W:K3(K[Q*4>*NL V-3#Q $62\P>BBR'2[0PA$2/PPH3Z)/]\)SX:2-?'/>
MGI;:^2&\-%">=% 741R:6PH0V.5D1@5N(:S97XX])1C.,-+L)J*G06EP6@W%
MURW97>:*^:EE9S^XJ*LWM_UVK1A"Z6[(F5-!L/HNVB<?S_+_0:GKT:B>:3IR
MXH'9HFGU6:*"I0_<PHO$?Q1,1%2EUD="S))J'[B^]I_@I&-FH2520Q%QW6S0
M ^]Y%]B_3->[;ZVH")9 ]2JA\2$5UDIR0Q3*CV%KC=JVP2YG? &1SAP=C8QV
M784E/$IS"8.&A=J/-_'HO'5.<:8/:#9D_F=WUP:TPVI0O*C31K46OX=AEQ^Q
M:]@=;:0KA6:/DYOF$<V:(0_0R'H3PK+;GCUSRSPY2KNW(4ZK,@,I>6G-PBES
M]<P\"N^;,17+8K 8)(W-V# QRA> D]7M_)),\:RIE/2Q$EE?23MPMU#8](VT
MKDV=<#0>CC-E2/2RD9PE&2U.-Y3HH6NHMC"'NB0K,!YNN0A%![&WA CE__M_
MGO^./,%XP,35$5F9:..T:Y0D8]FAG,Y,!,TWO5>Q6%M5"[9/R<M(Y3;6\/3V
MW+O=K:V)C&/.9&U;AFJ'\/3 --,HTM3LL_2=:5@LM]Q9LUY.#9"R8\-(.V7;
MV.*2/9;%OGZT$A@Q/<IR&]UULZHG<!@(,U;D&N1XEZ+F/CQ!/4@C$=&WW7!:
MTQV??$[:D]TU\OB1)#4A^:*7OFN#82=$*T5DP1G37 (.2 )XN#6->I$1S2B]
M#*P6Q8/UZESY@0I$"E&$*&5DB7:2DNKA%X[.=W<=LQXX&#BSN,C3CTTA)&MD
M0H4OU51/G-">S8$LHN0H?(#D/96,RM;N0\<,"M9^K4MFC*O3M,FH036]A3RC
MPTW3UA4V6KX5\S86C="YNC8H 0C%QGUC[K-C&4D=YR5:$O5G2C&5E6I0FJE*
M'7JN64K;@],D#GK[9O%7\%(/8+J;-YS6I<.4UZBQ5Z#ILQ#2<"LM/@>3K4W:
MS$]4"($J=[V34="@CX!3?Q6.0^VP!/ KEJQQG#NF0.[$B(Z\]]J9?4'[7!]F
M)/#QRD&/; VK=/@1/TF8L7!;#<C>YH;B988;S@ #)DKFB5 H35 Y(BA==OXT
MGL;2DIJO* _X<,E >H?%=6VL5"K OE@@O59-T!W#0N#0(,.FM'4Q!0_ZNH+%
M^%AR+DJ(SGZ:)WCAXN*"<3C%7_)P@J0(,Q!(3"%9H[F=>&PLS:$L(] >:G4&
MLY,XOAQTEYY@89H>R'I^#";^^6?99'(\Y">4+7["%N[CU;>:OH+-+(WG*PB<
MO6FVI9N1+9RY"S BWC/5F(Y]%;Q9N\:H+#HNX.QDNT*?9Y^'@I(E1P>)B[9W
MRF?VMW->$UY^C.E%0N1S:!P-OV'@F,RW9DU&:8=P_+&W<GJDD[AN$$!9^?#!
MT^&!E7*2 !1^'._<C TMH9*8/:5D%*XLZZ<!@89-"2Q2NZ-YVRABB\DC^>R"
MV6^[PJ,\O7J9IZF)0,WDX>=G"8>+E 4A7[H92.X:U %\UB5\RO1 X?*HIIZ@
M$_CU56">GUL%)H6D_^X1"/[GG[]-E>8%Y;:6!O63<\3M/__T*48@-3_LW;G8
ME\KX0Z,96B7]U]VC6UZ0@=ZT15@RBV_R-B\X(G*N0C4X6HHVI;NN1V.Z_N+C
M/Q^63<EEG?XRZY16#&7+@OL!MP4-_0="N5 !YG'NUF(L B\= 1Q=T],!":7#
M_</'LI7W0M3.B.2L/THRZ)4!ATQ-MG#0<O:-P!^@ ?6'6 :JJ!$*2T')Y'+Q
M!\M:35U[X"C>I1'E8.94@L6'%-T).Q8A;D!.I]4!AK./3 #(F4.H_W')BR2&
M?*&C!QNT'-&:)!>"EN!!7';U95?+KB[@L"HK"[==EGM0Y&2=;S#9@4 #[N=_
MIJ]<AVW/['ZE9!=T7;"Y652,]GT!ZZ1E9:;8I?-+^A46\F@99HK1AY?E?UG^
MIN'@Q-]=LT[,HLWS1 90'35]S\KNZ[ P5T9%8S\9K7%)&FQ>MJ9B%2NIN8NW
MOCPHL-=^:#0UP36L) Z4QV>,N9 H)_T,*N+$"4B6E=++-F$7]CL!5^9%P/ J
MI]@>%K?0 _F&R[I^UW5=)^N'UYO+S%/66SN^R5"*WC$E?JDO8K]U"TMC UHI
M[>&D%L^).V3^G@;O2)PG5' 70_RK7+!S/P3AA-*(<'&ELG;52K7#R2\6;41:
M7P_)>=.%I]$(;4I-\5(U*%T'"MQ +MT39D-@;'=4L'>BW09,6'@844D&;*JA
MD; S@TZ?'YL^G"EKB:G"U:4SY!T?&7$#DG&B=V@U@Y_UQ!=C_Q'M'0HTIX/@
M2^J!:#*5WW+N2:#8:BV*VFS#F6YR_.<TC(Q,8?!H]3/RX::N$&\K/'WI4JR'
MZ_8@59,DEO6HS .6L2Q].X@NA\>O<@-D&4T!<Z4J=*S*9[_*N\UJKN/G.A%<
M>H7AY,Q65E _N0T.,]'E;$=<ENMEN7K$EKH]VI[VF$56%I>&-TZ$3(UYZTS:
M%&$E#[ T?:S'^+\RE=/SWS*5$S6(IP$<'ZJCB4Y<-ZID)?#%$B)2T=><.U^S
M"6LY(R^9>T,TS=IC3B759TWKI VQ4W8AYT$TZV7BJ'==8.^SU^LDRNA;%+6_
M%><X3,HKCQR'_&48P#!JWU&KR=DR.H!,6[TZ=,WH 7M'\M:M"K*3T#FOBRW(
M([=(\>ZA^+&AOP[2&,Q"]V<)-Z7Q()(T*9W$<5GQ3//PA%V5).%(-RW\H,/%
M7?'2,D$*)NBVVI(*46P%-*7*\(&[X-,3BD+J/E'CU(0KA Q+(##<%*U3!:A8
MN*)T)/!D9:BA$U@AD&Y O'3:UD/%!>HH#D/-,P=J\);Q )E!OYUVV2M%V'6_
M":X[H[RG3D-+*9=1]\P WRL"<"(]3Z(J;>W+)T!-OU[\R"?GAA_YF'?]?PU]
MO?:06.O]\7U:'9@$[ARQD(=J+AD+P/KJ8;UEAD'N8>/\2W'A)SQP4?J;'X.P
M(M,X-H)Z#78(#LZS+^BHNOJ*/X5?/?^"FB3-27 M9P)-O(B[?!")A-;Z)EV#
MWV.EVA[(O/2C7X&H(/4GRS:7B?ZG3;34Y5S'8EK- Y*XZZE7T40PDLX,G3XY
M"-LX[=Z)%WC898[?]QS[-MJ5:R[(>DW]?&?[4I%'5A>[S.%[GD,]AH>$E]"A
MQ6C&A']&8-VNJ'FQLA_-#@PS2#1/B12V9<D2 F)/0$'- Z0V=9FZ]SUUR31)
M9#@Q;I%Z]SOFTH8 J*37I;<3[!]K^5L4CDO*IEP+ODSJAQ%[6PU3>]#\XKJA
MQ()PI[UICI%)^C(][_VPR[W-J>240,[8-2<XV/%8.9!TWG3]8]^&3Q.G*=/T
MY$W6@U7:&&5TD8CZ.#T>PLKN^* <A21=R/H,3>_##_3-4UE"Z+BIGM"M9=))
MQ#'R--5=O3V.ETE__Y.>9Y[)4/__[5UI<]O(F?XK**>R9:=(BI=DR=Y,E2S9
M$R?VV&N-,[O[9:M)-$7$($#C$,W\^NWWZ ,@2%&RQ$/$I))1)+*!OM[[?9X"
M3I$-!2OYC)C6/FP>!?-CHA$8%(!0L=&OWLE-[^0B"A%OYZW1?H@%QDF]8QNG
M?RJV'BD%FAOH]+$4838>0@'V5,Q1GJ9*0LJ:OG;S^P1!FUP[]YS_"R*&MP:L
M)X8_J8KO"\C:(\>031V.912K'16FA0MVGV/U/.#W7,I_2P[6+R\4JC?\<39\
MC/=N94H3FB"@O%VK/*0:3A%I+C-;S5\,P2HR!P1'KZ_Q5IT<KHQ6BL_VBMG"
M/S9LU0;6(?1M7<%E(I6\TP;7^R-BHO%5*=[C8KO6&[?IC5.W*DC,I6*C%&"1
M_68\&F$T5FU/,Y\ZI8\U9>0V=HI+@DQO7^,65-/]9($L TT6*[@,&Z.5+R!S
M4(XH)VDIO)+%JEPH[UI@6? N/OWS_66S<Z8L>748U4I3B=;"KTVQ)F&?8H&G
MP1;V<WNK *F/R>42"4U1J<6UI;&1GX/JR[!*#/U _1C$T;+<=)9]8=U2@Q)
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M<'$Q@9?+' .U>'AB-+F7$[-E-@E-#>W+"?P+B:(J6;5J9;[- O5"P3-Y[RL
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M^&LTAR51+'B4FG]8-:)@S]4,4ZW)?U]4DFJ81 1%45/>)6Q294>613#Q<P%
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MPC7+C$A-;!VP](/>+HHZ08.]XS;:)DT;Y<Q0@^GBG *.AF:D830#=3W0.\1
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MS3ZW1@D:^&A?@I]/8J)\OI23 =<@3THHOD;*@X8'I3EAB"']I 91G3J5>^H
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ME^K>E]+PSL9*3'),-HXX"6%YHK'B0R _'F84('!#:/,1&L"<Y4"IK7UNL*S
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M"C23IL"C&RHO#]9[OS80K,V?V:NGL@Q0 ?=;W*J78D%G'>Y*O,-.530T+I6
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M=\+V98WO_N\@]N?J7^-L$O[R_U!+ P04    " "<@0E5=E0"5,0,  !C@@
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MC"&0ETV60+:6YHIE,KA#.ZCG:+]+[K76X@H"[GQB\ :G%R'EC0[U;!8!R4
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M1)0[KLX<AB?;B+]U<.?_A,&W<7AW$L:G(<V#$F$P>35,9TF[GAL3'(>"O!9
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M%6@G'^F1D]6_6L:T-AE+1]G\+<=QF,3_)@09'9EVCYVQTBJMHG607#VGRT:
M5PJ!EV0<-Z)XUMIG/7ZFWG'SX.B)NHU2.^KR4?M/UT8$M $M@_!:9N%5=+1C
MJ%IVBB<(JG;#2R0:)6+DK'6?EY5 ]F_I'TZW*YJ$[*:8#F)O/X_&GT=C\G&O
M&B!+<#:;F&MC02D\N23"D_D:=6U@88.P2FF>6J=:WPKHNV9/*T5UL.;\_N$?
MHR\X'LX7XT](P[_NW9XWM3#HA,ZUBJ$'Y8N!VF0)A&6>,8X1=>M&C9MB^XZY
MU8GZ.@AU_?[AXWA^-/CM!K(@I8N*%6#U=CP-G.R X -8G8N*@EN76D<FUJ/Y
MKJG41$5KXUN=YP&<?S8JBPM?R]_ET3"\KT.J;<GGQV:-,P"V?W%'9_\[2N#:
MJ7_4HF!*M>RI5<FY$*T-)D9;>"I2Q96G_MM#V#$N=?:^JV][.[SZLM^'HSBA
MV;5(?OD\FUZ]*W@1^Z,!FV3JB94VB;9CLN="% C9HN/>2*-,:[^N\1!VMBO#
MI!8XKO^K%RB_A$%=8,Y!ONQ/:MR1$/8T=[3".#* :4PU:4W7W46!31HQ!_+C
M4O,>A)N"V_]"?D@FWC Y.]'A'A((UAZQ%*D3:B= >F9K1P )T4L)QBEKA4>5
M;?/&AT=[!'9,5.M$@UWD LQ%M6H*Q"QLE &! ))I;&3M(ATY%,?)[/%*\NOU
M'W:GUCHPWSF7FNBH _>EC9"6-SQT"&1-&6")5S=?,?#<*3 ZIHRF"#Q2"V.O
M)[;'1,M#:?]8SGY76Q/ST+WR/C-?:A5H[VK,*D,P@<;DK"C!*Q-U:^=]/9I#
MG0 ?C!\;67U;ZZF#S?<]3J;C?IIB7HUQ]:?+Z,,FV#LZ'-X%]V$.@UMQX$:_
MVSTK\-A(F!S+Q7"SF(TJ1P<Q%P\&A;6%D?W:O&3/\9'OCO/=8^3>-GKK@'._
MC8;X;7';Y=?9,%\<^D058F&0>8W3*LUKSQ9??TR,UQ)IS4N:KT:R?W]C?]J\
M419I9U5T<HJ[ZF@Y"(6"20NB2')WM"A EH""F%"Y+%3,J74QI",Y\S\8/797
M1 ?+Q[J,&6]J&3SC(;$40,D2:: L0?):&A&*]JSU;G1D69?'8G.WT% ' 8NF
MIXJ;C.5'=N8ZHK8@2)=);_?1[K%G9\;:F",7#L4RLCE]2.!,$"",1MKM95:B
M=2OGXV?J/;,SCX:HVRAU;]F9+OBL64D@G0O+"LID&9"(<@[!2.]]ZPO31V*I
M'4ZW&UENVRAF[]F9S!H;8Q)DHTJR.&PJ-4]'@Q1984AD5]KV]OWCS<[<C3VM
M%'7([$Q#([=9<0A"U(+KVH-+J$$E%H7$Z@JU3A+_3K(S=^%6)^K;<W9FR9'7
M(JXF(<T"K(6IN'> /'K!?!)>MRZ1^FBS,W>C4A,5=7#[^-P3?_'M_-O_W<<Q
MO>3DVVO\@H.Y&6F4B8)S!/3UMH0W$IQ46,,IF<5H1+2M"WQMANR[CV"TUU^7
M++N4:SJYB7<YTS8!VU'$8BN@!PI)=*#Q=:3J3%U=1%NW YV=-T8PX,'23AV=
MA<"T ,9T9BSE3-[QX^/674&$HZ/6%EKJDE+SI7LREP _NS^80_+6^WH'IP96
MR":(I2"04R%+BHF9YM7G;X%SP,S#]HI<1YD=M=!!G& 5-+&$EKGAGHM<B\*2
MO5BJ\QFPGD\B#X$C+[EU;.D6.-\;0>ZCA;4K2-/+3^_&([(SI]_",-<ST,]5
M+D.<?IB=UC*N.UQNVNS!#2XOW6,$URXG2=12U:H\CK:0VG$B!2F3XCP4+KSS
MO<U>L=OD/7O'NT$@!__2BUZ?YYU&R2U*%H&V- 6J7O2-(B;PR07A8S!)M0[,
MW(UJUT5K[1OFU=9Z7(92DF:U8%(M2AD\.*L]R,QM0:ETLJTSG&]'M/^EJS$S
MKJ]7#170Q:6>B_)[+_'S&-/"5:7O!S@7^S O2YG./U\[F%[,I&=$!3[2%Y42
M0BB8@*3FN#/<,FS=^JD5]D='N8,HM0.+?"VP-SCM8=%6&<\!#3DGJI!%&&)*
MD!RKB42^\- Z2'4;GD='HF;"[R (?E$C<"W*1;"-<V-01(24D3P&+NNA(GUA
M6CD:/4NRM#Z\VQ3;OF[G=$R33E1Q++=IU@[IQ;=ZA#"/C_!LI9#$?66S U5[
M+GA7ZGE01B-S)C>G];6:#6 =OG=22SILNC3=4RW[W+HJP*47O G$CB+?&\ [
M3+R[N6HWI<Z.>CD0A5!S\J1SO6OK!9!S'<"I+( GP1W+7#BS-R.H:^K<$<X^
M!N9LHXZ&C*G1H=[K$&MNS&C\[1S9651,%IZ2RQ!4JE9\K9I>A(7(R8Q+Q82,
MUX+7-\--M[_BB(S?^VICU%R4'7CKKVO/U9/1(+\Z_3Q>MGX]2RW0PDA$G0 3
M(Y-<%8186T^I'&,)04<36Q>>OP7.XV%$:]FWGO=O2^DG/!\MC?S7V9B$/1OC
M$IT(SLI"]KQVP=4^E0&\+@9*CBXS[D*\'M=<,__O?-7CT7H'HNW #ZY]NV93
M'%]?IDK@R5KRS$O6]7(5C^!1.AJV]BHS8Y5N7U%T)93'PXB6,N\@Z:9V(227
M.%7AOJHAO4]CG)RM3]$*+U(A,*'V(33!0DC<T7@)(4M%2=^\^M<M>!XC*1I)
M_R8S5 >GDA^FH_1'W<MP/*FBF'Y[$\9D\?2_X Y'DAL\M<%YY+;8KQU&.B9B
MO=B>N/+*,>8E5\HAS5>)Q0?9V^#Y.\[409A,WI;Y>RYB<,&&Y!TOP$(U(<B<
M %^;AOKB$SI:0H1KW=YP)9"=0[.A!G_FSWPSJ_2G'TX"S897D\D,\ZOA/$TW
MS&=*3YK$O7.6ID(,H (3=="EUHM2D?NLC6V=5K,-OOVO4[MSXT9\MBM]=.#>
M7,+Z;DR6USL<S['VLN*\KL'5JF:@>$1:07U-G#4N)N>4;7Z'>AV61\:)^\NY
MM1]#FV9"S)-?20"5FV&8"&2],#8:SJ$NSLM9<C7#)X-0@79IIPO$Y.E++(;3
MX,GFTALY,YN][R&KNRNQ=N#(O O?YO[T<MQG0&OSU,D\U&JL=I"$==5^JI<F
M,$$,S"J+]&EI7<[^-CP/F1+-Y=V!)S-?BEZ$2>V=>_H9:7-:2)?VJ4^X".A>
M_,ER(,__#.-\=7][/IN>C,:UD62/VYBS20:PT*B4IN]"\1H$1U_%1 -N'1IK
M/HC'P+K#:G:M:W7/#:OY:&@;3M4E)0I.J@/R._V[CZ.?PR#-<WE>#5.]5H8]
MD96?%_9/R=):G0SYD^1+@I,T,Y&C%&6S>-ZA1O"0N?QP5'^3[_IP2_-H^/9S
M_=N%1WWION7;V70R#</<'WY:"*>G75!.D%9L"K4:@/+@?=+@@\*(B?'B6K>I
MW,>X'C+ICU;_-SENCL7\N%1K_1_T;Z>]7#"4+#*@)IDK<J8@FL3HB]/!,<M$
M:!WAZ6HLWS>7&^KY)G]MB]HW2]?NY_"Y/PV#!=#W6*\F8R:<O\[J$=:9T=]3
MZ+DM-H(7F;Q^'TWU^CV(K"T:EW(RK<WCK4$^!L9UJYF;5'*[4NF7T\^#T3?$
M%S@D@4_GA156SIJ>C=J)*!D$HR79);5I<A :)(_*%O(@R1QO3*&-P3T&ZG2C
MB9N4\8?QB"[75YB=S@V%R3]HJ.,P&'S[Y>MGK$5&/^+XM"=%CAXE)S[4M%&K
M!#A5V]$R+USR,63GN_5]-L;ZD'EWC.I<$7#>_<2AY1#/1O:R_Z6?<9C?D^?6
M"P6-+8R!]3:!0O+=O+ T8)V<3DPQK5I?#.Y\4 ^9V<>I^17<WCE_^-XC_"U\
M[9_.3L_VG ^S.$GC_GRD\X&A9:@-&23,FU@S7<BVE?3%9250&F0\M[[QT-58
MOFLFM]3S"@+?^U!HM\WGEE$]/QW-R$'3/CF3A8$4$@?%; #'@X-<DHDR&]IW
M<K<VQ)T8'S(OCTE]*VC9YGPJWCVT>'UH[V;C=$(?SL_<KYS!+L._/2\2F>[)
M@_&U*+ZA4066,EGP+/'@A5>R==YF=Z-YR!P^,EVOH/&!SJ[>EH*UWAV-HC_*
M/2FE#R:21+5E9+]+"=%% ]GP7&NNHC*NVZ7T*J"'S+F#*68%NW8_*3I+*R"C
M>':!:Q'PFO_R[9GI7.M!TV!Z46$4*0<@VZ+FWZ*&D+,%[J/.)D1"W'SQVQKE
M0R;8GG2S@DZ['\K<!OFB#\W\S^;389G5I$,RUA9PFCFR8$L-Q9,M6VQ4/HFL
M5&CN?-\+Z:.G51L=K:#6SN<E]U]Q%Y/DY@$F"Y9V-YXAF5JFSK@"GI'?9)$;
M'52VJ1Q-R&?=(!X%(0^JV15<W?E YJ*ZPEQ,+[[-A;8HJ."S],A(/DD8 _5R
M SCO-;"27<AD5+K0^@CF%CC[JF[2 6L:R?A8:IA\F(;I_(F71;7H%B-1V,0Y
M.%>[/1J6P"'QVM<K:\&@2Z)UR:ZU8 Y?KV1';=_8#%M(O8O6.)?PG'65V@!1
M1W5(;J(Y3-F11NJZ?N#?1M;[84$62<42$AA/.YH2M>.!4K+&(RQFHTHTS?O<
M[$G[=U0.V9ORMQ%Q1UVQED&HY<U4+DM"K&TMXKP>2CVBTB+2,B<+#X[;I%JG
M6MX <5A+\SZ:69_6<P^Q=M+/J@*:C_+%66\DU)*,H@A<FMH;53$(-9M(%.,B
M+X85W_JBY4T4CT33]Q9L!U/ZFEN]!(4A^J)3!&')7%%,*G BUS)'O&"PV1G=
M^L+42B /7N&[B[>+NW*#,'P33A<5K8JPCF?/0-9@KXJ9-B=E%00DXY2;J&WS
M7O>7W__8S/9[R[9#/2]YO F:KJH%7D%RH,* ]];,&A7O(-8NBOU=1:5ML*H&
MV TB!Z54(4"%0X@F9V)T=+JU8;8/)=]5PJ\C'6\CS=;7VI^3H-FK83WR[7_!
MQ=DPH3NK)V>\BIAKN;":K9NE 2]E!HW<HD83L[S6_'C-^>FMKSE O9T=%##J
M1'H-[>QS9&*1I5)=QU?#/$NX^&X-6NY=2L4GT)SGBC9 $%F!Y-EB]$P8M5GE
M@JU?_;#UWYV46\_U_R)(. Z+-(\+2,QG38N6J19H F4XT937H$(02;/$R"7<
M;)*O?O[#U6X#>36TNR;C:>]]/1J:;S^9,Z4U2D"?R+'+HD ,@8.,Y#ADI;A,
M&V4CT%,O[;[TT\7.>^6%C\62OK\4&Y:2. =QWA?J;AC;V,Z;*+7]Y+S;6-Y!
M^-?5MX/D&BZKU^%8YY5RS@&M$ &4)HX[72^-E!)*3@DM;N3N'EJ!:PSA]OK;
M1F"-];;,Y#U;U 5CN6@%MM26;\5[<%QYB"9$P2T!V2R[ZP[-77GI_G;&G<0^
M:B&S+GI#5=/JO'9ZS+FH6BS=TJI/;$3"87T&C(X%9HW(O'5WM"L 'LL&N;MT
M&Q:RV3A59K(N5^9B&,-\S2[<9$P=1:RZ&,]AXEX[T&3;=*A]Z;B#\%DG8S-&
M^Y+K!3Z=!?DUY%2Z6NS?)I>QYNASN?<\OJ/A[1VAO".G[3:J[8"NY[>;+I*M
MS^SM@E%@)&>7L5(;JV7ZKC!@1F>7=!11M^;<6C#[#RP<7M=KZB[LIJ@.;+,K
MP,[,Q:2P5!ND2,9!66O(&G$:A'6%2^OP1C"Y+7=^L*:1<O:6*."B3)EY"T'Z
MFKV@,WA9+'TA[[(4LFU5ZPS0(TD4.#K.[*Z@#HZ@KX'ZG;0R>?_A][/F)\EH
MQ.1)R37W)64/(18%)4;A&=,6FW<9N170#Q8U5%@7A7UG<=+/_3#^=JD ^=P^
MI)50ID N=+($1UG#( I:(6D?C<YG7UQLW9]D+9C'%F=H(_4NBHE>ZDQ ['];
M+G4B6$Z%31!V%4&X$]V!,M7;J/.6+A$-==&%IW\W4A6R*(I%0(MEX6TZM!JB
ML2QGGU/1S<M]'X@M=V6V'XHLVZB@]2G\R_X8T_3L/OQ90!ZSUHK).L$2J,A"
MS<:6(+THWMDL0KAFJZPY@U_U] ,8'HU5,&HIO]:I-K^.!H/1GV^'UR!QFXWQ
M6@#/&&LS5_+ L=!XG<M9AN2CWJP,^NKG/RZE-I!A!XMY-8#?EDOV\N+<4Z:(
MQ5@@8]776[:I%M 58(+7UJ*G[UN?-*T$\M@LP=VEW4&Y[<O.$OE";T;#</')
MI0EPUDQO$[@=F81;0CV,?=A R=</*O>@H0[6EFUAVR2DH/457*CYQCH2;)4L
M&4B&*68=,\WOSQ\%H>XP(0_/IVT4T\FMR<%@T0^\9INN1/H?_>G)NS">?OLX
M6O?7R[$D9842*4/VR8%2SD"@K1<T[<$I6<N";5TZLR7^_=M$G9+EQO6^ VFZ
MBU:*Y/GA?\\(SR]?<-'F=CYQK6<JI5P@FU+OK@D/@64&P;GJ":)AS6VK-5 >
MFW750N(=M(-8 6OI2VP"K*O@VCI0AXNI[:RZN^FP@]R["*2M!1@LQ^30@;'U
MQJP7"-$6!]ZYR!TWSF 7T?@]$F*#L-G^^+"-N+OGP=EQM?;.1F: 2R9I^Q*1
M1EE[VEA4&+)D7#7ON+L*R &B,&T4=;OZ[R'EM49"QYWA5Y? ;=HF_O97=-(S
M?HM176\@GPNK[;&U\$X95F*4*"TZPWW,$?.*!O*WO^Q Y0M?GU=+B\EF7;VW
M8K@"56IQ3V,C"*$UD5Q$DUM7_MD=]<[A@<'\;W!-'YW:T6%8&R[23'1.*Y!)
MU1DJ!?B(]",IOFC-G!>M<QPV0W:$R0YMF78C;-!>85WX71?>Q;US0Q:^2,8H
M6%8,A%?DBW#:&[QD#"17=5\0+&+S<LBMP.^K^N.!*7D891]+8<E70]I?\;QX
MVNOZ#^J@JZ4LO> V^@R:.T>6<A80,]/ H]*(FDMM6E<@N@7.$80:]LF/43=Z
MZL#W6 -M:6]O JZC ,6MP X3I&BFQLWHL8,.]DX46L&CDJJ0&\4CJ)@21%T\
M&"&]R]%RQUH'-0] D#N"%H?AQS:B[R:M'>F!)\^'^25^P<'H<\6XM 673G9Q
MY*RA+A!5X;6)J@>O4I@GXD=K)>?74W]:I"G?!6O_]GM#1=[,.FZJA0[L\F7[
M24+X/)^2J"?3Q<'-59")"\4+3^"%%P22W(C:L!D8"HS)Q\AU:T]X(V"/B2SM
M-;%V73E(9&PYCCT$R*Z]:8]QLMO&>"U<EK,LN13-E,U*2N.2<@)-*E8J9H38
M.%QV[9T'CYIQ:T7FK)9XD*R:Y!J<81)B+-(4;C&9UK?M'DS4+-.J'I5"X+5,
MJBK"0.12@F76\!HWU<T+T#[BJ-DV3+MGU&P;A1UUU$QBB?7V%+A<+5T1 P1#
MVU-2.@89A3+9M9Z5WV'4;!=*'D;9QQ(UNU88(>A"MHP'P4TM3IT+.*09&$,@
MK\R84E+SA?+(BNKLDP.WE^#90A</I83))F/Z48)GNQ(\V]!D+R5X[J'CA\)?
ME[1.GNP2>I\%932C[[P$;W+1M,>08]$\7?'!\':[$CS'1MMM5+O7$CR,.>\3
M<MI'(@<EC08?DX840PF\I)":[\F/O03/5KK>N 3/-HK:4PF>:%2DB91 J&H7
M:Z199B,#)I44GJOLFJ]7C[<$3S/6W$,YK2\EK^I_6R\TK"K8<0:7_.["C0(T
MG"Q;5],-,RL@I$6;F;#*;]9;??MW?\<$VH>VUE;JZ3A@_6OHC_\9!C-\/IG,
M3A=-;LMH?+GE=].P]1;OZR1X?=_Q7@MA,X$F>J]5<5QIH8-3T04L2BM=$E^5
M\;G%FW?;A"Z_".=7I%[W0^P/2'Y(U R3V1CSV^%[3+-QO?>]N$,U/ON19E-_
M4O_]?+I]Q'0R[/_W#"<7D1['M>6)61#&TAQR&,#I3/XU%INBLP5]Z]/3KL=T
ML([AJUA1([!U0?GG:$"/H3%^>Q^F^!O-@-/9:2_2^J5192@JU58(JMZSI&4L
M.4E2,PZU;MZB=V^CV_\N<U2SI5F[\FYIU46X?P\C7112[YF$,<M40/HB0"66
M( 19+VX$64(]AFQ_'K"WT?V80 ^!5EW%VFZ<D-\<:=QFI!]Q?,IKJAA:;QTP
MYE5M.D$*D*4N#98%IH5TS8]NNQO-CPERC+3IH%!ITZG_OC_YX]<QXJO:G8H\
MOLL[9_!*,^'$_,XGJ& ]!.$]H.">*1\EFM:-&?<UMA^3Y?@IU455UL['N=PS
M/:_5C.?%KVNSY!IY"Y(6"^F=11&=H\$^N*GSPQ [R-2Y!Z5N3IWNN^;<Q^!\
MV?_2SSC,=9P]+"A,L0BIWA)7UF2(M5)?<2HDQP4OQSUG5@WJQV0Y8A)U4.>Y
M(^DOTG^XY=[R8J"6OP3%DJO7?35$);1FW#"F\L,(3^XU!?"H9\31$.8X<P;)
MS6(129;&*1)MK)8CDQ)TR2IAMJZXUI=4CB)G\'AH<6L:X3;J>2AI6)N,Z4<:
MX59IA%O19!_Y6/?1\4/A;T"'R:D(SM;K#<8:\$HJL*(8'XK4'%M;"0^'MUNE
M$1X=;;=1[5[3""4+VM6+-,F1D%3T&KRI%?,+MTDGY1COM!O;(TPCW$K7&Z<1
M;J.HAH>A5WM]VR($TRZ##I+L#YI&X$3PD'5*BB%/&Q9,V:2Q^0\C[A(_[J^&
MAL<8-]J';P!C&WOKT.WNUYE&.PA_7;_[>TBNX;9P'4[BJ;#@#93 :&VQS(-S
M/D(L*1.DDEG>J)WKH16XQD9HK[]M!-98;\OSF//.*%X&4R(PGCBH['@M!2U!
M"2MINT@\XD;;]QV:N_+2_6W3.XE]U$)FC7?2Y8G $HC.VGMA I#%4*\S1PF1
M)0O2^624Y\1%T4)YEU_Z )5W;YD=JN+&FK3:7SZ\>[>/Q.7+[]EGPO+:\5U/
M5.8NHPBH-#/*&.>S%F0228=,H/=;)"I??N-11O\O(LW:)!E4#) EN:7*)00O
M--F M8<=$X%%T[I2]8\$9>PY$[.724#*/(-"7Y/?5 81 B(M]"FPUIU,]C"L
M1W@VN<W\.$!&Y59$ZBH7N9N<.&>LBJD6R,K:UM*R$API X1D+D8NO>:=7%[^
MD4JYIYEQ>-H<(@"_:_).+Z%/A5QP,E S@@I&0.#)0$K2H(S9AGS422VK!O5C
M>APQB8X]X7AEUHXC^YU)I2"$7$!I7R P;B&%Z+S!*'5Y$ ;6(T_].II9LC.)
M.L@M[C3:+QEF+S)MD=S79FU%@0M> P9=+#>*D^@?AN/WN%*_=ID11T.8XTS]
M,EHZ95& 05\/0)4DT=;\.MH-63&.^^8]01Y_ZM=6M+@U]6L;]3R4U)E-QO0C
M]6NKU*^M:+*/')K[Z/BA\+<>@0C,&:RF+4EIGB#$$J'89% X:[1IWLSRP?!V
MJ]2OHZ/M-JKM.O5K>8CF:K7SD#58ES0H52$9:2!K3B:1=4&'C0X>[YOT]:C2
MO;;2[P;UO[91SMI(<\<GG+]7JV7T:=C_UU51_CR:3)L><6[RHD[..+<>X;5#
M3JN*,8*'D+11UN9ZR(FQ^!RC4"ZP%8><F[SRX/T$:MQ*F+J\YD)L3]*!8Y[,
MX]H;A3[CRC3O]W?P?@+GTQ3'7_H)5P,B4_X+3J:X6"LF'T?$L>MJ?#.:_E^<
MOC]7\^5*6SVD92,K8<$PK6CB:P_110?:U>M(0D6R\[M:E;L<V!&N\VUYOG95
M/QJZ=%E7M/D@SY^T^$=OIR<X_G@2AF<#U];$$H(%Q@*"*K6W=2X(Q2&IQG'+
M?.N;90<;[(^Y<Y2TZM).;SWP=SCNC_*OH_'RH_IWO$>&"3I1&%A$<I/"O*>[
M,> C&2XH,O>L]>GF?D?X8^8<#X&Z.-ELUIK#9\$MR@A.U;H#(27P"17P2/NK
M#R()T?S6W7?8BV<7:A]&V<=YN!*S*P$C Z&3(+.OD-E76 ;N4W)2",E9Z_/$
MHSA<.1 ';N_%LX4N'DHD>I,Q_3A)V:X7SS8TV4LOGGOH^*'P-Q2>C.<*)*H$
MREL-SF6$D'G,&:WQI75L^^'P=KM>/,=&VVU4N]=+]$'(((JK[87KF9,2:M%5
M04L>"M.:"?^C%T^'NM[X$OTVBNH@9G:M,<<25 XV\>0=V"#)'M%20N2U'8@L
MR)5ERH36U?-7 OG!G 8*ZF#=6=7.Y?V'W\_ I<AR79LQ&P0E./GATCJ0TF2K
M?&"L>27L6P']8%%#A740.%EUY*QBYK9823M];5&6> #OG87L:XYD4$:5UMDG
MCS<?H-G.=0_EK$V.;IH/\ :GKT>3R3L<D]A.1\.YB)X/I_W<'\RF_2_XH:8T
MSK,>=T@&N,=;&F0"[#JV:VD V052O@U9E*Q8]EY;DTT@!2KC"F.]>[QOQVC2
MRF?_\C4-9@3[5YHC=2[,IO.I\+;\$L;#_O!3!3B'=A'04R58G1R"EYQX+I*"
MP-&#E<8D%;10[;-\&V'?.2*W&X[GIZ/9<-JSB58)IA-@(+&I7!@$*P19I"'E
MG"4KJGDDKP7P_:_3!^'LC=#?WI7>Q3WB\RCJCL-9A%*111<**C!(]K!27D"(
MLH"HE9R-$KJXYGV+FHY@7P<H1\'@ RK_:,Y2=AOXBV^K'S"/ER6RW4DB!KRN
M=?^DL.!JI1KMG(S%6A]YZ_RM#H=S^'.>_9.T[8K?C"P=Q!16([N<U;P!OHZ.
M@>["=J CG6,APT8DW5&3AV"<KB4CN-%0<B$_MV0RBM#7>QQD,C&;6#3-"\8?
MA&EW'<(\5*)MH\"]'L]$S,;HD$'Z6GDNE@1!,@^&!EQ")@]==!K>.NSQ3%N]
M;7S4LHW0]W;4$H/2TN0 -A4-2EL'KB@.+ 3RPGB((K;.]3J2HY9.6;"[L/=^
M;!*M4P$1 76>U_.R$$5FP&M*?4BQL-0Z>G5DQR;[9,0.PE][!-(TI/T>!V%:
M0_SCZ;>7_4EU26?CG<+7=SRQ0:AZ&\S7;Z?Q@%P9DS$5I8V-+A93O)6."Z$\
M]NYX]JXS\^+A'\=A. EI.?IED",B!INU HM953-%0M1<D^>&,C+IK5 ;U:/>
M:G+>CFG7U>CE##^.+KV$IMK/L_&XGB?-JT"DQ0\]:YA5-@8PV1;:-@,#YWB!
M8%%F;[-(V'KH&T+;_PK5E"?75Z@N%-+0CJD+2EU%D9YV0HA>XA<<C#[7&%@M
MH32<T.+6/XVS\61Q4-ESAF9N*ADP.09*, G.!EJ\2]$EN\"#+G>M6=N^])%0
MHE-9=V#9O!N/$F*>5%_P0ZBALE>T-PP_]>-@67JF%QEZ298W.$.X5$Q(A+4"
MDI1<A)0)8NNLD+M1/1*Z=*2&3B_)K!'$Y,6W*[^9ATR59H@2#?ADR.Z3G$!7
M,S#*6%RVB2SYYK5([@-T7V<WG9*H>Q4=R]'+9N.;AZE$BC&X9&EDSM.TX;ZF
MO$BPJFB3,PU=M<]IVQ3=X0]&.F/*#2>N$XUUXNM?<E<6WNLFB#HZP+B)YC!'
M%EWI[Q::["#\_="BE"A2+A:P1J:4C!F<1P9D XN"0JN2VR=;[X<.=YPK'(X-
MV\B\<;>DYZ7T!_T*Z)?AM#_]M@Q ><NX-YZ#=H$0(8'QGL:;:71%*!2);63B
MW-%Y9_7;#VL&WT<GHZ8"[23:OY+;<S+K(I%Q@[4@%Y&Y)LNX)&BD*$3A*7L5
M6W=>N07.=V\];*V3#ORB-=#.XMX;@-N#Y7 #V%$9$=NK<3-Z[*"#C@V(FR"3
MHW4MN P8'!+(8B!:5BO\%VG0*U6P=0+O 0AR/[.B8WYL(_J&O)A'"G\+DRF.
MEV56)L\_C7'N*)_UZ<U)FB +&%W+<F4IP!7.(603,!E="KMVQ+PF#GOK:XXF
ME'8??8PZ$6;C5HT7&^:B.N-O.#T9Y5?S\CGSR/"-3Q'KX>F<^-QQ[3$IL(;1
MOBE<@9B5 OJ(,6.]L'RCE>$.^W(7C(_?$-FK%ANVI:BXU^%:3K=-D#7LO'P[
MFOTW8]Z?5D>=JJ2QLWL'0N&24D9;\&AK U:,X,C; T8KMS?21J4W2GXZ0K+<
MTOCY&+FRC29:6R__A;4_5?AX0E\^XVS:3Y/7TWRVWZ(CE1@)EI$OK[30Y,:3
MU5:+=QFK4\T3W<AXN>TM^VU!W%(5HR[DN&T-[^7']4MMV_?WO_Q_4$L#!!0
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M;[-5!;\R]C#[6"X?5%D_?IRS17V[D*__MBH>[%+XXO&+:>OV>U'-B$"Q0IK
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M[&[SI]+F?!:IS*,DI5#FQ*P9PNP&F<HP5#*2.%."8>1Y0W.NNZDM[9]7O$D
M'ZCT:POIE>Y+WD ]I^_2#6C$'<%OZ0DL0SLMM9U-PV/IB>+.[DI/W^IYVK1E
MK\JT_7ZY8-N?[&8_7H>EH$A3FD0V[SZC$%-!(=.,0<$TB<W_:9QXY=WW[']J
MY/+29M/B2YM\XYMZ8IPTAQ([__Y0WZD2U'=L 9Z^].NKY3TK%IX)(WS'S?$
M:;C1&)C!QA@(_^.A?G"&.@7R['W<PYY^T!R<Z?1LID?$^P>M"Z&VOJ(+^695
M+HIZ5:HN2[/F&2%)#C%GYH_(<"-E0L"8D206/,Z9<,K@[M;=U*BP%1BHC<NS
MG7BZD]DC$/LRT.?)+#Q\ W/7&KFML[B1%FS$O1P@V0="CQCVH%".%+M^'M)
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M5V6C<#BR'W9  JT" PDYZO(P+-#[Z\; O?5;4$PS6REN:[-H\543JOYE^=Z
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MD[I@O)B;!>G+\H6RI0)>K513]\16.GEC/LQ9Q' <46Y-2<8A%C*%N98<QK'
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M&A*FL0W,EY#+7$&B<4Q(G) $>5F"3KU.C?U.YM$J%C:-YD*U=5A_*^H[P!9
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M.[NM7[*R?#1\V70YRU.I<,H%U#R)C<F4:YA'-C,<UBP1.1="2*^\3RZ]3HW
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M'#. :6J7:QD&'"L(-*$Y2C*)4^'5^,U)ZMR(J%&ZFC+LF=K#<IG<H'?CH."
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M 7?CAE%@')DV*@3M46#UEX[:SWI.[U4/F([DBU:HQ"-GN=.F&/G"<91,Y/V
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M.5")27GR.J .Z?+*IPVN4O=U?;*8E9%FVY,UQU64,8U5(@U#VJ;0"FK H%#
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MP3\^OZ-&(6IAB'YJ@?CY)MIA$;5@5/4&HQJ.@ 5=7V080U6+G5;Y:4O1OLC
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MI:]69](E=BCP#E?>P9X[C)[?WC\LUT]*O5(KI8LJ@N?TAV812XQUK!7(6<H
M@E@"JE(,&$[2!"N20^1U2.$L>6Z$VRH>\4;S:D*7';=2=+3WHUSWX7#CUE%
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MK3Q:':4;VPP1%)[L/72LW,AZ@A$8F9N[X+<V5%!75MR<&) Q,_FNQ#-4H/E
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M*$+)$EFQZ;BDY9W+[@>-CC.7QPMS9#0\.\%YKO7E+V?AXR23=0N2!_*,%1V
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MNV+^M Y"J$WS%%[[ 0L*%ARG8-"S4&][,-_;$_SX6/N!)T_SHJT!,--$V!V
M9BN22;#&V.0"H&66HD ,X'/6M1J-69>SB?J^VKW#8^QQ6N -=J_U($%V$$Z_
MGH8XG6V2UN0];>J3/RUF)/35UBA>B":PVBI%1=#"$[:9H(,S,T4>52ET=!I]
M?V?-0P"R+VWCAMF#WZH/HJ(.+,\5OFYFMVBG!"Y5 B$=;:)4ZV!E49 TQ8$R
M%U2RM=^[FYIQ;TN'T?YNB!VCB@Y ]2REVJ9V]39\J_=TYTG.XJ(7NM26$+F
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M3]]^7]79LQ?/L9Y1\/EEZWE?O G4W!HM+411QR7Q8, Y82CN# 8#>IM]Z['
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M62Q7=";]&I9_QTW.\?+<.J+ LN7R@_FC3>3Q& ZLTE+IFE$S1A90L1 TK?/
MI+3&6ZM0M+[^&=F!G21/_V>R@<)# L6L B^% VVT94H*EF3[%IC?):MC=_4A
M&#G 77V00CHX]B_&9KZ:DX!.ZW;?U&KI6M%@HX5H-7DO.CN(R9+'[7.QWI9H
M;&L'= <IXV*IN<IOYF,:R+\#&)V_%:J.Q'M<?IDF\AFNC"._Y&[U@3YR=?=?
MG15P2:NTBM9!<K6<)AL!7BD$7I)QW(CB6>LVTBWI']GXM0#4HA/M=H!L<GY.
M<%E9>1L^X_*L\$_+++R*CC9ZG41F>8*@M 6?2)1*Q,A9Z_CF3D+&Q=IXN+@U
MN/18)76!M.7GQ3*L\?J9<\:,S29FSA5(X1DHX0WXJ*L'8X.P2FG>?(S@O02-
MF_+I"'FME-8! G]__\OB"R[GFT/C(\[3)IB[@R]7##JA<VT!6[LK%@,1G05A
MF6>,8T3=^J9@7]K&S=QT@\M!5-D%1#\L-YF);[<X"5*ZJ%@!5I\>DZ#(UPD^
M@-6YJ"BX=:EU*+R;FG&+4SJ"81-U=0"\R]3IS2#PDK/7ER_@E35): H$78ID
M^!,#Q\CO]DPQ%3POV@SW4G4/ L<]O8<.JH?350= O,G2#6&>+);KZ3\P/U^L
MUIND_02=9D6Q6B<F)"C.)(0ZP\HF623*P)ANW=3BH33V\M2U.5P6CZB[P[&Y
M6(?98V SI=.3TUDM2OUEN5BM?I_3V3"K#-=!+3_5*P7:_%\G0D916/20;1W(
MYU2":*0ES@T:$^G@**WS/TT([^6QVL@H'D#+_9O=G4S7IPJ73!MG'"97I[*D
M.NTY"(@"&80H<N"1BZ1:I]6;$-[+]*A>H7VXEKLH[]\MUNL"(*<]8K'!D9?N
M:--:VK2^%J.GQ)@KUK#V\R_VI:V705&/#=$FNCK8P'[!95P\=H%&BT[R>WWN
M8"45C]))_OY[<&8=&E\@Z\!K^)WI^-4)F".?TN;BDVJ=+1FO5N*ZH7Z[V#9$
M^NVT)B+>E//O5Y/B:A<21;N11PHZ<YVDE;F!VN2PI*"9=JT;;C0AO.=ZBP?@
M[&'U%D,HM0-'\\,RY.G\XW6S/D$L)OE@07A!QES'6-_^A\J$5=EY*;#U6Z [
M">FXTO<8I!TO] Z0<\AVF7A)'\0Y22WZ3+N#1?!2QCI]-V)*P9?8.M@^A,Z.
M"W(?V\(]2&5/J^[V9ET]R>1VR>F A;<'KC]@Y6T+B3R*.^DDH2XDB+G>;Y>,
M$ ,*,#Q9[T+*&EM[3D.ZD_\39_G#XOQUQ_5CX5(3_SY=?YK.W\SQ/S L+\B9
MQ!J^*6'!)4_A?]((WF "6U+1W#+/FX^E/X;>GIW'!Z#JIFE]-!5V</+?GQ.X
MY/99H36)V0^?EHO3CY]>4@!:^5Y=,EXDEE!4!&Y8?;7$/03.,J!1/CADC.?'
M3? \@/B>?=,C@#R.<I\0JM^3YUY?HEP^Q9LHY-(5[Z'DY$$A\1RT"\"5EUZH
MD(MK7:!T.+4]^[:/@-LCU=?LVO,1/-R+GY$/MWEW=_[2;C$/UY_:-79M'[[P
M8#[MD3)X#&?6**U"05:[V9&=3*@AEB(A)[1!^*B#>$J-$&Z\]=SUNO/W^2*N
M</EEVX+R\^GZ^A2%LU:G.H3DG &6>*UC50P\=PJ,CBFC*8(BX:%$<SSY';NZ
M#\'<SJ8NCZS@#GR$YV'UZ=D\U__4(1]?Z)R9K[?MQI7WF?F203GO:LEUAF "
ML>.L*,$K$W7K,&PW-9T@[[$!<K-:OHVV.L#=.Z1].TUKS'?S=/=/STI?DV.Y
M&&ZV@E,Y.O*OB@>#PMK"A,?F?;:/H7=<[+;"S&(D!78 UE\7<_RV?:G_\G2>
M+U^G1!5B89!Y+>Q6FH.+UM=O$^-U=F7S28]W4S(NP!X/";=Z<A^ME@[ =??;
MNR 4"B8MB"(I@M.B )T4"F)"Y;)0,:?6K1@.?R Y6$YH-&@=KY0CZM+:M.C>
M]9#9F\P-^1B06 J@9(DD%I8@>2V-"$5[UOKP/*8SP?#YQI%]NA9ZZL",-7TR
M%>NPU%PX%,MJ9Z20P)D@0!B-9-ME5B*VK];XDW<P>!"@ANQ@\!#M=H#LN\\"
M%WS6K"20SH6S:>AT")!(<P[!2.]]ZU=!?_8.!@_"Q5X']D.4U+"$=Z@>!LP:
M&V,2Y,S4WDLVE?J25(,466%(Y(#8]D[A?X\>!L=AKY72.K!V>S]\-R0IFQ6'
M((0%);0'5[.N*K$H)%9_NW4+E_^&/0R.P>4@JNS"3-[W++[DR.N(&I.0]AS6
M(9G<.T >O6 ^":];-Z+^;]'%X#@@-E%7%]"["!M_^G;QY?^<XI+(^O3M-7[!
MV<;9-LI$P3D"^MH[R1L)3BJL^8+,8C0BVL'J^>ZEK)-BB;&#[O9:[.#LOJM<
M8'6;O[,=;;+SQ@@&/%BR]=%9"$P+8$QGQE+.%!4.!=%]".SDRJ\A0G:!L+FZ
M>L+B9O^N-A+CYXWE<DC>>E^;)-5,!!THL10$\H5E23$QTWSHVCWD=(*S]B#8
M!;<C-=(IN,09*YD;[KG(=4HZ.2JEQEL!ZQT0\A X\I);)V;N(:>3'/<HX#I$
M(SV!ZR@?Y?7%8W5,R213&W5HDVIT96LC X1LT7$Z,.@(Z;/DZ_6#NET-%L9T
MYS..@(L.ML7==ZUWU.1--'?9".> (KC:F8[KVAQ1@4T:,0>=72J/4CAV!W&=
M'/9C0&BO6K)C]=D!4/=N\%&D3JB= .F9):<')40O)1BGK!4>5;:M;\*;-F/I
M_&J\#4P'T68/*-V(]J[M%K.P408$8LB#,K(.D8P<BN/21:\D=ZW+RG82\V?(
M%C7"81-]]?K8YNT2/X=I_OGK9YRO<!7F^<WZ$RZW3!_RB.;^#VSR..8!-#=Z
M]/+B3&.UO^3J>?@\76^["YQ1\NP:!9<(N1P\ZXL-F1Q/)^CX5$H%B#G102I5
M,E+E&$3K)B1'DGRLE;OSPZ],0'.Y.#048II,G@5/&EPH2!&GC\Y)Y0UKG26_
MGZ*QA^4\'KYNVK>&FNJU9\:]!N/P$<?[?.SP!F_ H<?'PI(E;WSQ$9(J 51*
MB0[(Y,!XRXH+.:O4NE)@9+-WX/)79O4J$HSBACP513M91 6TRW)];LY+<:JD
MV(G(_B2F\R$8O=V$Z!&U_22-ZQ&OL??ZW.'-ZY!OJ8_%KN911\[HG ^,T]D<
M%(3  _A0*,1QT?#4^KGUR/;U;)E7<_K0,$\X*>2:2&4]2/)Q0%&\#]$5#2)(
M([/ 1!Y+8Q'<I.%IV[^'8.BF_3M*&R.F8JJQ.2?^_:*L_R!)OYZFNOM)7K^&
MZ9RV]X8AJ8MS0AA@(1B2CO;@C7 0N5?!!&X#LN\9LKU7&WNVR.,#:1A%C(VL
MEXLE3C_.WY'^ZBTK<?*BWHHN/F\ZTQ$QTS4=KZ?S/#'(4M96@#3.@<I%0HRN
MOL/UQF@=/=Y\2+H#7GLO.6Y>;S2,#:.2L8%V)K8=7%493T+04D=R+IUPM>5E
MR,0)22Q@X<Z%*#B:AQBP>]8:][)X;//52@D=W%"\(JM+VJO9=)QNDNN3'.G7
ME-.@#,5&2GH##JT%16:9.V:SY:U+&6Y3L1? ])\)8(TTT@&F7ISB2Q+I.]P,
M 7D;EO7J[OGILDI^8FW4TGH%)N=0&XU;B"H)8$))GG,VEK6NW+J/GKUP9OZ,
M.&NFI;%/QHV(KL?UD^(D>8E"@)410:DZR%M) QJ9,]D'8N&[28E='[X79.R?
M"3)-Q-R!8;I._75135C0*(W)X&JW3V68@$!V%S3+*)Q5:$/K=Y?WT;,7RMR?
M"67-M=3!K+_[>/EM,4]GYE8S;9/R"42)=*Q'5L#7D0JZ*.:9<3JYUH?B?I3M
MA4+_WPV%!VJNBZ=M]_%U?OI+%957-D,,W .=^QP\ID+?1D,_24F9UITY]B!K
MO]PK^^\&QD.4UN\DLWWN9R8W^F^WNV.B3WZT6Z:;7%S<,_UXN.P6GW&Y_D;+
MU6+?35)BCNO#A'7W1S62SAYT-KIV.U_K[2S,U\^N+'BQ+TL)F)*5((*1H)B2
M$)F(X"3GVI&W(6-[O^\[1!UOY'<L<-?%M&8AD\..P+@FEXHB/S),)4 .=7*R
M1ZN;YWL>0M^X5VYM\7/;K@^DIWX+".[<^L?49=WW@4.:JP%KL;X/.LT\SS$3
MU+2NH*OM+W6B/XK1@F6FHVU=/CZ>T;K< D5G),>: =O<.6<3P#GO(18LSG M
MI&U? ? ]JGHW4 _!RMX&ZC"=/#&S]/[TY"0LOQU5V+3/!P]IIN[CX=',%4J3
MBC9U=G/9=&DE,/),H4H226>>0_&M)[H/;JXNAUGOWB2;VQO.C4$1$5+&0(&?
MK*WIZ ^FE0LFL21+:P=S7]IZ-UT/P<U-TS6(?KI(8N_@YJ=OM<'3IF$)SU8*
MF1)YB=F!(A,,OM9FJ?K^6>9L!'NT<_*2K''1-@P>]CTO#U1.SWBK#)TUE4#-
M95*YOH[SY ,813Z R@)X$MRQS(4SK9_X[$%6I];M4"CL[9H=II>QKW'I$VI_
MS<7RVP4GYZU%9.$IN0Q!)56G_C (15@Z"K#H5$S(*+[GB-V_1*=(.523B^9B
M[< .O<:PPD^+67YU\GFY^+)M<W/>V4@8B:@38&+U'KH@1(:R>@RQA*"CB:T'
M<MY#SKBUO4.AJ;4>QK8W;TJ9)KST.>?YY>ER/EV?+O&,&Q&<E24FT"Z0=;8E
M@-?%0,G19<9=B&K/(I+O+35NI>Z@]J>MF#NP0\\7)Y]/Z>-NFM,2>+*6(]&M
M:ZS"(WB4CL2DO<K,6*5;I^1VD#)N<>[0]J>%_+N T:;[;JIJ>34GH7TD/9W;
MT6B%%ZD0\2&3]33!0DC<D7R((Y:*DKYY<Z5[Z!FW&'=X0#721 >HVBFKUQ?]
M4:+D%B6+(&+M'\"Y@BC(^OKDZ@A-BG!OGFK#Q6JO']1\;C"7:=S4P&&JZ1EL
MORP7*PIN92@E:0:^WHDJ'CPXJSW(S&U!J72RCW:OO*&HTRCO0/WO"Z^'*Z,#
M:#U+Z?3D=%.9_@*)B+3M\D1?SW"CL'E^=K)8KJ?_V/Q\)_.3F DCB I\Q!KD
M)J0@%Q.0E!UWAEN&K;OQM**]TS"R#5Q'4? 1X_H^5DJ'M9J_X7J"15ME/ <T
MY,FJP@*$F!(DQ^I80U]X>+1$ZF^X'P0?/RX=V&(^5!']]GN[\T;XM[!<TF=_
MP?;WVK<^>LB;[?OY>+2[;16*(SP@6(,1E"N\UO4F,-+Q6'A-[[=N,#KXW?8^
M)GDB2E:"U^:;NH9&FKB/04C:(DX:K2SY&.T;W7V?KDZ]O(/P<KL)46.]]%J0
M0^[!\A0O"J@/,5$W/Z*)*;J7KE8F)WS;E!96O=;EPFQU 9Z$D>N<.&AC73WO
M"CGTNH!&1R<@LREYU]K8[":G@9>_.)VO5V=+G*] $)R&.)UM&P#?40GKHW'<
M:$Z0)G=/11*%\YD!$XEV4!%*^-85-0>2.K(Q:H2D.YSWP?7V1"S3X97+=W_0
M$%9JR$KE>Q#FM,NXZ0AEZA@&%AP==(Z#+5ARL:G$W/P5V7"VZC)'>!OK&P%?
MPCS+@-KG.G"BMI5AW$&4AB(3KU@IAL?VC.]/7;\6Z2%XV5WLUU0[3\0('1'(
M[?BD(<S0H&':/;A27J-1(M1>R0E45AH<%@;&VN)S"3*:YF\EVMNAS67ZF43O
MZ3]TT<!#6"Q*U%'82"@/WD)0HD#,(DOAO<3DOX>-ARW9KV%Y" "NU2X,(^X.
MTNL_DVE8?$,\:_YRQ5A>,)28RL@58(P4I89,O'BO("=ME+8BN^9S([]+U,@)
M\<8(&T87'8#K;->\72X*KE:DG3![B9?<)),S\6" 1Y?JC&$.WG/ZUAG'-!<)
M6?/))_=2-'*2>R!8-=3"V)5Z9ZS\@G-<AED55#Z9SJ=52#7]>\T02V>=0-HA
M@NPOA;4VD,@<;1TFLZV>GTSZ(>?>/HN.7&\UX,G77.0=F*<WG[$R,?^X*60]
M-[??SKGQS!OER+JR6&J;#N(K\%B/\\P]%JYM:MV*YWZ*1BZ^&L@\-=1"!Y@Z
MVRZOYA3[X(?P]=+..LLX\]H#8GT=:VI0RZ6!5(3)&)@RMG7;]IW$C-OK<."#
M[DC9]P.B.QS $&)F*2=P=?2=\EQ"E$6 ];7B-3$I0NOGLSN)&;?[X< @.E+V
MO18"O%\OTM_KDPW":KV07'\[)%5TQZ<T21-]C[I&*:+M1U^@Q:? ,BH.67!&
MQL$6J(.UP)LLBE!%.]EZ3UVGX.B$]"VQ_;98XUW7+KPPQV6)A%GB5RGI(#HI
M0/O"#%>,J^83Z?8F;MRLT1&8N)6!'D0=O2:@;W-[^$78SL\:R+H,>!UV T_"
M,A$=1=6Q/D11M2]?%"9 D6BB2BQKW]KY:VQC+JY5SK-4[W'Y99KP_2?:7S^1
MYY[K<QR<K[9;=K;Y2/KJ3:GC63_.-PT2<3E=;-LF7FX"Q7WD-ALPB7ER\"."
MLQ0^"D;18O8\Y^;%X8,QTY4->PCF=M^BC:GN#ESQ2T%<<DZNYZ:.ZX^PS!NC
M\N9S97U5)P5OQ;%:G9YL?W;CRM'(9'2Q#KCA$122(^D]"S6+*YTC?>70_ !N
MRL&XF?=!$/[HBGT"L+[8]54*;T^7Z1/]1JUDW$,4&EFR)AE@D7P954@>47,%
MWAD799)<I-9/%@=D9]P[@4<$_&.IO /T7_KB5X5Q[4!;+L/\X[:CP4_?[A;8
ME6HV;V,VPH-P5H)RF:(%9S,P*>BT8TRIYDV6&K,P[L5%0Y2/J=JG$Z*U>/BQ
MQZ<.%+8]RG./&YC$Q(.Q:, ZA77<4JZ]+0T$A5(%EW),K9]C#17 ;03ZT[?G
ML[#:VO&)S](C0X0DC 'E5:W&]1I8R2[DP)(+PX5@M\CI*HAZB-[O.7&/$GD'
M)^9[4L#&9&Y8.&-HT[C,2Q0V<4YB*9LQ+ D<DN/K:[>-8-"E 5**.XCII:W@
MD>J^E4]L(?L.0'25_K-N'5DD%4M(8'S-LPKZRBDEP0=F,1M5HFG]?N,V%2/#
MIHUZ;[8R.4[6/:!E<7*RF&\8..O PF5)FPM<BJ9KCT2TX'7MK^]EX<%QFU3K
MBYI;1(R+E6.U>KN!TA$B[@8C&ZG\=,8!0RV##1&X-)X.;,4@^&A % I%>3&L
M^-;EJK>I&#=+-@A*#A9R!S!YA^3-3=,:\U6L8XB^Z!1!6#J)%9-U4F^N+5=Y
MP6"S,[KUG<R=A(R;86H,EN-%W0%>:M;KMW"R[<Q;A'4\>P;2U,F6,=,!K*R"
M@.2S<1.U]<U?]5]9OY=^6&U]VH,EW!$ZSG:+ML%NQN(:Q'J)K\IFPC>$:'(F
MH42GFT\TN$;!R,]M#M;D#D@<(-;1R]))0^S5/)&XIE]PDT&LW)QW5S9>1<RU
M 6Z=NI*E 2]E!HW<HD83L[SQ"'17(?I]R_2!@D.4MQA$DCU@0FSO5&IP]VJ>
M3Q-NO]K!'?<NI>(3:,YSY2Y $%F!Y-EB]$P8M>>#A8<N/?)SJH;8&4[B8^/I
M/XD%7(;M[=PE"\QG3<;55%\M@3*<M@2O*8,@DF:)4="VGW&Y^_-'?A'5"!D-
M9#>B^E?+]>1=O;+:'+&9,Z4U2D"?*/3*]6EI"!QD)/<\*\5EVNO1''WJ%5>#
MOKMT,ZXM."X"6ON?A\NR!P"<X=8ZKY1S#@B^@:+O6D*EE0!72B@Y);2X5T2R
M#P3&="Z.4-9-=1\@N9$5_FOX.CTY/3DW5?3QN6@%ME@*FXOWX+CR$$V(@ELB
MW+78]=<6'5GIAZALT4)^'828VR*$\]E ,>>B:CL42Q:-D(]$M_49,#H6F#4B
M\]9]NJ\1,&YQR% IB,-EW % #B]MN61[GF_X5\9H7S)C8'46Y%^18^SJ&"";
M7*[WX)[+U@]>A^!CW$CX"%C=O/<=6\<=X/Q:4>*V&O<\%U P"HSDK3-6:EO>
M3%\5!LSH[)*.(NK68-U)S,@7R*/C9$<?D^.4UAOZSCV)I+#4@Z9(1D&HM8:.
M'*=!6%>XM YO9?/:XJZ'C$W?B#M 41U@[>Z+LUH]G5GM(25]O6C5&;PLEOZ@
M@*<4<GY4Z^JJ#N\HN\/;\<KJ#W&_SZ?KU;OWOY_/8DM&(U*D+5B]XD_90XA%
M08E1>,:TQ>9#S.XE:.0@I',$'J&\#I#X_C2NIGD:EM_>AXM ;^,_D\66*5!L
MEVP=^VT-@RC(DI.O$)W/OKC8_"W1+F+&;;\S6'5I$]GW *)+\NL>>U,^T.9<
MA<TPM[,-IT(61;$(:+%LHS&'5D,TEN7L<RJZ]7#8[U,U<O#01OTW0=56%V/?
MO;V8+C&MWQ1:>3K_>)Z8Q*RU8A(RE@0JLE"K)"5(+TI](B1"N'% [KAYN^O3
M1P9%8_4M6LIR;#"\7,QFBS_>S&^P4-^T&Z\%\%R'>0B9:\\ADH]S.<N0?-3[
MC0B^^_-'#O@&!$0#>79P^E0/[TVYXA!N[ZQDBEB,!?+&R \S+I$\D@ 3O+86
M/7W=.G-_)R'C]GL;RG4Y7N8= .=J#$$APF^+>;C\R95M=CZ&UB8A!6TV<*&6
MV.E([*EDZ90V3#'KF&G^5N^!)(Y[=C4 Q<V+H@$UU $ GY/]#7&Q?5'[[$[.
M_GVZ_O0V+-??/BQV_?89[TE9H43*D'UR%-(Z X$,.&BRY"E9RX)M_1*^)?TC
M7QT-";1;CSI&TGH'B*\Q#_[7*='_\Q?<#@_?& GKF4HI%\BFU%<*PD-@F4%P
MKL9 :%CSTWH'*>.VUAPRU7"LW/N$SYD/'"S'Y-"!L?7AC!<(T18'WKG('3?.
MX!#9JCN)&3^M<+2JOP^? ^3>'X#.[ZLT1;J1&>"2 F&E1"2IB%SC*84A2\95
MZW=&=Q+2'7 .4?+]T#E XAW YNI+O=<7<X^#I5C8\0(L,'("))EF3P$R^.(3
M.NV5<*WG0-Y)R%ZP<4_MR#I>YAT YVKVYK0B_ZPUTNK5:K7IEW[%Z9M(DSAM
M*0L\Q0 J,%%Y*^!R5)'[K(UM_7[Z(?3U\_[^0#C<DREOJIN^</=V.4WX%I<;
MWB99<<X=RQ 9LFT/4)(@ T]6/";GE&7-C[H=M/3S4K\YG@Z7^=@I]K?+14+,
MJY<DL+H/PCP14U>Z5?RR7*Q6$[+<GHN<@8)@ <KI C%Y^B,6PTE8'N5^#^;V
M6Z^?=_K'064H$7=@<<X*+\[E=,[8I@7Q)&,)QFI'?D"=<VP"AT N)<3 K+)(
M/RVM^SW<1\^X!2WM+4\SV7> H^^6^^RJ]KE^AC\[77]:+&LK[ FW,>?:(14+
M24%I^BH4<D(%1U_%2@)J7GK0FHEQ"V &."M'U?+8AVQS[LG5J.^L/Q!\5[5?
MY^_T[SXLGH=9.JWS+%_-T[).^)J(3#&80@LI63I3DK%D"Q*"DV0%D*,49;^;
M\K$X&/<VM;$C\"1@\*2/A,5\^P9BVUGTU7RU7IYN3\K3]6H=YGDZ_[@5YD2[
MH)P@+=H4*,!CRH/W28,/"B,FQHMKW4OF,?@:]SJCIX-C("P\Z?UQW8Y\"=-9
M3=N]7"Q_H7^[KF^&0LDU+:M)1XH"U7IUS^@/IX-CEHG0.L$Y%"_CYDA[V@<-
M==X!]J^$S<_#Y^DZS+:,U7'QRR^8B:^7I^O3)9X'11.%GMMB(WB1ZV5&-#4;
MXT%D;=&XE)-I'0X\F,B]T.J?#EJ'U5(',#Q_!?<3SK%,-S4D=^_0B8W:B2@9
M!%,;:26KZ%@1&B2/RA:*SBE<:0R_O8G;+\//G@[NAE'+DPT?7X;ILHZ4P2OC
M9,ZFB\^^_?SU,]9'31]P>3*1(D>/DA.8:NN/.B7,J4A' ?/")1]#=G[80'%O
M6O<#[1.XE^I1MQV8UJ82.1?$B^F7:<9Y?D=A\204-+;4QX#>)E!8.V\+2_+1
MR>G$%-/JT9MO',O4?KOB*=VN=06#I[POSMHS73S</XVKM)QN!+.1 UJ&VI#7
MQ;R)H#(GYU_2'RXK@=(@X[EU(?%0O.RW"Y[ Q6%72G^R_L\]0GAVLCBEZ%?[
MY$P6!E)('!2S 1P/#G)))LILZ'C,P_H]WZ5Q/TP_@=O+GG39BSV/WY=$O"F)
MBX&1M>CD6B'!V7W Q(M$H4WR8+Q3]0K806 IUZD"M=>!\$JV;B@Q'#?[X?^I
MW86.K_@G:]7/7Z]N9UY/I)0^U![X7EM&X8V4$%TTD W/&)) 9=RP)OPZ0?OA
M]4]_9WF$EGHPSN=U-10SG%ZRL<UB7IU7_?-7VGI3XGT2%4:1<@!RGP3M/=00
M:@=M[J/.)D1BL+G1?3"5^X'S*=T/#JNHWJ%XHS?19N>=E1/JD(RU!9QFCAS\
M4N]UR-4O-BJ?1%8J-$]R'$3I?I!\2E=UPRNL!U@>?#!L]^/M6W@6+)W(/$,R
M+-2'XP4\HY#4(C<ZJ&Q3Z28MMXN)_<#\A&[RQE7STQGS?;=3WW3F]_U+##0
M_ %\#3,-/.IBA=02"H]T6D>9Z+0F RE8<$K$;)UH/;9VL&G@!W<VW+ZNR^2W
ML*P84!QG0'$1P4O&0')5'U *%K&YA]F*^*XFC3\$4_=,&G]$=79PX+^:DYG
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M;&]Y;64N:'1M4$L! A0#%     @ G($)57UEED9;"   :2H  !L
M     ( !RU\  'IE;G1A;&ES,3 M<7$R,C R,F5X,S$Q+FAT;5!+ 0(4 Q0
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M+FAT;5!+ 0(4 Q0    ( )R!"55V5 )4Q P  &."   1              "
M >%, P!Z;G1L+3(P,C(P-C,P+GAS9%!+ 0(4 Q0    ( )R!"56C?DS09AL
M ,\( 0 5              "  =19 P!Z;G1L+3(P,C(P-C,P7V-A;"YX;6Q0
M2P$"% ,4    " "<@0E5098+K,LS  "B1 ( %0              @ %M=0,
M>FYT;"TR,#(R,#8S,%]D968N>&UL4$L! A0#%     @ G($)5=W.-4>=I0
M1>4& !4              ( !:ZD# 'IN=&PM,C R,C V,S!?;&%B+GAM;%!+
M 0(4 Q0    ( )R!"55R1IB.XF,  %N(!  5              "  3M/! !Z
J;G1L+3(P,C(P-C,P7W!R92YX;6Q02P4&      L "P#Z @  4+,$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
